PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ALTER, MJ; MARGOLIS, HS; KRAWCZYNSKI, K; JUDSON, FN; MARES, A; ALEXANDER, WJ; HU, PY; MILLER, JK; GERBER, MA; SAMPLINER, RE; MEEKS, EL; BEACH, MJ				ALTER, MJ; MARGOLIS, HS; KRAWCZYNSKI, K; JUDSON, FN; MARES, A; ALEXANDER, WJ; HU, PY; MILLER, JK; GERBER, MA; SAMPLINER, RE; MEEKS, EL; BEACH, MJ			THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; ACUTE NON-A; CHRONIC LIVER-DISEASE; POSTTRANSFUSION HEPATITIS; VIRAL-HEPATITIS; VIRUS-INFECTION; EPIDEMIOLOGY; TRANSMISSION; ANTIBODIES; REGIONS	Background. Chronic liver disease develops in more than half of patients with post-transfusion hepatitis C, but little is known about the natural history of community-acquired hepatitis C. Methods. In 1985 and 1986 we identified adults with acute non-A, non-B hepatitis in four counties in the United States and followed them prospectively. We used three markers to detect hepatitis C virus (HCV) infection in stored samples of serum: antibody to HCV (anti-HCV) detected by second-generation serologic assays; HCV RNA detected by polymerase-chain-reaction assay; and antibody to HCV antigen (anti-HCVAg) detected by fluorescent-antibody-blocking assay. Results. Of 130 patients with non-A, non-B hepatitis, 106 (82 percent) had HCV infection, 93 were positive for anti-HCV, and 13 were positive only for HCV RNA or anti-HCVAg. Chronic hepatitis developed in 60 (62 percent) of 97 HCV-infected patients followed for 9 to 48 months, with no relation to the risk factors for infection. Ten of the 30 patients who had liver biopsies had chronic active hepatitis. In samples collected 42 to 48 months after the onset of hepatitis, HCV RNA was detected in 12 of 13 tested patients with chronic hepatitis and in all 15 tested patients with hepatitis that had resolved. Anti-HCV persisted in all but two of the initially positive patients, for a rate of antibody loss of 0.6 per 100 person-years. Conclusions. Patients with community-acquired hepatitis C have a high rate of chronic hepatitis. HCV may be a major cause of chronic liver disease in the United States, and in most patients HCV infection seems to persist for at least several years, even in the absence of active liver disease.	DENVER PUBL HLTH, DENVER, CO USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA; TACOMA PIERCE CTY DEPT HLTH, TACOMA, WA USA; JEFFERSON CTY DEPT HLTH, BIRMINGHAM, AL USA; PINELLAS CTY DEPT HLTH, ST PETERSBURG, FL USA; TULANE UNIV, SCH MED, DEPT PATHOL, NEW ORLEANS, LA 70112 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT MED, TUCSON, AZ 85724 USA; VET AFFAIRS MED CTR, TUCSON, AZ USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tulane University; University of Arizona; University of Arizona Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	ALTER, MJ (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA.				PHS HHS [224-90-1002, 224-85-1001] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; [Anonymous], 1977, LANCET, V2, P914; BEACH MJ, 1992, J MED VIROL, V36, P226, DOI 10.1002/jmv.1890360314; BORTOLOTTI F, 1991, J HEPATOL, V12, P176, DOI 10.1016/0168-8278(91)90935-5; BRADLEY DW, 1983, J INFECT DIS, V148, P254, DOI 10.1093/infdis/148.2.254; GERBER MA, 1992, MODERN PATHOL, V5, P483; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; INOUE Y, 1991, NATURE, V353, P609, DOI 10.1038/353609a0; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MATHIESON RD, 1986, AM J CLIN PATHOL, V85, P353, DOI 10.1093/ajcp/85.3.353; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; MIMMS L, 1990, LANCET, V336, P1590, DOI 10.1016/0140-6736(90)93377-2; NAGATA A, 1985, AM J GASTROENTEROL, V80, P298; NORKRANS G, 1979, SCAND J INFECT DIS, V11, P259, DOI 10.3109/inf.1979.11.issue-4.01; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; RIESTRA S, 1990, ANN INTERN MED, V113, P411; SAMPLINER RE, 1984, J MED VIROL, V13, P125, DOI 10.1002/jmv.1890130203; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; 1986, MMWR MORB MORTAL WKL, V35, P655	29	1540	1573	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1899	1905		10.1056/NEJM199212313272702	http://dx.doi.org/10.1056/NEJM199212313272702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1280771				2022-12-24	WOS:A1992KE50500002
J	HARDING, FA; MCARTHUR, JG; GROSS, JA; RAULET, DH; ALLISON, JP				HARDING, FA; MCARTHUR, JG; GROSS, JA; RAULET, DH; ALLISON, JP			CD28-MEDIATED SIGNALING CO-STIMULATES MURINE T-CELLS AND PREVENTS INDUCTION OF ANERGY IN T-CELL CLONES	NATURE			English	Article							HUMAN-LYMPHOCYTES; ANTIGEN; ACTIVATION; EXPRESSION; PATHWAY; COMPLEX	OCCUPANCY of the T-cell antigen receptor is insufficient to induce T-cell activation optimally; a second co-stimulatory signal is required 1. Exposure of T-cell clones to complexes of antigen with major histocompatibility complex molecules in the absence of the co-stimulatory signal induces a state of clonal anergy. This requirement for two stimuli for T-cell activation could have an important role in vivo in establishing peripheral tolerance to antigens not encountered in the thymus 1,2. The receptor on T cells required for the co-stimulatory stimulus involved in the prevention of anergy has not been identified. The human T-cell antigen CD28 provides a signal that can synergize with T-cell antigen receptor stimulation in activating T cells to proliferate and secrete lymphokines 3-6. Here we report that a monoclonal antibody against the murine homologue of CD28 (ref. 7; J.A.G. et al., manuscript in preparation) can provide a co-stimulatory signal to naive CD4+ T cells and to T-cell clones. Moreover, we demonstrate that this costimulatory signal can block the induction of anergy in T-cell clones.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV WASHINGTON,DEPT IMMUNOL SL05,SEATTLE,WA 98195	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle				Allison, James/0000-0001-8980-5697; Raulet, David/0000-0002-1257-8649				FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GROSS JA, 1990, J IMMUNOL, V144, P3201; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; WEISS A, 1986, J IMMUNOL, V137, P819	17	1556	1666	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					607	609		10.1038/356607a0	http://dx.doi.org/10.1038/356607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1313950				2022-12-24	WOS:A1992HP03100050
J	COLOMBO, MI; MAYORGA, LS; CASEY, PJ; STAHL, PD				COLOMBO, MI; MAYORGA, LS; CASEY, PJ; STAHL, PD			EVIDENCE OF A ROLE FOR HETEROTRIMERIC GTP-BINDING PROTEINS IN ENDOSOME FUSION	SCIENCE			English	Article							ENDOCYTIC PATHWAYS; PERTUSSIS TOXIN; INVITRO; TRANSPORT; LOCALIZATION; STIMULATION; TRANSDUCERS; MASTOPARAN; MECHANISM; SYSTEMS	Guanosine triphosphate (GTP)-binding proteins are required for intracellular vesicular transport. Mastoparan is a peptide component of wasp venom that increases nucleotide exchange in some classes of G-alpha-subunits of regulatory heterotrimeric GTP-binding proteins (G proteins). Mastoparan and other compounds that increase nucleotide exchange by G proteins inhibited endosome fusion in vitro and reversed the effects of guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S), a nonhydrolyzable GTP analog. Addition of beta-gamma-subunits of G proteins to the fusion assay antagonized the stimulatory effect of GTP-gamma-S, confirming the participation of G proteins. These results indicate that GTP-binding proteins are required for endosome fusion and in particular that a G protein is involved. Given the function of G proteins in signal transduction, these findings may provide insight into the mechanism by which endosomal vesicles become competent for fusion after their formation at the cell surface.	NATL UNIV CUYO,CONSEJO NACL CIENT & TECN,FAC CIENCIAS MED,INST HISTOL & EMBRIOL,RA-5500 MENDOZA,ARGENTINA; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Duke University; Duke University	COLOMBO, MI (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110, USA.		Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671; Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020015, R37AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20015] Funding Source: Medline; NIGMS NIH HHS [GM 42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1987, NATURE, V328, P112, DOI 10.1038/328112a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COLOMBO MG, UNPUB; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TUICHIBAEV M U, 1988, Biokhimiya, V53, P219; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751	31	140	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1695	1697		10.1126/science.1348148	http://dx.doi.org/10.1126/science.1348148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1348148				2022-12-24	WOS:A1992HK81200034
J	WARLOW, C				WARLOW, C			SECONDARY PREVENTION OF STROKE	LANCET			English	Article							TRANSIENT ISCHEMIC ATTACKS; OXFORDSHIRE; PROGNOSIS; PROJECT				WARLOW, C (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; DUNBABIN DW, 1990, STROKE, V21, P36; DUTCH TIA, 1991, NEW ENGL J MED, V325, P1261; HANKEY GJ, 1991, J NEUROL NEUROSUR PS, V54, P793, DOI 10.1136/jnnp.54.9.793; HANKEY GJ, IN PRESS J NEUROL NE; HUNTER GC, 1987, ARCH SURG-CHICAGO, V122, P311; KRUL JMJ, 1989, STROKE, V20, P324, DOI 10.1161/01.STR.20.3.324; LOFTUS CM, 1987, NEUROSURGERY, V20, P490, DOI 10.1227/00006123-198703000-00026; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; WARLOW C, 1982, RECENT ADV CLIN NEUR, V3, P191; WARLOW CP, TICLOPIDINE NEW ANTI, P185; 1991, LANCET, V337, P1235; 1991, J NEUROL NEUROSUR PS, V54, P1044; 1988, BRIT MED J, V296, P320; 1985, NEW ENGL J MED, V313, P1191; 1991, LANCET, V338, P1345; 1991, NEW ENGL J MED, V325, P445	20	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					724	727		10.1016/0140-6736(92)90608-6	http://dx.doi.org/10.1016/0140-6736(92)90608-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347592				2022-12-24	WOS:A1992HK32000013
J	WALSH, KP; SREERAM, N; FRANKS, R; ARNOLD, R				WALSH, KP; SREERAM, N; FRANKS, R; ARNOLD, R			BALLOON DILATATION OF THE ARTERIAL DUCT IN CONGENITAL HEART-DISEASE	LANCET			English	Note							INTERRUPTED AORTIC-ARCH; PROSTAGLANDIN-E1	The systemic circulation of newborn infants with congenital left-heart obstruction is supplied from the right ventricle via a patent arterial duct between the pulmonary artery and descending aorta. The duct closes during the first few days of life, but infusion of prostaglandin E2 can prevent closure in some cases. We report four newborn infants (aged 3-8 days) with intractable heart failure due to severe obstruction of the left heart in the presence of a closing arterial duct. Infusion of prostaglandin E2 did not improve their clinical condition. Cardiac catheterisation and balloon dilatation of their arterial ducts resulted in a dramatic improvement in the babies' clinical condition; during subsequent surgical repair of the infants' hearts, the arterial ducts were found to be widely patent. Balloon dilatation gives immediate and sustained wide patency of the arterial duct in infants who do not respond adequately to prostaglandin E2.			WALSH, KP (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP,HEART CLIN,LIVERPOOL L12 2AP,ENGLAND.							COLLINSNAKAI RL, 1976, J PEDIATR-US, V88, P959, DOI 10.1016/S0022-3476(76)81049-9; FREED MD, 1981, CIRCULATION, V64, P899, DOI 10.1161/01.CIR.64.5.899; LANG P, 1977, J PEDIATR-US, V91, P805, DOI 10.1016/S0022-3476(77)81047-0; RADFORD DJ, 1976, LANCET, V2, P95	4	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					331	332		10.1016/0140-6736(92)91648-R	http://dx.doi.org/10.1016/0140-6736(92)91648-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346412				2022-12-24	WOS:A1992HC77100005
J	SUTTER, RW; COCHI, SL				SUTTER, RW; COCHI, SL			PERTUSSIS HOSPITALIZATIONS AND MORTALITY IN THE UNITED-STATES, 1985-1988 - EVALUATION OF THE COMPLETENESS OF NATIONAL REPORTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHOOPING-COUGH; SURVEILLANCE; TRANSMISSION; EPIDEMIC	Objective. - To determine the magnitude of hospitalizations for pertussis and pertussis mortality and to estimate the total burden of clinically significant pertussis in the United States. Design. - Capture-recapture methods for estimating population size from independent surveillance systems were used to analyze morbidity and mortality data from case report forms received at the Centers for Disease Control (CDC) from the states, and compared these data with pertussis hospitalizations compiled from a database of US hospitals participating in the Commission on Professional and Hospital Activities-Professional Activities Survey (CPHA-PAS) and death certificate reports compiled by the National Center for Health Statistics (NCHS). Population Studied. - All pertussis hospitalizations and pertussis-related deaths in the United States, 1985 through 1988. Results. - We estimated that 13 557 pertussis hospitalizations (95% confidence interval [CI], 12953 to 14162) and 98 pertussis deaths had occurred during the 4-year study period (an average of more than 3300 hospitalizations and 25 deaths per year). The completeness of reporting hospitalizations to the CDC was 32% and to the CPHA-PAS, 23%, while the completeness of reporting pertussis deaths to the CDC was 33% and to NCHS, 23%. Patients who were hospitalized with per-tussis and reported to CDC were at a higher risk for developing pneumonia (31.0% vs 20.0%, relative risk [RR], 1.6; 95% CI, 1.4 to 1.7), seizures (3.7% vs 2.1 %; RR, 1.9; 95% CI, 1.4 to 2.5) and encephalitis (1.2% vs 0.2%; RR, 5.3; 95% CI, 2.4 to 11.6) compared with patients recorded in the CPHA-PAS system. Conclusions. - Our study suggests that there is substantial underreporting of pertussis, that severe complications of pertussis (including hospitalizations) are reported preferentially to the CDC, and that the national health impact of pertussis based on these indicators is considerably higher than previously published reports have suggested.			SUTTER, RW (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,INFORMAT SERV,MAILSTOP E07,ATLANTA,GA 30333, USA.							BIELLIK RJ, 1988, J INFECT DIS, V157, P1134, DOI 10.1093/infdis/157.6.1134; BIELLIK RJ, 1989, 29TH INT C ANT AG CH, P145; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BROOME CV, 1981, J INFECT DIS, V144, P187, DOI 10.1093/infdis/144.2.187; Chapman D. G., 1951, U CALIFORNIA PUBL ST, V1, P131; CHERRY JD, 1990, JAMA-J AM MED ASSOC, V263, P1679; COCHI SL, 1989, AM J EPIDEMIOL, V129, P349, DOI 10.1093/oxfordjournals.aje.a115138; Cormack R. M., 1969, Oceanogr. mar. Biol., V6, P455; EDDINS DL, 1985, 20TH IMM C P DALL, P51; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; HICKS T, 1987, PERTUSSIS HAWAII COM; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; MILLER CL, 1976, BRIT MED J, P117; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; NKOWANE BM, 1986, AM J DIS CHILD, V140, P433, DOI 10.1001/archpedi.1986.02140190043021; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; POLLOCK TM, 1984, ARCH DIS CHILD, V59, P162, DOI 10.1136/adc.59.2.162; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P1420, DOI 10.2105/AJPH.75.12.1420; SEKAR CC, 1949, J AM STAT ASSOC, V44, P101, DOI 10.2307/2280353; SNEDEOR GW, 1989, STATISTICAL METHODS; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; WASSILAK S, 1983, 18TH P IMM C ATL GA, P37; 1987, PEDIATRIC LENGTH STA; 1988, PEDIATRIC LENGTH STA; 1985, MMWR, V34, P399; 1991, REPORT COMMITTEE INF, P358; 1991, MMWR, V40, P1; 1989, STATE IMMUNIZATION R; 1987, VITAL STATISTICS US, V2; 1989, PEDIATRIC LENGTH STA; 1977, INT CLASSIFICATION D; 1985, MMWR, V34, P390; 1983, MMWR, V32, P297; 1987, VERSION 6; 1990, MMWR, V38, P51; 1988, CATALOGUE PUBLIC USE; 1953, REPORTED INCIDENCE S; 1986, PEDIATRIC LENGTH STA	40	139	141	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					386	391		10.1001/jama.267.3.386	http://dx.doi.org/10.1001/jama.267.3.386			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1309387				2022-12-24	WOS:A1992GY43700036
J	GROSS, E; GOLDBERG, D; LEVITZKI, A				GROSS, E; GOLDBERG, D; LEVITZKI, A			PHOSPHORYLATION OF THE SACCHAROMYCES-CEREVISIAE CDC25 IN RESPONSE TO GLUCOSE RESULTS IN ITS DISSOCIATION FROM RAS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; YEAST; EXCHANGE; KINASE	IN the yeast Sacchromyces cerevisiae, addition of glucose to starved cells triggers a transient rise in the intracellular level of cyclic AMP that induces a protein phosphorylation cascade1. The glucose signal is processed by the Cdc25/Ras/adenylyl cyclase pathway2, where the role of Cdc25 is to catalyse the GDP-GTP exchange on Ras3. The molecular mechanisms involved in the regulation of the activity of Cdc25 are unknown. We report here the use of highly selective anti-Cdc25 antibodies4 to demonstrate that Cdc25 is a phospho protein and that in response to glucose it is hyperphosphorylated, within seconds, by the cyclic AMP-dependent protein kinase. It is also demonstrated that, concomitantly with hyperphosphorylation, Cdc25 partially relocalizes to the cytoplasm, reducing its accessibility to membrane-bound Ras. These results are of general significance because of the highly conserved sequence of Ras-guanyl nucleotide exchange factors from yeasts to mammals.	HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	LEVITZKI, A (corresponding author), HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL.							CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; DUFAU ML, 1977, P NATL ACAD SCI USA, V74, P3419, DOI 10.1073/pnas.74.8.3419; ENGELBERG D, 1989, CELL SIGNAL, V1, P1, DOI 10.1016/0898-6568(89)90015-6; ERASO P, 1985, FEBS LETT, V191, P51, DOI 10.1016/0014-5793(85)80991-1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GROSS E, 1992, MOL CELL BIOL, V12, P2653, DOI 10.1128/MCB.12.6.2653; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MBONYI K, 1990, MOL CELL BIOL, V10, P4518, DOI 10.1128/MCB.10.9.4518; MUNDER T, 1989, FEBS LETT, V242, P341, DOI 10.1016/0014-5793(89)80498-3; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SCHOMERUS C, 1990, MOL GEN GENET, V223, P426, DOI 10.1007/BF00264449; SEGAL M, IN PRESS J BIOL CHEM; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7	18	79	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 24	1992	360	6406					762	765		10.1038/360762a0	http://dx.doi.org/10.1038/360762a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334534				2022-12-24	WOS:A1992KE47200041
J	KOCH, AE; POLVERINI, PJ; KUNKEL, SL; HARLOW, LA; DIPIETRO, LA; ELNER, VM; ELNER, SG; STRIETER, RM				KOCH, AE; POLVERINI, PJ; KUNKEL, SL; HARLOW, LA; DIPIETRO, LA; ELNER, VM; ELNER, SG; STRIETER, RM			INTERLEUKIN-8 AS A MACROPHAGE-DERIVED MEDIATOR OF ANGIOGENESIS	SCIENCE			English	Article							SYNOVIAL TISSUE MACROPHAGES; TUMOR NECROSIS FACTOR; MESSENGER-RNA; NEUTROPHIL; PEPTIDE; NEOVASCULARIZATION; PURIFICATION; INHIBITION; INDUCTION; MONOCYTES	Angiogenic factors produced by monocytes-macrophages are involved in the pathogenesis of chronic inflammatory disorders characterized by persistent angiogenesis. The possibility was tested that interleukin-8 (IL-8), which is a cytokine that is chemotactic for lymphocytes and neutrophils, is also angiogenic. Human recombinant IL-8 was potently angiogenic when implanted in the rat cornea and induced proliferation and chemotaxis of human umbilical vein endothelial cells. Angiogenic activity present in the conditioned media of inflamed human rheumatoid synovial tissue macrophages or lipopolysaccharide-stimulated blood monocytes was equally blocked by antibodies to either IL-8 or tumor necrosis factor-alpha. An IL-8 antisense oligonucleotide specifically blocked the production of monocyte-induced angiogenic activity. These data suggest a function for macrophage-derived IL-8 in angiogenesis-dependent disorders such as rheumatoid arthritis, tumor growth, and wound repair.	UNIV MICHIGAN,DEPT OPHTHALMOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT MED,DIV PULM,ANN ARBOR,MI 48109; LAKESIDE VET ADM MED CTR,CHICAGO,IL 60611; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; LOYOLA UNIV,MED CTR,DEPT SURG,MAYWOOD,IL 60153	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Loyola University Chicago	KOCH, AE (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ARTHRIT & CONNECT TISSUE DIS SECT,WARD BLDG 3-315,CHICAGO,IL 60611, USA.		Koch, Alisa E/B-6894-2011; Huang, H/E-9490-2010; Polverini, Peter/AAJ-8392-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692, R29AR041492] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39926] Funding Source: Medline; NIAMS NIH HHS [AR30692, AR41492] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BRENNAN FM, 1990, EUR J IMMUNOL, V20, P2141, DOI 10.1002/eji.1830200938; DEMARCO D, 1991, BIOCHEM BIOPH RES CO, V174, P411, DOI 10.1016/0006-291X(91)91431-B; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1988, BIOCHEM BIOPH RES CO, V154, P205, DOI 10.1016/0006-291X(88)90671-7; KOCH AE, 1986, ARTHRITIS RHEUM, V29, P471, DOI 10.1002/art.1780290403; KOCH AE, 1991, J IMMUNOL, V147, P2187; KOCH AE, 1986, J LEUKOCYTE BIOL, V39, P233, DOI 10.1002/jlb.39.2.233; KOCH AE, 1988, J RHEUMATOL, V15, P1058; KOCH AE, 1991, AGENTS ACTIONS, V34, P350, DOI 10.1007/BF01988728; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEICHL P, 1992, ANN RHEUM DIS, V51, P19, DOI 10.1136/ard.51.1.19; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; POLVERINI PJ, 1989, CYTOKINES, P54; SCHRODER JM, 1986, J INVEST DERMATOL, V87, P53, DOI 10.1111/1523-1747.ep12523566; SELTZ M, 1991, J CLIN INVEST, V87, P463; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; STOECKLE M Y, 1990, New Biologist, V2, P313; VISSERS MCM, 1988, J IMMUNOL METHODS, V110, P203, DOI 10.1016/0022-1759(88)90104-4; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355	27	1857	1933	1	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1798	1801		10.1126/science.1281554	http://dx.doi.org/10.1126/science.1281554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1281554				2022-12-24	WOS:A1992KB96400040
J	BOCSKEI, Z; GROOM, CR; FLOWER, DR; WRIGHT, CE; PHILLIPS, SEV; CAVAGGIONI, A; FINDLAY, JBC; NORTH, ACT				BOCSKEI, Z; GROOM, CR; FLOWER, DR; WRIGHT, CE; PHILLIPS, SEV; CAVAGGIONI, A; FINDLAY, JBC; NORTH, ACT			PHEROMONE BINDING TO 2 RODENT URINARY PROTEINS REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							NASAL-MUCOSA; RESOLUTION; REFINEMENT; CRYSTALLIZATION; SEQUENCE; REGION	THE principal protein excreted in male rat urine, urinary alpha2-globulin and the homologous mouse protein, major urinary protein, have been well characterized, although their functions remain unclear. Male rat urine affects the behaviour and sexual response of female rats1, leading to the proposal that rodent urinary proteins are responsible for binding pheromones and their subsequent release from drying urine2. Urinary alpha2-globulin is also involved in hyaline droplet nephropathy, an important toxicological syndrome in male rats resulting from exposure to a number of industrial chemicals and characterized by the accumulation of liganded urinary alpha2-globulin in lysosomes in the kidney, followed by the induction of renal cancer3. We now report the three-dimensional structures of mouse major urinary protein (at 2.4 angstrom resolution) and rat urinary alpha2-globulin (at 2.8 angstrom resolution). The results corroborate the role of these proteins in pheromone transport and elaborate the structural basis of ligand binding.	UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV PARMA,IST FISIOL UMANA,I-43100 PARMA,ITALY	University of Leeds; University of Parma			Flower, Darren/F-1263-2010	Flower, Darren/0000-0002-8542-7067; Phillips, Simon/0000-0001-8922-0250; Groom, Colin/0000-0001-8921-9575	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACCHINI A, IN PRESS EXPERIMENTI; BOCSKEI Z, 1991, J MOL BIOL, V218, P699, DOI 10.1016/0022-2836(91)90258-8; BORGHOFF SJ, 1990, ANNU REV PHARMACOL, V30, P349, DOI 10.1146/annurev.pa.30.040190.002025; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVAGGIONI A, 1990, COMP BIOCHEM PHYS B, V96, P513, DOI 10.1016/0305-0491(90)90049-Y; CAVAGGIONI A, 1987, FEBS LETT, V212, P225, DOI 10.1016/0014-5793(87)81349-2; CHERFILS J, 1988, J APPL CRYSTALLOGR, V21, P985, DOI 10.1107/S002188988800932X; CLARK AJ, 1985, EMBO J, V4, P3159, DOI 10.1002/j.1460-2075.1985.tb04059.x; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; Cowley J. J., 1978, Biological determinants of sexual behaviour., P87; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1991, J MOL GRAPHICS, V9, P257, DOI 10.1016/0263-7855(91)80021-Q; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; ICHIYOSHI Y, 1987, BIOCHIM BIOPHYS ACTA, V910, P43, DOI 10.1016/0167-4781(87)90093-5; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KIMURA H, 1991, J BIOL CHEM, V266, P5963; NORTH ACT, 1991, BIOCH SOC S, V57, P35; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PARRYSMITH DJ, 1991, COMPUT APPL BIOSCI, V7, P233; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; TIRINDELLI R, 1989, EUR J BIOCHEM, V185, P569, DOI 10.1111/j.1432-1033.1989.tb15151.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90	27	354	365	2	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					186	188		10.1038/360186a0	http://dx.doi.org/10.1038/360186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1279439				2022-12-24	WOS:A1992JX75200069
J	MUSACCHIO, A; NOBLE, M; PAUPTIT, R; WIERENGA, R; SARASTE, M				MUSACCHIO, A; NOBLE, M; PAUPTIT, R; WIERENGA, R; SARASTE, M			CRYSTAL-STRUCTURE OF A SRC-HOMOLOGY-3 (SH3) DOMAIN	NATURE			English	Article							PHOSPHOLIPASE-C; ALPHA-SPECTRIN; PROTEIN; SRC; SIMILARITY; REFINEMENT; SEQUENCES; ELEMENTS; ERRORS; BRAIN	THE Src-homologous SH3 domain is a small domain present in a large number of proteins that are involved in signal transduction, such as the Src protein tyrosine kinase, or in membrane-cytoskeleton interactions, but the function of SH3 is still unknown (reviewed in refs 1-3). Here we report the three-dimensional structure at 1.8 angstrom resolution of the SH3 domain of the cytoskeletal protein spectrin expressed in Escherichia coli. The domain is a compact beta-barrel made of five antiparallel beta-strands. The amino acids that are conserved in the SH3 sequences are located close to each other on one side of the molecule. This surface is rich in aromatic and carboxylic amino acids, and is distal to the region of the molecule where the N and C termini reside and where SH3 inserts into the alpha-spectrin chain. We suggest that a protein ligand binds to this conserved surface of SH3.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Musacchio, Andrea/0000-0003-2362-8784; Noble, Martin/0000-0002-3595-9807				ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; Bennett V, 1990, CURR OPIN CELL BIOL, V2, P51, DOI 10.1016/S0955-0674(05)80030-4; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1988, ONCOGENE, V3, P491; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SAHR KE, 1990, J BIOL CHEM, V265, P4434; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; 1979, CCP4 PACKAGE	35	415	426	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					851	855		10.1038/359851a0	http://dx.doi.org/10.1038/359851a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279434				2022-12-24	WOS:A1992JV77700071
J	MIICK, SM; MARTINEZ, GV; FIORI, WR; TODD, AP; MILLHAUSER, GL				MIICK, SM; MARTINEZ, GV; FIORI, WR; TODD, AP; MILLHAUSER, GL			SHORT ALANINE-BASED PEPTIDES MAY FORM 3(10)-HELICES AND NOT ALPHA-HELICES IN AQUEOUS-SOLUTION	NATURE			English	Article							RIBONUCLEASE-A; PROTEINS; RESONANCE; SPECTRA; ANALOG	SHORT alanine peptides, containing 16 or 17 residues, appear to form alpha-helices in aqueous solution1-4. But the main spectroscopic analyses used on helical peptides (circular dichroism5 and nuclear magnetic resonance6-8) cannot distinguish between an alpha-helix (in which the ith residue is hydrogen-bonded to residue i + 4; ref. 9) a nd the next most common peptide helix, the 3(10)-helix10 (i --> i + 3 hydrogen-bonding). To address this problem we have designed single and doubly spin-labelled analogues of alanine-based peptides in which the nitroxide spin label forms an unbranched side chain extending from the sulphur atom of a cysteine residue. Here we report the circular dichroism, Fourier-transform infrared and electron-spin resonance spectra of these peptides under helix-forming conditions. The infrared absorbance gives an amide I' band with a frequency that is substantially different from that observed for alpha-helices. The electron-spin resonance spectra of doubly labelled helices show that the ranking of distances between side chains, around a single turn (residues 4-8), is inconsistent with an alpha-helical structure. Our experiments suggest that the more likely peptide geometry is a 3(10)-helix.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P2025, DOI 10.1002/bip.360231016; FALLE HR, 1966, MOL PHYS, V11, P49, DOI 10.1080/00268976600100841; GAUTAM B, 1991, BIOPOLYMERS, V31, P1763; KARLE IL, 1990, BIOCHEMISTRY-US, V29, P6747, DOI 10.1021/bi00481a001; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KRYSTEK SR, 1992, FEBS LETT, V299, P255, DOI 10.1016/0014-5793(92)80127-3; LEMAIRE H, 1968, MOL PHYS, V14, P441, DOI 10.1080/00268976800100551; LUCKHURST GR, 1976, SPIN LABELING THEORY, pCH4; MALCOLM BR, 1983, BIOPOLYMERS, V22, P319, DOI 10.1002/bip.360220140; MANNING MC, 1991, BIOPOLYMERS, V31, P569, DOI 10.1002/bip.360310511; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009; TODD AP, 1991, BIOCHEMISTRY-US, V30, P5515, DOI 10.1021/bi00236a026; TONIOLO C, 1991, TRENDS BIOCHEM SCI, V16, P350; Voet D VJ, 1990, BIOCHEMISTRY; WURTHRICH K, 1986, NMR PROTEINS NUCLEIC	25	213	213	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					653	655		10.1038/359653a0	http://dx.doi.org/10.1038/359653a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1328890				2022-12-24	WOS:A1992JT82400063
J	MISIANI, R; BELLAVITA, P; FENILI, D; BORELLI, G; MARCHESI, D; MASSAZZA, M; VENDRAMIN, G; COMOTTI, B; TANZI, E; SCUDELLER, G; ZANETTI, A				MISIANI, R; BELLAVITA, P; FENILI, D; BORELLI, G; MARCHESI, D; MASSAZZA, M; VENDRAMIN, G; COMOTTI, B; TANZI, E; SCUDELLER, G; ZANETTI, A			HEPATITIS-C VIRUS-INFECTION IN PATIENTS WITH ESSENTIAL MIXED CRYOGLOBULINEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; HEPATITIS ANTIBODIES; RHEUMATOID FACTOR	LONG-TERM; B VIRUS; GLOMERULONEPHRITIS; VASCULITIS	Objective: To study the association between hepatitis C virus (HCV) infection and essential mixed cryoglobulinemia. Setting: Wards and clinics of the Ospedali Riuniti di Bergamo and Ospedale di Treviglio e Caravaggio, Italy. Patients: Fifty-one patients with essential mixed cryoglobulinemia associated with glomerulonephritis and 45 controls with noncryoglobulinemic glomerulopathies. Measurements: Antibodies to hepatitis C virus (anti-HCV) in sera from patients with essential mixed cryoglobulinemia and from controls, using two enzyme-linked immunosorbent assays (C100 ELISA and c22/c200 ELISA) and a recombinant immunoblot assay (4-RIBA); cryoprecipitate anti-HCV before and after use of dithiothreitol, a substance able to destroy IgM antibodies with rheumatoid factor activity, in patients with essential mixed cryoglobulinemia; serum HCV RNA by polymerase chain reaction in patients with essential mixed cryoglobulinemia. Results: In patients with essential mixed cryoglobulinemia, the c22/c200 ELISA detected anti-HCV in 98% of serum samples (95% Cl, 90% to 100%), whereas the rate of reactivity remained at 2% (Cl, 0% to 12%) in the control group (P < 0.0001). These results were confirmed by the 4-RIBA in 66% of patients with essential mixed cryoglobulinemia. The study of cryoprecipitate by c100 ELISA showed anti-HCV in 41% (Cl, 28% to 56%) of patients. After dithiothreitol, the rate of reactivity increased to 94% (Cl, 84% to 99%; P < 0.0001 by the McNemar paired chi-square test), suggesting that the elimination of rheumatoid factor leads to unmasking of anti-HCV in cryoprecipitate. Polymerase chain reaction detected HCV RNA in 13 of 16 sera from patients with essential mixed cryoglobulinemia. Conclusions: The extremely high prevalence of anti-HCV in serum and cryoprecipitate along with the frequently associated serum HCV RNA suggests a close relation between essential mixed cryoglobulinemia and chronic HCV infection.	OSPED RIUNITI BERGAMO, DEPT IMMUNOHEMATOL, LARGO BAROZZI 1, I-24100 BERGAMO, ITALY; OSPED TREVIGLIO & CARAVAGGIO, TREVIGLIO, SPAIN; UNIV MILAN, I-20122 MILAN, ITALY; UNIV CAMERINO, I-62032 CAMERINO, ITALY	Ospedali Riuniti di Bergamo; University of Milan; University of Camerino			Tanzi, Elisabetta/M-9066-2016	Tanzi, Elisabetta/0000-0002-4119-701X				BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; BONOMO L, 1971, CLIN EXP IMMUNOL, V9, P175; BOUDART D, 1990, LANCET, V336, P63, DOI 10.1016/0140-6736(90)91585-X; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CORDONNIER D, 1975, AM J MED, V59, P867, DOI 10.1016/0002-9343(75)90480-5; CREAM JJ, 1971, BRIT J DERMATOL, V84, P48, DOI 10.1111/j.1365-2133.1971.tb14196.x; DURAND JM, 1991, LANCET, V337, P499, DOI 10.1016/0140-6736(91)93443-D; DUSSAIX E, 1990, LANCET, V335, P1160, DOI 10.1016/0140-6736(90)91163-5; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HOUGHTON M, 1989, Patent No. 883109225; HURWITZ D, 1975, CLIN EXP IMMUNOL, V19, P131; JORI GP, 1977, GUT, V18, P245, DOI 10.1136/gut.18.3.245; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; LEVO Y, 1977, ANN INTERN MED, V87, P287, DOI 10.7326/0003-4819-87-3-287; MAGGIORE Q, 1982, KIDNEY INT, V21, P387, DOI 10.1038/ki.1982.34; Masson P L, 1981, Methods Enzymol, V74 Pt C, P106; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MCINTOSH RM, 1976, Q J MED, V45, P23; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MELTZER M, 1966, AM J MED, V40, P828, DOI 10.1016/0002-9343(66)90199-9; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; POPP JW, 1980, ANN INTERN MED, V92, P379, DOI 10.7326/0003-4819-92-3-379; REALDI G, 1974, Z IMMUNITATSFORSCH, V147, P114; Riethmuller G, 1966, Clin Exp Immunol, V1, P337; SINICO RA, 1988, KIDNEY INT, V34, P109, DOI 10.1038/ki.1988.152; SPALLUTO JL, 1962, AM J MED, V32, P142; TARANTINO A, 1978, CLIN EXP IMMUNOL, V32, P77; THEILMANN L, 1990, LANCET, V335, P1345; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I	31	518	523	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					573	577		10.7326/0003-4819-117-7-573	http://dx.doi.org/10.7326/0003-4819-117-7-573			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1326246				2022-12-24	WOS:A1992JQ22600005
J	MIZUUCHI, M; BAKER, TA; MIZUUCHI, K				MIZUUCHI, M; BAKER, TA; MIZUUCHI, K			ASSEMBLY OF THE ACTIVE FORM OF THE TRANSPOSASE-MU DNA COMPLEX - A CRITICAL CONTROL POINT IN MU-TRANSPOSITION	CELL			English	Article							STRAND-TRANSFER-REACTION; INTEGRATION HOST FACTOR; BACTERIOPHAGE-MU; PHAGE-MU; B-PROTEIN; SITE; ENHANCER; ENDS; TRANSPOSOSOMES; RECOMBINATION	Discovery and characterization of a new intermediate in Mu DNA transposition allowed assembly of the transposition machinery to be separated from the chemical steps of recombination. This stable intermediate, which accumulates in the presence of Ca2+, consists of the two ends of the Mu DNA synapsed by a tetramer of the Mu transposase. Within this stable synaptic complex (SSC), the recombination sites are engaged but not yet cleaved. Thus, the SSC is structurally related to both the cleaved donor and strand transfer complexes, but precedes them on the transposition pathway. Once the active protein-DNA complex is constructed, it is conserved throughout transposition. The participation of internal sequence elements and accessory factors exclusively during SSC assembly allows recombination to be controlled prior to the irreversible chemical steps.			MIZUUCHI, M (corresponding author), NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Cox M. M., 1989, MOBILE DNA, P661; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Furth M., 1983, LAMBDA 2, P145; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LABHART P, 1985, NUCLEIC ACIDS RES, V13, P8999, DOI 10.1093/nar/13.24.8999; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI M, 1986, NUCLEIC ACIDS RES, V14, P3813, DOI 10.1093/nar/14.9.3813; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; THOMPSON JF, 1989, MOBILE DNA, P1; WEISBERG RA, 1983, LAMBDA, V2, P211	39	151	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					303	311		10.1016/0092-8674(92)90104-K	http://dx.doi.org/10.1016/0092-8674(92)90104-K			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1322248				2022-12-24	WOS:A1992JE75700013
J	HOSFORD, DA; CLARK, S; CAO, Z; WILSON, WA; LIN, FH; MORRISETT, RA; HUIN, A				HOSFORD, DA; CLARK, S; CAO, Z; WILSON, WA; LIN, FH; MORRISETT, RA; HUIN, A			THE ROLE OF GABA(B) RECEPTOR ACTIVATION IN ABSENCE SEIZURES OF LETHARGIC (IH/IH) MICE	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; PETIT-MAL EPILEPSY; THALAMIC NUCLEI; CALCIUM CURRENT; NEURONS; CAT; ELECTROPHYSIOLOGY; ETHOSUXIMIDE; POTENTIALS; RELEASE	Lethargic (lh/lh) mice, which function as an animal model of absence seizures, have spontaneous seizures that have behavioral and electrographic features and anticonvulsant sensitivity similar to those of human absence seizures. Antagonists of the gamma-aminobutyric acid(B) (GABA(B)) receptor suppressed these seizures in lethargic mice, whereas agonists of GABA(B) receptors exacerbated them. Furthermore, GABA(B) receptor binding and synaptically evoked GABA(B) receptor-mediated inhibition of N-methyl-D-aspartate responses were selectively increased in lh/lh mice. Therefore, enhanced GABA(B) receptor-mediated synaptic responses may underlie absence seizures in lh/lh mice, and GABA(B) receptor antagonists hold promise as anticonvulsants for absence seizures.	UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705	University of Nebraska System; University of Nebraska Medical Center; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	HOSFORD, DA (corresponding author), DUKE UNIV,MED CTR,DEPT MED NEUROL,DURHAM,NC 27710, USA.			Clark PharmBS PhD, Suzanne/0000-0002-7018-1113				BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; CLARK S, 1991, EPILEPSIA S3, V32, P66; Cochran W.G, 1957, STAT METHODS, V6th ed; COULTER DA, 1989, ANN NEUROL, V25, P582, DOI 10.1002/ana.410250610; CRUNELLI V, 1988, J PHYSIOL-LONDON, V399, P153; CRUNELLI V, 1991, TRENDS NEUROSCI, V14, P16, DOI 10.1016/0166-2236(91)90178-W; CRUNELLI V, 1989, J PHYSIOL-LONDON, V413, P543, DOI 10.1113/jphysiol.1989.sp017668; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DESCHENES M, 1984, J NEUROPHYSIOL, V51, P1196, DOI 10.1152/jn.1984.51.6.1196; Dickie MM, 1964, MOUSE NEWS LETT, V30, P31; DUNG HC, 1971, TEX REP BIOL MED, V29, P273; HELLER AH, 1983, EPILEPSIA, V25, P25; HOSFORD D A, 1991, Society for Neuroscience Abstracts, V17, P170; JASPER HH, 1946, P ASS RES NERV MENT, V26, P272; KABRA PM, 1977, CLIN CHEM, V23, P1284; KARLSSON G, 1990, GABAB RECEPTORS IN MAMMALIAN FUNCTION, P349; KELLY KM, 1990, NEUROSCI LETT, V116, P233, DOI 10.1016/0304-3940(90)90416-7; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; KRALL RL, 1978, EPILEPSIA, V19, P409, DOI 10.1111/j.1528-1157.1978.tb04507.x; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIRSKY AF, 1986, J CLIN NEUROPHYSIOL, V3, P179; MORRISETT RA, 1991, J NEUROSCI, V11, P203; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Noebels J L, 1986, Adv Neurol, V44, P97; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; PELLEGRINI A, 1979, EXP NEUROL, V66, P285, DOI 10.1016/0014-4886(79)90081-5; ROY JP, 1984, J NEUROPHYSIOL, V51, P1220, DOI 10.1152/jn.1984.51.6.1220; SHEN C, 1985, J NEUROSCI, V5, P2696; Sidman RL, 1965, CATALOG NEUROLOGICAL, P34; SNEAD OC, 1992, EUR J PHARMACOL, V213, P343, DOI 10.1016/0014-2999(92)90623-C; SNEAD OC, 1991, SOC NEUR ABSTR, V17, P506; SNEAD OC, 1991, EPILEPSIA S3, V32, P66; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; TAYLOR SM, 1985, EUR J PHARMACOL, V118, P163, DOI 10.1016/0014-2999(85)90675-2; WALDMEIER PC, 1988, N-S ARCH PHARMACOL, V337, P289; WILLIAMS D, 1953, BRAIN, V76, P50, DOI 10.1093/brain/76.1.50; YEH GC, 1989, P NATL ACAD SCI USA, V86, P8157, DOI 10.1073/pnas.86.20.8157	38	289	295	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					398	401		10.1126/science.1321503	http://dx.doi.org/10.1126/science.1321503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321503				2022-12-24	WOS:A1992JD67400037
J	KANO, M; REXHAUSEN, U; DREESSEN, J; KONNERTH, A				KANO, M; REXHAUSEN, U; DREESSEN, J; KONNERTH, A			SYNAPTIC EXCITATION PRODUCES A LONG-LASTING REBOUND POTENTIATION OF INHIBITORY SYNAPTIC SIGNALS IN CEREBELLAR PURKINJE-CELLS	NATURE			English	Article							GABAA RECEPTOR FUNCTION; PATCH-CLAMP; TERM DEPRESSION; PLASTICITY; DENDRITES; SYNAPSES; NEURONS; INVITRO; SLICES; RAT	PERSISTENT changes in synaptic efficacy are thought to underlie the formation of learning and memory in the brain 1. High-frequency activation of an afferent excitatory fibre system can induce long-term potentiation 2,3, and conjunctive activation of two distinct excitatory synaptic inputs to the cerebellar Purkinje cells can lead to long-term depression of the synaptic activity of one of the inputs 4. Here we report a new form of neural plasticity in which activation of an excitatory synaptic input can induce a potentiation of inhibitory synaptic signals to the same cell. In cerebellar Purkinje cells stimulation of the excitatory climbing fibre synapses is followed by a long-lasting (up to 75 min) potentiation of gamma-aminobutyric acid A (GABA(A)) receptor-mediated inhibitory postsynaptic currents (i.p.s.cs), a phenomenon that we term rebound potentiation. Using whole-cell patch-clamp recordings in combination with fluorometric video imaging of intracellular calcium ion concentration, we find that a climbing fibre-induced transient increase in postsynaptic calcium concentration triggers the induction of rebound potentiation: Because the response of Purkinje cells to bath-applied exogenous GABA is also potentiated after climbing fibre-stimulation with a time course similar to that of the rebound potentiation of i.p.s.cs, we conclude that the potentiation is caused by a calcium-dependent upregulation of postsynaptic GABA(A) receptor function. We propose that rebound potentiation is a mechanism by which in vivo block of climbing fibre activity induces an increase in excitability in Purkinje cells 5,6. Moreover, rebound potentiation of i.p.s.cs is a cellular mechanism which, in addition to the long-term depression of parallel fibre synaptic activity 4, may have an important role for motor learning in the cerebellum.	MAX PLANCK INST BIOPHYS CHEM,FASSBERG,W-3400 GOTTINGEN,GERMANY	Max Planck Society				Kano, Masanobu/0000-0002-0725-3292				BENEDETTI F, 1984, EXP BRAIN RES, V55, P368; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; CHEUN J E, 1991, Society for Neuroscience Abstracts, V17, P602; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; ECCLES JC, 1966, J PHYSIOL-LONDON, V182, P268, DOI 10.1113/jphysiol.1966.sp007824; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISON NL, 1989, NEUROSCI LETT, V105, P137, DOI 10.1016/0304-3940(89)90025-6; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1990, Neuroreport, V1, P129; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KNOPFEL T, 1991, EUR J NEUROSCI, V3, P343, DOI 10.1111/j.1460-9568.1991.tb00821.x; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KONNERTH A, IN PRESS P NATN ACAD; KUBA K, 1990, PROG NEUROBIOL, V34, P197, DOI 10.1016/0301-0082(90)90012-6; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LLANO I, 1991, NEURON, V7, P577, DOI 10.1016/0896-6273(91)90370-F; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MARCHENKO SM, 1991, BRAIN RES, V546, P355, DOI 10.1016/0006-8993(91)91502-R; MONTAROLO PG, 1982, J PHYSIOL-LONDON, V332, P187, DOI 10.1113/jphysiol.1982.sp014409; MOUGINOT D, 1991, J PHYSL, V427, P109; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659	32	312	315	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					601	604		10.1038/356601a0	http://dx.doi.org/10.1038/356601a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1313949				2022-12-24	WOS:A1992HP03100048
J	PATERSON, Y				PATERSON, Y			MAPPING ANTIBODY-BINDING SITES ON PROTEIN ANTIGENS	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; CYTOCHROME-C; COMPLEX; EXCHANGE; NMR	The large surfaces of protein antigens that interact with antibody-combining sites can be determined using deuterium-exchange labelling and two-dimensional H-1 nuclear magnetic resonance (NMR). This technique may also be applied to other protein-protein interactions to identify key residues that contribute to the affinity.			PATERSON, Y (corresponding author), UNIV PENN, SCH MED, DEPT MICROBIOL, 209 JOHNSON PAVIL, PHILADELPHIA, PA 19104 USA.			Paterson, Yvonne/0000-0002-9406-4958				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENTLEY GA, 1989, COLD SH Q B, V54, P239; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; MARKLEY JL, 1989, METHOD ENZYMOL, V176, P12; MYLVAGANAM SE, 1991, J MOL BIOL, V221, P455, DOI 10.1016/0022-2836(91)80066-4; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATERSON Y, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P177; PATERSON Y, 1990, SCIENCE, V249, P755, DOI 10.1126/science.1697101; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	14	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					456	457		10.1038/356456a0	http://dx.doi.org/10.1038/356456a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1313552				2022-12-24	WOS:A1992HL83000072
J	OPPENHEIMER, S; HACHINSKI, V				OPPENHEIMER, S; HACHINSKI, V			COMPLICATIONS OF ACUTE STROKE	LANCET			English	Article							INFARCTION		JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON N6A 3K7,ONTARIO,CANADA	Johns Hopkins University; Western University (University of Western Ontario)	OPPENHEIMER, S (corresponding author), JOHNS HOPKINS UNIV HOSP,CEREBROVASC PROGRAM,MEYER 5-181,600 N WOLFE ST,BALTIMORE,MD 21205, USA.							BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; BLACK SE, 1982, CAN J NEUROL SCI, V9, P291; BRUCE DA, 1979, CEREBROVASC DIS, P191; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; DUTHA AJ, 1987, STROKE, V18, P386; GHANDHAVADI B, 1988, ARCH PHYS MED REHAB, V69, P130; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; Hachinski V, 1985, ACUTE STROKE; HART RG, 1986, STROKE, V17, P586, DOI 10.1161/01.STR.17.4.586; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; HORNER J, 1988, NEUROLOGY, V38, P1359; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; LODDER J, 1988, STROKE, V19, P1482, DOI 10.1161/01.STR.19.12.1482; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; NORRIS JW, 1986, BMJ-BRIT MED J, V292, P21, DOI 10.1136/bmj.292.6512.21; OPPENHEIMER SM, 1991, BRAIN RES, V550, P115, DOI 10.1016/0006-8993(91)90412-O; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1015; POUNGVARIN N, 1987, NEW ENGL J MED, V316, P1229, DOI 10.1056/NEJM198705143162001; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; STARKSTEIN SE, 1988, STROKE, V19, P1491, DOI 10.1161/01.STR.19.12.1491; WARLOW C, 1976, BRIT MED J, V1, P1178, DOI 10.1136/bmj.1.6019.1178; 1984, STROKE, V5, P779	25	96	100	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					721	724		10.1016/0140-6736(92)90607-5	http://dx.doi.org/10.1016/0140-6736(92)90607-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347591				2022-12-24	WOS:A1992HK32000012
J	HUANG, YQ; LI, JJ; RUSH, MG; POIESZ, BJ; NICOLAIDES, A; JACOBSON, M; ZHANG, WG; COUTAVAS, E; ABBOTT, MA; FRIEDMANKIEN, AE				HUANG, YQ; LI, JJ; RUSH, MG; POIESZ, BJ; NICOLAIDES, A; JACOBSON, M; ZHANG, WG; COUTAVAS, E; ABBOTT, MA; FRIEDMANKIEN, AE			HPV-16-RELATED DNA-SEQUENCES IN KAPOSIS-SARCOMA	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ENDEMIC AFRICAN; HOMOSEXUAL MEN; CELLS; ASSOCIATION; CANCER; GROWTH; AMPLIFICATION; VIRUS; RISK	In the USA, Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS-KS) is ten times more common in homosexual or bisexual men than in heterosexual men with AIDS. One explanation for this finding is that AIDS-KS may be caused by an infectious agent. Because there is a high incidence of human papillomavirus (HPV) infection, especially HPV-16, in homosexual men, we have sought HPV DNA sequences in Kaposi's sarcoma. We used the polymerase chain reaction with a primer pair specific for the highly conserved E6 region of HPV-16 to detect HPV-16 homologous DNA fragments in tumour tissues from 97 patients with KS and in KS-derived cell cultures. HPV DNA sequences were found in 11 of 69 KS skin tumours from homosexual men with AIDS-KS, in 3 of 11 KS biopsy specimens from homosexual men who had no clinical or laboratory evidence of HIV-infection, and in 5 of 17 KS skin lesions from HIV-1-negative elderly men and women with classic KS. The same primer pair amplified HPV-16 homologous fragments from two different continuous cell cultures derived from pleural effusion fluid of patients with pulmonary AIDS-KS and two continuous cell cultures derived from KS skin lesions. The findings suggest that HPV-16-related DNA sequences are associated with different forms of KS and may have a role in the pathogenesis of this neoplasm.	NYU MED CTR, DEPT MICROBIOL, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT DERMATOL, NEW YORK, NY 10016 USA; NYU, SCH MED, NEW YORK, NY 10003 USA; SUNY HLTH SCI CTR, DEPT MED, DIV ONCOL, SYRACUSE, NY USA	New York University; New York University; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Coutavas, Elias/0000-0003-4904-0081; Friedman Kien, Alvin/0000-0002-5854-2852				ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; AMBINDER RF, 1987, J INFECT DIS, V156, P193, DOI 10.1093/infdis/156.1.193; ASHINOFF R, 1991, ARCH DERMATOL, V127, P1813, DOI 10.1001/archderm.127.12.1813; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; BAYLEY AC, 1985, LANCET, V1, P359; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BIGGAR RJ, 1985, J NATL CANCER I, V74, P793; BOOTH M, 1989, LANCET, V1, P616; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOVI PD, 1986, CANCER RES, V46, P6333; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FOLKMAN J, 1990, AIDS RES HUM RETROV, V6, P107; FRAZER IH, 1986, LANCET, V2, P657; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; FRIEDMANKIEN AE, 1990, J AM ACAD DERMATOL, V22, P1237, DOI 10.1016/0190-9622(90)70169-I; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LI JJ, 1990, LANCET, V335, P1590; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; NICKOLOFF BJ, 1992, LANCET, V339, P548, DOI 10.1016/0140-6736(92)90364-9; NICKOLOFF BJ, 1989, SCIENCE, V243, P1736, DOI 10.1126/science.2564703; SAFAI B, 1981, CANCER, V31, P3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCINICARIELLO F, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93446-G; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990	34	113	115	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	1992	339	8792					515	518		10.1016/0140-6736(92)90338-4	http://dx.doi.org/10.1016/0140-6736(92)90338-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346878				2022-12-24	WOS:A1992HF63100003
J	DEVRIES, C; ESCOBEDO, JA; UENO, H; HOUCK, K; FERRARA, N; WILLIAMS, LT				DEVRIES, C; ESCOBEDO, JA; UENO, H; HOUCK, K; FERRARA, N; WILLIAMS, LT			THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR	SCIENCE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN; AMINO-ACID; FAMILY; EXPRESSION; SEQUENCE; SECRETE; FLT	The fms-like tyrosine kinase (Flt) is a transmembrane receptor in the tyrosine kinase family. Expression of flt complementary DNA in COS cells conferred specific, high-affinity binding of vascular endothelial growth factor, also known as vascular permeability factor (VEGF-VPF), a factor that induces vascular permeability when injected in the guinea pig skin and stimulates endothelial cell proliferation. Expression of Flt in Xenopus laevis oocytes caused the oocytes to release calcium in response to VEGF-VPF. These findings show that flt encodes a receptor for VEGF-VPF.	UNIV CALIF SAN FRANCISCO,DEPT MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Roche Holding; Genentech			Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249	NHLBI NIH HHS [R01 HL-32898, P01 HL-43821] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; CRISCUOLO GR, 1988, J NEUROSURG, V69, P254, DOI 10.3171/jns.1988.69.2.0254; DEVRIES CAM, UNPUB; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEUNG DW, 1991, METHOD ENZYMOL, V198, P391; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OLANDER V, 1991, BIOCHEM BIOPH RES CO, V175, P68; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SATOH H, 1987, JPN J CANCER RES, V78, P772; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1990, CANCER RES, V50, P1774; SHIBUYA M, 1990, ONCOGENE, V5, P519; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; YARDEN Y, 1988, ANN REV BIOCH, V57	31	1830	1996	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					989	991		10.1126/science.1312256	http://dx.doi.org/10.1126/science.1312256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1312256				2022-12-24	WOS:A1992HE60500042
J	BENGAL, E; RANSONE, L; SCHARFMANN, R; DWARKI, VJ; TAPSCOTT, SJ; WEINTRAUB, H; VERMA, IM				BENGAL, E; RANSONE, L; SCHARFMANN, R; DWARKI, VJ; TAPSCOTT, SJ; WEINTRAUB, H; VERMA, IM			FUNCTIONAL ANTAGONISM BETWEEN C-JUN AND MYOD PROTEINS - A DIRECT PHYSICAL ASSOCIATION	CELL			English	Article							LEUCINE ZIPPER DOMAIN; DNA-BINDING PROTEINS; MYOGENIC DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; AUTO-REGULATION; FOS; CELLS; MYC; ENHANCER; ELEMENT	The product of the proto-oncogene Jun inhibits myogenesis. Constitutive expression of Jun in myoblasts interferes with the expression and the function of MyoD protein. In transient transfection assays Jun inhibits transactivation of the MyoD promoter, the muscle creatine kinase enhancer, and a reporter gene linked to MyoD DNA-binding sites. Conversely, MyoD suppresses the transactivation by Jun of genes linked to an AP-1 site. We demonstrate that both in vivo and in vitro MyoD and Jun proteins physically interact. Mutational analysis suggests that this interaction occurs via the leucine zipper domain of Jun and the helix-loop-helix region of MyoD.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	BENGAL, E (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.		scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X	NATIONAL CANCER INSTITUTE [F32CA008585] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08585-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT G, 1990, CELL, V62, P1189; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	44	409	411	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					507	519		10.1016/0092-8674(92)90187-H	http://dx.doi.org/10.1016/0092-8674(92)90187-H			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310896				2022-12-24	WOS:A1992HD39800011
J	WONG, YH; CONKLIN, BR; BOURNE, HR				WONG, YH; CONKLIN, BR; BOURNE, HR			GZ-MEDIATED HORMONAL INHIBITION OF CYCLIC-AMP ACCUMULATION	SCIENCE			English	Article							NUCLEOTIDE-BINDING PROTEINS; PERTUSSIS TOXIN; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; MOLECULAR-CLONING; ADP-RIBOSYLATION; PHOSPHOLIPASE-C; GS-ALPHA; RECEPTOR; SITE	Hormones inhibit synthesis of adenosine 3',5' monophosphate (cAMP) in most cells via receptors coupled to pertussis toxin (PTX)-sensitive guanine nucleotide-binding (G) proteins. Mutationally activated alpha-subunits of G(i2) (alpha(i2)) constitutively inhibit cAMP accumulation when transfected into cells. Cells have now been transfected with mutant alpha-subunits of four other G proteins-G(z), a PTX-insensitive G protein of unknown function, and G(i1), G(i3), and G(o), which are PTX-sensitive. Mutant alpha(z), alpha(i1), and alpha(i3) inhibited cAMP accumulation but alpha(o) did not. Moreover, expression of wild-type alpha(z) produced cells in which PTX did not block hormonal inhibition of cAMP accumulation. Thus, G(z) can trigger an effector pathway in response to hormone receptors that ordinarily interact with PTX-sensitive G(i) proteins.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DIAZLAVIADA I, 1991, J BIOL CHEM, V266, P1170; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HINTON DR, 1990, J NEUROSCI, V10, P2763; HSU WH, 1990, J BIOL CHEM, V265, P11220; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES SB, 1991, MOL PHARMACOL, V39, P239; KATADA T, 1986, J BIOL CHEM, V261, P5215; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAHAN LC, 1991, MOL PHARMACOL, V440, P1; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAMBI P, 1988, BIOCHEM J, V254, P449, DOI 10.1042/bj2540449; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PARKER EM, 1991, J BIOL CHEM, V266, P519; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; WONG Y, UNPUB; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	36	250	254	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					339	342		10.1126/science.1347957	http://dx.doi.org/10.1126/science.1347957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1347957				2022-12-24	WOS:A1992GZ69500045
J	SPEISER, DE; STUBI, U; ZINKERNAGEL, RM				SPEISER, DE; STUBI, U; ZINKERNAGEL, RM			EXTRATHYMIC POSITIVE SELECTION OF ALPHA-BETA-T-CELL PRECURSORS IN NUDE-MICE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; BONE-MARROW TRANSPLANTATION; CYTOLYTIC LYMPHOCYTE-T; ANTIGEN RECEPTOR; NEGATIVE SELECTION; SELF-RECOGNITION; IMMUNE-RESPONSE; THYMUS GRAFTS; VIRUS; SPECIFICITY	T LYMPHOCYTES expressing alpha-beta-T-cell receptors with sufficient affinity to major histocompatibility complex (MHC) molecules expressed on thymus epithelial cells are positively selected and mature to functional T cells 1-6. But several studies have demonstrated that athymic nude mice 7-9 grafted with MHC-incompatible thymuses developed T cells specific for nude host rather than thymic MHC 10-14. We examined this paradox by analysing the specificity of T lymphocytes derived from nude mice. We report here that nude T lymphocyte precursors transferred to allogeneic SCID (severe combined immunodeficiency) mice with a functioning thymus (but lacking T or B cells 15-17) generated host MHC-restricted effector T cells but also contained T cells restricted to donor MHC. If nude T cells were depleted from nude lymphohaemopoietic donor cells before or after transfer, only host MHC-specific T cells matured. The results may explain the unusual MHC specificities of nude T lymphocytes described in earlier studies 10-14 and demonstrate two separate differentiation steps: in nude mice, T cells may be positively. selected for self-MHC restriction specificity extrathymically; then a functional thymus is required for efficient T cell maturation.			SPEISER, DE (corresponding author), UNIV HOSP ZURICH,INST PATHOL,EXPTL PATHOL LAB,CH-8091 ZURICH,SWITZERLAND.		Speiser, Daniel E./F-2173-2013					ANDO I, 1981, NATURE, V289, P494, DOI 10.1038/289494a0; BEVAN MJ, 1978, IMMUNOL REV, V42, P4; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CHARAN S, 1986, J IMMUNOL, V136, P3057; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; GILLIS S, 1979, J EXP MED, V149, P1460, DOI 10.1084/jem.149.6.1460; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HAMAOKA T, 1973, J EXP MED, V137, P1393, DOI 10.1084/jem.137.6.1393; HEDRICK SM, 1979, J EXP MED, V150, P646, DOI 10.1084/jem.150.3.646; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; HUNIG T, 1980, J EXP MED, V152, P688, DOI 10.1084/jem.152.3.688; ISHIKAWA H, 1980, J EXP MED, V151, P965, DOI 10.1084/jem.151.4.965; KAST WM, 1984, J EXP MED, V160, P1752, DOI 10.1084/jem.160.6.1752; KEEVER CA, 1989, BLOOD, V73, P1340; Kindred B, 1979, Prog Allergy, V26, P137, DOI 10.1159/000314466; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KRUISBEEK AM, 1981, J IMMUNOL, V127, P2168; LAKE JP, 1980, J EXP MED, V152, P1805, DOI 10.1084/jem.152.6.1805; LAKE JP, 1991, CELL IMMUNOL, V135, P259, DOI 10.1016/0008-8749(91)90270-L; LONGO DL, 1985, P NATL ACAD SCI USA, V82, P5900, DOI 10.1073/pnas.82.17.5900; LOOR F, 1976, EUR J IMMUNOL, V6, P663, DOI 10.1002/eji.1830060914; MACDONALD HR, 1987, J EXP MED, V166, P195, DOI 10.1084/jem.166.1.195; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARYANSKI JL, 1981, J IMMUNOL, V126, P871; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PANTELOURIS EM, 1971, IMMUNOLOGY, V20, P247; RAFF MC, 1973, NATURE, V246, P350, DOI 10.1038/246350a0; ROCHA B, 1990, EUR J IMMUNOL, V20, P919, DOI 10.1002/eji.1830200430; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SOIFFER RJ, 1990, BLOOD, V75, P2076; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; STUTMAN O, 1978, IMMUNOL REV, V42, P138, DOI 10.1111/j.1600-065X.1978.tb00261.x; Wortis H H, 1974, Contemp Top Immunobiol, V3, P243; ZINKERNAGEL RM, 1988, J EXP MED, V168, P1187, DOI 10.1084/jem.168.3.1187; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1979, J EXP MED, V150, P693, DOI 10.1084/jem.150.3.693; ZINKERNAGEL RM, 1980, J EXP MED, V151, P376, DOI 10.1084/jem.151.2.376	46	40	40	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					170	172		10.1038/355170a0	http://dx.doi.org/10.1038/355170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1346064				2022-12-24	WOS:A1992GY62900061
J	SIEGFRIED, E; CHOU, TB; PERRIMON, N				SIEGFRIED, E; CHOU, TB; PERRIMON, N			WINGLESS SIGNALING ACTS THROUGH ZESTE-WHITE 3, THE DROSOPHILA HOMOLOG OF GLYCOGEN-SYNTHASE KINASE-3, TO REGULATE ENGRAILED AND ESTABLISH CELL FATE	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; PROTEIN-KINASE; SPATIAL-DISTRIBUTION; MULTIPLE FUNCTIONS; MOLECULAR-CLONING; LETHAL MUTATIONS; NERVOUS-SYSTEM; PATCHED GENE; EXPRESSION	Intrasegmental patterning in the Drosophila embryo is regulated by cell-cell communication. One of the signaling pathways that operates to specify positional information throughout the segment is mediated by the wingless (wg) protein, which is the homolog of the proto-oncogene Wnt-1. The early role of wg is to stabilize engrailed (en) expression by initiating a phase of en autoregulation in the adjacent more posterior cells. Here, we report that the segment polarity gene zeste-white 3 (zw3; also known as shaggy) acts as a repressor of en autoregulation. Genetic epistasis experiments indicate that wg signaling operates by inactivating the zw3 repression of en autoactivation. In addition, we demonstrate that zw3 encodes the Drosophila homolog of mammalian glycogen synthase kinase-3.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	SIEGFRIED, E (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.		Chou, Tze-Bin/S-1188-2017	Chou, Tze-Bin/0000-0003-2453-0164; Perrimon, Norbert/0000-0001-7542-472X				AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHOU TB, 1992, GENETICS, V131, P643; DEGROOT RP, 1992, IN PRESS ONCOGENE; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, IN PRESS NATURE; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; GAY NJ, 1988, NUCLEIC ACIDS RES, V16, P6637, DOI 10.1093/nar/16.14.6637; GERGEN J P, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P49; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1992, IN PRESS DEVELOPMENT; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBERTSON HM, 1988, GENETICS, V118, P461; SAKSELA K, 1992, ONCOGENE, V7, P347; Sambrook J., 1989, MOL CLONING LAB MANU; SHANNON MP, 1972, GENETICS, V72, P615; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1988, DEVELOPMENT, V103, P391; SIMPSON P, 1989, DEVELOPMENT, V106, P57; Spradling AC, 1986, P ELEMENT MEDIATED T, P175; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	74	368	375	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1167	1179		10.1016/S0092-8674(05)80065-0	http://dx.doi.org/10.1016/S0092-8674(05)80065-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335365				2022-12-24	WOS:A1992KE60400011
J	ROBERTS, RW; CROTHERS, DM				ROBERTS, RW; CROTHERS, DM			STABILITY AND PROPERTIES OF DOUBLE AND TRIPLE HELICES - DRAMATIC EFFECTS OF RNA OR DNA BACKBONE COMPOSITION	SCIENCE			English	Article							RIBONUCLEASE-H; HYBRID; INHIBITION; OLIGONUCLEOTIDE; TRANSCRIPTION; POLYMERASE; PROMOTER; BINDING; R(GCG)D(TATACGC); CLEAVAGE	Studies of a series of short oligonucleotide double and triple helices containing either all RNA, all DNA, or a mixture of the two show strand-dependent variation in their stability and structure. The variation in stability for both groups falls over a range of greater than 10 kilocalories per mole. In forming the triple helix, RNA is favored on both pyrimidine strands, whereas DNA is favored on the purine strand. In general, relatively unstable duplexes form particularly stable triplexes and vice versa. Structural data indicate that the strands in hybrid helices adopt a conformation that is intermediate between molecules containing all DNA and all RNA. Thus, RNA-DNA hybrids were not forced into the conformation of the RNA (A-form). The provocative stability of the triplex with an RNA third strand + DNA duplex points to novel antisense strategies and opens the possibility of an in vivo role of these structures. Overall, the data emphasize the fundamental role of sugars in determining the properties of nucleic acid complexes.			ROBERTS, RW (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NIAMS NIH HHS [GAR21966] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOTT S, 1986, J MOL BIOL, V188, P631, DOI 10.1016/S0022-2836(86)80011-0; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; CHAMBERLIN MJ, 1965, FED PROC, V24, P1446; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2435, DOI 10.1021/bi00432a014; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; GRAY DM, 1980, NUCLEIC ACIDS RES, V8, P3695, DOI 10.1093/nar/8.16.3695; HAASNOOT CAG, 1983, J BIOMOL STRUCT DYN, V1, P131, DOI 10.1080/07391102.1983.10507430; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEHRMAN EA, 1977, NUCLEIC ACIDS RES, V4, P1381, DOI 10.1093/nar/4.5.1381; MACAYA R, 1992, J MOL BIOL, V225, P755, DOI 10.1016/0022-2836(92)90399-5; MACAYA RF, 1992, J AM CHEM SOC, V114, P781, DOI 10.1021/ja00028a067; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MELLEMA JR, 1983, NUCLEIC ACIDS RES, V11, P5717, DOI 10.1093/nar/11.16.5717; MILLER HI, 1973, J BIOL CHEM, V248, P2621; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROBERTS RL, UNPUB; ROBERTS RW, 1991, P NATL ACAD SCI USA, V88, P9397, DOI 10.1073/pnas.88.21.9397; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	39	444	475	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1463	1466		10.1126/science.1279808	http://dx.doi.org/10.1126/science.1279808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279808				2022-12-24	WOS:A1992JZ62500022
J	QUINTON, PM; REDDY, MM				QUINTON, PM; REDDY, MM			CONTROL OF CFTR CHLORIDE CONDUCTANCE BY ATP LEVELS THROUGH NONHYDROLYTIC BINDING	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CHANNEL	SITE-SPECIFIC mutation1 and membrane reconstitution2 experiments provide compelling evidence that the product of the gene which is at fault in the disease cystic fibrosis, termed the cystic fibrosis transmembrane conductance regulator (CFTR)3, is a small-conductance chloride channel activated by phosphorylation4. As transport of chloride ions is passive, the predicted presence of two nucleotide-binding domains in CFTR seems as puzzling as a report5 that ATP hydrolysis is essential to activate the channel. We now find that in the sweat duct, which expresses high levels of CFTR6 and has a very high Cl- conductance7, intracellular concentrations of ATP must be about normal (5 mM)8 for activation of this conductance, apparently by a non-hydrolytic, perhaps allosteric, mechanism. This passive dependence on ATP should mean that even a modest depletion of cell energy levels will significantly lower the energy demands of electrolyte transport by decreasing chloride conductance. We believe this direct coupling between cellular ATP levels and chloride channel activity is an adaptive mechanism to protect the tissue from damage resulting from excessive energy depletion9.			QUINTON, PM (corresponding author), UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521, USA.							ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ATKINSON DE, 1977, METABOLISM ITS REGUL; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; KARTNER N, IN PRESS NATURE GENE; QUINTON PM, 1991, ADV EXP MED BIOL, V290, P159; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	17	164	165	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					79	81		10.1038/360079a0	http://dx.doi.org/10.1038/360079a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1279436				2022-12-24	WOS:A1992JW71700060
J	ROWLAND, AS; BAIRD, DD; WEINBERG, CR; SHORE, DL; SHY, CM; WILCOX, AJ				ROWLAND, AS; BAIRD, DD; WEINBERG, CR; SHORE, DL; SHY, CM; WILCOX, AJ			REDUCED FERTILITY AMONG WOMEN EMPLOYED AS DENTAL ASSISTANTS EXPOSED TO HIGH-LEVELS OF NITROUS-OXIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPRAGUE-DAWLEY RATS; SPONTANEOUS-ABORTION; DELAYED CONCEPTION; CIGARETTE-SMOKING; ANESTHETIC-GASES; PREGNANCY; EXPOSURES; WORKPLACE; DENTISTS; TOXICITY	Background. Fertility is reduced in female rats exposed to levels of nitrous oxide similar to those found in some dental offices. Epidemiologic studies have suggested an association between exposure to mixed anesthetic gases and impaired fertility. We investigated the effects of occupational exposure to nitrous oxide on the fertility of female dental assistants. Methods. Screening questionnaires were mailed to 7000 female dental assistants, ages 18 to 39, registered by the California Department of Consumer Affairs. Sixty-nine percent responded. Four hundred fifty-nine women were determined to be eligible, having become pregnant during the previous four years for reasons unrelated to the failure of birth control, and 91 percent of these women completed telephone interviews. Detailed information was collected on exposure to nitrous oxide and fertility (measured by the number of menstrual cycles without contraception that the women required to become pregnant). Results. After controlling for covariates, we found that women exposed to high levels of nitrous oxide were significantly less fertile than women who were unexposed or exposed to lower levels of nitrous oxide. The effect was evident only in the 19 women with five or more hours of exposure per week. These women were only 41 percent (95 percent confidence interval, 23 to 74 percent; P<0.003) as likely as unexposed women to conceive during each menstrual cycle. Conclusions. Occupational exposure to high levels of nitrous oxide may adversely affect a woman's ability to become pregnant.	NIEHS,DIV BIOMETRY & RISK ASSESSMENT,STAT & BIOMATH BRANCH,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	ROWLAND, AS (corresponding author), NIEHS,EPIDEMIOL BRANCH,A3-05,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Wilcox, Allen J/C-7723-2019; Baird, Donna D/D-5214-2017; Rowland, Andy/AAH-4049-2019	Wilcox, Allen J/0000-0002-3376-1311; Baird, Donna D/0000-0002-5544-2653; Weinberg, Clarice/0000-0002-7713-8556				AXELSSON G, 1982, INT J EPIDEMIOL, V11, P250, DOI 10.1093/ije/11.3.250; BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BAIRD DD, 1986, AM J EPIDEMIOL, V124, P470, DOI 10.1093/oxfordjournals.aje.a114417; BARLOW SM, 1982, REPRODUCTIVE HAZARDS, P386; COATE WB, 1979, ANESTHESIOLOGY, V50, P310, DOI 10.1097/00000542-197904000-00006; COHEN EN, 1971, ANESTHESIOLOGY, V35, P343; COHEN EN, 1980, J AM DENT ASSOC, V101, P21, DOI 10.14219/jada.archive.1980.0345; COHEN EN, 1975, J AM DENT ASSOC, V90, P1291, DOI 10.14219/jada.archive.1975.0270; FERSTANDIG LL, 1978, ANESTH ANALG, V57, P328; FUJINAGA M, 1991, TERATOLOGY, V43, P151, DOI 10.1002/tera.1420430207; HENRY RJ, 1991, J DENT RES, V70, P1286, DOI 10.1177/00220345910700091001; JASTAK JT, 1989, INT ANESTHESIOL CLIN, V27, P92, DOI 10.1097/00004311-198902720-00005; KNILLJON.RP, 1972, LANCET, V1, P1326; KUGEL G, 1989, Journal of Dental Research, V68, P313; Kugel G, 1990, Anesth Prog, V37, P176; LEMASTERS GK, 1989, J CLIN EPIDEMIOL, V42, P975, DOI 10.1016/0895-4356(89)90162-5; LINN S, 1982, JAMA-J AM MED ASSOC, V247, P629; MAZZE RI, 1988, TERATOLOGY, V38, P121, DOI 10.1002/tera.1420380204; MAZZE RI, 1987, BRIT J ANAESTH, V59, P1291, DOI 10.1093/bja/59.10.1291; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; McGlothlin JD, 1988, STUDY PROTOCOL CONTR; NUNN JF, 1985, NITROUS OXIDE N2O, P211; RACHOOTIN P, 1983, J OCCUP ENVIRON MED, V25, P394; ROYSTON BD, 1988, ANESTHESIOLOGY, V68, P213, DOI 10.1097/00000542-198802000-00006; SPENCE AA, 1977, JAMA-J AM MED ASSOC, V238, P955, DOI 10.1001/jama.238.9.955; SURUDA AJ, 1990, J OCCUP ENVIRON MED, V32, P682; SWEENEY B, 1985, BRIT MED J, V291, P567, DOI 10.1136/bmj.291.6495.567; TIETZE C, 1968, INT J FERTIL, V13, P385; VESSEY MP, 1978, ANAESTHESIA, V33, P430, DOI 10.1111/j.1365-2044.1978.tb12461.x; WEINBERG CR, 1989, AM J EPIDEMIOL, V129, P1072, DOI 10.1093/oxfordjournals.aje.a115211; WEINBERG CR, IN PRESS STAT MED; WHITCHER CE, 1977, J AM DENT ASSOC, V95, P763, DOI 10.14219/jada.archive.1977.0493; 1977, DHEW NIOSH77140 NAT; 1992, EMPLOY EARN, V39, P185; 1981, DENTISTS DESK REFERE, P23	35	221	222	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					993	997		10.1056/NEJM199210013271405	http://dx.doi.org/10.1056/NEJM199210013271405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1298226				2022-12-24	WOS:A1992JQ22500005
J	STODDARD, BL; KOSHLAND, DE				STODDARD, BL; KOSHLAND, DE			PREDICTION OF THE STRUCTURE OF A RECEPTOR PROTEIN COMPLEX USING A BINARY DOCKING METHOD	NATURE			English	Article							MALTOSE-BINDING; ASPARTATE; CHEMORECEPTOR; CHEMOTAXIS	TO validate procedures of rational drug design, it is important to develop computational methods that predict binding sites between a protein and a ligand molecule. Many small molecules have been tested using such programs, but examination of protein-protein and peptide-protein interactions has been sparse. We were able to test such applications once the structures of both the maltose-binding protein1 (MBP) and the ligand-binding domain of the aspartate receptor2, which binds MBP, became available. Here we predict the binding site of MBP to its receptor using a 'binary docking' technique in which two MBP octapeptide sequences containing mutations that eliminate maltose chemotaxis are independently docked to the receptor. The peptides in the docked solutions superimpose on their original positions in the structure of MBP and allow the formation of an MBP-receptor complex. The consistency of the computational and biological results supports this approach for predicting protein-protein and peptide-protein interactions.			STODDARD, BL (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV BIOCHEM,534 BARKER HALL,BERKELEY,CA 94720, USA.							FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; GASTEIGER J, 1978, TETRAHEDRON LETT, V34, P3181; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL D, 1991, PROTEIN-STRUCT FUNCT, V8, P195; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; MANSON MD, 1986, J BACTERIOL, V165, P34, DOI 10.1128/jb.165.1.34-40.1986; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202	12	67	68	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					774	776		10.1038/358774a0	http://dx.doi.org/10.1038/358774a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1324436				2022-12-24	WOS:A1992JK69900059
J	BERSTEIN, G; BLANK, JL; JHON, DY; EXTON, JH; RHEE, SG; ROSS, EM				BERSTEIN, G; BLANK, JL; JHON, DY; EXTON, JH; RHEE, SG; ROSS, EM			PHOSPHOLIPASE C-BETA-1 IS A GTPASE-ACTIVATING PROTEIN FOR GQ/11, ITS PHYSIOLOGICAL REGULATOR	CELL			English	Article								Purified M1 muscarinic cholinergic receptor and G(q/11) were coreconstituted in lipid vesicles. Addition of purified phospholipase C-beta-1 (PLC-beta-1) further stimulated the receptor-promoted steady-state GTPase activity of G(q/11) up to 20-fold. Stimulation depended upon receptor-mediated GTP-GDP exchange. Addition of PLC-beta-1 caused a rapid burst of hydrolysis of G(q/11)-bound GTP that was at least 50-fold faster than in its absence. Thus, PLC-beta-1 stimulates hydrolysis of G(q/11)-bound GTP and acts as a GTPase-activating protein (GAP) for its physiologic regulator, G(q/11). GTPase-stimulating activity was specific both for PLC-beta-1 and G(g/11). Such GAP activity by an effector coupled to a trimeric G protein can reconcile slow GTP hydrolysis by pure G proteins in vitro with fast physiologic deactivation of G protein-mediated signaling.	VANDERBILT UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	BERSTEIN, G (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				FIC NIH HHS [TW04475] Funding Source: Medline; NIGMS NIH HHS [GM30355] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASSEL D, 1977, J CYCLIC NUCL PROT, V3, P393; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1985, J BIOL CHEM, V260, P7927; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAY DC, 1985, J BIOL CHEM, V260, P5829; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAVON SE, 1984, J BIOL CHEM, V259, P6686; PARK D, 1992, IN PRESS J BIOL CHEM; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1991, BETA ADRENERGIC RECE, P125; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, J BIOL CHEM, V263, P14497; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	45	350	354	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					411	418		10.1016/0092-8674(92)90165-9	http://dx.doi.org/10.1016/0092-8674(92)90165-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322796				2022-12-24	WOS:A1992JH12400006
J	CENCIARELLI, C; HOU, D; HSU, KC; RELLAHAN, BL; WIEST, DL; SMITH, HT; FRIED, VA; WEISSMAN, AM				CENCIARELLI, C; HOU, D; HSU, KC; RELLAHAN, BL; WIEST, DL; SMITH, HT; FRIED, VA; WEISSMAN, AM			ACTIVATION-INDUCED UBIQUITINATION OF THE T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							ZETA-CHAIN; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; POLYPEPTIDE; DEGRADATION; COMPONENT; ANTIBODY; PROTEIN; SUBUNIT	The zeta-subunit of the T cell antigen receptor (TCR) exists primarily as a disulfide-linked homodimer. This receptor subunit is important in TCR-mediated signal transduction and is a substrate for a TCR-activated protein tyrosine kinase. The zeta-chain was found to undergo ubiquitination in response to receptor engagement. This posttranslational modification occurred in normal T cells and tumor lines. Both nonphosphorylated and phosphorylated zeta-molecules were modified, and at least one other TCR subunit, CD3-delta, was also ubiquitinated after activation of the receptor. These findings suggest an expanded role for ubiquitination in transmembrane receptor function.	NCI,DIV CANC BIOL DIAG & CTR,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York Medical College				Wiest, David/0000-0002-0792-3188				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CENCIARELLI C, UNPUB; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1990, New Biologist, V2, P227; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; Fried V A, 1989, Prog Clin Biol Res, V317, P733; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORI S, 1992, J BIOL CHEM, V267, P6429; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PATEL MD, 1987, J BIOL CHEM, V262, P5831; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	32	197	198	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					795	797		10.1126/science.1323144	http://dx.doi.org/10.1126/science.1323144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323144				2022-12-24	WOS:A1992JG85100034
J	WILLIAMS, ME; BRUST, PF; FELDMAN, DH; PATTHI, S; SIMERSON, S; MAROUFI, A; MCCUE, AF; VELICELEBI, G; ELLIS, SB; HARPOLD, MM				WILLIAMS, ME; BRUST, PF; FELDMAN, DH; PATTHI, S; SIMERSON, S; MAROUFI, A; MCCUE, AF; VELICELEBI, G; ELLIS, SB; HARPOLD, MM			STRUCTURE AND FUNCTIONAL EXPRESSION OF AN OMEGA-CONOTOXIN SENSITIVE HUMAN N-TYPE CALCIUM-CHANNEL	SCIENCE			English	Article							CHICK SENSORY NEURONS; CURRENTS; PEPTIDES; REQUIREMENTS; BINDING; PROBES; BRAIN; GVIA	N-type calcium channels are omega-conotoxin (omega-CgTx)-sensitive, voltage-dependent ion channels involved in the control of neurotransmitter release from neurons. Multiple subtypes of voltage-dependent calcium channel complexes exist, and it is the alpha-1 subunit of the complex that forms the pore through which calcium enters the cell. The primary structures of human neuronal calcium channel alpha-1B subunits were deduced by the characterization of overlapping complementary DNAs. Two forms (alpha-1B-1 and alpha-1B-2) were identified in human neuroblastoma (IMR32) cells and in the central nervous system, but not in skeletal muscle or aorta tissues. The alpha-1B-1 subunit directs the recombinant expression of N-type calcium channel activity when it is transiently co-expressed with human neuronal beta-2 and alpha-2b subunits in mammalian HEK293 cells. The recombinant channel was irreversibly blocked by omega-CgTx but was insensitive to dihydropyridines. The alpha-1B-1-alpha-2b-beta-2-transfected cells displayed a single class of saturable, high-affinity (dissociation constant = 55 pM) omega-CgTx binding sites. Co-expression of the beta-2 subunit was necessary for N-type channel activity, whereas the alpha-2b subunit appeared to modulate the expression of the channel. The heterogeneity of alpha-1B subunits, along with the heterogeneity of alpha-2 and beta-subunits, is consistent with multiple, biophysically distinct N-type calcium channels.	SIBIA INC,505 COAST BLVD S,LA JOLLA,CA 92037									AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; COHEN MW, 1991, J NEUROSCI, V11, P1032; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PLUMMER MR, 1991, NATURE, V351, P657, DOI 10.1038/351657a0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHER E, 1988, FEBS LETT, V235, P178, DOI 10.1016/0014-5793(88)81258-4; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STANLEY EF, 1991, J NEUROSCI, V11, P985; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	43	463	485	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					389	395		10.1126/science.1321501	http://dx.doi.org/10.1126/science.1321501			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321501				2022-12-24	WOS:A1992JD67400035
J	MASLANSKI, JA; LESHKO, L; BUSA, WB				MASLANSKI, JA; LESHKO, L; BUSA, WB			LITHIUM-SENSITIVE PRODUCTION OF INOSITOL PHOSPHATES DURING AMPHIBIAN EMBRYONIC MESODERM INDUCTION	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; EARLY XENOPUS EMBRYOS; LAEVIS EMBRYOS; ACTIVIN-A; IDENTIFICATION; DIACYLGLYCEROL; COMPETENCE; PATTERN; BRAIN; EGG	Mesoderm induction and body axis determination in frog (Xenopus) embryos are thought to involve growth factor-mediated cell-cell signaling, but the signal transduction pathways are unknown. Li+, which inhibits the polyphosphoinositide (PI) cycle signal transduction pathway in many cells, also disrupts axis determination and mesoderm induction. Amounts of the PI cycle-derived second messenger, inositol 1,4,5-trisphosphate, increased during mesoderm induction in normal embryos; addition of Li+ inhibited the embryonic inositol monophosphatase and reversed this increase. Embryonic PI cycle activity thus shows characteristics that indicate it may function in mesoderm induction and axis determination.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University					NICHD NIH HHS [HD27546, HD22879] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022879, R29HD022879, R01HD027546] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; AULT KT, UNPUB; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; COOKE J, 1991, CURR TOP DEV BIOL, V25, P45; DALE L, 1987, DEVELOPMENT, V100, P279; GERHART J, 1989, DEVELOPMENT, V107, P37; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GRUNZ H, 1986, ROUX ARCH DEV BIOL, V195, P467, DOI 10.1007/BF00375751; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; JONES EA, 1987, DEVELOPMENT, V101, P557; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; MASLANSKI JA, UNPUB; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; SHEPARD TH, 1986, CATALOG TERATOGENIC, pR21; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLACK JMW, 1991, DEVELOPMENT, V113, P661; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0	33	89	89	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					243	245		10.1126/science.1314424	http://dx.doi.org/10.1126/science.1314424			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1314424				2022-12-24	WOS:A1992HM89600036
J	STIRLING, CJ; HEWITT, EW				STIRLING, CJ; HEWITT, EW			THE SACCHAROMYCES-CEREVISIAE SEC65 GENE ENCODES A COMPONENT OF YEAST SIGNAL RECOGNITION PARTICLE WITH HOMOLOGY TO HUMAN SRP19	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; PROTEIN; DNA; EXPRESSION; SEQUENCE; SUBUNIT; GROWTH; SYSTEM; RNA	TRANSLOCATION of proteins across the endoplasmic reticulum (ER) membrane represents the first step in the eukaryotic secretory pathway. In mammalian cells, the targeting of secretory and membrane protein precursors to the ER is mediated by signal recognition particle (SRP), a cytosolic ribonucleoprotein complex comprising a molecule of 7SL RNA and six polypeptide subunits (relative molecular masses 9, 14, 19, 54, 68 and 72K) 1. In Saccharomyces cerevisiae, a homologue of the 54K subunit (SRP54) 2,3 co-purifies with a small cytoplasmic RNA, scR1 (refs 4,5). Genetic data indicate that SRP54 and scR1 are involved in translocation in vivo, suggesting the existence of an SRP-like activity in yeast 5,6. Whether this activity requires additional components similar to those found in mammalian SRP is not known. We have recently reported a genetic selection that led to the isolation of a yeast mutant, sec65-1, which is conditionally defective in the insertion of integral membrane proteins into the ER7. Here we report the cloning and sequencing of the SEC65 gene, which encodes a 31.2K protein with significant sequence similarity to the 19K subunit of human SRP (SRP19) 8. We also report the cloning of a multicopy suppressor of sec65-1, and its identification as the previously defined SRP54 gene, providing genetic evidence for an interaction between these gene products in vivo.			STIRLING, CJ (corresponding author), UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND.			Hewitt, Eric/0000-0002-6238-6303				AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; DEMONTIGNY J, 1989, MOL GEN GENET, V215, P455, DOI 10.1007/BF00427043; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING CJ, IN PRESS MOL BIOL CE; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOODS A, 1989, J CELL SCI, V93, P491	20	88	90	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					534	537		10.1038/356534a0	http://dx.doi.org/10.1038/356534a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1313948				2022-12-24	WOS:A1992HN23100063
J	MACDONALD, F; MORTON, DG; RINDL, PM; HAYDON, J; CULLEN, R; GIBSON, J; NEOPTOLEMOS, JP; KEIGHLEY, MRB; MCKEOWN, CM; HULTEN, M				MACDONALD, F; MORTON, DG; RINDL, PM; HAYDON, J; CULLEN, R; GIBSON, J; NEOPTOLEMOS, JP; KEIGHLEY, MRB; MCKEOWN, CM; HULTEN, M			PREDICTIVE DIAGNOSIS OF FAMILIAL ADENOMATOUS POLYPOSIS WITH LINKED DNA MARKERS - POPULATION BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER; CHROMOSOME-5; LOCALIZATION; GENE; LINKAGE; COLI	Objectives-To evaluate the use of polymorphic DNA probes linked to the APC gene in the presymptomatic diagnosis of familial adenomatous polyposis. Design-Four DNA probes were tested on an unselected population of patients at risk of familial adenomatous polyposis. Subjects-The first 47 families notified to the West Midlands familial adenomatous polyposis register. Plus five families sent to our hospital as part of the West of Britain DNA consortium. Main outcome measures-The proportion of families and family members in whom DNA testing could be used to adjust the estimate of risk. Results-Only 17 families on the register (containing 46% (74/162) of the population at risk) had a suitable pedigree structure for DNA analysis. DNA was analysed in 12 of these families plus the five families from the West of Britain consortium. At least one probe was informative in 27 of the 33 subjects born with 50% risk, but the most informative probe (pi-227) was the one with the highest recombination rate (10%). Flanking markers were informative in only four of the 33 subjects. Conclusions-These findings confirm the potential for accurate predictive diagnosis of familial adenomatous polyposis with polymorphic DNA probes, but such an approach is currently limited to about one third of affected families. A combined approach to presymptomatic diagnosis, which includes DNA testing and indirect ophthalmoscopy, is advocated.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT SURG,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT OPHTHALMOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT CLIN GENET,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND	University of Birmingham	MACDONALD, F (corresponding author), E BIRMINGHAM DIST GEN HOSP,REG GENET SERV,DNA LAB,BIRMINGHAM B9 52T,ENGLAND.		Neoptolemos, John/HGU-7742-2022; Neoptolemos, John P/G-4488-2010	Neoptolemos, John/0000-0002-6201-7399; Gibson, Jonathan M/0000-0002-9281-5244				BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BREUKEL C, 1991, NUCLEIC ACIDS RES, V19, P685, DOI 10.1093/nar/19.3.685-a; BULOW S, 1987, DAN MED BULL, V34, P1; BURN J, 1989, J MED GENET, V26, P207; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CACHONGONZALEZ MB, 1991, J MED GENET, V28, P681, DOI 10.1136/jmg.28.10.681; CHAPMAN PD, 1989, BRIT MED J, V298, P353, DOI 10.1136/bmj.298.6670.353; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOPS CMJ, 1991, HUM GENET, V86, P365; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MURDAY V, 1989, CANCER SURV, V8, P139; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; REED TE, 1955, AM J HUM GENET, V7, P236; ROMEO G, 1986, LANCET, V2, P8; Sambrook J., 1989, MOL CLONING LAB MANU; SOLOMON E, 1990, NATURE, V343, P412, DOI 10.1038/343412a0; TOPS CMJ, 1989, LANCET, V2, P1361	24	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					869	872		10.1136/bmj.304.6831.869	http://dx.doi.org/10.1136/bmj.304.6831.869			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1327364	Green Published, Bronze			2022-12-24	WOS:A1992HM83500021
J	KELLY, RW; LEASK, R; CALDER, AA				KELLY, RW; LEASK, R; CALDER, AA			CHORIODECIDUAL PRODUCTION OF INTERLEUKIN-8 AND MECHANISM OF PARTURITION	LANCET			English	Note							HUMAN-FETAL MEMBRANES; PROGESTERONE; LEUKOCYTES; PREGNANCY	Both prostaglandins and antiprogestagens can induce labour and ripen the cervix, but the mechanisms are unclear. The collagenases that bring about cervical ripening are neutrophil derived. We examined the potential of uterine tissues to control neutrophil attraction by measuring interleukin-8 production. Choriodecidual cells in culture produced substantial amounts of interleukin-8; release was inhibited by progesterone and stimulated by the antiprogestagen mifepristone. Interleukin-8 production was similar in cells from spontaneously delivered placentas and from those obtained at caesarean section. Since prostaglandin E and interleukin-8 have synergistic effects, we suggest that interleukin-8 activity is the final common step of prostaglandin and antiprogestagen action in parturition.	UNIV EDINBURGH,CTR REPROD BIOL,DEPT OBSTET & GYNAECOL,EDINBURGH EH3 9EW,SCOTLAND	University of Edinburgh	KELLY, RW (corresponding author), UNIV EDINBURGH,CTR REPROD BIOL,MRC,REPROD BIOL UNIT,37 CHALMERS ST,EDINBURGH EH3 9EW,SCOTLAND.							CHEUNG PYC, 1990, AM J OBSTET GYNECOL, V163, P1445, DOI 10.1016/0002-9378(90)90603-5; COLDITZ IG, 1990, IMMUNOL CELL BIOL, V68, P397, DOI 10.1038/icb.1990.53; HEGELEHARTUNG C, 1989, HUM REPROD, V4, P369, DOI 10.1093/oxfordjournals.humrep.a136909; JUNQUEIRA LCU, 1980, AM J OBSTET GYNECOL, V138, P273, DOI 10.1016/0002-9378(80)90248-3; KALEY G, 1971, ANN NY ACAD SCI, V180, P338, DOI 10.1111/j.1749-6632.1971.tb53203.x; NAKLA S, 1986, AM J OBSTET GYNECOL, V155, P1337, DOI 10.1016/0002-9378(86)90170-5; ROMERO R, 1990, UTERINE CONTRACTILIT, P353; Roseblade CK, 1990, ACTA OBSTET GYN SCAN, V69, P399, DOI 10.3109/00016349009013301; STAPLES LD, 1983, PLACENTA, V4, P339, DOI 10.1016/S0143-4004(83)80037-X; STITES DP, 1983, IMMUNOL REV, V75, P117, DOI 10.1111/j.1600-065X.1983.tb01093.x	10	139	141	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					776	777		10.1016/0140-6736(92)91896-G	http://dx.doi.org/10.1016/0140-6736(92)91896-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347804				2022-12-24	WOS:A1992HL50100004
J	REINHART, WH; BERCHTOLD, PE				REINHART, WH; BERCHTOLD, PE			EFFECT OF HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY ON BLOOD RHEOLOGY	LANCET			English	Article							GEOMETRY; ROLES	Stroke has been reported after high-dose intravenous immunoglobulin (IVIG) therapy, so a study was conducted to find out what effect IVIG has on factors influencing blood flow. The influence of IVIG on plasma viscosity, blood viscosity, and erythrocyte aggregation was examined in vitro and in vivo. For the in-vitro experiments different amounts of IVIG were added to whole blood or plasma from healthy subjects. The in-vivo effects were assessed during five courses of treatment with IVIG (24-54 g/day) in 4 patients with chronic immune thrombocytopenia (ITP). Concentration of IgG infused correlated strongly with viscosity of plasma and whole blood, both in vitro and in vivo, and plasma viscosity increased to beyond the normal range after IVIG treatment. The changes in viscosity that occur after IVIG therapy can impair blood flow, and in patients at risk of cardiovascular and thromboembolic events they might be sufficient to produce myocardial infarction or stroke.	UNIV BERN,INSELSPITAL,DEPT INTERNAL MED,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern								CHIEN S, 1975, RED BLOOD CELL, P1031; CRAWFORD J, 1985, AM J MED, V79, P13, DOI 10.1016/0002-9343(85)90540-6; REINHART WH, 1990, EUR J CLIN INVEST, V20, P458, DOI 10.1111/j.1365-2362.1990.tb01884.x; REINHART WH, 1985, AM J PHYSIOL, V248, pC473, DOI 10.1152/ajpcell.1985.248.5.C473; REINHART WH, IN PRESS EUR J CLIN; RIENHART WH, IN PRESS J LAB CLIN; Somer T, 1987, Baillieres Clin Haematol, V1, P695, DOI 10.1016/S0950-3536(87)80021-5; WOODRUFF RK, 1986, LANCET, V2, P217	8	171	177	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					662	664		10.1016/0140-6736(92)90806-E	http://dx.doi.org/10.1016/0140-6736(92)90806-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347348				2022-12-24	WOS:A1992HH74300014
J	MURCH, SH; BRAEGGER, CP; SESSA, WC; MACDONALD, TT				MURCH, SH; BRAEGGER, CP; SESSA, WC; MACDONALD, TT			HIGH ENDOTHELIN-1 IMMUNOREACTIVITY IN CROHNS-DISEASE AND ULCERATIVE-COLITIS	LANCET			English	Article							CELLS; REJECTION	Both immunological hypersensitivity and vascular abnormalities have been implicated in the pathogenesis of inflammatory bowel disease. In an attempt to link the two hypotheses, we sought evidence of local production of endothelin-1, a potent vasoconstrictor, in patients with Crohn's disease and ulcerative colitis. An immunohistochemical method was used to detect endothelin-1 in tissue samples from sixteen Crohn's disease patients, nine ulcerative colitis patients, and thirteen controls. In the controls, positively staining cells were infrequent in both lamina propria (mean 0.9% of total cells, 95% confidence interval 0.1-1.7%) and submucosa (2.3%, 0.4-4.1%). The percentage of endothelin-immunoreactive cells was significantly higher in the two disease groups than in the controls. Among the Crohn's disease patients, there were more immunoreactive cells in the submucosa than in the lamina propria (19.1%, 15.2-22.1% vs 12.3%, 8.1-16.5%, p < 0.001), whereas the converse was true for the ulcerative colitis group (8.6%, 1.1-16.1% vs 24.4%, 14.1-34.6%, p < 0.001). Immunoreactive macrophage aggregates around submucosal blood vessels were common in samples from Crohn's disease patients. Endothelin concentrations, measured by radioimmunoassay, in supernatants of homogenised tissue samples were significantly higher in Crohn's disease and ulcerative colitis than in controls. We suggest that local endothelin production by inflammatory cells may contribute to vasculitis in chronic inflammatory bowel disease by inducing intestinal ischaemia through vasoconstriction.	ST BARTHOLOMEWS HOSP, WILLIAM HARVEY RES INST, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London	MURCH, SH (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT PAEDIAT GASTROENTEROL, LONDON EC1A 7BE, ENGLAND.		Sessa, William C/B-6844-2011; Braegger, Christian Peter/ABC-9884-2021	Sessa, William C/0000-0001-5759-1938; Braegger, Christian/0000-0001-8069-9875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236; BANERJEE AK, 1990, GASTROENTEROLOGY, V99, P1190, DOI 10.1016/0016-5085(90)90654-J; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; CHOY MY, 1990, GUT, V31, P1365, DOI 10.1136/gut.31.12.1365; EBINA T, 1990, JPN J CANCER RES, V81, P1307, DOI 10.1111/j.1349-7006.1990.tb02695.x; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; GASSEL AM, 1990, AM J CLIN PATHOL, V94, P274, DOI 10.1093/ajcp/94.3.274; HALSTENSEN TS, 1990, GASTROENTEROLOGY, V98, P1264, DOI 10.1016/0016-5085(90)90343-Y; HIOKI Y, 1991, BIOCHEM BIOPH RES CO, V174, P446, DOI 10.1016/0006-291X(91)91436-G; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISAACSON PG, 1983, PRACTICAL APPLICATIO, P249; KAUFMAN DB, 1990, J EXP MED, V172, P291, DOI 10.1084/jem.172.1.291; KEICHO N, 1991, CELL IMMUNOL, V132, P285, DOI 10.1016/0008-8749(91)90028-A; LEHR HA, 1991, J CLIN INVEST, V87, P2036, DOI 10.1172/JCI115233; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; SANDERSON IR, 1987, ARCH DIS CHILD, V62, P123, DOI 10.1136/adc.62.2.123; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V168, P1230, DOI 10.1016/0006-291X(90)91160-T; SESSA WC, 1991, BIOCHEM BIOPH RES CO, V174, P613, DOI 10.1016/0006-291X(91)91461-K; SESSA WC, IN PRESS J CARDIOVAS; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; VANE JR, 1990, NEW ENGL J MED, V323, P27; VICAUT E, 1991, J CLIN INVEST, V87, P1537, DOI 10.1172/JCI115165; WAKEFIELD AJ, 1989, LANCET, V2, P1057; WAKEFIELD AJ, 1991, GASTROENTEROLOGY, V100, P1279; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R	30	132	139	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					381	385		10.1016/0140-6736(92)90077-G	http://dx.doi.org/10.1016/0140-6736(92)90077-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346658				2022-12-24	WOS:A1992HD65900002
J	SHAM, JSK; CLEEMANN, L; MORAD, M				SHAM, JSK; CLEEMANN, L; MORAD, M			GATING OF THE CARDIAC CA2+ RELEASE CHANNEL - THE ROLE OF NA+ CURRENT AND NA+-CA2+ EXCHANGE	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; SARCOPLASMIC-RETICULUM; GUINEA-PIG; ACTIVATES CONTRACTION; VENTRICULAR MYOCYTES; CA-2+ RELEASE; PURKINJE-CELL; HEART-MUSCLE; VOLTAGE; INACTIVATION	In cardiac myocytes, calcium influx through the calcium channel is the primary pathway for triggering calcium release. Recently it has been suggested that the calcium-induced calcium release mechanism can also be activated indirectly by the sodium current, which elevates the sodium concentration under the cell membrane, thereby favoring the entry of "trigger" calcium via the sodium-calcium exchanger. To test this hypothesis, sodium current was suppressed by reducing the external sodium concentration or applying tetrodotoxin. At potentials positive to -30 millivolts, calcium release was unaffected. A small calcium release at more negative potentials could be attributed to partial activation of calcium channels, because it was unaltered by replacement of sodium with lithium and was blocked by cadmium. Thus, sodium influx or its accumulation does not initiate calcium release. In addition, sodium-calcium exchange-related calcium release at potentials positive to +80 millivolts has slower kinetics than calcium channel-induced release. Therefore, only the calcium channel gates the fast release of calcium from the sarcoplasmic reticulum in the range of the action potential.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Sham, James/0000-0002-3571-8712	NHLBI NIH HHS [HL-16152, HL-07400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADRIAN RH, 1973, J PHYSIOL-LONDON, V235, P103, DOI 10.1113/jphysiol.1973.sp010380; Baker P F, 1972, Prog Biophys Mol Biol, V24, P177, DOI 10.1016/0079-6107(72)90007-7; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BROWN AM, 1981, J PHYSIOL-LONDON, V318, P455; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; JOHNSON EA, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.1848371; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; MORAD M, 1983, NATURE, V304, P635, DOI 10.1038/304635a0; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NILIUS B, 1988, J PHYSIOL-LONDON, V399, P537; PEACHEY LD, 1973, STRUCTURE FUNCTION M, V3, P1; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820	26	149	154	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					850	853		10.1126/science.1311127	http://dx.doi.org/10.1126/science.1311127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1311127				2022-12-24	WOS:A1992HD54800038
J	MEDORI, R; TRITSCHLER, HJ; LEBLANC, A; VILLARE, F; MANETTO, V; CHEN, HY; XUE, R; LEAL, S; MONTAGNA, P; CORTELLI, P; TINUPER, P; AVONI, P; MOCHI, M; BARUZZI, A; HAUW, JJ; OTT, J; LUGARESI, E; AUTILIOGAMBETTI, L; GAMBETTI, P				MEDORI, R; TRITSCHLER, HJ; LEBLANC, A; VILLARE, F; MANETTO, V; CHEN, HY; XUE, R; LEAL, S; MONTAGNA, P; CORTELLI, P; TINUPER, P; AVONI, P; MOCHI, M; BARUZZI, A; HAUW, JJ; OTT, J; LUGARESI, E; AUTILIOGAMBETTI, L; GAMBETTI, P			FATAL FAMILIAL INSOMNIA, A PRION DISEASE WITH A MUTATION AT CODON-178 OF THE PRION PROTEIN GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CREUTZFELDT-JAKOB DISEASE; SCRAPIE PRION	Background. We previously described two members of a family affected by an apparently genetically determined fatal disease characterized clinically by progressive insomnia, dysautonomia, and motor signs and characterized pathologically by severe atrophy of the anterior ventral and mediodorsal thalamic nuclei. Five other family members who died of this disease, which we termed "fatal familial insomnia," had broader neuropathologic changes suggesting that fatal familial insomnia could be a prion disease. Methods. We used antibodies to prion protein (PrP) to perform dot and Western blot analyses, with and without proteinase K, on brain tissue obtained at autopsy from two patients with fatal familial insomnia, three patients with sporadic Creutzfeldt-Jakob disease, and six control subjects. The coding region of the PrP gene was amplified and sequenced in the samples from the two patients with fatal familial insomnia. Restriction-enzyme analysis was carried out with amplified PrP DNA from 33 members of the kindred. Results. Protease-resistant PrP was found in both patients with fatal familial insomnia, but the size and number of protease-resistant fragments differed from those in Creutzfeldt-Jakob disease. In the family with fatal familial insomnia, all 4 affected members and 11 of the 29 unaffected members had a point mutation in PrP codon 178 that results in the substitution of asparagine for aspartic acid and elimination of the Tth111 I restriction site. Linkage analysis showed a close relation between the point mutation and the disease (maximal lod score, 3.4 when theta was zero). Conclusions. Fatal familial insomnia is a prion disease with a mutation in codon 178 of the PrP gene, but the disease phenotype seems to differ from that of previously described kindreds with the same point mutation.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10027; NEUROL INST,BOLOGNA,ITALY; HOP LA PITIE SALPETRIERE,NEUROL CLIN,F-75651 PARIS 13,FRANCE; HOP LA PITIE SALPETRIERE,LAB NEUROPATHOL R ESCOUROLLE,F-75651 PARIS 13,FRANCE	Case Western Reserve University; Columbia University; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Tinuper, Paolo/AAB-7760-2020; Avoni, Patrizia/AAC-1879-2020; Cortelli, Pietro/K-6063-2016	AVONI, PATRIZIA/0000-0003-0719-6803; tinuper, paolo/0000-0002-0588-3063; Cortelli, Pietro/0000-0002-3633-8818	NHGRI NIH HHS [R01 HG000008, UM1 HG006493] Funding Source: Medline; NIA NIH HHS [AG-08012, AG-08992] Funding Source: Medline; NINDS NIH HHS [NS-14509] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000008, UM1HG006493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008992, P50AG008012] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; FRIEDE RL, 1964, ARCH NEUROL-CHICAGO, V10, P181, DOI 10.1001/archneur.1964.00460140067009; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, ANN NEUROL, V31, P274, DOI 10.1002/ana.410310308; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; GUIDON G, 1978, THESIS U RENNES RENN; HALTIA M, 1979, Journal of the Neurological Sciences, V42, P381, DOI 10.1016/0022-510X(79)90171-0; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; KITAMOTO T, 1988, AM J PATHOL, V131, P435; KITAMOTO T, 1991, BRAIN RES, V545, P319, DOI 10.1016/0006-8993(91)91306-L; KOVANEN J, 1988, ACTA NEUROL SCAND, V77, P474, DOI 10.1111/j.1600-0404.1988.tb05943.x; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MANETTO V, IN PRESS NEUROLOGY; Maniatis T., 1982, MOL CLONING; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MAY WW, 1968, ARCH NEUROL-CHICAGO, V19, P137, DOI 10.1001/archneur.1968.00480020023002; NIETO A, 1991, LANCET, V337, P622, DOI 10.1016/0140-6736(91)91696-R; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1991, EXP NEUROL, V112, P240, DOI 10.1016/0014-4886(91)90075-N; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEXLER NS, 1991, ANNU REV NEUROSCI, V14, P503, DOI 10.1146/annurev.neuro.14.1.503	27	497	544	1	48	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					444	449		10.1056/NEJM199202133260704	http://dx.doi.org/10.1056/NEJM199202133260704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1346338	Green Accepted			2022-12-24	WOS:A1992HD16400004
J	HUANG, YY; COLINO, A; SELIG, DK; MALENKA, RC				HUANG, YY; COLINO, A; SELIG, DK; MALENKA, RC			THE INFLUENCE OF PRIOR SYNAPTIC ACTIVITY ON THE INDUCTION OF LONG-TERM POTENTIATION	SCIENCE			English	Article							TRANSMISSION; HIPPOCAMPUS; STIMULATION; AFFERENTS; VOLLEYS	Long-term potentiation (LTP) is an extensively studied model of synaptic plasticity, in part because it is a plausible biological correlate for the Hebbian synaptic modification that forms the basis for theoretical models of neural development, learning, and memory. Although these models must incorporate algorithms that constrain synaptic weight changes, physiological evidence for such mechanisms is limited. Examination of LTP in area CA1 of the hippocampus revealed that the threshold for LTP induction was not fixed but could be strongly influenced by the recent history of synaptic activity. This effect was transient, synapse-specific, and dependent on postsynaptic N-methyl-D-aspartate (NMDA) receptor activation. These results suggest that the threshold for LTP induction may be continually adjusted according to the recent history of NMDA receptor activation and provide a physiological mechanism by which LTP can be transiently inhibited.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Colino, Asuncion/H-6970-2017	Colino, Asuncion/0000-0002-7061-9197	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH045334] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45334, MH00942] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAHAM WC, 1986, NEUROSCI LETT, V70, P217, DOI 10.1016/0304-3940(86)90466-0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLINO A, 1992, J NEUROSCI, V12, P180; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Gluck M. A., 1990, NEUROSCIENCE CONNECT; HEBB DO, 1949, ORG BEHAVIOR; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; WINSON J, 1986, SCIENCE, V234, P985, DOI 10.1126/science.3775372; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299	18	332	334	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					730	733		10.1126/science.1346729	http://dx.doi.org/10.1126/science.1346729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1346729				2022-12-24	WOS:A1992HC50600043
J	ZHANG, XK; HOFFMANN, B; TRAN, PBV; GRAUPNER, G; PFAHL, M				ZHANG, XK; HOFFMANN, B; TRAN, PBV; GRAUPNER, G; PFAHL, M			RETINOID X-RECEPTOR IS AN AUXILIARY PROTEIN FOR THYROID-HORMONE AND RETINOIC ACID RECEPTORS	NATURE			English	Article							RESPONSE ELEMENT; HUMAN TESTIS; BINDING; GENE; IDENTIFICATION; SUPERFAMILY; ENHANCE	THYROID hormones and retinoic acid function through nuclear receptors that belong to the steroid/thyroid-hormone receptor superfamily (reviewed in refs 1-4). Thyroid hormone receptors (TRs) and retinoic acid receptors (RARs) require auxiliary nuclear proteins for efficient DNA binding 5-10. Here we report that retinoid X receptors RXR-alpha (ref. 11) is one of these nuclear proteins. RXR-alpha interacts both with TRs and with RARs, forming heterodimers in solution that strongly interact with a variety of T3/retinoic acid response elements. Transfection experiments show that RXR-alpha can greatly enhance the transcriptional activity of TR and RAR at low retinoic acid concentrations that do not significantly activate RXR-alpha itself. Thus, RXR-alpha enhances the transcriptional activity of other receptors and its own ligand sensitivity by heterodimer formation. Our studies reveal a new subclass of receptors and a regulatory pathway controlling nuclear receptor activities by heterodimer formation.	LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HUSHMAN M, 1991, MOL CELL BIOL, V11, P4097; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; PFAHL M, 1990, METHOD ENZYMOL, V153, P256; PFAHL M, 1992, RETINOIDS NORMAL DEV, P51; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, NEW BIOL, V3, P1	29	934	968	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					441	446		10.1038/355441a0	http://dx.doi.org/10.1038/355441a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1310350				2022-12-24	WOS:A1992HB53000068
J	FIGUERAS, A; MORALESOLIVAS, FJ; CAPELLA, D; PALOP, V; LAPORTE, JR				FIGUERAS, A; MORALESOLIVAS, FJ; CAPELLA, D; PALOP, V; LAPORTE, JR			BOVINE GANGLIOSIDES AND ACUTE MOTOR POLYNEUROPATHY	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUTONOMA BARCELONA,CSU VALL DHEBRON,INST CATALA FARMACOL,SERV FARMACOL CLIN,E-08035 BARCELONA,SPAIN; UNIV VALENCIA,FAC MED,DEPT FARMACOL,VALENCIA,SPAIN; CTR FARMACOVIGILANCIA COMUNITAT VALENCIANA,VALENCIA,SPAIN	Autonomous University of Barcelona; University of Valencia			Figueras, Albert/I-7421-2013; Laporte, Joan-Ramon/A-1302-2011; Figueras, Albert/H-7743-2012	Figueras, Albert/0000-0002-2740-2013; Figueras, Albert/0000-0002-2740-2013				BRADLEY WG, 1990, MUSCLE NERVE, V13, P853; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; SCHONHOFER PS, 1991, LANCET, V338, P757; 1985, LANCET, V1, P1137	5	70	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1330	1331		10.1136/bmj.305.6865.1330	http://dx.doi.org/10.1136/bmj.305.6865.1330			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1309191	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992KA77300022
J	FABER, DS; YOUNG, WS; LEGENDRE, P; KORN, H				FABER, DS; YOUNG, WS; LEGENDRE, P; KORN, H			INTRINSIC QUANTAL VARIABILITY DUE TO STOCHASTIC PROPERTIES OF RECEPTOR-TRANSMITTER INTERACTIONS	SCIENCE			English	Article							CENTRAL INHIBITORY SYNAPSE; LONG-TERM POTENTIATION; GLYCINE RECEPTORS; CENTRAL NEURON; NEUROMUSCULAR SYNAPSE; HIPPOCAMPAL SLICES; CHANNEL ACTIVATION; SPINAL-CORD; TRANSMISSION; ACETYLCHOLINE	Synaptic events at the neuromuscular junction are integer multiples of a quantum, the postsynaptic response to transmitter released from one presynaptic vesicle. At central synapses where quanta are small, it has been suggested they are invariant due to occupation of all postsynaptic receptors, a concept neglecting inherent fluctuations in channel behavior. If this did occur, the quantal release model would not apply there and could not be used to localize sites of synaptic modification. Monte Carlo simulations of quanta include transmitter diffusion and interactions with postsynaptic receptors that are treated probabilistically. These models suggest that when there are few postsynaptic channels available at a synapse, their stochastic behavior produces significant intrinsic variance in response amplitude and kinetics, and saturation does not occur. These results were confirmed by analysis of inhibitory quanta in embryonic and adult Mauthner cells involving a small and large number of channels, respectively. The findings apply to excitatory synapses as well.	SUNY BUFFALO, NEUROBIOL LAB, BUFFALO, NY 14214 USA; INST PASTEUR, INSERM, U261, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NINDS NIH HHS [NS21848] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021848] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAGI H, 1988, SCIENCE, V242, P270, DOI 10.1126/science.2845580; BARTOL TM, 1991, BIOPHYS J, V59, P1290, DOI 10.1016/S0006-3495(91)82344-X; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BUSCH C, 1990, COLD SH Q B, V55, P69; DIAMOND J, 1973, J PHYSIOL-LONDON, V232, P113, DOI 10.1113/jphysiol.1973.sp010259; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; EDWARDS FR, 1976, J PHYSIOL-LONDON, V259, P689, DOI 10.1113/jphysiol.1976.sp011489; FABER DS, 1988, P NATL ACAD SCI USA, V85, P8708, DOI 10.1073/pnas.85.22.8708; FABER DS, 1985, P NATL ACAD SCI USA, V82, P3504, DOI 10.1073/pnas.82.10.3504; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; FABER DS, 1980, SCIENCE, V208, P612, DOI 10.1126/science.6245449; FABER DS, 1988, J NEUROPHYSIOL, V60, P1982, DOI 10.1152/jn.1988.60.6.1982; FABER DS, 1982, J NEUROPHYSIOL, V48, P654, DOI 10.1152/jn.1982.48.3.654; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P65, DOI 10.1113/jphysiol.1981.sp013972; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KORN H, 1990, J NEUROPHYSIOL, V63, P198, DOI 10.1152/jn.1990.63.1.198; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; KORN H, 1987, P NATL ACAD SCI USA, V84, P5981, DOI 10.1073/pnas.84.16.5981; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; Legendre P., 1992, Society for Neuroscience Abstracts, V18, P1357; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARGAROLI A, 1992, NATURE, V357, P134; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P287; SEITANIDOU T, 1988, J NEUROSCI, V8, P4319; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; SOLODKIN M, 1991, J NEUROPHYSIOL, V65, P927, DOI 10.1152/jn.1991.65.4.927; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708; TWYMAN RE, 1991, J PHYSIOL-LONDON, V435, P303, DOI 10.1113/jphysiol.1991.sp018512; VRENSEN G, 1980, BRAIN RES, V184, P23, DOI 10.1016/0006-8993(80)90585-5; YOUNG AB, 1973, P NATL ACAD SCI USA, V70, P2832, DOI 10.1073/pnas.70.10.2832	43	155	155	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1992	258	5087					1494	1498		10.1126/science.1279813	http://dx.doi.org/10.1126/science.1279813			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279813				2022-12-24	WOS:A1992JZ62500032
J	GAUR, A; WIERS, B; LIU, A; ROTHBARD, J; FATHMAN, CG				GAUR, A; WIERS, B; LIU, A; ROTHBARD, J; FATHMAN, CG			AMELIORATION OF AUTOIMMUNE ENCEPHALOMYELITIS BY MYELIN BASIC-PROTEIN SYNTHETIC PEPTIDE INDUCED ANERGY	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; T-CELL TOLERANCE; MULTIPLE-SCLEROSIS; MONOCLONAL-ANTIBODY; ANTIGEN; DETERMINANT; EPITOPES; MICE; PREVENTION; REVERSAL	Experimental autoimmune encephalomyelitis (EAE), a demyelinating disease of the central nervous system that can be induced in susceptible strains of mice by immunization with myelin basic protein (MBP) or its immunodominant T cell determinants, serves as a model of human multiple sclerosis. Tolerance to MBP in adult mice was induced by intraperitoneal injection of synthetic peptides of immunodominant determinants of MBP and prevented MBP-induced EAE. Furthermore, tolerance-inducing regimens of peptides administered to mice after the disease had begun (10 days after induction with MBP) blocked the progression and decreased the severity of EAE. Peptide-induced tolerance resulted from the induction of anergy in proliferative, antigen-specific T cells.	STANFORD UNIV,MED CTR,SCH MED,DIV IMMUNOL & RHEUMATOL,STANFORD,CA 94305; IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304	Stanford University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027989] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27989] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALVORD EC, 1965, ANN NY ACAD SCI, V1220, P333; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; CAMPBELL B, 1973, ARCH NEUROL-CHICAGO, V29, P10, DOI 10.1001/archneur.1973.00490250028003; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; DEMAGISTRIS TM, 1992, CELL, V68, P625; DRISCOLL BF, 1976, J IMMUNOL, V117, P110; DRISCOLL BF, 1974, J IMMUNOL, V112, P392; EYLAR EH, 1972, NATURE, V236, P74, DOI 10.1038/236074a0; FRITZ RB, 1983, J IMMUNOL, V130, P191; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; HAFLER DA, 1988, J EXP MED, V167, P1313, DOI 10.1084/jem.167.4.1313; HASHIM GA, 1973, ARCH BIOCHEM BIOPHYS, V156, P287, DOI 10.1016/0003-9861(73)90367-6; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KONO DH, 1988, J EXP MED, V168, P213, DOI 10.1084/jem.168.1.213; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MARTIN R, 1992, J IMMUNOL, V148, P1359; OKI A, 1985, J EXP MED, V161, P897, DOI 10.1084/jem.161.5.897; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; SMILEK DE, 1991, P NATL ACAD SCI USA, V88, P9633, DOI 10.1073/pnas.88.21.9633; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	29	239	249	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1491	1494		10.1126/science.1279812	http://dx.doi.org/10.1126/science.1279812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279812				2022-12-24	WOS:A1992JZ62500031
J	COSSON, P; BONIFACINO, JS				COSSON, P; BONIFACINO, JS			ROLE OF TRANSMEMBRANE DOMAIN INTERACTIONS IN THE ASSEMBLY OF CLASS-II MHC MOLECULES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE-PROTEINS; RECEPTOR; EXPRESSION; PRODUCTS; DISTINCT; COMMON; GENES; MODEL; CLONE	Evidence is presented that suggests a role for transmembrane domain interactions in the assembly of class II major histocompatibility complex (MHC) molecules. Mutations in the transmembrane domains of the class II MHC alpha or beta chains resulted in proteins that did not generate complexes recognized by conformation-dependent antibodies and that were largely retained in the endoplasmic reticulum. Insertion of the alpha and beta transmembrane domains into other proteins allowed the chimeric proteins to assemble, suggesting a direct interaction of the alpha and beta transmembrane domains. The interactions were mediated by a structural motif involving several glycine residues on the same face of a putative alpha helix.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Bonifacino, Juan S./0000-0002-5673-6370				BISHOP GA, 1988, IMMUNOGENETICS, V28, P184, DOI 10.1007/BF00375858; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; COSSON P, UNPUB; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESTESS P, 1986, P NATL ACAD SCI USA, V83, P3594, DOI 10.1073/pnas.83.11.3594; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KABAT EA, 1991, SEQUENCES PROTEINS I, P816; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NIELSEN LK, 1990, J IMMUNOL, V144, P2915; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PIERRES M, 1980, EUR J IMMUNOL, V10, P950, DOI 10.1002/eji.1830101211; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P79; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TRAVERS P, 1984, NATURE, V310, P235, DOI 10.1038/310235a0; VANDENELSEN P, 1985, NATURE, V314, P542, DOI 10.1038/314542a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	33	191	208	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					659	662		10.1126/science.1329208	http://dx.doi.org/10.1126/science.1329208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329208				2022-12-24	WOS:A1992JU74500060
J	ARTALEJO, CR; ROSSIE, S; PERLMAN, RL; FOX, AP				ARTALEJO, CR; ROSSIE, S; PERLMAN, RL; FOX, AP			VOLTAGE-DEPENDENT PHOSPHORYLATION MAY RECRUIT CA2+ CURRENT FACILITATION IN CHROMAFFIN CELLS	NATURE			English	Article							CARDIAC CALCIUM-CHANNEL; RABBIT SKELETAL-MUSCLE; PROTEIN KINASE-C; OKADAIC ACID; POTENT INHIBITORS; PHOSPHATASE-2A; RECEPTOR	BOVINE chromaffin cells have two components of whole-cell Ca2+ current: 'standard' Ca2+ currents that are activated by brief depolarizations, and 'facilitation' Ca2+ currents, which are normally quiescent but can be activated by large pre-depolarizations or by repetitive depolarizations to physiological potentials 1-5. The activation of protein kinase A can also stimulate Ca2+ current facilitation, indicating that phosphorylation can play a part in facilitation 6. Here we investigate the role of protein phosphorylation in the recruitment of facilitation Ca2+ currents by pre-pulses or repetitive depolarizations. We find that recruitment of facilitation by depolarization is a rapid first-order process which is suppressed by inhibitors of protein phosphorylation or by injection of phosphatase 2A into cells. Recruitment of facilitation Ca2+ current by voltage is normally reversible but phosphatase inhibitors render it irreversible. Our results indicate that recruitment of these Ca2+ currents by pre-pulses or repetitive depolarizations involves voltage-dependent phosphorylation of the facilitation Ca2+ channel or a closely associated regulatory protein. Voltage-dependent phosphorylation may therefore be a mechanism by which membrane potential can modulate ion channel activity.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR,CHICAGO,IL 60637; UNIV AUTONOMA MADRID,FAC MED,DEPT FARMACOL,E-28029 MADRID,SPAIN; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Chicago; University of Chicago; University of Chicago; Autonomous University of Madrid; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Perlman, Robert/GZH-2102-2022					ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; AMADOR M, 1991, NEUROSCI LETT, V124, P251, DOI 10.1016/0304-3940(91)90106-4; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V432, P681, DOI 10.1113/jphysiol.1991.sp018406; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V444, P213, DOI 10.1113/jphysiol.1991.sp018874; CHUNG S, 1991, SCIENCE, V253, P56; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOSHI T, 1984, P NATL ACAD SCI-BIOL, V81, P5871, DOI 10.1073/pnas.81.18.5871; HOSHI T, 1987, J NEUROSCI, V7, P571; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; NESTLER EJ, 1989, BASIC NEUROCHEMISTRY; TESSMER GW, 1977, J BIOL CHEM, V252, P5666; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YOUNT RG, 1975, ADV ENZYMOL, V34, P1	24	127	128	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					63	66		10.1038/358063a0	http://dx.doi.org/10.1038/358063a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1319555				2022-12-24	WOS:A1992JB34100054
J	KULHANJIAN, JA; SOROUSH, V; AU, DS; BRONZAN, RN; YASUKAWA, LL; WEYLMAN, LE; ARVIN, AM; PROBER, CG				KULHANJIAN, JA; SOROUSH, V; AU, DS; BRONZAN, RN; YASUKAWA, LL; WEYLMAN, LE; ARVIN, AM; PROBER, CG			IDENTIFICATION OF WOMEN AT UNSUSPECTED RISK OF PRIMARY INFECTION WITH HERPES-SIMPLEX VIRUS TYPE-2 DURING PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENITAL HERPES; DELIVERY; INFANTS; ACQUISITION; CULTURES; PARTNER	Background. Primary infections with herpes simplex virus type 2 (HSV-2) acquired by women during pregnancy account for about half of the morbidity and mortality from HSV-2 among neonates. The other half results from reactivation of old infections. Better methods are needed to identify which women are at risk for primary HSV-2 infection. Methods. We prospectively studied HSV-2 infections among pregnant women who were patients in private obstetrical practices. Using an enzyme-linked immunosorbent assay that detects type-specific antibodies to HSV-2 glycoprotein G, we determined the prevalence at base line of HSV-2 infections among pregnant women and their husbands, the frequency of discordance for infection between partners, and the risk of seroconversion during pregnancy among the seronegative women whose husbands were seropositive. Results. The seroprevalence of HSV-2 was 32 percent among the 277 women followed throughout their pregnancies and 25 percent among the 190 husbands studied. Two thirds of the HSV-2-seropositive women had no history of genital herpes. Of the 190 couples, 139 (73 percent) were serologically concordant for HSV-2 antibodies (57 percent being seronegative and 16 percent being seropositive), whereas 51 couples (27 percent) were discordant, despite having been sexually intimate for a mean of 6.1 years. Eighteen women who were seronegative for HSV-2 (9.5 percent) had seropositive partners, of whom 10 (56 percent) had no history of genital herpes. Thus, approximately 5 percent of these pregnant women had an unsuspected risk of contracting a primary HSV-2 infection. One of the 18 seronegative women with a seropositive husband seroconverted to HSV-2 during pregnancy; none of the other women seroconverted. Conclusions. In this study about 10 percent of pregnant women were at risk of contracting a primary HSV-2 infection from their HSV-2-seropositive husbands. In addition, about a third of these women were seropositive for HSV-2 and thus at risk for asymptomatic, reactivated infections. Serologic testing of couples can identify women who are at risk for primary or reactivated HSV-2 infections during pregnancy.	STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV INFECT DIS,RM A367,STANFORD,CA 94305	Stanford University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016080] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16080] Funding Source: Medline; PHS HHS [A1008844] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLERSTORTHZ K, 1985, AM J OBSTET GYNECOL, V151, P582, DOI 10.1016/0002-9378(85)90143-7; ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BROWN ZA, 1987, NEW ENGL J MED, V317, P1246, DOI 10.1056/NEJM198711123172002; FRENKEL LM, 1987, PEDIATR RES, V21, pA325; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109	19	123	125	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					916	920		10.1056/NEJM199204023261403	http://dx.doi.org/10.1056/NEJM199204023261403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1311799	Bronze			2022-12-24	WOS:A1992HL26100003
J	NOBLEJAMIESON, G; THIRU, S; JOHNSTON, P; FRIEND, P; BARNES, ND				NOBLEJAMIESON, G; THIRU, S; JOHNSTON, P; FRIEND, P; BARNES, ND			GLOMERULONEPHRITIS WITH END-STAGE LIVER-DISEASE IN CHILDHOOD	LANCET			English	Note							CIRRHOSIS	Renal biopsies were done perioperatively in 18 children receiving liver grafts. All specimens showed glomerulonephritis, which was mesangial-proliferative in 15 and mesangio-capillary in 3. Of the 16 children who were alive four or more months after transplantation, only 1 showed progressive deterioration of renal function; 1 other had a subnormal but static glomerular filtration rate. In all 6 children who had proteinuria before operation, the urine became normal.	ADDENBROOKES HOSP, DEPT PATHOL, CAMBRIDGE CB2 2QQ, ENGLAND; ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CAMBRIDGE, CAMBRIDGE, ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	NOBLEJAMIESON, G (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, HILLS RD, CAMBRIDGE CB2 2QQ, ENGLAND.							[Anonymous], 1987, PEDIATRICS, V79, P1; BENE MC, 1988, AM J CLIN PATHOL, V89, P769, DOI 10.1093/ajcp/89.6.769; CHESNEY RW, 1987, PEDIATR CLIN N AM, V34, P609; EGIDO J, 1987, SEMIN NEPHROL, V7, P289; FISHER ER, 1959, AM J CLIN PATHOL, V32, P48; LAI KN, 1988, CLIN NEPHROL, V29, P229; LAMM ME, 1987, SEMIN NEPHROL, V7, P280; MOROZ SP, 1976, PEDIATRICS, V57, P232; MYERS BD, 1973, AM J CLIN PATHOL, V60, P222; PAPADAKIS MA, 1987, AM J MED, V82, P945, DOI 10.1016/0002-9343(87)90156-2	10	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1992	339	8795					706	707		10.1016/0140-6736(92)90600-8	http://dx.doi.org/10.1016/0140-6736(92)90600-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347585				2022-12-24	WOS:A1992HK32000005
J	MORABIA, A; WYNDER, EL				MORABIA, A; WYNDER, EL			RELATION OF BRONCHIOLOALVEOLAR CARCINOMA TO TOBACCO	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; CIGARETTE SMOKERS	Objective - To determine whether bronchioalveolar carcinoma is related to tobacco use. Design - Case-control study. Setting - 11 teaching hospitals of Chicago, Long Island, New York, and Philadelphia, 1977-89. Subjects - 87 patients with histologically diagnosed bronchioloalveolar carcinoma (cases) and 286 non-cancer and 297 cancer patients matched to cases on age, sex, race, hospital, and date of admission. Results - 10% of male cases and 25% of female cases had never smoked. Relative risks of bronchioloalveolar carcinoma (as estimated by the relative odds) were greater for subjects who started smoking at a younger age, smoked for a longer time, or smoked more cigarettes per day. Relative risks decreased proportionally to the duration of smoking cessation. Conclusion - Smoking plays an important part in the aetiology of bronchioloalveolar carcinoma but is not the only potential cause because of the large proportion of never smokers among patients with this disease.	AMER HLTH FDN, 320 E43RD ST, NEW YORK, NY 10017 USA	American Health Foundation								Breslow N, 1980, STATISTICAL METHODS, V32; CLAYTON F, 1988, PATHOL ANNU, V23, P361; EDWARDS CW, 1984, THORAX, V39, P166, DOI 10.1136/thx.39.3.166; FEINSTEI.AR, 1970, AM REV RESPIR DIS, V101, P671; GEDDES DM, 1987, BRIT MED J, V294, P3, DOI 10.1136/bmj.294.6563.3; GRECO RJ, 1986, ANN THORAC SURG, V41, P652, DOI 10.1016/S0003-4975(10)63082-2; GROVER FL, 1989, ANN SURG, V209, P779, DOI 10.1097/00000658-198906000-00016; HOIDAL JR, 1981, AM REV RESPIR DIS, V123, P85; HOIDAL JR, 1982, AM REV RESPIR DIS, V126, P548; IVES JC, 1983, AM REV RESPIR DIS, V128, P195, DOI 10.1164/arrd.1983.128.1.195; JONES JG, 1980, LANCET, V1, P66; LIEBOW A A, 1960, Adv Intern Med, V10, P329; MANNING JT, 1984, CANCER-AM CANCER SOC, V54, P525, DOI 10.1002/1097-0142(19840801)54:3<525::AID-CNCR2820540324>3.0.CO;2-X; MORABIA A, 1991, CANCER, V68, P2074, DOI 10.1002/1097-0142(19911101)68:9<2074::AID-CNCR2820680939>3.0.CO;2-X; ROSENOW EC, 1979, CA-CANCER J CLIN, V29, P233, DOI 10.3322/canjclin.29.4.233; SCHRAUFNAGEL D, 1982, AM REV RESPIR DIS, V125, P74; STANLEY KE, 1981, J NATL CANCER I, V66, P989, DOI 10.1093/jnci/66.6.989; VINCENT RG, 1977, CANCER, V39, P1647, DOI 10.1002/1097-0142(197704)39:4<1647::AID-CNCR2820390439>3.0.CO;2-H; WYNDER EL, 1977, CANCER RES, V37, P4608; 1984, DATA NATIONAL HLTH I	20	42	43	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 29	1992	304	6826					541	543		10.1136/bmj.304.6826.541	http://dx.doi.org/10.1136/bmj.304.6826.541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1313719	Green Published, Bronze			2022-12-24	WOS:A1992HG59900019
J	LOPEZ, A; MIRANDA, P; TEJADA, E; FISHBEIN, DB				LOPEZ, A; MIRANDA, P; TEJADA, E; FISHBEIN, DB			OUTBREAK OF HUMAN RABIES IN THE PERUVIAN JUNGLE	LANCET			English	Article								Transmission of rabies to man by vampire bats has been known for 60 years but there have been few reports of the features of rabies transmitted in this way. These aspects of the disease were investigated during an outbreak in Peru in early 1990. Between Jan 1 and April 30, 1990, 29 (5%) of 636 residents of the two rural communities in the Amazon Jungle in Peru acquired an illness characterised by hydrophobia, fever, and headache and died shortly thereafter. A census in one of the two towns revealed that the proportion affected was significantly higher for 5-14 year olds (17%) than for other age-groups (p < 10(-5)). Interviews conducted with 23 of the patients or their families revealed that 22 (96%) had a history of bat bite, compared with 66 (22%) of 301 community members who remained healthy (p < 10(-6)). A rabies virus strain identical to those isolated from vampire bats (Desmodus rotundus) was isolated from the brain of the only person on whom necropsy could be done. Because of the extreme isolation of this and other communities affected by bat-transmitted rabies, preventive measures should be directed at decreasing the risk of nocturnal exposure to bats by bat proofing dwellings or use of mosquito nets and at prompt wound care. Rabies pre-exposure or postexposure vaccination is clearly indicated, but may not be feasible in these isolated populations.	CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL, INT BRANCH,MAILSTOP C08, ATLANTA, GA 30333 USA; MINIST SALUD, PROGRAMA ENTRENAMIENTO & EPIDEMIOL CAMPO, OFICIANA GEN EPIDEMIOL, LIMA, PERU; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								Acha P N, 1967, Bull Off Int Epizoot, V67, P343; ARELLANOSOTA C, 1988, REV INFECT DIS, V10, pS707; Carini A, 1911, ANN I PASTEUR PARIS, V25, P843; Dean A. G., 1990, EPI INFO VERSION 5 W; GOLDWASSER RA, 1958, P SOC EXP BIOL MED, V98, P219, DOI 10.3181/00379727-98-23996; GUT H. JAMES, 1959, JOUR MAMMAL, V40, P534, DOI 10.2307/1376270; Hurst EW, 1931, LANCET, V2, P622; Hurst EW, 1932, J PATHOL BACTERIOL, V35, P301, DOI 10.1002/path.1700350302; Johnson H. N., 1971, Rabies. Proceedings of working conference on rabies, Tokyo, 1970., P237; LORD R D, 1975, Journal of Wildlife Diseases, V11, P210; MALAGAALBA A, 1954, AM J PUBLIC HEALTH, V44, P909, DOI 10.2105/AJPH.44.7.909; MCCARTHY TJ, 1989, AM J TROP MED HYG, V40, P320, DOI 10.4269/ajtmh.1989.40.320; NEHAUL BBG, 1955, AM J TROP MED HYG, V4, P550, DOI 10.4269/ajtmh.1955.4.550; NEHAUL BBG, 1965, AM J TROP MED HYG, V14, P295, DOI 10.4269/ajtmh.1965.14.295; SMITH JS, 1989, ADV VIRUS RES, V36, P215; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; VERLINDE JD, 1975, TROP GEOGR MED, V27, P137; WATERMAN J A, 1959, Caribb Med J, V21, P46; 1983, MMWR, V32, P494; 1987, WHORABIES89199	20	46	55	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					408	411						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346669				2022-12-24	WOS:A1992HD65900013
J	GOLDSMITH, R; YARBOUGH, PO; REYES, GR; FRY, KE; GABOR, KA; KAMEL, M; ZAKARIA, S; AMER, S; GAFFAR, Y				GOLDSMITH, R; YARBOUGH, PO; REYES, GR; FRY, KE; GABOR, KA; KAMEL, M; ZAKARIA, S; AMER, S; GAFFAR, Y			ENZYME-LINKED-IMMUNOSORBENT-ASSAY FOR DIAGNOSIS OF ACUTE SPORADIC HEPATITIS-E IN EGYPTIAN CHILDREN	LANCET			English	Article							NON-B-HEPATITIS; TRANSMITTED NON-A; VIRUS-LIKE PARTICLES; CYNOMOLGUS MACAQUES; POST-TRANSFUSION; EPIDEMIC; ETIOLOGY; TRANSMISSION; RECOVERY	Hepatitis E virus (HEV) is thought to be a cause of enterically transmitted non-A, non-B (ET-NANB) hepatitis. Waterborne epidemics have been recorded in many developing countries, mainly affecting young-to-middle-aged adults; sporadic infection and overt illness in children are rare. However, a convenient and sensitive diagnostic test for HEV infection is not yet available. We now report the use of a solid-phase enzyme-linked immunoassay (ELISA) that detects IgM and IgG antibody to HEV. In a prospective study of endemic acute hepatitis during 1986 in rural Benha, Egypt, 15 (42%) of 36 children with NANB hepatitis (from whom convalescent-phase sera were available every 3 months to 9 or 12 months) were positive for anti-HEV-IgG by ELISA. Of 20 sera from healthy Benha children (controls), 5 (25%) were also positive for anti-HEV-IgG. When evaluated for anti-HEV-IgM, 6 of the 15 IgG-positive children, but none of the controls, were IgM positive and were thus regarded as having confirmed acute HEV infections. These 6 cases together with 2 presumptive cases (IgM negative, IgG seroconversion from positive to negative) presented sporadically over 9 months. This ELISA is a convenient method for the diagnosis of HEV infection; we have shown that the disease is present in Egypt, that it can occur endemically as sporadic cases, and that children do have overt infection.	GENELABS INC,DEPT MOLEC VIROL,REDWOOD CITY,CA; BENHA UNIV,DEPT PEDIAT,BENHA,EGYPT; UNIV CAIRO,DEPT CLIN PATHOL,CAIRO,EGYPT; UNIV CAIRO,DEPT TROP MED,CAIRO,EGYPT; AIN SHAMS UNIV,DEPT MED,CAIRO,EGYPT	Egyptian Knowledge Bank (EKB); Benha University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Ain Shams University	GOLDSMITH, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1989, ANN INTERN MED, V110, P583, DOI 10.7326/0003-4819-110-8-583; ARANKALLE VA, 1988, LANCET, V1, P550; ARANKALLE VA, 1988, LANCET, V2, P1199; BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1987, P NATL ACAD SCI USA, V84, P6277, DOI 10.1073/pnas.84.17.6277; BRADLEY DW, 1986, SEMIN LIVER DIS, V6, P56, DOI 10.1055/s-2008-1040794; DECOCK KM, 1987, ANN INTERN MED, V106, P227, DOI 10.7326/0003-4819-106-2-227; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; KRAWCZYNSKI K, 1989, J INFECT DIS, V159, P1042, DOI 10.1093/infdis/159.6.1042; PANDA SK, 1989, HEPATOLOGY, V10, P466, DOI 10.1002/hep.1840100411; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; SKIDMORE SJ, 1991, LANCET, V337, P1541, DOI 10.1016/0140-6736(91)93227-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SREENIVASAN MA, 1984, J GEN VIROL, V65, P1005, DOI 10.1099/0022-1317-65-5-1005; TABOR E, 1985, LANCET, V1, P743; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281; WONG DC, 1980, LANCET, V2, P876; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; ZAKARIA S, 1988, TROP GEOGR MED, V40, P285; ZUCKERMAN AJ, 1990, BRIT MED J, V300, P1475, DOI 10.1136/bmj.300.6738.1475; 1990, LANCET, P1158	24	192	204	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					328	331		10.1016/0140-6736(92)91647-Q	http://dx.doi.org/10.1016/0140-6736(92)91647-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346411				2022-12-24	WOS:A1992HC77100004
J	HARLEY, HG; BROOK, JD; RUNDLE, SA; CROW, S; REARDON, W; BUCKLER, AJ; HARPER, PS; HOUSMAN, DE; SHAW, DJ				HARLEY, HG; BROOK, JD; RUNDLE, SA; CROW, S; REARDON, W; BUCKLER, AJ; HARPER, PS; HOUSMAN, DE; SHAW, DJ			EXPANSION OF AN UNSTABLE DNA REGION AND PHENOTYPIC VARIATION IN MYOTONIC-DYSTROPHY	NATURE			English	Article							GENE	MYOTONIC dystrophy is the commonest adult form of muscular dystrophy, with an estimated incidence of 1 per 7,500, although this is likely to be an underestimate because of the difficulty of detecting minimally affected individuals. It is a multisystem autosomal dominant disorder of unknown biochemical basis 1. No case of new mutation has been proven. We have isolated a human genomic clone that detects novel restriction fragments specific to individuals with myotonic dystrophy. A two-allele EcoRI polymorphism is seen in normal individuals, but in most affected individuals one of the normal alleles is replaced by a larger fragment, which Varies in length both between unrelated affected individuals and within families. The unstable nature of this region may explain the characteristic variation in severity and age at onset of the disease. A second polymorphism at this locus is in almost complete linkage disequilibrium with myotonic dystrophy, strongly supporting our earlier results which indicated that most cases are descended from one original mutation 2.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	HARLEY, HG (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 6EJ,WALES.			Brook, John David/0000-0002-5946-6740	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; FU YH, 1991, CELL, V67, P1; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1991, HUM GENET, V87, P73, DOI 10.1007/BF01213096; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JANSEN G, 1991, AM J HUM GENET, V49, P82; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PENROSE LS, 1948, ANN EUGENIC, V14, P125; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; Sambrook J., 1989, MOL CLONING LAB MANU; SHUTLER, 1991, GENOMICS, V9, P500; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; THIBAULT MC, IN PRESS CYTOGENET C; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YULE GU, 1968, INTRO THEORY STATIST	24	694	714	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					545	546		10.1038/355545a0	http://dx.doi.org/10.1038/355545a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346923				2022-12-24	WOS:A1992HC52600058
J	SHAH, M; FOREMAN, DM; FERGUSON, MWJ				SHAH, M; FOREMAN, DM; FERGUSON, MWJ			CONTROL OF SCARRING IN ADULT WOUNDS BY NEUTRALIZING ANTIBODY TO TRANSFORMING GROWTH-FACTOR-BETA	LANCET			English	Note								Adult wounds heal with scar-tissue formation, whereas fetal wounds heal without scarring and with a lesser inflammatory and cytokine response. We injected the margins of healing dermal wounds in adult rats with neutralising antibody (NA) to transforming growth factor-beta (TGF-beta). All control wounds (irrelevant antibody, or TGF-beta, or no injection) healed with scarring, whereas the NA-treated wounds healed without scar-tissue formation; NA-treated wounds had fewer macrophages and blood vessels, lower collagen and fibronectin contents, but identical tensile strength and more normal dermal architecture than the other wounds. Early manipulation of the concentrations of selected cytokines may be a new approach to the control of scarring.	UNIV MANCHESTER, SCH BIOL SCI, DEPT CELL & STRUCT BIOL, STOPFORD BLDG, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; KRUMMEL TM, 1988, J PEDIATR SURG, V23, P647, DOI 10.1016/S0022-3468(88)80638-9; KSANDER GA, 1989, ANNU REP MED CHEM, V24, P223; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; MCGRATH MH, 1990, CLIN PLAST SURG, V17, P421; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WHITBY DJ, 1991, DEVELOPMENT, V112, P651	10	517	570	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1992	339	8787					213	214		10.1016/0140-6736(92)90009-R	http://dx.doi.org/10.1016/0140-6736(92)90009-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346175				2022-12-24	WOS:A1992HA58900006
J	BREATHNACH, AS; JENKINS, DR; PEDLER, SJ				BREATHNACH, AS; JENKINS, DR; PEDLER, SJ			STETHOSCOPES AS POSSIBLE VECTORS OF INFECTION BY STAPHYLOCOCCI	BRITISH MEDICAL JOURNAL			English	Article											BREATHNACH, AS (corresponding author), ROYAL VICTORIA INFIRM,DEPT CLIN MICROBIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							AYCLIFF GA, 1992, CONTROL HOSPITAL INF, P78; AYCLIFFE GA, 1990, J HOSP INFECT, V16, P351; GERKEN A, 1972, LANCET, V1, P1214; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; Waldvogel F. A., 1990, PRINCIPLES PRACTICES, P1489	5	58	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1573	1574		10.1136/bmj.305.6868.1573	http://dx.doi.org/10.1136/bmj.305.6868.1573			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286393	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992KD77100030
J	HANVEY, JC; PEFFER, NJ; BISI, JE; THOMSON, SA; CADILLA, R; JOSEY, JA; RICCA, DJ; HASSMAN, CF; BONHAM, MA; AU, KG; CARTER, SG; BRUCKENSTEIN, DA; BOYD, AL; NOBLE, SA; BABISS, LE				HANVEY, JC; PEFFER, NJ; BISI, JE; THOMSON, SA; CADILLA, R; JOSEY, JA; RICCA, DJ; HASSMAN, CF; BONHAM, MA; AU, KG; CARTER, SG; BRUCKENSTEIN, DA; BOYD, AL; NOBLE, SA; BABISS, LE			ANTISENSE AND ANTIGENE PROPERTIES OF PEPTIDE NUCLEIC-ACIDS	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; RNASE-H; INHIBITION; DNA; OLIGONUCLEOTIDES; TRANSCRIPTION; TRANSLATION; INVITRO	Peptide nucleic acids (PNAs) are polyamide oligomers that can strand invade duplex DNA, causing displacement of one DNA strand and formation of a D-loop. Binding of either a T10 PNA or a mixed sequence 15-mer PNA to the transcribed strand of a G-free transcription cassette caused 90 to 100 percent site-specific termination of pol II transcription elongation. When a T10 PNA was bound on the nontranscribed strand, site-specific inhibition never exceeded 50 percent. Binding of PNAs to RNA resulted in site-specific termination of both reverse transcription and in vitro translation, precisely at the position of the PNA . RNA heteroduplex. Nuclear microinjection of cells constitutively expressing SV40 large T antigen (T Ag) with either a 15-mer or 20-mer PNA targeted to the T Ag messenger RNA suppressed T Ag expression. This effect was specific in that there was no reduction in beta-galactosidase expression from a coinjected expression vector and no inhibition of T Ag expression after microinjection of a 10-mer PNA.	GLAXO INC,RES INST,DEPT CELL BIOL,5 MOORE DR,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT MED CHEM,RES TRIANGLE PK,NC 27709; HOOD COLL,DEPT BIOL,FREDERICK,MD 21701	GlaxoSmithKline; GlaxoSmithKline								BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P59; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WICKSTROM E, 1991, PROSPECTS ANTISENSE; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	19	464	571	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1481	1485		10.1126/science.1279811	http://dx.doi.org/10.1126/science.1279811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279811				2022-12-24	WOS:A1992JZ62500028
J	WINSLOW, GM; SCHERER, MT; KAPPLER, JW; MARRACK, P				WINSLOW, GM; SCHERER, MT; KAPPLER, JW; MARRACK, P			DETECTION AND BIOCHEMICAL-CHARACTERIZATION OF THE MOUSE MAMMARY-TUMOR VIRUS-7 SUPERANTIGEN (MLS-1(A))	CELL			English	Article							RECEPTOR V-BETA; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RESPONSES; STAPHYLOCOCCAL ENTEROTOXIN-B; DISPARATE STIMULATOR CELLS; MLS-MODIFIED PRODUCTS; BONE-MARROW CHIMERAS; OPEN READING FRAME; CLONAL DELETION; DENDRITIC CELLS	Mouse mammary tumor viruses encode superantigens that bind to class II major histocompatibility complex proteins and engage T cells that bear particular V(beta)s. Among these superantigens is the long known, but previously uncharacterized, Mls-1a product, encoded by Mtv-7. Using a monoclonal antibody, we detect the Mtv-7 superantigen on the surface of activated B cells, but not on T cells or resting B cells. The superantigen is synthesized as a 45 kd transmembrane glycoprotein precursor, but is proteolytically processed to yield an 18.5 kd surface protein that we suggest is the functional form of the superantigen.	UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL & MED, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WINSLOW, GM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DIV BASIC IMMUNOL, HOWARD HUGHES MED INST, DENVER, CO 80206 USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	NIAID NIH HHS [AI 18785, AI 17134] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018785, R01AI018785, R01AI017134, R37AI017134, R56AI017134] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; ANDERSON GD, 1989, J IMMUNOL, V143, P3757; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEUTNER U, 1992, P NATL ACAD SCI USA, V89, P5432, DOI 10.1073/pnas.89.12.5432; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BRANDTCARLSON C, 1991, J VIROL, V65, P6051, DOI 10.1128/JVI.65.11.6051-6060.1991; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DEKRUYFF RH, 1986, J IMMUNOL, V137, P1109; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FIRESTONE GL, 1982, NATURE, V300, P221, DOI 10.1038/300221a0; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOLLOB KJ, 1991, J IMMUNOL, V147, P2447; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAINAUT P, 1990, CANCER RES, V50, P3754; HAMILOS DL, 1989, J IMMUNOL, V142, P1069; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HEDO JA, 1983, J BIOL CHEM, V258, P20; HELD W, 1992, J EXP MED, V175, P1623, DOI 10.1084/jem.175.6.1623; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; Herrmann T, 1991, Curr Top Microbiol Immunol, V174, P21; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JOUVINMARCHE E, 1992, P NATL ACAD SCI USA, V89, P3232, DOI 10.1073/pnas.89.8.3232; KAIN SR, 1992, J BIOL CHEM, V267, P8128; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KATZ ME, 1985, J IMMUNOL, V134, P2064; KING LB, 1990, MOL CELL BIOL, V10, P4211, DOI 10.1128/MCB.10.8.4211; KING LB, 1990, J IMMUNOL, V144, P3218; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KNIGHT AM, 1992, EUR J IMMUNOL, V22, P879, DOI 10.1002/eji.1830220339; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUBO RT, 1983, MOL IMMUNOL, V20, P67, DOI 10.1016/0161-5890(83)90106-2; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSONSCIARD EL, 1990, EUR J IMMUNOL, V20, P1223, DOI 10.1002/eji.1830200605; LIEGLER TJ, 1986, J VIROL, V59, P159, DOI 10.1128/JVI.59.1.159-162.1986; LYNCH DH, 1985, J IMMUNOL, V134, P2071; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARCHEJOUVIN E, 1992, P NATL ACAD SCI USA, V89, P3232; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MAZDA O, 1991, J EXP MED, V173, P539, DOI 10.1084/jem.173.3.539; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NANDI S, 1972, J NATL CANCER I, V48, P1085; NICOLAS JF, 1987, EUR J IMMUNOL, V17, P1561, DOI 10.1002/eji.1830171106; OZATO K, 1980, J IMMUNOL, V124, P533; PAPIERNIK M, 1992, J EXP MED, V175, P453, DOI 10.1084/jem.175.2.453; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROSS SR, 1985, P NATL ACAD SCI USA, V82, P5880, DOI 10.1073/pnas.82.17.5880; RUDY CK, 1992, J EXP MED, V175, P1613, DOI 10.1084/jem.175.6.1613; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SINGER PA, 1990, EMBO J, V9, P3641, DOI 10.1002/j.1460-2075.1990.tb07575.x; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; SPEISER DE, 1989, J EXP MED, V170, P2165, DOI 10.1084/jem.170.6.2165; TSUBURA A, 1988, CANCER RES, V48, P6555; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVEREN P, 1988, J VIROL, V62, P4410, DOI 10.1128/JVI.62.11.4410-4413.1988; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1990, SCIENCE, V248, P1643; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1991, J EXP MED, V174, P1255, DOI 10.1084/jem.174.5.1255; YAGI JJ, 1990, J IMMUNOL, V144, P892	102	103	105	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					719	730		10.1016/0092-8674(92)90549-R	http://dx.doi.org/10.1016/0092-8674(92)90549-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330323				2022-12-24	WOS:A1992JZ63300003
J	SPERA, RV; FARBER, BF				SPERA, RV; FARBER, BF			MULTIPLY-RESISTANT ENTEROCOCCUS-FAECIUM - THE NOSOCOMIAL PATHOGEN OF THE 1990S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VANCOMYCIN		N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DIV INFECT DIS & IMMUNOL,MANHASSET,NY 11030	Cornell University; Northwell Health; North Shore University Hospital								HANDWERGER S, 1992, CLIN INFECT DIS, V14, P655, DOI 10.1093/clinids/14.3.655; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; RAMPHAL R, 1992, ANTIMICROB AGENTS CH, V36, P1062, DOI 10.1128/AAC.36.5.1062; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173, DOI 10.1017/S0950268800030478; VANDERAUWERA P, 1990, 30TH INT C ANT AG CH; WADE J, 1991, LANCET, V337, P1616, DOI 10.1016/0140-6736(91)93320-9	12	75	78	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2563	2564		10.1001/jama.268.18.2563	http://dx.doi.org/10.1001/jama.268.18.2563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1308665				2022-12-24	WOS:A1992JW61600030
J	NAGEL, G; HWANG, TC; NASTIUK, KL; NAIRN, AC; GADSBY, DC				NAGEL, G; HWANG, TC; NASTIUK, KL; NAIRN, AC; GADSBY, DC			THE PROTEIN KINASE-A-REGULATED CARDIAC CL- CHANNEL RESEMBLES THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article							CFTR CHLORIDE CHANNEL; AUTONOMIC REGULATION; MYOCYTES; GENE; EXPRESSION; CELLS; PHOSPHORYLATION; IDENTIFICATION; ADRENALINE; ACID	STIMULATION of beta-adrenoceptors in cardiac ventricular myocytes activates a strong chloride ion conductance1-5 as a result of phosphorylation by cyclic AMP-dependent protein kinase (PKA)2,4. This Cl- conductance, which is time- and voltage-independent1-5, counters2,5 the tendency of the simultaneously enhanced Ca2+ channel current to prolong the ventricular action potential. Using inside-out giant patches6 excised from guinea-pig myocytes, we show here that phosphorylation by the PKA catalytic subunit plus Mg-ATP elicits discrete Cl- channel currents. In almost symmetrical Cl- solutions (approximately 150 mM), unitary current amplitude scales with membrane potential, and reverses sign near 0 mV, to yield a single channel conductance of approximately 12 pS. Opening of the phosphorylated channels requires hydrolysable nucleoside triphosphate, indicating that phosphorylation by PKA is necessary, but not sufficient, for channel activation. The properties of these PKA-regulated cardiac Cl- channels are very similar, if not identical, to those of the cystic fibrosis transmembrane conductance regulator (CFTR)7, the epithelial cell Cl- channel whose regulation is defective in patients with cystic fibrosis. The full cardiological impact of these Cl- channels and of their possible malfunction in patients with cystic fibrosis remains to be determined.	ROCKEFELLER UNIV,CARDIAC MEMBRANE PHYSIOL LAB,1230 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Rockefeller University; Rockefeller University				Nairn, Angus/0000-0002-7075-0195; Nagel, Georg/0000-0001-8174-8712				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BENSON LN, 1984, AM REV RESPIR DIS, V130, P987; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHERON G, 1984, ACTA PAEDIATR SCAND, V73, P697, DOI 10.1111/j.1651-2227.1984.tb09999.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; EHARA T, 1990, NATURE, V347, P284, DOI 10.1038/347284a0; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; Hilgemann D, 1991, SODIUM PUMP RECENT D, P543; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; Hwang Tzyh-Chang, 1992, Journal of General Physiology, V100, p69A; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; MATSUOKA S, 1990, J PHYSIOL-LONDON, V425, P579, DOI 10.1113/jphysiol.1990.sp018119; OVERHOLT J L, 1992, Biophysical Journal, V61, pA442; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 1989, MOL CLONING LAB MANU; SULLIVAN MM, 1986, CHEST, V90, P239, DOI 10.1378/chest.90.2.239; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417	30	162	165	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					81	84		10.1038/360081a0	http://dx.doi.org/10.1038/360081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1279437				2022-12-24	WOS:A1992JW71700061
J	PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; QUAN, S; SAYRE, KR; JOHNSON, PJ; WILBER, JC; LEVEY, AS				PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; QUAN, S; SAYRE, KR; JOHNSON, PJ; WILBER, JC; LEVEY, AS			PREVALENCE OF HEPATITIS-C VIRUS-RNA IN ORGAN DONORS POSITIVE FOR HEPATITIS-C ANTIBODY AND IN THE RECIPIENTS OF THEIR ORGANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; CHRONIC NON-A; LONG-TERM; LIVER-DISEASE; RENAL-TRANSPLANTATION; VIRAL-HEPATITIS; SGOT ACTIVITY; TRANSMISSION; SERUM; COMPLICATIONS	Background. There is a high prevalence of liver disease among the recipients of organs from donors with antibodies to hepatitis C virus (HCV). We undertook a study to determine the frequency of persistent HCV infection, as indicated by the presence of HCV RNA, among both cadaveric organ donors positive for antibodies to HCV (anti-HCV) and the recipients of organs from these donors. Methods. Serum samples from donors and recipients were tested for HCV RNA with the reverse transcriptase polymerase chain reaction, with use of primers from the 5' untranslated region of the HCV genome, and for anti-HCV with the first-generation enzyme-linked immunosorbent assay (ELISA) and two second-generation tests. Results. HCV RNA was detected in 9 of the 11 organ donors (82 percent) with a positive first-generation ELISA for anti-HCV. Among the organ recipients, the prevalence of HCV RNA increased after transplantation: 7 of 26 patients (27 percent) had positive samples before transplantation, as compared with 23 of 24 patients (96 percent) after transplantation (P<0.001). Among 13 recipients who were HCV RNA-negative before receiving organs from the nine HCV RNA-positive donors, HCV infection was detected in all 13 after transplantation, and anti-HCV developed in 8 (62 percent). On the basis of a positive test for HCV RNA, the maximal sensitivity of the three anti-HCV tests was 57 percent (positive in 4 of 7 patients with end-stage organ failure) before transplantation and 70 percent (positive in 16 of 23 patients) after transplantation. Conclusions. Nearly all the recipients of organs from anti-HCV-positive donors become infected with HCV. The current tests for anti-HCV antibodies underestimate the incidence of transmission and the prevalence of HCV infection among immunosuppressed organ recipients.	NEW ENGLAND ORGAN BANK INC,1 GATEWAY CTR,WASHINGTON ST & NEWTON CORNER,NEWTON,MA 02158; ORTHO DIAGNOST SYST INC,RARITAN,NJ; CHIRON CORP,EMERYVILLE,CA	Novartis								ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRAUN WE, 1990, KIDNEY INT, V37, P1363, DOI 10.1038/ki.1990.123; CHA TA, 1991, J CLIN MICROBIOL, V29, P2528, DOI 10.1128/JCM.29.11.2528-2534.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN GA, 1976, ANN INTERN MED, V84, P275, DOI 10.7326/0003-4819-84-3-275; Debure A, 1988, Adv Nephrol Necker Hosp, V17, P375; DIETHELM AG, 1992, NEW ENGL J MED, V326, P410, DOI 10.1056/NEJM199202063260612; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; EVANS CS, 1992, TRANSFUSION, V32, P408, DOI 10.1046/j.1537-2995.1992.32592327712.x; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HESS G, 1989, LANCET, V2, P987; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAQUAGLIA MP, 1981, TRANSPLANTATION, V32, P504, DOI 10.1097/00007890-198112000-00011; MAHONY JF, 1989, TRANSPLANT P, V21, P1433; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PEREIRA BJG, 1992, 11 ANN M AM SOC TRAN, P322; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; PIRSCH JD, 1992, NEW ENGL J MED, V326, P412; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; RIESTRA S, 1990, ANN INTERN MED, V113, P411; ROTH D, 1991, Journal of the American Society of Nephrology, V2, P815; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WARNOCK LG, 1974, CLIN CHEM, V20, P1213; WEIR MR, 1985, KIDNEY INT, V28, P839, DOI 10.1038/ki.1985.206; WOLF PL, 1972, CLIN CHEM, V18, P567; 1991, MMWR MORB MORTAL W S, V40, P1	32	235	236	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					910	915		10.1056/NEJM199209243271302	http://dx.doi.org/10.1056/NEJM199209243271302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1325035				2022-12-24	WOS:A1992JP01400002
J	BURNETT, SD; WOOLF, CM; YUDKIN, JS				BURNETT, SD; WOOLF, CM; YUDKIN, JS			DEVELOPING A DISTRICT DIABETIC REGISTER	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objectives-To compile a district wide diabetic register of all diabetic patients registered with general practitioners in the catchment area of a single district general hospital and to compare different approaches to identifying patients. Design-Information for a register was obtained from general practitioners' practice registers, the Prescription Pricing Authority, and hospital diabetic clinic records. Setting-Catchment area of an inner London district general hospital with a large diabetic clinic. Subjects-All patients with a diagnosis of diabetes resident in or attending general practitioners or hospital clinics in the district or its catchment area. Main outcome measures-Prevalence of diabetes, population of patients elicited by different approaches, proportion attending the local district general hospital, cost of using prescription returns for identifying diabetic patients. Results-4674 patients with diabetes were identified from all sources of information, which corresponds to a mean of 22.4 patients per general practitioner and the prevalence of known diabetes of 1.17%. 39.4% of patients identified had Prescription Pricing Authority returns and 42.8% of patients appeared on practices' diabetic registers. Only 56.5% of patients identified attended the district general hospital. For practices where all sources of information were available, practice registers included 60.4% of all patients, and prescription returns and the clinic register identified 64.9% and 40.6% respectively. The cost of using prescription returns to identify patients not detected in other ways was Pound 6-37 per patient. Conclusion-The task of developing district diabetic registers may prove, even in one cross sectional attempt, a major task in many inner city health districts.			BURNETT, SD (corresponding author), WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT MED,LONDON N19 5NF,ENGLAND.		Yudkin, John S/C-1988-2008					COULTER A, 1989, J EPIDEMIOL COMMUN H, V43, P25, DOI 10.1136/jech.43.1.25; HURWITZ B, 1990, DIABETES CLIN MANAGE, P110; JONES RB, 1989, PRACTICAL DIABETES, V3, P129; KOPELMAN P, 1990, DIABETIC MED, V7, P558, DOI 10.1111/j.1464-5491.1990.tb01446.x; MCMAHON C, 1991, DIABETIC MED, V8, P770, DOI 10.1111/j.1464-5491.1991.tb01698.x; NABARRO J, 1987, J ROY COLL GEN PRACT, V37, P389; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277; 1991, RECOMMENDATIONS DIAB	8	30	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					627	630		10.1136/bmj.305.6854.627	http://dx.doi.org/10.1136/bmj.305.6854.627			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1294089	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JN69800022
J	DENT, P; HASER, W; HAYSTEAD, TAJ; VINCENT, LA; ROBERTS, TM; STURGILL, TW				DENT, P; HASER, W; HAYSTEAD, TAJ; VINCENT, LA; ROBERTS, TM; STURGILL, TW			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE BY V-RAF IN NIH 3T3 CELLS AND INVITRO	SCIENCE			English	Article							GROWTH; DEFINITION	Mitogen-activated protein (MAP) kinases are 42- and 44-kD serine-threonine protein kinases that are activated by tyrosine and threonine phosphorylation in cells stimulated with mitogens and growth factors. MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p37(22W)) of the c-Raf-1 protein kinase. The v-Raf proteins purified from cells infected with ECl 2 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro. Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p37(22W)) also activated MAP kinase kinase in vitro. These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.	UNIV VIRGINIA,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Virginia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA050661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NCI NIH HHS [CA50661] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALLEMAIN GL, 1992, J MOL CELL BIOL, V12, P2222; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DENT P, UNPUB; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GALLEGO C, IN PRESS P NATL ACAD; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HASER W, UNPUB; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1992, J BIOL CHEM, V267, P14373; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	27	666	683	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1404	1407		10.1126/science.1326789	http://dx.doi.org/10.1126/science.1326789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1326789				2022-12-24	WOS:A1992JL61200035
J	WEINTRAUB, SJ; PRATER, CA; DEAN, DC				WEINTRAUB, SJ; PRATER, CA; DEAN, DC			RETINOBLASTOMA PROTEIN SWITCHES THE E2F SITE FROM POSITIVE TO NEGATIVE ELEMENT	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; TRANSCRIPTION FACTOR; CELL-CYCLE; EXPRESSION; PROMOTER; BINDING	ORIGINALLY E2F sites were identified as elements in the promoters of adenovirus early genes that are necessary for activation of these genes by the early protein E1a (ref. 1). E2F promoter elements have been shown to be important for transcriptional activation of several genes critical for progression through the cell cycle2-4. During the G1 phase of the cell cycle, the E2F protein forms a complex with the cell-cycle protein Rb (ref. 5) and it has been suggested that this binding of Rb to E2F inactivates E2F (ref. 5). Here we show that Rb-E2F is an active complex that, when bound to the E2F site, inhibits the activity of other promoter elements and thus silences transcription. We propose that the ability of this complex to inhibit transcription is integral to the function of Rb and provide evidence that E2F is a positive element in the absence of an active form of Rb. It has been shown that binding of Rb to E2F depends on the phosphorylation state of Rb (only the underphosphorylated form binds)5 and that the phosphorylation state of Rb changes during progression through the cell cycle6,7. We therefore suggest that the E2F site alternates between a positive and negative element with the phosphorylation/dephosphorylation cycle of Rb. This cyclic activity may be responsible for activating and then inhibiting genes during the cell cycle.	WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; HEARING P, 1983, CELL, V33, P692; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	20	639	655	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					259	261		10.1038/358259a0	http://dx.doi.org/10.1038/358259a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1321348				2022-12-24	WOS:A1992JD58700061
J	LEE, KF; LI, E; HUBER, LJ; LANDIS, SC; SHARPE, AH; CHAO, MV; JAENISCH, R				LEE, KF; LI, E; HUBER, LJ; LANDIS, SC; SHARPE, AH; CHAO, MV; JAENISCH, R			TARGETED MUTATION OF THE GENE ENCODING THE LOW AFFINITY NGF RECEPTOR P75 LEADS TO DEFICITS IN THE PERIPHERAL SENSORY NERVOUS-SYSTEM	CELL			English	Article							GROWTH-FACTOR RECEPTORS; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; SYMPATHETIC NEURONS; FACTOR FAMILY; CHICK-EMBRYO; SUBSTANCE-P; EXPRESSION; CELLS; BRAIN	We have generated mice carrying a mutation of the gene encoding the low affinity NGF receptor p75NGFR by targeted mutation in embryonic stem cells. Mice homozygous for the mutation were viable and fertile. Immunohistochemical analyses of the footpad skin of mutant mice revealed markedly decreased sensory innervation by calcitonin gene-related peptide- and substance P-immunoreactive fibers. The defective innervation was correlated with loss of heat sensitivity and associated with the development of ulcers in the distal extremities. Complicated by secondary bacterial infection, the ulcers progressed to toenail and hair loss. Crossing a human transgene encoding p75NGFR into the mutant animals rescued the absent heat sensitivity and the occurrence of skin ulcers and increased the density of neuropeptide-immunoreactive sensory innervation of footpad skin. The mutation in the gene encoding p75NGFR did not decrease the size of sympathetic ganglia or the density of sympathetic innervation of the iris or salivary gland. Our results suggest that p75NGFR has an important role in the development and function of sensory neurons.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT NEUROSCI, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Cornell University; Case Western Reserve University	LEE, KF (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Chao, Moses/0000-0002-6969-3744	NICHD NIH HHS [HD 23315] Funding Source: Medline; NINDS NIH HHS [NS 023678, NS 21072] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072, R01NS023678] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P1028; ALOE L, 1981, NATURE, V291, P413, DOI 10.1038/291413a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BYERS MR, 1990, DEVELOPMENT, V109, P461; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HAEGERSTRAND A, 1990, P NATL ACAD SCI USA, V87, P3299, DOI 10.1073/pnas.87.9.3299; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1983, NEUROSCIENCE, V8, P631, DOI 10.1016/0306-4522(83)90204-X; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Levi-Montalcini R, 1990, PROG NEUROENDOCRINOL, V3, P1; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDBERGER M, 1989, J NEUROL SCI, V93, P289, DOI 10.1016/0022-510X(89)90198-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; PATIL N, 1990, NEURON, V4, P437, DOI 10.1016/0896-6273(90)90056-L; PEARSON J, 1982, NATURE, V295, P61, DOI 10.1038/295061a0; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROHRER H, 1988, DEVELOPMENT, V103, P545; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; SCHOTZINGER RJ, 1990, NEURON, V5, P91, DOI 10.1016/0896-6273(90)90037-G; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONBARTHELD CS, 1991, DEVELOPMENT, V113, P455; WAKADE AR, 1984, NEUROSCI LETT, V45, P71, DOI 10.1016/0304-3940(84)90331-8; WEIHER H, 1990, CELL, V62, P425, DOI 10.1016/0092-8674(90)90008-3; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WYATT S, 1990, NEURON, V4, P421, DOI 10.1016/0896-6273(90)90054-J; YAN H, 1991, J BIOL CHEM, V266, P12099; YAN Q, 1988, J NEUROSCI, V8, P3481; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	85	863	880	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					737	749		10.1016/0092-8674(92)90286-L	http://dx.doi.org/10.1016/0092-8674(92)90286-L			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1317267				2022-12-24	WOS:A1992HW83800005
J	REYES, H; REISZPORSZASZ, S; HANKINSON, O				REYES, H; REISZPORSZASZ, S; HANKINSON, O			IDENTIFICATION OF THE AH RECEPTOR NUCLEAR TRANSLOCATOR PROTEIN (ARNT) AS A COMPONENT OF THE DNA-BINDING FORM OF THE AH RECEPTOR	SCIENCE			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; HEAT-SHOCK PROTEIN; DIOXIN RECEPTOR; GLUCOCORTICOID RECEPTOR; MUTAGENIC ACTIVATION; CARCINOGENIC ARYLAMINES; AROMATIC-AMINES; MOUSE-LIVER; P-450C GENE; RAT-LIVER	The Ah (dioxin) receptor binds a number of widely disseminated environmental pollutants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and polycyclic aromatic hydrocarbons, and mediates their carcinogenic effects. The ligand-bound receptor activates Cyp1a1 gene transcription through interaction with specific DNA sequences, termed xenobiotic responsive elements (XREs). The Ah receptor nuclear translocator protein (Arnt) is required for Ah receptor function. Arnt is now shown to be a structural component of the XRE binding form of the Ah receptor. Furthermore, Arnt and the ligand-binding subunit of the receptor were extracted as a complex from the nuclei of cells treated with ligand. Arnt contains a basic helix-loop-helix motif, which may be responsible for interacting with both the XRE and the ligand-binding subunit.	UNIV CALIF LOS ANGELES,DEPT PATHOL LAB MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA 28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA T, 1990, CANCER RES, V50, P2060; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; COON MJ, 1983, SOMATIC CELL GENET, V9, P497; COON MJ, 1980, MICROSOMES DRUG OXID, P1149; COON MJ, 1981, SOMATIC CELL GENET, V7, P373; CULLITON BJ, 1991, NATURE, V352, P753, DOI 10.1038/352753a0; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DEGAWA M, 1989, CARCINOGENESIS, V10, P1119, DOI 10.1093/carcin/10.6.1119; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1986, EUR J BIOCHEM, V155, P223, DOI 10.1111/j.1432-1033.1986.tb09480.x; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HANKINSON O, UNPUB; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HENRY EC, 1989, BIOCHEMISTRY-US, V28, P6430, DOI 10.1021/bi00441a041; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OKEY AB, 1980, J BIOL CHEM, V255, P1415; PERDEW GH, 1988, J BIOL CHEM, V263, P9848; PERDEW GH, 1987, J BIOL CHEM, V262, P13802; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND A, 1984, BANBURY REPORT, V18, P109; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REYES H, UNPUB; ROBERTS L, 1991, SCIENCE, V251, P624, DOI 10.1126/science.1846976; ROBERTS L, 1991, SCIENCE, V251, P866, DOI 10.1126/science.2000488; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	45	726	749	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1193	1195		10.1126/science.256.5060.1193	http://dx.doi.org/10.1126/science.256.5060.1193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1317062				2022-12-24	WOS:A1992HV19200033
J	GUTNIAK, M; ORSKOV, C; HOLST, JJ; AHREN, B; EFENDIC, S				GUTNIAK, M; ORSKOV, C; HOLST, JJ; AHREN, B; EFENDIC, S			ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFUSED RAT PANCREAS; SECONDARY FAILURE; INCRETIN CONCEPT; HUMAN-PLASMA; INSULIN; GLUCOSE; SOMATOSTATIN; RELEASE; RADIOIMMUNOASSAY; PROGLUCAGON	Background. Glucagon-like peptide-1 (7-36) amide (glucagon-like insulinotropic peptide, or GLIP) is a gastrointestinal peptide that potentiates the release of insulin in physiologic concentrations. Its effects in patients with diabetes mellitus are not known. Methods. We compared the effect of an infusion of GLIP that raised plasma concentrations of GLIP twofold with the effect of an infusion of saline, on the meal-related release of insulin, glucagon, and somatostatin in eight normal subjects, nine obese patients with non-insulin-dependent diabetes mellitus (NIDDM), and eight patients with insulin-dependent diabetes mellitus (IDDM). The blood glucose concentrations in the patients with diabetes were controlled by a closed-loop insulin-infusion system (artificial pancreas) during the infusion of each agent, allowing measurement of the meal-related requirement for exogenous insulin. In the patients with IDDM, normoglycemic-clamp studies were performed during the infusions of GLIP and saline to determine the effect of GLIP on insulin sensitivity. Results. In the normal subjects, the infusion of GLIP significantly lowered the meal-related increases in the blood glucose concentration (P < 0.01) and the plasma concentrations of insulin and glucagon (P < 0.05 for both comparisons). The insulinogenic index (the ratio of insulin to glucose) increased almost 10-fold, indicating that GLIP had an insulinotropic effect. In the patients with NIDDM, the infusion of GLIP reduced the mean (+/- SE) calculated isoglycemic meal-related requirement for insulin from 17.4 +/- 2.8 to 2.0 +/- 0.5 U (P < 0.001), so that the integrated area under the curve for plasma free insulin was decreased (P < 0.05) in spite of the stimulation of insulin release. In the patients with IDDM, the GLIP infusion decreased the calculated isoglycemic meal-related insulin requirement from 9.4 +/- 1.5 to 4.7 +/- 1.4 U. The peptide decreased glucagon and somatostatin release in both groups of patients. In the normoglycemic-clamp studies in the patients with IDDM, the GLIP infusion significantly increased glucose utilization (saline vs. GLIP, 7.2 +/- 0.5 vs. 8.6 +/- 0.4 mg per kilogram of body weight per minute; P < 0.01). Conclusions. GLIP has an antidiabetogenic effect, and it may therefore be useful in the treatment of patients with NIDDM.	UNIV COPENHAGEN,PANUM INST,INST MED PHYSIOL C,DEPT ENDOCRINOL,DK-2200 COPENHAGEN,DENMARK; UNIV LUND,DEPT PHARMACOL,S-22101 LUND,SWEDEN	University of Copenhagen; Lund University	GUTNIAK, M (corresponding author), KAROLINSKA INST,KAROLINSKA SJUKHUSET,DEPT ENDOCRINOL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN.		Holst, Jens/AAA-8022-2022	Orskov, Cathrine/0000-0002-7762-2372; Holst, Jens Juul/0000-0001-6853-3805				ARIMURA A, 1978, METABOLISM, V27, P1139, DOI 10.1016/0026-0495(78)90032-X; BROWN JC, 1979, CLIN ENDOCRINOL META, V8, P365, DOI 10.1016/S0300-595X(79)80047-X; CONLON JM, 1988, DIABETOLOGIA, V31, P563, DOI 10.1007/BF00264761; CREUTZFELDT W, 1985, DIABETOLOGIA, V28, P565, DOI 10.1007/BF00281990; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; DEFRONZO RA, 1982, DIABETOLOGIA, V23, P313; DRUCKER DJ, 1990, PANCREAS, V5, P484, DOI 10.1097/00006676-199007000-00018; EBERT R, 1979, GASTROENTEROLOGY, V76, P515; EFENDIC S, 1978, FEBS LETT, V92, P33, DOI 10.1016/0014-5793(78)80715-7; EFENDIC S, 1980, FRONTIERS HORMONE RE, V7, P41; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FEHMANN HC, 1991, FEBS LETT, V279, P335, DOI 10.1016/0014-5793(91)80182-3; FINEGOOD DT, 1988, DIABETES, V37, P1025, DOI 10.2337/diabetes.37.8.1025; GENNARO WD, 1975, CLIN CHEM, V21, P873; GUTNIAK M, 1987, DIABETES, V36, P802, DOI 10.2337/diabetes.36.7.802; GUTNIAK M, 1987, DIABETES CARE, V10, P545, DOI 10.2337/diacare.10.5.545; GUTNIAK M, 1990, AM J PHYSIOL, V258, pE805, DOI 10.1152/ajpendo.1990.258.5.E805; HANSEN IL, 1985, DIABETES, V34, P751, DOI 10.2337/diabetes.34.8.751; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HUGGETT ASG, 1957, LANCET, V2, P368; JOHANSSON C, 1981, DIGESTION, V22, P126, DOI 10.1159/000198619; KREJS GJ, 1980, GASTROENTEROLOGY, V78, P26; KREYMANN B, 1987, LANCET, V2, P1300; LABARRE J, 1930, AM J PHYSIOL, V91, P649; Lebovitz H E, 1978, Diabetes Care, V1, P189; MILLER LL, 1960, NATURE, V185, P248, DOI 10.1038/185248a0; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; Moore B, 1906, BIOCHEM J, V1, P28, DOI 10.1042/bj0010028; ORSKOV C, 1987, DIABETOLOGIA, V30, P874; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; ORSKOV C, 1991, J CLIN INVEST, V87, P415, DOI 10.1172/JCI115012; PENMAN E, 1979, ANN CLIN BIOCHEM, V16, P15, DOI 10.1177/000456327901600103; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; ROBERTSON DA, 1988, BAILLIERE CLIN ENDOC, V2, P407, DOI 10.1016/S0950-351X(88)80040-5; SARSON DL, 1984, DIABETES, V33, P389, DOI 10.2337/diabetes.33.4.389; SCHEEN AJ, 1989, DIABETES RES CLIN PR, V6, pS33, DOI 10.1016/0168-8227(89)90076-4; SIMON M, 1982, CLIN CHEM, V28, P9; SUTHERLAND EW, 1960, PHARMACOL REV, V12, P265; SUZUKI S, 1989, ENDOCRINOLOGY, V125, P3109, DOI 10.1210/endo-125-6-3109; TAKAHASHI H, 1990, BIOMED RES-TOKYO, V11, P99, DOI 10.2220/biomedres.11.99; VERDONK CA, 1980, HORM METAB RES, V12, P133, DOI 10.1055/s-2007-996224; WETTERGREN A, 1990, Digestion, V46, P120; 1979, DIABETES, V28, P1039	44	800	951	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1316	1322		10.1056/NEJM199205143262003	http://dx.doi.org/10.1056/NEJM199205143262003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1348845				2022-12-24	WOS:A1992HT80300003
J	COHEN, J; SCHAMROTH, A; NAZARETH, I; JOHNSON, M; GRAHAM, S; THOMSON, D				COHEN, J; SCHAMROTH, A; NAZARETH, I; JOHNSON, M; GRAHAM, S; THOMSON, D			PROBLEM DRUG-USE IN A CENTRAL LONDON GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL SURVEY; OPIATE MISUSE; PRACTITIONERS; ADDICTION	Objective - To describe the profile of problem drug users presenting in general practice and to determine whether they can be cared for in general practice. Design - Study of consultations by problem drug users. Setting - Central London general practice. Subjects - 150 problem drug users presenting over two years. Main outcome measures - Stopping drug use, alterations in lifestyle, obtaining paid work, and stopping drug related crime. Results - Of the 150 patients, 111 were men and 39 women, and 106 were unemployed. 121 patients used heroin, 112 of whom injected. 145 patients accepted a methadone reduction programme and 81 completed it. A further 25 were stabilised on reducing doses of methadone, until places became available for them as inpatients at drug dependency units or rehabilitation projects. Conclusion - Withdrawal programmes for patients who misuse drugs can be successfully managed in general practice.			COHEN, J (corresponding author), WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND.			Nazareth, Irwin/0000-0003-2146-9628				COHEN J, 1990, DRUG ALCOHOL DEPEN, V25, P315, DOI 10.1016/0376-8716(90)90157-A; COOK CCH, 1987, J ROY SOC MED, V80, P782, DOI 10.1177/014107688708001222; GLANZ A, 1986, BRIT MED J, V293, P543, DOI 10.1136/bmj.293.6546.543; GLANZ A, 1986, BRIT MED J, V293, P486, DOI 10.1136/bmj.293.6545.486; MARTIN E, 1987, J ROY SOC MED, V80, P305, DOI 10.1177/014107688708000516; NEVILLE RG, 1988, BRIT MED J, V296, P755, DOI 10.1136/bmj.296.6624.755; PARKER J, 1987, J ROY COLL GEN PRACT, V37, P260; ROBERTSON JR, 1985, BRIT MED J, V290, P34, DOI 10.1136/bmj.290.6461.34; SKIDMORE CA, 1987, J ROY COLL GEN PRACT, V37, P397; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219	10	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1158	1160		10.1136/bmj.304.6835.1158	http://dx.doi.org/10.1136/bmj.304.6835.1158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1327365	Bronze, Green Published			2022-12-24	WOS:A1992HT23200027
J	BERKENSTAM, A; RUIZ, MDV; BARETTINO, D; HORIKOSHI, M; STUNNENBERG, HG				BERKENSTAM, A; RUIZ, MDV; BARETTINO, D; HORIKOSHI, M; STUNNENBERG, HG			COOPERATIVITY IN TRANSACTIVATION BETWEEN RETINOIC ACID RECEPTOR AND TFIID REQUIRES AN ACTIVITY ANALOGOUS TO E1A	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; TATA-BOX; BINDING-PROTEIN; BETA-GENE; ACTIVATION; ALPHA; CELLS; DIFFERENTIATION; IDENTIFICATION	In embryonal carcinoma (EC) cells retinoic acid (RA) strongly induces transcription from the RA receptor beta-2 (RAR-beta-2) promoter through an RA response element (RARE) located in close proximity to the TATA box. Here we demonstrate that recombinant human TATA box-binding protein, hTFIID, and RAR functionally cooperate in transactivation of the RAR-beta-2 promoter in EC cells in a strictly RA-dependent manner. We demonstrate that the core domain of hTFIID is sufficient to mediate RAR-dependent transcription and that Drosophila, but not yeast, TFIID can substitute for hTFIID. In COS cells ectopic expression of the E1A protein is a prerequisite for hTFIID and RAR to cooperate in transactivation. We propose a model for transcriptional regulation of the RAR-beta-2 promoter in EC cells in which RAR, following activation by RA, functionally interacts with hTFIID via an E1A-like activity present in EC cells.	ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	BERKENSTAM, A (corresponding author), EUROPEAN MOLEC BIOL LAB, GENE EXPRESS PROGRAM, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Berkenstam, Anders/E-7136-2012; Stunnenberg, Hendrik G./D-6875-2012; Vivanco, Maria/G-2393-2011	Stunnenberg, Hendrik G./0000-0002-0066-1576; Vivanco, Maria/0000-0002-9540-247X				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIGNAM JD, 1983, NUCL ACIDS RES, V11; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RUI MDM, 1991, EMBO J, V10, P3829; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	59	125	127	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					401	412		10.1016/0092-8674(92)90443-G	http://dx.doi.org/10.1016/0092-8674(92)90443-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316240				2022-12-24	WOS:A1992HT07800004
J	KOSUNEN, TU; SEPPALA, K; SARNA, S; SIPPONEN, P				KOSUNEN, TU; SEPPALA, K; SARNA, S; SIPPONEN, P			DIAGNOSTIC-VALUE OF DECREASING IGG, IGA, AND IGM ANTIBODY-TITERS AFTER ERADICATION OF HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORI; GASTRIC-MUCOSA; SERUM IGG	Titres of antibody to Helicobacter pylori are known to fall with eradication of bacteria. To find out what degree of fall would reliably indicate eradication, 144 patients with Helicobacter pylori infection were given antimicrobial therapy for 2 weeks and then followed up at 6 weeks, 6 months, and 12 months with serological tests, bacterial cultures, and histological studies of gastric specimens. 6 weeks after treatment IgG titres had fallen by 20-30% irrespective of the success of bacterial eradication. In the 121 bacteria-negative patients the decrease continued. 6 and 1 2 months after treatment the titre was 50% or less of pretreatment value in 97% of these patients. In the 23 patients who remained infected, the initial drop of IgG titres, if any, was followed by unchanged or slightly rising titres. IgA and IgM titres, initially raised in 64% and 4% of the patients, respectively, showed similar trends. The high sensitivity (97%) of the IgG antibody tests and a consistent fall within 6 months after eradication of H pylori infection made IgG the most useful immunoglobulin class for follow-up of antimicrobial therapy in individual patients. IgA antibodies were valuable in the 2% patients who had raised titres in this immunoglobulin class only. The few patients (5-5%) who had raised IgM titres also had high IgG titres. Serological tests thus are a cheap and reliable means of monitoring success of eradication of H pylori.	JORVI HOSP,DEPT PATHOL,ESPOO,FINLAND; UNIV HELSINKI,DEPT MED 2,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; University of Helsinki	KOSUNEN, TU (corresponding author), UNIV HELSINKI,DEPT BACTERIOL & IMMUNOL,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.			Sarna, Seppo/0000-0003-3458-1627				BELL GD, 1987, LANCET, V1, P1367; BORODY TJ, 1987, MED J AUSTRALIA, V146, P450, DOI 10.5694/j.1326-5377.1987.tb120344.x; GOODWIN CS, 1985, J CLIN PATHOL, V38, P1127, DOI 10.1136/jcp.38.10.1127; GRAHAM DY, 1987, LANCET, V1, P1174; HIRSCHL AM, 1988, EUR J CLIN MICROBIOL, V7, P570, DOI 10.1007/BF01962618; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; JONES DM, 1984, J CLIN PATHOL, V37, P1002, DOI 10.1136/jcp.37.9.1002; KOSUNEN TU, 1989, SCAND J GASTROENTERO, V24, P110, DOI 10.3109/00365528909092247; MORRIS AJ, 1991, ANN INTERN MED, V114, P662, DOI 10.7326/0003-4819-114-8-662; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ODERDA G, 1989, LANCET, V1, P690; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; VAIRA D, 1988, BMJ-BRIT MED J, V297, P397, DOI 10.1136/bmj.297.6645.397; VALLE J, 1991, SCAND J GASTROENTERO, V26, P1057, DOI 10.3109/00365529109003956; VANBOHEMEN CG, 1989, IMMUNOL LETT, V20, P59, DOI 10.1016/0165-2478(89)90069-2; VEENENDAAL RA, 1991, GUT, V32, P1291, DOI 10.1136/gut.32.11.1291; VILLAKO K, 1990, ENDOSCOPY, V22, P114, DOI 10.1055/s-2007-1012814	18	377	380	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					893	895		10.1016/0140-6736(92)90929-W	http://dx.doi.org/10.1016/0140-6736(92)90929-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348298				2022-12-24	WOS:A1992HN48300004
J	COOLEY, L; VERHEYEN, E; AYERS, K				COOLEY, L; VERHEYEN, E; AYERS, K			CHICKADEE ENCODES A PROFILIN REQUIRED FOR INTERCELLULAR CYTOPLASM TRANSPORT DURING DROSOPHILA OOGENESIS	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; MEDIATED ENHANCER DETECTION; ACTIN-BINDING PROTEINS; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; INSERTIONAL MUTAGENESIS; ACANTHAMOEBA PROFILIN; ANTERIOR PATTERN; GENE FAMILY; MELANOGASTER	The entire cytoplasmic contents of 15 highly polyploid nurse cells are transported rapidly to the oocyte near the end of Drosophila oogenesis, chickadee is one of a small group of genes whose mutant phenotype includes a disruption of this nurse cell cytoplasm transport. We have cloned the chickadee gene and found that cDNA clones encode a protein 40% identical to yeast and Acanthamoeba profilin. The nurse cells from chickadee egg chambers that lack ovary-specific profilin fail to synthesize cytoplasmic actin networks correctly. In addition, the nurse cell nuclei in chickadee egg chambers become displaced and often partially stretched through the channels leading into the oocyte, blocking the flow of cytoplasm. We suggest that the newly synthesized cytoplasmic actin networks are responsible for maintaining nuclear position in the nurse cells.			COOLEY, L (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Verheyen, Esther/0000-0002-9795-5094	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07149] Funding Source: Medline; NIGMS NIH HHS [GM43301] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BINETTE F, 1990, DNA CELL BIOL, V9, P323, DOI 10.1089/dna.1990.9.323; BOHRMANN J, 1987, DEVELOPMENT, V101, P279; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIMARIO P, 1986, CELL TISSUE RES, V246, P103; Engels W.R, 1989, MOBILE DNA, P437; FASANO L, 1988, DEVELOPMENT, V104, P245; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GONDOS B, 1987, INT J GYNECOL PATHOL, V6, P114, DOI 10.1097/00004347-198706000-00003; GONDOS B, 1973, Differentiation, V1, P177, DOI 10.1111/j.1432-0436.1973.tb00112.x; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; GUTZEIT HO, 1986, J CELL SCI, V80, P159; GUTZEIT HO, 1986, J EMBRYOL EXP MORPH, V93, P291; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JAFFE LF, 1979, P NATL ACAD SCI USA, V76, P1328, DOI 10.1073/pnas.76.3.1328; JAFFE LF, 1969, DEVELOP BIOL       S, V3, P83; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; King R. C., 1970, OVARIAN DEV DROSOPHI; KNIPPLE DC, 1984, MOL GEN GENET, V198, P75, DOI 10.1007/BF00328704; KNIPPLE DC, 1991, MOL GEN GENET, V226, P241, DOI 10.1007/BF00273609; KOTARSKI MA, 1983, GENETICS, V105, P371; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MARKEY F, 1981, CELL, V23, P145, DOI 10.1016/0092-8674(81)90279-8; MINDRINOS MN, 1985, EMBO J, V4, P147, DOI 10.1002/j.1460-2075.1985.tb02329.x; MLODZIK M, 1991, IN PRESS METHODS NEU, V9; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1991, CELL MOTIL CYTOSKEL, V20, P169, DOI 10.1002/cm.970200209; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; POPODI E, 1988, DEV BIOL, V127, P248, DOI 10.1016/0012-1606(88)90312-0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SPARDLING A, 1992, IN PRESS DROSOPHILA; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; SUN YA, 1992, IN PRESS DEV BIOL; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WIDADA JS, 1989, NUCLEIC ACIDS RES, V17, P2855, DOI 10.1093/nar/17.7.2855; WOODRUFF RI, 1980, NATURE, V286, P84, DOI 10.1038/286084a0; WOODRUFF RI, 1988, ROUX ARCH DEV BIOL, V197, P231, DOI 10.1007/BF02439430; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276	70	322	330	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					173	184		10.1016/0092-8674(92)90128-Y	http://dx.doi.org/10.1016/0092-8674(92)90128-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1339308				2022-12-24	WOS:A1992HM44500016
J	GAILANI, MR; BALE, SJ; LEFFELL, DJ; DIGIOVANNA, JJ; PECK, GL; POLIAK, S; DRUM, MA; PASTAKIA, B; MCBRIDE, OW; KASE, R; GREENE, M; MULVIHILL, JJ; BALE, AE				GAILANI, MR; BALE, SJ; LEFFELL, DJ; DIGIOVANNA, JJ; PECK, GL; POLIAK, S; DRUM, MA; PASTAKIA, B; MCBRIDE, OW; KASE, R; GREENE, M; MULVIHILL, JJ; BALE, AE			DEVELOPMENTAL DEFECTS IN GORLIN SYNDROME RELATED TO A PUTATIVE TUMOR SUPPRESSOR GENE ON CHROMOSOME-9	CELL			English	Article							BASAL-CELL-CARCINOMA; NEVUS SYNDROME; CANCER; RETINOBLASTOMA; FIBROBLASTS; RADIATION; TISSUE	Gorlin syndrome is an autosomal dominant disorder that predisposes to basal cell carcinomas of the skin, ovarian fibromas, and medulloblastomas. Unlike other hereditary disorders associated with cancer, it features widespread developmental defects. To investigate the possibility that the syndrome is caused by mutation in a tumor suppressor gene, we searched for loss of heterozygosity in 16 sporadic basal cell carcinomas, 2 hereditary basal cell carcinomas, and 1 hereditary ovarian fibroma and performed genetic linkage studies in five Gorlin syndrome kindreds. Eleven sporadic basal cell carcinomas and all 3 hereditary tumors had allelic loss of chromosome 9q31, and all informative kindreds showed tight linkage between the Gorlin syndrome gene and a genetic marker in this region. Loss of heterozygosity at this chromosomal location, particularly in hereditary tumors, implies that the gene is homozygously inactivated and normally functions as a tumor suppressor. In contrast, hemizygous germline mutations lead to multiple congenital anomalies.	NIH, CTR CLIN, DEPT RADIOL, BETHESDA, MD 20892 USA; WESTAT CORP, ROCKVILLE, MD 20852 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06510 USA; NCI, ENVIRONM EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; NIDR, CLIN INVEST & PATIENT CARE BRANCH, BETHESDA, MD 20892 USA; NCI, DERMATOL BRANCH, BETHESDA, MD 20892 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; NCI, CLIN EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Westat; Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GAILANI, MR (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.			DiGiovanna, John J./0000-0002-2750-2313				ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; APPLEGATE LA, 1990, CANCER RES, V50, P637; BALE AE, 1989, CANCER GENET CYTOGEN, V42, P273, DOI 10.1016/0165-4608(89)90095-2; BALE SJ, 1991, AM J MED GENET, V40, P206, DOI 10.1002/ajmg.1320400217; BASSUKAS ID, 1990, LANCET, V336, P825, DOI 10.1016/0140-6736(90)93301-5; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN GL, 1983, AM J PATHOL, V111, P50; FEARS TR, 1982, JNCI-J NATL CANCER I, V69, P365; FEATHERSTONE T, 1983, AM J HUM GENET, V35, P58; FERGUSON-SMITH M A, 1971, Birth Defects Original Article Series, V7, P157; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GAO JS, 1985, CHINESE MED J-PEKING, V98, P538; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIBBS PM, 1986, CANCER GENET CYTOGEN, V20, P369, DOI 10.1016/0165-4608(86)90097-X; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GORLIN RJ, 1960, NEW ENGL J MED, V262, P908, DOI 10.1056/NEJM196005052621803; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HAPPLE R, 1973, CLIN GENET, V4, P17; HOWELL JB, 1959, ARCH DERMATOL, V79, P67, DOI 10.1001/archderm.1959.01560130069008; JACOBS GH, 1982, CANCER, V49, P533, DOI 10.1002/1097-0142(19820201)49:3<533::AID-CNCR2820490322>3.0.CO;2-O; JUNG EG, 1982, ARCH DERMATOL RES, V272, P151; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP M, 1988, GENOMICS, V3, P361, DOI 10.1016/0888-7543(88)90128-0; LITTLE JB, 1989, CANCER RES, V49, P4705; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Nagasawa H, 1984, Basic Life Sci, V29 Pt B, P775; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POVEY S, 1990, CYTOGENET CELL GENET, V55, P136, DOI 10.1159/000133005; RINGBORG U, 1981, J INVEST DERMATOL, V76, P268, DOI 10.1111/1523-1747.ep12526102; ROMKE C, 1985, ARCH DERMATOL RES, V277, P370, DOI 10.1007/BF00509235; Sambrook J., 1989, MOL CLONING LAB MANU; SARTO F, 1989, MUTAT RES, V225, P21, DOI 10.1016/0165-7992(89)90027-4; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRONG LC, 1977, CANCER, V40, P1861, DOI 10.1002/1097-0142(197710)40:4+<1861::AID-CNCR2820400815>3.0.CO;2-9; TROMOVITCH TA, 1978, CANCER-AM CANCER SOC, V41, P653, DOI 10.1002/1097-0142(197802)41:2<653::AID-CNCR2820410232>3.0.CO;2-X; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEITNAUER L, 1989, NUCLEIC ACIDS RES, V17, P10514, DOI 10.1093/nar/17.24.10514	46	360	364	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					111	117		10.1016/0092-8674(92)90122-S	http://dx.doi.org/10.1016/0092-8674(92)90122-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348213				2022-12-24	WOS:A1992HM44500010
J	ABRAMOWICZ, D; PRADIER, O; MARCHANT, A; FLORQUIN, S; DEPAUW, L; VEREERSTRAETEN, P; KINNAERT, P; VANHERWEGHEM, JL; GOLDMAN, M				ABRAMOWICZ, D; PRADIER, O; MARCHANT, A; FLORQUIN, S; DEPAUW, L; VEREERSTRAETEN, P; KINNAERT, P; VANHERWEGHEM, JL; GOLDMAN, M			INDUCTION OF THROMBOSES WITHIN RENAL GRAFTS BY HIGH-DOSE PROPHYLACTIC OKT3	LANCET			English	Note							TUMOR-NECROSIS-FACTOR; TRANSPLANT RECIPIENTS; MONOCLONAL-ANTIBODY; INTERFERON; SERUM	Among 93 consecutive kidney-transplant patients who received prophylactic OKT3 10 mg/day for 2 weeks, 9 had intragraft thromboses within 2 weeks of transplantation. The thromboses were in graft artery in 1 patient and veins in 3. The other 5 had thromboses in glomerular capillaries and thrombotic microangiopathy similar to that of haemolyticuraemic syndrome. All attempted treatments failed, and the 9 grafts had to be removed. The finding that plasma concentrations of prothrombin fragment 1 and 2 were higher 4 h after the first OKT3 dose in OKT3 recipients than in transplant patients who received other prophylaxis (mean 5.88 [SEM 0.76] vs 2.25 [0.59] nmol/l, p < 0.01) confirms that OKT3 has procoagulant effects in vivo.	CLIN UNIV BRUXELLES,HOP ERASME,DEPT HAEMATOL,BRUSSELS,BELGIUM; CLIN UNIV BRUXELLES,HOP ERASME,DEPT PATHOL,BRUSSELS,BELGIUM; CLIN UNIV BRUXELLES,HOP ERASME,DEPT IMMUNOL,BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Universite Libre de Bruxelles	ABRAMOWICZ, D (corresponding author), CLIN UNIV BRUXELLES,HOP ERASME,DEPT NEPHROL,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.		Florquin, Sandrine/B-8242-2012					ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; ABRAMOWICZ D, IN PRESS TRANSPLANTA; CHATENOUD L, 1989, NEW ENGL J MED, V320, P1420; COLVIN RB, 1991, TRANSPL P, V23, P2052; COTRAN RS, 1989, KIDNEY INT, V35, P969, DOI 10.1038/ki.1989.80; KREIS H, 1991, TRANSPLANT REV, V5, P181; VANBUREN D, 1985, SURGERY, V98, P54; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302	8	85	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					777	778		10.1016/0140-6736(92)91897-H	http://dx.doi.org/10.1016/0140-6736(92)91897-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347805				2022-12-24	WOS:A1992HL50100005
J	BRAHAMS, D				BRAHAMS, D			MISSED DIAGNOSIS OF TESTICULAR CANCER	LANCET			English	Editorial Material																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					734	735		10.1016/0140-6736(92)90618-D	http://dx.doi.org/10.1016/0140-6736(92)90618-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347594				2022-12-24	WOS:A1992HK32000016
J	PONNIGHAUS, JM; FINE, PEM; STERNE, JAC; WILSON, RJ; MSOSA, E; GRUER, PJK; JENKINS, PA; LUCAS, SB; LIOMBA, NG; BLISS, L				PONNIGHAUS, JM; FINE, PEM; STERNE, JAC; WILSON, RJ; MSOSA, E; GRUER, PJK; JENKINS, PA; LUCAS, SB; LIOMBA, NG; BLISS, L			EFFICACY OF BCG VACCINE AGAINST LEPROSY AND TUBERCULOSIS IN NORTHERN MALAWI	LANCET			English	Article							TRIAL; DIAGNOSIS	Protection afforded by BCG (bacillus Calmette-Guerin) vaccines against tuberculosis and leprosy varies widely between different populations. In the only controlled trial which assessed protective efficacy of BCG (Danish and Pasteur strains) against both diseases, there was slightly more protection against leprosy than against tuberculosis. We have studied the protective efficacy of BCG (Glaxo, freeze dried) vaccine against these two diseases in Karonga District, northern Malawi. BCG vaccination was introduced into this population in 1974. Prior information about BCG scar status was available for 83 455 individuals followed up between 1979 and 1989. 414 new cases of leprosy and 180 new cases of tuberculosis were found in this population over that period. Protection was estimated at 50% or greater against leprosy, and there was no evidence for lower protection against multibacillary (84%; 95% confidence interval 26% to 97%) than against paucibacillary (51%; 30% to 66%) disease. There was no statistically significant protection by BCG against tuberculosis in this population. These findings add to the evidence that BCG vaccines afford greater protection against leprosy than against tuberculosis.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND; LEPRA,CHILUMBA,MALAWI; QUEEN ELIZABETH HOSP,BLANTYRE,MALAWI; UNIV COLL & MIDDLESEX SCH MED,LONDON,ENGLAND; UNIV HOSP WALES,PUBL HLTH LAB SERV,MYCOBACTERIUM REFERENCE UNIT,CARDIFF,WALES	University of London; London School of Hygiene & Tropical Medicine; University of Malawi; University of London; University College London; Cardiff University			Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				ABEL L, 1990, LANCET, V335, P1536, DOI 10.1016/0140-6736(90)93086-5; BAGSHAWE A, 1989, B WORLD HEALTH ORGAN, V67, P389; BLIN P, 1986, TUBERCLE, V67, P283, DOI 10.1016/0041-3879(86)90017-6; FINE PEM, 1988, BRIT MED BULL, V44, P691, DOI 10.1093/oxfordjournals.bmb.a072277; FINE PEM, 1988, T ROY SOC TROP MED H, V82, P810, DOI 10.1016/0035-9203(88)90003-X; FINE PEM, 1986, LANCET, V2, P499, DOI 10.1016/S0140-6736(86)90367-3; FINE PEM, 1982, EPIDEMIOL REV, V4, P161, DOI 10.1093/oxfordjournals.epirev.a036245; FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35; KAKLAMANI E, 1991, LANCET, P304; LWIN K, 1985, B WORLD HEALTH ORGAN, V63, P1069; MULIYIL J, 1991, INT J LEPROSY, V59, P229; PONNIGHAUS JM, 1988, T ROY SOC TROP MED H, V82, P803, DOI 10.1016/0035-9203(88)90002-8; PONNIGHAUS JM, 1991, INT J LEPROSY, V59, P221; PONNIGHAUS JM, 1987, INT J LEPROSY, V55, P454; PONNIGHAUS JM, 1987, LEPROSY REV, V58, P359; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHAW MA, 1991, LEPROSY REV, V62, P87; STANLEY SJ, 1981, J HYG CAMB, V87, P223; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; TRIPATHY SP, 1983, ANN NATL ACAD MED SC, V19, P12; 1980, INDIAN J MED RES S, V72, P1	21	160	164	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					636	639		10.1016/0140-6736(92)90794-4	http://dx.doi.org/10.1016/0140-6736(92)90794-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347338				2022-12-24	WOS:A1992HH74300003
J	BUSTELO, XR; LEDBETTER, JA; BARBACID, M				BUSTELO, XR; LEDBETTER, JA; BARBACID, M			PRODUCT OF VAV PROTOONCOGENE DEFINES A NEW CLASS OF TYROSINE PROTEIN-KINASE SUBSTRATES	NATURE			English	Article							SEQUENCE	SEVERAL proteins implicated in the regulation of cellular responses to mitogenic stimuli contain a common non-catalytic domain, SH2 (for src-homologous domain 2), that mediates their interaction with activated tyrosine protein kinases. Here we report that p95vav, a proto-oncogene product specifically expressed in cells of the haematopoietic system, contains an SH2 domain and is a substrate for tyrosine protein kinases. Exposure of quiescent NIH3T3 cells ectopically expressing p95vav to either epidermal or platelet-derived growth factors induces the rapid phosphorylation of this protein on tyrosine residues. Activation of the receptors for these growth factors by their cognate ligand results in their association with p95vav, a process mediated by its SH2 domain. In T cells, co-activation of the T-cell receptor and the accessory CD4 cell-surface protein also results in the phosphorylation of the endogenous p95vav protein in tyrosine residues. Phosphorylation of p95vav is rapid, transient and precedes the appearance of most other phosphotyrosine-containing proteins. In addition to the SH2 domain, p95vav contains structural motifs not found in other tyrosine kinase substrates. One such motif is a helix-loop-helix/leucine zipper-like domain which shares some sequence similarity with these motifs in the Myc and Max proteins. Deletion of the helix-loop-helix-like motif causes oncogenic activation of p95vav. These results indicate that p95vav is a new type of signal transduction molecule and suggest a possible role for this protein in the transduction of tyrosine phosphorylation signalling into transcriptional events.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC SCI, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEDBETTER JA, 1991, BLOOD, V77, P1271; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEFTON BM, 1991, ONCOGENE, V6, P683	21	297	298	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					68	71		10.1038/356068a0	http://dx.doi.org/10.1038/356068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1311423				2022-12-24	WOS:A1992HG60200058
J	SIDRANSKY, D; MIKKELSEN, T; SCHWECHHEIMER, K; ROSENBLUM, ML; CAVANEE, W; VOGELSTEIN, B				SIDRANSKY, D; MIKKELSEN, T; SCHWECHHEIMER, K; ROSENBLUM, ML; CAVANEE, W; VOGELSTEIN, B			CLONAL EXPANSION OF P53 MUTANT-CELLS IS ASSOCIATED WITH BRAIN-TUMOR PROGRESSION	NATURE			English	Article							CHROMOSOME-17; MUTATIONS	TUMOUR progression is a fundamental feature of the biology of cancer 1. Cancers do not arise de novo in their final form, but begin as small, indolent growths, which gradually acquire characteristics associated with malignancy. In the brain, for example, low-grade tumours (astrocytomas) evolve into faster growing, more dysplastic and invasive high-grade tumours (glioblastomaS) 2,3. To define the genetic events underlying brain tumour progression, we analysed the p53 gene in ten primary brain tumour pairs. Seven pairs consisted of tumours that were high grade both at presentation and recurrence (group A) and three pairs consisted of low-grade tumours that had progressed to higher grade tumours (group B). In group A pairs, four of the recurrent tumours contained a p53 gene mutation; in three of them, the same mutation was found in the primary tumour. In group B pairs, progression to high grade was associated with a p53 gene mutation. A subpopulation of cells were present in the low-grade tumours that contained the same p53 gene mutation predominant in the cells of the recurrent tumours that had progressed to glioblastoma. Thus, the histological progression of brain tumours was associated with a clonal expansion of cells that had previously acquired a mutation in the p53 gene, endowing them with a selective growth advantage. These experimental observations strongly support Nowell's clonal evolution model of tumour progression 4.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; LUDWIG INST CANC RES,MONTREAL H3A 1A1,QUEBEC,CANADA; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT NEUROL SURG,BRAIN TUMOR RES CTR,SAN FRANCISCO,CA 94143; UNIV FREIBURG,INST PATHOL,NEUROPATOL ABT,W-7800 FREIBURG,GERMANY	Johns Hopkins University; Ludwig Institute for Cancer Research; University of California System; University of California San Francisco; University of Freiburg								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGNER SH, 1988, CANCER RES, V48, P405; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULDS L, 1975, NEOPLASTIC DEV, V2; FOULDS L, 1969, NEOPLASTIC DEV, V1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; RUSSELL DS, 1977, PATHOL TUMOURS NER, P226; SCHERER JH, 1940, AM J CANCER, V40, P159; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123	15	675	682	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					846	848		10.1038/355846a0	http://dx.doi.org/10.1038/355846a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311419				2022-12-24	WOS:A1992HF63600062
J	MARION, MH; KLAP, P; PERRIN, A; COHEN, M				MARION, MH; KLAP, P; PERRIN, A; COHEN, M			STRIDOR AND FOCAL LARYNGEAL DYSTONIA	LANCET			English	Note							PARALYSIS	Fibreoptic laryngoscopy in 6 patients with laryngeal stridor showed immobile vocal cords in a paramedian position but no other local cause. Thus a diagnosis of Gerhardt's syndrome, usually ascribed to paralysis of vocal-cord abductor muscles, was made in 3 patients who had no other signs or symptoms of dystonia, and in 3 patients who had multifocal dystonia. Electromyography (EMG) showed evidence of overactivity of vocal-cord adductors, with no evidence of denervation in the abductor muscles. Botulinum toxin injection of the overactive thyroarytenoid muscles abolished stridor. These clinical and EMG findings indicate that Gerhardt's syndrome is not caused by paralysis of vocal-cord abductors, but represents a focal laryngeal dystonia which may be treatable by botulinum toxin injections of vocal-cord adductor muscles rather than by arytenoidopexy or tracheostomy.	FDN ADOLPHE DE ROTHSCHILD,DEPT OTORHINOLARYNGOL,F-75940 PARIS 19,FRANCE; FDN ADOLPHE DE ROTHSCHILD,NEUROPHYSIOL LAB,F-75940 PARIS 19,FRANCE									ALAJOUANINE T, 1953, Ann Otolaryngol, V70, P365; BANNISTER R, 1981, BRAIN, V104, P351, DOI 10.1093/brain/104.2.351; BLITZER A, 1991, ANN OTO RHINOL LARYN, V100, P85, DOI 10.1177/000348949110000201; Gerhardt C., 1863, VIRCHOWS ARCH, V27, P68; GERHARDT C, 1863, VIRCHOWS ARCH, V27, P296; LAPRESLE J, 1979, J NEUROPATHOL EXP NE, V28, P401; MARION MH, IN PRESS REV NERUOL; MARSDEN CD, 1982, NEUROLOGY, V32, P1202, DOI 10.1212/WNL.32.10.1202; ROTHWELL JC, 1987, MOVEMENT DISORD, V2, P313; WILLIAMS A, 1979, J NEUROL NEUROSUR PS, V42, P151, DOI 10.1136/jnnp.42.2.151; WOODMAN D, 1946, ARCH OTOLARYNGOL, V43, P63	11	44	46	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					457	458		10.1016/0140-6736(92)91060-L	http://dx.doi.org/10.1016/0140-6736(92)91060-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346820				2022-12-24	WOS:A1992HE93200005
J	JACK, T; BROCKMAN, LL; MEYEROWITZ, EM				JACK, T; BROCKMAN, LL; MEYEROWITZ, EM			THE HOMEOTIC GENE APETALA3 OF ARABIDOPSIS-THALIANA ENCODES A MADS BOX AND IS EXPRESSED IN PETALS AND STAMENS	CELL			English	Article							SERUM RESPONSE ELEMENT; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; FLORAL DEVELOPMENT; MORPHOGENESIS	Mutations in the APETALA3 (AP3) gene of A. thaliana result in homeotic transformations of petals to sepals and stamens to carpels. We have cloned the AP3 gene from Arabidopsis based on its homology to the homeotic flower gene deficiens (DEFA) from the distantly related plant Antirrhinum majus. The sequence of four ap3 mutant alleles and genetic mapping analysis prove that the DEFA homolog is AP3. Like several other plant homeotic genes, the AP3 gene contains a MADS box and likely acts as a transcription factor. The region-specific spatial expression pattern of AP3 rules out certain types of sequential models of flower development and argues in favor of a spatial model based on positional information. Since DEFA and AP3 have very similar protein products, mutant phenotypes, and spatial expression patterns, it is likely that these genes are cognate homologs.			JACK, T (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009		NIGMS NIH HHS [GM 13667-02] Funding Source: Medline; OHS HRSA HHS [ST32-GM07616] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COX KH, 1988, PLANT MOL BIOL PRACT, P1; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; CRONQUIST A, 1981, INTEGRATED SYSTEM CL; Darwin C, 1903, MORE LETT C DARWIN, V2; DILCHER D, 1984, NAT HIST, V93, P57; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; Heslop-Harrison J., 1964, BROOKHAVEN SYM BIOL, V16, P109; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HOLDER N, 1979, J THEOR BIOL, V77, P195, DOI 10.1016/0022-5193(79)90307-2; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; Lord EM., 1991, FLOWERING NEWSLETTER, V11, P4; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MCHUGHEN A, 1980, BOT GAZ, V141, P389; MULLER J, 1981, BOT REV, V47, P1, DOI 10.1007/BF02860537; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; Pruitt RE, 1987, GENETIC REGULATION D, P327; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SOMMER H, 1991, DEVELOPMENT S, V1, P169; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	43	754	836	8	95	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					683	697		10.1016/0092-8674(92)90144-2	http://dx.doi.org/10.1016/0092-8674(92)90144-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1346756				2022-12-24	WOS:A1992HF44000009
J	DURKOP, H; LATZA, U; HUMMEL, M; EITELBACH, F; SEED, B; STEIN, H				DURKOP, H; LATZA, U; HUMMEL, M; EITELBACH, F; SEED, B; STEIN, H			MOLECULAR-CLONING AND EXPRESSION OF A NEW MEMBER OF THE NERVE GROWTH-FACTOR RECEPTOR FAMILY THAT IS CHARACTERISTIC FOR HODGKINS-DISEASE	CELL			English	Article							TUMOR-NECROSIS-FACTOR; STERNBERG-REED CELLS; MONOCLONAL-ANTIBODY; POINT MUTATIONS; LYMPHOID-CELLS; KI-1 ANTIGEN; PROTEIN; LINES; TRANSLOCATION; EFFICIENCY	In man, Hodgkin's disease (HD) represents the most frequent lymphoma entity whose pathogenesis is still unknown. In order to contribute to the characterization of the molecular mechanisms of this disease, cDNAs coding for the HD characteristic antigen CD30 were cloned from expression libraries of the human HUT-102 cell line using the monoclonal antibodies Ki-1 and Ber-H2. The open reading frame of the cDNA that can be translated from two mRNA species of 2.6 kb, and 3.8 kb, respectively, predicts a 595 amino acid protein with leader, extracellular, single transmembrane, and intracellular domains. When expressed in COS-1 cells, the cDNA presented properties comparable to native CD30 antigen. The CD30 extracellular domain proved to be homologous to members of the nerve growth factor receptor superfamily. Six cysteine-rich motifs could be recognized within the putative ligand-binding domain.	FREE UNIV BERLIN,KLINIKUM STEGLITZ,INST PATHOL,W-1000 BERLIN 45,GERMANY; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Free University of Berlin; Harvard University; Massachusetts General Hospital								ANDREESEN R, 1984, BLOOD, V63, P1299; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYLSTON AW, 1985, EUR J IMMUNOL, V15, P738, DOI 10.1002/eji.1830150719; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DIEHL V, 1982, CANCER TREAT REP, V66, P615; DIEHL V, 1981, J CANCER RES CLIN, V101, P111, DOI 10.1007/BF00405072; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ESCHENFELDT WH, 1987, METHOD ENZYMOL, V152, P335; FROESE P, 1987, J IMMUNOL, V139, P2081; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUEBLER U, 1983, GENE, V25, P263; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN H, 1990, RES IMMUNOL, V141, P13, DOI 10.1016/0923-2494(90)90098-J; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES DB, 1985, HEMATOL ONCOL, V3, P133, DOI 10.1002/hon.2900030205; KAMESAKI H, 1986, BLOOD, V68, P285; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MATSUI M, 1990, ONCOGENE, V5, P249; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING 3; MORGAN R, 1989, BLOOD, V73, P2155; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; OTSU M, 1987, MOL CELL BIOL, V7, P708, DOI 10.1128/MCB.7.2.708; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAGSDALE C, 1991, NATURE, V350, P660, DOI 10.1038/350660a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAADT M, 1980, INT J CANCER, V26, P723, DOI 10.1002/ijc.2910260605; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SCHWARTING R, 1989, LEUCOCYTE TYPING 4, P419; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; STEIN H, 1989, CANCER RES, V117, P15; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SWAN D, 1972, P NATL ACAD SCI USA, V69, P1408; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VONHEINJE G, 1985, NUCLEIC ACIDS RES, V14, P483	63	605	650	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					421	427		10.1016/0092-8674(92)90180-K	http://dx.doi.org/10.1016/0092-8674(92)90180-K			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310894				2022-12-24	WOS:A1992HD39800004
J	KLIEWER, SA; UMESONO, K; MANGELSDORF, DJ; EVANS, RM				KLIEWER, SA; UMESONO, K; MANGELSDORF, DJ; EVANS, RM			RETINOID X-RECEPTOR INTERACTS WITH NUCLEAR RECEPTORS IN RETINOIC ACID, THYROID-HORMONE AND VITAMIN-D3 SIGNALING	NATURE			English	Article							RESPONSE ELEMENT; BETA-GENE; IDENTIFICATION; BINDING; COMPLEXES; SEQUENCE; PROTEIN	CELLULAR responsiveness to retinoic acid and its metabolites is conferred through two structurally and pharmacologically distinct 1 families of receptors: the retinoic acid receptors (RAR) 2,3 and the retinoid X receptors (RXR) 1. Here we report that the transcriptional activity of RAR and RXR can be reciprocally modulated by direct interactions between the two proteins. RAR and RXR have a high degree of cooperativity in binding to target DNA, consistent with previous reports indicating that the binding of either RAR or RXR to their cognate response elements is enhanced by factors present in nuclear extracts 4,5. RXR also interacts directly with and enhances the binding of nuclear receptors conferring responsiveness to vitamin D3 and thyroid hormone T3; the DNA-binding activities of these receptors are also stimulated by the presence of nuclear extracts 6-9. Together these data indicate that RXR has a central role in multiple hormonal signalling pathways.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute	KLIEWER, SA (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y	21	1357	1386	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					446	449		10.1038/355446a0	http://dx.doi.org/10.1038/355446a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1310351	Green Accepted			2022-12-24	WOS:A1992HB53000069
J	JAHR, CE				JAHR, CE			HIGH PROBABILITY OPENING OF NMDA RECEPTOR CHANNELS BY L-GLUTAMATE	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; ANTICONVULSANT MK-801; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; TIME COURSE; CURRENTS; DESENSITIZATION; POTENTIATION; ANTAGONIST; RESPONSES	Synaptic plasticity can be triggered by calcium flux into neurons through synaptically activated N-methyl-D-aspartate (NMDA) receptor channels. The amplitude and time course of the resulting intracellular calcium transient depend on the number of open NMDA receptor channels and the kinetics of their activation. Short applications of L-glutamate to outside-out patches from hippocampal neurons in the presence and absence of MK-801 revealed that about 30 percent of L-glutamate-bound channels are open at the peak of the current. This high probability of opening suggests that very few channels are required to guarantee a large, localized postsynaptic calcium transient.			JAHR, CE (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST L474, PORTLAND, OR 97201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021419] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21419] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; DALE N, 1985, J PHYSIOL-LONDON, V363, P35, DOI 10.1113/jphysiol.1985.sp015694; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GIBB AJ, 1991, P R SOC LONDON, V243, P34; HALLIWELL RF, 1989, BRIT J PHARMACOL, V96, P480, DOI 10.1111/j.1476-5381.1989.tb11841.x; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JAHR CE, UNPUB; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LESTER RAJ, IN PRESS J NEUROSCI; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACDONALD JF, 1991, J PHYSIOL-LONDON, V432, P483, DOI 10.1113/jphysiol.1991.sp018396; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; RANDALL AD, 1990, NEUROSCI LETT, V114, P191, DOI 10.1016/0304-3940(90)90070-P; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROSENMUND C, 1991, Society for Neuroscience Abstracts, V17, P957; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; VYKLICKY L, 1990, J PHYSIOL-LONDON, V428, P313, DOI 10.1113/jphysiol.1990.sp018214; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	28	124	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1992	255	5043					470	472		10.1126/science.1346477	http://dx.doi.org/10.1126/science.1346477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1346477				2022-12-24	WOS:A1992HA59000043
J	LEID, M; KASTNER, P; LYONS, R; NAKSHATRI, H; SAUNDERS, M; ZACHAREWSKI, T; CHEN, JY; STAUB, A; GARNIER, JM; MADER, S; CHAMBON, P				LEID, M; KASTNER, P; LYONS, R; NAKSHATRI, H; SAUNDERS, M; ZACHAREWSKI, T; CHEN, JY; STAUB, A; GARNIER, JM; MADER, S; CHAMBON, P			PURIFICATION, CLONING, AND RXR IDENTITY OF THE HELA-CELL FACTOR WITH WHICH RAR OR TR HETERODIMERIZES TO BIND TARGET SEQUENCES EFFICIENTLY	CELL			English	Article							RETINOIC-ACID RECEPTOR; THYROID-HORMONE RECEPTORS; MOUSE ESTROGEN-RECEPTOR; VITAMIN-D RECEPTOR; V-ERB-A; RESPONSE ELEMENT; NUCLEAR RECEPTOR; BETA-GENE; EXPRESSION; PROTEIN	We have purified and cloned a HeLa cell nuclear protein that strongly stimulates binding of retinoic acid and thyroid hormone receptors (RARs and TRs) to resPonse elements. The purified protein is a human retinoid X receptor-beta (hRXR-beta). Three murine members of the RXR family (mRXR-alpha, beta, and gamma) have also been cloned, and their interactions with RARs and TRs have been investigated. Under conditions where RAR, RXR, and TR bound poorly as homodimers to various response elements, strongly cooperative RAR-RXR and TR-RXR binding was observed. The binding efficiency was dependent on the sequence, relative orientation, and spacing of the repeated motifs of response elements. We show also that unstable RAR-RXR heterodimers were formed in solution, and that C-terminal sequences and the DNA-binding domains of both receptors were required for efficient formation of stable heterodimers on response elements. These findings suggest a convergence of the signaling pathways of some members of the nuclear receptor superfamily.	FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	LEID, M (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE.			Nakshatri, Harikrishna/0000-0001-8876-0052				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DESBOIS C, 1991, ONCOGENE, V6, P2129; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1992, IN PRESS EMBO J; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PERLMAN AJ, 1982, J BIOL CHEM, V257, P930; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	98	1206	1252	0	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					377	395		10.1016/0092-8674(92)90478-U	http://dx.doi.org/10.1016/0092-8674(92)90478-U			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310259				2022-12-24	WOS:A1992HB35300016
J	LEVIN, AA; STURZENBECKER, LJ; KAZMER, S; BOSAKOWSKI, T; HUSELTON, C; ALLENBY, G; SPECK, J; KRATZEISEN, C; ROSENBERGER, M; LOVEY, A; GRIPPO, JF				LEVIN, AA; STURZENBECKER, LJ; KAZMER, S; BOSAKOWSKI, T; HUSELTON, C; ALLENBY, G; SPECK, J; KRATZEISEN, C; ROSENBERGER, M; LOVEY, A; GRIPPO, JF			9-CIS RETINOIC ACID STEREOISOMER BINDS AND ACTIVATES THE NUCLEAR RECEPTOR RXR-ALPHA	NATURE			English	Article							THYROID-HORMONE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; ANALOGS; CELLS	VITAMIN-A (retinol) and its natural derivatives are required for many physiological processes 1-3. The activity of retinoids is thought to be mediated by interactions with two subfamilies of nuclear retinoic acid receptors, RAR and RXR. The RARs bind all-trans retinoic acid (t-RA) with high affinity and alter gene expression as a consequence of this direct ligand interaction 4-10. RXR-alpha is activated by t-RA, yet has little binding affinity for this ligand (ref. 11). t-RA may be converted to a more proximate ligand that directly binds and activates RXR-alpha, and we have developed a method of nuclear receptor-dependent ligand trapping to test this hypothesis. Here we report the identification of a stereoisomer of retinoic acid, 9-cis retinoic acid, which directly binds and activates RXR-alpha. These results suggest a new role for isomerization in the physiology of natural retinoids.	HOFFMANN LA ROCHE INC,DEPT MED CHEM,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT DRUG METAB,NUTLEY,NJ 07110	Roche Holding; Roche Holding	LEVIN, AA (corresponding author), HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110, USA.							ALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605; ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAVEY MT, 1990, ANAL BIOCHEM, V186, P19, DOI 10.1016/0003-2697(90)90565-Q; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWARD WA, 1969, BRIT J NUTR, V23, P619, DOI 10.1079/BJN19690069; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DELEENHEER AP, 1990, METHOD ENZYMOL, V189, P104; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; GARLAND WA, 1991, TRAC-TREND ANAL CHEM, V10, P177, DOI 10.1016/0165-9936(91)85018-M; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUSELTON CA, 1990, LIQUID CROMATOGRAPHY, P166; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHULE R, 1991, P NATL ACAD SCI USA, V88, P6092; THAILER C, 1987, NATURE, V327, P625; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169	35	1231	1290	6	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					359	361		10.1038/355359a0	http://dx.doi.org/10.1038/355359a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309942				2022-12-24	WOS:A1992HA59100071
J	ONEILL, D				ONEILL, D			PHYSICIANS, ELDERLY DRIVERS, AND DEMENTIA	LANCET			English	Article							AGE; MEDICINE	In western countries, the proportion of drivers who are elderly is increasing rapidly; over a quarter of the driving population will be 55 years of age or older by the year 2000. Although elderly drivers tend to drive less and may avoid night driving, the number of car accidents and the severity of injuries sustained in such accidents by distance driven increases strikingly after the age of 65. But how can doctors identify those elderly drivers who are a danger to themselves and others? And, once they are identified, how should clinicians balance the effects of removing a driving license, which may greatly affect a patient's lifestyle, against public safety and breach of confidentiality if the patient refuses to give up his or her license voluntarily? Medical decisions about illnesses that predispose to loss of consciousness are fairly clear-cut, but normal ageing processes and dementia can be much more difficult to identify and to assess; moreover, there seems little correlation between tests of mental performance and driving ability. Comparisons between practices in different countries may provide some answers, but the introduction of modified driving tests for elderly drivers with some evidence of mild impairment but who wish to retain their driving license should be considered.			ONEILL, D (corresponding author), FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				[Anonymous], 1990, LANCET, V336, P781; BETTS T, 1988, INT CLIN PSYCHOPH S1, V3, P88; CARR D, 1991, J AM GERIATR SOC, V39, pA62; CARTWRIGHT A, 1990, BRIT MED BULL, V46, P63, DOI 10.1093/oxfordjournals.bmb.a072395; COOPERSMITH HG, 1989, CAN MED ASSOC J, V140, P375; Donnelly R E, 1990, J Geriatr Psychiatry Neurol, V3, P67, DOI 10.1177/089198879000300203; DRACHMAN DA, 1988, ANN NEUROL, V24, P787, DOI 10.1002/ana.410240614; EVANS L, 1988, J GERONTOL, V43, pS186, DOI 10.1093/geronj/43.6.S186; Evans L., 1991, TRAFFIC SAFETY DRIVE; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HART S, 1991, NEUROPSYCHOLOGY DEME; HOLLAND CA, IN PRESS APPL COGNIT; HUTTON J, 1991, CARERS PROFESSIONALS, P279; KLAMM ER, 1985, DRIVERS 55 PLUS NEED, P87; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; MALFETTI JL, 1985, DRIVERS 55 PLUS NEED; MCFARLAND RA, 1964, J GERONTOL, V19, P190, DOI 10.1093/geronj/19.2.190; OCONNOR DW, 1988, BMJ-BRIT MED J, V297, P1107, DOI 10.1136/bmj.297.6656.1107; ODENHEIMER G, 1991, J AM GERIATR SOC, V39, pA9; ONEILL D, IN PRESS J R SOC MED; PFEIFFER RI, 1987, AM J EPIDEMIOL, V125, P420; PONDS RWHM, 1988, J GERONTOL, V43, pP151, DOI 10.1093/geronj/43.6.P151; RAFFLE A, 1985, MED ASPECTS FITNESS, P92; RETCHIN SM, 1988, J AM GERIATR SOC, V36, P813, DOI 10.1111/j.1532-5415.1988.tb04265.x; REUBEN DB, 1988, J AM GERIATR SOC, V36, P1135, DOI 10.1111/j.1532-5415.1988.tb04403.x; SEIB H, 1990, Z GERONTOL, V23, P86; TAIRA ED, 1989, ASSESSING DRIVING AB; WALLER JA, 1967, J CHRON DIS, V20, P615, DOI 10.1016/0021-9681(67)90038-0; WALSH JB, 1980, J IRISH MED ASSOC, V73, P62; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; WILLIAMS C, 1991, J AM GERIATR SOC, V39, pA72; 1985, TRAFFIC SAFETY ELDER; 1985, PROFESSIONAL CONDUCT, P19; 1988, MOTORING OLDER DRIVE, P40; 1990, MED ASPECTS FITNESS; 1983, JAMA-J AM MED ASSOC, V249, P3216; 1984, CALDMVRSS8292 CAL ST	39	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					41	43		10.1016/0140-6736(92)90155-V	http://dx.doi.org/10.1016/0140-6736(92)90155-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY043	1345962				2022-12-24	WOS:A1992GY04300015
J	THORNTON, HM				THORNTON, HM			BREAST-CANCER TRIALS - A PATIENTS VIEWPOINT	LANCET			English	Editorial Material											THORNTON, HM (corresponding author), SAIONARA,31 REGENT ST,COLCHESTER CO5 7EA,ESSEX,ENGLAND.							Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; HAMILTON CR, 1990, BRIT MED J, V301, P224, DOI 10.1136/bmj.301.6745.224	2	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					44	45		10.1016/0140-6736(92)90157-X	http://dx.doi.org/10.1016/0140-6736(92)90157-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345963				2022-12-24	WOS:A1992GY04300016
J	FEINMESSER, R; MIYAZAKI, I; CHEUNG, R; FREEMAN, JL; NOYEK, AM; DOSCH, HM				FEINMESSER, R; MIYAZAKI, I; CHEUNG, R; FREEMAN, JL; NOYEK, AM; DOSCH, HM			DIAGNOSIS OF NASOPHARYNGEAL CARCINOMA BY DNA AMPLIFICATION OF TISSUE OBTAINED BY FINE-NEEDLE ASPIRATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; BURKITTS-LYMPHOMA; CELLS; ANTIBODIES; EXPRESSION; SEROLOGY; GENOMES; NODES	Background. In nasopharyngeal carcinoma the primary lesion is often difficult to find. Metastatic lesions occur frequently but are difficult to distinguish from other head and neck tumors. The viral genome of the Epstein-Barr virus (EBV) can be identified in the cells of this carcinoma. Methods. We used the polymerase chain reaction (PCR) to test for the presence of EBV genomes in 15 samples of metastatic squamous-cell carcinoma of the neck obtained by fine-needle aspiration and in 26 samples obtained by biopsy of lymph nodes. For controls we used disease-free lymph nodes from 10 patients with various head and neck tumors, tonsillar tissue from 46 subjects, blood from 59 EBV-seropositive blood donors, and mononuclear cells from 8 patients with fatal lymphoproliferative lesions. Results. Of the 41 malignant lesions examined, only the nine nasopharyngeal carcinomas (one primary lesion and eight metastases) contained EBV genomes. None of the 20 nodes with other types of cancer, the 10 disease-free nodes, or any of the 105 normal control samples contained detectable EBV. In two patients with suspected metastases from occult primary tumors, the presence of EBV was predictive of nasopharyngeal carcinoma; in both cases overt nasopharyngeal carcinoma developed within one year. Conclusions. In patients with suspected nasopharyngeal carcinoma, fine-needle aspiration can provide tissue for diagnosis by DNA amplification of EBV genomes. The presence of EBV in metastases from an occult primary tumor is predictive of the development of overt nasopharyngeal carcinoma.	HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; MT SINAI HOSP,DEPT OTOLARYNGOL,TORONTO M5G 1X5,ONTARIO,CANADA; BEILINSON MED CTR,TEL AVIV,ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Rabin Medical Center								AMMATUNA P, 1988, MICROBIOLOGICA, V11, P89; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; Atichartakarn V, 1985, Southeast Asian J Trop Med Public Health, V16, P619; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CAI WM, 1983, INT J RADIAT ONCOL, V9, P1763, DOI 10.1016/0360-3016(83)90341-3; CHAN MKM, 1989, ACTA CYTOL, V33, P344; DOSCH HM, 1990, INT IMMUNOL, V2, P833, DOI 10.1093/intimm/2.9.833; DOSCH HM, 1991, INT IMMUNOL, V3, P731, DOI 10.1093/intimm/3.7.731; FEDDER M, 1985, AM J MED, V79, P365, DOI 10.1016/0002-9343(85)90315-8; FRABLE MS, 1982, LARYNGOSCOPE, V92, P1414; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; HENLE W, 1973, JNCI-J NATL CANCER I, V51, P361; HERBST H, 1990, AM J PATHOL, V137, P13; HO JHC, 1978, INT J RADIAT ONCOL, V4, P182; JESSE RH, 1973, CANCER, V31, P854, DOI 10.1002/1097-0142(197304)31:4<854::AID-CNCR2820310414>3.0.CO;2-D; KLINE TS, 1980, ARCH PATHOL LAB MED, V104, P117; Levine P H, 1981, Cancer Detect Prev, V4, P307; LINZ U, 1990, BIOTECHNIQUES, V9, P286; MACCOMB WS, 1972, AM J SURG, V124, P441, DOI 10.1016/0002-9610(72)90064-5; NEEL HB, 1983, OTOLARYNG HEAD NECK, V91, P255, DOI 10.1177/019459988309100310; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PEARSON GR, 1983, CANCER, V51, P260, DOI 10.1002/1097-0142(19830115)51:2<260::AID-CNCR2820510216>3.0.CO;2-#; PEIPER SC, 1990, ARCH PATHOL LAB MED, V114, P711; ROBINSON D W, 1959, Plast Reconstr Surg Transplant Bull, V23, P27, DOI 10.1097/00006534-195901000-00004; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; SMITH PE, 1967, AM J SURG, V113, P633, DOI 10.1016/0002-9610(67)90309-1; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	32	128	129	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					17	21		10.1056/NEJM199201023260103	http://dx.doi.org/10.1056/NEJM199201023260103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1309196	Bronze			2022-12-24	WOS:A1992GX31500003
J	BORDER, WA; NOBLE, NA; YAMAMOTO, T; HARPER, JR; YAMAGUCHI, Y; PIERSCHBACHER, MD; RUOSLAHTI, E				BORDER, WA; NOBLE, NA; YAMAMOTO, T; HARPER, JR; YAMAGUCHI, Y; PIERSCHBACHER, MD; RUOSLAHTI, E			NATURAL INHIBITOR OF TRANSFORMING GROWTH-FACTOR-BETA PROTECTS AGAINST SCARRING IN EXPERIMENTAL KIDNEY-DISEASE	NATURE			English	Article							EXPERIMENTAL GLOMERULONEPHRITIS; EXTRACELLULAR-MATRIX; RAT GLOMERULUS; FIBRONECTIN	THE central pathological feature of human kidney disease that leads to kidney failure is the accumulation of extracellular matrix in glomeruli. Overexpression of transforming growth factor-beta (TGF-beta) underlies the accumulation of pathological matrix in experimental glomerulonephritis1. Administration of an antibody raised against TGF-beta to glomerulonephritic rats suppresses glomerular matrix production and prevents matrix accumulation in the injured glomeruli2. One of the matrix components induced by TGF-beta, the proteoglycan decorin, can bind TGF-beta and neutralize its biological activity3, so decorin may be a natural regulator of TGF-beta (refs 3, 4). We tested whether decorin could antagonize the action of TGF-beta in vivo using the experimental glomerulonephritis model1. We report here that administration of decorin inhibits the increased production of extracellular matrix and attenuates manifestations of disease, confirming our hypothesis. On the basis of our results, decorin may eventually prove to be clinically useful in diseases associated with overproduction of TGF-beta.	TELIOS PHARMACEUT INC,SAN DIEGO,CA 92121; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute	BORDER, WA (corresponding author), UNIV UTAH,SCH MED,DIV NEPHROL,SALT LAKE CITY,UT 84132, USA.							BALZA E, 1988, FEBS LETT, V228, P42, DOI 10.1016/0014-5793(88)80580-5; BORDER WA, 1988, KIDNEY INT, V34, P419, DOI 10.1038/ki.1988.197; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1990, KIDNEY INT, V37, P289; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; COURTOY PJ, 1980, J CELL BIOL, V87, P691, DOI 10.1083/jcb.87.3.691; COURTOY PJ, 1982, J HISTOCHEM CYTOCHEM, V30, P874, DOI 10.1177/30.9.7130672; GINSBERG JM, 1992, J CLIN INVEST, V90, P1; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OOMURA A, 1989, VIRCHOWS ARCH A, V415, P151, DOI 10.1007/BF00784353; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; ROBERTS AB, 1989, HDB EXPT PHARM, P419; WANG A, 1991, J BIOL CHEM, V266, P15598; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	16	958	1012	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					361	364		10.1038/360361a0	http://dx.doi.org/10.1038/360361a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280332				2022-12-24	WOS:A1992JZ63000057
J	DAUBE, SS; VONHIPPEL, PH				DAUBE, SS; VONHIPPEL, PH			FUNCTIONAL TRANSCRIPTION ELONGATION COMPLEXES FROM SYNTHETIC RNA-DNA BUBBLE DUPLEXES	SCIENCE			English	Article							TERNARY COMPLEXES; CHAIN ELONGATION; POLYMERASE-II; BINDING; INITIATION; HOLOENZYME; TEMPLATE; PROTEIN; INVITRO; VIEW	A synthetic RNA-DNA bubble duplex construct intended to mimic the nucleic acid frame-work of a functional transcription elongation complex was designed and assembled. The construct consisted of a double-stranded DNA duplex of variable length (the template and nontemplate strands) containing an internal noncomplementary DNA "bubble" sequence. The 3' end of an RNA oligonucleotide that is partially complementary to the template DNA strand was hybridized within the DNA bubble to form an RNA-DNA duplex with a noncomplementary 5'-terminal RNA tail. The addition of either Escherichia coli or T7 RNA polymerase to this construct formed a complex that synthesized RNA with good efficiency from the hybridized RNA primer in a template-directed and processive manner, and displayed other features of a normal promoter-initiated transcription elongation complex. Other such constructs can be designed to examine many of the functional and regulatory properties of transcription systems.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	DAUBE, SS (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; CHAMBERLIN MJ, 1973, J BIOL CHEM, V148, P2235; DAUBE SS, UNPUB; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, IN PRESS J MOL BIOL; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; REDDY MK, 1992, J BIOL CHEM, V267, P14157; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WEBSTER KR, 1991, BIOTECHNIQUES, V11, P658; WHEELER AR, 1987, BIOCHEMISTRY-US, V26, P3322, DOI 10.1021/bi00386a012; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	28	92	108	3	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 20	1992	258	5086					1320	1324		10.1126/science.1280856	http://dx.doi.org/10.1126/science.1280856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1280856				2022-12-24	WOS:A1992JY95800026
J	HORAK, ER; LEEK, R; KLENK, N; LEJEUNE, S; SMITH, K; STUART, N; GREENALL, M; STEPNIEWSKA, K; HARRIS, AL				HORAK, ER; LEEK, R; KLENK, N; LEJEUNE, S; SMITH, K; STUART, N; GREENALL, M; STEPNIEWSKA, K; HARRIS, AL			ANGIOGENESIS, ASSESSED BY PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE ANTIBODIES, AS INDICATOR OF NODE METASTASES AND SURVIVAL IN BREAST-CANCER	LANCET			English	Article							TUMOR ANGIOGENESIS; ANTIGEN	Animal models suggest a role for new vessel formation (angiogenesis) in tumours with metastatic potential, and there is some evidence that this is true for human tumours. What is needed is a sensitive and specific label for endothelial cells, and one candidate would be a monoclonal antibody to platelet/endothelial cell adhesion molecule (PECAM). We have counted microvessels in 103 primary breast cancers using the JC70 antibody to PECAM (or CD31). We compared our findings with various pathological indicators (lymph node status and tumour grade, size, and type and markers (oestrogen receptor, and c-erbB-2 expression and detection of mutant p53). Tumours showed significantly higher vascularisation than normal breast tissue and the number of blood vessels/mm2 was significantly associated with node metastasis. Only 2 out of 50 tumours with 99 vessel/mm2 or less were node positive whereas 31 out of 39 tumours with counts above 140/mm2 were positive (p<0.0001). Tumour size and grade also correlated with node metastasis and vascularisation also increased with the size of the primary and with poor differentiation. However, within each subgroup of size or differentiation tumours without node involvement had much lower vascular counts, and multivariate analysis showed that vascular count alone explains the association of size and grade with node metastasis. Other markers, conventional or novel, did not correlate with vascularisation. Even with the short follow-up in this series, vascular counts correlated with early death. These results suggest that angiogenesis is closely linked to metastasis, that it is acquired at a critical density of vessels, and that this process occurs as tumours enlarge or become more poorly differentiated. Counting of newly formed microvessels stained with endothelium-specific antibodies may prove to be a useful tool in the early detection of metastatic potential and in the selection of patients for whom anti-angiogenesis drugs might be beneficial.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND; IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC1,ENGLAND	University of Oxford; University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Stepniewska, Kasia/0000-0002-1713-6209; Leek, Russell/0000-0002-8038-8660				ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GANNON JV, 1990, EMBO J, V9, P3927; Gatter KC, 1984, RECENT ADV HISTOPATH, P35; Goldmann E, 1907, LANCET, V2, P1236; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HORAK E, 1991, ONCOGENE, V6, P2277; JENSEN HM, 1982, SCIENCE, V218, P293, DOI 10.1126/science.6181563; KUZU I, 1992, J CLIN PATHOL, V45, P143, DOI 10.1136/jcp.45.2.143; LIOTTA LA, 1974, CANCER RES, V34, P997; MAHADEVAN V, 1990, ACTA ONCOL, V29, P97, DOI 10.3109/02841869009089997; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; NICHOLSON S, 1989, LANCET, V1, P182; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690; SCHMIDT JG, 1992, LANCET, V339, P810, DOI 10.1016/0140-6736(92)91937-4; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; STARKEY JR, 1988, INT J CANCER, V42, P48, DOI 10.1002/ijc.2910420110; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	21	810	868	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1120	1124		10.1016/0140-6736(92)93150-L	http://dx.doi.org/10.1016/0140-6736(92)93150-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1279332				2022-12-24	WOS:A1992JX13400003
J	KOUTSKY, LA; HOLMES, KK; CRITCHLOW, CW; STEVENS, CE; PAAVONEN, J; BECKMANN, AM; DEROUEN, TA; GALLOWAY, DA; VERNON, D; KIVIAT, NB				KOUTSKY, LA; HOLMES, KK; CRITCHLOW, CW; STEVENS, CE; PAAVONEN, J; BECKMANN, AM; DEROUEN, TA; GALLOWAY, DA; VERNON, D; KIVIAT, NB			A COHORT STUDY OF THE RISK OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE-2 OR GRADE-3 IN RELATION TO PAPILLOMAVIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-1; CANCER; WOMEN; HERPES; ANTIBODIES	Background Human papillomavirus (HPV) has been associated with cervical intraepithelial neoplasia, but the temporal relation between the infection and the neoplasia remains unclear, as does the relative importance of the specific type of HPV, other sexually transmitted diseases, and other risk factors. Methods. We studied prospectively a cohort of 241 women who presented for evaluation of sexually transmitted disease and had negative cervical cytologic tests. The women were followed every four months with cytologic and colposcopic examinations of the uterine cervix and tests for HPV DNA and other sexually transmitted diseases. Results. Cervical intraepithelial neoplasia grade 2 or 3 was confirmed by biopsy in 28 women. On the basis of survival analysis, the cumulative incidence of cervical intraepithelial neoplasia at two years was 28 percent among women with a positive test for HPV and 3 percent among those without detectable HPV DNA. The risk was highest among those with HPV type 16 or 18 infection (adjusted relative risk as compared with that in women without HPV infection, 11; 95 percent confidence interval, 4.6 to 26; attributable risk, 52 percent). All 24 cases of cervical intraepithelial neoplasia grade 2 or 3 among HPV-positive women were detected within 24 months after the first positive test for HPV. After adjustment for the presence of HPV infection, the development of cervical intraepithelial neoplasia was also associated with younger age at first intercourse, the presence of serum antibodies to Chlamydia trachomatis, the presence of serum antibodies to cytomegalovirus, and cervical infection with Neisseria gonorrhoeae. Conclusions. Cervical intraepithelial neoplasia is a common and apparently early manifestation of cervical infection by HPV, particularly types 16 and 18.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT OBSTET & GYNECOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DEPT TUMOR BIOL, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center			, Holmes/K-6215-2019		NATIONAL CANCER INSTITUTE [R01CA034493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024756, P01AI012192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34493] Funding Source: Medline; NIAID NIH HHS [AI 12192, AI 24756] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; Breslow N E, 1987, IARC Sci Publ, P1; CAMPION MJ, 1986, LANCET, V2, P237; CUZICK J, 1989, BRIT J CANCER, V60, P238, DOI 10.1038/bjc.1989.261; DEVILLIERS EM, 1987, LANCET, V2, P703; DONNAN SPB, 1989, INT J EPIDEMIOL, V18, P32, DOI 10.1093/ije/18.1.32; HARRIS RWC, 1980, BRIT J CANCER, V42, P359, DOI 10.1038/bjc.1980.246; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; KIVIAT NB, 1992, INT J GYNECOL PATHOL, V11, P197, DOI 10.1097/00004347-199207000-00005; Koss L. G, 1979, DIAGNOSTIC CYTOLOGY; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LORINCZ A, 1990, SEXUALLY TRANSMITTED, P953; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; LORINCZ AT, 1990, AM J OBSTET GYNECOL, V162, P645, DOI 10.1016/0002-9378(90)90974-C; LORINCZ AT, 1986, VIRAL ETIOLOGY CERVI, P225; MCDOUGALL JK, 1986, CIBA F SYMP, V120, P86; Paavonen J, 1988, Obstet Gynecol Surv, V43, P373, DOI 10.1097/00006254-198807000-00001; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; PRATILI M A, 1986, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V15, P45; REEVES WC, 1987, INT J CANCER, V40, P450, DOI 10.1002/ijc.2910400403; REID R, 1987, AM J OBSTET GYNECOL, V156, P212, DOI 10.1016/0002-9378(87)90241-9; RITTER DB, 1988, AM J OBSTET GYNECOL, V159, P1517, DOI 10.1016/0002-9378(88)90587-X; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331; SMILEY L, 1990, SEXUALLY TRANSMITTED, P415; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STAMM WE, 1990, SEXUALLY TRANSMITTED, P917; SYRJANEN K, 1987, PAPILLOMAVIRUSES, V5, P281; WILLETT GD, 1989, INT J GYNECOL PATHOL, V8, P18, DOI 10.1097/00004347-198903000-00003; ZANINETTI P, 1986, INT J EPIDEMIOL, V15, P477, DOI 10.1093/ije/15.4.477; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238	33	763	795	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1272	1278		10.1056/NEJM199210293271804	http://dx.doi.org/10.1056/NEJM199210293271804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1328880				2022-12-24	WOS:A1992JV25900004
J	ADAMS, DE; SHEKHTMAN, EM; ZECHIEDRICH, EL; SCHMID, MB; COZZARELLI, NR				ADAMS, DE; SHEKHTMAN, EM; ZECHIEDRICH, EL; SCHMID, MB; COZZARELLI, NR			THE ROLE OF TOPOISOMERASE-IV IN PARTITIONING BACTERIAL REPLICONS AND THE STRUCTURE OF CATENATED INTERMEDIATES IN DNA-REPLICATION	CELL			English	Article							ESCHERICHIA-COLI; TN3 RESOLVASE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; SALMONELLA-TYPHIMURIUM; NUCLEOID SEGREGATION; RECOMBINATION; MUTANTS; SITES; DECATENATION	Mutants in bacterial topoisomerase (topo) IV are deficient in chromosomal partitioning. To investigate the basis of this phenotype, we examined plasmid DNA topology in conditionally lethal topo IV mutants. We found that dimeric catenated plasmids accumulated in vivo after topo IV inhibition. The catenanes were supercoiled, contained from 2 to >32 nodes, and were the products of DNA synthesis. Electron microscopy and recombination tests proved that the catenanes have the unique structure predicted for replication intermediates. These data provide strong evidence for a model in which unlinking of the double helix can occur in two stages during DNA replication and for the critical role of topo IV in the second stage. The interlocks in the catenanes appear to be sequestered from DNA gyrase, perhaps by compartmentalization in an enzyme complex dedicated to partitioning.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	ADAMS, DE (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Zechiedrich, Elizabeth Lynn/S-4720-2019	Zechiedrich, Lynn/0000-0003-0533-1637	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14574-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, J MOL BIOL, V226, P661, DOI 10.1016/0022-2836(92)90623-R; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CLEWELL DB, 1970, BIOCHEMISTRY-US, V9, P4428; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DROGE P, 1992, METHOD ENZYMOL, V212, P120; FIELDSBERRY SC, 1989, NUCLEIC ACIDS RES, V17, P3261, DOI 10.1093/nar/17.8.3261; GARRARD WT, 1990, NUCLEIC ACIDS MOL BI, V4, P163; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHII S, 1991, J BACTERIOL, V173, P5551, DOI 10.1128/jb.173.17.5551-5553.1991; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; Kornberg A., 1992, DNA REPLICATION; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RYAN KA, 1988, P NATL ACAD SCI USA, V85, P5844, DOI 10.1073/pnas.85.16.5844; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID MB, 1990, J BACTERIOL, V172, P5416, DOI 10.1128/jb.172.9.5416-5424.1990; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STECK TR, 1984, J BACTERIOL, V158, P397, DOI 10.1128/JB.158.2.397-403.1984; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	41	282	291	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					277	288		10.1016/0092-8674(92)90356-H	http://dx.doi.org/10.1016/0092-8674(92)90356-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1330320				2022-12-24	WOS:A1992JU39500013
J	MCCONNELL, HM; OWICKI, JC; PARCE, JW; MILLER, DL; BAXTER, GT; WADA, HG; PITCHFORD, S				MCCONNELL, HM; OWICKI, JC; PARCE, JW; MILLER, DL; BAXTER, GT; WADA, HG; PITCHFORD, S			THE CYTOSENSOR MICROPHYSIOMETER - BIOLOGICAL APPLICATIONS OF SILICON TECHNOLOGY	SCIENCE			English	Article							CELL-AFFECTING AGENTS	A silicon-based device, dubbed a microphysiometer, can be used to detect and monitor the response of cells to a variety of chemical substances, especially ligands for specific plasma membrane receptors. The microphysiometer measures the rate of proton excretion from 104 to 106 cells. This article gives an overview of experiments currently being carried out with this instrument with emphasis on receptors with seven transmembrane helices and tyrosine kinase receptors. As a scientific instrument, the microphysiometer can be thought of as serving two distinct functions. In terms of detecting specific molecules, selected biological cells in this instrument serve as detectors and amplifiers. The microphysiometer can also investigate cell function and biochemistry. A major application of this instrument may prove to be screening for new receptor ligands. In this respect, the microphysiometer appears to offer significant advantages over other techniques.	MOLEC DEVICES CORP,4700 BOHANNAN DR,MENLO PK,CA 94025; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University								BAXTER GW, UNPUB; BRIGGS J, 1991, ANAL CHEM, V63, P850, DOI 10.1021/ac00009a003; FRASER CM, 1989, MOL PHARMACOL, V36, P840; HAFEMAN DG, 1988, SCIENCE, V240, P1182, DOI 10.1126/science.3375810; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; INDELICATO SR, 1991, 5TH INT C IMM TAMP; McConnell HM, 1991, CURR OPIN STRUC BIOL, V1, P647, DOI 10.1016/S0959-440X(05)80091-0; MILLER DL, 1991, FASEB J, V5, pA1014; NAG B, 1992, J IMMUNOL, V148, P2040; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1990, ANN BIOL CLIN-PARIS, V48, P639; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; RALEYSUSMAN KM, 1992, J NEUROSCI, V12, P773; RICE PA, 1991, FASEB J, V5, pA1014; RICE PA, 1991, THESIS STANFORD U ST; ROSSER M P, 1991, Society for Neuroscience Abstracts, V17, P818; SALON J A, 1991, Society for Neuroscience Abstracts, V17, P86; WADA HG, IN PRESS J CELL PHYS; WADA HG, 1990, MAY NAT I ALL INF DI	20	564	651	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1906	1912		10.1126/science.1329199	http://dx.doi.org/10.1126/science.1329199			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1329199				2022-12-24	WOS:A1992JP59400023
J	JOHNSON, E				JOHNSON, E			EVIDENCE OF SUBSTANCE-ABUSE FOUND WITH POSTTRAUMATIC-STRESS-DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							COTTLER LB, 1992, AM J PSYCHIAT, V149, P664	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-24	WOS:A1992JN25600006
J	SACHS, AB; DEARDORFF, JA				SACHS, AB; DEARDORFF, JA			TRANSLATION INITIATION REQUIRES THE PAB-DEPENDENT POLY(A) RIBONUCLEASE IN YEAST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; PROTEIN-KINASE; REGULATORY SUBUNIT; TRANSFORMATION; DEADENYLATION; SEQUENCE; BINDING; SYSTEM; TAIL	Messenger RNA translation initiation and cytoplasmic poly(A) tail shortening require the poly(A)-binding protein (PAB) in yeast. The PAB-dependent poly(A) ribonuclease (PAN) has been purified to near homogeneity from S. cerevisiae based upon its PAB requirement, and its gene has been cloned. The essential PAN1 gene encodes a 161 kd protein organized into distinct domains containing repeated sequence elements. Deletion analysis of the gene revealed that only one-third of the protein is needed to maintain cell viability. Conditional mutations in PAN1 lead to an arrest of translation initiation and alterations in mRNA poly(A) tail lengths. These data suggest that PAN could mediate each of the PAB-dependent reactions within the cell, and they provide evidence for a direct relationship between translation initiation and mRNA metabolism.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute	SACHS, AB (corresponding author), UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [R29 GM43164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, 5 FLUOROOROTIC ACID; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNISAWA R, 1987, NUCLEIC ACIDS RES, V15, P368, DOI 10.1093/nar/15.1.368; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	32	184	190	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					961	973		10.1016/0092-8674(92)90246-9	http://dx.doi.org/10.1016/0092-8674(92)90246-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1339314				2022-12-24	WOS:A1992JN78100011
J	EHRMANN, DA; ROSENFIELD, RL; BARNES, RB; BRIGELL, DF; SHEIKH, Z				EHRMANN, DA; ROSENFIELD, RL; BARNES, RB; BRIGELL, DF; SHEIKH, Z			DETECTION OF FUNCTIONAL OVARIAN HYPERANDROGENISM IN WOMEN WITH ANDROGEN EXCESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; POLYCYSTIC OVARIES; IDIOPATHIC HIRSUTISM; LUTEINIZING HORMONE; DISEASE; DEXAMETHASONE; RESPONSES; PATHOGENESIS; SECRETION; CELLS	Background. Distinguishing between ovarian and adrenal causes of androgen excess may be difficult. We have found that women with the polycystic ovary syndrome have supranormal plasma 17-hydroxyprogesterone responses to the gonadotropin-releasing hormone agonist nafarelin. We determined the usefulness of testing with nafarelin to distinguish ovarian causes of hyperandrogenism in women. Methods. We studied 40 consecutive women with hyperandrogenism who had oligomenorrhea, hirsutism, or acne. All 40 underwent testing with nafarelin, dexamethasone, and corticotropin with measurement of circulating concentrations of gonadotropins and steroid hormones, and 19 underwent ovarian ultrasonography. Results. The plasma 17-hydroxyprogesterone response to nafarelin was supranormal in 23 of the 40 women (58 percent), and the plasma androgen response to corticotropin was elevated in 23; 13 women had both abnormalities. Only one woman had conclusive evidence of a steroidogenic block; she had nonclassic adrenal 21-hydroxylase deficiency. Of the 23 women with abnormal responses to nafarelin, only 11 (48 percent) had elevated base-line serum luteinizing hormone concentrations. Of the 13 women with abnormal responses to nafarelin who underwent ultrasonography, 7 (54 percent) had polycystic ovaries. Peak plasma 17-hydroxyprogesterone concentrations after nafarelin administration correlated closely with plasma free testosterone concentrations after dexamethasone administration (r = 0.75, P<0.001). Conclusions. Approximately half of women with oligomenorrhea, hirsutism, or acne have an abnormal response to the gonadotropin-releasing hormone agonist nafarelin, suggesting an ovarian cause of their androgen excess.	UNIV CHICAGO,PRITZKER SCH MED,DEPT OBSTET GYNECOL,CHICAGO,IL 60637	University of Chicago	EHRMANN, DA (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,ENDOCRINOL SECT,5841 S MARYLAND AVE,MC 1027,CHICAGO,IL 60637, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007011] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00055] Funding Source: Medline; NICHD NIH HHS [HD-06308] Funding Source: Medline; NIDDK NIH HHS [DK-07011-17] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM GE, 1976, OBSTET GYNECOL, V47, P395; ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; BARNES R, 1989, ANN INTERN MED, V110, P386, DOI 10.7326/0003-4819-110-5-386; BARNES RB, 1989, NEW ENGL J MED, V320, P559, DOI 10.1056/NEJM198903023200904; BERGER MJ, 1975, FERTIL STERIL, V26, P619; CARA JF, 1988, ENDOCRINOLOGY, V123, P733, DOI 10.1210/endo-123-2-733; CHANG RJ, 1983, J CLIN ENDOCR METAB, V56, P897, DOI 10.1210/jcem-56-5-897; DAVOREN JB, 1986, ENDOCRINOLOGY, V118, P888, DOI 10.1210/endo-118-2-888; ELDARGEVA T, 1990, NEW ENGL J MED, V323, P855, DOI 10.1056/NEJM199009273231302; EMANS SJ, 1988, J PEDIATR-US, V112, P821, DOI 10.1016/S0022-3476(88)83217-7; ERICKSON GF, 1985, ENDOCR REV, V6, P371, DOI 10.1210/edrv-6-3-371; FAUSER BCJM, 1991, J CLIN ENDOCR METAB, V73, P811, DOI 10.1210/jcem-73-4-811; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; HAGUE WM, 1989, CLIN ENDOCRINOL, V30, P355, DOI 10.1111/j.1365-2265.1989.tb00433.x; HATCH R, 1981, AM J OBSTET GYNECOL, V140, P815, DOI 10.1016/0002-9378(81)90746-8; HERNANDEZ ER, 1990, ENDOCRINOLOGY, V127, P2804, DOI 10.1210/endo-127-6-2804; HILLIER SG, 1991, MOL CELL ENDOCRINOL, V75, pR1, DOI 10.1016/0303-7207(91)90234-J; HILLIER SG, 1991, J CLIN ENDOCR METAB, V72, P1206, DOI 10.1210/jcem-72-6-1206; JIALAL I, 1987, J CLIN ENDOCR METAB, V64, P1066, DOI 10.1210/jcem-64-5-1066; JUDD HL, 1973, AM J OBSTET GYNECOL, V117, P976, DOI 10.1016/0002-9378(73)90071-9; KIRSCHNER MA, 1976, NEW ENGL J MED, V294, P637, DOI 10.1056/NEJM197603182941204; MULHERON GW, 1991, ENDOCRINOLOGY, V129, P368, DOI 10.1210/endo-129-1-368; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; POLSON DW, 1988, LANCET, V1, P870; RITTMASTER RS, 1990, J CLIN ENDOCR METAB, V70, P1096, DOI 10.1210/jcem-70-4-1096; ROSENFIELD RL, 1990, FERTIL STERIL, V53, P785; ROSENFIELD RL, 1985, J CLIN ENDOCR METAB, V60, P585, DOI 10.1210/jcem-60-3-585; Rosenfield RL, 1992, POLYCYSTIC OVARY SYN, P83; SIEGEL SF, 1990, NEW ENGL J MED, V323, P849, DOI 10.1056/NEJM199009273231301; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; STEWART PM, 1990, LANCET, V335, P431, DOI 10.1016/0140-6736(90)90664-Q; Timor-Tritsch IE, 1988, TRANSVAGINAL SONOGRA; WALDSTREICHER J, 1988, J CLIN ENDOCR METAB, V66, P165, DOI 10.1210/jcem-66-1-165; YEH HC, 1987, RADIOLOGY, V163, P111, DOI 10.1148/radiology.163.1.3547491; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435	35	268	279	2	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					157	162		10.1056/NEJM199207163270304	http://dx.doi.org/10.1056/NEJM199207163270304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1319000				2022-12-24	WOS:A1992JD31900004
J	HAMM, CW; RAVKILDE, J; GERHARDT, W; JORGENSEN, P; PEHEIM, E; LJUNGDAHL, L; GOLDMANN, B; KATUS, HA				HAMM, CW; RAVKILDE, J; GERHARDT, W; JORGENSEN, P; PEHEIM, E; LJUNGDAHL, L; GOLDMANN, B; KATUS, HA			THE PROGNOSTIC VALUE OF SERUM TROPONIN-T IN UNSTABLE ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CREATINE KINASE-MB; HIGH-RISK SUBGROUP; PLATELET ACTIVATION; SKELETAL-MUSCLE; PECTORIS; IDENTIFICATION; THROMBUS; ISCHEMIA; DEATH	Background. Cardiac troponin T is a regulatory contractile protein not normally found in blood. Its detection in the circulation has been shown to be a sensitive and specific marker for myocardial cell damage. We used a newly developed enzyme immunoassay for troponin T to determine whether its presence in the serum of patients with unstable angina was a prognostic indicator. Methods. We screened 109 patients with unstable angina (25 with accelerated or subacute angina and 84 with acute angina at rest) for serum creatine kinase activity, creatine kinase isoenzyme MB activity, and troponin T every eight hours for two days after admission to the hospital. The outcomes of interest during the hospitalization were death and myocardial infarction. Results. Troponin T was detected (range, 0.20 to 3.64-mu-g per liter; mean, 0.78; median, 0.50) in the serum of 33 of the 84 patients (39 percent) with acute angina at rest. Only three of these patients had elevated creatine kinase MB activity (two were positive for troponin T, and one was negative). Of the 33 patients who were positive for troponin T, 10 (30 percent) had myocardial infarction (3 after coronary-artery bypass surgery), and 5 of these died during hospitalization. In contrast, only 1 of the 51 patients with angina at rest who were negative for troponin T had an acute myocardial infarction (P<0.001), and this patient died (P = 0.03). Thus, 10 of the 11 patients with myocardial infarctions had detectable levels of troponin T; only 1 had elevated creatine kinase MB activity. Troponin T was not detected in any of the 25 patients with accelerated or subacute angina, and none of these patients died. Conclusions. Cardiac troponin T in serum appears to be a more sensitive indicator of myocardial-cell injury than serum creatine kinase MB activity, and its detection in the circulation may be a useful prognostic indicator in patients with unstable angina.	AARHUS UNIV HOSP,DEPT INTERNAL MED,DK-8000 AARHUS,DENMARK; UNIV HOSP HEIDELBERG,DEPT MED,HEIDELBERG,GERMANY; ODENSE UNIV HOSP,DEPT CLIN CHEM,DK-5000 ODENSE,DENMARK; UNIV BERN,INSELSPITAL,DEPT CLIN CHEM,CH-3010 BERN,SWITZERLAND; NYA LASARETTET,DEPT CLIN CHEM,HELSINGBORG,SWEDEN; NYA LASARETTET,DEPT CARDIOL,HELSINGBORG,SWEDEN	Aarhus University; Ruprecht Karls University Heidelberg; University of Southern Denmark; Odense University Hospital; University of Bern; University Hospital of Bern	HAMM, CW (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT CARDIOL,MED CLIN,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161				ARMSTRONG PW, 1982, AM J CARDIOL, V49, P1849, DOI 10.1016/0002-9149(82)90201-6; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRESNAHAN DR, 1985, J AM COLL CARDIOL, V6, P285, DOI 10.1016/S0735-1097(85)80161-3; BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DONSKY MS, 1976, BRIT HEART J, V38, P257; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GERHARDT W, 1982, CLIN CHEM, V28, P277; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; HAMM CW, 1987, J AM COLL CARDIOL, V10, P998, DOI 10.1016/S0735-1097(87)80336-4; HAMM CW, 1987, DEUT MED WOCHENSCHR, V112, P1812, DOI 10.1055/s-2008-1068333; HOLMES DR, 1981, BRIT HEART J, V45, P411; HORDER M, 1979, SCAND J CLIN LAB INV, V39, P1, DOI 10.3109/00365517909104932; HORDER M, 1990, BIOCH CLIN, V14, P77; JORGENSEN PJ, 1990, CLIN CHEM, V36, P1502; JULIAN DG, 1985, UNSTABLE ANGINA CURR, P65; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; KATUS HA, 1991, AM J CARDIOL, V67, P1360, DOI 10.1016/0002-9149(91)90466-X; KATUS HA, 1988, J AM COLL CARDIOL, V11, P487, DOI 10.1016/0735-1097(88)91521-5; KATUS HA, 1990, UNSTABLE ANGINA /, P92; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; MESSMER BJ, 1990, UNSTABLE ANGINA /, P245; MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7; NAUNHEIM KS, 1989, ANN THORAC SURG, V47, P569, DOI 10.1016/0003-4975(89)90435-9; NORDLANDER R, 1979, BRIT HEART J, V41, P647; OLSON HG, 1981, CIRCULATION, V64, P674, DOI 10.1161/01.CIR.64.4.674; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; SCLAROVSKY S, 1988, AM HEART J, V116, P933, DOI 10.1016/0002-8703(88)90143-3; VETROVEC GW, 1981, AM HEART J, V102, P1202, DOI 10.1016/0002-8703(81)90653-0; VONARNIM T, 1988, EUR HEART J, V9, P435; WHITE RD, 1985, AM J CARDIOL, V55, P1478, DOI 10.1016/0002-9149(85)90957-9; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WURZBURG U, 1977, J CLIN CHEM CLIN BIO, V15, P131; ZACK PM, 1984, AM HEART J, V108, P1408, DOI 10.1016/0002-8703(84)90684-7; 1971, ISCHAEMIC HEART DISE	41	864	892	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					146	150		10.1056/NEJM199207163270302	http://dx.doi.org/10.1056/NEJM199207163270302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1290492				2022-12-24	WOS:A1992JD31900002
J	BICKMORE, WA; OGHENE, K; LITTLE, MH; SEAWRIGHT, A; VANHEYNINGEN, V; HASTIE, ND				BICKMORE, WA; OGHENE, K; LITTLE, MH; SEAWRIGHT, A; VANHEYNINGEN, V; HASTIE, ND			MODULATION OF DNA-BINDING SPECIFICITY BY ALTERNATIVE SPLICING OF THE WILMS-TUMOR WT1 GENE TRANSCRIPT	SCIENCE			English	Article							EARLY GROWTH-RESPONSE; FINGER; PROTEIN; SEQUENCES; DELETION; GENOME; LOCUS; EGR-1	The technique of whole-genome polymerase chain reaction was used to study the DNA binding properties of the product of the wt1 gene. The zinc finger region of this gene is alternatively spliced such that the major transcript encodes a protein with three extra amino acids between the third and fourth fingers. The minor form of the protein binds specifically to DNA. It is now shown that the major form of wt1 messenger RNA encodes a protein that binds to DNA with a specificity that differs from that of the minor form. Therefore, alternative splicing within the DNA binding domain of a transcription factor can generate proteins with distinct DNA binding specificities and probably different physiological targets.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Bickmore, Wendy A/C-7314-2013; Little, Melissa H/A-6170-2010; van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022	Bickmore, Wendy A/0000-0001-6660-7735; Little, Melissa H/0000-0003-0380-2263; van Heyningen, Veronica/0000-0003-0359-0141; 	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BORDEREAUX D, 1990, ONCOGENE, V5, P925; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1990, AM J HUM GENET, V47, P28; KENT JF, UNPUB; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; LITT M, 1989, AM J HUM GENET, V44, P397; LITTLE MH, IN PRESS P NATL ACAD; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIYAGAWA K, UNPUB; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283	23	225	229	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					235	237		10.1126/science.1321494	http://dx.doi.org/10.1126/science.1321494			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321494				2022-12-24	WOS:A1992JC58500037
J	SENGUPTA, DJ; BOROWIEC, JA				SENGUPTA, DJ; BOROWIEC, JA			STRAND-SPECIFIC RECOGNITION OF A SYNTHETIC DNA-REPLICATION FORK BY THE SV40 LARGE TUMOR-ANTIGEN	SCIENCE			English	Article							LARGE T-ANTIGEN; SIMIAN VIRUS-40 DNA; TERMINATION FACTOR-RHO; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; UNWINDING ACTIVITY; HELICASE ACTIVITY; ORIGIN; INVITRO; BINDING	The mechanism by which DNA helicases unwind DNA was tested; an "unwinding complex" between the SV40 large tumor antigen (T antigen) and a DNA molecule designed to resemble a replication fork was probed. In an adenosine triphosphate (ATP)-dependent reaction, T antigen quantitatively recognized this synthetic replication fork and bound the DNA primarily as a hexamer. The T antigen bound only one of the two strands at the fork, an asymmetric interaction consistent with the 3' --> 5' directionality of the DNA helicase activity of T antigen. Binding to chemically modified DNA substrates indicated that the DNA helicase recognized the DNA primarily through the sugar-phosphate backbone. Ethylation of six top strand phosphates at the junction of single-stranded and double-stranded DNA inhibited the DNA helicase activity of T antigen. Neither a 3' single-stranded end on the DNA substrate nor ATP hydrolysis was required for T antigen to bind the replication fork. These data suggest that T antigen can directly bind the replication fork through recognition of a fork-specific structure.			SENGUPTA, DJ (corresponding author), NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016, USA.				NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029963] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 16087] Funding Source: Medline; NIAID NIH HHS [AI29963] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5247; AUBORN KJ, 1988, J VIROL, V62, P2204, DOI 10.1128/JVI.62.6.2204-2208.1988; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1989, UCLA S MOL CELL BIOL, V127, P315; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GOETZ GS, 1988, J BIOL CHEM, V263, P383; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T., 1982, MOL CLONING; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; ODA T, 1972, J MOL BIOL, V71, P799; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1983, J VIROL, V47, P65, DOI 10.1128/JVI.47.1.65-76.1983; STAHL H, 1985, J VIROL, V54, P473, DOI 10.1128/JVI.54.2.473-482.1985; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TJIAN R, 1981, CELL, V26, P1, DOI 10.1016/0092-8674(81)90026-X; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989	46	64	65	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1656	1661		10.1126/science.256.5064.1656	http://dx.doi.org/10.1126/science.256.5064.1656			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1319087				2022-12-24	WOS:A1992HZ17400038
J	NEWELL, ML; DUNN, D; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE				NEWELL, ML; DUNN, D; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE			RISK-FACTORS FOR MOTHER-TO-CHILD TRANSMISSION OF HIV-1	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; TYPE-1; INFECTION; WOMEN; ANTIBODIES; INFANTS; BORN	Children born to women known to be infected with human immunodeficiency virus type 1 (HIV-1) before delivery were followed prospectively from birth in nineteen European centres. This analysis, encompassing the period end-December, 1984, to beginning-August, 1991, focuses on risk factors for mother-to-child transmission of HIV-1 infection. Rate of vertical transmission, based on 721 children born to 701 mothers more than 18 months before the time of analysis, was 14.4% (95% Cl 12.0-17.1%). Transmission was associated with maternal p24-antigenaemia and a CD4 count of less than 700/mu-l. In a multivariate analysis, odds ratios of transmission were: 2.25 (95% Cl 0.97-5.23) in breastfed children vs never-breastfed children; 3.80 (1.62-8.91) in children born before 34 weeks' gestation; and 0.56 (0.30-1.04) in children delivered by caesarean section. Transmission was higher with vaginal deliveries in which episiotomy, scalp electrodes, forceps, or vacuum extractors were used, but only in centres where these procedures were not routine. On the basis of these results, HIV-infected women contemplating pregnancy should be counselled according to their immunological findings and, if they have p24-antigenaemia or a low CD4 count, warned of an increased risk of viral transmission. Caesarean deliveries may have a protective effect, although it is premature to recommend routine operative delivery. The mechanism for the higher infection rate in children born before 34 weeks' gestation is unclear, but could reflect inadequate passive or active immunity at that age, combined with substantial transmission during labour or delivery. The balance of evidence suggests that mothers with established infection can transmit HIV infection through breastmilk, although the relative importance of this route remains to be defined.	INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; COORDINATING CTR,LONDON,ENGLAND; OSPED SAO PAOLO,MILAN,ITALY	University of London; University College London			Newell, Marie-Louise/AAE-8222-2019; De Rossi, A./L-3128-2015	Newell, Marie-Louise/0000-0002-1074-7699; De Rossi, A./0000-0001-6435-7509; Dunn, David/0000-0003-1836-4446; GIAQUINTO, CARLO/0000-0001-9365-0413				ANDIMAN WA, 1990, AM J DIS CHILD, V144, P758, DOI 10.1001/archpedi.1990.02150310026020; BIGGAR RJ, 1989, AM J OBSTET GYNECOL, V161, P1239, DOI 10.1016/0002-9378(89)90674-1; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CUMMINS LM, 1991, BLOOD, V77, P1111; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; HANSHAW GB, 1985, VIRAL DISEASE FETUS; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; SCHULTZ R, 1991, BRIT MED J, V303, P1369, DOI 10.1136/bmj.303.6814.1369; SPRECHER S, 1986, LANCET, V2, P288; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VENET A, 1991, AIDS, V5, P283, DOI 10.1097/00002030-199103000-00006; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; ZAROU DM, 1964, AM J OBSTET GYNECOL, V88, P565, DOI 10.1016/0002-9378(64)90881-6; 1988, LANCET, V2, P1043; 1988, LANCET, V2, P1039; 1987, MMWR, V36, pS3; 1989, LANCET, V2, P36; 1991, LANCET, V337, P253; 1987, WEEKLY EPIDEMIOL REC, V33, P245; 1987, MMWR, V15, P225	34	266	272	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1007	1012						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349050				2022-12-24	WOS:A1992HQ43500002
J	ELLIOTT, P; HILLS, M; BERESFORD, J; KLEINSCHMIDT, I; JOLLEY, D; PATTENDEN, S; RODRIGUES, L; WESTLAKE, A; ROSE, G				ELLIOTT, P; HILLS, M; BERESFORD, J; KLEINSCHMIDT, I; JOLLEY, D; PATTENDEN, S; RODRIGUES, L; WESTLAKE, A; ROSE, G			INCIDENCE OF CANCERS OF THE LARYNX AND LUNG NEAR INCINERATORS OF WASTE SOLVENTS AND OILS IN GREAT-BRITAIN	LANCET			English	Article								The Small Area Health Statistics Unit (SAHSU) is a new independent facility for the investigation of disease near industrial installations in the UK. SAHSU analysed the incidence of cancers of the larynx and lung near the incinerator of waste solvents and oils at Charnock Richard, Coppull, Lancashire (which operated between 1972 and 1980) and nine other similar incinerators in Great Britain, after reports of a cluster of cases of cancer of the larynx near the Charnock Richard site. Postcoded cancer registration data were available for 1974-84 in England and Wales and 1975-87 in Scotland. Lag periods of 5 and 10 years were used between start-up (or first registration) of the incinerators and cancer incidence. Standardised observed/expected (O/E) ratios were assessed within 3 km and 3-10 km of each site and then aggregated over all sites. Expected values were based on national rates (regionally adjusted) with and without stratification by Carstairs' index, a measure of the socioeconomic profile of areas that uses census data for enumeration districts. Data were also assessed over a range of circles up to 10 km to test for trend in O/E ratios with distance. For Charnock Richard, none of the O/E ratios within 3 km or from 3-10 km differed significantly from unity, for either cancer or lag period. In the analysis of all sites with stratification by Carstairs' index, none of these O/E ratios differed significantly from unity for the two cancers. There was no evidence of decreasing risk with distance from the sites of either cancer. We conclude that the apparent cluster of cases of cancer of the larynx reported near Charnock Richard was unlikely to be due to its former incinerator.			ELLIOTT, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,ENVIRONM EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.							[Anonymous], 1986, MODERN EPIDEMIOLOGY, P58; AUSTIN DF, 1982, CANCER EPIDEMIOL, P554; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; DIGGLE PJ, 1990, J ROY STAT SOC A STA, V153, P349, DOI 10.2307/2982977; Doll R, 1981, THE CAUSES OF CANCER; EASTON DF, 1988, BRIT J IND MED, V45, P652; ELLIOTT P, IN PRESS J EPIDEMIOL; ELLIOTT P, IN PRESS GEOGRAPHICA; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FRAUMENI JF, 1982, CANCER EPIDEMIOL, P564; GATRELL AC, UNPUB CANCERS CHORLE; GATRELL AC, 1990, 9 LANC U NW REG RES; GATRELL AC, 1990, 8 LANC U NW REG RES; JOLLEY D, IN PRESS GEOGRAPHICA; KLEINSCHMIDT I, IN PRESS GEOGRAPHICA; Rothman K J, 1980, Epidemiol Rev, V2, P195; STONE RA, 1988, STAT MED, V7, P649, DOI 10.1002/sim.4780070604; SWERDLOW AJ, 1986, J ROY STAT SOC A STA, V149, P146, DOI 10.2307/2981527; WOODFIELD M, 1987, ENV IMPACT REFUSE IN; 1983, NIH832607 US NCI PUB; 1973, IARC MONOGRAPHS EVAL, V3; 1980, CANCER STATISTIC MB1; 1982, IARC MONOGRAPHS E S4, V1	23	74	75	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					854	858		10.1016/0140-6736(92)90290-J	http://dx.doi.org/10.1016/0140-6736(92)90290-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347867				2022-12-24	WOS:A1992HM44100014
J	GLENN, GM; LINEHAN, WM; HOSOE, S; LATIF, F; YAO, M; CHOYKE, P; GORIN, MB; CHEW, E; OLDFIELD, E; MANOLATOS, C; ORCUTT, ML; WALTHER, MM; WEISS, GH; TORY, K; JENSSON, O; LERMAN, MI; ZBAR, B				GLENN, GM; LINEHAN, WM; HOSOE, S; LATIF, F; YAO, M; CHOYKE, P; GORIN, MB; CHEW, E; OLDFIELD, E; MANOLATOS, C; ORCUTT, ML; WALTHER, MM; WEISS, GH; TORY, K; JENSSON, O; LERMAN, MI; ZBAR, B			SCREENING FOR VONHIPPEL-LINDAU DISEASE BY DNA POLYMORPHISM ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKAGE; MANIFESTATIONS; CHROMOSOME-3; MEMBERS; REGION; KIDNEY	Objective.-Von Hippel-Lindau (VHL) disease is a rare, inherited multisystem neoplastic disorder. There is no biochemical test available to distinguish VHL disease gene carriers from their healthy siblings. We evaluated DNA polymorphism analysis as a method for identifying disease gene carriers. Design.-Prospective comparison of the results of DNA analysis with a comprehensive clinical screening examination. Setting.-The Clinical Center of the National Institutes of Health. Patients.-Blood was collected from 182 members of 16 families with VHL disease. Forty-eight asymptomatic individuals, at risk of developing this hereditary illness (with an affected parent or sibling), were examined for occult disease at the Clinical Center of the National Institutes of Health and tested by DNA polymorphism analysis. Results.-DNA polymorphism analysis predicted nine disease gene carriers and 33 individuals with the wild-type (normal) allele among the 48 individuals at risk of developing VHL disease; the test was not informative in six individuals. All nine individuals predicted to carry the VHL gene had evidence of occult disease on clinical examination. There was no clinical evidence of VHL disease in 32 of 33 individuals predicted to carry the wild-type allele. Conclusions.-DNA polymorphism analysis can identify individuals likely to carry the VHL disease gene among asymptomatic members of disease families. This technique serves to focus attention on those individuals who require periodic medical examination and may help to alleviate the morbidity and mortality associated with this disease.	NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,BLDG 560,ROOM 12-71,FREDERICK,MD 21701; NCI,CANC DIAG BRANCH,FREDERICK,MD 21701; NCI,SURG BRANCH,FREDERICK,MD 21701; NEI,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892; NEI,CTR CLIN,DEPT NURSING,BETHESDA,MD 20892; NEI,CLIN BRANCH,BETHESDA,MD 20892; NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892; EYE & EAR INST,PITTSBURGH,PA; PROGRAM RESOURCES INC,FREDERICK,MD; NATL UNIV HOSP REYKJAVIK,BLOOD BANK,REYKJAVIK,ICELAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Landspitali National University Hospital					Intramural NIH HHS [Z99 EY999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CAVENEE WK, 1986, NEW ENGL J MED, V314, P1201, DOI 10.1056/NEJM198605083141901; CHOYKE PL, 1990, RADIOLOGY, V174, P815, DOI 10.1148/radiology.174.3.2305064; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; DLUHY RG, 1991, NEW ENGL J MED, V324, P1119; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FILLINGKATZ MR, 1989, J COMPUT ASSIST TOMO, V13, P743, DOI 10.1097/00004728-198909000-00001; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GLENN GM, 1990, PROBL UROL, V4, P312; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; LAMIELL JM, 1989, MEDICINE, V68, P1; LANDER E, 1988, GENOME ANAL PRACTICA, P171; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATIF F, 1990, NUCLEIC ACIDS RES, V18, P1088; LAUCKS SP, 1981, BRIT J RADIOL, V54, P12, DOI 10.1259/0007-1285-54-637-12; LERMAN MI, 1991, HUM GENET, V86, P567; LYNCH HT, 1985, CANCER GENET CYTOGEN, V16, P13, DOI 10.1016/0165-4608(85)90073-1; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MAHER ER, 1990, J NEUROL SCI, V100, P27, DOI 10.1016/0022-510X(90)90008-B; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; OTT J, 1985, ANAL HUMAN GENETIC L; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SOBOL H, 1989, NEW ENGL J MED, V321, P996, DOI 10.1056/NEJM198910123211502; Thompson J. S., 1986, GENETICS MED; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; VANCE JM, 1990, GENOMICS, V6, P565, DOI 10.1016/0888-7543(90)90488-G	35	72	73	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1226	1231		10.1001/jama.267.9.1226	http://dx.doi.org/10.1001/jama.267.9.1226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1347089	Green Submitted			2022-12-24	WOS:A1992HF43900024
J	SPITZER, WO; SUISSA, S; ERNST, P; HORWITZ, RI; HABBICK, B; COCKCROFT, D; BOIVIN, JF; MCNUTT, M; BUIST, AS; REBUCK, AS				SPITZER, WO; SUISSA, S; ERNST, P; HORWITZ, RI; HABBICK, B; COCKCROFT, D; BOIVIN, JF; MCNUTT, M; BUIST, AS; REBUCK, AS			THE USE OF BETA-AGONISTS AND THE RISK OF DEATH AND NEAR DEATH FROM ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESCRIBED FENOTEROL; SALBUTAMOL; TERBUTALINE; ZEALAND	Background. Morbidity and mortality from asthma appear to be increasing, and it has been suggested that medications used to treat asthma are contributing to this trend. We investigated a possible association between death or near death from asthma and the regular use of beta-2-agonist bronchodilators. Methods. Using linked health insurance data bases from Saskatchewan, Canada, we conducted a matched case-control study of subjects drawn from a cohort of 12,301 patients for whom asthma medications had been prescribed between 1978 and 1987. We matched 129 case patients who had fatal or near-fatal asthma with 655 controls (who had received medications for asthma but had not had fatal or near-fatal events) with respect to region of residence, age, receipt of social assistance, and previous hospitalization for asthma. Results. The use of beta-agonists administered by a metered-dose inhaler was associated with an increased risk of death from asthma (odds ratio, 2.6 per canister per month; 95 percent confidence interval, 1.7 to 3.9) and of death or near death from asthma, considered together (odds ratio, 1.9; 95 percent confidence interval, 1.6 to 2.4). For death from asthma, use of the beta-agonist fenoterol was associated with an odds ratio of 5.4 per canister, as compared with 2.4 for the beta-agonist albuterol. On a microgram-equivalent basis, the odds ratio for this outcome with fenoterol was 2.3, as compared with 2.4 with albuterol. Conclusions. An increased risk of death or near death from asthma was associated with the regular use of inhaled beta-2-agonist bronchodilators, especially fenoterol. Regardless of whether beta-agonists are directly responsible for these adverse effects or are simply a marker for more severe asthma, heavy use of these agents should alert clinicians that it is necessary to reevaluate the patient's condition.	MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; UNIV SASKATCHEWAN,DEPT COMMUNITY HLTH & EPIDEMIOL,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; SASKATCHEWAN HLTH,LAB & DIS CONTROL SERV BRANCH,HE ROBERTSON LAB,REGINA,SASKATCHEWAN,CANADA; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201; UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; TORONTO HOSP,DIV RESP MED,TORONTO,ONTARIO,CANADA	McGill University; Yale University; University of Saskatchewan; University of Saskatchewan; Oregon Health & Science University; Oregon Health & Science University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	SPITZER, WO (corresponding author), MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,PURVIS HALL,1020 PINE AVE W,MONTREAL H3A 1A2,QUEBEC,CANADA.							ARAI Y, 1983, EUR J RESPIR DIS S, V128, P506; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CRANE J, 1989, LANCET, V1, P917; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HOCKLEY B, 1983, POSTGRAD MED J, V59, P504, DOI 10.1136/pgmj.59.694.504; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LULICH KM, 1986, MED TOXICOL ADV DRUG, V1, P289; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; OLSSON OAT, 1979, ACTA PHARMACOL TOX, V44, P272; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; POYNTER D, 1987, J ALLERGY CLIN IMMUN, V80, P423, DOI 10.1016/0091-6749(87)90067-4; ROTHMAN KJ, 1986, MODERN EIDEMIOLOGY; SALOME CM, 1988, MECHANISMS ASTHMA PH, V263, P405; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPEIZER FE, 1975, NEW ENGL J MED, V292, P624, DOI 10.1056/NEJM197503202921207; STERK PJ, 1991, AM REV RESPIR DIS, V143, P1433, DOI 10.1164/ajrccm/143.6.1433; STORER BE, 1985, J AM STAT ASSOC, V80, P139, DOI 10.2307/2288064; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; TANG OT, 1984, POSTGRAD MED J, V60, P24; VANSHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P792; WEST R, 1987, AM J PREV MED S2, V4, P25; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; ZAAGSMA J, 1984, EUR J RESPIR DIS S, V135, P16; 1980, IARC SCI PUBLICATION, V32; 1980, DHHS PHS801260 PUBL	27	1011	1029	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					501	506		10.1056/NEJM199202203260801	http://dx.doi.org/10.1056/NEJM199202203260801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1346340				2022-12-24	WOS:A1992HD65800001
J	ZANOLARI, B; RATHS, S; SINGERKRUGER, B; RIEZMAN, H				ZANOLARI, B; RATHS, S; SINGERKRUGER, B; RIEZMAN, H			YEAST PHEROMONE RECEPTOR ENDOCYTOSIS AND HYPERPHOSPHORYLATION ARE INDEPENDENT OF G PROTEIN-MEDIATED SIGNAL TRANSDUCTION	CELL			English	Article							ALPHA-FACTOR RECEPTOR; BETA-ADRENERGIC-RECEPTOR; TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; PEPTIDE PHEROMONE; INSULIN-RECEPTOR; GAMMA-SUBUNITS; EGF RECEPTOR; S-CEREVISIAE	When alpha factor binds to the yeast alpha factor receptor a signal is transmitted via a tripartite G protein that prepares the cell for conjugation. As a result of alpha factor binding the receptor also undergoes a regulated internalization and hyperphosphorylation. Using cells that lack activity of this tripartite G protein, we show that G protein-mediated pheromone signal transduction is not necessary for regulation of receptor internalization or hyperphosphorylation. Therefore, the processes of signal transduction and down regulation can be uncoupled. We propose that binding of alpha factor to its receptor results in a receptor conformation change that permits receptor hyperphosphorylation and interaction with the endocytic machinery.			ZANOLARI, B (corresponding author), UNIV BASEL, BIOCTR, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.			Riezman, Howard/0000-0003-4680-9422				BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DULIC V, 1990, J CELL SCI, V97, P517; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; GASSER SM, 1982, J BIOL CHEM, V257, P3034; HAGEN DC, 1984, J MOL BIOL, V178, P835, DOI 10.1016/0022-2836(84)90314-0; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARI J, 1987, J BIOL CHEM, V262, P15341; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUVARD D, 1983, EMBO J, V2, P1655, DOI 10.1002/j.1460-2075.1983.tb01640.x; Maniatis T., 1982, MOL CLONING; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; Sprague G F Jr, 1990, Adv Genet, V27, P33; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; TERNYNCK T, 1976, ANN INST PASTEUR IMM, VC127, P197; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; ZANOLARI B, 1991, MOL CELL BIOL, V11, P5251, DOI 10.1128/MCB.11.10.5251	49	70	70	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					755	763		10.1016/0092-8674(92)90552-N	http://dx.doi.org/10.1016/0092-8674(92)90552-N			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330324				2022-12-24	WOS:A1992JZ63300006
J	HEGDE, RS; GROSSMAN, SR; LAIMINS, LA; SIGLER, PB				HEGDE, RS; GROSSMAN, SR; LAIMINS, LA; SIGLER, PB			CRYSTAL-STRUCTURE AT 1.7-ANGSTROM OF THE BOVINE PAPILLOMAVIRUS-1 E2 DNA-BINDING DOMAIN BOUND TO ITS DNA TARGET	NATURE			English	Article							PROTEIN STRUCTURES; TERMINAL DOMAIN; NUCLEIC-ACIDS; REPRESSOR; RECOGNITION; RESOLUTION; COMPLEX; OPERATOR; ACTIVATION; E2-PROTEIN	The dominant transcriptional regulator of the papillomaviruses, E2, binds to its specific DNA target through a previously unobserved dimeric antiparallel beta-barrel. The DNA is severely but smoothly bent over the barrel by the interaction of successive major grooves with a pair of symmetrically disposed alpha-helices. The specific interface is an 'interwoven' network of interactions where the identifying base pairs of the target contact more than one amino-acid side chain and the discriminating amino acids interact with more than one base pair.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Yale University; University of Chicago; Howard Hughes Medical Institute; University of Chicago	HEGDE, RS (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510, USA.							ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HANDSCHUMACHER MD, 1983, ACCESS YALE U; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MCBRIDE AA, 1989, COMMON MECHANISMS TR, P115; MONINI P, 1991, J VIROL, V65, P2124, DOI 10.1128/JVI.65.4.2124-2130.1991; MOSKALUK C, 1988, P NATL ACAD SCI USA, V85, P1826, DOI 10.1073/pnas.85.6.1826; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SOUSA R, 1990, BIOCHIM BIOPHYS ACTA, V1032, P19, DOI 10.1016/0304-419X(90)90010-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; USTAV M, 1991, EMBO J, V10, P445; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	40	309	317	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					505	512		10.1038/359505a0	http://dx.doi.org/10.1038/359505a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1328886				2022-12-24	WOS:A1992JR85900050
J	MIYAKE, M; TAKI, T; HITOMI, S; HAKOMORI, S				MIYAKE, M; TAKI, T; HITOMI, S; HAKOMORI, S			CORRELATION OF EXPRESSION OF H/LE(Y)/LE(B) ANTIGENS WITH SURVIVAL IN PATIENTS WITH CARCINOMA OF THE LUNG	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-EMBRYOS; CARBOHYDRATE; BLADDER; CANCERS	Background. The level of expression of H/Le(y)/Le(b) antigens is high in various histologic types of lung cancer, a feature that may be related to deletion of A and B blood-group antigens. We evaluated the possibility that expression of this antigen, which can be defined by the monoclonal antibody MIA-15-5, might be of prognostic value, as suggested by our previous observation that MIA-15-5 inhibits tumor-cell motility and metastasis. Methods. We used MIA-15-5 to stain tissue sections from 149 patients with primary lung cancer whose clinico-pathological histories were well documented. The survival curves for patients whose tumors stained positively were compared with the curves for those whose tumors stained negatively. Multivariate analyses were performed with a Cox proportional-hazards regression model. Results. Among the 149 patients studied, five-year survival in the 91 patients with MIA-positive tumors was significantly lower than survival in the 58 with MIA-negative tumors (20.9 percent vs. 58.6 percent, P<0.001). Among the 67 patients with squamous-cell carcinoma, the rates also differed significantly (10.5 percent vs. 62.1 percent, P<0.001). The difference in survival between patients with MIA-positive tumors and those with MIA-negative tumors was significant among patients with blood groups A and AB (P<0.001), but not among those with blood group B or 0 (P = 0.071 and 0.068, respectively). Multivariate analysis with the Cox regression model indicated that positivity best correlated with five-year mortality, followed by lymph-node status (N stage) and tumor size (T stage), whereas sex, age, and blood group did not correlate with mortality. Conclusions. Positivity for MIA (i.e., immunohistologic staining by MIA-15-5, which defines H/Le(y)/Le(b) antigens) is inversely correlated with survival among patients with primary lung cancer and may be of prognostic value.	KYOTO UNIV, CHEST DIS RES INST, DEPT THORAC SURG, KYOTO 606, JAPAN; UNIV WASHINGTON, INST BIOMEMBRANE, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	Kyoto University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	MIYAKE, M (corresponding author), KITANO HOSP, TAZUKE KOFUKAI MED RES INST, DEPT THORAC SURG, KITA KIE, OSAKA 530, JAPAN.				NCI NIH HHS [CA-42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, AM J CLIN PATHOL, V77, P123; COON JS, 1985, CANCER, V56, P797, DOI 10.1002/1097-0142(19850815)56:4<797::AID-CNCR2820560417>3.0.CO;2-H; COX DR, 1972, J R STAT SOC B, V34, P187; DABELSTEEN E, 1983, CANCER RES, V43, P1451; DABELSTEEN E, 1975, ACTA PATH MICRO IM A, VA 83, P292; DAVIDSOHN I, 1969, ARCH PATHOL, V87, P306; DAVIDSOHN I, 1966, ARCH PATHOL, V81, P381; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAKOMORI S, 1974, ANTIGENS, V2, P79; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hermanek P, 1987, TNM CLASSIFICATION M, P69; ITAI S, 1990, CANCER RES, V50, P7603; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY HE, 1961, J NATL CANCER I, V26, P1349; KOVARIK S, 1968, ARCH PATHOL, V86, P12; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASAMUNE H, 1952, Tohoku J Exp Med, V56, P37; MASAMUNE H, 1958, TOHOKU J EXP MED, V8, P81; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MIYAKE M, 1988, CANCER RES, V48, P7150; ORNTOFT TF, 1989, INT J CANCER, V43, P774, DOI 10.1002/ijc.2910430505; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; SILLETTI S, 1991, CANCER RES, V51, P3507; STANFORD DR, 1986, INT J CANCER, V37, P435, DOI 10.1002/ijc.2910370316; STELLNER K, 1973, BIOCHEM BIOPH RES CO, V55, P439, DOI 10.1016/0006-291X(73)91106-6	27	232	249	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					14	18		10.1056/NEJM199207023270103	http://dx.doi.org/10.1056/NEJM199207023270103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1317941				2022-12-24	WOS:A1992JA76100003
J	GOESSLING, LS; DANIELSMCQUEEN, S; BHATTACHARYYAPAKRASI, M; LIN, JJ; THACH, RE				GOESSLING, LS; DANIELSMCQUEEN, S; BHATTACHARYYAPAKRASI, M; LIN, JJ; THACH, RE			ENHANCED DEGRADATION OF THE FERRITIN REPRESSOR PROTEIN DURING INDUCTION OF FERRITIN MESSENGER-RNA TRANSLATION	SCIENCE			English	Article							ELEMENT-BINDING-PROTEIN; ELECTROPHORETIC TRANSFER; AFFINITY PURIFICATION; POLYACRYLAMIDE GELS; CHELATABLE IRON; HEPATOMA-CELLS; RABBIT LIVER; HEMIN; EXPRESSION; NITROCELLULOSE	Induction of ferritin synthesis in cultured cells by heme or iron is accompanied by degradation of the ferritin repressor protein (FRP). Intermediates in the degradative pathway apparently include FRP covalently linked in larger aggregates. The effect of iron on FRP degradation is enhanced by porphyrin precursors but is decreased by inhibitors of porphyrin synthesis, which implies that heme is an active agent. These results suggest that translational induction in this system may be caused by enhanced repressor degradation. While unique among translational regulatory systems, this process is common to a variety of other biosynthetic control mechanisms.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)					NIAID NIH HHS [AI 20484] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020484] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOTTOMLEY SS, 1985, J BIOL CHEM, V260, P6811; BROWN PH, 1989, J BIOL CHEM, V264, P13383; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG CS, 1982, J BIOL CHEM, V257, P3650; CHERNIK RJ, 1989, HEPATOLOGY, V10, P359; CIECHANOVER A, 1990, P NATL ACAD SCI USA, V63, P1129; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DANIELSMCQUEEN S, UNPUB; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EISENSTEIN RS, 1991, ENZYME BASEL, V44, P42; GOESSLING LS, UNPUB; HARFORD JB, 1991, ENZYME, V44, P28; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; IWASA F, 1989, BIOCHEM J, V262, P807, DOI 10.1042/bj2620807; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; LAWSON TG, 1989, J VIROL, V63, P5013, DOI 10.1128/JVI.63.12.5013-5022.1989; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; LIN JJ, 1991, ENZYME, V44, P59; MULLEREBERHARD U, 1988, J BIOL CHEM, V263, P14753; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; ROBERTS JW, 1981, NATURE, V290, P422, DOI 10.1038/290422a0; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROUAULT T, 1985, J BIOL CHEM, V260, P4862; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SWENSON GR, 1991, BIOL MET, V4, P48, DOI 10.1007/BF01135557; THEIL EC, 1991, ENZYME, V44, P68; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WALDEN WE, 1987, GENE, V61, P317, DOI 10.1016/0378-1119(87)90195-8; WARD JH, 1984, J BIOL CHEM, V259, P3235; ZHENG L, COMMUNICATION	42	48	47	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					670	673		10.1126/science.1316633	http://dx.doi.org/10.1126/science.1316633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1316633				2022-12-24	WOS:A1992HR18500034
J	XI, YG; INGROSSO, L; LADOGANA, A; MASULLO, C; POCCHIARI, M				XI, YG; INGROSSO, L; LADOGANA, A; MASULLO, C; POCCHIARI, M			AMPHOTERICIN-B TREATMENT DISSOCIATES INVIVO REPLICATION OF THE SCRAPIE AGENT FROM PRP ACCUMULATION	NATURE			English	Article							INCUBATION PERIOD; MOUSE SCRAPIE; PROTEIN; HAMSTERS; PRION; STRAINS; FIBRILS; CURVES; BRAIN; ASSAY	SCRAPIE and related animal and human disorders are neurodegenerative diseases 1 characterized by the formation of a modified, partly proteinase-resistant protein (PrP) of the host 2,3, which tends to aggregate as amyloid fibrils 4 and accumulate in the brain of infected individuals 5. There is a general consensus that the pathological form of PrP (PrP(Sc)) is essential for the clinical appearance of the disease 6, but whether it is part of the scrapie agent 7 or a by-product of viral infection 8,9 is still controversial. Here we report that treatment of scrapie-infected hamsters with amphotericin B delays the accumulation in the brain of the proteinase-resistant portion of PrP(Sc) by about 30 days without affecting scrapie replication. The consequence is that hamsters treated with amphotericin B developed clinical signs of disease later than infected controls. We argue that the proteinase-resistant portion of PrP(Sc) is necessary for the development of the disease but that it is unlikely to be essential for scrapie replication.	IST SUPER SANITA, VIROL LAB, I-00161 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST NEUROL, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST PATOL GEN, I-00168 ROME, ITALY	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			INGROSSO, LOREDANA/C-6487-2016; Ladogana, Anna/K-1415-2016; Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486; ladogana, Anna/0000-0002-7504-6906				BRAIG HR, 1985, EMBO J, V4, P2300; BRUNORI M, 1988, TRENDS BIOCHEM SCI, V13, P309, DOI 10.1016/0968-0004(88)90126-0; CASACCIA P, 1990, TRENDS IN NEUROIMMUNOLOGY, P135; CASACCIA P, 1991, ANTIMICROB AGENTS CH, V35, P1486, DOI 10.1128/AAC.35.7.1486; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1988, CIBA F S, V135, P209; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; GAJDUSEK DC, 1990, VIROLOGY, P2289; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANUELIDIS L, 1987, EMBO J, V6, P341, DOI 10.1002/j.1460-2075.1987.tb04760.x; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEDOFF G, 1983, ANNU REV PHARMACOL, V23, P303, DOI 10.1146/annurev.pa.23.040183.001511; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; POCCHIARI M, 1989, J INFECT DIS, V160, P795, DOI 10.1093/infdis/160.5.795; POCCHIARI M, 1989, NEUROLOGIA SCI BASE, P571; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; REED L. J., 1938, AMER JOUR HYG, V27, P493; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	31	147	157	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					598	601		10.1038/356598a0	http://dx.doi.org/10.1038/356598a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348570				2022-12-24	WOS:A1992HP03100047
J	BENIGNI, A; BOCCARDO, P; NORIS, M; REMUZZI, G; SIEGLER, RL				BENIGNI, A; BOCCARDO, P; NORIS, M; REMUZZI, G; SIEGLER, RL			URINARY-EXCRETION OF PLATELET-ACTIVATING-FACTOR IN HEMOLYTIC UREMIC SYNDROME	LANCET			English	Note							HEMOLYTIC-UREMIC SYNDROME	Since some of the features of haemolytic uraemic syndrome (HUS), such as platelet activation and glomerular injury, could be brought about by platelet-activating factor (PAF), we have studied the urinary excretion of PAF in 10 children with HUS and in 10 healthy age-matched controls. Urinary PAF concentrations, measured by radioimmunoassay, were significantly higher in acute-phase HUS patients than in controls (mean 2.04 [SD 1.66] vs 0.72 [0.43] ng/mg creatinine, p < 0.05) but were similar to those in controls in samples taken after recovery. High PAF concentrations during the acute phase of HUS may reflect platelet activation and glomerular injury, the lower values after recovery suggest that urinary PAF may be a marker of disease activity.	UNIV UTAH,DEPT PEDIAT,DIV NEPHROL & HYPERTENS,50 N MED DR,SALT LAKE CITY,UT 84132; OSPED RIUNITI BERGAMO,DIV NEPHROL,I-24100 BERGAMO,ITALY; MARIO NEGRI INST PHARMACOL RES,BERGAMO,ITALY	Utah System of Higher Education; University of Utah; Ospedali Riuniti di Bergamo; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			NORIS, MARINA/ABG-2219-2020; Boccardo, Paola/ABG-7647-2020; Ariela, Benigni/ABH-3492-2020; Remuzzi, Giuseppe/V-9766-2017	NORIS, MARINA/0000-0001-7651-5033; Boccardo, Paola/0000-0003-4969-6187; Ariela, Benigni/0000-0002-4721-5485; Remuzzi, Giuseppe/0000-0002-6194-3446				APPIANI AC, 1982, CLIN NEPHROL, V17, P195; CAMUSSI G, 1986, KIDNEY INT, V29, P469, DOI 10.1038/ki.1986.23; LEVY M, 1980, HEMOSTASIS PROSTAGLA, P383; MOAKE JL, 1984, BLOOD, V64, P592; NORIS M, 1990, J BIOL CHEM, V265, P19414; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; WALTERS MDS, 1988, KIDNEY INT, V33, P107, DOI 10.1038/ki.1988.17	8	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					835	836		10.1016/0140-6736(92)90281-7	http://dx.doi.org/10.1016/0140-6736(92)90281-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347859				2022-12-24	WOS:A1992HM44100006
J	DENNIS, M				DENNIS, M			STROKE SERVICES	LANCET			English	Article							CONTROLLED TRIAL; MANAGEMENT				DENNIS, M (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; MORRIS AD, 1991, IN PRESS J NEUROL NE; RICCI S, 1991, J NEUROL NEUROSUR PS, V54, P695, DOI 10.1136/jnnp.54.8.695; STEVENS RS, 1984, AGE AGEING, V13, P65, DOI 10.1093/ageing/13.2.65; STONE SP, 1987, AGE AGEING, V16, P81, DOI 10.1093/ageing/16.1.81; WOODDAUPHINEE S, 1984, STROKE, V15, P864, DOI 10.1161/01.STR.15.5.864; 1988, BRIT MED J, V297, P126; 1991, LANCET, V337, P1235; 1988, BRIT MED J, V296, P320; 1991, NEW ENGL J MED, V325, P445	13	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					793	795		10.1016/0140-6736(92)91907-P	http://dx.doi.org/10.1016/0140-6736(92)91907-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347815				2022-12-24	WOS:A1992HL50100015
J	KAWASAKI, S; MAKUUCHI, M; ISHIZONE, S; MATSUNAMI, H; TERADA, M; KAWARAZAKI, H				KAWASAKI, S; MAKUUCHI, M; ISHIZONE, S; MATSUNAMI, H; TERADA, M; KAWARAZAKI, H			LIVER-REGENERATION IN RECIPIENTS AND DONORS AFTER TRANSPLANTATION	LANCET			English	Note							VOLUME; GRAFT	Reduced-size liver grafts from related donors may not be of an optimal size for adequate function in the recipient. Therefore, liver-graft regeneration is clinically important. We evaluated liver regeneration by liver-volume determinations with serial computed tomography scans in four recipients (aged 9 months to 12 years) and their donors (all fathers of the recipients) after living-related liver transplantation. Standard liver volume was calculated from the recipient's body-surface area. In each recipient, the size of the transplanted liver tended to converge to the standard liver volume with time, regardless of whether initial liver-graft volume was smaller or larger than standard liver volume. In addition, transplanted liver in the recipient regenerated much faster than remnant liver in the donor, even though both consisted of the same hepatocytes, which suggests that regeneration is regulated mainly by factors other than the hepatocytes themselves.	UNIV TOKYO,FAC MED,DEPT PAEDIAT SURG,TOKYO 113,JAPAN	University of Tokyo	KAWASAKI, S (corresponding author), SHINSHU UNIV,SCH MED,DEPT SURG 1,ASAHI 3-1-1,MATSUMOTO,NAGANO 390,JAPAN.							BISMUTH H, 1984, SURGERY, V95, P367; DEHEMPTINNE B, 1987, TRANSPLANT P, V19, P3317; HENDERSON JM, 1989, HEPATOLOGY, V10, P288, DOI 10.1002/hep.1840100306; HEYMSFIELD SB, 1979, ANN INTERN MED, V90, P185, DOI 10.7326/0003-4819-90-2-185; KAHAN D, 1988, TRANSPLANT P, V20, P850; KAM I, 1987, HEPATOLOGY, V7, P362, DOI 10.1002/hep.1840070225; KANEKO U, 1982, NIPPON HUMAN ANATOMY, V2; MAKUUCHI M, IN PRESS SURGERY; RAIA S, 1989, LANCET, V2, P497; STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106	10	170	178	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					580	581		10.1016/0140-6736(92)90867-3	http://dx.doi.org/10.1016/0140-6736(92)90867-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347095				2022-12-24	WOS:A1992HH07500005
J	PETERSON, CL; HERSKOWITZ, I				PETERSON, CL; HERSKOWITZ, I			CHARACTERIZATION OF THE YEAST SWI1, SWI2, AND SWI3 GENES, WHICH ENCODE A GLOBAL ACTIVATOR OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-II; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; HO-GENE; BINDING-PROTEIN; DNA-BINDING; ALCOHOL-DEHYDROGENASE; MESSENGER-RNA; EXPRESSION; SUBUNIT	The yeast SWI1, SWI2 (SNF2), and SWI3 genes are required for transcription of HO and INO1 genes. We show that they are also required for transcription of ADH1, ADH2, SUC2, GAL1, and GAL10 and for function of simple UAS elements with binding sites for yeast GAL4 or Drosophila ftz proteins. SWI3 encodes a 99 kd nuclear protein containing a large, highly acidic N-terminal domain. SWI1 is identical to ADR6, which encodes a positive regulator of ADH1 and ADH2. Transcription of HO also requires SNF5 and SNF6. These and other observations suggest that SWI1, SWI2, SWI3, SNF5, and SNF6 may be components of a large multi-subunit complex. We propose that these products perform a general role in transcription by assisting gene-specific regulatory proteins.			PETERSON, CL (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA09270-16] Funding Source: Medline; NIAID NIH HHS [AI8738] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HAPPEL AM, 1991, GENETICS, V128, P69; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KEMPHUES KJ, 1983, GENETICS, V105, P345; KLIED D, 1981, SCIENCE, V214, P1125; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; Miller J.H., 1972, EXPT MOL GENETICS; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NEIGEBORN L, 1984, GENETICS, V108, P845; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHARA PJ, 1988, NUCLEIC ACIDS RES, V16, P10153, DOI 10.1093/nar/16.21.10153; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	45	507	518	0	24	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					573	583		10.1016/0092-8674(92)90192-F	http://dx.doi.org/10.1016/0092-8674(92)90192-F			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1339306				2022-12-24	WOS:A1992HD39800016
J	BEWLEY, S; BEWLEY, TH				BEWLEY, S; BEWLEY, TH			DRUG-DEPENDENCE WITH ESTROGEN REPLACEMENT THERAPY	LANCET			English	Editorial Material							ESTRADIOL IMPLANTS; ESTROGEN DEFICIENCY; HORMONE IMPLANTS; SYMPTOMS; WOMEN	Dependence on some drugs can be hard to recognise. Hormone replacement therapy (HRT) has been widely prescribed only in the past two decades, and the indications for treatment and the risk/benefit ratio are still disputed. Oestrogens are psychoactive: they lift mood, can be given by injection, and their use has powerful psychological effects. Reports of women with supraphysiological oestradiol concentrations may represent tolerance and withdrawal. Dependence on substances occurring naturally in the body has been reported before. We propose that HRT dependence occurs.	ST GEORGE HOSP,SCH MED,DEPT ADDICT BEHAV,LONDON SW17,ENGLAND	St Georges University London	BEWLEY, S (corresponding author), UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,LONDON WC1E 6HX,ENGLAND.			bewley, susan/0000-0001-8064-652X				APPLEBY L, 1991, PROGR OBSTETRICS GYN, V9, P289; BRINCAT M, 1984, LANCET, V1, P16; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR K, 1991, BRIT J OBSTET GYNAEC, V98, P607, DOI 10.1111/j.1471-0528.1991.tb10383.x; GANGAR KF, 1990, BRIT MED J, V300, P436, DOI 10.1136/bmj.300.6722.436; GARNETT T, 1990, BRIT J OBSTET GYNAEC, V97, P917, DOI 10.1111/j.1471-0528.1990.tb02447.x; GINSBURG J, 1991, BRIT MED J, V302, P1601; LADER M, 1981, AUST NZ J PSYCHIAT, V15, P1, DOI 10.3109/00048678109159402; Magos AL, 1984, PROGR OBSTETRICS GYN, V4, P334; MONTGOMERY JC, 1987, LANCET, V1, P297; NOTT PN, 1976, BRIT J PSYCHIAT, V128, P379, DOI 10.1192/bjp.128.4.379; SHERWIN BB, 1985, PSYCHONEUROENDOCRINO, V10, P325, DOI 10.1016/0306-4530(85)90009-5; STUDD J, 1989, BRIT MED J, V299, P1400, DOI 10.1136/bmj.299.6712.1400-b; STUDD J, 1991, BRIT J OBSTET GYNAEC, V5, P502; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; 1987, DIAGNOSTIC STATISTIC, P167; 1990, MENTAL BEHAVIOURAL D, P54; 1988, HLTH CONSEQUENCES SM, V4, P177	20	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					290	291		10.1016/0140-6736(92)91344-8	http://dx.doi.org/10.1016/0140-6736(92)91344-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346294				2022-12-24	WOS:A1992HB52900016
J	CHIN, KV; UEDA, K; PASTAN, I; GOTTESMAN, MM				CHIN, KV; UEDA, K; PASTAN, I; GOTTESMAN, MM			MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53	SCIENCE			English	Article							MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; HUMAN-TUMORS; CELLS; EXPRESSION; TISSUES; PROTEIN; LIVER; DNA; TRANSFORMATION	Drug resistance in human cancer is associated with overexpression of the multidrug resistance (MDR1) gene, which confers cross-resistance to hydrophobic natural product cytotoxic drugs. Expression of the MDR1 gene can occur de novo in human cancers in the absence of drug treatment. The promoter of the human MDR1 gene was shown to be a target for the c-Ha-Ras-1 oncogene and the p53 tumor suppressor gene products, both of which are associated with tumor progression. The stimulatory effect of c-Ha-Ras-1 was not specific for the MDR1 promoter alone, whereas a mutant p53 specifically stimulated the MDR1 promoter and wild-type p53 exerted specific repression. These results imply that the MDR1 gene could be activated during tumor progression associated with mutations in Ras and p53.	NCI,CELL BIOL LAB,BLDG 37,ROOM 1B22,BETHESDA,MD 20892; KYOTO UNIV,DEPT AGR CHEM,KYOTO 606,JAPAN; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chin, Khew-Voon/F-2670-2013; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Ueda, Kazumitsu/0000-0003-2980-6078				ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KJ, UNPUB; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GORMAN CM, 1982, MOL CELL BIOL, V2, P10144; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P666; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1989, JPN J CANCER RES, V80, P1127, DOI 10.1111/j.1349-7006.1989.tb02269.x	43	806	840	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					459	462		10.1126/science.1346476	http://dx.doi.org/10.1126/science.1346476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1346476				2022-12-24	WOS:A1992HA59000039
J	ATSUMI, T; MCCARTER, L; IMAE, Y				ATSUMI, T; MCCARTER, L; IMAE, Y			POLAR AND LATERAL FLAGELLAR MOTORS OF MARINE VIBRIO ARE DRIVEN BY DIFFERENT ION-MOTIVE FORCES	NATURE			English	Article							SWARMER CELL-DIFFERENTIATION; NA+ PUMP; ALKALOPHILIC BACILLUS; PROTONMOTIVE FORCE; PARAHAEMOLYTICUS; ALGINOLYTICUS; AMILORIDE; MOTILITY	VARIOUS species of marine Vibrio produce two distinct types of flagella, each adapted for a different type of motility 1. A single, sheathed polar flagellum is suited for swimming in liquid medium, and numerous unsheathed lateral flagella, which are produced only under viscous conditions, are suited for swarming over viscous surfaces 2,3. Both types of flagella are driven by reversible motors embedded in the cytoplasmic membrane. Here we report that the energy source for the polar flagellar motor of Vibrio parahaemolyticus is the sodium-motive force, whereas the lateral flagellar motors are driven by the proton-motive force. This is evidence that two distinct types of flagella powered by different energy sources are functionally active in one cell.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN; THE AGOURON INST,LA JOLLA,CA 92037	Nagoya University								ALLEN RD, 1971, J BACTERIOL, V107, P295, DOI 10.1128/JB.107.1.295-302.1971; ATSUMI T, 1990, J BACTERIOL, V172, P1634, DOI 10.1128/jb.172.3.1634-1639.1990; CHERNYAK BV, 1983, FEBS LETT, V164, P38, DOI 10.1016/0014-5793(83)80014-3; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; MANSON MD, 1977, P NATL ACAD SCI USA, V74, P3060, DOI 10.1073/pnas.74.7.3060; MATSUURA S, 1977, FEBS LETT, V82, P187, DOI 10.1016/0014-5793(77)80581-4; MCCARTER L, 1988, CELL, V54, P345, DOI 10.1016/0092-8674(88)90197-3; MCCARTER L, 1990, MOL MICROBIOL, V4, P1057, DOI 10.1111/j.1365-2958.1990.tb00678.x; SUGIYAMA S, 1988, J BIOL CHEM, V263, P8215; TOKUDA H, 1988, J BIOCHEM-TOKYO, V103, P650, DOI 10.1093/oxfordjournals.jbchem.a122323; TOKUDA H, 1982, J BIOL CHEM, V257, P7; TSUCHIYA T, 1985, J BACTERIOL, V162, P794, DOI 10.1128/JB.162.2.794-798.1985; YOSHIDA S, 1990, J BIOL CHEM, V265, P20346	13	196	206	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					182	184		10.1038/355182a0	http://dx.doi.org/10.1038/355182a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1309599				2022-12-24	WOS:A1992GY62900065
J	Wejstal, R; Widell, A; Mansson, AS; Hermodsson, S; Norkrans, G				Wejstal, R; Widell, A; Mansson, AS; Hermodsson, S; Norkrans, G			Mother-to-Infant Transmission of Hepatitis-C Virus	ANNALS OF INTERNAL MEDICINE			English	Article						Hyponatremia; Encephalopathy, Hyponatremic; Postoperative Complications; Menstruation	POLYMERASE CHAIN-REACTION; NON-B HEPATITIS; CHRONIC NON-A; VERTICAL TRANSMISSION; RNA; INFECTION	Objective: To describe the rate of perinatal transmission of hepatitis C virus (HCV). Design: Follow-up study of newborn children of mothers with chronic HCV infection. Setting: A university hospital in Sweden. Participants: Fourteen women with chronic HCV infection and their 21 newly born children. Main Outcome Measures: Detection of HCV RNA in serum by the polymerase chain reaction and detection of anti-HCV antibody by second generation assays. Results: All mothers were found to be positive for anti-HCV antibody both by second-generation enzyme-linked immunosorbent assay (ELISA) and by second-generation recombinant immunoblot assay (RIBA-2); all also had detectable serum HCV RNA. Two children had long-lasting alanine aminotransferase (ALT) elevations, and one of them became HCV RNA positive. None of the other children developed biochemical hepatitis. However, two additional children had temporary viremia. Only the child with biochemical and biopsy-proven hepatitis and detectable HCV RNA in multiple blood samples actively produced anti-HCV antibody. Conclusions: Mother-to-infant transmission of HCV infection from chronically infected women without human immunodeficiency virus (HIV) infection seems to be uncommon.	Gothenburg Univ, Ostra Hosp, Dept Infect Dis, S-41685 Gothenburg, SWEDEN; Gothenburg Univ, Sahlgrens Hosp, S-41345 Gothenburg, SWEDEN; Malmo Gen Hosp, S-21401 Malmo, SWEDEN; Univ Lund, S-22101 Lund, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Lund University	Wejstal, R (corresponding author), Gothenburg Univ, Ostra Hosp, Dept Infect Dis, S-41685 Gothenburg, SWEDEN.							[Anonymous], 1977, LANCET, V2, P914; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BUSCH MP, 1992, NEW ENGL J MED, V326, P64, DOI 10.1056/NEJM199201023260114; CHEN DS, 1991, J INFECT DIS, V164, P428, DOI 10.1093/infdis/164.2.428; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAXI A, 1991, LANCET, V337, P1354, DOI 10.1016/0140-6736(91)93037-A; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; ERCILLA M G, 1991, Journal of Hepatology, V13, pS26, DOI 10.1016/0168-8278(91)91092-U; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FORTUNY C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P418; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; NOVATI R, 1991, Journal of Hepatology, V13, pS56, DOI 10.1016/0168-8278(91)91213-Z; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; ROUDOTTHORAVAL F, 1991, HEPATOLOGY, V14, pA130; STEVENS CE, 1991, PERINATAL SEXUAL TRA, P407; TAYLOR PE, 1991, POST TRANSFUSION HEP, P441; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TONG MJ, 1981, GASTROENTEROLOGY, V80, P999; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WEINTRUB PS, 1990, HEPATOLOGY, V12, P850; WEJSTAL R, 1989, SCAND J INFECT DIS, V21, P485, DOI 10.3109/00365548909037875; WEJSTAL R, 1990, J MED VIROL, V30, P178, DOI 10.1002/jmv.1890300306; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409	25	145	144	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					887	890		10.7326/0003-4819-117-11-887	http://dx.doi.org/10.7326/0003-4819-117-11-887			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1332562				2022-12-24	WOS:A1992JZ27600002
J	JOHNSON, E				JOHNSON, E			RECALL OF DRINKING PATTERNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							GLADSJO JA, 1992, ADDICT BEHAV, V17, P347, DOI 10.1016/0306-4603(92)90040-3	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-24	WOS:A1992JN25600005
J	FREMONT, DH; MATSUMURA, M; STURA, EA; PETERSON, PA; WILSON, IA				FREMONT, DH; MATSUMURA, M; STURA, EA; PETERSON, PA; WILSON, IA			CRYSTAL-STRUCTURES OF 2 VIRAL PEPTIDES IN COMPLEX WITH MURINE MHC CLASS-I H-2K(B)	SCIENCE			English	Article							ANTIGEN-BINDING SITE; T-CELL RECOGNITION; HISTOCOMPATIBILITY ANTIGEN; MOLECULES; RECEPTOR; RESOLUTION; ANTIBODY; HLA-B27; HLA-A2	The x-ray structures of a murine MHC class I molecule (H-2K(b)) were determined in complex with two different viral peptides, derived from the vesicular stomatitis virus nucleoprotein(52-59), VSV-8, and the Sendai virus nucleoprotein(324-332), SEV-9. The H-2K(b) complexes were refined at 2.3 angstrom for VSV-8 and 2.5 angstrom for SEV-9. The structure of H-2K(b) exhibits a high degree of similarity with human HLA class I, although the individual domains can have slightly altered dispositions. Both peptides bind in extended conformations with most of their surfaces buried in the H-2K(b) binding groove. The nonamer peptide maintains the same amino- and carboxyl-terminal interactions as the octamer primarily by the insertion of a bulge in the center of an otherwise beta-conformation. Most of the specific interactions are between side-chain atoms of H-2K(b) and main-chain atoms of peptide. This binding scheme accounts in large part for the enormous diversity of peptide sequences that bind with high affinity to class I molecules. Small but significant conformational changes in H-2K(b) are associated with peptide binding, and these synergistic movements may be an integral part of the T cell receptor recognition process.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego			Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; Fremont, Daved/0000-0002-8544-2689	NCI NIH HHS [CA-97489, CA-09523] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, UNPUB; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHEN Y, TUBES WERE GENERATED; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, CALCULATE SOLVENT AC; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FILMAN D, PROGRAM HARADA; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, CALCULATE PSEUDO ROT; FREMONT DH, UNPUB; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACKSON MR, IN PRESS P NATL ACAD; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, IN PRESS CELL; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATSUMURA M, IN PRESS J BIOL CHEM; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROGNAN D, 1992, PROTEINS, V13, P70, DOI 10.1002/prot.340130107; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STURA EA, IN PRESS J MOL BIOL; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WILSON IA, 1991, METHOD ENZYMOL, V203, P153	59	892	925	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					919	927		10.1126/science.1323877	http://dx.doi.org/10.1126/science.1323877			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323877				2022-12-24	WOS:A1992JH82700024
J	MCGEE, HM; HORGAN, JH				MCGEE, HM; HORGAN, JH			CARDIAC REHABILITATION PROGRAMS - ARE WOMEN LESS LIKELY TO ATTEND	BRITISH MEDICAL JOURNAL			English	Article							EXERCISE				MCGEE, HM (corresponding author), BEAUMONT HOSP,DEPT CARDIOL,POB 1297,DUBLIN 9,IRELAND.		McGee, Hannah M/D-6480-2012	McGee, Hannah M/0000-0003-1417-993X				OCALLAGHAN WG, 1984, EUR HEART J, V5, P649, DOI 10.1093/oxfordjournals.eurheartj.a061721; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE MB, 1980, AM HEART J, V338, P1366; OLDRIDGE NB, 1978, CAN MED ASSOC J, V118, P361; 1991, LANCET, V338, P1366	5	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					283	284		10.1136/bmj.305.6848.283-a	http://dx.doi.org/10.1136/bmj.305.6848.283-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1285764	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JG74000018
J	THOMPSON, AM				THOMPSON, AM			THE OXIDIZING CAPACITY OF THE EARTHS ATMOSPHERE - PROBABLE PAST AND FUTURE CHANGES	SCIENCE			English	Article							ACID DEPOSITION MODEL; TROPOSPHERIC OZONE PRODUCTION; CLIMATE CHANGE; HYDROGEN-PEROXIDE; SULFUR-DIOXIDE; SURFACE OZONE; METHANE; CHEMISTRY; OXIDANTS; MECHANISMS	The principal oxidants in the lower atmosphere are ozone (O3) and two by-products of O3 photodissociation, the hydroxyl radical (OH) and hydrogen peroxide (H2O2). A number of critical atmospheric chemical problems depend on the earth's "oxidizing capacity," which is essentially the global burden of these oxidants. There is limited direct evidence for changes in the earth's oxidizing capacity since recent preindustrial times when, because of industrial and population growth, increasing amounts of O3 precursor trace gases (carbon monoxide, nitrogen oxides, and hydrocarbons) have been released into the atmosphere. The concentrations of O3 and possibly H2O2 have increased over large regions. Models predict that tropospheric O3 will increase approximately 0.3 to 1% per year over the next 50 years with both positive and negative trends possible for OH and H2O2. Models and the observational network for oxidants are improving, but validation of global models is still at an early stage.			THOMPSON, AM (corresponding author), NASA, GODDARD SPACE FLIGHT CTR, ATMOSPHERES LAB, GREENBELT, MD 20771 USA.		Thompson, Anne M/C-3649-2014; Thompson, Anne Mee/V-5862-2019	Thompson, Anne M/0000-0002-7829-0920; Thompson, Anne Mee/0000-0002-7829-0920				ATHERTON CS, 1990, J GEOPHYS RES-ATMOS, V95, P14027, DOI 10.1029/JD095iD09p14027; ATKINSON R, 1989, MONOGRAPH AM I PHYSI, V1; BECK JP, 1992, ATMOS ENVIRON A-GEN, V26, P17, DOI 10.1016/0960-1686(92)90257-L; BLAKE DR, 1986, J ATMOS CHEM, V4, P43, DOI 10.1007/BF00053772; BOJKOV RD, 1986, J CLIM APPL METEOROL, V25, P343, DOI 10.1175/1520-0450(1986)025<0343:SODTSH>2.0.CO;2; BRUHL C, 1989, GEOPHYS RES LETT, V16, P703, DOI 10.1029/GL016i007p00703; BRUHL C, 1991, JUN UN ENV PROGR WOR; Bruhl C., 1988, CLIM DYNAM, V2, P173, DOI 10.1007/BF01053474; BRUNE WH, 1992, SCIENCE, V256, P1154, DOI 10.1126/science.256.5060.1154; BUTLER JH, 1991, J GEOPHYS RES-ATMOS, V96, P22347, DOI 10.1029/91JD02126; CHAMEIDES WL, 1982, J GEOPHYS RES-OCEANS, V87, P4863, DOI 10.1029/JC087iC07p04863; CHAMEIDES WL, 1977, J GEOPHYS RES-OC ATM, V82, P1795, DOI 10.1029/JC082i012p01795; CHANG JS, 1987, J GEOPHYS RES-ATMOS, V92, P14681, DOI 10.1029/JD092iD12p14681; CHATFIELD RB, 1984, J GEOPHYS RES-ATMOS, V89, P7111, DOI 10.1029/JD089iD05p07111; CRAIG H, 1982, GEOPHYS RES LETT, V9, P1221, DOI 10.1029/GL009i011p01221; CRUTZEN P, 1973, PURE APPL GEOPHYS, V106, P1385, DOI 10.1007/BF00881092; CRUTZEN PJ, 1979, NATURE, V282, P253, DOI 10.1038/282253a0; CRUTZEN PJ, 1983, J GEOPHYS RES-OCEANS, V88, P6641, DOI 10.1029/JC088iC11p06641; CRUTZEN PJ, 1991, TELLUS A, V43, P136, DOI 10.1034/j.1600-0870.1991.00012.x; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; CUNNOID DM, 1992, J GEOPHYS RES, V96, P17392; DEMORE WB, 1990, NASA JPL PUBL, V901; DERWENT RG, 1982, ATMOS ENVIRON, V16, P1997, DOI 10.1016/0004-6981(82)90470-X; DICKERSON RR, 1987, SCIENCE, V235, P460, DOI 10.1126/science.235.4787.460; DODGE MC, 1989, J GEOPHYS RES-ATMOS, V94, P5121, DOI 10.1029/JD094iD04p05121; DORN H-P, 1988, Tellus Series B Chemical and Physical Meteorology, V40, P437; EHHALT DH, 1988, CHANGING ATMOSPHERE, P25; Finlayson-Pitts B.J., 1986, ATMOSPHERIC CHEM FUN; FISHMAN J, 1990, J GEOPHYS RES-ATMOS, V95, P3599, DOI 10.1029/JD095iD04p03599; FISHMAN J, 1991, SCIENCE, V252, P1693, DOI 10.1126/science.252.5013.1693; FISHMAN J, COMMUNICATION; GERY MW, 1989, J GEOPHYS RES-ATMOS, V94, P12925, DOI 10.1029/JD094iD10p12925; GERY MW, 1991, ENV EFFECTS OZONE DE; GERY MW, 1986, J GEOPHYS RES, V91, P10905; Graedel T. E., 1978, CHEM COMPOUNDS ATMOS; GRAEDEL TE, 1981, REV GEOPHYS, V19, P505, DOI 10.1029/RG019i004p00505; GUNZ DW, 1990, ATMOS ENVIRON A-GEN, V24, P1601, DOI 10.1016/0960-1686(90)90496-A; Guthrie PD, 1989, GLOBAL BIOGEOCHEM CY, V3, P287, DOI 10.1029/GB003i004p00287; HAMEED S, 1979, J GEOPHYS RES-OCEANS, V84, P763, DOI 10.1029/JC084iC02p00763; HOFZUMAHAUS A, 1991, ATMOS ENVIRON A-GEN, V25, P2017, DOI 10.1016/0960-1686(91)90281-B; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; HOUGH AM, 1990, NATURE, V344, P645, DOI 10.1038/344645a0; HOUGH AM, 1988, J GEOPHYS RES-ATMOS, V93, P3789, DOI 10.1029/JD093iD04p03789; ISAKSEN I S A, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P271, DOI 10.1111/j.1600-0889.1987.tb00099.x; Isaksen I. S. A., 1988, CHANGING ATMOSPHERE, P141; ISAKSEN ISA, 1992, SCI ASSESSMENT OZONE, pCH5; ISAKSEN ISA, 1989, OZONE ATMOSPHERE, P576; Jackman C., 1989, NASA C PUBLICATION, V3042; JOHNSON C, 1992, NATURE, V355, P69, DOI 10.1038/355069a0; KANAKIDOU M, 1991, J GEOPHYS RES-ATMOS, V96, P15395, DOI 10.1029/91JD01345; KANAKIDOU M, IN PRESS CHEMOSPHERE; KHALIL MAK, 1985, ATMOS ENVIRON, V19, P397, DOI 10.1016/0004-6981(85)90161-1; KLEY D, 1989, GLOBAL REGIONAL ENV, P9; LACIS AA, 1990, J GEOPHYS RES-ATMOS, V95, P9971, DOI 10.1029/JD095iD07p09971; LASHOF DA, 1990, USEPA21P20031 REP; LAW KS, 1991, ATMOS ENVIRON A-GEN, V25, P1863, DOI 10.1016/0960-1686(91)90269-D; LEIFER IS, 1991, EOS, V72, P99; LELIEVELD J, 1990, NATURE, V343, P227, DOI 10.1038/343227a0; LEONE JA, 1985, ATMOS ENVIRON, V19, P437, DOI 10.1016/0004-6981(85)90166-0; LEVINE JS, 1985, NATURE, V318, P254, DOI 10.1038/318254a0; LEVY H, 1972, PLANET SPACE SCI, V20, P919, DOI 10.1016/0032-0633(72)90177-8; LIN X, 1988, J GEOPHYS RES-ATMOS, V93, P15879, DOI 10.1029/JD093iD12p15879; LIU SC, 1988, J ATMOS CHEM, V6, P221, DOI 10.1007/BF00053857; LIU SC, 1980, J GEOPHYS RES-OCEANS, V85, P7546, DOI 10.1029/JC085iC12p07546; LIU SC, 1987, J GEOPHYS RES-ATMOS, V92, P4191, DOI 10.1029/JD092iD04p04191; LOGAN JA, 1985, J GEOPHYS RES-ATMOS, V90, P10463, DOI 10.1029/JD090iD06p10463; LOGAN JA, 1988, TROPOSPHERIC OZONE, P327; LU Y, 1991, CHEMOSPHERE, V23, P397, DOI 10.1016/0045-6535(91)90194-I; Lu Y.R., UNPUB; LUBIN D, 1989, J GEOPHYS RES-ATMOS, V94, P8491, DOI 10.1029/JD094iD06p08491; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P465, DOI 10.1029/92GL00378; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P37, DOI 10.1029/91GL02954; MCELROY MB, 1989, PHYS CH EAR, V8, P363; MOUNT GH, 1992, J GEOPHYS RES-ATMOS, V97, P2427, DOI 10.1029/91JD02971; MOUNT GH, 1992, SCIENCE, V256, P1187, DOI 10.1126/science.256.5060.1187; NEFTEL A, 1984, NATURE, V311, P43, DOI 10.1038/311043a0; OLTMANS SJ, 1986, J GEOPHYS RES-ATMOS, V91, P5229, DOI 10.1029/JD091iD04p05229; PENKETT SA, 1979, ATMOS ENVIRON, V13, P123, DOI 10.1016/0004-6981(79)90251-8; PENKETT SA, 1986, NATURE, V319, P655, DOI 10.1038/319655a0; PICKERING KE, 1990, J GEOPHYS RES-ATMOS, V95, P14049, DOI 10.1029/JD095iD09p14049; PINTO JP, 1991, TELLUS B, V43, P347, DOI 10.1034/j.1600-0889.1991.t01-2-00001.x; PRATHER M, 1990, J GEOPHYS RES-ATMOS, V95, P18723, DOI 10.1029/JD095iD11p18723; PRATHER MJ, 1989, NASA C PUBL, V3023; PRINN R, 1987, SCIENCE, V238, P945, DOI 10.1126/science.238.4829.945; PRINN R, 1992, J GEOPHYS RES-ATMOS, V97, P2445, DOI 10.1029/91JD02755; RASMUSSEN RA, 1981, J GEOPHYS RES-OCEANS, V86, P9826, DOI 10.1029/JC086iC10p09826; RASMUSSEN RA, 1984, J GEOPHYS RES-ATMOS, V89, P1599, DOI 10.1029/JD089iD07p11599; RAYNAUD D, 1988, NATURE, V333, P655, DOI 10.1038/333655a0; RIND D, 1990, J ATMOS SCI, V47, P475, DOI 10.1175/1520-0469(1990)047<0475:CCATMA>2.0.CO;2; SANDRONI S, 1992, J GEOPHYS RES-ATMOS, V97, P2535, DOI 10.1029/91JD02660; SCHNELL RC, 1991, NATURE, V351, P726, DOI 10.1038/351726a0; SIGG A, 1991, NATURE, V351, P557, DOI 10.1038/351557a0; SIGG A, 1992, J ATMOS CHEM, V14, P223, DOI 10.1007/BF00115235; Sigg A., 1988, ANN GLACIOL, V10, P157; SOLBERG S, 1989, OZONE ATMOSPHERE, P548; SPIVAKOVSKY CM, 1991, J GEOPHYS RES-ATMOS, V96, P17395, DOI 10.1029/91JD01669; STAUFFER B, 1985, SCIENCE, V229, P1386, DOI 10.1126/science.229.4720.1386; STAUFFER B, 1988, NATURE, V332, P812, DOI 10.1038/332812a0; STOCKWELL WR, 1986, ATMOS ENVIRON, V20, P1615, DOI 10.1016/0004-6981(86)90251-9; STOCKWELL WR, 1990, J GEOPHYS RES-ATMOS, V95, P16343, DOI 10.1029/JD095iD10p16343; STOLARSKI RS, 1991, GEOPHYS RES LETT, V18, P1015, DOI 10.1029/91GL01302; SZE N D, 1977, Science (Washington D C), V195, P673, DOI 10.1126/science.195.4279.673; Thompson AD, UNPUB; THOMPSON AM, 1986, J GEOPHYS RES-ATMOS, V91, P853, DOI 10.1029/JD091iD10p10853; THOMPSON AM, 1990, J GEOPHYS RES-ATMOS, V95, P9829, DOI 10.1029/JD095iD07p09829; THOMPSON AM, 1989, ATMOS ENVIRON, V23, P519, DOI 10.1016/0004-6981(89)90001-2; THOMPSON AM, 1991, ATMOS ENVIRON A-GEN, V25, P1837, DOI 10.1016/0960-1686(91)90267-B; THOMPSON AM, 1991, J GEOPHYS RES-ATMOS, V96, P13089, DOI 10.1029/91JD01056; THOMPSON AM, 1984, J GEOPHYS RES-ATMOS, V89, P1341, DOI 10.1029/JD089iD01p01341; THOMPSON AM, 1991, NATURE, V352, P282, DOI 10.1038/352282a0; THOMPSON AM, IN PRESS ATMOS ENV; VALENTIN KM, 1990, THESIS JOHANNESGUTEN; VOLZ A, 1988, NATURE, V332, P240, DOI 10.1038/332240a0; WANG WC, 1980, J ATMOS SCI, V37, P333, DOI 10.1175/1520-0469(1980)037<0333:CEDTHC>2.0.CO;2; WATSON RT, 1990, CLIMATE CHANGE IPCC, pCH1; WUEBBLES DJ, 1989, JAPCA J AIR WASTE MA, V39, P22, DOI 10.1080/08940630.1989.10466502; WUEBBLES DJ, 1989, 1988 SENS URB REG CH; WUEBBLES DJ, 1987, UCRL21178 LAWR LIV N; ZIMMERMANN PH, 1988, AIR POLLUTION MODELI, V6, P593; 1990, NOAACMDL18 SUMM REP, P40	121	612	643	14	216	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1157	1165		10.1126/science.256.5060.1157	http://dx.doi.org/10.1126/science.256.5060.1157			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1317061				2022-12-24	WOS:A1992HV19200024
J	HUGHES, PH; BRANDENBURG, N; BALDWIN, DC; STORR, CL; WILLIAMS, KM; ANTHONY, JC; SHEEHAN, DV				HUGHES, PH; BRANDENBURG, N; BALDWIN, DC; STORR, CL; WILLIAMS, KM; ANTHONY, JC; SHEEHAN, DV			PREVALENCE OF SUBSTANCE USE AMONG UNITED-STATES PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YOUTHFUL PRECURSORS; ALCOHOL-ABUSE; DRUG; STUDENTS	Objective.-To estimate the prevalence of substance use among US physicians. Design.-A mailed, anonymous, self-report survey that assessed use of 13 substances and permitted comparison with results of the National Household Survey on Drug Abuse. Rates of physician substance use were weighted to provide national prevalence estimates. Participants.-A national sample of 9600 physicians, stratified by specialty and career stage, and randomly selected from the American Medical Association master file. The response rate after three mailings was 59%. Demographic characteristics of respondents closely reflected those of the US physician population. Main Outcome Measures.-Subjects' self-reported use of 13 substances in their lifetime, the past year, and the past month; reasons for use; self-admitted substance abuse or dependence; and whether treatment was received. For controlled prescription substances, respondents were asked to report only use "not prescribed by another physician for a legitimate medical or psychiatric condition." Results.-Physicians were less likely to have used cigarettes and illicit substances, such as marijuana, cocaine, and heroin, in the past year than their age and gender counterparts in the National Household Survey on Drug Abuse. They were more likely to have used alcohol and two types of prescription medication-minor opiates and benzodiazepine tranquilizers. Prescription substances were used primarily for self-treatment, whereas illicit substances and alcohol were used primarily for recreation. Current daily use of illicit or controlled substances was rare. Conclusions.-Although physicians were as likely to have experimented with illicit substances in their lifetime as their age and gender peers in society, they were far less likely to be current users of illicit substances. The higher prevalence of alcohol use among respondents may be more a characteristic of their socioeconomic class than of their profession. A unique concern for physicians, however, is their high rate of self-treatment with controlled medications-a practice that could increase their risk of drug abuse or dependence. Uniform national guidelines are needed to sensitize medical students and physicians to the dangers of self-treatment with controlled prescription substances.	UNIV S FLORIDA, INST RES PSYCHIAT, TAMPA, FL 33620 USA; JAMES A HALEY VET HOSP, TAMPA, FL USA; UNIV S FLORIDA, COLL PUBL HLTH, TAMPA, FL 33620 USA; AMER MED ASSOC, DIV MED EDUC RES, CHICAGO, IL 60610 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; American Medical Association; Johns Hopkins University			Anthony, Jim/H-3637-2011; Sheehan, David V/L-6879-2013	Anthony, Jim/0000-0001-7176-0929; Sheehan, David V/0000-0002-5118-7050	NIDA NIH HHS [1 RO1 DA04877] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004877] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1973, JAMA, V223, P684; [Anonymous], 1987, JAMA-J AM MED ASSOC, V257, P3110; BALDWIN DC, 1991, JAMA-J AM MED ASSOC, V265, P2074, DOI 10.1001/jama.265.16.2074; BALTER M, 1991, MAY ANN M AM PSYCH A; BISSELL L, 1989, American Pharmacy, V29, P19; Bissell L, 1984, ALCOHOLISM PROFESSIO; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; COTTLER LB, 1987, AM J EPIDEMIOL, V125, P329, DOI 10.1093/oxfordjournals.aje.a114534; Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1; Fleiss JL, 1981, STAT METHODS RATES P; FRANKEL M, 1983, HDB SURVEY RES; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; HOLT D, 1979, J ROY STAT SOC A STA, V142, P33, DOI 10.2307/2344652; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; KNUPFER G, 1989, BRIT J ADDICT, V84, P1305; KRAKOWSKI AJ, 1984, PSYCHOTHER PSYCHOSOM, V42, P143, DOI 10.1159/000287838; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; MADDUX JF, 1987, J MED EDUC, V62, P852; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MCAULIFFE WE, 1991, AM J PUBLIC HEALTH, V81, P177, DOI 10.2105/AJPH.81.2.177; MOORE RD, 1990, AM J MED, V88, P332, DOI 10.1016/0002-9343(90)90485-V; MORSE RM, 1984, JAMA-J AM MED ASSOC, V251, P743, DOI 10.1001/jama.251.6.743; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V264, P1039, DOI 10.1001/jama.264.8.1039; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; ROBACK G, 1990, PHYSICIAN CHARACTERI; ROUSE B, 1985, RES MONOGRAPH NATION, V57; SHEIKH K, 1981, J EPIDEMIOL COMMUN H, V35, P293, DOI 10.1136/jech.35.4.293; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; VAILLANT GE, 1970, NEW ENGL J MED, V282, P365, DOI 10.1056/NEJM197002122820705; 1989, NATIONAL HOUSEHOLD S; 1990, NATIONAL HOUSEHOLD S	32	240	244	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2333	2339		10.1001/jama.267.17.2333	http://dx.doi.org/10.1001/jama.267.17.2333			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1348789				2022-12-24	WOS:A1992HR01500025
J	KIRBY, AJ; SPIEGELHALTER, DJ; DAY, NE; FENTON, L; SWANSON, K; MANN, EMF; MACGREGOR, JE				KIRBY, AJ; SPIEGELHALTER, DJ; DAY, NE; FENTON, L; SWANSON, K; MANN, EMF; MACGREGOR, JE			CONSERVATIVE TREATMENT OF MILD MODERATE CERVICAL DYSKARYOSIS - LONG-TERM OUTCOME	LANCET			English	Article							SMEARS	There is some controversy about the management of women with mild or moderate dyskaryotic cervical smears. To assess the strategy of an established cervical cytology screening programme (Grampian region, northeast Scotland) we identified 500 women who had had mild or moderate cervical dyskaryosis in 1978 or 1979, and 500, matched by age, who had had a normal smear at that time. Follow-up smear results and any subsequent investigation by colposcopy, cone biopsy, or hysterectomy, with biopsy result were recorded. Of the 500 women who initially had an abnormal smear, 300 (60%) had a smear that was normal or inflammatory at their last visit (after seven years' median follow-up). 184 (37%) had undergone biopsy, 97 (19%) of whom were cervical intraepithelial neoplasia grade III or worse. Survival curves for time to biopsy and ten-year biopsy rates show that women with an abnormal smear before their baseline year were the most likely to have a subsequent biopsy. Older women had a biopsy less often and at biopsy were more likely to have minor abnormalities. Mild or moderate dyskaryotic smears should not be an indication for immediate referral for colposcopy, since under a conservative management policy most women return to normal without needing treatment. Nevertheless, the increased risk associated with abnormal smears justifies rigorous surveillance.	MRC,BIOSTAT UNIT,5 SHAFTESBURY RD,CAMBRIDGE CB2 2BW,ENGLAND; UNIV ABERDEEN,HARRIS BIRTHRIGHT RES CTR,DEPT PATHOL,ABERDEEN AB9 1FX,SCOTLAND	MRC Biostatistics Unit; University of Aberdeen								CAMPION MJ, 1986, LANCET, V2, P237; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; FOX H, 1987, BRIT MED J, V294, P1307, DOI 10.1136/bmj.294.6583.1307; MACGREGOR JE, 1991, BRIT J OBSTET GYNAEC, V98, P6, DOI 10.1111/j.1471-0528.1991.tb10302.x; Matthews D.E., 2016, ACTA HAEMATOL-BASEL, V135, P194; Posner T, 1988, PREVENTION CERVICAL; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; WOODMAN CBJ, 1989, LANCET, V2, P88; 1990, GRAMPIAN HLTH BOARD	9	52	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					828	831		10.1016/0140-6736(92)90278-B	http://dx.doi.org/10.1016/0140-6736(92)90278-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347856				2022-12-24	WOS:A1992HM44100003
J	SURETTE, MG; CHACONAS, G				SURETTE, MG; CHACONAS, G			THE MU-TRANSPOSITIONAL ENHANCER CAN FUNCTION IN TRANS - REQUIREMENT OF THE ENHANCER FOR SYNAPSIS BUT NOT STRAND CLEAVAGE	CELL			English	Article							INTEGRATION HOST FACTOR; SITE-SPECIFIC RECOMBINATION; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; MICROSCOPIC ANALYSIS; PHAGE-MU; DNA; PROTEIN; MECHANISM; TRANSPOSOSOMES	The phage Mu transpositional enhancer has been previously shown to stimulate the initial rate of the Mu DNA strand transfer reaction by a factor of 100. We now show that the Mu enhancer can function in trans on an unlinked DNA molecule. This activity is greatly facilitated by the presence of a free DNA end proximal to the enhancer element. Function of the enhancer in trans does not alter either the requirement for donor DNA supercoiling or for the two Mu ends to be in their proper orientation on the donor plasmid. An important consequence of these findings is that we have been able to evaluate directly the step in the transposition reaction for which the enhancer is required. We show that the role of the enhancer is limited to promoting productive synapsis; efficient strand cleavage can occur in the absence of the enhancer.			SURETTE, MG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BOOCOCK MR, 1985, BIOCHEM SOC T, V14, P214; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; GLASGOW AC, 1989, MOBILE DNA, P637; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAFFTER P, 1988, EMBO J, V7, P3991, DOI 10.1002/j.1460-2075.1988.tb03287.x; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Pato ML, 1989, MOBILE DNA, P23; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; Sherratt D. J., 1987, DNA REPLICATION RECO, P703; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; SURETTE MG, 1990, THESIS U W ONTARIO L	37	65	65	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1101	1108		10.1016/0092-8674(92)90081-M	http://dx.doi.org/10.1016/0092-8674(92)90081-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312394				2022-12-24	WOS:A1992HK67400013
J	CHANG, SW; KATZ, MH; HERNANDEZ, SR				CHANG, SW; KATZ, MH; HERNANDEZ, SR			THE NEW AIDS CASE DEFINITION - IMPLICATIONS FOR SAN-FRANCISCO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIV; INFECTION; COUNTS		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CHANG, SW (corresponding author), SAN FRANCISCO DEPT PUBL HLTH,AIDS OFF,25 VAN NESS AVE,SUITE 500,SAN FRANCISCO,CA 94102, USA.							ARNO PS, 1986, AM J PUBLIC HEALTH, V76, P1325, DOI 10.2105/AJPH.76.11.1325; BALL J, 1991, PHS910015 PUBL, V15, P1; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1990, BIOMETRICS, V46, P1151, DOI 10.2307/2532455; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P92; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MCCARTHY RC, 1989, ARCH PATHOL LAB MED, V113, P658; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PAYNE SF, 1990, AIDS, V4, P335, DOI 10.1097/00002030-199004000-00008; PHILLIPS AN, 1991, LANCET, V337, P389; SHEPPARD HW, 1991, JAMA-J AM MED ASSOC, V266, P2221; STEINBERG C, 1989, JAMA-J AM MED ASSOC, V262, P1526; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VALDISERRI RO, 1991, AM J PUBLIC HEALTH, V81, P491, DOI 10.2105/AJPH.81.4.491; 1991, MMWR, V40, P787; 1991, FED REG         1217, V56, P65498; 1987, MMWR, V36, pS3; [No title captured]; 1990, MMWR, V39, P1; 1988, ANN INTERN MED, V108, P470; 1985, MMWR, V34, P373	25	28	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					973	975		10.1001/jama.267.7.973	http://dx.doi.org/10.1001/jama.267.7.973			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1346406				2022-12-24	WOS:A1992HD15500033
J	LANE, DA; RYAN, K; IRELAND, H; CURTIS, JR; NURMOHAMED, MT; KREDIET, RT; ROGGEKAMP, MC; STEVENS, P; TENCATE, JW				LANE, DA; RYAN, K; IRELAND, H; CURTIS, JR; NURMOHAMED, MT; KREDIET, RT; ROGGEKAMP, MC; STEVENS, P; TENCATE, JW			DERMATAN SULFATE IN HEMODIALYSIS	LANCET			English	Note							HEPARIN	Experimental work suggests that dermatan sulphate has potential as an antithrombotic agent: it can inhibit venous thrombi yet has less effect upon bleeding than heparin. While heparin functions as an anticoagulant primarily by its ability to accelerate the action of the plasma protein inhibitor antithrombin III, dermatan sulphate acts selectively through a structurally related inhibitor, heparin co-factor II, to inhibit thrombin. We have done a series of dose-finding studies of the use of dermatan sulphate as an anticoagulant/antithrombotic agent in patients on maintenance haemodialysis. Dermatan sulphate proved to be an effective anticoagulant in this setting.	UNIV AMSTERDAM, ACAD MED CTR, CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT NEPHROL, 1105 AZ AMSTERDAM, NETHERLANDS; DIATEL AMSTERDAM, CTR DIALYSIS, AMSTERDAM, NETHERLANDS; CHARING CROSS & WESTMINSTER HOSP, DEPT HAEMATOL, LONDON, ENGLAND; CHARING CROSS & WESTMINSTER HOSP, DEPT MED, LONDON, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT MED, LONDON, ENGLAND	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; Imperial College London; Imperial College London	LANE, DA (corresponding author), CHARING CROSS & WESTMINSTER MED SCH, DEPT HAEMATOL, LONDON W6 8RF, ENGLAND.		Ireland, Helen A/B-9868-2008; Krediet, Raymond/GLT-2390-2022; Krediet, Raymond/AAP-3291-2021	Ireland, Helen A/0000-0002-7980-548X; Krediet, Raymond/0000-0002-9851-8507; Nurmohamed, Michael/0000-0002-6274-1934				BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; FERNANDEZ F, 1986, BRIT J HAEMATOL, V64, P309, DOI 10.1111/j.1365-2141.1986.tb04124.x; HIRSH J, 1990, ACTA CHIR SCAND, P42; MCKENNA JV, 1989, THROMB HAEMOSTASIS, V61, P7; OKWUSIDI J, 1990, THROMB HAEMORRH DISO, V1, P77; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713	7	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1992	339	8789					334	335		10.1016/0140-6736(92)91650-W	http://dx.doi.org/10.1016/0140-6736(92)91650-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346414				2022-12-24	WOS:A1992HC77100007
J	GOODWIN, FK				GOODWIN, FK			HICKORY DICKORY DOCK - WHOS INHERITED MOUSIES CLOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					480	480		10.1001/jama.267.4.480	http://dx.doi.org/10.1001/jama.267.4.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309583				2022-12-24	WOS:A1992GZ43900005
J	LEVERETTE, RD; ANDREWS, MT; MAXWELL, ES				LEVERETTE, RD; ANDREWS, MT; MAXWELL, ES			MOUSE U14 SNRNA IS A PROCESSED INTRON OF THE COGNATE HSC70 HEAT-SHOCK PREMESSENGER RNA	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; PROTEIN; GENE; NUCLEAR; CELLS; U3; EXPRESSION; SEQUENCE	U14 snRNA is a small nucleolar RNA species essential for eukaryotic pre-rRNA processing. We have previously shown that the mouse U14 snRNA genes are positioned within introns 5, 6, and 8 on the coding strand of the constitutively expressed cognate hsc70 heat shock gene. This genomic organization suggested the possibility that U14 snRNAs are transcribed as part of the hsc70 pre-mRNA and then excised from the intron to yield mature U14 snRNA species. To test this hypothesis directly, we have microinjected Xenopus oocytes with hsc70 pre-mRNA transcripts possessing intron 5 and the encoded U14 snRNA sequence. Processing results demonstrate that, in addition to the splicing of upstream and downstream exons, a mature 87 nt U14 snRNA is excised from the intron. Accurate excision of U14 snRNA from hsc70 intron 5 can occur in the absence of splicing. These results demonstrate a biosynthetic pathway for an snRNA species and provide a novel example of a eukaryotic pre-mRNA intron that is processed to produce a stable, biologically functional RNA species.	N CAROLINA STATE UNIV,DEPT GENET,RALEIGH,NC 27695	University of North Carolina; North Carolina State University	LEVERETTE, RD (corresponding author), N CAROLINA STATE UNIV,DEPT BIOCHEM,RALEIGH,NC 27695, USA.				NICHD NIH HHS [HD-24673] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD024673] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIU J, 1990, NUCLEIC ACIDS RES, V18, P6565, DOI 10.1093/nar/18.22.6565; MAXWELL ES, 1986, P NATL ACAD SCI USA, V83, P7261, DOI 10.1073/pnas.83.19.7261; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Sambrook J., 1989, MOL CLONING LAB MANU; SHANAB GM, 1991, NUCLEIC ACIDS RES, V19, P4891, DOI 10.1093/nar/19.18.4891; SHANAB GM, 1992, EUR J BIOCHEM, V206, P391, DOI 10.1111/j.1432-1033.1992.tb16939.x; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; TRINHROHLIK Q, 1988, NUCLEIC ACIDS RES, V16, P521; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	25	94	96	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1215	1221		10.1016/S0092-8674(05)80069-8	http://dx.doi.org/10.1016/S0092-8674(05)80069-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1282084				2022-12-24	WOS:A1992KE60400015
J	REINUS, JF; LEIKIN, EL; ALTER, HJ; CHEUNG, L; SHINDO, M; JETT, B; PIAZZA, S; SHIH, JWK				REINUS, JF; LEIKIN, EL; ALTER, HJ; CHEUNG, L; SHINDO, M; JETT, B; PIAZZA, S; SHIH, JWK			FAILURE TO DETECT VERTICAL TRANSMISSION OF HEPATITIS-C VIRUS	ANNALS OF INTERNAL MEDICINE			English	Article						MATERNAL-FETAL EXCHANGE; HEPATITIS-C; HEPATITIS ANTIBODIES; PREGNANCY COMPLICATIONS, INFECTIOUS	NON-B-HEPATITIS; MATERNAL-INFANT TRANSMISSION; CHRONIC NON-A; INFECTION; ANTIBODY; MOTHER; HIV	Objective: To search for transmission of hepatitis C virus (HCV) from infected mothers to their infants. Design: Prospective clinical, serologic, and molecular biologic follow-up (at least 3 months) of the infants of mothers with anti-HCV antibody. Setting: A county hospital providing primary and referral care in high-risk obstetrics (perinatology). Patients: Twenty-three mothers with anti-HCV antibody and their 24 infants. Methods: An enzyme-linked immunosorbent assay (EIA) and a four-antigen recombinant immunoblot assay (RIBA) were used to test for anti-HCV antibody; serum HCV RNA was measured in two independent laboratories by reverse transcription and polymerase chain reaction (PCR) using nested primers in the 5'-noncoding region. Infant samples were tested for HCV RNA by PCR at delivery and after 3 to 6 months of follow-up. Each sample was tested at least four times in two independent laboratories. Results: Twenty-nine of 648 mothers (4.5%; 95% CI, 3.0% to 6.4%) had anti-HCV antibody; these women had 30 babies. Twenty-three mothers and their 24 babies were followed at least 3 months (mean follow-up, 52 weeks). Of the 23 mothers, 21 (91%; CI, 72% to 99%) had a reactive RIBA; one woman had an indeterminate RIBA and was positive for HCV RNA by PCR. In 16 of 23 mothers (70%; CI, 47% to 87%), PCR yielded a positive result in both laboratories. The mean maternal alanine aminotransferase (ALT) level was 1.6 times the normal value. All the babies had anti-HCV antibody in cord-blood samples, but antibody disappeared or diminished in strength in interval samples, and no infant had evidence of active production of anti-HCV antibody. Only 1 of 24 (4%; CI, 0.1% to 21%) cord-blood samples was HCV RNA positive, and none of 24 (0%; CI, 0% to 14%) follow-up samples was positive for HCV RNA by PCR in either laboratory. Four mothers and one baby had antibody to HIV. Conclusions: Infant anti-HCV antibody is most likely acquired passively in utero, and vertical transmission of HCV is uncommon.			REINUS, JF (corresponding author), MONTEFIORE MED CTR, DIV GASTROENTEROL, 111 E 210TH ST, BRONX, NY 10467 USA.		Jett, Betsy/AAT-5154-2021					ALFORD CA, 1975, AM J DIS CHILD, V129, P455, DOI 10.1001/archpedi.1975.02120410043014; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P410; BUSCH MP, 1992, NEW ENGL J MED, V326, P64, DOI 10.1056/NEJM199201023260114; CHEN DS, 1991, J INFECT DIS, V164, P428, DOI 10.1093/infdis/164.2.428; ESTEBAN R, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P413; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FORTUNY C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P418; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; JOUNG MK, 1991, 3RD P INT S HCV STRA, P96; KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; LEE SD, 1991, HEPATOLOGY, V13, P830, DOI 10.1016/0270-9139(91)90249-U; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; NOVATI R, 1992, J INFECT DIS, V165, P720, DOI 10.1093/infdis/165.4.720; ROUDOTTHORAVAL E, 1991, 3RD P INT S HCV STRA, P85; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SMOLEN P, 1983, J PEDIATR-US, V103, P917, DOI 10.1016/S0022-3476(83)80714-8; STEVENS CE, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P407; STEVENS CE, 1984, VIRAL HEPATITIS LIVE, P275; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TONG MJ, 1981, GASTROENTEROLOGY, V80, P999; WEJSTAL R, 1990, J MED VIROL, V30, P178, DOI 10.1002/jmv.1890300306	26	139	138	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					881	886		10.7326/0003-4819-117-11-881	http://dx.doi.org/10.7326/0003-4819-117-11-881			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1332561				2022-12-24	WOS:A1992JZ27600001
J	HOWE, LR; LEEVERS, SJ; GOMEZ, N; NAKIELNY, S; COHEN, P; MARSHALL, CJ				HOWE, LR; LEEVERS, SJ; GOMEZ, N; NAKIELNY, S; COHEN, P; MARSHALL, CJ			ACTIVATION OF THE MAP KINASE PATHWAY BY THE PROTEIN-KINASE RAF	CELL			English	Article							C-MYC; ONCOGENE PRODUCT; GROWTH; PHOSPHORYLATION; REQUIREMENT; EXPRESSION; MUTANT; SUBSTRATE; CASCADE; INSULIN	Both MAP kinases and the protein kinase p74raf-1 are activated by many growth factors in a c-ras-dependent manner and by oncogenic p21ras. We were therefore interested in determining the relationship between MAP kinases and raf. The MAP kinase ERK2 is activated by expression of oncogenically activated raf, independently of cellular ras. Overexpressed p74raf-1 potentiates activation of ERK2 by EGF and TPA. MAP kinase kinase inactivated by phosphatase 2A treatment is phosphorylated and reactivated by incubation with p74raf-1 immunoprecipitated from phorbol ester-treated cells. We conclude that raf protein kinase is upstream of MAP kinases and is either a MAP kinase kinase kinase or a MAP kinase kinase kinase kinase.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	HOWE, LR (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON,ENGLAND.		Gomez, Nestor/I-2522-2015	Gomez, Nestor/0000-0002-1348-2737; Howe, Louise/0000-0002-1468-7136				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANCOCK JF, 1988, ONCOGENE, V3, P187; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, IN PRESS ONCOGENE; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	44	803	812	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					335	342		10.1016/0092-8674(92)90361-F	http://dx.doi.org/10.1016/0092-8674(92)90361-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1330321				2022-12-24	WOS:A1992JU39500018
J	RUDENSKY, AY; PRESTONHURLBURT, P; ALRAMADI, BK; ROTHBARD, J; JANEWAY, CA				RUDENSKY, AY; PRESTONHURLBURT, P; ALRAMADI, BK; ROTHBARD, J; JANEWAY, CA			TRUNCATION VARIANTS OF PEPTIDES ISOLATED FROM MHC CLASS-II MOLECULES SUGGEST SEQUENCE MOTIFS	NATURE			English	Article							B-CELL INTERACTION; IA MOLECULE; IDENTIFICATION; ANTIGEN; SELF; IMMUNOGLOBULIN; PROTEIN; RECOGNITION; EPITOPE; CLONES	T CELLS recognize foreign protein antigens in the form of peptide fragments bound tightly to the outer aspect of molecules encoded by the major histocompatibility complex (MHC). Most of the amino-acid differences that distinguish MHC allelic variants line the peptide-binding cleft, and different allelic forms of MHC molecules bind distinct peptides1,2. It has been demonstrated that peptide-binding to MHC class I involves anchor residues in certain positions and that antigenic peptides associated with MHC class I exhibit allele-specific structural motifs3. We have previously reported an analysis of MHC class II-associated peptide sequences4. Here we extend this analysis and show that certain amino-acid residues occur at particular positions in the sequence of peptides binding to a given MHC class II molecule. These sequence motifs require the amino terminus to be shifted one or two positions to obtain alignment; such shifts occur naturally for a single peptide sequence without qualitatively altering CD4 T-cell recognition.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University	RUDENSKY, AY (corresponding author), IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304, USA.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CHEN JS, 1991, J IMMUNOL, V147, P3672; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINNEGAN A, 1986, J EXP MED, V164, P897, DOI 10.1084/jem.164.3.897; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HEBERKATZ E, 1983, J MOL CELL IMMUNOL, V1, P3; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KABAT EA, 1991, NIH913242 US DEP HLT; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; MARGULIES D H, 1992, Current Biology, V2, P211, DOI 10.1016/0960-9822(92)90542-I; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MURRAY JS, 1992, EUR J IMMUNOL, V22, P559, DOI 10.1002/eji.1830220239; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; R/tzschke O., 1990, NATURE, V348, P253; RATH S, IN PRESS EUR J IMMUN; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; RUDENSKY AY, 1989, EUR J IMMUNOL, V19, P1677, DOI 10.1002/eji.1830190923; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SHASTRI N, 1986, J EXP MED, V164, P882, DOI 10.1084/jem.164.3.882; SHUMACHER TNM, 1991, NATURE, V350, P703; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VANBLEEK GM, 1990, NATURE, V348, P213; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; YURIN VL, 1989, EUR J IMMUNOL, V19, P1685, DOI 10.1002/eji.1830190924	29	247	255	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					429	431		10.1038/359429a0	http://dx.doi.org/10.1038/359429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1328884				2022-12-24	WOS:A1992JQ62400061
J	BROUN, ER; NICHOLS, CR; KNEEBONE, P; WILLIAMS, SD; LOEHRER, PJ; EINHORN, LH; TRICOT, GJK				BROUN, ER; NICHOLS, CR; KNEEBONE, P; WILLIAMS, SD; LOEHRER, PJ; EINHORN, LH; TRICOT, GJK			LONG-TERM OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY GERM-CELL TUMORS TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW RESCUE	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; GERM CELL NEOPLASMS; CARBOPLATIN; ETOPOSIDE	PHASE-I; TRANSPLANTATION; CARBOPLATIN; VP-16-213; CANCER	Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Design: Cohort study. Setting: A university hospital. Patients: Forty consecutive patients with recurrent or refractory germ cell tumors treated at Indiana University between September 1986 and June 1989. Interventions: Patients were treated with high-dose carboplatin (900 to 2000 mg/m2 body surface area) and etoposide (1200 mg/m2). Three patients also received ifosfamide (10g/m2). All patients had autologous bone marrow rescue. Of the 40 study patients, 26 received two full courses of therapy. Measurements: Patient charts were reviewed to determine the rate and duration of complete and partial remission and the number of long-term, disease-free survivors. The influence of cisplatin-refractory disease and the site of the primary tumor on the incidence of remission and survival were also investigated. Results: Of the 40 study patients, 26 (65%) responded to treatment; 12 (30%) achieved a complete response, and 14 (35%) achieved a partial response. Of the 12 complete responders, 5 relapsed, and 1 died of treatment-related acute leukemia 27.5 months after treatment without evidence of germ cell cancer. Six (15%) of the original 40 patients, of whom 3 were refractory to cisplatin, remained in complete remission after at least 24 months of follow-up. Eight of 40 patients had primary mediastinal germ cell tumors with no complete remissions and a median survival of 2 months (range, 0.5 to 9.0 months). Conclusions: Treatment with high-dose carboplatin and etoposide in conjunction with autologous bone marrow rescue in patients with relapsed or refractory germ cell tumors is a potentially curative therapeutic option, even for heavily pretreated or cisplatin-refractory patients. Some degree of disease resistance to cisplatin can be overcome with dose escalation of platinum compounds. Patients with multiple recurrences of relapsed or refractory primary mediastinal germ cell tumors were not helped by this approach.			BROUN, ER (corresponding author), INDIANA UNIV HOSP, 926 W MICHIGAN, ROOM 1730, INDIANAPOLIS, IN 46202 USA.		Nichols, Craig/ABE-1107-2020		NATIONAL CANCER INSTITUTE [R23CA038844] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 38844-07] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTAL M, 1991, J CLIN ONCOL, V9, P865, DOI 10.1200/JCO.1991.9.5.865; BAUME D, 1990, B CANCER, V77, P169; BROUN ER, 1991, CANCER, V68, P1513, DOI 10.1002/1097-0142(19911001)68:7<1513::AID-CNCR2820680708>3.0.CO;2-8; BROUN ER, 1991, BONE MARROW TRANSPL, V7, P53; DEPAUW BE, 1990, BONE MARROW TRANSPL, V5, P179; EINHORN LH, 1981, CANCER RES, V41, P3275; ENGLISH D, 1989, TRANSFUSION, V29, P12, DOI 10.1046/j.1537-2995.1989.29189101156.x; HAINSWORTH JD, 1983, AM J MED, V75, P817, DOI 10.1016/0002-9343(83)90413-8; HARTSTRICK A, 1991, J CLIN ONCOL, V9, P1549; HEIMDAHL A, 1989, ORAL SURG ORAL MED O, V68, P711, DOI 10.1016/0030-4220(89)90160-6; HORWITZ LJ, 1989, AUTOLOGOUS BONE MARR, P67; LINKESCH W, 1990, P AN M AM SOC CLIN, V9, P141; MOTZER RJ, 1990, CANCER, V66, P2476, DOI 10.1002/1097-0142(19901215)66:12<2476::AID-CNCR2820661206>3.0.CO;2-D; MULDER POM, 1988, EUR J CANCER CLIN ON, V24, P675, DOI 10.1016/0277-5379(88)90298-2; MUNSHI NC, 1990, P AN M AM SOC CLIN, V9, P134; NICHOLS CR, 1992, J CLIN ONCOL, V10, P558, DOI 10.1200/JCO.1992.10.4.558; NICHOLS CR, 1989, J CLIN ONCOL, V7, P932, DOI 10.1200/JCO.1989.7.7.932; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PIZZOCARO G, 1990, P ASCO, V9, P131; SHEA TC, 1989, J CLIN ONCOL, V7, P651, DOI 10.1200/JCO.1989.7.5.651; SPINOLO JA, 1990, CANCER, V66, P619, DOI 10.1002/1097-0142(19900815)66:4<619::AID-CNCR2820660403>3.0.CO;2-Z; VALTEAU D, 1990, Bone Marrow Transplantation, V5, P133; VILLABLANCA JG, 1990, BONE MARROW TRANSPL, V5, P387; WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503; WOLFF SN, 1983, J CLIN ONCOL, V1, P701, DOI 10.1200/JCO.1983.1.11.701	25	146	147	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					124	128		10.7326/0003-4819-117-2-124	http://dx.doi.org/10.7326/0003-4819-117-2-124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1318648				2022-12-24	WOS:A1992JD12300005
J	DAVIS, RL; WEINTRAUB, H				DAVIS, RL; WEINTRAUB, H			ACQUISITION OF MYOGENIC SPECIFICITY BY REPLACEMENT OF 3 AMINO-ACID-RESIDUES FROM MYOD INTO E12	SCIENCE			English	Article							DISTINCT TRANSCRIPTION FACTORS; ENHANCER MU-E5/KE2 MOTIF; DNA-BINDING DOMAIN; DROSOPHILA-MELANOGASTER; MYC HOMOLOGY; MUSCLE; FIBROBLASTS; EXPRESSION; MYOBLASTS; PROTEIN	The basic helix-loop-helix (bHLH) protein MyoD is a transcription factor that is important for the induction of the myogenic phenotype. The DNA binding basic region (13 amino acids) is necessary for recognition of the consensus MyoD binding site, for transcriptional activation, and for conversion of fibroblasts to muscle. In contrast, the non-tissue-specific bHLH protein E12 can bind to the MyoD binding site but does not induce myogenesis. Here, it is shown that only two amino acids in the MyoD basic region and a single amino acid from the junction, which separates the basic region and helix 1, are sufficient for myogenic specificity when substituted into the corresponding region of E12. These findings suggest that the recognition of particular determinants in the basic region is required for conversion of fibroblasts to muscle.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST LAB,SEATTLE,WA 98104	Fred Hutchinson Cancer Center								BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GARCIABELLIDO A, 1979, GENETICS, V91, P491; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JP, IN PRESS P NATL ACAD; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MULLER HJ, 1955, BROOKHAVEN SYM BIOL, V8, P126; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242	31	135	135	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1027	1030		10.1126/science.1317057	http://dx.doi.org/10.1126/science.1317057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1317057				2022-12-24	WOS:A1992HU22400041
J	PEREZ, A; LABBOK, MH; QUEENAN, JT				PEREZ, A; LABBOK, MH; QUEENAN, JT			CLINICAL-STUDY OF THE LACTATIONAL AMENORRHEA METHOD FOR FAMILY-PLANNING	LANCET			English	Article							CHILEAN WOMEN; OVULATION; MENSTRUATION; FERTILITY; PATTERNS	The effect of breastfeeding on fertility is well known; however, its use as a method of family planning was, until recently, untested. In 1988, the Bellagio Consensus Conference proposed guidelines that became the basis for a method of family planning called the lactational amenorrhoea method (LAM). The principle of LAM is that a woman who continues to fully or nearly fully breastfeed her infant and who remains amenorrhoeic during the first 6 months postpartum is protected from pregnancy during that time. We have assessed this method in the context of a breastfeeding support intervention study of 422 middle-class women in urban Santiago, Chile. The cumulative 6-month life-table pregnancy rate was 0.45% among women who relied on LAM as their only family planning method (1 woman pregnant in month 6). The findings indicate that LAM, with its high acceptance and efficacy, is a viable method of family planning and can safely serve as an introductory method for breastfeeding women.	GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,3800 RESERVOIR RD,NW PHC3,WASHINGTON,DC 20007; CATHOLIC UNIV CHILE,SCH MED,DEPT OBSTET & GYNECOL,SANTIAGO,CHILE; GEORGETOWN UNIV,SCH MED,INST REPROD HLTH,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,INST REPROD HLTH,WASHINGTON,DC 20007	Georgetown University; Pontificia Universidad Catolica de Chile; Georgetown University; Georgetown University; Georgetown University				Labbok, Miriam/0000-0001-9515-3963				BERMAN ML, 1972, AM J OBSTET GYNECOL, V114, P524, DOI 10.1016/0002-9378(72)90215-3; DIAZ S, 1988, CONTRACEPTION, V38, P37; DIAZ S, 1988, CONTRACEPTION, V38, P53, DOI 10.1016/0010-7824(88)90095-9; Ginneken J. K. van, 1977, Journal of Biosocial Science, P41, DOI 10.1017/S0021932000023828; GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; HOWIE PW, 1982, J REPROD FERTIL, V65, P545, DOI 10.1530/jrf.0.0650545; JAIN AK, 1981, STUD FAMILY PLANN, V12, P79, DOI 10.2307/1966370; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; LABBOK M, 1990, GUIDELINES BREASTFEE; LABBOK MH, 1983, NEW ENGL J MED, V308, P51; PEREZ A, 1971, POP STUD-J DEMOG, V25, P491, DOI 10.1080/00324728.1971.10405820; PEREZ A, 1991, AM J OBSTET GYNECOL, V165, P2039, DOI 10.1016/S0002-9378(11)90576-6; RIVERA R, 1985, J BIOSOC SCI S, V9, P112; SAADEH R, 1990, B WORLD HEALTH ORGAN, V68, P625; SHORT RV, 1991, LANCET, V37, P715; VALDES V, IN PRESS J TROP PAED	17	92	97	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					968	970		10.1016/0140-6736(92)91538-J	http://dx.doi.org/10.1016/0140-6736(92)91538-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP036	1348806	hybrid			2022-12-24	WOS:A1992HP03600011
J	SANDSON, TA; WEN, PY; LEMAY, M				SANDSON, TA; WEN, PY; LEMAY, M			REVERSED CEREBRAL ASYMMETRY IN WOMEN WITH BREAST-CANCER	LANCET			English	Note							HYPOTHESIS; HANDEDNESS	Altered intrauterine hormonal environment might predispose to both atypical cerebral asymmetry and breast cancer. We therefore investigated computed tomographic scans of 79 right-handed, white patients with breast cancer and 97 controls to assess the pattern of cerebral asymmetry. Women with breast cancer had a reversed pattern of cerebral asymmetry significantly more often than did controls (p < 0.0001) for both frontal and occipital width. Our findings suggest that an intrauterine or early life factor, probably hormonal, could predispose to breast cancer in adulthood.	BETH ISRAEL HOSP,DIV NEUROL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	SANDSON, TA (corresponding author), BETH ISRAEL HOSP,DEPT NEUROL,BEHAV NEUROL UNIT,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Wen, Patrick/AAE-3776-2022					BEAR D, 1986, ARCH NEUROL-CHICAGO, V43, P598, DOI 10.1001/archneur.1986.00520060060019; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; KELSEY JL, 1990, EPIDEMIOL REV, V12, P228, DOI 10.1093/oxfordjournals.epirev.a036056; KRAMER MA, 1985, NURS RES, V34, P333; LEMAY M, 1978, J COMPUT ASSIST TOMO, V2, P471; LeMay M., 1984, CEREBRAL DOMINANCE B, P26; LEMAY M, IN PRESS AM J NEUROR; MCCLUSKY NJ, 1981, SCIENCE, V211, P1294; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; WEINBERGER DR, 1982, ANN NEUROL, V11, P97, DOI 10.1002/ana.410110118	10	47	48	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					523	524		10.1016/0140-6736(92)90341-Y	http://dx.doi.org/10.1016/0140-6736(92)90341-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346881				2022-12-24	WOS:A1992HF63100006
J	GOODWIN, FK				GOODWIN, FK			BEHAVIORAL STRESS REACTIVITY RELATED TO ARTHRITIS SUSCEPTIBILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					910	910						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1310338				2022-12-24	WOS:A1992HD15500004
J	SCHLAGHECKE, R; KORNELY, E; SANTEN, RT; RIDDERSKAMP, P				SCHLAGHECKE, R; KORNELY, E; SANTEN, RT; RIDDERSKAMP, P			THE EFFECT OF LONG-TERM GLUCOCORTICOID THERAPY ON PITUITARY-ADRENAL RESPONSES TO EXOGENOUS CORTICOTROPIN-RELEASING HORMONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA ADRENOCORTICOTROPIN; CORTISOL RESPONSE; DOSE-RESPONSE; DEXAMETHASONE; SECRETION; RECOVERY; AXIS; ACTH; RAT	Background. Suppression of pituitary-adrenal function is a well-known consequence of glucocorticoid therapy, manifested principally by decreased corticotropin secretion. To determine the degree of suppression of pituitary-adrenal function in patients treated with different doses of synthetic glucocorticoid medication for different periods, we measured the pituitary-adrenal response to the administration of exogenous human corticotropin-releasing hormone (CRH). Methods. We studied 279 patients who were receiving daily therapy with 5 to 30 mg of prednisone or its equivalent to treat various chronic diseases, principally collagen vascular disorders, and 50 normal subjects. Therapy ranged in duration from 1 week to 15 years. Stimulation tests using 100-mu-g of CRH as a bolus injection were performed in the morning, 24 hours after the most recent dose of glucocorticoids. In 61 patients an insulin hypoglycemia test, thought by many to be the reference standard, was also performed to assess the reliability of the CRH results. Results. After the administration of CRH, 43 patients had no increase in plasma concentrations of corticotropin and cortisol. The response was blunted in 133 patients and normal in 103. There was poor correlation between the plasma cortisol response after the administration of CRH and the dose or duration of therapy or the basal plasma cortisol concentration. Although plasma cortisol concentrations after stimulation with CRH were generally lower than those after insulin administration, there was a significant correlation between the plasma cortisol responses to the two stimuli (r = 0.82). Conclusions. Pituitary-adrenal function in patients treated with synthetic glucocorticoids cannot be reliably estimated from the dose of glucocorticoid, the duration of therapy, or the basal plasma cortisol concentration. In such patients, testing with CRH is nearly as useful as insulin hypoglycemia testing in the assessment of pituitary-adrenal function.			SCHLAGHECKE, R (corresponding author), UNIV DUSSELDORF,DEPT ENDOCRINOL & RHEUMATOL,MOORENSTR 5,W-4000 DUSSELDORF 1,GERMANY.							BECKER KL, 1990, PRINCIPLES PRACTICE, P1740; BOLT HM, 1980, THERAPIEWOCHE, V30, P6257; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; CARNES M, 1987, NEUROENDOCRINOLOGY, V45, P160, DOI 10.1159/000124718; CHRISTY NP, 1971, HUMAN ADRENAL CORTEX, P395; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; EBERWINE JH, 1984, J BIOL CHEM, V259, P2166; HAGG E, 1987, CLIN ENDOCRINOL, V26, P221, DOI 10.1111/j.1365-2265.1987.tb00780.x; HARRISON BDW, 1982, CLIN ENDOCRINOL, V17, P109, DOI 10.1111/j.1365-2265.1982.tb01570.x; HASHIMOTO K, 1988, J CLIN INVEST, V82, P13, DOI 10.1172/JCI113561; JINGAMI H, 1985, ENDOCRINOLOGY, V117, P1314, DOI 10.1210/endo-117-4-1314; KELLERWOOD ME, 1984, ENDOCR REV, V51, P1; LIVANOU T, 1967, LANCET, V2, P856; MCEVEN BS, 1986, PHYSIOL REV, V66, P1121; MELBY JC, 1974, ANN INTERN MED, V81, P505, DOI 10.7326/0003-4819-81-4-505; MULLER OA, 1986, PSYCHONEUROENDOCRINO, V11, P49, DOI 10.1016/0306-4530(86)90031-4; NINK M, 1991, KLIN WOCHENSCHR, V69, P185, DOI 10.1007/BF01646939; ORTH DN, 1983, J CLIN INVEST, V71, P587, DOI 10.1172/JCI110804; SCHURMEYER TH, 1985, J CLIN ENDOCR METAB, V61, P22, DOI 10.1210/jcem-61-1-22; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; STEWART PM, 1988, LANCET, V1, P1208; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TAYLOR AL, 1988, NEW ENGL J MED, V319, P213, DOI 10.1056/NEJM198807283190405; VALE W, 1983, ENDOCRINOLOGY, V113, P1121, DOI 10.1210/endo-113-3-1121; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VOIGT KH, 1981, THERAPIEWOCHE, V31, P6230; WAND GS, 1985, CLIN ENDOCRINOL META, V14, P33, DOI 10.1016/S0300-595X(85)80064-5; WATSON AC, 1988, CLIN ENDOCRINOL, V28, P471, DOI 10.1111/j.1365-2265.1988.tb03681.x	29	293	298	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					226	230		10.1056/NEJM199201233260403	http://dx.doi.org/10.1056/NEJM199201233260403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1309389				2022-12-24	WOS:A1992HA43100003
J	DEVOTO, SH; MUDRYJ, M; PINES, J; HUNTER, T; NEVINS, JR				DEVOTO, SH; MUDRYJ, M; PINES, J; HUNTER, T; NEVINS, JR			A CYCLIN-A-PROTEIN KINASE COMPLEX POSSESSES SEQUENCE-SPECIFIC DNA-BINDING ACTIVITY - P33CDK2 IS A COMPONENT OF THE E2F-CYCLIN-A COMPLEX	CELL			English	Article							ADENOVIRUS E1A PROTEINS; MATURATION-PROMOTING FACTOR; E2F TRANSCRIPTION FACTOR; CELL-DIVISION CYCLE; LARGE-T-ANTIGEN; SV40 LARGE-T; FISSION YEAST; M-PHASE; CONTROL GENE; SACCHAROMYCES-CEREVISIAE	The E2F transcription factor has been found in association with the cyclin A protein, and this complex accumulates during the S phase of the cell cycle, suggesting that E2F may play a role in cell cycle control. In independent studies, cyclin A has been shown to be associated with two other proteins, the Rb-related p107 protein and the cdc2-related p33 cdk2 protein kinase. Through an analysis of the E2F-cyclin A complex, we now find that both the p107 protein and the cdc2-related p33cdk2 kinase are components of the previously described complex. Moreover, the complex possesses H1 kinase activity. These results thus define a cyclin A-cdk2 kinase complex that possesses sequence-specific DNA binding activity. This suggests that the cdk2 kinase may phosphorylate other DNA-bound substrates, and that one role of the E2F factor may be to localize this protein kinase to the DNA.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute	DEVOTO, SH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,DURHAM,NC 27710, USA.			Devoto, Stephen/0000-0001-9513-3962; Pines, Jonathon/0000-0002-5227-6004				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN M, 1991, IN PRESS SCIENCE; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1991, IN PRESS SCIENCE; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEYERSON M, 1991, IN PRESS COLD SPRING, V58; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINES J, 1991, IN PRESS COLD SPRING, V58; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	81	367	383	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					167	176		10.1016/0092-8674(92)90215-X	http://dx.doi.org/10.1016/0092-8674(92)90215-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1310073				2022-12-24	WOS:A1992GZ58300018
J	MCBRIDE, D; GILL, F; PROOPS, D; HARRINGTON, M; GARDINER, K; ATTWELL, C				MCBRIDE, D; GILL, F; PROOPS, D; HARRINGTON, M; GARDINER, K; ATTWELL, C			NOISE AND THE CLASSICAL MUSICIAN	BRITISH MEDICAL JOURNAL			English	Article							HEARING	Objectives-To test the hypothesis that noise exposure may cause hearing loss in classical musicians. Design-Comparison of hearing levels between two risk groups identified during the study by measuring sound levels. Setting-Symphony orchestra and occupational health department in the west Midlands, Main outcome measures-Hearing level as measured by clinical pure tone audiometry. Results-Trumpet and piccolo players received a noise dose of 160% and 124%, respectively, over mean levels during part of the study. Comparison of the hearing levels of 18 woodwind and brass musicians with 18 string musicians matched for age and sex did not show a significant difference in hearing, the mean difference in the hearing levels at the high (2, 4, and 8 KHz) audiometric frequencies being 1.02 dB (95% confidence interval -2.39 to 4.43). Conclusions-This study showed that there is a potential for occupational hearing loss in classical orchestral musicians.	QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham	MCBRIDE, D (corresponding author), UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		McBride, David I/F-9664-2010	McBride, David I/0000-0001-5531-7687				Axelsson A, 1981, Acta Otolaryngol Suppl, V377, P3; Burns W, 1973, J Soc Occup Med, V23, P86; RABINOWITZ J, 1982, MED HYG, V40, P1; ROYSTER JD, 1991, J ACOUST SOC AM, V89, P2793, DOI 10.1121/1.400719; SANTUCCI M, 1990, MED PROBL PERFORM AR, V5, P136; SATALOFF RT, 1991, AM J OTOL, V12, P122; 1989, NOISE WORK REGULATIO	7	44	49	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1561	1563		10.1136/bmj.305.6868.1561	http://dx.doi.org/10.1136/bmj.305.6868.1561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KD771	1286387	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992KD77100024
J	TAYLOR, S				TAYLOR, S			CONFESSIONS OF A BENEDICTINE DRINKER	BRITISH MEDICAL JOURNAL			English	Article											TAYLOR, S (corresponding author), ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND.							DEQUINCEY T, CONFESSIONS ENGLISH	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1585	1586		10.1136/bmj.305.6868.1585	http://dx.doi.org/10.1136/bmj.305.6868.1585			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286404	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992KD77100043
J	DOUGAN, S; DINARDO, S				DOUGAN, S; DINARDO, S			DROSOPHILA WINGLESS GENERATES CELL TYPE DIVERSITY AMONG ENGRAILED EXPRESSING CELLS	NATURE			English	Article							SEGMENT-POLARITY GENE; LARVAL EPIDERMIS; FUSHI-TARAZU; ZYGOTIC LOCI; MELANOGASTER; EMBRYOS; PATTERN; CUTICLE; CHROMOSOME; PROTEIN	DURING embryogenesis, body pattern is established in a stepwise process1. After specification of the body axis, the embryo is subdivided into smaller units. Within these units, a diverse array of cell types is then generated. The subdivisions of the Drosophila embryo, called parasegments2, are defined by the interface between cells expressing the homeoprotein Engrailed and cells expressing the secreted protein Wingless3-5. We have examined the generation of cell-type diversity within parasegments by focusing on the choice of cell fate made by the engrailed (en)-expressing cells. These cells differentiate as one of two alternative cell types6. We report here that this choice is mediated by wingless (wg), in a function distinct from its early role maintaining en expression7,8. Thus, en cells exhibit different responses to the wg signal at different developmental stages. Early wg input stabilizes the subdivision of the body axis by maintaining en expression, whereas later input generates cell-type diversity.			DOUGAN, S (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Dougan, Scott/B-8416-2008	Dougan, Scott/0000-0003-0214-4772; DiNardo, Stephen/0000-0003-4131-5511				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HILLMAN R, 1970, J MORPHOL, V131, P383, DOI 10.1002/jmor.1051310403; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KASSIS JA, 1991, GENETICS, V128, P751; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	22	111	111	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					347	350		10.1038/360347a0	http://dx.doi.org/10.1038/360347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280330				2022-12-24	WOS:A1992JZ63000052
J	LARKMAN, A; HANNAY, T; STRATFORD, K; JACK, J				LARKMAN, A; HANNAY, T; STRATFORD, K; JACK, J			PRESYNAPTIC RELEASE PROBABILITY INFLUENCES THE LOCUS OF LONG-TERM POTENTIATION	NATURE			English	Article							QUANTAL ANALYSIS; HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; LTP; NEURONS	THE quantal hypothesis proposes that chemical synaptic transmission involves the probabilistic release of multimolecular packets of transmitter1. Analysis of the resulting trial-to-trial fluctuations in postsynaptic response can provide estimates both of the number of quanta released and of the size of their postsynaptic effect. This in turn permits the quantification of the relative contributions of pre- and postsynaptic factors to the strength of a given synapse. Quantal analysis of excitatory synapses in the hippocampus has proved difficult2-6 and has led to contradictory conclusions when applied to long-term potentiation7-14. Here we report the use of a combination of quantal analysis procedures to provide evidence that both pre- and postsynaptic changes can contribute substantially to the maintenance of long-term potentiation in the CA1 region of the hippocampus. The initial setting of the presynaptic release mechanism seems to determine their relative importance.			LARKMAN, A (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.			Hannay, Timo/0000-0002-5941-3390	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LARKMAN A, 1991, NATURE, V353, P396, DOI 10.1038/353396b0; MAGLEBY KL, 1981, J PHYSIOL-LONDON, V311, P267, DOI 10.1113/jphysiol.1981.sp013584; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; VORONIN LL, 1983, NEUROSCIENCE, V10, P1051, DOI 10.1016/0306-4522(83)90099-4	20	193	193	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					70	73		10.1038/360070a0	http://dx.doi.org/10.1038/360070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1331808				2022-12-24	WOS:A1992JW71700057
J	PLATE, KH; BREIER, G; WEICH, HA; RISAU, W				PLATE, KH; BREIER, G; WEICH, HA; RISAU, W			VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A POTENTIAL TUMOR ANGIOGENESIS FACTOR IN HUMAN GLIOMAS INVIVO	NATURE			English	Article							METASTASIS; FEATURES; MITOGEN; FAMILY	CLINICAL and experimental studies suggest that angiogenesis is a prerequisite for solid tumour growth1,2. Several growth factors with mitogenic or chemotactic activity for endothelial cells in vitro have been described, but it is not known whether these mediate tumour vascularization in vivo3,4. Glioblastoma, the most common and most malignant brain tumour in humans, is distinguished from astrocytoma by the presence of necroses and vascular proliferations5,6. Here we show that expression of an endothelial cell-specific mitogen, vascular endothelial growth factor (VEGF), is induced in astrocytoma cells but is dramatically upregulated in two apparently different subsets of glioblastoma cells. The high-affinity tyrosine kinase receptor for VEGF, flt, although not expressed in normal brain endothelium, is upregulated in tumour endothelial cells in vivo. These observations strongly support the concept that tumour angiogenesis is regulated by paracrine mechanisms and identify VEGF as a potential tumour angiogenesis factor in vivo.	MAX PLANCK INST PSYCHIAT,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; UNIV FREIBURG,INST MOLEK ZELLBIOL,W-7800 FREIBURG,GERMANY; MAX PLANCK INST PHYSIOL & CLIN RES,W-6350 BAD NAUHEIM,GERMANY	Max Planck Society; University of Freiburg; Max Planck Society			Breier, Georg/E-3580-2016	Breier, Georg/0000-0002-9467-780X				BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; BREIER G, 1992, DEVELOPMENT, V114, P521; BREM SS, 1990, AM J PATHOL, V137, P1121; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1991, BIOL THERAPY CANCER, P743; GERMANO IM, 1989, J NEUROSURG, V70, P701, DOI 10.3171/jns.1989.70.5.0701; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JAIN RK, 1988, CANCER RES, V48, P2641; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLAGSBRUN M, 1990, HDB EXPT PHARM, V95, P549; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; PLATE KH, 1992, LAB INVEST, V67, P529; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; RISAU W, IN PRESS GROWTH FACT; Russell D., 1989, PATHOLOGY TUMORS NER; Scherer HJ, 1935, VIRCHOWS ARCH A, V294, P823, DOI 10.1007/BF01889141; SHIBUYA M, 1990, ONCOGENE, V5, P519; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4	31	2103	2215	3	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					845	848		10.1038/359845a0	http://dx.doi.org/10.1038/359845a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279432				2022-12-24	WOS:A1992JV77700069
J	NAGPAL, S; SAUNDERS, M; KASTNER, P; DURAND, B; NAKSHATRI, H; CHAMBON, P				NAGPAL, S; SAUNDERS, M; KASTNER, P; DURAND, B; NAKSHATRI, H; CHAMBON, P			PROMOTER CONTEXT-DEPENDENT AND RESPONSE ELEMENT-DEPENDENT SPECIFICITY OF THE TRANSCRIPTIONAL ACTIVATION AND MODULATING FUNCTIONS OF RETINOIC ACID RECEPTORS	CELL			English	Article							HUMAN ESTROGEN-RECEPTOR; HUMAN PROGESTERONE-RECEPTOR; DIFFERENTIAL PATTERN; NUCLEAR RECEPTORS; BINDING-PROTEINS; BETA-GENE; MOUSE; GAMMA; IDENTIFICATION; DOMAINS	Using several naturally occurring and synthetic retinoic acid (RA)-responsive reporter genes, we show that the patterns of transcriptional activation by various retinoic acid receptor (RAR) and retinoid X receptor (RXR) forms vary according to the nature of the RA response element and the context of the stimulated promoter. We demonstrate the presence of autonomous, ligand-inducible, and promoter context-dependent transactivation functions (AF-2s) located in the C-terminal region of all RARs and RXRs. In addition, promoter context-specific modulating transactivation functions are associated with the N-terminal A and B regions of RARs and RXRs. We also show that these transactivation and modulating functions exhibit response-element specificity. The modulating functions display a marked specificity in their cooperation with the AF-2 transactivation functions, cooperation that depends on the receptor origin of the modulating and transactivation functions and the promoter context of the RA-responsive gene, thus accounting for the specific transactivation properties of RAR and RXR types.			NAGPAL, S (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,UNITE BIOL MOLEC & GENIE GENET,CNRS,F-67085 STRASBOURG,FRANCE.		DURAND, Beatrice C/J-6387-2015; Nagpal, Sunil/A-8007-2009	DURAND, Beatrice C/0000-0002-0047-288X; Nakshatri, Harikrishna/0000-0001-8876-0052				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EVANS RM, 1988, SCIENCE, V240, P89; GAUB MP, 1992, IN PRESS EXP CELL RE, V201; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADER S, 1992, IN PRESS J BIOL CHEM, V267; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; NAGATA T, 1992, P NATL ACAD SCI USA, V89, P937, DOI 10.1073/pnas.89.3.937; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; SAURAT JH, 1990, RETINOIDS 10 YEARS O; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TURCOTTE B, 1991, J BIOL CHEM, V266, P2582; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1988, COLD SPRING HARB SYM, V53, P819, DOI 10.1101/SQB.1988.053.01.093; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	71	336	342	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1007	1019		10.1016/0092-8674(92)90250-G	http://dx.doi.org/10.1016/0092-8674(92)90250-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326406	Green Published			2022-12-24	WOS:A1992JN78100015
J	KLIEWER, SA; UMESONO, K; NOONAN, DJ; HEYMAN, RA; EVANS, RM				KLIEWER, SA; UMESONO, K; NOONAN, DJ; HEYMAN, RA; EVANS, RM			CONVERGENCE OF 9-CIS RETINOIC ACID AND PEROXISOME PROLIFERATOR SIGNALING PATHWAYS THROUGH HETERODIMER FORMATION OF THEIR RECEPTORS	NATURE			English	Article							HORMONE; GENE; RAT	PEROXISOMES are cytoplasmic organelles which are important in mammals in modulation of lipid homeostasis, including the metabolism of long-chain fatty acids and conversion or cholesterol to bile salts (reviewed in refs 1 and 2). Amphipathic carboxylates such as clofibric acid have been used in man as hypolipidaemic agents and in rodents they stimulate the proliferation of peroxisomes. These agents, termed peroxisome proliferators, and all-trans retinoic acid activate genes involved in peroxisomal-mediated beta-oxidation of fatty acids1-4. Here we show that the receptor activated by peroxisome proliferators5 and the retinoid X receptor-alpha (ref. 6) form a heterodimer that activates acyl-CoA oxidase gene expression in response to either clofibric acid or the retinoid X receptor-alpha ligand, 9-cis retinoic acid, an all-trans retinoic acid metabolite7,8; simultaneous exposure to both activators results in a synergistic induction of gene expression. These data demonstrate the coupling of the peroxisome proliferator and retinoid signalling pathways and provide evidence for a physiological role for 9-cis retinoic acid in modulating lipid metabolism.	LIGAND PHARMACEUT,SAN DIEGO,CA 92121	Ligand Pharmaceuticals	KLIEWER, SA (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; HERTZ R, 1992, BIOCHEM J, V281, P41, DOI 10.1042/bj2810041; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIJKATA M, 1990, J BIOL CHEM, V265, P4600; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NEMALI MR, 1988, CANCER RES, V48, P5316; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vamecq J, 1989, Essays Biochem, V24, P115; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	20	1528	1603	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					771	774		10.1038/358771a0	http://dx.doi.org/10.1038/358771a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1324435	Green Accepted			2022-12-24	WOS:A1992JK69900058
J	FERGUSON, M; TORRI, AF; WARD, DC; ENGLUND, PT				FERGUSON, M; TORRI, AF; WARD, DC; ENGLUND, PT			INSITU HYBRIDIZATION TO THE CRITHIDIA-FASCICULATA KINETOPLAST REVEALS 2 ANTIPODAL SITES INVOLVED IN KINETOPLAST DNA-REPLICATION	CELL			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; MINICIRCLES; MITOCHONDRIA; NETWORKS; LOCALIZATION; ORGANIZATION; TRANSCRIPT; PROTOZOA; CLONING	Kinetoplast DNA is a network of interlocked minicircles and maxicircles. In situ hybridization, using probes detected by digital fluorescence microscopy, has clarified the in vivo structure and replication mechanism of the network. The probe recognizes only nicked minicircles. Hybridization reveals prereplication kinetoplasts (with closed minicircles), donut-shaped replicating kinetoplasts (with nicked minicircles on the periphery and closed minicircles in the center), and postreplication kinetoplasts (with nicked minicircles). Replicating kinetoplasts are associated with two peripheral structures containing free minicircle replication intermediates and DNA polymerase. Replication may involve release of closed minicircles from the center of the kinetoplast and their migration to the peripheral structures, replication of the free minicircles therein, and then peripheral reattachment of the progeny minicircles to the kinetoplast.	YALE UNIV,DEPT BIOCHEM & GENE,NEW HAVEN,CT 06510; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Yale University; Johns Hopkins University	FERGUSON, M (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013604, R37GM027608, R01GM027608, R01GM040115] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-27608, GM-40115, GM13604-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON W, 1969, J CELL SCI, V4, P611; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BIRKENMEYER L, 1987, J BIOL CHEM, V262, P2384; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOYLE AR, 1990, CURRENT PROTOCOLS S, V12; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; DELAIN E, 1969, CR ACAD SCI D NAT, V268, P1225; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; ENGLUND PT, 1979, J BIOL CHEM, V254, P4895; ENGLUND PT, 1982, MITOCHONDRIAL GENES, P423; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; GONZALEZ A, 1990, MOL BIOCHEM PARASIT, V40, P233, DOI 10.1016/0166-6851(90)90045-N; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KUSEL JP, 1967, J PROTOZOOL, V14, P283, DOI 10.1111/j.1550-7408.1967.tb01999.x; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; SILVER LE, 1986, CELL, V47, P537, DOI 10.1016/0092-8674(86)90618-5; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; STUART K, 1983, MOL BIOCHEM PARASIT, V9, P93, DOI 10.1016/0166-6851(83)90103-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; TORRI AF, 1992, J BIOL CHEM, V267, P4786	33	115	115	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					621	629		10.1016/0092-8674(92)90431-B	http://dx.doi.org/10.1016/0092-8674(92)90431-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1324122				2022-12-24	WOS:A1992JJ88600011
J	MAGID, D; SCHWARTZ, B; CRAFT, J; SCHWARTZ, JS				MAGID, D; SCHWARTZ, B; CRAFT, J; SCHWARTZ, JS			PREVENTION OF LYME-DISEASE AFTER TICK BITES - A COST-EFFECTIVENESS ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOSORBENT-ASSAY; WHITE-TAILED DEER; BORRELIA-BURGDORFERI; ENDEMIC AREA; MANIFESTATIONS; SPIROCHETE; ABNORMALITIES; CEFTRIAXONE; PREVALENCE; DIAGNOSIS	Background. In areas of endemic disease, the probability of Lyme disease after a tick bite ranges from about 0.012 to 0.05. Early treatment with oral antibiotics prevents most complications of Lyme disease, but antibiotics are generally not prescribed until rash or other symptoms develop. Methods. We used decision analysis to evaluate the outcomes, costs, and cost effectiveness of three alternative strategies to treat patients bitten by ixodes ticks in areas of endemic Lyme disease: empirically treat all patients with two weeks of doxycycline, treat only patients in whom erythema migrans develops, and treat only patients with erythema migrans or a positive serologic test for Lyme disease one month after exposure. Results. Empirical treatment is the least expensive strategy and results in the fewest cases of Lyme disease and the fewest complications when the probability of Borrelia burgdorferi infection after a tick bite is 0.036 or higher. For probabilities of infection below 0.036, empirical therapy prevents most major complications, sequelae, and adverse events, but it incurs additional minor complications, especially as the probability of infection falls below 0.01. Conclusions. Empirical treatment of patients with tick bites is indicated when the probability of B. burgdorferi infection after a bite is 0.036 or higher, and this treatment may be preferred when the probability of infection ranges from 0.01 to 0.035. When the probability of infection after a tick bite is less than 0.01, empirical therapy is not warranted.	UNIV PENN, LEONARD DAVIS INST HLTH ECON, 3641 LOCUST WALK, PHILADELPHIA, PA 19104 USA; DENVER GEN HOSP, EMERGENCY MED SERV, DENVER, CO 80204 USA; UNIV COLORADO, HLTH SCI CTR, EMERGENCY MED RES CTR, DENVER, CO 80262 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV OCCUPAT HLTH, BALTIMORE, MD 21218 USA; YALE UNIV, SCH MED, DEPT MED, RHEUMATOL SECT, NEW HAVEN, CT 06510 USA; UNIV PENN, SCH MED, DIV GEN INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, CLIN EPIDEMIOL UNIT, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, DEPT HLTH CARE SYST, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University; Yale University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026853] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26853] Funding Source: Medline; NIAMS NIH HHS [AR 4007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRE F, 1991, AM J DIS CHILD, V145, P391; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BOSLER EM, 1984, YALE J BIOL MED, V57, P651; BOWEN GS, 1984, YALE J BIOL MED, V57, P661; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; BURGDORFER W, 1989, RHEUM DIS CLIN N AM, V15, P775; Centers for Disease Control (CDC), 1988, MMWR Suppl, V37, P1; CLARK JR, 1985, LARYNGOSCOPE, V95, P1341; COCKBURN J, 1987, BRIT MED J, V295, P814, DOI 10.1136/bmj.295.6602.814; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1988, LANCET, V1, P1191; FALCO RC, 1988, ANN NY ACAD SCI, V539, P456, DOI 10.1111/j.1749-6632.1988.tb31905.x; GELMAN CR, 1992, DOXYCYCLINE DRUG EVA, V72; GELMAN CR, 1992, CEFTRIAXONE DRUG EVA, V72; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; LACOMBE E, 1992, 5TH INT C LYM BORR W, pA49; LANE RS, 1988, ANN NY ACAD SCI, V539, P192, DOI 10.1111/j.1749-6632.1988.tb31853.x; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; LIU N Y, 1989, Arthritis and Rheumatism, V32, pS46; MAGNARELLI LA, 1988, J CLIN MICROBIOL, V26, P1482, DOI 10.1128/JCM.26.8.1482-1486.1988; MAGNARELLI LA, 1984, J WILDLIFE DIS, V20, P21, DOI 10.7589/0090-3558-20.1.21; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MAGNARELLI LA, 1988, ANN NY ACAD SCI, V539, P154, DOI 10.1111/j.1749-6632.1988.tb31848.x; MALAWISTA SE, 1986, ADV INTERNAL MED, V31, P147; MATHER TN, 1992, 5TH INT C LYM BORR W, pA49; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MOSKOVITZ BL, 1984, AM J MED, V77, P84; NADELMAN RB, 1992, 5TH INT C LYM BORR W, pA80; NEU HC, 1988, ANN NY ACAD SCI, V539, P314, DOI 10.1111/j.1749-6632.1988.tb31865.x; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHEIFE RT, 1976, DRUG EFFECTS HOSPITA, P263; Schoen R T, 1989, Conn Med, V53, P335; SHAPIRO ED, 1992, 5TH P INT C LYM BORR, pA47; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1979, ANN INTERN MED, V91, P730, DOI 10.7326/0003-4819-91-5-730; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; 1989, MED LETT DRUGS THER, V31, P57; 1991, LYME DISEASE SURVEIL, V2, P1	51	137	139	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					534	541		10.1056/NEJM199208203270806	http://dx.doi.org/10.1056/NEJM199208203270806			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1298217	Bronze			2022-12-24	WOS:A1992JJ45700006
J	KHAN, AA; STEINER, JP; KLEIN, MG; SCHNEIDER, MF; SNYDER, SH				KHAN, AA; STEINER, JP; KLEIN, MG; SCHNEIDER, MF; SNYDER, SH			IP3 RECEPTOR - LOCALIZATION TO PLASMA-MEMBRANE OF T-CELLS AND COCAPPING WITH THE T-CELL RECEPTOR	SCIENCE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CEREBELLAR PURKINJE-CELLS; LYMPHOCYTES-T; RAT-LIVER; ENDOPLASMIC-RETICULUM; INSP3 RECEPTOR; ACINAR-CELLS; K+ CHANNELS; PATCH CLAMP; ACTIVATION	Immune responses in lymphocytes require cellular accumulation of large amounts of calcium (Ca2+) from extracellular sources. In the T cell tumor line Jurkat, receptors for the Ca2+-releasing messenger inositol 1,4,5-trisphosphate (IP3) were localized to the plasma membrane (PM). Capping of the T cell receptor-CD3 complex, which is associated with signal transduction, was accompanied by capping of IP3 receptors. The IP3 receptor on T cells appears to be responsible for the entry of Ca2+ that initiates proliferative responses.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore					NHLBI NIH HHS [P01-HL27867] Funding Source: Medline; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGARD DA, 1984, ANNU REV BIOPHYS BIO, V13, P191; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, SIGNAL TRANSDUCTION, P111; Castleman KR., 1979, DIGITAL IMAGE PROCES; CUNNINGHAM A, UNPUB; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DARGEMONT C, 1988, BIOCHEM J, V256, P117, DOI 10.1042/bj2560117; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KHAN AT, UNPUB; KIMBALL PM, 1988, CELL IMMUNOL, V113, P107, DOI 10.1016/0008-8749(88)90010-X; KLEIN DP, 1990, J IMMUNOL, V145, P2967; KUNO M, 1986, NATURE, V323, P269, DOI 10.1038/323269a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SHARP AH, 1991, BIOPHYS J, V59, P525; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169	49	204	205	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					815	818		10.1126/science.1323146	http://dx.doi.org/10.1126/science.1323146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323146				2022-12-24	WOS:A1992JG85100041
J	LIMPER, AH; CARPENTER, PC; SCHEITHAUER, B; STAATS, BA				LIMPER, AH; CARPENTER, PC; SCHEITHAUER, B; STAATS, BA			THE CUSHING SYNDROME INDUCED BY BRONCHIAL CARCINOID-TUMORS	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; NORFLOXACIN; CAMPYLOBACTER INFECTIONS; SALMONELLA INFECTIONS; DYSENTERY	ECTOPIC ACTH SYNDROME; CORTICOTROPIN; DIAGNOSIS; SECRETION; ADENOMA; LUNG	Objectives: To define the clinical spectrum of bronchial carcinoid tumors in patients presenting with the Cushing syndrome, to evaluate the role of chest radiographs and computed tomography in their diagnosis, to review the characteristic histologic features, and to determine patient outcome. Design: Retrospective analysis of consecutive patients. Setting. A referral-based medical center. Patients: Fifteen consecutive patients with the Cushing syndrome evaluated at the Mayo Clinic with histologically proven bronchial carcinoid tumors. Measurements: Clinical, radiographic, and histologic features. Results: The Cushing syndrome was the initial clinical presentation, and bronchial carcinoid tumors were found later in all 15 patients. The diagnosis of carcinoid tumor was proved histologically in all cases. Ten biopsies showed typical carcinoid tumors, three were histologically atypical, and three were metastatic. Corticotropin was detected by immunostaining in seven of these tumors. Biochemical analysis showed marked elevations of circulating corticotropin with a mean serum value of 156 +/- 58 pmol/L (normal, 4 to 22 pmol/L). Additional clinical features included hypokalemia in six patients and glucocorticoid response to either high-dose dexamethasone or metyrapone in 6 of 13. These hormonally active carcinoid tumors were frequently radiographically occult, with 10 of 15 patients initially having normal chest radiographs. Computed tomography was successful in locating carcinoid tumors in five patients with negative chest radiographs evaluated after 1980. All five remaining patients with normal chest radiographs evaluated before 1980 eventually developed nodular lesions on standard chest radiography from 1 to 10 years later. Ten patients achieved complete remission and two patients, partial remission of the Cushing syndrome after surgical resection. Three patients continued to have symptomatic glucocorticoid excess due to metastatic disease. Conclusions: Although uncommon, the Cushing syndrome may be the initial clinical manifestation of an otherwise indolent bronchial carcinoid tumor. Radiographic imaging of occult lesions can be successfully accomplished with computed tomography. Surgical resection is curative in most patients with this disorder.	MAYO CLIN & MAYO FDN, DIV ENDOCRINOL & INTERNAL MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL & LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic	LIMPER, AH (corresponding author), MAYO CLIN & MAYO FDN, DIV THORAC DIS & INTERNAL MED, E-18B, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ALTMAN RL, 1973, THORAX, V28, P433, DOI 10.1136/thx.28.4.433; ARRIGONI MG, 1972, J THORAC CARDIOV SUR, V64, P413; AZZOPARDI JG, 1968, CANCER-AM CANCER SOC, V22, P274, DOI 10.1002/1097-0142(196808)22:2<274::AID-CNCR2820220204>3.0.CO;2-W; CARPENTER PC, 1988, ENDOCRIN METAB CLIN, V17, P445, DOI 10.1016/S0889-8529(18)30412-2; DELGAUDIO A, 1988, INT SURG, V73, P44; DESTEPHANO DB, 1984, HUM PATHOL, V15, P890, DOI 10.1016/S0046-8177(84)80151-3; DOPPMAN JL, 1989, RADIOLOGY, V172, P115, DOI 10.1148/radiology.172.1.2544919; FINDLING JW, 1986, ARCH INTERN MED, V146, P929, DOI 10.1001/archinte.146.5.929; HOWLETT TA, 1986, CLIN ENDOCRINOL, V24, P699, DOI 10.1111/j.1365-2265.1986.tb01667.x; JEX RK, 1985, AM J SURG, V149, P276; KAO PC, 1979, CLIN CHEM, V25, P1267; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LAWSON RM, 1976, THORAX, V31, P245, DOI 10.1136/thx.31.3.245; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; MALCHOFF CD, 1988, AM J MED, V84, P760, DOI 10.1016/0002-9343(88)90116-7; MASON A M S, 1972, Clinical Endocrinology, V1, P3, DOI 10.1111/j.1365-2265.1972.tb00374.x; MCDANIEL HG, 1980, SOUTHERN MED J, V73, P1194, DOI 10.1097/00007611-198009000-00008; MURRAY RJ, 1988, CHEST, V93, P1249, DOI 10.1378/chest.93.6.1249; OKIKE N, 1976, ANN THORAC SURG, V22, P270, DOI 10.1016/S0003-4975(10)64915-6; OLURIN EO, 1973, CANCER, V31, P1514, DOI 10.1002/1097-0142(197306)31:6<1514::AID-CNCR2820310631>3.0.CO;2-C; RAFF H, 1989, CLIN CHEM, V35, P596; Roberts L, 1985, WILLIAMS TXB ENDOCRI, P1363; ROZENMAN J, 1987, CHEST, V92, P145, DOI 10.1378/chest.92.1.145; SCHTEINGART DE, 1986, J CLIN ENDOCR METAB, V63, P770, DOI 10.1210/jcem-63-3-770; SKRABANEK P, 1978, CANCER, V42, P1263, DOI 10.1002/1097-0142(197809)42:3<1263::AID-CNCR2820420335>3.0.CO;2-O; STROTT CA, 1968, AM J MED, V44, P97, DOI 10.1016/0002-9343(68)90240-4; WHITE FE, 1982, BRIT MED J, V284, P771, DOI 10.1136/bmj.284.6318.771; ZARATE A, 1986, CLIN ENDOCRINOL, V24, P523, DOI 10.1111/j.1365-2265.1986.tb03281.x; 1981, NEW ENGL J MED, V305, P1637	30	110	113	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					209	214		10.7326/0003-4819-117-3-209	http://dx.doi.org/10.7326/0003-4819-117-3-209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1319693				2022-12-24	WOS:A1992JF30400006
J	GRAF, T; MCNAGNY, K; BRADY, G; FRAMPTON, J				GRAF, T; MCNAGNY, K; BRADY, G; FRAMPTON, J			CHICKEN ERYTHROID-CELLS TRANSFORMED BY THE GAG-MYB-ETS-ENCODING E26 LEUKEMIA-VIRUS ARE MULTIPOTENT	CELL			English	Article							MYELOMONOCYTIC GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; MYELOID CELLS; PHILADELPHIA-CHROMOSOME; MONOCLONAL-ANTIBODY; AUTOCRINE GROWTH; VULVAR INDUCTION; GENE-EXPRESSION; TARGET-CELLS; DIFFERENTIATION	The E26 avian leukemia virus encodes a transcriptional activator-type oncoprotein consisting of Gag, Myb, and Ets domains, and transforms early erythroid cells as well as myeloblasts. Surprisingly, we have found that "early erythroid" transformants obtained in culture are multipotent, since they can be induced to differentiate into myeloblasts and eosinophils after superinfection with retroviruses containing kinase-type or ras oncogenes. In addition, TPA is an efficient inducer that generates predominantly eosinophils at low concentrations and myeloblasts at high concentrations. The determination process involves the complete extinction of erythroid/thrombocytic markers and the subsequent activation of myelomonocytic/eosinophilic properties, including the acquisition of specific growth factor requirements. "Erythroleukemic" cells from virus-infected animals were likewise found to be multipotent, making this a unique system to study the genesis of stem cell leukemias and the molecular basis of lineage commitment during hematopoiesis.			GRAF, T (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY.		Graf, Thomas/B-4252-2015; McNagny, Kelly/P-5239-2014	Graf, Thomas/0000-0003-2774-4117; McNagny, Kelly/0000-0003-4737-3499				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BROWN G, 1986, LEUKEMIA, V1, P150; BRUNE K, 1973, J INFECT DIS, V127, P84, DOI 10.1093/infdis/127.1.84; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dieterlen-Lievre F., 1988, P257; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EWERT DL, 1984, J IMMUNOL, V132, P2524; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1988, LEUKEMIA, V2, P127; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREENBERG SM, 1988, BLOOD, V72, P1968; GREENBERGER JS, 1983, J NATL CANCER I, V70, P323; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAPLOW LS, 1965, BLOOD-J HEMATOL, V26, P215, DOI 10.1182/blood.V26.2.215.215; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KLINKEN SP, 1991, CANCER CELL-MON REV, V3, P373; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lucas AM, 1961, AGR MONOGRAPH, V25; MANDI Y, 1987, IMMUNOBIOLOGY, V174, P292, DOI 10.1016/S0171-2985(87)80004-9; Maniatis T., 1982, MOL CLONING; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCNAGNY K, 1992, IN PRESS LEUKEMIA; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NAVARRO S, 1991, EXP HEMATOL, V19, P11; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGAWA M, 1983, BLOOD, V61, P823; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU T, 1988, BLOOD, V72, P1029; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; POOLE AR, 1977, LYSOSOMES LABORATORY; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEIGNEURIN D, 1987, EXP HEMATOL, V15, P822; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; YU G, 1989, J BIOL CHEM, V264, P10276	65	138	138	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					201	213		10.1016/0092-8674(92)90096-U	http://dx.doi.org/10.1016/0092-8674(92)90096-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1322247				2022-12-24	WOS:A1992JE75700005
J	JOHNSON, EM				JOHNSON, EM			METHADONE AND AZT TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							FRIEDLAND, J ACQUIRED IMMUNODEF	1	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-24	WOS:A1992JD47200003
J	BODE, W; GOMISRUTH, FX; HUBER, R; ZWILLING, R; STOCKER, W				BODE, W; GOMISRUTH, FX; HUBER, R; ZWILLING, R; STOCKER, W			STRUCTURE OF ASTACIN AND IMPLICATIONS FOR ACTIVATION OF ASTACINS AND ZINC-LIGATION OF COLLAGENASES	NATURE			English	Article							AMINO-ACID SEQUENCE; HUMAN FIBROBLAST COLLAGENASE; THERMOLYSIN; PROTEASE; PROTEINS	ASTACIN, a digestive zinc-endopeptidase from the crayfish Astacus astacus L. 1,2, is the prototype for the 'astacin family' 3-5, which includes mammalian metallo-endopeptidases 5 and developmentally regulated proteins of man 6, fruitfly 7, frog 8 and sea urchin 9,10. Here we report the X-ray crystal structure of astacin, which reveals a deep active-site cleft, with the zinc at its bottom ligated by three histidines, a water molecule and a more remote tyrosine. The third histidine (His 102) forms part of a consensus sequence, shared not only by the members of the astacin family, but also by otherwise sequentially unrelated proteinases, such as vertebrate collagenases 11. It may therefore represent the elusive 'third' zinc ligand in these enzymes. The amino terminus of astacin is buried forming an internal salt-bridge with Glu 103, adjacent to His 102. Astacin pro-forms extended at the N terminus, as observed for some 'latent' mammalian astacin homologues, did not exhibit this 'active' conformation, indicating an activation mechanism reminiscent of trypsin-like serine proteinases.	UNIV HEIDELBERG,INST ZOOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	BODE, W (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.		Stöcker, Walter/AAB-9704-2019	Stöcker, Walter/0000-0002-1515-6994; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				BARRETT AJ, 1991, BIOCHEM SOC T, V19, P707, DOI 10.1042/bst0190707; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, XPLOR MANUAL VERSION; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JONES TA, 1978, ACTA CRYSTALLOGR A, V34, P931; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17530; LEPAGE T, 1992, DEVELOPMENT, V114, P147; Lipscomb W N, 1968, Brookhaven Symp Biol, V21, P24; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; STOCKER W, 1988, BIOCHEMISTRY-US, V27, P5026; STOCKER W, 1991, BIOL CHEM H-S, V372, P385, DOI 10.1515/bchm3.1991.372.1.385; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; TURK D, 1992, THESIS TU MUNCHEN; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	30	297	306	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					164	167		10.1038/358164a0	http://dx.doi.org/10.1038/358164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319561				2022-12-24	WOS:A1992JC58300057
J	WIENANDS, J; RETH, M				WIENANDS, J; RETH, M			GLYCOSYL-PHOSPHATIDYLINOSITOL LINKAGE AS A MECHANISM FOR CELL-SURFACE EXPRESSION OF IMMUNOGLOBULIN-D	NATURE			English	Article							NATURAL-KILLER CELLS; ANTIGEN RECEPTOR COMPLEX; LINKED MEMBRANE-PROTEIN; B-CELLS; MOLECULAR-COMPONENTS; IGM; GENE; GLYCOPROTEIN; DIFFER; LFA-3	THE B-cell antigen receptor of the IgM and IgD class is a multimeric complex consisting of the membrane-bound form of the immunoglobulin molecule and two other proteins, Ig-alpha and Ig-beta 1-8. The Ig-alpha and Ig-beta proteins form a disulphide-linked alpha/beta heterodimer and are encoded by the mb-1 (refs 9, 10) and B29 genes 11,12, respectively 13,14. Surface expression of the membrane-bound IgM molecule requires assembly with the alpha/beta heterodimer 1,3,4,8. The IgD molecule, however, can be expressed on the cell surface in an alpha/beta-dependent and -independent forms 8,15. We show here that in the alpha/beta-independent form the IgD molecule is anchored in the plasma membrane through a glycosyl-phosphatidylinositol linker. In the presence of the alpha/beta heterodimer, most of the otherwise glycosyl-phosphatidylinositol-linked IgD molecule is expressed on the cell surface as transmembrane proteins.			WIENANDS, J (corresponding author), MAX PLANCK INST IMMUNBIOL,STUBEWEG 51,W-7800 FREIBURG,GERMANY.							BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; DHAR A, 1991, BIOCHIM BIOPHYS ACTA, V1091, P15, DOI 10.1016/0167-4889(91)90215-J; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HOMBACH J, 1988, J EXP MED, V167, P652, DOI 10.1084/jem.167.2.652; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; PARKHOUSE RME, 1990, IMMUNOLOGY, V69, P298; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; VANNOESEL CJM, 1990, EUR J IMMUNOL, V20, P2789, DOI 10.1002/eji.1830201238; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WALLNER BP, 1987, J EXP MED, V166, P923, DOI 10.1084/jem.166.4.923; WIENANDS J, 1991, EUR J IMMUNOL, V21, P2373, DOI 10.1002/eji.1830211012; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x	29	63	63	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					246	248		10.1038/356246a0	http://dx.doi.org/10.1038/356246a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313152				2022-12-24	WOS:A1992HJ94400060
J	MILLER, DM; SHEN, MM; SHAMU, CE; BURGLIN, TR; RUVKUN, G; DUBOIS, ML; GHEE, M; WILSON, L				MILLER, DM; SHEN, MM; SHAMU, CE; BURGLIN, TR; RUVKUN, G; DUBOIS, ML; GHEE, M; WILSON, L			C-ELEGANS UNC-4 GENE ENCODES A HOMEODOMAIN PROTEIN THAT DETERMINES THE PATTERN OF SYNAPTIC INPUT TO SPECIFIC MOTOR NEURONS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSPOSABLE ELEMENT; NERVOUS-SYSTEM; CELL LINEAGES; DROSOPHILA; HOMEOBOX; EXPRESSION; PRODUCT	THE creation of neural circuits depends on the formation of synapses between specific sets of neurons. Little is known, however, of the molecular mechanisms governing synaptic choice. A mutation in the unc-4 gene alters the pattern of synaptic input to one class of motor neurons in the Caenorhabditis elegans ventral nerve cord. In unc-4(e120), the presynaptic partners of VA motor neurons are replaced with interneurons appropriate to motor neurons of the VB class. This change in neural specificity is not accompanied by any detectable effects on neuronal morphology or process extension 1,2. We show that the absence of a functional unc-4 gene product accounts for the mutant phenotype. The unc-4 gene encodes a homeodomain protein and thus is likely to function as a transcription factor. The limited effect of the unc-4 null mutation on cell fate may mean that unc-4 regulates the expression of a small number of target genes and that the products of these genes are directly involved in the choice of synaptic partners.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	MRC Laboratory Molecular Biology; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	MILLER, DM (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.		Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657				AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BABU P, 1981, MUTAT RES, V82, P269, DOI 10.1016/0027-5107(81)90156-1; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1990, NATURE, V355, P184; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DURBIN R, 1987, THESIS CAMBRIDGE U; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; EMMONS SW, 1988, NEMATODE CAENORHABDI, P47; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERMAN RK, 1978, GENETICS, V88, P49; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; LIAO LW, 1983, P NATL ACAD SCI-BIOL, V80, P3585, DOI 10.1073/pnas.80.12.3585; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAMU CE, 1989, THESIS CAMBRIDGE U; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SHEN MM, 1988, THESIS CAMBRIDGE U; SIGURDSON DC, 1984, GENETICS, V108, P331; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, COLD SPRING HARB SYM, V48, P443, DOI 10.1101/SQB.1983.048.01.049; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1992, NATURE, V355, P838, DOI 10.1038/355838a0; [No title captured]	40	156	158	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					841	845		10.1038/355841a0	http://dx.doi.org/10.1038/355841a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1347150				2022-12-24	WOS:A1992HF63600061
J	ATKINSON, MA; KAUFMAN, DL; CAMPBELL, L; GIBBS, KA; SHAH, SC; BU, DF; ERLANDER, MG; TOBIN, AJ; MACLAREN, NK				ATKINSON, MA; KAUFMAN, DL; CAMPBELL, L; GIBBS, KA; SHAH, SC; BU, DF; ERLANDER, MG; TOBIN, AJ; MACLAREN, NK			RESPONSE OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS TO GLUTAMATE-DECARBOXYLASE IN INSULIN-DEPENDENT DIABETES	LANCET			English	Note								Insulin-dependent diabetes is characterised by autoantibodies to several pancreatic-islet-cell antigens, including glutamate decarboxylase. We measured the proliferative responses to this antigen of peripheral-blood mononuclear cells from patients with newly diagnosed insulin-dependent diabetes, relatives of diabetic patients, and healthy controls. The likelihood of a positive response was substantially greater among the diabetic patients and relatives positive for islet-cell autoantibodies (ICA) than among subjects at low risk of diabetes (controls and ICA-negative relatives). Glutamate decarboxylase may have a pathogenetic role in insulin-dependent diabetes.	UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV S FLORIDA,DEPT PEDIAT,TAMPA,FL 33620	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of South Florida	ATKINSON, MA (corresponding author), UNIV FLORIDA,DEPT PATHOL,POB 100275,GAINESVILLE,FL 32610, USA.		Kaufman, Daniel/AAU-1228-2021; Campbell, Lesley V/B-2271-2008	Kaufman, Daniel/0000-0002-9844-5918; 				ATKINSON MA, 1990, SCI AM, V263, P62, DOI 10.1038/scientificamerican0790-62; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BU DF, IN PRESS P NATL ACAD; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; JAMES SP, 1990, CURRENT PROTOCOLS IM; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U	10	279	286	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					458	459		10.1016/0140-6736(92)91061-C	http://dx.doi.org/10.1016/0140-6736(92)91061-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346821				2022-12-24	WOS:A1992HE93200006
J	MAKI, H; SEKIGUCHI, M				MAKI, H; SEKIGUCHI, M			MUTT PROTEIN SPECIFICALLY HYDROLYZES A POTENT MUTAGENIC SUBSTRATE FOR DNA-SYNTHESIS	NATURE			English	Article							ESCHERICHIA-COLI; POLYMERASE SUBUNIT; MOLECULAR-CLONING; FIDELITY; MUTATOR; PURIFICATION; REPLICATION; SITE	ERRORS in the replication of DNA are a major source of spontaneous mutations, and a number of cellular functions are involved in correction of these errors to keep the frequency of spontaneous mutations very low 1. We report here a novel mechanism which prevents replicational errors by degrading a potent mutagenic substrate for DNA synthesis. This error-avoiding process is catalysed by a protein encoded by the mutT gene of Escherichia coli, mutations of which increase the occurrence of A . T --> C . G transversions 100 to 10,000 times the level of the wild type 2. Spontaneous oxidation of dGTP forms 8-oxo-7,8-dihydro-2'-dGTP (8-oxodGTP), which is inserted opposite dA and dC residues of template DNA with almost equal efficiency, and the MutT protein specifically degrades 8-oxodGTP to the monophosphate. This indicates that elimination from the nucleotide pool of the oxidized form of guanine nucleotide is important for the high fidelity of DNA synthesis.			MAKI, H (corresponding author), KYUSHU UNIV,FAC MED,DEPT BIOCHEM,FUKUOKA 812,JAPAN.							AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; FERSHT A, 1977, ENZYME STRUCTURE MEC, P91; HORIUCHI T, 1989, B I PASTEUR, V87, P309; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KASAI H, 1984, JPN J CANCER RES, V75, P1037; MAKI H, 1985, J BIOL CHEM, V260, P2987; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	19	814	834	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					273	275		10.1038/355273a0	http://dx.doi.org/10.1038/355273a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1309939				2022-12-24	WOS:A1992GZ69400075
J	HEALY, B				HEALY, B			RELATIVE TOXICITY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ARTHRITIS RHEUM, V34, P1353	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-24	WOS:A1992GY04600004
J	GOGOS, JA; HSU, T; BOLTON, J; KAFATOS, FC				GOGOS, JA; HSU, T; BOLTON, J; KAFATOS, FC			SEQUENCE DISCRIMINATION BY ALTERNATIVELY SPLICED ISOFORMS OF A DNA-BINDING ZINC FINGER DOMAIN	SCIENCE			English	Article							SITE SELECTION ANALYSIS; OLIGONUCLEOTIDE MIXTURES; PROTEIN; RECOGNITION; DROSOPHILA; COMPLEX; MYOD; FORM	Two major developmentally regulated isoforms of the Drosophila chorion transcription factor CF2 differ by an extra zinc finger within the DNA binding domain. The preferred DNA binding sites were determined and are distinguished by an internal duplication of TAT in the site recognized by the isoform with the extra finger. The results are consistent with modular interactions between zinc fingers and trinucleotides and also suggest rules for recognition of AT-rich DNA sites by zinc finger proteins. The results show how modular finger interactions with trinucleotides can be used, in conjunction with alternative splicing, to alter the binding specificity and increase the spectrum of sites recognized by a DNA binding domain. Thus, CF2 may potentially regulate distinct sets of target genes during development.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; UNIV CRETE,FORTH,INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,GREECE; UNIV CRETE,DEPT BIOL,GR-71110 IRAKLION,GREECE	Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Crete; University of Crete								BALDWIN AS, 1987, CURRENT PROTOCOLS MO; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GOGOS JA, 1991, NUCLEIC ACIDS RES, V19, P1449, DOI 10.1093/nar/19.7.1449; GOGOS JA, UNPUB; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU AL, 1981, J BIOL CHEM, V256, P13200; MAINA CV, 1988, GENE, V74, P355; MARSTON FA, 1987, DNA CLONING PRACTICA, P65; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UEDA H, 1991, NUCLEIC ACIDS RES, V19, P3689, DOI 10.1093/nar/19.13.3689; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	27	91	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1951	1955		10.1126/science.1290524	http://dx.doi.org/10.1126/science.1290524			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1290524				2022-12-24	WOS:A1992JP59400033
J	MACKOWIAK, PA; WASSERMAN, SS; LEVINE, MM				MACKOWIAK, PA; WASSERMAN, SS; LEVINE, MM			A CRITICAL-APPRAISAL OF 98.6-DEGREES-F, THE UPPER LIMIT OF THE NORMAL BODY-TEMPERATURE, AND OTHER LEGACIES OF WUNDERLICH,CARL,REINHOLD,AUGUST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate critically Carl Wundedich's axioms on clinical thermometry. Design.-Descriptive analysis of baseline oral temperature data from volunteers participating in Shigella vaccine trials conducted at the University of Maryland Center for Vaccine Development, Baltimore. Setting.-Inpatient clinical research unit. Participants.-One hundred forty-eight healthy men and women aged 18 through 40 years. Main Measurements.-Oral temperatures were measured one to four times daily for 3 consecutive days using an electronic digital thermometer. Results.-Our findings conflicted with Wunderlich's in that 36.8-degrees-C (98.2-degrees-F) rather than 37.0-degrees-C (98.6-degrees-F) was the mean oral temperature of our subjects; 37.7-degrees-C (99.9-degrees-F) rather than 38.0-degrees-C (100.4-degrees-F) was the upper limit of the normal temperature range; maximum temperatures, like mean temperatures, varied with time of day; and men and women exhibited comparable thermal variability. Our data corroborated Wunderlich's in that mean temperature varied diurnally, with a 6 AM nadir, a 4 to 6 PM zenith, and a mean amplitude of variability of 0.5-degrees-C (0.9-degrees-F); women had slightly higher normal temperatures than men; and there was a trend toward higher temperatures among black than among white subjects. Conclusions.-Thirty-seven degrees centigrade (98.6-degrees-F) should be abandoned as a concept relevant to clinical thermometry; 37.2-degrees-C (98.9-degrees-F) in the early morning and 37.7-degrees-C (99.9-degrees-F) overall should be regarded as the upper limit of the normal oral temperature range in healthy adults aged 40 years or younger, and several of Wundedich's other cherished dictums should be revised.	UNIV MARYLAND,SCH MED,CTR VACCINE DEV,BALTIMORE,MD 21218; UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21218	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	MACKOWIAK, PA (corresponding author), UNIV MARYLAND,VET AFFAIRS MED CTR,SCH MED,MED SERV 111,3900 LOCH RAVEN BLVD,BALTIMORE,MD 21218, USA.							[Anonymous], 1871, MED THERMOMETRY HUMA; Beutler B, 1992, CECIL TXB MED, P1568; BRENGELMANN GL, 1989, TXB PHYSL, P1584; DINARELLO CA, 1978, NEW ENGL J MED, V298, P607, DOI 10.1056/NEJM197803162981107; DINARELLO CA, 1990, PRINCIPLES PRACTICE, P462; Dominguez E, 1991, FEVER BASIC MECH MAN, P71; GARRISON FH, 1929, INTRO HIST MED, P757; GUYTON AC, 1991, TXB MED PHYSL, P6; HENSYL WR, 1990, STEDMANS MED DICT, P574; HORVATH STEVEN M., 1950, JOUR AMER MED ASSOC, V144, P1562; IVY AC, 1944, B NW U MED SCH, V18, P22; Linder F.E., 1935, HUM BIOL, V7, P24; PETERSDORF RG, 1991, HARRISONS PRINCIPLES, P2194; TANNER JM, 1951, J PHYSIOL-LONDON, V115, P391, DOI 10.1113/jphysiol.1951.sp004677; TAUBER MG, 1990, INTERNAL MED, P1240; THOMAS CL, 1989, TABERS CYCLOPEDIC ME, P665; Whiting MH, 1915, BIOMETRIKA, V11, P1; Wunderlich C.A., 1869, AM J MED SCI, V57, P425, DOI DOI 10.1097/00000441-186904000-00021; WUNDERLICH CA, 1871, TEMPERATURE DISEASES, P71; Wunderlich CA, 1868, VERHALTEN EIAENWARME; 1982, HLTH DEVICES, V12, P3	21	328	333	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1578	1580		10.1001/jama.268.12.1578	http://dx.doi.org/10.1001/jama.268.12.1578			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1302471				2022-12-24	WOS:A1992JN25600029
J	MOUNTJOY, KG; ROBBINS, LS; MORTRUD, MT; CONE, RD				MOUNTJOY, KG; ROBBINS, LS; MORTRUD, MT; CONE, RD			THE CLONING OF A FAMILY OF GENES THAT ENCODE THE MELANOCORTIN RECEPTORS	SCIENCE			English	Article							MELANOCYTE STIMULATING HORMONE; POTENT ALPHA-MELANOTROPIN; FUNCTIONAL EXPRESSION; CANNABINOID RECEPTOR; CELLS; CDNA; SEQUENCE; PROTEIN; BINDING; DNA	Melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) regulate pigmentation and adrenal cortical function, respectively. These peptides also have a variety of biological activities in other areas, including the brain, the pituitary, and the immune system. A complete understanding of the biological activities of these hormones requires the isolation and characterization of their corresponding receptors. The murine and human MSH receptors (MSH-Rs) and a human ACTH receptor (ACTH-R) were cloned. These receptors define a subfamily of receptors coupled to guanine nucleotide-binding proteins that may include the cannabinoid receptor.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Mountjoy, Kathy/L-4473-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043859] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43859-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; CANNON JG, 1986, J IMMUNOL, V137, P2232; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5924; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWIED D, 1982, PHYSIOL REV, V62, P977; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; ELLERKMANN E, 1992, ENDOCRINOLOGY, V130, P133, DOI 10.1210/en.130.1.133; GERARD C, 1990, NUCLEIC ACIDS RES, V18, P7142, DOI 10.1093/nar/18.23.7142; GERST JE, 1988, ENDOCRINOLOGY, V123, P1792, DOI 10.1210/endo-123-4-1792; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GRAHAMES.DG, 1967, J BIOL CHEM, V242, P5535; HANNEMAN E, 1989, PEPTIDE HORMONES PRO, P53; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MERTZ LM, 1991, P NATL ACAD SCI USA, V88, P8525, DOI 10.1073/pnas.88.19.8525; MOUNTJOY KG, UNPUB; MURPHY MT, 1983, SCIENCE, V221, P192, DOI 10.1126/science.6602381; PAWELEK J, 1976, J INVEST DERMATOL, V66, P210; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; SLOMINSKI A, 1992, LIFE SCI, V50, P1103, DOI 10.1016/0024-3205(92)90347-R; SOLCA F, 1989, J BIOL CHEM, V264, P14277; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TATRO JB, 1990, J CLIN INVEST, V85, P1825, DOI 10.1172/JCI114642; TATRO JB, 1990, BRAIN RES, V536, P124, DOI 10.1016/0006-8993(90)90016-5; TATRO JB, 1990, CANCER RES, V50, P1237; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	37	1401	1474	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1248	1251		10.1126/science.1325670	http://dx.doi.org/10.1126/science.1325670			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325670				2022-12-24	WOS:A1992JL05000024
J	PITCHER, JA; INGLESE, J; HIGGINS, JB; ARRIZA, JL; CASEY, PJ; KIM, C; BENOVIC, JL; KWATRA, MM; CARON, MG; LEFKOWITZ, RJ				PITCHER, JA; INGLESE, J; HIGGINS, JB; ARRIZA, JL; CASEY, PJ; KIM, C; BENOVIC, JL; KWATRA, MM; CARON, MG; LEFKOWITZ, RJ			ROLE OF BETA-GAMMA-SUBUNITS OF G-PROTEINS IN TARGETING THE BETA-ADRENERGIC-RECEPTOR KINASE TO MEMBRANE-BOUND RECEPTORS	SCIENCE			English	Article							MAMMALIAN BETA-2-ADRENERGIC RECEPTOR; AGONIST-DEPENDENT PHOSPHORYLATION; NUCLEOTIDE-BINDING-PROTEIN; ROD OUTER SEGMENTS; ADENYLYL CYCLASE; RHODOPSIN KINASE; GTP-BINDING; TRANSDUCIN; INHIBITION; PURIFICATION	The rate and extent of the agonist-dependent phosphorylation of beta-2-adrenergic receptors and rhodopsin by beta-adrenergic receptor kinase (beta-ARK) are markedly enhanced on addition of G protein beta-gamma subunits. With a model peptide substrate it was demonstrated that direct activation of the kinase could not account for this effect. G protein beta-gamma subunits were shown to interact directly with the COOH-terminal region of beta-ARK, and formation of this beta-ARK-beta-gamma complex resulted in receptor-facilitated membrane localization of the enzyme. The beta-gamma subunits of transducin were less effective at both enhancing the rate of receptor phosphorylation and binding to the COOH-terminus of beta-ARK, suggesting that the enzyme preferentially binds specific beta-gamma complexes. The beta-gamma-mediated membrane localization of beta-ARK serves to intimately link receptor activation to beta-ARK-mediated desensitization.	DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Duke University; Duke University; Duke University; Duke University; Jefferson University			Pitcher, Julie/ABH-2078-2020; Kwatra, Madan/ABD-2008-2020; Lefkowitz, Robert/AAW-2649-2021	Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [4R37-HL16039] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1986, NATURE, V322, P869; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, IN PRESS NATURE; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PITCHER JA, UNPUB; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	42	626	631	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1264	1267		10.1126/science.1325672	http://dx.doi.org/10.1126/science.1325672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325672				2022-12-24	WOS:A1992JL05000029
J	HILES, ID; OTSU, M; VOLINIA, S; FRY, MJ; GOUT, I; DHAND, R; PANAYOTOU, G; RUIZLARREA, F; THOMPSON, A; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD				HILES, ID; OTSU, M; VOLINIA, S; FRY, MJ; GOUT, I; DHAND, R; PANAYOTOU, G; RUIZLARREA, F; THOMPSON, A; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD			PHOSPHATIDYLINOSITOL 3-KINASE - STRUCTURE AND EXPRESSION OF THE 110KD CATALYTIC SUBUNIT	CELL			English	Article							RECEPTOR TYROSINE KINASES; DEPENDENT PROTEIN-KINASE; FACTOR-I RECEPTOR; MIDDLE T-ANTIGEN; PDGF RECEPTOR; BOVINE BRAIN; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; ACTIVATED NEUTROPHILS; PHOSPHOLIPASE-C	Purified bovine brain phosphatidylinositol 3-kinase (Pl3-kinase) is composed of 85 kd and 110 kd subunits. The 85 kd subunit (p85-alpha) lacks Pl3-kinase activity and acts as an adaptor, coupling the 110 kd subunit (p110) to activated protein tyrosine kinases. Here the characterization of the p110 subunit is presented. cDNA cloning reveals p110 to be a 1068 aa protein related to Vps34p, a S. cerevisiae protein involved in the sorting of proteins to the vacuole. p110 expressed in insect cells possesses Pl3-kinase activity and associates with p85-alpha into an active p85-alpha-p110 complex that binds the activated colony-stimulating factor 1 receptor. p110 expressed in COS-1 cells is catalytically active only when complexed with p85-alpha.	UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	University of London; University College London; European Molecular Biology Laboratory (EMBL); Cancer Research UK	HILES, ID (corresponding author), LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND.		Volinia, Stefano/AAA-9264-2019; Parker, Peter j/D-5192-2013; Hsuan, Justin/C-8825-2009; Volinia, Stefano/A-3029-2010	Volinia, Stefano/0000-0003-0910-3893; Hsuan, Justin/0000-0001-6083-7564; Volinia, Stefano/0000-0003-0910-3893; Ruiz Larrea, Fernanda/0000-0001-5610-7745; parker, peter/0000-0002-6218-2933; Fry, Michael/0000-0001-8518-1370				ASHMUN RA, 1989, BLOOD, V73, P827; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARVEY RJ, 1991, NUCLEIC ACIDS RES, V19, P4002, DOI 10.1093/nar/19.14.4002; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Maniatis T., 1982, MOL CLONING; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGE MJ, 1989, NUCLEIC ACIDS RES, V17, P454, DOI 10.1093/nar/17.1.454; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TOTTY NF, 1992, IN PRESS PROTEIN SCI, V1; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITLEY GSJ, 1987, MOL CELL ENDOCRINOL, V52, P279, DOI 10.1016/0303-7207(87)90056-6; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	63	644	815	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					419	429		10.1016/0092-8674(92)90166-A	http://dx.doi.org/10.1016/0092-8674(92)90166-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322797	Bronze			2022-12-24	WOS:A1992JH12400007
J	PRYCIAK, PM; VARMUS, HE				PRYCIAK, PM; VARMUS, HE			NUCLEOSOMES, DNA-BINDING PROTEINS, AND DNA-SEQUENCE MODULATE RETROVIRAL INTEGRATION TARGET SITE SELECTION	CELL			English	Article							I-HYPERSENSITIVE SITES; CHROMATIN STRUCTURE; PREFERRED TARGETS; CORE PARTICLE; INVITRO; REGIONS; MAP; PROMOTER; OPERATOR; COMPLEX	Integration of retroviral DNA can serve as a paradigm for cellular functions that are affected by the packaging of DNA into chromatin. We have used a novel polymerase chain reaction-based assay to survey DNA and chromatin for the precise distribution of many integration sites. Integration into naked DNA targets is non-uniform, implying a nucleotide sequence bias. In chromatin, integration occurs preferentially at positions where the major groove is on the exposed face of the nucleosomal DNA helix, generating a 10 bp periodic spacing of preferred sites. Chromatin assembly enhances the reactivity of many sites, so that integration occurs most frequently at sites in nucleosomal, rather than nucleosome-free, regions of minichromosomes. In contrast, integration is prevented in a region occupied by a site-specific DNA-binding protein. Comparisons of integration events mediated by viral nucleoprotein complexes or by two different retroviral integrases show that the integration machinery also affects target site selection.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PRYCIAK, PM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		Pryciak, Peter/P-7205-2019	Pryciak, Peter/0000-0001-9142-1369				BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; DREW HR, 1990, DNA TOPOLOGY ITS BIO, P1; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KING W, 1985, SCIENCE, V228, P554, DOI 10.1126/science.3838595; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; VARMUS H, 1989, MOBILE DNA, P53; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WOLFFE A P, 1991, Current Biology, V1, P366, DOI 10.1016/0960-9822(91)90195-3	44	240	247	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					769	780		10.1016/0092-8674(92)90289-O	http://dx.doi.org/10.1016/0092-8674(92)90289-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1317268				2022-12-24	WOS:A1992HW83800008
J	GORLICH, D; HARTMANN, E; PREHN, S; RAPOPORT, TA				GORLICH, D; HARTMANN, E; PREHN, S; RAPOPORT, TA			A PROTEIN OF THE ENDOPLASMIC-RETICULUM INVOLVED EARLY IN POLYPEPTIDE TRANSLOCATION	NATURE			English	Article							SIGNAL RECOGNITION PARTICLE; OUTER-MEMBRANE PROTEIN; NASCENT PREPROLACTIN; SECRETORY PROTEIN; SEQUENCE RECEPTOR; IMPORT; SRP; PHOTOCROSSLINKING; IDENTIFICATION; COMPONENT	To identify components of the mammalian endoplasmic reticulum involved in the translocation of secretory proteins, crosslinking and reconstitution methods were combined. A multispanning abundant membrane glycoprotein was found which is in proximity to nascent chains early in translocation. In reconstituted proteoliposomes, this protein is stimulatory or required for the translocation of secretory proteins.	MAX DELBRUCK CTR MOLEC MED, ROBERT ROSSLE STR 10, O-1115 BERLIN, GERMANY; HUMBOLDT UNIV, INST BIOCHEM, O-1040 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Hartmann, Enno/C-5687-2013; Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MEYER DI, 1982, NATURE, V297, P503; MUSCH A, IN PRESS CELL; NICCHITTA C, 1991, METHOD CELL BIOL, V34, P263; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; ROTHBLATT JA, 1989, J CELL BIOL, V72, P61; SANDERS S, IN PRESS CELL; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	31	258	263	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1992	357	6373					47	52		10.1038/357047a0	http://dx.doi.org/10.1038/357047a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1315422				2022-12-24	WOS:A1992HT22900052
J	CUZICK, J; TERRY, G; HO, L; HOLLINGWORTH, T; ANDERSON, M				CUZICK, J; TERRY, G; HO, L; HOLLINGWORTH, T; ANDERSON, M			HUMAN PAPILLOMAVIRUS TYPE-16 DNA IN CERVICAL SMEARS AS PREDICTOR OF HIGH-GRADE CERVICAL-CANCER	LANCET			English	Note							COLPOSCOPY	The management of women with mild to moderately dyskaryotic cervical smears would benefit from a non-invasive test that predicts which women have high-grade cervical intraepithelial neoplasia. Detection of human papillomavirus type 16 (HPV16) DNA in cervical smears may be such a test. With the polymerase chain reaction (PCR), we estimated the amount of HPV16 DNA in cervical smears from 85 women referred for colposcopy because of abnormal cytology. An intermediate or high amount of HPV16 DNA predicted the presence of high-grade cervical intraepithelial neoplasia in a subsequent biopsy in almost 90% of patients irrespective of the cytological grade of the referral smear. This technique may allow early identification of those women with low-grade cytological abnormalities who have high-grade underlying cervical disease	UNIV LONDON UNIV COLL,DEPT CHEM PATHOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT MED MICROBIOL,LONDON WC1E 6BT,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT OBSTET,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND	University of London; University College London; University of London; University College London; University of Nottingham; University of Nottingham	CUZICK, J (corresponding author), IMPERIAL CANC RES FUND,POB 123,LONDON WC2A 3PX,ENGLAND.							FUCHS PG, 1988, INT J CANCER, V41, P41, DOI 10.1002/ijc.2910410109; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; KOCHEL HG, 1990, INT J GYNECOL OBSTET, V31, P145, DOI 10.1016/0020-7292(90)90712-T; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; NUOVO GJ, 1991, AM J PATHOL, V138, P53; NUOVO GJ, 1990, OBSTET GYNECOL, V75, P1006; NUOVO GJ, 1989, OBSTET GYNECOL, V74, P673; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; VANDENBRULE AJC, 1991, INT J CANCER, V48, P404, DOI 10.1002/ijc.2910480317	10	134	135	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					959	960		10.1016/0140-6736(92)91532-D	http://dx.doi.org/10.1016/0140-6736(92)91532-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348800				2022-12-24	WOS:A1992HP03600005
J	KROHN, K; UIBO, R; AAVIK, E; PETERSON, P; SAVILAHTI, K				KROHN, K; UIBO, R; AAVIK, E; PETERSON, P; SAVILAHTI, K			IDENTIFICATION BY MOLECULAR-CLONING OF AN AUTOANTIGEN ASSOCIATED WITH ADDISONS-DISEASE AS STEROID 17-ALPHA-HYDROXYLASE	LANCET			English	Article							AUTOIMMUNE HEPATITIS; AUTOANTIBODIES; EXPRESSION; ANTIGEN; GENES	Idiopathic Addison's disease is characterised by a progressive failure in the synthesis of all classes of steroid hormones and by an immune response against the steroid-producing cells of the adrenal cortex; the nature of the adrenal autoantigens is not known. We have used molecular cloning and sequencing to identify the target antigens. We screened a human fetal adrenal cDNA expression library in lambda-gt11 vector with serum samples from patients with Addison's disease as part of the type 1 polyendocrine autoimmunity syndrome. Samples from 3 patients, which had precipitating antibodies against two adrenal proteins detected by immunodiffusion and against five adrenal proteins of molecular mass 55, 48, 43, 39, and 19 kDa as judged by immunoblotting, were used to identify 60 immunoreactive clones 39 of these were subcloned, inserted into the M13mp10 vector, and sequenced by the dideoxy method or identified by Southern and dot-blot hybridisation. All but 1 of the inserts showed more than 98.8% homology with the published sequence of steroid 17-alpha-hydroxylase. This protein was expressed by insertion of 1 of the clones into the pGEMEX-1 vector. Only serum from patients with Addison's disease and type 1 polyendocrine autoimmunity syndrome that reacted with the 55 kDa adrenal protein recognised the recombinant 17-alpha-hydroxylase protein on immunoblotting. Our results show that one of the key enzymes in steroid biosynthesis, 17-alpha-hydroxylase, is an autoantigen involved in the pathogenesis of adrenocortical failure.	TARTU STATE UNIV, INST GEN & MOLEC PATHOL, TARTU, ESTONIA, USSR; TARTU STATE UNIV, INST CELLULAR & MOLEC BIOL, TARTU, ESTONIA, USSR	University of Tartu; University of Tartu	KROHN, K (corresponding author), UNIV TAMPERE, INST BIOMED SCI, POB 607, SF-33101 TAMPERE, FINLAND.		Peterson, Pärt/A-5788-2009	Peterson, Pärt/0000-0001-6755-791X; Uibo, Raivo/0000-0002-2298-1300				ANDERSON J. R., 1968, CLIN EXP IMMUNOL, V3, P107; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BLIZZARD RM, 1963, J CLIN INVEST, V42, P1653, DOI 10.1172/JCI104851; BRIGHT GM, 1990, J CLIN ENDOCR METAB, V70, P95, DOI 10.1210/jcem-70-1-95; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; CZAZNOCKA B, 1985, FEBS LETT, V190, P147; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HEINONEN E, 1977, MED BIOL, V55, P48; HEINONEN E, 1976, ACTA U TAMPERENSIS, V81, P92; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KROHN K, 1974, CLIN IMMUNOL IMMUNOP, V3, P59, DOI 10.1016/0090-1229(74)90023-3; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; MACLAREN NK, 1985, AUTOIMMUNE DISEASES, P201; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MEESE E, 1990, NUCLEIC ACIDS RES, V18, P1923, DOI 10.1093/nar/18.7.1923; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OUCHTERLONY O, 1948, ACTA PATHOL MIC SC, V25, P186; Sambrook J., 1989, MOL CLONING LAB MANU; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VOUTILAINEN R, 1991, J CLIN ENDOCR METAB, V72, P761, DOI 10.1210/jcem-72-4-761; WADSWORTH C, 1957, INT ARCH ALLER A IMM, V10, P355, DOI 10.1159/000228394; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	27	158	162	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1992	339	8796					770	773		10.1016/0140-6736(92)91894-E	http://dx.doi.org/10.1016/0140-6736(92)91894-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347802				2022-12-24	WOS:A1992HL50100002
J	TASAKI, T; OHTO, H; HASHIMOTO, C; ABE, R; SAITOH, A; KIKUCHI, S				TASAKI, T; OHTO, H; HASHIMOTO, C; ABE, R; SAITOH, A; KIKUCHI, S			RECOMBINANT-HUMAN-ERYTHROPOIETIN FOR AUTOLOGOUS BLOOD DONATION - EFFECTS ON PERIOPERATIVE RED-BLOOD-CELL AND SERUM ERYTHROPOIETIN PRODUCTION	LANCET			English	Article							TRANSFUSION; ANTIBODY; VIRUS	To speed collection of blood for autologous transfusion during elective surgery, patients may be given recombinant human erythropoietin (r-HuEPO). In a controlled trial, we evaluated the effects of r-HuEPO on perioperative red-blood-cell and serum erythropoietin (s-EPO) production in patients, donating blood before elective orthopaedic surgery. Patients were assigned randomly to receive no r-HuEPO (1 2 patients), or 3000 U (4), 6000 U (5), or 9000 U (4) of r-HuEPO intravenously twice a week from the time of the first blood donation. All patients received iron sulphate. 1200 ml blood was collected from each patient in three weekly donations of 400 ml. The 3000, 6000, and 9000 U treatment groups produced 284, 350, and 383 ml, respectively, of red cells during donation, and the untreated controls produced 211 ml. s-EPO concentrations were within the normal range during donation. After surgery, s-EPO concentrations peaked on postoperative day 1 in untreated patients and on day 7 in treated patients; therefore, r-HuEPO may suppress endogenous erythropoietin secretion. Although administration of r-HuEPO increases production of red blood cells, the preoperative anaemia induced by repeated phlebotomy without r-HuEPO may accelerate the postoperative secretion of endogenous erythropoietin.	FUKUSHIMA MED SCH,DEPT ORTHOPAED SURG,FUKUSHIMA 96012,JAPAN	Fukushima Medical University	TASAKI, T (corresponding author), FUKUSHIMA MED SCH,BLOOD TRANSFUS SERV,HIKARIGA OKA,FUKUSHIMA 96012,JAPAN.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; CUMMING PD, 1989, NEW ENGL J MED, V321, P914; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; HOWARD JE, 1978, TRANSFUSION, V18, P496, DOI 10.1046/j.1537-2995.1978.18478251250.x; INABA S, 1989, TRANSFUSION, V29, P7, DOI 10.1046/j.1537-2995.1989.29189101168.x; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; LEVINE E, 1990, TRANSFUSION, V30, P295, DOI 10.1046/j.1537-2995.1990.30490273433.x; MAEDA H, 1989, LANCET, V2, P284; NADLER SB, 1962, SURGERY, V51, P224; OWINGS DV, 1989, JAMA-J AM MED ASSOC, V262, P1963	13	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					773	775		10.1016/0140-6736(92)91895-F	http://dx.doi.org/10.1016/0140-6736(92)91895-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347803				2022-12-24	WOS:A1992HL50100003
J	ENGELBERG, H				ENGELBERG, H			LOW SERUM-CHOLESTEROL AND SUICIDE	LANCET			English	Note							LIPID FLUIDITY; MEMBRANES; SEROTONIN; BEHAVIOR; MICROVISCOSITY; PARAMETERS; MORTALITY; BINDING	Primary prevention trials which have shown that the lowering of serum cholesterol concentrations in middle-aged subjects by diet, drugs, or both leads to a decrease in coronary heart disease have also reported an increase in deaths due to suicide or violence. There has been no adequate explanation for this association. I have reviewed the relevant published work and describe a physiological mechanism that might account for this curious finding. One of the functions of serotonin in the central nervous system is the suppression of harmful behavioural impulses. When mouse brain synaptosomal membrane cholesterol is increased there is a pronounced increase in the number of serotonin receptors. Low membrane cholesterol decreases the number of serotonin receptors. Since membrane cholesterol exchanges freely with cholesterol in the surrounding medium, a lowered serum cholesterol concentration may contribute to a decrease in brain serotonin, with poorer suppression of aggressive behaviour.	CEDARS SINAI MED CTR, DEPT MED, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center								ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; BOROCHOV H, 1976, P NATL ACAD SCI USA, V73, P4526, DOI 10.1073/pnas.73.12.4526; COOPER RA, 1978, J SUPRAMOL STR CELL, V8, P413, DOI 10.1002/jss.400080404; HERON DS, 1980, P NATL ACAD SCI-BIOL, V77, P7463, DOI 10.1073/pnas.77.12.7463; HERSHKOWITZ M, 1982, PROG BRAIN RES, V56, P419; HORROBIN DF, 1990, BRIT MED J, V301, P554, DOI 10.1136/bmj.301.6751.554-b; JENKINS CD, 1969, PSYCHOSOM MED, V31, P115; JOHNSON DA, 1979, MOL PHARMACOL, V15, P739; KAPLAN JR, 1990, PSYCHOSOM MED, V52, P226; MCLOUGHLIN I, 1989, BRIT J PSYCHIAT, V154, P275, DOI 10.1192/S0007125000226275; MULDOON MF, 1990, BRIT MED J, V301, P554, DOI 10.1136/bmj.301.6751.554-a; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SLAP GB, 1989, PEDIATRICS, V84, P762; SLETTEN IW, 1964, PSYCHOSOM MED, V26, P261, DOI 10.1097/00006842-196405000-00005; SMITH GD, 1990, BRIT MED J, V301, P552; SOUBRIE P, 1986, BEHAV BRAIN SCI, V9, P319, DOI 10.1017/S0140525X00022871; THILO L, 1977, BIOCHEMISTRY-US, V16, P1283, DOI 10.1021/bi00626a007; VIKKUNEN M, 1983, NEUROPSYCHOBIOLOGY, V10, P65; VIKKUNEN M, 1984, NEUROPSYCHOBIOLOGY, V19, P435; VIKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27; 1987, LANCET, V2, P949	25	393	401	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1992	339	8795					727	729		10.1016/0140-6736(92)90609-7	http://dx.doi.org/10.1016/0140-6736(92)90609-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347593				2022-12-24	WOS:A1992HK32000014
J	DENNY, T; YOGEV, R; GELMAN, R; SKUZA, C; OLESKE, J; CHADWICK, E; CHENG, SC; CONNOR, E				DENNY, T; YOGEV, R; GELMAN, R; SKUZA, C; OLESKE, J; CHADWICK, E; CHENG, SC; CONNOR, E			LYMPHOCYTE SUBSETS IN HEALTHY-CHILDREN DURING THE 1ST 5 YEARS OF LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CONTROLLED TRIAL; CELL SUBSETS; INFECTION; ZIDOVUDINE	Objective. - To assess whether relative and absolute values of CD4 and CD8 lymphocytes and CD4/CD8 ratio change in relation to age, and to estimate the fifth and 95th percentiles for these values in children of various ages. Patients and Methods. - Phenotypic analysis of lymphocyte subsets was performed on blood samples from 208 healthy children, aged 1 through 59 months, using standard flow cytometric techniques. Results. - Regression analysis demonstrated that CD4 and CD8 lymphocyte counts declined significantly with advancing age (P < .000001 and P = .03, respectively). Since CD4 and CD8 counts depend on total lymphocyte count, the percentage of total lymphocytes of each phenotype was also analyzed and demonstrated that the CD4 percentage was highly age dependent (P < .000001). The CD8 percentage increased with age (P = .0001) but not as much as the CD4 percentage decreased. Median CD4 counts (fifth and 95th percentiles) for children 2 through 3, 4 through 8, 12 through 23, and 24 through 59 months of age were 2.83 (1.46 to 5.11), 2.95 (1.69 to 4.61), 2.07 (1.02 to 3.60), and 1.80 (0.90 to 2.86) x 10(9)/L, respectively. Conclusion. - Healthy children's CD4 lymphocyte counts are considerably higher than previously established adult values. These data demonstrate that age is an important consideration in interpretation of lymphocyte subsets in children. This may be especially relevant in children who are infected with the human immunodeficiency virus, where CD4 lymphocyte values play a central role in monitoring disease progression and determining thresholds for medical interventions.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PEDIAT,185 S ORANGE AVE,NEWARK,NJ 07103; CHILDRENS HOSP NEW JERSEY,NEWARK,NJ; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,AIDS CLIN TRIALS UNIT,NEWARK,NJ 07103; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT PEDIAT,CHICAGO,IL 60614; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,AIDS CLIN TRIALS UNIT,CHICAGO,IL 60614; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Brugnara, Carlo/A-8041-2010; Oleske, James/C-1951-2016	Brugnara, Carlo/0000-0001-8192-8713; Oleske, James/0000-0003-2305-5605; Denny, Thomas/0000-0002-7364-8276	NIAID NIH HHS [N01-AI-95030, 5UO1-AI27559, 1UO1-AI25883] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025883, N01AI095030, U01AI027559] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCHER DP, 1991, 31ST INT C ANT AG CH; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; Breiman L., 1982, CLASSIFICATION REGRE; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; CULVER KW, 1987, J PEDIATR-US, V111, P230, DOI 10.1016/S0022-3476(87)80073-2; DALLMAN PR, 1978, AM J CLIN NUTR, V31, P377, DOI 10.1093/ajcn/31.3.377; DANGOSTINO RB, 1986, GOODNESS FIT TECHNIQ; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GIORGI JV, 1986, MANUAL CLIN LABORATO, P236; JACKSON A, 1986, MANUAL CLIN LABORATO, P236; JOHNSON L, 1986, CONTINUOUS UNIVARIAT, P73; KARAYALCIN G, 1972, NEW YORK STATE J MED, V72, P1815; KENDALL M, 1977, ADV THEORY STAT, V1, P258; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P52; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; LIEBOVITZ E, 1990, NEW ENGL J MED, V323, P531; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; TOLLERUD DJ, 1989, J CLIN IMMUNOL, V9, P214, DOI 10.1007/BF00916817; TOLLERUD DJ, 1990, CLIN IMMUNOL IMMUNOP, V56, P88, DOI 10.1016/0090-1229(90)90172-M; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1989, MMWR S5, V38, P1; 1991, MMWR, V40, P1	25	189	191	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1484	1488		10.1001/jama.267.11.1484	http://dx.doi.org/10.1001/jama.267.11.1484			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1347086				2022-12-24	WOS:A1992HH48800028
J	KOELLE, DM; BENEDETTI, J; LANGENBERG, A; COREY, L				KOELLE, DM; BENEDETTI, J; LANGENBERG, A; COREY, L			ASYMPTOMATIC REACTIVATION OF HERPES-SIMPLEX VIRUS IN WOMEN AFTER THE 1ST EPISODE OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						PATIENT EDUCATION; HERPES GENITALIS; SEXUALLY TRANSMITTED DISEASES; PREGNANCY COMPLICATIONS, INFECTIOUS; CONTRACEPTIVE DEVICES, MALE	ORAL ACYCLOVIR; INTRAVENOUS ACYCLOVIR; CONTROLLED TRIAL; INFECTION; TRANSMISSION; ACQUISITION; RECURRENCES; ANTIBODIES; FREQUENCY; PARTNER	Objective: To determine frequency, anatomic site, and host factors associated with asymptomatic shedding of herpes simplex virus after initial episodes of genital herpes. Design: Cohort study with follow-up for a median of 63 weeks. Setting: Referral clinic. Patients: Women (306) with first episode of herpes; 43 had primary herpes simplex virus type 1, and 227 and 36 had primary and nonprimary herpes simplex virus type 2, respectively. Measurements: Cultures were obtained for herpes simplex virus every 4 to 6 weeks at times in which genital lesions and symptoms were not present. Main Results: Asymptomatic shedding was detected among 11.9%, 18.3%, and 22.9% of women with primary herpes simplex virus type 1, primary HSV type 2, and nonprimary HSV type 2, respectively. Among patients with type 2 infection, previous type 1 antibody was associated with a lower rate of asymptomatic vulvar shedding. Asymptomatic cervical shedding was 3 times more frequent during the first three months after resolution of primary type 2 disease than during later time periods. In contrast, the rate of symptomatic recurrent herpes did not change over time. Conclusions: Asymptomatic genital herpes simplex type 2 is more common than type 1. Asymptomatic genital shedding occurs more often during the first 3 months after acquisition of primary type 2 disease than during later periods. Patients with HSV type 2 should be advised of this high early rate of asymptomatic shedding and of potential transmission to sexual partners.	UNIV WASHINGTON, DIV VIROL, 1200 12TH AVE S, ROOM 9301, SEATTLE, WA 98144 USA; CHILDRENS HOSP & MED CTR, SEATTLE, WA USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital			Corey, Lawrence/AAE-1796-2020; Koelle, David/Q-6529-2016	Corey, Lawrence/0000-0002-2179-2436; Koelle, David/0000-0003-1255-9023	NATIONAL CANCER INSTITUTE [R44CA094611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381, P01AI030731] Funding Source: NIH RePORTER; NCI NIH HHS [R44 CA094611] Funding Source: Medline; NIAID NIH HHS [P01 AI030731, AI-30731, AI-20381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM E, 1979, OBSTET GYNECOL, V54, P171; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1986, GENITOURIN MED, V62, P181; BARTON SE, 1987, GENITOURIN MED, V63, P102; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; BUCHMAN TG, 1978, J INFECT DIS, V138, P488, DOI 10.1093/infdis/138.4.488; COREY L, 1985, SEX TRANSM DIS, V12, P215, DOI 10.1097/00007435-198510000-00009; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; GUINAN ME, 1981, NEW ENGL J MED, V304, P759, DOI 10.1056/NEJM198103263041305; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; MCCAUGHTRY ML, 1982, J MED VIROL, V10, P283, DOI 10.1002/jmv.1890100408; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MINDEL A, 1986, GENITOURIN MED, V62, P28; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; REEVES WC, 1981, NEW ENGL J MED, V305, P315, DOI 10.1056/NEJM198108063050604; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; STONE KM, 1990, REV INFECT DIS, V12, pS610; STONE KM, 1989, SEX TRANSM DIS, V16, P152, DOI 10.1097/00007435-198907000-00007; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; 1991, EGRET REFERENCE MANU	28	172	173	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					433	437		10.7326/0003-4819-116-6-433	http://dx.doi.org/10.7326/0003-4819-116-6-433			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1310837	Green Accepted			2022-12-24	WOS:A1992HJ59800001
J	VAHAKANGAS, KH; SAMET, JM; METCALF, RA; WELSH, JA; BENNETT, WP; LANE, DP; HARRIS, CC				VAHAKANGAS, KH; SAMET, JM; METCALF, RA; WELSH, JA; BENNETT, WP; LANE, DP; HARRIS, CC			MUTATIONS OF P53 AND RAS GENES IN RADON-ASSOCIATED LUNG-CANCER FROM URANIUM MINERS	LANCET			English	Article							POINT MUTATIONS; RISK; CARCINOMA; EXPOSURE; FREQUENT; CELLS	Radon increases the risk of lung cancer in smoking and non-smoking underground miners. To investigate the mutational spectrum associated with exposure to high levels of radon, we sequenced exons 5-9 of the p53 tumour suppressor gene and codons 12-13 of the Ki-ras protooncogene in 19 lung cancers from uranium miners exposed to radon and tobacco smoke. Mutations were not found in Ki-ras, but 9 p53 mutations, including 2 deletions, were found in 7 patients by direct DNA sequencing after polymerase chain reaction amplification of DNA from formalin-fixed, paraffin-embedded tissue. In tumours from 5 patients, the mutation produced an aminoacid change and an increased nuclear content of p53 protein. The tumours with either a stop codon or frame-shift deletion in the p53 gene were negative by immunohistochemistry. None of the mutations were G:C to T:A transversions in the coding strand of the p53 gene, which are the most frequent base substitutions associated with tobacco smoking, and none were found at the hotspot codons described in lung cancer. The observed differences from the usual lung cancer mutational spectrum may reflect the genotoxic effects of radon.	NCI, HUMAN CARCINOGENESIS LAB, BLDG 37, ROOM 2C05, BETHESDA, MD 20892 USA; UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; UNIV NEW MEXICO, MED CTR, CTR CANC, NEW MEXICO TUMOR REGISTRY, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, MED CTR, DEPT MED, ALBUQUERQUE, NM 87131 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Dundee; University of New Mexico; University of New Mexico			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545	NCI NIH HHS [N01 CN-55426] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN055426] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT WP, 1991, ONCOGENE, V6, P1779; BOS JL, 1989, CANCER RES, V49, P4682; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRENNAN J, 1991, CANCER RES, V51, P1708; BRIDGES BA, 1991, LANCET, V337, P1187, DOI 10.1016/0140-6736(91)92859-Z; CHIBA I, 1990, ONCOGENE, V5, P1603; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; GROSOVSKY AJ, 1988, P NATL ACAD SCI USA, V85, P185, DOI 10.1073/pnas.85.1.185; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HARLEY NH, 1990, CA-CANCER J CLIN, V40, P265, DOI 10.3322/canjclin.40.5.265; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SAMET JM, 1989, HEALTH PHYS, V56, P415, DOI 10.1097/00004032-198904000-00002; SAMET JM, 1991, HEALTH PHYS, V61, P745, DOI 10.1097/00004032-199112000-00005; SAMET JM, 1990, RISK ANAL, V10, P65, DOI 10.1111/j.1539-6924.1990.tb01021.x; SCHWARTZ JL, 1990, ENVIRON MOL MUTAGEN, V16, P178; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; 1988, HLTH RISKS RADON OTH	30	298	304	2	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					576	580		10.1016/0140-6736(92)90866-2	http://dx.doi.org/10.1016/0140-6736(92)90866-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347094				2022-12-24	WOS:A1992HH07500004
J	VALLANCE, P; LEONE, A; CALVER, A; COLLIER, J; MONCADA, S				VALLANCE, P; LEONE, A; CALVER, A; COLLIER, J; MONCADA, S			ACCUMULATION OF AN ENDOGENOUS INHIBITOR OF NITRIC-OXIDE SYNTHESIS IN CHRONIC-RENAL-FAILURE	LANCET			English	Article							NG-METHYLARGININE; BLOOD-PRESSURE; L-ARGININE; NG,NG-DIMETHYLARGININE; PURIFICATION; INVIVO	Nitric oxide (NO), synthesised from L-arginine, contributes to the regulation of blood pressure and to host defence. We describe in-vitro and in-vivo evidence that NO synthesis can be inhibited by an endogenous compound, N(G),N(G)-dimethylarginine (asymmetrical dimethylarginine, ADMA). In man, this inhibitor is found in plasma and more than 1 0 mg is excreted in urine over 24 h. However, in patients with end-stage chronic renal failure, who have little or no urine output, elimination is blocked and circulating concentrations of the inhibitor rise sufficiently to inhibit NO synthesis. Accumulation of endogenous ADMA, leading to impaired NO synthesis, might contribute to the hypertension and immune dysfunction associated with chronic renal failure.	WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON SW17,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; St Georges University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CARNEGIE PR, 1977, METABOLISM, V26, P531, DOI 10.1016/0026-0495(77)90097-X; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; ESCHBACH JW, 1991, KIDNEY, P2019; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; GRANGER DL, 1991, J IMMUNOL, V146, P1294; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIRSCHBERG RR, 1988, KIDNEY INT, V33, P1147, DOI 10.1038/ki.1988.123; KAKIMOTO Y, 1970, J BIOL CHEM, V245, P5751; KEANE WF, 1983, REPLACEMENT RENAL FU, P646; LIEW FY, 1990, J IMMUNOL, V144, P4794; LOU MF, 1979, SCIENCE, V203, P668, DOI 10.1126/science.760213; MCDERMOTT JR, 1976, BIOCHEM J, V154, P179, DOI 10.1042/bj1540179; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V230, P212; NAKAMURA T, 1991, HYPERTENSION, V17, P875, DOI 10.1161/01.HYP.17.6.875; OGAWA T, 1990, J BIOL CHEM, V265, P20938; OGAWA T, 1989, J BIOL CHEM, V264, P10205; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARK KS, 1988, J CHROMATOGR, V440, P225, DOI 10.1016/S0021-9673(00)94526-6; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SADASIVUDU B, 1974, CLINICIAN, V38, P114; TOLINS JP, 1991, HYPERTENSION, V17, P1045, DOI 10.1161/01.HYP.17.6.1045; TOLKOFFRUBIN NE, 1990, NEW ENGL J MED, V322, P770, DOI 10.1056/NEJM199003153221109; VALLANCE P, 1989, LANCET, V2, P997; WALDER CE, 1991, BRIT J PHARMACOL, V102, P967, DOI 10.1111/j.1476-5381.1991.tb12285.x	28	1893	1960	1	42	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					572	575						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347093				2022-12-24	WOS:A1992HH07500003
J	MINTZ, IM; VENEMA, VJ; SWIDEREK, KM; LEE, TD; BEAN, BP; ADAMS, ME				MINTZ, IM; VENEMA, VJ; SWIDEREK, KM; LEE, TD; BEAN, BP; ADAMS, ME			P-TYPE CALCIUM CHANNELS BLOCKED BY THE SPIDER TOXIN OMEGA-AGA-IVA	NATURE			English	Article							FUNNEL-WEB SPIDER; CHICK SENSORY NEURONS; BRAIN MESSENGER-RNA; AGELENOPSIS-APERTA; CONOTOXIN GVIA; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; XENOPUS OOCYTES; VENOM; CURRENTS	VOLTAGE-DEPENDENT calcium channels mediate calcium entry into neurons, which is crucial for many processes in the brain including synaptic transmission, dendritic spiking, gene expression and cell death 1-5. Many types of calcium channels exist in mammalian brains 6-19, but high-affinity blockers are available for only two types, L-type channels (targeted by nimodipine and other dihydropyridine channel blockers 20-22) and N-type channels (targeted by omega-conotoxin 22-26). In a search for new channel blockers, we have identified a peptide toxin from funnel web spider venom, omega-Aga-IVA, which is a potent inhibitor of both calcium entry into rat brain synaptosomes and of 'P-type' calcium channels 8 in rat Purkinje neurons. omega-Aga-IVA will facilitate characterization of brain calcium channels resistant to existing channel blockers and may assist in the design of neuroprotective drugs.	UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	University of California System; University of California Riverside; Harvard University; Harvard Medical School; City of Hope; Beckman Research Institute of City of Hope			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113				ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; ADAMS ME, 1990, J BIOL CHEM, V265, P861; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BINDOKAS VP, 1989, J NEUROBIOL, V20, P171, DOI 10.1002/neu.480200402; BINDOKAS VP, 1991, J NEUROPHYSIOL, V66, P590, DOI 10.1152/jn.1991.66.2.590; BOSSU JL, 1989, PFLUG ARCH EUR J PHY, V414, P92, DOI 10.1007/BF00585632; DUTAR P, 1989, EUR J PHARMACOL, V174, P261, DOI 10.1016/0014-2999(89)90318-X; FEIGENBAUM P, 1988, BIOCHEM BIOPH RES CO, V154, P298, DOI 10.1016/0006-291X(88)90684-5; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HYUI A, 1991, NEURON, V7, P35; JASYS VJ, 1990, J AM CHEM SOC, V112, P6696, DOI 10.1021/ja00174a037; KUAN YF, 1986, EUR J PHARMACOL, V130, P273, DOI 10.1016/0014-2999(86)90278-5; LEONARD JP, 1987, J NEUROSCI, V7, P875; LIN JW, 1990, P NATL ACAD SCI USA, V87, P4538, DOI 10.1073/pnas.87.12.4538; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LUNDY PM, 1991, EUR J PHARM-MOLEC PH, V206, P61, DOI 10.1016/0922-4106(91)90147-A; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MINTZ M, 1991, P NATL ACAD SCI USA, V88, P6628; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; QUISTAD GB, 1990, BIOCHEM BIOPH RES CO, V169, P51, DOI 10.1016/0006-291X(90)91431-Q; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REGAN LJ, 1991, NEURON, V6, P259; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SCROGGS RS, 1991, J NEUROSCI, V11, P1334; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SUSZKIW JB, 1989, J NEUROCHEM, V52, P1260, DOI 10.1111/j.1471-4159.1989.tb01874.x; SUSZKIW JB, 1986, J NEUROSCI, V6, P1349; TAKAHASHI K, 1989, NEUROSCI LETT, V104, P229, DOI 10.1016/0304-3940(89)90359-5; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WEISS JH, 1990, SCIENCE, V247, P1474, DOI 10.1126/science.2157282; YAARI Y, 1987, SCIENCE, V235, P680, DOI 10.1126/science.2433765	47	842	853	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					827	829		10.1038/355827a0	http://dx.doi.org/10.1038/355827a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311418				2022-12-24	WOS:A1992HF63600056
J	FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M				FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M			HYPERNATREMIA SURVEILLANCE DURING A NATIONAL DIARRHEAL DISEASES CONTROL PROJECT IN EGYPT	LANCET			English	Article							ORAL REHYDRATION SOLUTION; INFANTILE DIARRHEA; CHILDREN	The nationwide introduction of oral rehydration therapy to Egypt has led to improvement in diarrhoea case management and a fall in infant and child mortality. With the wider use of oral rehydration solution (ORS) prepared from packets, the incidence of hypernatraemia (serum sodium > 150 mmol/l) in inpatients with dehydration seen at Abu El-Reeche Hospital, Cairo, increased between 1980 and 1984. Systematic surveillance of hypernatraemia in the outpatient rehydration unit began in late 1984, and we report trends in hypernatraemia and analyses of key variables affecting its incidence in dehydrated children. In 1980, 17 of 100 children sampled had hypernatraemia and 2 had severe hypernatraemia (ie, serum sodium > 165 mmol/l). The frequency in inpatients peaked at 49% of 222 children in 1984 (19% with severe hypernatraemia). Between 1 986 and 1 989, at least 1 000 dehydrated outpatients were surveyed each year; by 1989 the incidence of hypernatraemia had fallen to around 10% (2% severe hypernatraemia). The rise and decline coincided with increasing use of ORS and then increasing ability of mothers to mix the solution correctly. Hypernatraemia was positively related to the quantity of ORS taken, severity of dehydration, nutritional status, and the cooler season, and negatively related to age and duration of diarrhoea. Explanations for our findings include improved use of ORS and better case-management. Good practice promoted through the mass media has facilitated these changes, if the standard of ORS use is not maintained, there may be a case for reducing the sodium content of ORS.	JOHN SNOW INC, BOSTON, MA USA; MINIST HLTH CAIRO, NATL CONTROL DIARRHEAL DIS PROJECT, CAIRO, EGYPT	Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	FAYAD, IM (corresponding author), UNIV CAIRO, CHILDRENS HOSP, ABU EL REECHE HOSP, FAC MED, GASTROENTERITIS UNIT, CAIRO, EGYPT.							BLACK RE, 1984, PEDIATRICS, V73, P799; CLEARY TG, 1981, J PEDIATR-US, V99, P739, DOI 10.1016/S0022-3476(81)80397-6; ELMOUGI M, 1989, J TROP PEDIATRICS, V35, P230, DOI 10.1093/tropej/35.5.230; ELRAFIE M, 1990, LANCET, V335, P334; FARTHING MJG, 1988, DRUGS, V36, P80, DOI 10.2165/00003495-198800364-00011; FORTIN J, 1978, J TROP PED ENV CH H, V24, P110, DOI 10.1093/tropej/24.3.110; HELMY N, 1988, J PEDIATR GASTR NUTR, V7, P417, DOI 10.1097/00005176-198805000-00018; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; PANETH N, 1980, AM J DIS CHILD, V134, P785, DOI 10.1001/archpedi.1980.02130200053017; PIZARRO D, 1984, J PEDIATR-US, V104, P316, DOI 10.1016/S0022-3476(84)81023-9; SANTOSHAM M, 1990, J PEDIATR-US, V116, P868, DOI 10.1016/S0022-3476(05)80642-0; 1988, LANCET, V2, P145; 1977, B WORLD HEALTH ORGAN, V55, P87	13	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					389	393		10.1016/0140-6736(92)90079-I	http://dx.doi.org/10.1016/0140-6736(92)90079-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346660				2022-12-24	WOS:A1992HD65900004
J	LANDI, G				LANDI, G			CLINICAL-DIAGNOSIS OF TRANSIENT ISCHEMIC ATTACKS	LANCET			English	Article							ISCHEMIC ATTACKS; INTEROBSERVER AGREEMENT; STROKE; RELIABILITY; COMMUNITY; RIND				LANDI, G (corresponding author), OSPED POLICLIN, NEUROL CLIN, VIA F SFORZA 35, I-20122 MILAN, ITALY.							BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CALANCHINI PR, 1977, JAMA-J AM MED ASSOC, V238, P2029, DOI 10.1001/jama.238.19.2029; CAPLAN LR, 1983, STROKE, V14, P431, DOI 10.1161/01.STR.14.3.431; DENNIS M, 1990, J NEUROL, V237, P257, DOI 10.1007/BF00314630; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DENNIS MS, 1989, LANCET, V1, P185; FISHER CM, 1986, STROKE, V17, P1033, DOI 10.1161/01.STR.17.5.1033; FISHER CM, 1982, NEUROLOGY, V32, P871, DOI 10.1212/WNL.32.8.871; HANKEY GJ, 1991, LANCET, V337, P335, DOI 10.1016/0140-6736(91)90953-M; HODGES JR, 1990, BRAIN, V113, P639, DOI 10.1093/brain/113.3.639; KAPPELLE LJ, 1991, ANCET, V337, P339; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; LANDI G, IN PRESS CEREBROVASC; LARSEN BH, 1990, J NEUROL NEUROSUR PS, V53, P1029, DOI 10.1136/jnnp.53.12.1029; LEE H, 1990, NEUROLOGY, V40, P165, DOI 10.1212/WNL.40.1.165; MEISSNER I, 1986, NEUROLOGY, V36, P1029, DOI 10.1212/WNL.36.8.1029; PORTENOY RK, 1984, STROKE, V15, P1009, DOI 10.1161/01.STR.15.6.1009; SHINAR D, 1987, ARCH NEUROL-CHICAGO, V44, P149, DOI 10.1001/archneur.1987.00520140021012; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOMASELLO F, 1982, STROKE, V13, P32, DOI 10.1161/01.STR.13.1.32; WAXMAN SG, 1983, STROKE, V14, P433, DOI 10.1161/01.STR.14.3.433; WIEBERS DO, 1982, NEUROLOGY, V32, P459, DOI 10.1212/WNL.32.5.459; YANAGIHARA T, 1985, ANN NEUROL, V18, P244, DOI 10.1002/ana.410180212	24	39	41	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					402	405		10.1016/0140-6736(92)90086-I	http://dx.doi.org/10.1016/0140-6736(92)90086-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346667				2022-12-24	WOS:A1992HD65900011
J	TABAR, L; FAGERBERG, G; DAY, NE; DUFFY, SW; KITCHIN, RM				TABAR, L; FAGERBERG, G; DAY, NE; DUFFY, SW; KITCHIN, RM			BREAST-CANCER-TREATMENT AND NATURAL-HISTORY - NEW INSIGHTS FROM RESULTS OF SCREENING	LANCET			English	Editorial Material							COMPARING TOTAL MASTECTOMY; TRIAL		MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; LINKOPING UNIV HOSP,DEPT DIAGNOST RADIOL,S-58185 LINKOPING,SWEDEN	MRC Biostatistics Unit; Linkoping University	TABAR, L (corresponding author), CENT HOSP FALUN,DEPT MAMMOG,S-79182 FALUN,SWEDEN.		Tabar, Laszlo Kornel/AGT-3287-2022					CHITTOOR SR, 1991, AM FAM PHYSICIAN, V44, P453; DUFFY SW, 1991, BRIT J CANCER, V64, P1133, DOI 10.1038/bjc.1991.477; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1980, CANCER RES, V40, P3863; FISHER ER, 1988, CONTROVERSIES BREAST, P151; MEYER JS, 1991, INT J CANCER, V47, P213, DOI 10.1002/ijc.2910470209; ROSNER D, 1990, CANCER, V66, P199, DOI 10.1002/1097-0142(19900715)66:2<199::AID-CNCR2820660202>3.0.CO;2-L; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TABAR L, IN PRESS RADIOL CLIN; TUBIANA M, 1991, BREAST CANCER RES TR, V18, P125, DOI 10.1007/BF01990028; 1992, LANCET, V339, P71	14	139	140	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					412	414		10.1016/0140-6736(92)90090-P	http://dx.doi.org/10.1016/0140-6736(92)90090-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346670				2022-12-24	WOS:A1992HD65900014
J	BRAEGGER, CP; NICHOLLS, S; MURCH, SH; STEPHENS, S; MACDONALD, TT				BRAEGGER, CP; NICHOLLS, S; MURCH, SH; STEPHENS, S; MACDONALD, TT			TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION	LANCET			English	Article							BOWEL-DISEASE	Measurement of disease activity in patients with inflammatory bowel disease is difficult. The best available methods are complex and time consuming, but it may be possible to use tumour necrosis factor alpha (TNF-alpha) concentration in stool as a marker of disease activity. We measured TNF-alpha concentrations in stool samples from normal children, infants with diarrhoea, and children with inflammatory bowel disease in active and inactive phases of the disease. In 10 normal children and 14 children with diarrhoea, median stool TNF-alpha concentrations were 58 and 45 pg/g stool, respectively. Compared with diarrhoeal controls, stool TNF-alpha concentrations were significantly increased in children with active Crohn's disease (n = 13, median 994 pg/g, p < 0.0002) and active ulcerative colitis (n = 4, range 276-5982 pg/g, p < 0.003). In patients with inactive disease, either as a result of surgery or treatment with steroids, the concentration of stool TNF-alpha fell to those of controls. Measurement of stool TNF-alpha concentations may provide a simple way to monitor disease activity in inflammatory bowel disease.	ST BARTHOLOMEWS HOSP,DEPT PAEDIAT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND; CELLTECH LTD,SLOUGH,BERKS,ENGLAND	University of London; Queen Mary University London; Celltech Group Ltd			Braegger, Christian Peter/ABC-9884-2021	Braegger, Christian/0000-0001-8069-9875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHONG SKF, 1984, BRIT MED J, V284, P101; DONNELLAN WL, 1966, GASTROENTEROLOGY, V50, P519; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; ELIAKIM R, 1988, GASTROENTEROLOGY, V95, P1176; LAURITSEN K, 1988, GASTROENTEROLOGY, V95, P11, DOI 10.1016/0016-5085(88)90284-3; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P351; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; SAVERYMUTTU SH, 1983, GASTROENTEROLOGY, V85, P1333; ZIFRONI A, 1983, GUT, V24, P659, DOI 10.1136/gut.24.7.659	10	600	626	1	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					89	91		10.1016/0140-6736(92)90999-J	http://dx.doi.org/10.1016/0140-6736(92)90999-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345871				2022-12-24	WOS:A1992GZ15600003
J	PELISKA, JA; BENKOVIC, SJ				PELISKA, JA; BENKOVIC, SJ			MECHANISM OF DNA STRAND TRANSFER-REACTIONS CATALYZED BY HIV-1 REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ROUS-SARCOMA VIRUS; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; RNASE-H; POLYMERASE; REPLICATION; SUBSTITUTIONS; MUTAGENESIS; HYDROLYSIS	Two DNA strand transfer reactions occur during retroviral reverse transcription. The mechanism of the first, minus strand strong-stop DNA, transfer has been studied in vitro with human immunodeficiency virus 1 reverse transcriptase (HIV-1 RT) and a model template-primer system derived from the HIV-1 genome. The results reveal that HIV-1 RT alone can catalyze DNA strand transfer reactions. Two kinetically distinct ribonuclease (RNase) H activities associated with HIV-1 RT are required for removal of RNA fragments annealed to the nascent DNA strand. Examination of the binding of DNA . RNA duplex and single-stranded RNA to HIV-1 RT during strand transfer supports a model where the enzyme accommodates both the acceptor RNA template and the nascent DNA strand before the transfer event is completed. The polymerase activity incorporated additional bases beyond the 5' end of the RNA template, resulting in a base misincorporation upon DNA strand transfer. Such a process occurring in vivo during retroviral homologous recombination could contribute to the hypermutability of the HIV-1 genome.			PELISKA, JA (corresponding author), PENN STATE UNIV, DEPT CHEM, University Pk, PA 16802 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008275] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08275] Funding Source: Medline; NIGMS NIH HHS [GM13306] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DARLIX JL, 1977, J VIROL, V23, P659, DOI 10.1128/JVI.23.3.659-668.1977; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, IN PRESS P NATL ACAD; GUISER RG, 1991, J BIOL CHEM, V266, P13103; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HUBER HE, 1989, J BIOL CHEM, V264, P4669; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sambrook J., 1989, MOL CLONING; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; YU H, 1992, J BIOL CHEM, V267, P10888	49	306	312	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1112	1118		10.1126/science.1279806	http://dx.doi.org/10.1126/science.1279806			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1279806				2022-12-24	WOS:A1992JX85200020
J	NIGHTINGALE, SL				NIGHTINGALE, SL			1ST DRUG AVAILABLE UNDER PARALLEL TRACK POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-24	WOS:A1992JW61600005
J	DURAND, B; SAUNDERS, M; LEROY, P; LEID, M; CHAMBON, P				DURAND, B; SAUNDERS, M; LEROY, P; LEID, M; CHAMBON, P			ALL-TRANS AND 9-CIS RETINOIC ACID INDUCTION OF CRABPII TRANSCRIPTION IS MEDIATED BY RAR-RXR HETERODIMERS BOUND TO DR1 AND DR2 REPEATED MOTIFS	CELL			English	Article							BINDING-PROTEIN GENE; HORMONE RECEPTOR SUPERFAMILY; RESPONSE ELEMENT; MOLECULAR-CLONING; NUCLEAR RECEPTORS; TERATOCARCINOMA CELLS; DIFFERENTIAL PATTERN; NEGATIVE REGULATION; THYROID-HORMONE; MESSENGER-RNA	Two cooperating retinoic acid response elements (RAREs) in the cellular retinoic acid-binding protein II (CRABPII) gene mediate differential transcriptional transactivation by retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in P19 embryonal carcinoma cells. RARE1 and RARE2 are direct repeats (DR) of two motifs separated by 2 bp (DR2) and 1 bp (DR1), respectively, and bind RAR-RXR heterodimers more efficiently than homodimers. Using all-trans and 9-cis RA, which differentially activate RARs and RXRs, and RAR and RXR dominant-negative mutants, RAR-RXR heterodimers bound to RARE1 and RARE2 are shown to be responsible for CRABPII promoter transactivation, arguing against a unique DR spacing specifying recognition by RARs. Within heterodimers, RAR and RXR independently and differentially transactivate, depending on the specific RARE. Consistent with these results, 9-cis RA increases CRABPII mRNA levels more efficiently than all-trans RA. In contrast, all-trans and 9-cis RA have identical effects on induction of RARbeta2 transcripts.			DURAND, B (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,INSERM,GENET MOLEC EUCARYOTES LAB, CNRS, UNITE 184, F-67085 STRASBOURG, FRANCE.		DURAND, Beatrice C/J-6387-2015	DURAND, Beatrice C/0000-0002-0047-288X				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BALLING R, 1991, TRENDS GENET, V7, P35; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BOCQUEL MT, IN PRESS; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BREITMAN TR, 1981, BLOOD, V57, P1000; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHYTIL F, 1991, RETINOIDS : 10 YEARS ON, P38; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DE LUCA LM, 1991, FASEB J, V5, P2924; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIDIERJEAN L, 1991, BIOCHEM BIOPH RES CO, V180, P204, DOI 10.1016/S0006-291X(05)81277-X; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KASTNER P, 1992, DEV PATTERNING VERTE, P75; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEROY P, 1992, RETINOIDS NORMAL DEV, P7; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIBBY PR, 1982, CARCINOGENESIS, V3, P481, DOI 10.1093/carcin/3.5.481; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MADEN M, 1989, DEVELOPMENT, V107, P109; Maden M., 1991, SEMIN DEV BIOL, V2, P161; MADER S, 1992, IN PRESS J BIOL CHEM, V267; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, IN PRESS CELL, V70; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTSON M, 1987, NATURE, V330, P420, DOI 10.1038/330420a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROSENBERGER M, 1992, IN PRESS P NATL ACAD, V89; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; RUBERTE E, 1992, IN PRESS DEVELOPMENT; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAURAT JH, 1990, RETINOIDS 10 YEARS; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SIEGENTHALER G, 1990, RETINOIDS 10 YEARS, P56; SMITH SM, 1989, DEVELOPMENT, V107, P121; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STONER CM, 1989, CANCER RES, V49, P1497; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WEI LN, 1991, DEVELOPMENT, V112, P847; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	91	409	417	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					73	85		10.1016/0092-8674(92)90267-G	http://dx.doi.org/10.1016/0092-8674(92)90267-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1327537	Green Published			2022-12-24	WOS:A1992JQ62300008
J	WIEBEL, FF; KUNAU, WH				WIEBEL, FF; KUNAU, WH			THE PAS2 PROTEIN ESSENTIAL FOR PEROXISOME BIOGENESIS IS RELATED TO UBIQUITIN-CONJUGATING ENZYMES	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ENCODES; GENE; DEGRADATION; MEMBER; FIBROBLASTS; FAMILY; SYSTEM	IN the yeast Saccharomyces cerevisiae, PAS genes are essential for the biogenesis and proliferation of peroxisomes1,2. Recently, the first two genes, PAS1 (ref. 3) and PAS3 (ref. 4), have been characterized. Here we report the cloning and sequencing of the PAS2 gene. It encodes a new member of the ubiquitin-conjugating (UBC) protein family5-7 and is the first member associated with peroxisomes. The proposed function of the Pas2 protein as a UBC enzyme (UBC10) is supported by the fact that site-directed mutagenesis of a strictly conserved and functionally essential cysteine residue of UBC proteins leads to mutant Pas2 proteins unable to complement pas2 mutant strains. Ubiquitination of proteins is known to play an important part in DNA repair, sporulation, cell cycle control and degradation of abnormal proteins5-8. We provide evidence for a crucial role of the ubiquitin-conjugation pathway in organelle formation.			WIEBEL, FF (corresponding author), RUHR UNIV BOCHUM,INST PHYSIOL CHEM,ZELLBIOCHEM ABT,W-4630 BOCHUM 1,GERMANY.							DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; ERDMANN R, IN PRESS CELL BIOCH; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; HOHFELD J, IN PRESS NEW COMPREH; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; QIN S, 1991, J BIOL CHEM, V266, P15549; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; Rose MD., 1990, METHODS YEAST GENETI; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	23	170	175	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					73	76		10.1038/359073a0	http://dx.doi.org/10.1038/359073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1326082				2022-12-24	WOS:A1992JL66200057
J	YOSHIKAWA, K; AIZAWA, T; HAYASHI, Y				YOSHIKAWA, K; AIZAWA, T; HAYASHI, Y			DEGENERATION INVITRO OF POSTMITOTIC NEURONS OVEREXPRESSING THE ALZHEIMER AMYLOID PROTEIN-PRECURSOR	NATURE			English	Article							CARCINOMA CELL-LINE; SENILE PLAQUES; DOWNS-SYNDROME; MESSENGER-RNA; DISEASE; DIFFERENTIATION; EXPRESSION; LOCALIZATION; MICROGLIA; PEPTIDE	A PATHOLOGICAL hallmark of Alzheimer's disease is the deposition of amyloid fibrils in the brain. The principal component of amyloid fibrils is beta/A4 amyloid protein1,2, which can be generated by the aberrant processing of a large membrane-bound glycoprotein, the beta/A4 amyloid protein precursor (App)3. To test whether overexpression of APP generates abnormally processed derivatives that affect the viability of neurons, we stably transfected full-length human APP complementary DNA into murine embryonal carcinoma P19 cells. These cells differentiate into post-mitotic neurons and astrocytes after exposure to retinoic acid4-6. When differentiation of the APP cDNA-transfected P19 cells was induced, all neurons showed severe degenerative changes and disappeared within a few days. The degenerating neurons contained large amounts of APP derivatives that were truncated at the amino terminus and encompassed the entire beta/A4 domain. These results suggest that post-mitotic neurons are vulnerable to overexpressed APP, which undergoes aberrant processing to generate potentially amyloidogenic fragments.	TOKYO INST PSYCHIAT, DEPT MOLEC BIOL, SETAGAYA KU, TOKYO 153, JAPAN; MORINAGA MILK IND CO LTD, BIOCHEM RES LAB, KANAGAWA 228, JAPAN	Tokyo Institute of Psychiatry; Morinaga Milk Industry Company, Ltd								AIZAWA T, 1991, DEV BRAIN RES, V59, P89, DOI 10.1016/0165-3806(91)90033-F; ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PROBST A, 1991, ACTA NEUROPATHOL, V83, P21, DOI 10.1007/BF00294426; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOSHIKAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P204, DOI 10.1016/0006-291X(90)91377-5	28	182	185	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					64	67		10.1038/359064a0	http://dx.doi.org/10.1038/359064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1301020				2022-12-24	WOS:A1992JL66200054
J	BAUER, PH; MULLER, S; PUZICHA, M; PIPPIG, S; OBERMAIER, B; HELMREICH, EJM; LOHSE, MJ				BAUER, PH; MULLER, S; PUZICHA, M; PIPPIG, S; OBERMAIER, B; HELMREICH, EJM; LOHSE, MJ			PHOSDUCIN IS A PROTEIN KINASE-A-REGULATED G-PROTEIN REGULATOR	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; PURIFICATION; BOVINE; DESENSITIZATION; PHOSPHOPROTEIN; TRANSDUCIN; COMPONENT; ARRESTIN; COMPLEX	SIGNAL transduction by G-protein-coupled receptors is regulated by various mechanisms acting at the receptor level; those studied most thoroughly are from the beta-adrenergic receptor/G(s)/adenylyl cyclase system 1-3. We report here a regulatory mechanism occurring at the level of the G proteins themselves. A protein with M(r) 33,000 that inhibits G(s)-GTPase activity was purified from bovine brain. This protein is very similar or identical to phosducin, a protein previously thought to be specific for retina and pineal gland 4-8. Recombinant phosducin inhibited the GTPase activity of several G proteins, and also inhibited G(s)-mediated adenylyl cyclase activation. Blockade of its inhibitory effects by protein kinase A suggests that phosducin may be part of a complex regulatory network controlling G-protein-mediated signalling.	UNIV WURZBURG,DEPT PHYSIOL CHEM,W-8700 WURZBURG,GERMANY	University of Wurzburg	BAUER, PH (corresponding author), UNIV MUNICH,MAX PLANCK INST BIOCHEM,MOLEC BIOL LAB,W-8033 MARTINSRIED,GERMANY.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4519; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; KUO CH, 1989, BIOCHEM BIOPH RES CO, V162, P1063, DOI 10.1016/0006-291X(89)90781-X; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LOHSE MJ, 1986, MOL PHARMACOL, V30, P403; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3210; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOHSE MJ, 1992, SIGNAL TRANSMISSION, P160; REIG JA, 1990, J BIOL CHEM, V265, P5816; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	30	184	185	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					73	76		10.1038/358073a0	http://dx.doi.org/10.1038/358073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1319556				2022-12-24	WOS:A1992JB34100057
J	CULVER, KW; RAM, Z; WALLBRIDGE, S; ISHII, H; OLDFIELD, EH; BLAESE, RM				CULVER, KW; RAM, Z; WALLBRIDGE, S; ISHII, H; OLDFIELD, EH; BLAESE, RM			INVIVO GENE-TRANSFER WITH RETROVIRAL VECTOR PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN-TUMORS	SCIENCE			English	Article							THYMIDINE KINASE GENES; RAT-BRAIN; INTERLEUKIN-2; POTENT	Direct in situ introduction of exogenous genes into proliferating tumors could provide an effective therapeutic approach for treatment of localized tumors. Rats with a cerebral glioma were given an intratumoral stereotaxic injection of murine fibroblasts that were producing a retroviral vector in which the herpes simplex thymidine kinase (HS-tk) gene had been inserted. After 5 days during which the HS-tk retroviral vectors that were produced in situ transduced the neighboring proliferating glioma cells, the rats were treated with the anti-herpes drug ganciclovir. Gliomas in the ganciclovir- and vector-treated rats regressed completely both macroscopically and microscopically. This technique exploits what was previously considered to be a disadvantage of retroviral vectors-that is, their inability to transfer genes into nondividing cells. Instead, this feature of retroviruses is used to target gene delivery to dividing tumor cells and to spare nondividing neural tissue.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	CULVER, KW (corresponding author), NCI,METAB BRANCH,CELLULAR IMMUNOL SECT,BETHESDA,MD 20892, USA.							BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CULVER KW, UNPUB; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GANSBACHER B, 1990, CANCER RES, V50, P7820; ISHII H, UNPUB; ITAYA T, 1987, CANCER RES, V47, P3136; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0	17	1486	1680	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1550	1552		10.1126/science.1317968	http://dx.doi.org/10.1126/science.1317968			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317968				2022-12-24	WOS:A1992HY07500027
J	SCHWEIGHOFFER, F; BARLAT, I; CHEVALLIERMULTON, MC; TOCQUE, B				SCHWEIGHOFFER, F; BARLAT, I; CHEVALLIERMULTON, MC; TOCQUE, B			IMPLICATION OF GAP IN RAS-DEPENDENT TRANSACTIVATION OF A POLYOMA ENHANCER SEQUENCE	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; RAS-P21 GTPASE; INHIBITION; DOMAIN; CELLS; P21; TRANSFORMATION; ONCOGENES; MUTANT	Controversy exists as to whether the interaction of a guanosine triphosphatase activating protein (GAP) with Ras proteins functions both to initiate and to terminate Ras-dependent signaling events or only to terminate them. GAP-C, a carboxyl-terminal fragment of GAP that is sufficient to stimulate GTPase activity, inhibited the stimulation of transcription produced by some oncoproteins (v-Src, polyoma middle T, wild-type Ras, and oncogenic Ras) but not that produced by v-Mos. Wild-type GAP did not affect transcription induced by oncogenic Ras but reversed the inhibitory effect of GAP-C on transcription induced by oncogenic Ras. These results indicate that GAP is a negative regulator of wild-type Ras and elicits a downstream signal by interacting with Ras-GTP (guanosine triphosphate).			SCHWEIGHOFFER, F (corresponding author), RHONE POULENC RORER, CTR RECH VITRY ALFORTVILLE, 13 QUAI JULES GUESDE, BP 14, F-94403 Vitry Sur Seine, FRANCE.							BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATA Y, 1990, J BIOL CHEM, V265, P7104; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; REY I, 1991, ONCOGENE, V6, P347; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHWEIGHOFFER F, UNPUB; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	32	57	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					825	827		10.1126/science.1317056	http://dx.doi.org/10.1126/science.1317056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1317056				2022-12-24	WOS:A1992HT23500041
J	MCCARRON, JG; MCGEOWN, JG; REARDON, S; IKEBE, M; FAY, FS; WALSH, JV				MCCARRON, JG; MCGEOWN, JG; REARDON, S; IKEBE, M; FAY, FS; WALSH, JV			CALCIUM-DEPENDENT ENHANCEMENT OF CALCIUM CURRENT IN SMOOTH-MUSCLE BY CALMODULIN-DEPENDENT PROTEIN KINASE-II	NATURE			English	Article							LIGHT-CHAIN KINASE; INTRACELLULAR CALCIUM; CA-2+ CURRENT; CELLS; CHANNELS; PHOSPHORYLATION; BINDING; SITE; IDENTIFICATION; ACETYLCHOLINE	CALCIUM entry through voltage-activated Ca2+ channels is important in regulating many cellular functions. Activation of these channels in many cell types results in feedback regulation of channel activity 1. Mechanisms linking Ca2+ channel activity with its downregulation have been described 2,3, but little is known of the events responsible for the enhancement of Ca2+ current that in many cells follows Ca2+ channel activation and an increase in cytoplasmic Ca2+ concentration 4,5. Here we investigate how this positive feedback is achieved in single smooth muscle cells. We find that in these cells voltage-activated calcium current is persistently but reversibly enhanced after periods of activation. This persistent enhancement of the Ca2+ current is mediated by activation of calmodulin-dependent protein kinase II because it is blocked when either the rise in cytoplasmic Ca2+ is inhibited or activation of calmodulin-dependent protein kinase II is prevented by specific peptide inhibitors of calcium-calmodulin or calmodulin-dependent protein kinase II itself. This mechanism may be important in different forms of Ca2+ current potentiation, such as those that depend on prior Ca2+ channel activation or are a result of agonist-induced release of Ca2+ from internal stores.	UNIV MASSACHUSETTS,MED CTR,DEPT PHYSIOL,WORCESTER,MA 01655; CASE WESTERN RESERVE UNIV,COLL MED,DEPT PHYSIOL,CLEVELAND,OH 44106	University of Massachusetts System; University of Massachusetts Worcester; Case Western Reserve University	MCCARRON, JG (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,BIOMED IMAGING GRP,WORCESTER,MA 01655, USA.							ARMSTRONG D, 1988, J GEN PHYSIOL, V92, pA10; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BENHAM CD, 1987, CIRC RES, V61, P10; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CLAPP LH, 1987, P NATL ACAD SCI USA, V84, P2092, DOI 10.1073/pnas.84.7.2092; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; FAY FS, 1973, P NATL ACAD SCI USA, V70, P641, DOI 10.1073/pnas.70.3.641; FAY FS, 1982, METHOD ENZYMOL, V85, P284; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P11242, DOI 10.1021/bi00503a013; IKEBE M, 1990, BIOCHEM BIOPH RES CO, V168, P714, DOI 10.1016/0006-291X(90)92380-I; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1990, J BIOL CHEM, V265, P17607; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; LUCCHESI P, 1989, AM J PHYSIOL, V255, pC226; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VIVAUDOU MB, 1991, PFLUG ARCH EUR J PHY, V418, P144, DOI 10.1007/BF00370463; VIVAUDOU MB, 1988, FASEB J, V2, P2497, DOI 10.1096/fasebj.2.9.2453389; WALSH JV, 1987, PFLUG ARCH EUR J PHY, V408, P83, DOI 10.1007/BF00581336; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WILLIAMS DA, 1986, AM J PHYSIOL, V250, pC779, DOI 10.1152/ajpcell.1986.250.5.C779; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	33	127	128	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					74	77		10.1038/357074a0	http://dx.doi.org/10.1038/357074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1315424				2022-12-24	WOS:A1992HT22900061
J	CEDERGRENZEPPEZAUER, ES; LARSSON, G; NYMAN, PO; DAUTER, Z; WILSON, KS				CEDERGRENZEPPEZAUER, ES; LARSSON, G; NYMAN, PO; DAUTER, Z; WILSON, KS			CRYSTAL-STRUCTURE OF A DUTPASE	NATURE			English	Article							DEOXYURIDINE TRIPHOSPHATE NUCLEOTIDOHYDROLASE; TUMOR NECROSIS FACTOR; ESCHERICHIA-COLI; RESOLUTION; PURIFICATION; SEQUENCE; PROTEIN; BINDING	THE enzyme dUTPase catalyses the hydrolysis of dUTP1 and maintains a low intracellular concentration of dUTP so that uracil cannot be incorporated into DNA 2. dUTPase from Escherichia coli is strictly specific for its dUTP substrate 3, the active site discriminating between nucleotides with respect to the sugar moiety as well as the pyrimidine base. Here we report the three-dimensional structure of E. coli dUTPase determined by X-ray crystallography at a resolution of 1.9 angstrom. The enzyme is a symmetrical trimer, and of the 152 amino acid residues in the subunit, the first 136 are visible in the crystal structure. The tertiary structure resembles a jelly-roll fold and does not show the 'classical' nucleotide-binding domain. In the quaternary structure there is a complex interaction between the subunits that may be important in catalysis. This possibility is supported by the location of conserved elements in the sequence.	UNIV LUND,CTR CHEM,DEPT BIOCHEM,S-22100 LUND,SWEDEN; DESY,EUROPEAN MOLEC BIOL LAB,W-2000 HAMBURG 52,GERMANY	Lund University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	CEDERGRENZEPPEZAUER, ES (corresponding author), UNIV STOCKHOLM,WENNER GREN INST,DEPT ZOOL CELL BIOL,S-10691 STOCKHOLM,SWEDEN.			Wilson, Keith/0000-0002-3581-2194				BERTANI LE, 1963, J BIOL CHEM, V238, P3407; BRANDEN CI, 1991, INTRO PROTEIN STRUCT, P70; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CEDERGRENZEPPEZAUER ES, 1988, PROTEINS, V4, P71, DOI 10.1002/prot.340040110; ECK MJ, 1989, J BIOL CHEM, V264, P17595; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HOFFMANN I, 1987, EUR J BIOCHEM, V164, P45, DOI 10.1111/j.1432-1033.1987.tb10990.x; HOFFMANN I, 1988, THESIS U SAARBRUCKEN; HOKARI S, 1987, ARCH BIOCHEM BIOPHYS, V253, P350, DOI 10.1016/0003-9861(87)90188-3; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kornberg A., 1991, DNA REPLICATION; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LUNDBERG LG, 1983, EMBO J, V2, P967, DOI 10.1002/j.1460-2075.1983.tb01529.x; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; WANG BC, 1985, METHOD ENZYMOL, V115, P90	19	140	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					740	743		10.1038/355740a0	http://dx.doi.org/10.1038/355740a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1311056				2022-12-24	WOS:A1992HE60400069
J	BALDWIN, CT; HOTH, CF; AMOS, JA; DASILVA, EO; MILUNSKY, A				BALDWIN, CT; HOTH, CF; AMOS, JA; DASILVA, EO; MILUNSKY, A			AN EXONIC MUTATION IN THE HUP2 PAIRED DOMAIN GENE CAUSES WAARDENBURG SYNDROME	NATURE			English	Article							SYNDROME TYPE-I; MOUSE; DNA; BOX	HERE We report the identification and characterization of a gene defect causing Waardenburg's syndrome with hearing loss in a large Brazilian family. This demonstrates a mutation causing Waardenburg's syndrome as well as a mutation causing a form of congenital deafness. The mutation was found in the HuP2 gene, a member of the paired domain family of proteins that bind DNA and regulate gene expression 1. The mutation occurred in 100% of the cases with the disease in this family and was absent in a random sample of 50 unrelated control subjects. Identification of the Waardenburg's syndrome gene and future characterization of its gene product is likely to increase our understanding of the pathogenesis of this disorder and may allow prevention of deafness of this type.	BOSTON UNIV, SCH MED, CTR HUMAN GENET, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02118 USA; FED UNIV PUERNAMBUCO, INST MATERNOINFANTIL PERNAMBUCO, RECIFE, PE, BRAZIL; FED UNIV PUERNAMBUCO, DEPT GENET, RECIFE, PE, BRAZIL	Boston University; Boston University				Milunsky, Aubrey/0000-0003-2114-4823; Baldwin, Clinton/0000-0002-3275-9463				ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; DASILVA EO, 1991, AM J MED GENET, V40, P65, DOI 10.1002/ajmg.1320400113; EPSTEIN D, 1991, CELL, V67, P1; FOY C, 1990, AM J HUM GENET, V46, P1017; GANGULY A, 1991, J BIOL CHEM, V266, P12035; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAGEMAN MJ, 1977, AM J HUM GENET, V29, P468; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; ISHIKIRIYAMA S, 1989, AM J MED GENET, V33, P505, DOI 10.1002/ajmg.1320330419; PROCKOP DJ, 1990, ADV HUM GENET, V19, P105; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALKI RK, 1966, SCIENCE, V80, P222; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; Tsui LC, 1991, CURR OPIN GENET DEV, V1, P4, DOI 10.1016/0959-437X(91)80032-H; WAARDENBURG PJ, 1951, AM J HUM GENET, V3, P195; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; White R, 1991, CURR OPIN GENET DEV, V1, P15, DOI 10.1016/0959-437X(91)80034-J	22	428	434	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1992	355	6361					637	638		10.1038/355637a0	http://dx.doi.org/10.1038/355637a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1347149				2022-12-24	WOS:A1992HD54700055
J	LI, L; JAMES, G; HELLERHARRISON, R; CZECH, MP; OLSON, EN				LI, L; JAMES, G; HELLERHARRISON, R; CZECH, MP; OLSON, EN			FGF INACTIVATES MYOGENIC HELIX-LOOP-HELIX PROTEINS THROUGH PHOSPHORYLATION OF A CONSERVED PROTEIN-KINASE-C SITE IN THEIR DNA-BINDING DOMAINS	CELL			English	Article							MUSCLE-SPECIFIC ENHANCER; FIBROBLAST GROWTH-FACTOR; H-RAS ONCOGENE; GENE-EXPRESSION; MYC HOMOLOGY; ACTIVATION; MYOD1; DIFFERENTIATION; SEQUENCE; REGION	Myogenin belongs to a family of myogenic helix-loop-helix (HLH) proteins that activate muscle transcription through binding to a conserved DNA sequence associated with numerous muscle-specific genes. Fibroblast growth factor (FGF) inhibits myogenesis by inactivating myogenic HLH proteins. We show that activated protein kinase C (PKC) can substitute for FGF and inhibit transcriptional activity of myogenic HLH proteins. In transfected cells, FGF induces phosphorylation of a conserved site in the DNA-binding domain of myogenin. This site is phosphorylated by PKC in vivo and in vitro and mediates repression of the myogenic program through a loss in DNA binding activity. A myogenin mutant lacking the PKC phosphorylation site is not repressed by FGF, confirming this site as a molecular target for FGF-dependent repression of muscle transcription. These results establish a direct link between the signal transduction pathways that inhibit myogenesis and the transcription factors directly activating muscle-specific genes.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	LI, L (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.				NIAMS NIH HHS [AR 39849, AR 40339] Funding Source: Medline; NIDDK NIH HHS [DK 30648] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039849, R01AR040339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUANNO S, 1990, CANCER RES, V50, P3377; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COHEN R, 1977, NATURE, V266, P538, DOI 10.1038/266538a0; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAS P, 1990, AM J PATHOL, V137, P1283; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Gorman C., 1985, DNA CLONING, V2; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIM SJ, 1992, J BIOL CHEM, V267, P15140; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OLSON EN, 1992, IN PRESS DEV BIOL; RAPP UR, 1991, ONCOGENE, V6, P495; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TONIN PN, 1991, CANCER RES, V51, P5100; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VINSON CR, 1992, NEW BIOL, V4, P396; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZHU YY, 1991, J CELL BIOL, V115, P745, DOI 10.1083/jcb.115.3.745	66	321	324	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1181	1194		10.1016/S0092-8674(05)80066-2	http://dx.doi.org/10.1016/S0092-8674(05)80066-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335366				2022-12-24	WOS:A1992KE60400012
J	YAN, Q; ELLIOTT, J; SNIDER, WD				YAN, Q; ELLIOTT, J; SNIDER, WD			BRAIN-DERIVED NEUROTROPHIC FACTOR RESCUES SPINAL MOTOR NEURONS FROM AXOTOMY-INDUCED CELL-DEATH	NATURE			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; RETROGRADE TRANSPORT; CORD MOTONEURONS; DEVELOPING RATS; FACTOR FAMILY; TRKB; NGF; EXPRESSION; MEMBER	CURRENT ideas about the dependence of neurons on target-derived growth factors were formulated on the basis of experiments involving neurons with projections to the periphery1,2. Nerve growth factor (NGF) and recently identified members of the NGF family of neuronal growth factors, known as neurotrophins, are thought to regulate survival of sympathetic and certain populations of sensory ganglion cells during development3-8. Far less is known about factors that regulate the survival of spinal and cranial motor neurons, which also project to peripheral targets. NGF has not been shown to influence motor neuron survival9,10, and whether the newly identified neurotrophins promote motor neuron survival is unknown. We show here that brain-derived neurotrophic factor (BDNF) is retrogradely transported by motor neurons in neonatal rats and that local application of BDNF to transected sciatic nerve prevents the massive death of motor neurons that normally follows axotomy in the neonatal period. These results show that BDNF has survival-promoting effects on motor neurons in vivo and suggest that BDNF may influence motor neuron survival during development.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL SURG NEUROL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	YAN, Q (corresponding author), AMGEN INC,AMGEN CTR,NEUROBIOL PROGRAM,THOUSAND OAKS,CA 91320, USA.							ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; KASHIHARA Y, 1987, J PHYSIOL-LONDON, V386, P135, DOI 10.1113/jphysiol.1987.sp016526; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WAYNE DB, 1988, DEV BIOL, V127, P220, DOI 10.1016/0012-1606(88)90203-5; YAN Q, 1988, NEURON, V1, P335; YAN Q, 1988, J NEUROSCI, V8, P3481; YAN Q, 1991, Society for Neuroscience Abstracts, V17, P1119	31	633	680	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					753	755		10.1038/360753a0	http://dx.doi.org/10.1038/360753a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1281520				2022-12-24	WOS:A1992KE47200037
J	PEANO, GM; FENOGLIO, LM; MENARDI, G; BALBO, R; MARENCHINO, D; FENOGLIO, S				PEANO, GM; FENOGLIO, LM; MENARDI, G; BALBO, R; MARENCHINO, D; FENOGLIO, S			HETEROSEXUAL TRANSMISSION OF HEPATITIS-C VIRUS IN FAMILY GROUPS WITHOUT RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							NON-B-HEPATITIS; SEXUAL TRANSMISSION; NON-A		OSPED S CROCE,SERV IMMUNOEMATOL & TRASFUSIONALE,USL 58,BLOOD BANK UNIT,MED STAFF,CUNEO,ITALY; UNIV TURIN,MED CLIN B,DIV MED GEN 1,I-10124 TURIN,ITALY	University of Turin	PEANO, GM (corresponding author), VIA Q SELLA 22,I-12100 CUNEO,ITALY.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; KIYOSAWA K, 1991, J MED VIROL, V33, P114, DOI 10.1002/jmv.1890330209; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; TEDDER RS, 1991, BRIT MED J, V302, P1299, DOI 10.1136/bmj.302.6788.1299	5	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1473	1474		10.1136/bmj.305.6867.1473	http://dx.doi.org/10.1136/bmj.305.6867.1473			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1283543	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992KC91800023
J	KITAJIMA, I; SHINOHARA, T; BILAKOVICS, J; BROWN, DA; XU, X; NERENBERG, M				KITAJIMA, I; SHINOHARA, T; BILAKOVICS, J; BROWN, DA; XU, X; NERENBERG, M			ABLATION OF TRANSPLANTED HTLV-I TAX-TRANSFORMED TUMORS IN MICE BY ANTISENSE INHIBITION OF NF-KAPPA-B	SCIENCE			English	Article							T-CELL LEUKEMIA; HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR; TRANSGENIC MICE; RETROVIRUS; EXPRESSION; LYMPHOMA; PROTEIN; GENE; OLIGODEOXYNUCLEOTIDES	Mice transgenic for the human T cell leukemia virus (HTLV-1) Tax gene develop fibroblastic tumors that express NF-kappaB-inducible early genes. In vitro inhibition of NF-kappaB expression by antisense oligodeoxynucleotides (ODNs) inhibited growth of these culture-adapted Tax-transformed fibroblasts as well as an HTLV-I-transformed human lymphocyte line. In contrast, antisense inhibition of Tax itself had no apparent effect on cell growth. Mice treated with antisense to NF-kappaB ODNs showed rapid regression of transplanted fibrosarcomas. This suggests that NF-kappaB expression may be necessary for the maintenance of the malignant phenotype and provides a therapeutic approach for HTLV-I-associated disease.	Scripps Res Inst, DEPT NEUROPHARMACOL, CVN 10, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCI NIH HHS [CA50234] Funding Source: Medline; NIMH NIH HHS [MH47680] Funding Source: Medline; NINDS NIH HHS [NS01330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V63, P1072; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; FELGNER PL, 1988, P NATL ACAD SCI USA, V85, P7413; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, UNPUB; KITAJIMA I, IN PRESS J BIOL CHEM; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MACGREGOR GR, 1989, METHODS MOL BIOL; MILLER PS, 1980, J BIOL CHEM, V255, P9659; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	27	270	295	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1792	1795		10.1126/science.1299224	http://dx.doi.org/10.1126/science.1299224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1299224				2022-12-24	WOS:A1992KB96400038
J	PELLETIER, H; KRAUT, J				PELLETIER, H; KRAUT, J			CRYSTAL-STRUCTURE OF A COMPLEX BETWEEN ELECTRON-TRANSFER PARTNERS, CYTOCHROME-C PEROXIDASE AND CYTOCHROME-C	SCIENCE			English	Article							SITE-DIRECTED MUTANTS; FERROCYTOCHROME-C; COMPOUND-I; 3-DIMENSIONAL STRUCTURE; PARAMAGNETIC RESONANCE; CHEMICAL MODIFICATION; ESCHERICHIA-COLI; BINDING DOMAINS; RADICAL SITE; RESOLUTION	The crystal structure of a 1:1 complex between yeast cytochrome c peroxidase and yeast iso-1-cytochrome c was determined at 2.3 angstrom resolution. This structure reveals a possible electron transfer pathway unlike any previously proposed for this extensively studied redox pair. The shortest straight line between the two hemes closely follows the peroxidase backbone chain of residues Ala194, Ala193, Gly192, and finally Trp191, the indole ring of which is perpendicular to, and in van der Waals contact with, the peroxidase heme. The crystal structure at 2.8 angstrom of a complex between yeast cytochrome c peroxidase and horse heart cytochrome c was also determined. Although crystals of the two complexes (one with cytochrome c from yeast and the other with cytochrome c from horse) grew under very different conditions and belong to different space groups, the two complex structures are closely similar, suggesting that cytochrome c interacts with its redox partners in a highly specific manner.			PELLETIER, H (corresponding author), UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA.				NIDDK NIH HHS [DK07233] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND P, 1991, STRUCT BOND, V75, P1; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, pCH3; BRUNGER AT, 1990, XPLOR MANUAL; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CORIN AF, 1991, BIOCHEMISTRY-US, V30, P11585, DOI 10.1021/bi00113a014; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HILDEBRANDT P, 1992, BIOCHEMISTRY-US, V31, P2384, DOI 10.1021/bi00123a025; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; KANG CH, 1978, J BIOL CHEM, V253, P6502; Keilin D, 1929, P R SOC LOND B-CONTA, V104, P206, DOI 10.1098/rspb.1929.0009; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; KIM KL, 1990, BIOCHEMISTRY-US, V29, P9150, DOI 10.1021/bi00491a008; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1465, DOI 10.1021/bi00704a023; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LUM VR, 1987, PROTEIN STRUCTURE FO, V2, P143; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; MAUK AG, 1991, STRUCT BOND, V75, P131; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MCLENDON G, 1991, STRUCT BOND, V75, P159; MILLER MA, 1988, BIOCHEMISTRY-US, V27, P9081, DOI 10.1021/bi00426a003; MILLER MA, 1992, BIOCHEMISTRY-US, V31, P2789, DOI 10.1021/bi00125a020; MOCHAN E, 1971, BIOCHEM J, V121, P69, DOI 10.1042/bj1210069; MOENCH SJ, 1992, BIOCHEMISTRY-US, V31, P3661, DOI 10.1021/bi00129a015; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; OCHI H, 1983, J MOL BIOL, V166, P407, DOI 10.1016/S0022-2836(83)80092-8; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; PELLETIER H, 1992, THESIS U CALIFORNIA; POULOS TL, 1980, J BIOL CHEM, V255, P322; POULOS TL, 1987, J BIOL CHEM, V262, P13881; SALEMME FR, 1973, J BIOL CHEM, V248, P7701; SCHOLES CP, 1989, ISRAEL J CHEM, V29, P85; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH L, 1965, BIOCHIM BIOPHYS ACTA, V105, P1, DOI 10.1016/S0926-6593(65)80170-9; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; YONETANI T, COMMUNICATION; [No title captured]; 1988, MERLOT MANUAL	47	720	723	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1992	258	5089					1748	1755		10.1126/science.1334573	http://dx.doi.org/10.1126/science.1334573			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1334573				2022-12-24	WOS:A1992KB96400026
J	TROELSTRA, C; VANGOOL, A; DEWIT, J; VERMEULEN, W; BOOTSMA, D; HOEIJMAKERS, JHJ				TROELSTRA, C; VANGOOL, A; DEWIT, J; VERMEULEN, W; BOOTSMA, D; HOEIJMAKERS, JHJ			ERCC6, A MEMBER OF A SUBFAMILY OF PUTATIVE HELICASES, IS INVOLVED IN COCKAYNES-SYNDROME AND PREFERENTIAL REPAIR OF ACTIVE GENES	CELL			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; NUCLEOTIDE EXCISION REPAIR; 7TH COMPLEMENTATION GROUP; STRAND-SPECIFIC REPAIR; CHINESE-HAMSTER CELLS; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; ESCHERICHIA-COLI; CDNA CLONING	Cells from patients with the UV-sensitive nucleotide excision repair disorder Cockayne's syndrome (CS) have a specific defect in preferential repair of lesions from the transcribed strand of active genes. This system permits quick resumption of transcription after UV exposure. Here we report the characterization of ERCC6, a gene involved in preferential repair in eukaryotes. ERCC6 corrects the repair defect of CS complementation group B (CS-B). It encodes a protein of 1493 amino acids, containing seven consecutive domains conserved between DNA and RNA helicases. The entire helicase region bears striking homology to segments in recently discovered proteins involved in transcription regulation, chromosome stability, and DNA repair. Mutation analysis of a CS-B patient indicates that the gene is not essential for cell viability and is specific for preferential repair of transcribed sequences.			TROELSTRA, C (corresponding author), ERASMUS UNIV, CTR MED GENET, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS.		van Gool, Alain J/G-3806-2010; Hoeijmakers, Jan/AAX-6972-2021; Vermeulen, Wim/W-8708-2019; van Gool, Alain J./L-4328-2015	Vermeulen, Wim/0000-0003-3616-734X; van Gool, Alain/0000-0003-0010-5286				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; [Anonymous], 1985, DNA REPAIR; ARLETT CF, 1982, INDUCED MUTAGENESIS, P249; BANG DD, 1992, IN PRESS NUCL ACIDS; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BUDD M, 1982, MUTAT RES, V103, P19, DOI 10.1016/0165-7992(82)90080-X; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DEWEERDK.EA, 1972, NATURE-NEW BIOL, V238, P80, DOI 10.1038/newbio238080a0; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRYNS JP, 1991, AM J MED GENET, V40, P343, DOI 10.1002/ajmg.1320400320; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HENDERSON EE, 1981, VIROLOGY, V115, P237, DOI 10.1016/0042-6822(81)90107-0; HIGGINS DR, 1983, P NATL ACAD SCI-BIOL, V80, P5680, DOI 10.1073/pnas.80.18.5680; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEHMANN A R, 1987, Cancer Reviews, V7, P82; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LOMMEL L, 1991, MUTAT RES, V255, P183, DOI 10.1016/0921-8777(91)90052-Q; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUBY SW, 1991, TRENDS GENET, V7, P79; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAEKI T, 1980, MUTAT RES, V73, P251, DOI 10.1016/0027-5107(80)90192-X; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHILD D, 1992, YEAST, V8, P385, DOI 10.1002/yea.320080506; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMPSON NE, 1990, CYTOGENET CELL GENET, V55, P142, DOI 10.1159/000133006; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; THOMPSON LH, 1989, MUTAGENESIS, V4, P140, DOI 10.1093/mutage/4.2.140; THOMPSON LH, 1988, SOMAT CELL MOLEC GEN, V14, P605, DOI 10.1007/BF01535314; TROELSTRA C, 1992, GENOMICS, V12, P745, DOI 10.1016/0888-7543(92)90304-B; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, THESIS STATE U LEIDE; VERMEULEN W, 1986, MUTAT RES, V165, P199, DOI 10.1016/0167-8817(86)90055-6; VERMEULEN W, 1991, MUTAT RES, V255, P201, DOI 10.1016/0921-8777(91)90054-S; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WOOD CM, 1987, EXP CELL RES, V169, P543, DOI 10.1016/0014-4827(87)90214-X; YAGI T, 1983, MUTAT RES, V112, P59, DOI 10.1016/0167-8817(83)90024-X; YE RD, 1987, J BIOL CHEM, V262, P3718; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P165, DOI 10.1016/0167-8817(88)90018-1; ZELLE B, 1980, MUTAT RES, V72, P491, DOI 10.1016/0027-5107(80)90121-9	93	631	646	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					939	953		10.1016/0092-8674(92)90390-X	http://dx.doi.org/10.1016/0092-8674(92)90390-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1339317	Green Published			2022-12-24	WOS:A1992KB99000007
J	LUIRINK, J; HIGH, S; WOOD, H; GINER, A; TOLLERVEY, D; DOBBERSTEIN, B				LUIRINK, J; HIGH, S; WOOD, H; GINER, A; TOLLERVEY, D; DOBBERSTEIN, B			SIGNAL-SEQUENCE RECOGNITION BY AN ESCHERICHIA-COLI RIBONUCLEOPROTEIN COMPLEX	NATURE			English	Article							4.5S RNA; NASCENT PREPROLACTIN; PARTICLE; PROTEINS; MEMBRANE; TRANSLOCATION; POLYPEPTIDE; INSERTION; DOMAIN; ER	HYDROPHOBIC signal-sequences direct the transfer of secretory proteins across the inner membrane of prokaryotes and the endoplasmic reticulum membranes of eukaryotes1. In mammalian cells, signal-sequences are recognized by the 54K protein (M(r) 54,000) of the signal recognition particle (SRP)2,3 which is believed to hold the nascent chain in a translocation-competent conformation until it contacts the endoplasmic reticulum membrane4. The SRP consists of a 7S RNA and six different polypeptides. The 7S RNA and the 54K signal-sequence-binding protein (SRP54) of mammalian SRP exhibit strong sequence similarity to the 4.5S RNA and P48 protein (Ffh) of Escherichia coli5-7 which form a ribonucleoprotein particle. Depletion of 4.5S RNA or overproduction of P48 causes the accumulation of the beta-lactamase precursor, although not of other secretory proteins8,9. Whether 4.5S RNA and P48 are part of an SRP-like complex with a role in protein export is controversial. Here we show that the P48/4.5S RNA ribonucleoprotein complex interacts specifically with the signal sequence of a nascent secretory protein and therefore is a signal recognition particle.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Luirink, Joen/AAB-8658-2021; Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772; High, Stephen/0000-0002-4532-8152				BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BROWN S, 1991, NEW BIOL, V3, P430; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201	19	158	161	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					741	743		10.1038/359741a0	http://dx.doi.org/10.1038/359741a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1279430	Green Submitted			2022-12-24	WOS:A1992JU65000060
J	CERAMI, C; FREVERT, U; SINNIS, P; TAKACS, B; CLAVIJO, P; SANTOS, MJ; NUSSENZWEIG, V				CERAMI, C; FREVERT, U; SINNIS, P; TAKACS, B; CLAVIJO, P; SANTOS, MJ; NUSSENZWEIG, V			THE BASOLATERAL DOMAIN OF THE HEPATOCYTE PLASMA-MEMBRANE BEARS RECEPTORS FOR THE CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM-FALCIPARUM SPOROZOITES	CELL			English	Article							HUMAN MALARIA PARASITES; VACCINE DEVELOPMENT; SYNTHETIC PEPTIDES; SURFACE-ANTIGEN; MONOCLONAL-ANTIBODIES; SULFATED GLYCOLIPIDS; VONWILLEBRAND-FACTOR; PROTECTIVE ANTIGEN; SEQUENCE HOMOLOGY; CELL EPITOPES	Minutes after injection into the circulation, malaria sporozoites enter hepatocytes. The speed and specificity of the invasion process suggest that it is receptor mediated. We show here that recombinant Plasmodium falciparum circumsporozoite protein (CS) binds specifically to regions of the plasma membrane of hepatocytes exposed to circulating blood in the Disse space. No binding has been detected in other organs, or even in other regions of the hepatocyte membrane. The interaction of CS with hepatocytes, as well as sporozoite invasion of HepG2 cells, is inhibited by synthetic peptides representing the evolutionarily conserved region II of CS. We conclude that region II is a sporozoite ligand for hepatocyte receptors localized to the basolateral domain of the plasma membrane. Our findings provide a rational explanation for the target cell specificity of malaria sporozoites.	NYU MED CTR, DEPT MED & MOLEC PARASITOL, NEW YORK, NY 10016 USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; CATHOLIC UNIV CHILE, SANTIAGO, CHILE	New York University; Roche Holding; Pontificia Universidad Catolica de Chile	CERAMI, C (corresponding author), NYU MED CTR, KAPLAN CANC CTR, DEPT PATHOL, MICHAEL HEIDELBERGER DIV IMMUNOL, NEW YORK, NY 10016 USA.			Frevert, Ute/0000-0001-9556-7330; Cerami, Carla/0000-0002-7634-0955	NCI NIH HHS [5T32CA9161-16] Funding Source: Medline; NIGMS NIH HHS [5T32GM07308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKAWA M, 1981, J IMMUNOL, V126, P2494; ALEY SB, 1986, J EXP MED, V164, P1915, DOI 10.1084/jem.164.6.1915; BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126; BEIER JC, 1991, MED VET ENTOMOL, V5, P71, DOI 10.1111/j.1365-2915.1991.tb00523.x; BURKOT TR, 1991, PARASITE IMMUNOL, V13, P161, DOI 10.1111/j.1365-3024.1991.tb00272.x; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; CLARKE LE, 1990, MOL BIOCHEM PARASIT, V41, P269, DOI 10.1016/0166-6851(90)90190-W; COCHRANE AH, 1976, J IMMUNOL, V116, P859; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DUKOR P, 1970, P NATL ACAD SCI USA, V67, P991, DOI 10.1073/pnas.67.2.991; EICHINGER DJ, 1986, MOL CELL BIOL, V6, P3965, DOI 10.1128/MCB.6.11.3965; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FREVERT U, 1992, IN PRESS INFECT IMMU; GALINSKI MR, 1987, CELL, V48, P311, DOI 10.1016/0092-8674(87)90434-X; GODSON GN, 1983, NATURE, V305, P29, DOI 10.1038/305029a0; GOOD MF, 1988, ANNU REV IMMUNOL, V6, P663, DOI 10.1146/annurev.iy.06.040188.003311; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDSTROM RC, 1990, WHO B OMS S, V68, P152; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; HOLLINGDALE MR, 1981, SCIENCE, V213, P1021, DOI 10.1126/science.7022652; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAL AA, 1987, J BIOL CHEM, V262, P2937; LAL AA, 1988, J BIOL CHEM, V263, P5495; LAL AA, 1988, MOL BIOCHEM PARASIT, V30, P291, DOI 10.1016/0166-6851(88)90099-0; LAMBERT JM, 1978, BIOCHEMISTRY-US, V17, P5406, DOI 10.1021/bi00618a014; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MEIS JFGM, 1983, PARASITOLOGY, V86, P231, DOI 10.1017/S003118200005040X; MOROOSE R, 1986, ANNU REV MED, V37, P157; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; SANTORO F, 1983, J BIOL CHEM, V258, P3341; SHIN SCJ, 1982, J PROTOZOOL, V29, P448, DOI 10.1111/j.1550-7408.1982.tb05431.x; Sinden R. E., 1981, Parasitological topics -- a presentation volume to P.C.C. Garnham, F.R.S. on the occasion of his 80th birthday, 1981., P242; SINDEN RE, 1990, WHO B S, V68, P115; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; VANDERBERG J, 1969, MIL MED, V134, P1183; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	65	306	315	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					1021	1033		10.1016/0092-8674(92)90251-7	http://dx.doi.org/10.1016/0092-8674(92)90251-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326407				2022-12-24	WOS:A1992JN78100016
J	FRANCIS, DP				FRANCIS, DP			TOWARD A COMPREHENSIVE HIV PREVENTION PROGRAM FOR THE CDC AND THE NATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVENTION				FRANCIS, DP (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,REG AIDS DIV,ATLANTA,GA 30333, USA.							[Anonymous], 1978, Bull World Health Organ, V56, P247; FRANCIS DP, 1989, JAMA-J AM MED ASSOC, V262, P2572, DOI 10.1001/jama.262.18.2572; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCITOVSKY AA, 1987, PUBLIC HLTH REPORTS, V102, P1; Shilts R., 1987, BAND PLAYED ON, P273; STALL R, 1989, EPIDEMIOLOGY AIDS EX, P266; WEINSTEIN I, 1947, AM J PUBLIC HEALTH, V37, P1376; ZWEIGHAFT RM, 1977, NEW ENGL J MED, V297, P803, DOI 10.1056/NEJM197710132971504; 1986, CONFRONTING AIDS DIR, P10; 1981, STATISTICAL ABSTRACT; 1990, MMWR, V39, P110	12	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1444	1447		10.1001/jama.268.11.1444	http://dx.doi.org/10.1001/jama.268.11.1444			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JM849	1324996				2022-12-24	WOS:A1992JM84900028
J	DAN, Y; POO, MM				DAN, Y; POO, MM			HEBBIAN DEPRESSION OF ISOLATED NEUROMUSCULAR SYNAPSES INVITRO	SCIENCE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC TRANSMISSION; EMBRYONIC NEURON; EVOKED RELEASE; HIPPOCAMPUS; ACETYLCHOLINE; MECHANISM; TRANSMITTER; ENHANCEMENT; INDUCTION	Modulation of synaptic efficacy may depend on the temporal correlation between pre- and postsynaptic activities. At isolated neuromuscular synapses in culture, repetitive postsynaptic application of acetylcholine pulses alone or in the presence of asynchronous presynaptic activity resulted in immediate and persistent synaptic depression, whereas synchronous pre- and postsynaptic coactivation had no effect. This synaptic depression was a result of a reduction of evoked transmitter release, but induction of the depression requires a rise in postsynaptic cytosolic calcium concentration. Thus, Hebbian modulation operates at isolated peripheral synapses in vitro, and transsynaptic retrograde interaction appears to be an underlying mechanism.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Dan, Yang/0000-0002-3818-877X	NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BETZ WJ, 1989, J PHYSIOL-LONDON, V418, P25, DOI 10.1113/jphysiol.1989.sp017827; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAN Y, UNPUB; DECKER ER, 1990, J NEUROSCI, V10, P3413; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; GIOVANELLI A, 1991, P NATL ACAD SCI USA, V88, P10069, DOI 10.1073/pnas.88.22.10069; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEBB DO, 1949, ORG BEHAVIOR; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POO MM, 1982, NATURE, V295, P332, DOI 10.1038/295332a0; POPOV S, 1992, J NEUROSCI, V12, P77; PURVES D, 1985, PRINCIPLES NEURAL DE; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEJNOWSKI T J, 1991, Current Biology, V1, P38, DOI 10.1016/0960-9822(91)90122-D; Sejnowski T.J., 1989, NEURAL MODELS PLASTI, P94; SKREDE KK, 1981, BRAIN RES, V208, P436, DOI 10.1016/0006-8993(81)90573-4; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tabti N., 1991, CULTURING NERVE CELL, P137; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	33	107	107	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1570	1573		10.1126/science.1317971	http://dx.doi.org/10.1126/science.1317971			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317971				2022-12-24	WOS:A1992HY07500033
J	WEBER, S; TRAUNECKER, A; OLIVERI, F; GERHARD, W; KARJALAINEN, K				WEBER, S; TRAUNECKER, A; OLIVERI, F; GERHARD, W; KARJALAINEN, K			SPECIFIC LOW-AFFINITY RECOGNITION OF MAJOR HISTOCOMPATIBILITY COMPLEX PLUS PEPTIDE BY SOLUBLE T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN; HEMAGGLUTININ; DETERMINANT; ANTIBODIES; LINES; SITE	THE T-cell receptor is necessary and sufficient for recognition of peptides presented by major histocompatibility complex molecules 1,2. Other adhesion molecules, like CD4 or CD8, play an auxiliary role in antigen recognition by T cells 3,4. Here we analyse T-cell receptor (TCR) binding using a soluble rather than a cell-bound receptor molecule. A TCR-immunoglobulin chimaera is constructed with the variable and the first constant regions of both the TCR alpha- and beta-chains linked to the immunoglobulin light-chain constant regions. This soluble TCR is expressed, assembled and secreted as an alpha-beta-heterodimer by a myeloma cell line transfected with the recombinant genes. Furthermore, the soluble TCR is biologically active: it specifically inhibits antigen-dependent activation of the relevant T-cell clones and thus discriminates between proper and irrelevant peptides presented by major histocompatibility complex molecules.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	WEBER, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Karjalainen, Klaus/A-2206-2011					BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; DAVIS MM, 1989, COLD SPRING HARB SYM, V54, P119; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HABERMAN AM, 1990, J IMMUNOL, V145, P3087; HACKETT CJ, 1983, J EXP MED, V158, P294, DOI 10.1084/jem.158.2.294; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; KAPPLER JW, 1984, REGULATION IMMUNE SY, P377; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; OZATO K, 1980, J IMMUNOL, V124, P533; RUBERTI G, 1992, J EXP MED, V175, P157, DOI 10.1084/jem.175.1.157; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; STAERZ U, 1985, MOL BIOL IMMUNE SYST, P61; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; TRAUNECKER A, 1986, EUR J IMMUNOL, V16, P851, DOI 10.1002/eji.1830160722; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WALKER E, 1982, J IMMUNOL, V128, P2164; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3	23	221	235	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					793	796		10.1038/356793a0	http://dx.doi.org/10.1038/356793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1315417				2022-12-24	WOS:A1992HR18600050
J	GOLDHAMER, DJ; FAERMAN, A; SHANI, M; EMERSON, CP				GOLDHAMER, DJ; FAERMAN, A; SHANI, M; EMERSON, CP			REGULATORY ELEMENTS THAT CONTROL THE LINEAGE-SPECIFIC EXPRESSION OF MYOD	SCIENCE			English	Article							GENE FAMILY; MYOGENESIS; MEMBER; DIFFERENTIATION; FIBROBLASTS; MUSCULATURE; HOMOLOGY; EMBRYOS; VECTORS; ORIGIN	The molecular basis of skeletal muscle lineage determination was investigated by analyzing DNA control elements that regulate the myogenic determination gene myoD. A distal enhancer was identified that positively regulates expression of the human myoD gene. The myoD enhancer and promoter were active in myogenic and several nonmyogenic cell lines. In transgenic mouse embryos, however, the myoD enhancer and promoter together directed expression of a lacZ transgene specifically to the skeletal muscle lineage. These data suggest that during development myoD is regulated by mechanisms that restrict accessibility of myoD control elements to positive trans-acting factors.	FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA; VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL	Fox Chase Cancer Center; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007796] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD007796] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NICHD NIH HHS [HD-07796] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FAERMAN A, UNPUB; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOLDHAMER DJ, UNPUB; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Hogan B., 1986, MANIPULATING MOUSE E; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEDEN K, 1982, CELL, V31, P71, DOI 10.1016/0092-8674(82)90406-8; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUGH R, 1990, MOUSE ITS REPRODUCTI; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	38	136	138	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					538	542		10.1126/science.1315077	http://dx.doi.org/10.1126/science.1315077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1315077				2022-12-24	WOS:A1992HQ18700069
J	FITZPATRICK, VD; PERCIVALSMITH, A; INGLES, CJ; KRAUSE, HM				FITZPATRICK, VD; PERCIVALSMITH, A; INGLES, CJ; KRAUSE, HM			HOMEODOMAIN-INDEPENDENT ACTIVITY OF THE FUSHI-TARAZU POLYPEPTIDE IN DROSOPHILA EMBRYOS	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; ULTRABITHORAX PROTEINS; ANTENNAPEDIA; REPRESSION; EXPRESSION; CELLS; EMBRYOGENESIS; MELANOGASTER; LOCALIZATION; SITE	THE Drosophila segmentation gene fushi tarazu (ftz) encodes a homeodomain-containing protein, ftz, that can act as a DNA-binding activator of transcription 1-5. In the developing embryo, ftz is expressed in seven stripes 6 which correspond to the even-numbered parasegments 7. These parasegments are missing in ftz- embryos 8. When ftz is expressed throughout blastoderm embryos under the control of a heat-shock promoter, the odd-numbered parasegments are lost 9. This 'anti-ftz' phenotype has been attributed to autoactivation of the endogenous ftz gene by the ectopically expressed protein 10. Here we show that the same phenotype is induced by ectopic expression of a ftz polypeptide containing a deletion in the homeodomain. Thus, ftz can alter gene expression without binding directly to DNA.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto				Krause, Henry/0000-0002-6182-7074				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CONDE BG, 1990, MOL CELLB IOL, V7, P3376; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRAUSE HM, 1989, EMBO J, V8, P1197, DOI 10.1002/j.1460-2075.1989.tb03492.x; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MURPHY P, 1991, DEVELOPMENT, V111, P61; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; WRIGHT CVE, 1987, EMBO J, V6, P4083, DOI 10.1002/j.1460-2075.1987.tb02754.x	27	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					610	612		10.1038/356610a0	http://dx.doi.org/10.1038/356610a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348571				2022-12-24	WOS:A1992HP03100051
J	FARIZO, KM; BUEHLER, JW; CHAMBERLAND, ME; WHYTE, BM; FROELICHER, ES; HOPKINS, SG; REED, CM; MOKOTOFF, ED; COHN, DL; TROXLER, S; PHELPS, AF; BERKELMAN, RL				FARIZO, KM; BUEHLER, JW; CHAMBERLAND, ME; WHYTE, BM; FROELICHER, ES; HOPKINS, SG; REED, CM; MOKOTOFF, ED; COHN, DL; TROXLER, S; PHELPS, AF; BERKELMAN, RL			SPECTRUM OF DISEASE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS DRUG-USERS; NEW-YORK-CITY; NON-HODGKINS LYMPHOMA; SYNDROME AIDS; HOMOSEXUAL MEN; HIV INFECTION; RISK; EPIDEMIC; TUBERCULOSIS; BACTERIAL	Objective. - To describe the spectrum of disease in persons with human immunodeficiency virus (HIV) infection. Design. - Retrospective survey of medical records. Setting. - More than 50 clinics, hospitals, and private medical practices in nine US cities. Patients. - A total of 626 women and 7008 men 13 years of age or older with HIV infection who received medical care from January 1990 through March 1991 were consecutively enrolled. Main Outcome Measures. - Any history of diseases in the 1987 case definition for the acquired immunodeficiency syndrome (AIDS), and during the 12-month period preceding enrollment (baseline period), the occurrence of other major diseases, hospitalizations, and results of CD4+ lymphocyte counts. Results. - Thirty-two percent of persons met the 1987 case definition for AIDS. The occurrence of an AIDS-indicator disease during the baseline period ranged from 3% (33/1011) to 46% (1254/2748) among persons with CD4+ lymphocyte counts of 0.50 x 10(9)/L or greater and fewer than 0.20 x 10(9)/L (greater-than-or-equal-to 500 and < 200 CD4+ lymphocytes per microliter), respectively, and, at comparable CD4+ lymphocyte levels, was similar among women compared with men, and among persons who reported intravenous drug use compared with men who reported male-to-male sex. The frequency of one or more other major infectious diseases (eg, other pneumonias, bacterial sepsis, pulmonary tuberculosis) ranged from 6% to 16% among persons with CD4+ lymphocyte counts of 0.50 x 10(9)/L or greater and fewer than 0.20 x 10(9)/L, respectively; these illnesses were also associated with a history of intravenous drug use. Among persons who did not meet the 1987 AIDS case definition, 30% of those with an available CD4+ lymphocyte count had fewer CD4+ cells than 0.20 x 10(9)/L, 8% had one or more major infectious diseases, and 14% had one or more hospital admissions. Conclusions.-For every person with AIDS at these sites, two additional persons with HIV infection were receiving medical care, many of whom had severe immunosuppression and a broad spectrum of serious HIV-related disease.	LOS ANGELES CTY DEPT HLTH,LOS ANGELES,CA; GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA 98104; TEXAS DEPT HLTH,AUSTIN,TX; MICHIGAN DEPT PUBL HLTH,DETROIT,MI; DENVER DEPT HLTH & HOSP,DENVER,CO; LOUISIANA DEPT HLTH & HOSP,NEW ORLEANS,LA; HLTH & HUMAN SERV DEPT,HOUSTON,TX	Texas Department of State Health Services; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	FARIZO, KM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,SURVEILLANCE BRANCH,ATLANTA,GA 30333, USA.		Hopkins, Sharon E E/GYV-4926-2022; Buehler, James/B-8419-2014	Hopkins, Sharon E E/0000-0002-2175-4202; 				AMES ED, 1991, HEMATOL ONCOL CLIN N, V5, P343, DOI 10.1016/S0889-8588(18)30446-5; BIGGAR RJ, 1987, AM J EPIDEMIOL, V126, P578, DOI 10.1093/oxfordjournals.aje.a114697; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P92; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404; Cohn D L, 1991, Infect Dis Clin North Am, V5, P485; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FELS AOS, 1988, CLIN CHEST MED, V9, P449; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; FRIESE K, 1989, GEBURTSH FRAUENHEILK, V49, P385, DOI 10.1055/s-2008-1026605; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GREENBERG AE, 1991, 7TH P INT C AIDS FLO; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P15; IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K; KRISTAL AR, 1988, AM J EPIDEMIOL, V128, P711, DOI 10.1093/oxfordjournals.aje.a115024; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; NICHOLSON JKA, 1989, AIDS RES HUM RETROV, V5, P205, DOI 10.1089/aid.1989.5.205; PALEFSKY J, 1991, HEMATOL ONCOL CLIN N, V5, P357, DOI 10.1016/S0889-8588(18)30447-7; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SCHAFER A, 1991, AM J OBSTET GYNECOL, V164, P593, DOI 10.1016/S0002-9378(11)80029-3; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; STEIN J, 1991, 7TH P INT C AIDS FLO; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P1141; TIRELLI U, 1988, CANCER DETECT PREV, V12, P267; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WILKINSON M, 1990, J UROLOGY, V144, P1157, DOI 10.1016/S0022-5347(17)39680-5; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1986, MMWR, V35, P587; 1987, MMWR, V36, P785; 1992, HIV AIDS SURVEILLANC, P1; 1987, MMWR, V36, pS3; 1991, 1992 REVISED CLASSIF; 1987, MMWR, V36, P133; 1990, MMWR, V39, P846	47	272	274	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1798	1805		10.1001/jama.267.13.1798	http://dx.doi.org/10.1001/jama.267.13.1798			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1347573				2022-12-24	WOS:A1992HK67200030
J	KUEHN, MJ; HEUSER, J; NORMARK, S; HULTGREN, SJ				KUEHN, MJ; HEUSER, J; NORMARK, S; HULTGREN, SJ			P PILI IN UROPATHOGENIC ESCHERICHIA-COLI ARE COMPOSITE FIBERS WITH DISTINCT FIBRILLAR ADHESIVE TIPS	NATURE			English	Article							CLATHRIN LATTICE MORPHOLOGY; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CYTOPLASMIC ACIDIFICATION; RECEPTOR-BINDING; PAP PILI; SUBUNIT; PROTEIN; LOCALIZATION; BIOGENESIS	ESCHERICHIA coli is a frequent cause of several common bacterial infections in humans and animals, including urinary tract infections, bacteraemia and bacteria-related diarrhoea and is also the main cause of neonatal meningitis 1. Microbial attachment to surfaces is a key event in colonization and infection and results mainly from a stereochemical fit between microbial adhesins and complementary receptors on host cells. Bacterial adhesins required for, extracellular colonization by Gram-negative bacteria are often minor components of heteropolymeric fibres called pili which must be oriented in an accessible manner in these structures to be able to bind to specific receptor architectures. P pili mediate the binding of uropathogenic E. coli to a digalactoside receptor determinant present in the urinary tract epithelium. We report here that the adhesin is a component of distinct fibrillar structures present at the tips of the pili. These virulence-associated tip fibrillae are thin, flexible polymers composed mostly of repeating subunits of PapE that frequently terminate with the alpha-D-galactopyranosyl-(1-4)-beta-D-galactopyranose or Gal-alpha(1-4)Gal binding PapG adhesin.	WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, BOX 8230, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019				BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BAGA M, 1984, J BACTERIOL, V157, P330; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; DEGRAAF FK, 1986, ADV MICROB PHYSIOL, V28, P65; DEGRAAF FK, 1981, INFECT IMMUN, V33, P877, DOI 10.1128/IAI.33.3.877-883.1981; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, IN PRESS EMBO J; HOSCHUTZKY H, 1989, INFECT IMMUN, V57, P76; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; Hultgren SJ, 1991, CURR OPIN GENET DEV, V1, P313, DOI 10.1016/S0959-437X(05)80293-X; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; JACOBS AAC, 1987, J BACTERIOL, V169, P735, DOI 10.1128/jb.169.2.735-741.1987; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LINDBERG F, 1986, P NATL ACAD SCI USA, V83, P1891, DOI 10.1073/pnas.83.6.1891; LINDBERG F, 1987, THESIS UMEA U; LINDBERG FP, 1984, EMBO J, V3, P1167, DOI 10.1002/j.1460-2075.1984.tb01946.x; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; RIEDE I, 1987, J MOL BIOL, V194, P23, DOI 10.1016/0022-2836(87)90712-1; ROOSENDAAL B, 1984, FEMS MICROBIOL LETT, V22, P253; WARD S, 1970, J MOL BIOL, V54, P15, DOI 10.1016/0022-2836(70)90443-2; WESTERLUND B, 1991, MOL MICROBIOL, V5, P2965, DOI 10.1111/j.1365-2958.1991.tb01856.x	28	269	282	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					252	255		10.1038/356252a0	http://dx.doi.org/10.1038/356252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1348107				2022-12-24	WOS:A1992HJ94400062
J	CLEMONS, MJ; CLEMONS, KR; SKINNER, R				CLEMONS, MJ; CLEMONS, KR; SKINNER, R			MEDICINE - THE HEARING PROFESSION	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV BRISTOL,BRISTOL BS8 1TH,ENGLAND	Newcastle University - UK; University of Bristol	SKINNER, R (corresponding author), ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							WALTERS S, 1988, BRIT MED J, V297, P1665	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1568	1569		10.1136/bmj.305.6868.1568	http://dx.doi.org/10.1136/bmj.305.6868.1568			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286390	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992KD77100027
J	THANOS, D; MANIATIS, T				THANOS, D; MANIATIS, T			THE HIGH MOBILITY GROUP PROTEIN HMG-I(Y) IS REQUIRED FOR NF-KAPPA-B-DEPENDENT VIRUS INDUCTION OF THE HUMAN IFN-BETA GENE	CELL			English	Article							DNA-BINDING PROTEIN; INTERFERON GENE; HMG-I; NUCLEAR FACTOR; CHROMOSOMAL-PROTEINS; REGULATORY ELEMENTS; INDUCIBLE ENHANCER; ESCHERICHIA-COLI; MAMMALIAN-CELLS; RNA-POLYMERASE	In this paper, we show that both NF-kappaB and the high mobility group protein I(Y) (HMG I(Y)) are required for virus induction of the human interferon-beta (IFN-beta) gene. NF-kappaB binds to the terminal regions of a 10 bp regulatory sequence through contacts in the major groove, while HMG I(Y) recognizes the central region of the same sequence through contacts in the minor groove. Mutations that interfere with binding of either protein decrease the level of virus induction, and activation of the gene can be blocked by either NF-kappaB or HMG I(Y) antisense RNA. HMG I(Y) stimulates the binding of NF-kappaB to the IFN-beta promoter, and it may also function as a promoter-specific accessory factor for NF-kappaB transcriptional activity.			THANOS, D (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, R37AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1990, HORMONAL CONTROL REG, P423; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FASHENA ST, 1991, MOL CELL BIOL, V12, P894; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1992, IN PRESS INT REV EXP; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEHN DA, 1988, BIOCHEM INT, V16, P963; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T., 1982, MOL CLONING; MANIATIS T, 1992, IN PRESS TRANSCRIPTI; MAUXION F, 1991, P NATL ACAD SCI USA, V88, P2141, DOI 10.1073/pnas.88.6.2141; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOLITOR JA, 1991, NEW BIOL, V3, P987; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; REEVES R, 1990, J BIOL CHEM, V265, P8573; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VILCEK J, 1990, HDB EXPT PHARM, V95, P1; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZABEL U, 1991, J BIOL CHEM, V266, P252	65	609	613	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 27	1992	71	5					777	789		10.1016/0092-8674(92)90554-P	http://dx.doi.org/10.1016/0092-8674(92)90554-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330326				2022-12-24	WOS:A1992JZ63300008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL TO PROVIDE MORE PEDIATRIC USE INFORMATION IN DRUG LABELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1902, FED REG         1016, V57, P47427	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-24	WOS:A1992JW61600004
J	HEMMATIBRIVANLOU, A; MELTON, DA				HEMMATIBRIVANLOU, A; MELTON, DA			A TRUNCATED ACTIVIN RECEPTOR INHIBITS MESODERM INDUCTION AND FORMATION OF AXIAL STRUCTURES IN XENOPUS EMBRYOS	NATURE			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; MESSENGER-RNA; BODY AXIS; NEURAL INDUCTION; EARLY RESPONSE; EXPRESSION; ANTERIOR; HOMOLOG; LAEVIS; CELLS	Activins can induce mesoderm in embryonic explants and have been proposed as the natural inducer in Xenopus. A mutant activin receptor that inhibits activin signalling is used to show that activin is required for the induction of mesoderm in vivo and the patterning of the embryonic body plan. Blocking the activin signal transduction pathway also reveals autonomous induction of a neural marker and unmasks a relationship between activin and fibroblast growth factor.			HEMMATIBRIVANLOU, A (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA ARI, 1990, TRENDS GENET, V6, P57; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1990, NATURWISSENSCHAFTEN, V77, P389, DOI 10.1007/BF01135742; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BOLCE M, IN PRESS; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1991, METHODS CELL BIOL; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; Harland RM, 1991, METHODS CELL BIOL; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLO.A, IN PRESS; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONAS EA, 1989, DEVELOPMENT, V106, P399; JONES CM, 1992, DEVELOPMENT, V115, P639; KELLER R, 1988, DEVELOPMENT, V103, P193; KELLER R, 1991, METHODS CELL BIOL; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SYMES K, 1987, DEVELOPMENT, V101, P185; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, XENOPUS LAEVIS PRACT, P361; WILSON PA, 1989, DEVELOPMENT, V105, P155	56	500	530	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					609	614		10.1038/359609a0	http://dx.doi.org/10.1038/359609a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1328888				2022-12-24	WOS:A1992JT82400047
J	YAO, TP; SEGRAVES, WA; ORO, AE; MCKEOWN, M; EVANS, RM				YAO, TP; SEGRAVES, WA; ORO, AE; MCKEOWN, M; EVANS, RM			DROSOPHILA ULTRASPIRACLE MODULATES ECDYSONE RECEPTOR FUNCTION VIA HETERODIMER FORMATION	CELL			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; RESPONSE ELEMENT; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; BETA-GENE; SUPERFAMILY; IDENTIFICATION; BINDING; MEMBER	The vertebrate retinoid X receptor (RXR) has been implicated in the regulation of multiple hormonal signaling pathways through the formation of heteromeric receptor complexes that bind DNA with high affinity. We now demonstrate that ultraspiracle (usp), a Drosophila RXR homolog, can substitute for RXR in stimulating the DNA binding of receptors for retinoic acid, T3, vitamin D, and peroxisome proliferator activators. These observations led to the search and ultimate identification of the ecdysone receptor (EcR) as a Drosophila partner of usp. Together, usp and EcR bind DNA in a highly cooperative fashion. Cotransfection of both EcR and usp expression vectors is required to render cultured mammalian cells ecdysone responsive. These results implicate usp as an integral component of the functional EcR. By demonstrating that receptor heterodimer formation precedes the divergence of vertebrate and invertebrate lineages, these data underscore a central role for RXR and its homolog usp in the evolution and control of the nuclear receptor-based endocrine system.	UNIV CALIF SAN DIEGO, DEPT BIOL, GRAD PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	YAO, TP (corresponding author), SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ANDRES AJ, 1992, TRENDS GENET, V8, P132, DOI 10.1016/0168-9525(92)90079-J; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1992, IN PRESS TRANSCRIPTI; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; ORO AE, 1991, THESIS U CALIFORNIA; Oro AE, 1992, CURR OPIN GENET DEV, V2, P269, DOI 10.1016/S0959-437X(05)80284-9; PICARD D, 1988, CELL, V54, P170; Ragsdale CW, 1991, CURR OPIN CELL BIOL, V3, P928, DOI 10.1016/0955-0674(91)90109-C; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RIDDIFORD LM, 1985, COMPREHENSIVE INSECT, V8, P38; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SLITER TJ, 1992, GENETICS, V130, P555; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STEEL CGH, 1985, COMPREHENSIVE INSECT, V8, P1; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	615	686	4	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					63	72		10.1016/0092-8674(92)90266-F	http://dx.doi.org/10.1016/0092-8674(92)90266-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1327536				2022-12-24	WOS:A1992JQ62300007
J	INOSTROZA, JA; MERMELSTEIN, FH; HA, I; LANE, WS; REINBERG, D				INOSTROZA, JA; MERMELSTEIN, FH; HA, I; LANE, WS; REINBERG, D			DR1, A TATA-BINDING PROTEIN ASSOCIATED PHOSPHOPROTEIN AND INHIBITOR OF CLASS-II GENE-TRANSCRIPTION	CELL			English	Article								We have discovered a protein termed Dr1 that interacts with the TATA-binding protein, TBP. The association of Dr1 with TBP results in repression of both basal and activated levels of transcription. The interaction of Dr1 with TBP precludes the formation of a transcription-competent complex by inhibiting the association of TFIIA and/or TFIIB with TBP. Dr1 activity is associated with a 19 kd protein. A cDNA clone encoding Dr1 was isolated. Dr1 is phosphorylated in vivo and phosphorylation of Dr1 affected its interaction with TBP. Our results suggest a regulatory role for Dr1 in repression of transcription mediated via phosphorylation.			INOSTROZA, JA (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037120, R37GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FLORES O, 1992, J BIOL CHEM, V267, P2786; GILL G, 1992, IN PRESS CURR OPIN G; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ZAWEL L, 1992, IN PRESS PROG NUCL A	45	338	342	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					477	489						13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1339312				2022-12-24	WOS:A1992JH12400013
J	LOWENSTEIN, EJ; DALY, RJ; BATZER, AG; LI, W; MARGOLIS, B; LAMMERS, R; ULLRICH, A; SKOLNIK, EY; BARSAGI, D; SCHLESSINGER, J				LOWENSTEIN, EJ; DALY, RJ; BATZER, AG; LI, W; MARGOLIS, B; LAMMERS, R; ULLRICH, A; SKOLNIK, EY; BARSAGI, D; SCHLESSINGER, J			THE SH2 AND SH3 DOMAIN CONTAINING PROTEIN GRB2 LINKS RECEPTOR TYROSINE KINASES TO RAS SIGNALING	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; BINDING-SITE; PHOSPHATIDYLINOSITOL-3 KINASE; SUBSTRATE-SPECIFICITY; CYTOPLASMIC PROTEIN; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; PDGF RECEPTOR	A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) containing one src homology 2 (SH2) domain and two SH3 domains was isolated. Immunoblotting experiments indicate that GRB2 associates with tyrosine-phosphorylated epidermal growth factor receptors (EGFRs) and platelet-derived growth factor receptors (PDGFRs) via its SH2 domain. Interestingly, GRB2 exhibits striking structural and functional homology to the C. elegans protein sem-5. It has been shown that sem-5 and two other genes called let-23 (EGFR like) and let-60 (ras like) lie along the same signal transduction pathway controlling C. elegans vulval induction. To examine whether GRB2 is also a component of ras signaling in mammalian cells, microinjection studies were performed. While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis. These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Max Planck Society; Cold Spring Harbor Laboratory	LOWENSTEIN, EJ (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Daly, Roger J/C-8179-2009	Bar-Sagi, Dafna/0000-0003-2597-8948; Daly, Roger/0000-0002-5739-8027	NATIONAL CANCER INSTITUTE [R37CA055360, P01CA046370, R01CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55360, CA 46370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1991, J BIOL CHEM, V266, P6808; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, IN PRESS NATURE; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROTIN D, 1992, J BIOL CHEM, V267, P9676; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY MG, 1988, SCIENCE, V242, P1696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG K, 1982, METHOD ENZYMOL, V85, P514; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	56	1512	1566	2	103	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					431	442		10.1016/0092-8674(92)90167-B	http://dx.doi.org/10.1016/0092-8674(92)90167-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322798	hybrid			2022-12-24	WOS:A1992JH12400008
J	ARSHAVSKY, VY; BOWNDS, MD				ARSHAVSKY, VY; BOWNDS, MD			REGULATION OF DEACTIVATION OF PHOTORECEPTOR G-PROTEIN BY ITS TARGET ENZYME AND CGMP	NATURE			English	Article							ROD OUTER SEGMENTS; CYCLIC-GMP PHOSPHODIESTERASE; MOLECULAR MECHANISM; VISUAL EXCITATION; TRANSDUCIN GTPASE; CASCADE; ACTIVATION; MEMBRANES; TURNOVER; SUBUNIT	THE photoreceptor G protein, transducin, is One of the class of heterotrimeric G proteins that mediates between membrane receptors and intracellular enzymes or ion channels. Light-activated rhodopsin catalyses the exchange of GDP for GTP on multiple transducin molecules. Activated transducin then stimulates cyclic GMP phosphodiesterase by releasing an inhibitory action of the phosphodiesterase gamma-subunits. This leads to a decrease in cGMP levels in the rod, and closure of plasma membrane cationic channels gated by cGMP 1-4. In this and other systems, turn-off of the response requires the GTP bound to G protein to be hydrolysed by an intrinsic GTPase activity 5-7. Here we report that the interaction of transducin with cGMP phosphodiesterase, specifically with its gamma-subunits, accelerates GTPase activity by several fold. Thus the gamma-subunits of the phosphodiesterase serve a function analogous to the GTPase-activating proteins that regulate the class of small GTP-binding proteins. The acceleration can be partially suppressed by cGMP, most probably through the non-catalytic cGMP-binding sites of phosphodiesterase alpha and beta-subunits. This cGMP regulation may function in light-adaptation of the photoresponse as a negative feedback that decreases the lifetime of activated cGMP phosphodiesterase as light causes decreases in cytoplasmic cGMP.	UNIV WISCONSIN,DEPT ZOOL,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	ARSHAVSKY, VY (corresponding author), UNIV WISCONSIN,DEPT ZOOL,MOLEC BIOL LAB,MADISON,WI 53706, USA.							ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; IYENGAR R, 1990, G PROTEINS; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAYLOR CW, 1990, BIOCHEM J, V272, P1; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	30	239	241	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					416	417		10.1038/357416a0	http://dx.doi.org/10.1038/357416a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1317509	Bronze, Green Published			2022-12-24	WOS:A1992HX17200067
J	JOHNSON, E				JOHNSON, E			ANIMAL-MODEL FOR AIDS DEMENTIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, SCIENCE, V255, P1246	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2293	2293						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1314314				2022-12-24	WOS:A1992HR01500005
J	CAGAN, RL; KRAMER, H; HART, AC; ZIPURSKY, SL				CAGAN, RL; KRAMER, H; HART, AC; ZIPURSKY, SL			THE BRIDE OF SEVENLESS AND SEVENLESS INTERACTION - INTERNALIZATION OF A TRANSMEMBRANE LIGAND	CELL			English	Article							GROWTH-FACTOR RECEPTOR; CELL FATE; DROSOPHILA RETINA; KINASE-ACTIVITY; PROTEIN; EYE; DOMAIN	During Drosophila retinal development, the R8 photo-receptor neuron induces a neighboring cell to assume an R7 cell fate through cell contact. This is mediated by the transmembrane protein bride of sevenless (boss) on the surface of the R8 cell, which binds the sevenless tyrosine kinase receptor (sev) on the surface of the R7 precursor cell. The boss protein, which contains a large extracellular domain, seven transmembrane segments, and a C-terminal cytoplasmic domain, has an exceptional structure for a ligand of a receptor tyrosine kinase. Using a panel of antibodies directed to various cytoplasmic and extracellular epitopes, we demonstrate that the entire boss protein from its extreme N-terminus to its extreme C-terminus is internalized by sev-expressing tissue culture cells and by the R7 precursor cell in the developing eye imaginal disc. The receptor-mediated transfer of a transmembrane ligand represents a novel mechanism for protein transfer between developing cells.			CAGAN, RL (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.		Cagan, Ross Leigh/AAV-9528-2021	Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181; Cagan, Ross/0000-0001-5297-450X	NIGMS NIH HHS [GM-07104] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1989, DROSPHILA LABORATORY; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; Holtzman E, 1989, LYSOSOMES; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAZARIDES E, 1979, SCI AM, V240, P100, DOI 10.1038/scientificamerican0579-100; MATSUMOTO B, 1987, PROC R SOC SER B-BIO, V230, P339, DOI 10.1098/rspb.1987.0023; MULLINS MC, 1991, P NATL ACAD SCI USA, V88, P9387, DOI 10.1073/pnas.88.21.9387; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	27	153	153	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					393	399		10.1016/0092-8674(92)90442-F	http://dx.doi.org/10.1016/0092-8674(92)90442-F			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316239				2022-12-24	WOS:A1992HT07800003
J	ROSS, RK; YUAN, JM; YU, MC; WOGAN, GN; QIAN, GS; TU, JT; GROOPMAN, JD; GAO, YT; HENDERSON, BE				ROSS, RK; YUAN, JM; YU, MC; WOGAN, GN; QIAN, GS; TU, JT; GROOPMAN, JD; GAO, YT; HENDERSON, BE			URINARY AFLATOXIN BIOMARKERS AND RISK OF HEPATOCELLULAR-CARCINOMA	LANCET			English	Article							HEPATITIS-B VIRUS; PRIMARY LIVER-CANCER; FREQUENCY; EXPOSURE; CHINA	Aflatoxins have long been suspected to be human hepatic carcinogens but no direct study was feasible until assays to measure individual aflatoxin exposure became available. We have used assays for urinary aflatoxin B1, its metabolites AFP1 and AFM1, and DNA-adducts (AFB1-N7-Gua) to assess the relation between aflatoxin exposure and liver cancer, as part of an ongoing prospective study of 18 244 middle-aged men in Shanghai, People's Republic of China. After 35 299 person-years of follow-up, 22 cases of liver cancer had been identified. For each case, 5 or 10 controls were randomly selected from cohort members without liver cancer on the date the disorder was diagnosed in the case and matched to within 1 year for age, within 1 month for sample collection, and for neighbourhood of residence. Subjects with liver cancer were more likely than were controls to have detectable concentrations of any of the aflatoxin metabolites (relative risk 2.4, 95% confidence interval 1.0-5.9). The highest relative risk was for aflatoxin P1 (6.2, 1.8-21.5). In an analysis adjusting for the effects of hepatitis B surface antigen seropositivity, level of education, cigarette smoking, and alcohol consumption, the relative risk for the presence of aflatoxin metabolites was 3-8 (1.2-12.2). There was a strong interaction between serological markers of chronic hepatitis B infection and aflatoxin exposure in liver-cancer risk. Reduction of aflatoxin exposure may be a useful intermediate goal in prevention of liver cancer, since the benefits of wide-scale hepatitis B vaccination will not be apparent for many years.	SHANGHAI CANC INST,SHANGHAI,PEOPLES R CHINA; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,DIV ENVIRONM CHEM & BIOL,BALTIMORE,MD 21218	Shanghai Jiao Tong University; Massachusetts Institute of Technology (MIT); Johns Hopkins University	ROSS, RK (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,1441 EASTLAKE AVE,ROOM 803,LOS ANGELES,CA 90033, USA.		/X-4205-2019; Gao, Yu/HGE-1937-2022	/0000-0003-4690-2133; Yuan, Jian-Min/0000-0002-4620-3108	NCI NIH HHS [KO4 CA01517, R01 CA043092-20, CA 43092, R01 CA043092] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001517, R01CA043092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPERT ME, 1971, CANCER, V28, P253, DOI 10.1002/1097-0142(197107)28:1&lt;253::AID-CNCR2820280151&gt;3.0.CO;2-G; BLUMBERG BS, 1985, JNCI-J NATL CANCER I, V74, P267; Breslow N, 1980, STATISTICAL METHODS, V32; BULATAOJAYME J, 1982, INT J EPIDEMIOL, V11, P112, DOI 10.1093/ije/11.2.112; Busby W. F., 1985, CHEM CARCINOGENS, P945; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CAMPBELL TC, 1991, CANCER RES, V51, P3826; GROOPMAN JD, 1985, P NATL ACAD SCI USA, V82, P6492, DOI 10.1073/pnas.82.19.6492; GROOPMAN JD, 1992, CANCER EPIDEM BIOMAR, V1, P221; GROOPMAN JD, 1992, CANCER RES, V52, P45; GROOPMAN JD, 1984, P NATL ACAD SCI-BIOL, V81, P7728, DOI 10.1073/pnas.81.24.7728; GROOPMAN JD, IN PRESS ENV HLTH PE; Groopman JD, 1991, MOL DOSIMETRY HUMAN, P303; LAM KC, 1982, CANCER RES, V42, P5246; LI J, 1979, ATLAS CANCER MORTALI, P39; MUIR C, 1987, CANCER 5 CONTINENTS, V5; NEWBERNE PM, 1969, CANCER RES, V29, P236; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PEERS F, 1987, INT J CANCER, V39, P545, DOI 10.1002/ijc.2910390502; WOGAN GN, 1967, CANCER RES, V27, P2370; Yeh F S, 1985, Natl Cancer Inst Monogr, V69, P47; YEH FS, 1989, CANCER RES, V49, P2506; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; 1987, IARC MONOGRAPHS EV S, V7, P83; 1983, LANCET, V1, P463	25	552	581	1	59	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					943	946		10.1016/0140-6736(92)91528-G	http://dx.doi.org/10.1016/0140-6736(92)91528-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348796				2022-12-24	WOS:A1992HP03600001
J	LEMOUELLIC, H; LALLEMAND, Y; BRULET, P				LEMOUELLIC, H; LALLEMAND, Y; BRULET, P			HOMEOSIS IN THE MOUSE INDUCED BY A NULL MUTATION IN THE HOX-3.1 GENE	CELL			English	Article							STEM-CELL LINES; HOMEOBOX GENE; HOMOLOGOUS RECOMBINATION; EXPRESSION PATTERN; HOMEOTIC GENES; SOMITIC MESODERM; MAMMALIAN-CELLS; FUSHI-TARAZU; DROSOPHILA; EMBRYO	We have replaced the Hox-3.1 coding sequence with the E. coli lacZ gene by means of homologous recombination in embryonic stem cells and thus produced null mutant mice. Homozygous mice were born alive, but most of them died within a few days. In the trunk region of homozygotes, several skeletal segments were transformed into the likeness of more anterior ones, as observed in Drosophila with loss-of-function homeotic mutations. The most obvious transformations were the attachment of the 8th pair of ribs to the sternum and the appearance of a 14th pair of ribs on the 1st lumbar vertebra. The pattern of beta-galactosidase activity was identical in heterozygotes and homozygotes and reflected faithfully the Hox-3.1 expression pattern. Thus, the mutation modified the identity, rather than the position, of embryonic cells that would normally express Hox-3.1.	INST PASTEUR,CNRS,URA 1148,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LEMOUELLIC, H (corresponding author), COLL FRANCE,UNITE GENET CELLULAIRE,25 RUE DOCTEUR ROUX,F-75231 PARIS 05,FRANCE.							AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM M, 1988, DEVELOPMENT, V104, P123; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BREIER G, 1988, EMBO J, V7, P1329, DOI 10.1002/j.1460-2075.1988.tb02948.x; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CHEN JM, 1953, J ANAT, V87, P130; CHEN JM, 1952, J ANAT, V86, P387; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COULY G, 1990, DEVELOPMENT, V108, P543; DALGLEISH AE, 1985, ACTA ANAT, V122, P91; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRUNEBERG H, 1952, GENETICS MOUSE; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; Hogan B., 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KIMMEL CB, 1987, NATURE, V327, P234, DOI 10.1038/327234a0; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAUGER A, 1972, J EMBRYOL EXP MORPH, V28, P343; NODEN DM, 1988, DEVELOPMENT, V103, P121; OUDEJANS CBM, 1990, DEVELOPMENT, V108, P471; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918	57	316	321	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					251	264		10.1016/0092-8674(92)90406-3	http://dx.doi.org/10.1016/0092-8674(92)90406-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348969				2022-12-24	WOS:A1992HQ18300005
J	PEPPELENBOSCH, MP; TERTOOLEN, LGJ; DENHERTOG, J; DELAAT, SW				PEPPELENBOSCH, MP; TERTOOLEN, LGJ; DENHERTOG, J; DELAAT, SW			EPIDERMAL GROWTH-FACTOR ACTIVATES CALCIUM CHANNELS BY PHOSPHOLIPASE-A2/5-LIPOXYGENASE-MEDIATED LEUKOTRIENE-C4 PRODUCTION	CELL			English	Article							C-FOS GENE; SIGNAL TRANSDUCTION; ARACHIDONIC-ACID; A431 CELLS; INOSITOL PHOSPHATES; PROTO-ONCOGENE; K+-CHANNEL; 3T3 CELLS; RECEPTOR; PHOSPHOLIPASE-A2	Epidermal growth factor (EGF) induces a Ca2+ influx in many cell types, but the underlying mechanisms are so far unresolved. We report that: EGF-induced Ca2+ channel activity is eliminated by lipoxygenase inhibition and is mimicked by artificial induction of lipoxygenase activity; addition of leukotriene C4 can fully mimic EGF in its ability to activate Ca2+ channels; and EGF induces a rapid accumulation of intracellular leukotriene C4. In addition, we show that EGF-induced, Ca2+-dependent membrane hyperpolarization and junB proto-oncogene expression are dependent on lipoxygenase activity, whereas EGF-induced cytoplasmic alkalinization is not. We conclude that PLA2/5-lipoxygenase-mediated leukotriene C4 production constitutes a novel and specific signal transduction pathway in growth factor action.			PEPPELENBOSCH, MP (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.			Peppelenbosch, Maikel/0000-0001-9112-6028				BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; DENHERTOG J, 1991, CELL GROWTH DIFFER, V2, P155; DENHERTOG J, 1991, EXP CELL RES, V196, P226, DOI 10.1016/0014-4827(91)90255-S; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P725, DOI 10.1113/jphysiol.1991.sp018576; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HACK M, 1991, BIOCHEM J, V275, P263; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HUANG N, 1991, J CELL PHYSL, V146, P473; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MAHOUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; Maniatis T., 1982, MOL CLONING; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	41	193	193	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					295	303		10.1016/0092-8674(92)90410-E	http://dx.doi.org/10.1016/0092-8674(92)90410-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1314702				2022-12-24	WOS:A1992HQ18300009
J	MENDALL, MA; GOGGIN, PM; MOLINEAUX, N; LEVY, J; TOOSY, T; STRACHAN, D; NORTHFIELD, TC				MENDALL, MA; GOGGIN, PM; MOLINEAUX, N; LEVY, J; TOOSY, T; STRACHAN, D; NORTHFIELD, TC			CHILDHOOD LIVING-CONDITIONS AND HELICOBACTER-PYLORI SEROPOSITIVITY IN ADULT LIFE	LANCET			English	Note							INFECTION	Infection with Helicobacter pylori increases an individual's risk of peptic ulceration and gastric cancer. In the developed world, prevalence of infection rises with age and varies with social class. We used a cross-sectional study design to test the hypothesis that H pylori infection would be more closely associated with childhood living conditions than with current socioeconomic status. Prevalence of IgG antibodies against H pylori was determined with an enzyme-linked immunosorbent assay in 21 5 subjects (median age 46 years, range 18-82) attending a health-screening clinic in London. Seropositivity varied from 9% (age < 30) to 67% (greater-than-or-equal-to 70). Subjects were asked about their living conditions at present and when they were aged 8 years. Absence of a fixed hot-water supply (p = 0.0005) and domestic crowding (p = 0.0005) in childhood were powerful independent risk factors for current infection with H pylori. Among current living conditions, only the number of children living in the household was independently associated with H pylori infection (p = 0.004). Most British adults infected with H pylori probably became infected by household contact in childhood.	ST GEORGE HOSP,SCH MED,DEPT MED,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; THE PRACTICE,WALLINGTON,SURREY,ENGLAND	St Georges University London; St Georges University London								BACKETT EM, 1957, LANCET, V1, P778; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; BARKER RJ, 1978, GLIM SYSTEM; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; SIURALA M, 1985, SCAND J GASTROENTERO, V20, P69, DOI 10.3109/00365528509103939	9	440	449	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					896	897		10.1016/0140-6736(92)90931-R	http://dx.doi.org/10.1016/0140-6736(92)90931-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348299				2022-12-24	WOS:A1992HN48300005
J	BERAL, V; BULL, D; DARBY, S; WELLER, I; CARNE, C; BEECHAM, M; JAFFE, H				BERAL, V; BULL, D; DARBY, S; WELLER, I; CARNE, C; BEECHAM, M; JAFFE, H			RISK OF KAPOSIS-SARCOMA AND SEXUAL PRACTICES ASSOCIATED WITH FECAL CONTACT IN HOMOSEXUAL OR BISEXUAL MEN WITH AIDS	LANCET			English	Article								The causal agent of Kaposi's sarcoma is unknown. That the disorder is ten times more common in homosexual or bisexual men with the acquired immunodeficiency syndrome (AIDS) than in other human immunodeficiency virus (HIV) transmission groups suggests that a certain aspect of their behaviour exposes them to the agent or facilitates its spread. We therefore assessed social and demographic characteristics, including sexual behaviour, of 65 homosexual or bisexual men with AIDS from London. Sexual practices in which there was contact with partner's faeces before AIDS developed were the main determinants of Kaposi's sarcoma risk. Risk increased with frequency of insertive "rimming" (oral-anal contact): Kaposi's sarcoma developed in 18% of the men with AIDS who reported never having practised insertive rimming compared with 50% who practised it less than once a month, 73% between once a week and once a month, and 75% or more once a week (two-sided exact p-value for trend < 0.001 ). 45 men had been interviewed about their sexual practices before AIDS developed, and 20 were interviewed at the time the syndrome developed. The findings were similar and statistically significant when each group was analysed separately. The men with Kaposi's sarcoma also tended to be more sexually active and were more likely to engage in other sexual activities that entailed contact with faeces than were the men who had other features of AIDS only. Other behaviours and exposures, including the use of "poppers" (nitrite inhalants), were not related to Kaposi's sarcoma risk, after taking into account whether the subjects had practised insertive rimming. The data suggest that faecal-oral contact is the main route of transmission of the agent of Kaposi's sarcoma in homosexual or bisexual men with AIDS.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON,ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	BERAL, V (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCHIBALD CP, 1990, J ACQ IMMUN DEF SYND, V3, pS18; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; CARNE CA, 1987, LANCET, V1, P656; DARROW WW, 1992, LANCET, P685; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; JACOBSEN L, 1990, 6TH INT C AIDS SAN F; JACOBSENLP, 1990, J ACQUIR IMMUNE D S1, V3, pS24; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; MOSS AR, 1987, AM J EPIDEMIOL, V125, P1035, DOI 10.1093/oxfordjournals.aje.a114619; 1986, ANN INTERN MED, V105, P231	12	178	185	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					632	635		10.1016/0140-6736(92)90793-3	http://dx.doi.org/10.1016/0140-6736(92)90793-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH743	1347337				2022-12-24	WOS:A1992HH74300002
J	BOLKER, M; URBAN, M; KAHMANN, R				BOLKER, M; URBAN, M; KAHMANN, R			THE A MATING TYPE LOCUS OF U-MAYDIS SPECIFIES CELL SIGNALING COMPONENTS	CELL			English	Article							YEAST RHODOSPORIDIUM-TORULOIDES; CONJUGATION TUBE FORMATION; USTILAGO-MAYDIS; SACCHAROMYCES-CEREVISIAE; TREMELLA-MESENTERICA; RHODOTORUCINE-A; SEXUAL-DIFFERENTIATION; NEUROSPORA-CRASSA; FISSION YEAST; B-LOCUS	The a mating type locus of the phytopathogenic fungus U. maydis controls fusion of haploid cells and filamentous growth of the dikaryotic mycelium. The a locus exists in two alleles, termed a1 and a2, which are defined by nonhomologous DNA regions comprising 4.5 kb for a1 and 8 kb for a2, flanked by identical sequences. Based on functional assays, mutants, and sequencing, we demonstrate that the mating type in each allele is determined by a set of two genes. One encodes a precursor for a lipopeptide mating factor, and the other specifies the receptor for the pheromone secreted by cells of opposite mating type. Thus, U. maydis employs a novel strategy to determine its mating type by providing the primary determinants of cell-cell recognition directly from the mating type locus.			BOLKER, M (corresponding author), INST GENBIOL FORSCH BERLIN GMBH, IHNESTR 63, W-1000 BERLIN 33, GERMANY.		; Urban, Martin/G-6004-2010	Bolker, Michael/0000-0002-7366-3855; Urban, Martin/0000-0003-2440-4352				ABE K, 1975, J BACTERIOL, V122, P710, DOI 10.1128/JB.122.2.710-718.1975; AKADA R, 1989, ARCH MICROBIOL, V152, P484, DOI 10.1007/BF00446934; AKADA R, 1989, MOL CELL BIOL, V9, P3491, DOI 10.1128/MCB.9.8.3491; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BETZ R, 1987, J BIOL CHEM, V262, P546; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DAY PR, 1971, P NATL ACAD SCI USA, V68, P533, DOI 10.1073/pnas.68.3.533; DAY PR, 1971, NATURE-NEW BIOL, V231, P19, DOI 10.1038/newbio231019a0; EGEL R, 1990, TRENDS GENET, V6, P369, DOI 10.1016/0168-9525(90)90279-F; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROELIGER EH, 1991, GENE, V100, P113, DOI 10.1016/0378-1119(91)90356-G; FUJINO M, 1980, NATURWISSENSCHAFTEN, V67, P406, DOI 10.1007/BF00405487; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GILLISSEN B, 1992, IN PRESS CELL, V68; GLASS NL, 1990, P NATL ACAD SCI USA, V87, P4912, DOI 10.1073/pnas.87.13.4912; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLIDAY R, 1961, GENET RES, V2, P231, DOI 10.1017/S0016672300000720; Holliday R., 1974, HDB GENETICS, P575, DOI 10.1007/978-1-4899-1710-2_31; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIBASHI Y, 1984, BIOCHEMISTRY-US, V23, P1399, DOI 10.1021/bi00302a010; KAMIYA Y, 1978, BIOCHEM BIOPH RES CO, V83, P1077, DOI 10.1016/0006-291X(78)91505-X; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KOHLER K, 1991, METHOD ENZYMOL, V194, P393; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; KRONSTAD JW, 1990, GENE DEV, V4, P1384, DOI 10.1101/gad.4.8.1384; KRONSTAD JW, 1989, P NATL ACAD SCI USA, V86, P978, DOI 10.1073/pnas.86.3.978; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; NAG DK, 1988, GENE, V64, P135, DOI 10.1016/0378-1119(88)90487-8; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; PUHALLA JE, 1969, PHYTOPATHOLOGY, V59, P1771; ROWELL JB, 1955, PHYTOPATHOLOGY, V45, P370; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; SAKAGAMI Y, 1979, AGR BIOL CHEM TOKYO, V43, P2643, DOI 10.1080/00021369.1979.10863880; SAKAGAMI Y, 1981, SCIENCE, V212, P1525, DOI 10.1126/science.212.4502.1525; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; [No title captured]	50	310	317	5	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					441	450		10.1016/0092-8674(92)90182-C	http://dx.doi.org/10.1016/0092-8674(92)90182-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310895	hybrid			2022-12-24	WOS:A1992HD39800006
J	ASLANIDIS, C; JANSEN, G; AMEMIYA, C; SHUTLER, G; MAHADEVAN, M; TSILFIDIS, C; CHEN, C; ALLEMAN, J; WORMSKAMP, NGM; VOOIJS, M; BUXTON, J; JOHNSON, K; SMEETS, HJM; LENNON, GG; CARRANO, AV; KORNELUK, RG; WIERINGA, B; DEJONG, PJ				ASLANIDIS, C; JANSEN, G; AMEMIYA, C; SHUTLER, G; MAHADEVAN, M; TSILFIDIS, C; CHEN, C; ALLEMAN, J; WORMSKAMP, NGM; VOOIJS, M; BUXTON, J; JOHNSON, K; SMEETS, HJM; LENNON, GG; CARRANO, AV; KORNELUK, RG; WIERINGA, B; DEJONG, PJ			CLONING OF THE ESSENTIAL MYOTONIC-DYSTROPHY REGION AND MAPPING OF THE PUTATIVE DEFECT	NATURE			English	Article							VECTORS; DNA	MYOTONIC dystrophy is a common dominant disorder (global incidence of 1:8,000) with variable onset and a protean nature of symptoms mainly involving progressive muscle wasting, myotonia and cataracts 1. To define the molecular defect, we have cloned the essential region of chromosome 19q13.3, including proximal and distal markers 2-7 in a 700-kilobase contig formed by overlapping cosmids and yeast artificial chromosomes (YACs). The central part of the contig bridges an area of about 350 kilobases between two new flanking crossover borders 4,5. This segment has been extensively characterized through the isolation of five YAC clones and the subsequent subcloning in cosmids from which a detailed EcoRI, HindIII, MluI and NotI restriction map has been derived. Two genomic probes and two homologous complementary DNA probes were isolated using the cosmids. These probes are all situated within approximately 10 kilobases of genomic DNA and detect an unstable genomic segment in myotonic dystrophy patients. The length variation in this segment shows similarities to the instability seen at the fragile X locus 8. The physical map location and the genetic characteristics of the length polymorphism is compatible with a direct role in the pathogenesis of myotonic dystrophy.	UNIV CALIF LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,DIV BIOMED SCI,L-452,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,FAC MED SCI,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,FAC MED SCI,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; CHILDRENS HOSP EASTERN ONTARIO,DIV GENET,OTTAWA K1H 8L1,ONTARIO,CANADA; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1N 6N5,ONTARIO,CANADA; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; Radboud University Nijmegen; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Imperial College London			Buxton, Jessica/L-9849-2019; Jansen, Gert/HCI-8852-2022; Buxton, Jessica L/I-4033-2014; Vooijs, Marc/K-3522-2019; Lennon, Greg/T-4717-2019; Wieringa, Berend/A-5346-2011	Buxton, Jessica L/0000-0002-0918-9335; Wieringa, Berend/0000-0001-9192-8020; Jansen, Gert/0000-0002-7524-171X; johnson, keith/0000-0002-8578-5921				BRANSCOMB E, 1990, GENOMICS, V8, P351, DOI 10.1016/0888-7543(90)90293-4; BROOK JD, 1991, J MED GENET, V28, P84, DOI 10.1136/jmg.28.2.84; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; BUXTON J, IN PRESS GENOMICS; CARRANO AV, 1989, GENOMICS, V4, P129, DOI 10.1016/0888-7543(89)90291-7; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; GRIGGS RC, 1989, NEUROLOGY, V39, P420, DOI 10.1212/WNL.39.3.420; HARLEY HG, 1991, AM J HUM GENET, V49, P68; Harper P.S., 1989, MYOTONIC DYSTROPHY; HERMENS R, 1991, NUCLEIC ACIDS RES, V19, P1726, DOI 10.1093/nar/19.7.1726; JANSEN G, IN PRESS GENOMICS; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LENNON GG, IN PRESS HUM MOL GEN; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; SHUTLER, 1991, GENOMICS, V9, P500; SHUTLER G, IN PRESS NUCLEIC ACI; SHUTLER G, IN PRESS GENOMICS; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; TSILFIDIS C, 1991, AM J HUM GENET, V49, P961; TSILFIDIS C, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157-a; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	25	476	486	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					548	551		10.1038/355548a0	http://dx.doi.org/10.1038/355548a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346925				2022-12-24	WOS:A1992HC52600060
J	SALSER, SJ; KENYON, C				SALSER, SJ; KENYON, C			ACTIVATION OF A C-ELEGANS ANTENNAPEDIA HOMOLOG IN MIGRATING CELLS CONTROLS THEIR DIRECTION OF MIGRATION	NATURE			English	Article							CAENORHABDITIS-ELEGANS; TRANSGENIC MICE; GENE; EXPRESSION; HOMEOBOX; NEMATODE	ANTERIOR-POSTERIOR patterning in insects, vertebrates and nematodes involves members of conserved Antennapedia-class homeobox gene clusters (HOM-C) that are thought to give specific body regions their identities 1-5. The effects of these genes on region-specific body structures have been described extensively, particularly in Drosophila, but little is known about how HOM-C genes affect the behaviours of cells that migrate into their domains of function. In Caenorhabditis elegans, the Antennapedia-like HOM-C gene mab-5 not only specifies postembryonic fates of cells in a posterior body region, but also influences the migration of mesodermal and neural cells that move through this region 5-7. Here we show that as one neuroblast migrates into this posterior region, it switches on mab-5 gene expression; mab-5 then acts as a developmental switch to control the migratory behaviour of the neuroblast descendants. HOM-C genes can therefore not only direct region-specific patterns of cell division and differentiation, but can also act within migrating cells to programme region-specific migratory behaviour.			SALSER, SJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; DAMSKY CH, IN PRESS J CLIN INVE; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HUNT P, 1991, DEVELOPMENT, V112, P43; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; MELLO C, IN PRESS EMBO J; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; STRINGHAM EG, IN PRESS MOL BIOL CE; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0	27	144	147	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					255	258		10.1038/355255a0	http://dx.doi.org/10.1038/355255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1346230				2022-12-24	WOS:A1992GZ69400069
J	GRUNDER, S; THIEMANN, A; PUSCH, M; JENTSCH, TJ				GRUNDER, S; THIEMANN, A; PUSCH, M; JENTSCH, TJ			REGIONS INVOLVED IN THE OPENING OF CIC-2 CHLORIDE CHANNEL BY VOLTAGE AND CELL-VOLUME	NATURE			English	Article							INACTIVATION; MECHANISMS; EXPRESSION	REGULATION of cell volume is essential for every cell and is accomplished by the regulated loss or gain of intracellular ions or other osmolytes1-4. Regulatory volume decrease often involves the parallel activation of potassium and chloride channels5-10. Overexpression of P-glycoprotein leads to volume-activated Cl-currents11,12 but its physiological importance for volume regulation is unclear13. ClC-2 is a ubiquitously expressed Cl- channel14 activatable by non-physiologically strong hyperpolarization. We now show that ClC-2 can be activated by extracellular hypotonicity, which suggests that it has a widespread role in volume regulation. Domains necessary for activation by both voltage and volume are localized to the amino terminus. Mutations in an 'essential' region lead to constitutively open channels unresponsive to medium tonicity, whereas deletions in a 'modulating' region produce partially opened channels responsive to both hypo- and hypertonicity. These domains can be transplanted to different regions of the protein without loss of function.	UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	University of Hamburg	JENTSCH, TJ (corresponding author), UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Pusch, Michael/0000-0002-8644-8847; Jentsch, Thomas/0000-0002-3509-2553				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; CHAN HC, 1992, SCIENCE, V257, P669, DOI 10.1126/science.1379742; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DUBINSKY WP, 1992, P NATL ACAD SCI USA, V89, P1770, DOI 10.1073/pnas.89.5.1770; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KUNZELMANN K, 1992, PFLUG ARCH EUR J PHY, V421, P238, DOI 10.1007/BF00374833; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; PIERCE SK, 1990, ANNU REV PHYSIOL, V52, P27, DOI 10.1146/annurev.ph.52.030190.000331; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WEISS H, 1992, J MEMBRANE BIOL, V126, P109; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	28	381	390	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					759	762		10.1038/360759a0	http://dx.doi.org/10.1038/360759a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334533				2022-12-24	WOS:A1992KE47200040
J	LIN, CJ; LIN, SC; CHANG, CP; ROSENFELD, MG				LIN, CJ; LIN, SC; CHANG, CP; ROSENFELD, MG			PIT-1-DEPENDENT EXPRESSION OF THE RECEPTOR FOR GROWTH-HORMONE RELEASING-FACTOR MEDIATES PITUITARY CELL-GROWTH	NATURE			English	Article							PANCREATIC-ISLET TUMOR; SOMATOSTATIN GENE; MESSENGER-RNA; TRANSCRIPTION; MICE; CREB; PHOSPHORYLATION; HYPERPLASIA; MUTATIONS; DWARFISM	IN Snell (dw) and Jackson (dw(J)) dwarf mice, mutations in the gene encoding Pit-1, a tissue-specific POU-domain transcription factor, lead to the absence of somatotroph, lactotroph and thyrotroph cells1-6. Pre-somatotroph proliferation is stimulated by increased intracellular levels of cyclic AMP, normally induced by growth hormone releasing factor (GRF; refs 7-17). Here we report the cloning of mouse and rat complementary DNAs encoding a new member of the seven-transmembrane-helix, G-protein-coupled receptor family restricted to the pituitary gland, which mediates increases in intracellular cAMP and cAMP-dependent gene transcription in response to GRF. The receptor is expressed in a spatial and temporal pattern corresponding precisely to growth hormone gene expression, and neither is expressed in dw/dw mice. The pituitary hypoplasia in these mice thus appears to be due, at least in part, to the absence of GRF receptor, which is in turn due to the absence of functional Pit-1.	UNIV CALIF SAN DIEGO,SCH & DEPT MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	LIN, CJ (corresponding author), UNIV CALIF SAN DIEGO,SCH & DEPT MED,HOWARD HUGHES MED INST,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		Lin, SC/G-4666-2010					BAIRD A, 1984, REGUL PEPTIDES, V10, P23, DOI 10.1016/0167-0115(84)90049-1; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; FROHMAN LA, 1986, ENDOCR REV, V7, P236; GICK GG, 1984, P NATL ACAD SCI-BIOL, V81, P1553, DOI 10.1073/pnas.81.5.1553; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; ISHIHARA T, 1992, NEURON, V8, P815; ISHIKAWA K, 1986, NEUROENDOCRINOLOGY, V43, P537, DOI 10.1159/000124579; JUPPNER H, 1991, SCIENCE, P1022; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; RIVIER J, 1982, NATURE, V300, P276, DOI 10.1038/300276a0; ROUSE M, 1982, CELL TISSUE RES, V223, P415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT H, 1985, NATURE, V313, P487, DOI 10.1038/313487a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; WILSON DB, 1986, ANAT EMBRYOL, V174, P277, DOI 10.1007/BF00824343; YASHIRO T, 1988, CELL TISSUE RES, V251, P249, DOI 10.1007/BF00215832	35	287	300	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					765	768		10.1038/360765a0	http://dx.doi.org/10.1038/360765a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334535				2022-12-24	WOS:A1992KE47200042
J	NEWENS, AJ; JARVIS, SN; GEORGE, R				NEWENS, AJ; JARVIS, SN; GEORGE, R			HOW TO GAIN WEIGHT BY LOOKING UP	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND; GATESHEAD HLTH AUTHOR,GATESHEAD NE8 3EP,ENGLAND	Newcastle University - UK	JARVIS, SN (corresponding author), UNIV NEWCASTLE UPON TYNE,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							BARELL V, 1988, AM J EPIDEMIOL, V128, P218, DOI 10.1093/oxfordjournals.aje.a114944; Townsend PP., 1988, HLTH DEPRIVATION INE; 1977, MANUAL INT STATISTIC, V1	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1576	1577		10.1136/bmj.305.6868.1576	http://dx.doi.org/10.1136/bmj.305.6868.1576			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286396	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992KD77100033
J	KANAI, Y; HEDIGER, MA				KANAI, Y; HEDIGER, MA			PRIMARY STRUCTURE AND FUNCTIONAL-CHARACTERIZATION OF A HIGH-AFFINITY GLUTAMATE TRANSPORTER	NATURE			English	Article							EXCITATORY AMINO-ACIDS; GLIAL-CELLS; RAT-BRAIN; SEROTONIN TRANSPORTER; EXPRESSION CLONING; RECEPTORS; CARRIER; IDENTIFICATION; METABOLISM; ASPARTATE	GLUTAMATE transport across plasma membranes of neurons, glial cells and epithelial cells of the small intestine and kidney proceeds by high- and low-affinity transport systems1-5. High-affinity (K(m) 2-50 muM) transport systems have been described1,6,7 that are dependent on Na+ but not Cl- ions and have a preference for L-glutamate and D- and L-aspartate. In neurons high-affinity glutamate transporters are essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft6,7. We have isolated a complementary DNA encoding an electrogenic Na+- but not Cl--dependent high-affinity glutamate transporter (named EAAC1) from rabbit small intestine by expression in Xenopus oocytes. We find EAAC1 transcripts in specific neuronal structures in the central nervous system as well as in the small intestine, kidney, liver and heart. The function and pharmacology of the expressed protein are characteristic of the high-affinity glutamate transporter already identified in neuronal tissues. The abnormal glutamate transport that is associated with certain neurodegenerative diseases8 and which occurs during ischaemia and anoxia7 Could be due to abnormalities in the function of this protein.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X				BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; COX DWG, 1977, J NEUROCHEM, V29, P579, DOI 10.1111/j.1471-4159.1977.tb10707.x; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EIEN A, 1992, CAN J NEUROL SCI, V19, P117; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1986, ANAL BIOCHEM, V159, P280, DOI 10.1016/0003-2697(86)90344-1; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; KANAI Y, IN PRESS AM J PHYSL; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KILTY J, 1991, SCIENCE, V254, P78; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROMANO PM, 1989, AM J PHYSIOL, V257, pR180, DOI 10.1152/ajpregu.1989.257.1.R180; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SIESJO BK, 1990, NEWS PHYSIOL SCI, V5, P120; SILBERNAGL S, 1979, KLIN WOCHENSCHR, V57, P1009, DOI 10.1007/BF01479986; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; WANG CD, 1991, MOL PHARMACOL, V40, P168; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WINGROVE TG, 1988, AM J PHYSIOL, V255, pC737, DOI 10.1152/ajpcell.1988.255.6.C737	43	1205	1233	0	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					467	471		10.1038/360467a0	http://dx.doi.org/10.1038/360467a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280334				2022-12-24	WOS:A1992KA79700061
J	ROCA, J; WANG, JC				ROCA, J; WANG, JC			THE CAPTURE OF A DNA DOUBLE HELIX BY AN ATP-DEPENDENT PROTEIN CLAMP - A KEY STEP IN DNA TRANSPORT BY TYPE-II DNA TOPOISOMERASES	CELL			English	Article							NUCLEOTIDE-SEQUENCE; YEAST; GYRASE; SITE; COMPLEXES; HOMOLOGY; CLEAVAGE; MITOSIS; GENE	The binding of linear and circular forms of DNA to yeast DNA topoisomerase II or its complex with AMPPNP, the nonhydrolyzable beta,gamma-imido analog of ATP, was carried out to probe the ATP analog-induced conformational change of the enzyme. Binding of the ATP analog is shown to convert the enzyme to a circular clamp with an annulet, through which only a linear DNA can pass; subsequent circularization of the bound linear DNA forms a salt-stable catenane between the protein circular clamp and the DNA ring. Analysis of catenane formation between a small DNA ring originally bound to the topoisomerase and a large DNA ring subsequently added, under conditions such that the two do not exchange, supports a model in which a second DNA double-helix can enter the open jaws of a DNA-bound protein clamp, and the closure of the jaws upon ATP-binding traps the second duplex and transports it through an enzyme-operated gate in the first DNA duplex.			ROCA, J (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Roca, Joaquim/AAP-1077-2020	Roca, Joaquim/0000-0003-1462-954X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; CARON PR, 1992, IN PRESS 1991 INT S; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; GOTO T, 1982, J BIOL CHEM, V257, P5866; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; HUANG WM, 1990, DNA TOPOLOGY ITS BIO, P265; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MIZZUUCHI K, 1980, PNAS, V77, P1847; MORRISON A, 1980, J BIOL CHEM, V255, P2211; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1980, MECHANISTIC STUDIES, P769; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YANAGIDA M, 1987, NUCLEIC ACIDS MOL BI, V1, P196; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	36	297	305	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					833	840		10.1016/0092-8674(92)90558-T	http://dx.doi.org/10.1016/0092-8674(92)90558-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330327				2022-12-24	WOS:A1992JZ63300012
J	SHWEIKI, D; ITIN, A; SOFFER, D; KESHET, E				SHWEIKI, D; ITIN, A; SOFFER, D; KESHET, E			VASCULAR ENDOTHELIAL GROWTH-FACTOR INDUCED BY HYPOXIA MAY MEDIATE HYPOXIA-INITIATED ANGIOGENESIS	NATURE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN; GLIOBLASTOMA-MULTIFORME; MESSENGER-RNA; EXPRESSION; GENE; SECRETE; PROTEIN; TUMORS; LINE	INEFFICIENT vascular supply and the resultant reduction in tissue oxygen tension often lead to neovascularization in order to satisfy the needs of the tissue1. Examples include the compensatory development of collateral blood vessels in ischaemic tissues that are otherwise quiescent for angiogenesis and angiogenesis associated with the healing of hypoxic wounds2. But the presumptive hypoxia-induced angiogenic factors that mediate this feedback response have not been identified. Here we show that vascular endothelial growth factor (VEGF; also known as vascular permeability factor) probably functions as a hypoxia-inducible angiogenic factor. VEGF messenger RNA levels are dramatically increased within a few hours of exposing different cell cultures to hypoxia and return to background when normal oxygen supply is resumed. In situ analysis of tumour specimens undergoing neovascularization show that the production of VEGF is specifically induced in a subset of glioblastoma cells distinguished by their immediate proximity to necrotic foci (presumably hypoxic regions) and the clustering of capillaries alongside VEGF-producing cells.	HADASSAH HEBREW UNIV HOSP,MED CTR,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL; HADASSAH HEBREW UNIV HOSP,MED CTR,DEPT PATHOL,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	SHWEIKI, D (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL.		Keshet, Eli/GQR-0445-2022					ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HIRANO A, 1975, HUM PATHOL, V6, P611, DOI 10.1016/S0046-8177(75)80045-1; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JELLINGER K, 1978, ACTA NEUROCHIR, V42, P5, DOI 10.1007/BF01406628; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KINASEWITZ GT, 1986, J APPL PHYSIOL, V61, P554, DOI 10.1152/jappl.1986.61.2.554; KNIGHTON D, 1987, CURRENT COMMUNICATIO, P150; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OLSEN SP, 1986, BRAIN RES, V368, P24; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x	30	3726	3915	7	286	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					843	845		10.1038/359843a0	http://dx.doi.org/10.1038/359843a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279431				2022-12-24	WOS:A1992JV77700068
J	JOHNSON, SW; SEUTIN, V; NORTH, RA				JOHNSON, SW; SEUTIN, V; NORTH, RA			BURST FIRING IN DOPAMINE NEURONS INDUCED BY N-METHYL-D-ASPARTATE - ROLE OF ELECTROGENIC SODIUM-PUMP	SCIENCE			English	Article							VENTRAL TEGMENTAL AREA; FREELY MOVING RATS; PARKINSONS-DISEASE; ELECTROPHYSIOLOGICAL PROPERTIES; IMPULSE FLOW; INVITRO; SYSTEM; INVIVO; MIDBRAIN; DRUGS	Dopamine-containing neurons of the mammalian midbrain are required for normal behavior and movements. In vivo they fire action potentials in bursts, but in vitro they discharge regularly spaced action potentials. Burst firing in vitro has now been shown to be robustly induced by the glutamate agonist N-methyl-D-aspartate (NMDA) although not by the non-NMDA agonists kainate or quisqualate. The hyperpolarization between bursts of action potentials results from electrogenic sodium ion extrusion by a ouabain-sensitive pump. This mechanism of burst generation in mammalian neurons may be important in the pathophysiology of schizophrenia and Parkinson's disease.	OREGON HLTH SCI UNIV, DEPT NEUROL, PORTLAND, OR 97201 USA	Oregon Health & Science University	JOHNSON, SW (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022					ADAMS WB, 1985, J PHYSIOL-LONDON, V360, P69, DOI 10.1113/jphysiol.1985.sp015604; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; Bjorklund A., 1984, HDB CHEM NEUROANAT 1, V2, P55; CHARLETY PJ, 1991, ACTA PHYSIOL SCAND, V142, P105, DOI 10.1111/j.1748-1716.1991.tb09134.x; CHRISTIE MJ, 1985, BRAIN RES, V333, P169, DOI 10.1016/0006-8993(85)90140-4; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COOK NS, 1985, J PHYSIOL-LONDON, V358, P373, DOI 10.1113/jphysiol.1985.sp015556; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; FREEMAN AS, 1985, LIFE SCI, V36, P1983, DOI 10.1016/0024-3205(85)90448-5; GONON FG, 1988, NEUROSCIENCE, V24, P19, DOI 10.1016/0306-4522(88)90307-7; GONON FG, 1985, NEUROSCIENCE, V14, P765, DOI 10.1016/0306-4522(85)90141-1; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRACE AA, 1984, J NEUROSCI, V4, P2877; GRACE AA, 1989, J NEUROSCI, V9, P3463; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; KRAMER RH, 1985, J PHYSIOL-LONDON, V362, P131, DOI 10.1113/jphysiol.1985.sp015667; LACEY MG, 1988, J PHYSIOL-LONDON, V406, pP18; LACEY MG, 1989, J NEUROSCI, V9, P1233; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Luria A.R., 1969, HDB CLIN NEUROLOGY V, P725; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; ROMO R, 1990, J NEUROPHYSIOL, V63, P592, DOI 10.1152/jn.1990.63.3.592; ROSS ED, 1981, NEUROLOGY, V31, P1435, DOI 10.1212/WNL.31.11.1435; RUSSELL WR, 1948, LANCET, V254, P356; SANGHERA MK, 1984, NEUROSCIENCE, V12, P793, DOI 10.1016/0306-4522(84)90171-4; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULTZ W, 1986, J NEUROPHYSIOL, V56, P1439, DOI 10.1152/jn.1986.56.5.1439; SEEMAN P, 1975, SCIENCE, V188, P1217, DOI 10.1126/science.1145194; SHEPARD PD, 1991, EXP BRAIN RES, V86, P141, DOI 10.1007/BF00231048; SMITH TG, 1975, NATURE, V253, P450, DOI 10.1038/253450a0; SNYDER SH, 1976, AM J PSYCHIAT, V133, P197; STRECKER RE, 1985, BRAIN RES, V361, P339, DOI 10.1016/0006-8993(85)91304-6; SVENSSON TH, 1989, ACTA PHYSIOL SCAND, V136, P135, DOI 10.1111/j.1748-1716.1989.tb08640.x; WHITTAM R, 1962, BIOCHEM J, V82, P205, DOI 10.1042/bj0820205; WISE RA, 1988, ANN NY ACAD SCI, V537, P228; YUNG WH, 1991, J PHYSIOL-LONDON, V436, P643, DOI 10.1113/jphysiol.1991.sp018571	44	378	386	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					665	667		10.1126/science.1329209	http://dx.doi.org/10.1126/science.1329209			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329209				2022-12-24	WOS:A1992JU74500062
J	FUKAMI, K; FURUHASHI, K; INAGAKI, M; ENDO, T; HATANO, S; TAKENAWA, T				FUKAMI, K; FURUHASHI, K; INAGAKI, M; ENDO, T; HATANO, S; TAKENAWA, T			REQUIREMENT OF PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE FOR ALPHA-ACTININ FUNCTION	NATURE			English	Article							CAPPING PROTEIN; SMOOTH-MUSCLE; POLYPHOSPHOINOSITIDE; COMPLEXES; GELSOLIN	INOSITOL phospholipid turnover is enhanced during mitogenic stimulation of cells by growth factors1 and the breakdown of phosphatidylinositol 4,5-bisphosphate (PtdInsP2) may be important in triggering cell proliferation. PtdInsP2 also binds actin-binding proteins to regulate their activity2-7, but it is not yet understood how this control is achieved. The protein alpha-actinin from striated muscle contains large amounts of endogenous PtdInsP2, whereas that from smooth muscle has only a little but will bind exogenously added PtdInsP2. In vitro alpha-actinin binds to F-actin and will crosslink actin filaments, increasing the viscosity of F-actin solutions8,9. We report here that alpha-actinin from striated muscle is an endogenous PtdInsP2-bound protein and that the specific interaction between alpha-actinin and PtdInsP2 regulates the F-actin-gelating activity of alpha-actinin. Although the F-actin-gelating activity of alpha-actinin from smooth muscle is much reduced compared with that from striated muscle, exogenous PtdInsP2 can enhance the activity of smooth muscle alpha-actinin to the level seen in striated muscles. These results show that PtdInsP2 is present in striated muscle alpha-actinin and that it is necessary for alpha-actinin to realize its maximum gelating activity.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,SAKAE CHO,ITABASHI KU,TOKYO 173,JAPAN; CHIBA UNIV,DEPT BIOL,YAYOI,CHIBA 260,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Chiba University; Aichi Cancer Center; Nagoya University			Inagaki, Masaki/B-9920-2016					ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FURUHASHI K, 1992, BIOCHEM BIOPH RES CO, V184, P121; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOBAYASHI R, 1984, EUR J BIOCHEM, V143, P125, DOI 10.1111/j.1432-1033.1984.tb08351.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MARUYAMA K, 1965, J BIOCH, V58, P7; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MEYER RK, 1982, P NATL ACAD SCI-BIOL, V79, P4280, DOI 10.1073/pnas.79.14.4280; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	23	310	316	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					150	152		10.1038/359150a0	http://dx.doi.org/10.1038/359150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1326084				2022-12-24	WOS:A1992JM49400053
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNINGS ISSUED ON NONSEDATING ANTIHISTAMINES TERFENADINE AND ASTEMIZOLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					705	705		10.1001/jama.268.6.705	http://dx.doi.org/10.1001/jama.268.6.705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1322467				2022-12-24	WOS:A1992JG66600004
J	BIRREN, SJ; VERDI, JM; ANDERSON, DJ				BIRREN, SJ; VERDI, JM; ANDERSON, DJ			MEMBRANE DEPOLARIZATION INDUCES P140(TRK) AND NGF RESPONSIVENESS, BUT NOT P75(LNGFR), IN MAH CELLS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; SUPERIOR CERVICAL-GANGLION; NEURONAL DIFFERENTIATION; SYMPATHETIC NEURONS; CHROMAFFIN CELLS; RECEPTOR; GLUCOCORTICOIDS; EXPRESSION; DEPENDENCE; DEATH	Nerve growth factor (NGF) is required for the maturation and survival of sympathetic neurons, but the mechanisms controlling expression of the NGF receptor in developing neuroblasts have not been defined. MAH cells, an immortalized sympathoadrenal progenitor cell line, did not respond to NGF and expressed neither low-affinity NGF receptor (p75) nor p140trk messenger RNAs. Depolarizing concentrations of potassium chloride, but none of a variety of growth factors, induced expression of p140trk but not p75 messenger RNA. A functional response to NGF was acquired by MAH cells under these conditions, suggesting that expression of p75 is not essential for this response. Depolarization also permitted a relatively high proportion of MAH cells to develop and survive as neurons in fibroblast growth factor and NGF. These data establish a relation between electrical activity and neurotrophic factor responsiveness in developing neurons, which may operate in the functioning of the mature nervous system as well.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute					NINDS NIH HHS [NS23476] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BIRREN SJ, UNPUB; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COUGHLIN MD, 1985, DEV BIOL, V110, P392, DOI 10.1016/0012-1606(85)90098-3; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; ERNSBERGER U, 1989, DEV BIOL, V135, P250, DOI 10.1016/0012-1606(89)90177-2; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KORSCHING S, 1988, DEV BIOL, V126, P40, DOI 10.1016/0012-1606(88)90236-9; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; MADERDRUT JL, 1988, BRAIN RES, V444, P189, DOI 10.1016/0006-8993(88)90928-6; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; RUBIN E, 1985, J NEUROSCI, V5, P673; RUBIN E, 1985, J NEUROSCI, V5, P697; RUBIN E, 1985, J NEUROSCI, V5, P685; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; UNSICKER K, 1989, INT J DEV NEUROSCI, V7, P413, DOI 10.1016/0736-5748(89)90002-6; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A	29	128	129	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					395	397		10.1126/science.1321502	http://dx.doi.org/10.1126/science.1321502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321502				2022-12-24	WOS:A1992JD67400036
J	KEREM, E; REISMAN, J; COREY, M; CANNY, GJ; LEVISON, H				KEREM, E; REISMAN, J; COREY, M; CANNY, GJ; LEVISON, H			PREDICTION OF MORTALITY IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-LUNG TRANSPLANTATION; PROGNOSTIC FACTORS; SURVIVAL; SEX; AGE	Background. The majority of patients with cystic fibrosis die in early adulthood of lung disease. Lung transplantation is a treatment option for patients with advanced pulmonary disease, although the waiting period for organs may be as long as two years. Our purpose was to determine whether the risk of death due to respiratory failure could be predicted one or two years in advance on the basis of pulmonary function, blood gas levels, and nutritional status. Methods. The study cohort consisted of 673 patients followed between 1977 and 1989. In each patient, pulmonary function, blood gas levels, nutritional status, and vital status were assessed between 1977 and 1987. Cox proportional-hazards regression analysis was used to compute the relative risk of death within one or two years after particular measurements. The effects of age and sex on mortality were also included in the analysis. Results. One hundred ninety patients (28 percent) died during the study period. Overall, patients with a forced expiratory volume in one second (FEV1) less than 30 percent of the predicted value, a partial pressure of arterial oxygen below 55 mm Hg, or a partial pressure of arterial carbon dioxide above 50 mm Hg had two-year mortality rates above 56 percent. Among the laboratory measurements, the FEV1 was the most significant predictor of mortality, but age and sex were also significant in predicting risk. After adjustment for age and sex, the relative risk of death within two years was 2.0 (95 percent confidence interval, 1.9 to 2.2) for each decrement in the FEV1 of 10 percent below the predicted value. Among patients with the same FEV1, the relative risk of death was 2.0 (95 percent confidence interval, 1.5 to 2.6) in patients 10 years younger than other patients, and 2.2 (1.6 to 3.1) in female patients as compared with male patients. Conclusions. Patients with cystic fibrosis should be considered candidates for lung transplantation when the FEV1 falls below 30 percent of the predicted value. Female patients and younger patients may need to be considered for transplantation at an earlier stage.	HOSP SICK CHILDREN,DEPT PEDIAT,DIV PULM,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BRITTON JR, 1989, BRIT MED J, V298, P483, DOI 10.1136/bmj.298.6672.483; CANNY GJ, 1986, PEDIATR PULM, V2, P313; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; HUANG NN, 1987, AM J MED, V82, P871, DOI 10.1016/0002-9343(87)90147-1; HUDSON I, 1987, PEDIATR PULM, V3, P288, DOI 10.1002/ppul.1950030503; HUTTER JA, 1988, AM J MED, V85, P4, DOI 10.1016/0002-9343(88)90496-2; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; MACLUSKY I, 1990, DISORDERS RESP TRACT, P692; MOORE DJ, 1985, NUTR RES, V5, P797, DOI 10.1016/S0271-5317(85)80167-6; ORENSTEIN DM, 1991, CHEST, V100, P1016, DOI 10.1378/chest.100.4.1016; PHELAN P, 1984, ARCH DIS CHILD, V59, P71, DOI 10.1136/adc.59.1.71; SCOTT J, 1988, LANCET, V2, P192; SITAL A, 1991, NEW ENGL J MED, V325, P1243; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; VEATCH RM, 1991, NEW ENGL J MED, V325, P1246, DOI 10.1056/NEJM199110243251711; WAGENER JS, 1980, PERSPECTIVES CYSTIC, P236; WHITEHEAD B, 1991, ARCH DIS CHILD, V66, P1018, DOI 10.1136/adc.66.9.1018; WHITEHEAD B, 1991, ARCH DIS CHILD, V66, P1022, DOI 10.1136/adc.66.9.1022; WOOD RE, 1984, CYSTIC FIBROSIS, P434; 1989, 1989 CAN CYST FIBR F; [No title captured]; 1988, BMJ, V297, P1599	23	735	751	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1187	1191		10.1056/NEJM199204303261804	http://dx.doi.org/10.1056/NEJM199204303261804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1285737				2022-12-24	WOS:A1992HR00800004
J	SABOOR, SA; JOHNSON, NM; MCFADDEN, J				SABOOR, SA; JOHNSON, NM; MCFADDEN, J			DETECTION OF MYCOBACTERIAL DNA IN SARCOIDOSIS AND TUBERCULOSIS WITH POLYMERASE CHAIN-REACTION	LANCET			English	Article							DIAGNOSIS	The cause of sarcoidosis is unknown. However, the histological similarity between the disorder and tuberculosis suggests that mycobacteria might contribute to the pathogenesis of sarcoidosis. We have used the polymerase chain reaction (PCR) to detect mycobacterial DNA in clinical samples from patients with sarcoidosis. 104 patients were included in the study (62 referred for possible tuberculosis and 20 for possible sarcoidosis, and 22 control patients who had undergone bronchoscopy for other reasons). Bronchoalveolar lavage samples, bronchial washings, and tissue specimens (1 from each patient) underwent assay by PCR as well as bacteriological, histological, and cytological examination. We used two PCR reactions: in the first the complex-specific insertion sequence IS986/IS6110 was used to specifically detect DNA from Mycobacterium tuberculosis complex bacteria; in the second, conserved sequences of the mycobacterial groEL gene were used to detect DNA from mycobacteria other than M tuberculosis. The PCR was more sensitive than culture for diagnosis of tuberculosis. However, the false-positive PCR rate for M tuberculosis was 9%. M tuberculosis DNA was found in half the sarcoidosis patients, and non-tuberculosis mycobacterial DNA in a further 20%. The findings that a significant proportion of the sarcoidosis patients in this study have mycobacteria in their lungs and that most of these mycobacteria belong to M tuberculosis complex suggest an aetiological role for mycobacteria in sarcoidosis.	UNIV SURREY,SCH BIOL SCI,MOLEC MICROBIOL GRP,GUILDFORD GU2 5XH,SURREY,ENGLAND; UNIV LONDON UNIV COLL,UNIV COLL & MIDDLESEX SCH MED,LONDON WC1E 6BT,ENGLAND; WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,LONDON N19 5NF,ENGLAND	University of Surrey; University of London; University College London; University of London; University College London				McFadden, Johnjoe/0000-0003-2145-0046				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRISSONNOEL A, 1991, LANCET, V338, P364, DOI 10.1016/0140-6736(91)90492-8; BURNET FM, 1959, CLONAL SELECTION THE, P160; DEWIT MYL, 1991, J CLIN MICROBIOL, V29, P906, DOI 10.1128/JCM.29.5.906-910.1991; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; Higuchi R., 1989, PCR TECHNOLOGY, P61; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; MUSCOVIC EA, 1978, PATHOL ANNU, V13, P69; Sambrook J., 1989, MOL CLONING LAB MANU; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668, DOI 10.1128/JCM.28.12.2668-2673.1990; VANEK J, 1970, AM REV RESPIR DIS, V101, P395; WALTERS EH, 1991, THORAX, V46, P613, DOI 10.1136/thx.46.9.613; WARRING FC, 1970, AM REV RESPIR DIS, V102, P714	16	225	228	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1012	1015		10.1016/0140-6736(92)90535-B	http://dx.doi.org/10.1016/0140-6736(92)90535-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349051				2022-12-24	WOS:A1992HQ43500003
J	ASHER, J				ASHER, J			COCAINE TOXICITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ASHER, J (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, BRAIN RES, V542, P1	1	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1584	1584		10.1001/jama.267.12.1584	http://dx.doi.org/10.1001/jama.267.12.1584			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1311777				2022-12-24	WOS:A1992HJ59700007
J	FARAG, SS; GREEN, MD; MORSTYN, G; SHERIDAN, WP; FOX, RM				FARAG, SS; GREEN, MD; MORSTYN, G; SHERIDAN, WP; FOX, RM			DELAY BY INTERNISTS IN OBTAINING DIAGNOSTIC BIOPSIES IN PATIENTS WITH SUSPECTED CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BIOPSY; LYMPHOMA; GASTROINTESTINAL NEOPLASMS; LUNG NEOPLASMS; COST CONTROL	UNKNOWN PRIMARY; METASTATIC CANCER; PRIMARY SITE; ORIGIN; ADENOCARCINOMA; CARCINOMA	Objective: To investigate the degree and type of delays in performing diagnostic biopsies in medical patients with suspected malignancy. Design: Retrospective survey of clinical histories of patients referred between January 1985 and March 1989. Setting: Inner city teaching hospital internal medicine (nononcologic) services. Patients: Patients with gastrointestinal and lung cancers, adenocarcinoma of unknown primary site, and lymphomas were referred as inpatients by internists. Two hundred fifty-five patients were eligible, and 177 were evaluable. Main Outcome Measures: The number, type, and results of tests done before and after biopsy were analyzed. Results: In 67% of patients the biopsied lesion was detected by the second day of evaluation; however, there was an 8- to 10-day delay before a biopsy was done. This delay was consistent across the four malignancy groups studied. Although logistic and other unavoidable delays occurred in 40% of the cases, in 60% delays could only be attributed to continued, frequently low yield, noninvasive tests. An average of 3.3 tests were made per patient, with only 24% leading to a definitive biopsy. Conclusion: Because of the performance of many other tests, a substantial delay exists in proceeding to biopsy during the diagnosis of cancer by internists.	ROYAL MELBOURNE HOSP, DEPT MED ONCOL, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital				Sheridan, William/0000-0001-8320-1323				GRECO FA, 1986, ANN INTERN MED, V104, P547, DOI 10.7326/0003-4819-104-4-547; GREENBERG BR, 1988, MED CLIN N AM, V72, P1055, DOI 10.1016/S0025-7125(16)30729-5; KIRSTEN F, 1987, OJ MED, V238, P143; LEVINE MN, 1985, CAN MED ASSOC J, V133, P977; MOERTEL CG, 1972, CANCER-AM CANCER SOC, V30, P1469, DOI 10.1002/1097-0142(197212)30:6<1469::AID-CNCR2820300609>3.0.CO;2-T; NYSTROM JS, 1979, JAMA-J AM MED ASSOC, V241, P381, DOI 10.1001/jama.241.4.381; NYSTROM JS, 1977, SEMIN ONCOL, V4, P53; SIMPSON GT, 1980, OTOLARYNG CLIN N AM, V13, P489; STEWART JF, 1979, BRIT MED J, V1, P1530, DOI 10.1136/bmj.1.6177.1530; ULTMANN JE, 1980, HARRISONS PRINCIPLES, P1583; ULTMANN JE, 1987, CANCER PRINCIPLES PR, P1843	11	21	21	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					473	478		10.7326/0003-4819-116-6-473	http://dx.doi.org/10.7326/0003-4819-116-6-473			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1310838				2022-12-24	WOS:A1992HJ59800007
J	KYLE, WS				KYLE, WS			SIMIAN RETROVIRUSES, POLIOVACCINE, AND ORIGIN OF AIDS	LANCET			English	Editorial Material																		ESSEX M, 1988, SCI AM, V259, P64, DOI 10.1038/scientificamerican1088-64; LINCOLN C, 1976, SCHOH LETT, V26, P1; MILSTIEN JB, 1975, J CLIN MICROBIOL, V1, P353, DOI 10.1128/JCM.1.4.353-358.1975; TAGER A, 1974, DERMATOLOGICA, V149, P253, DOI 10.1159/000251529; 1982, NEW ENGL J MED, V306, P252; 1980, FED REGISTER, V45, P25652; 1959, 1ST INT C LIV POL VA, P324; 1961, DEV RESPECT MANUFACT, P317	8	17	18	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					600	601		10.1016/0140-6736(92)90876-5	http://dx.doi.org/10.1016/0140-6736(92)90876-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347104				2022-12-24	WOS:A1992HH07500014
J	UCHIGATA, Y; KUWATA, S; TOKUNAGA, K; EGUCHI, Y; TAKAYAMAHASUMI, S; MIYAMOTO, M; OMORI, Y; JUJI, T; HIRATA, Y				UCHIGATA, Y; KUWATA, S; TOKUNAGA, K; EGUCHI, Y; TAKAYAMAHASUMI, S; MIYAMOTO, M; OMORI, Y; JUJI, T; HIRATA, Y			STRONG ASSOCIATION OF INSULIN AUTOIMMUNE SYNDROME WITH HLA-DR4	LANCET			English	Note								Insulin autoimmune syndrome is characterised by spontaneous hypoglycaemia without evidence of exogenous insulin administration, a high serum concentration of total immunoreactive insulin, and the presence of insulin autoantibodies in high titre. HLA typing of 27 patients with insulin autoimmune syndrome showed that all had DR4, which was present in only 43% of 51 healthy controls (odds ratio 72.1, p < 2 x l0(-6), and 19 (70%) of the patients were positive for the allelic combination, Cw4, Bw62, and DR4. Analysis of the nucleotide sequences of the DRB1, DQA1, and DQB1 genes showed that all the patients had DRB1*0406, DQA1*0301, and DQB1*0302, compared with only 14% of the controls (odds ratio 281, p < 1 x 10(-10)). We conclude that the development of insulin autoimmune syndrome is associated with a strong genetic predisposition.	UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,TOKYO 113,JAPAN	University of Tokyo	UCHIGATA, Y (corresponding author), TOKYO WOMENS MED COLL,CTR DIABET,8-1 KAWADA CHO,SHINJUKU KU,TOKYO 162,JAPAN.							BRONSTEIN I, 1989, NATURE, V338, P599, DOI 10.1038/338599a0; EGUCHI Y, 1989, Journal of the Japan Diabetes Society, V32, P887; HIRATA Y, 1983, LANCET, V2, P1037; Hirata Y., 1987, HYPOGLYCEMIA, P105; Hirata Y, 1970, J JPN DIABET SOC, V13, P312; PALMER JP, 1987, DIABETES METAB REV, V3, P1005, DOI 10.1002/dmr.5610030409; TOKUNAGA K, 1985, IMMUNOGENETICS, V22, P359, DOI 10.1007/BF00430919; WILKIN TJ, 1987, HYPOGLYCEMIA, P119; ZIEGLER R, 1991, DIABETES, V40, P709, DOI 10.2337/diabetes.40.6.709	9	83	97	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					393	394		10.1016/0140-6736(92)90080-M	http://dx.doi.org/10.1016/0140-6736(92)90080-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346661				2022-12-24	WOS:A1992HD65900005
J	ETTEHADIEH, E; SANGHERA, JS; PELECH, SL; HESSBIENZ, D; WATTS, J; SHASTRI, N; AEBERSOLD, R				ETTEHADIEH, E; SANGHERA, JS; PELECH, SL; HESSBIENZ, D; WATTS, J; SHASTRI, N; AEBERSOLD, R			TYROSYL PHOSPHORYLATION AND ACTIVATION OF MAP KINASES BY P56LCK	SCIENCE			English	Article							SERINE-THREONINE KINASE; CELL-CYCLE CONTROL; PROTEIN-KINASE; LYMPHOCYTES-T; CD4 RECEPTOR; CYTOPLASMIC DOMAINS; INSULIN; STIMULATION; MATURATION; COMPLEXES	T cell signaling via the CD4 surface antigen is mediated by the associated tyrosyl protein kinase p56lck. The 42-kilodalton mitogen-activated protein (MAP) kinase (p42mapk) was tyrosyl-phosphorylated and activated after treatment of the murine T lymphoma cell line 171CD4+, which expresses CD4, with antibody to CD3. Treatment of the CD4-deficient cell line 171 with the same antibody did not result in phosphorylation or activation of p42mapk. Purified p56lck both tyrosyl-phosphorylated and stimulated the seryl-threonyl phosphotransferase activity of purified p44mpk, a MAP kinase isoform from sea star oocytes. A synthetic peptide modeled after the putative regulatory phosphorylation site in murine p42mapk (Tyr185) was phosphorylated by p56lck with a similar V(max), but a fivefold lower Michaelis constant (K(m)) than a peptide containing the Tyr394 autophosphorylation site from p56lck. MAP kinases may participate in protein kinase cascades that link Src family protein-tyrosyl kinases to seryl-threonyl kinases such as those encoded by rsk and raf, which are putative substrates of MAP kinases.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of California System; University of California Berkeley; University of British Columbia; University of British Columbia					PHS HHS [R126604] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN NG, 1991, J BIOL CHEM, V256, P11487; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAREST D, IN PRESS; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTH Y, 1991, EMBO J, V10, P2661; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOSHI M, 1988, J BIOL CHEM, V263, P5396; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; NEL AE, 1991, J IMMUNOL, V147, P1933; NEL AE, 1990, J IMMUNOL, V145, P971; NEL AE, 1990, J IMMUNOL, V144, P2683; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SANGHERA J, UNPUB; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WATTS JD, 1992, IN PRESS J BIOL CHEM	48	138	141	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					853	855		10.1126/science.1311128	http://dx.doi.org/10.1126/science.1311128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1311128				2022-12-24	WOS:A1992HD54800039
J	MERTZ, GJ; BENEDETTI, J; ASHLEY, R; SELKE, SA; COREY, L				MERTZ, GJ; BENEDETTI, J; ASHLEY, R; SELKE, SA; COREY, L			RISK-FACTORS FOR THE SEXUAL TRANSMISSION OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES GENITALIS; HERPESVIRUS-HOMINIS; SEXUALLY TRANSMITTED DISEASES, VIRAL; ANTIBODIES, VIRAL; PREGNANCY COMPLICATIONS, INFECTIOUS	SIMPLEX VIRUS-INFECTIONS; DOUBLE-BLIND; ORAL ACYCLOVIR; TYPE-2; ACQUISITION; SUPPRESSION; ANTIBODIES; GONORRHEA; PARTNER; TRIAL	Objective: To determine the risk of sexual transmission of genital herpes simplex virus (HSV) in heterosexual couples. Design: Prospective study of couples who were participants in a clinical trial. Each source partner had symptomatic, recurrent genital HSV, and each susceptible partner was without serologic or clinical evidence of genital herpes. Couples were followed for a median of 334 days. Setting: Two university-based research clinics. Patients: One hundred forty-four heterosexual couples were studied out of an initial enrollment of 214 couples. Main Outcome Measures: Development of culture-proven HSV infection or type-specific antibodies in the susceptible partner. Main Results: Transmission occurred in 14 (9.7%) couples, including 11 (16.9%) of 65 couples with male and 3 (3.8%) of 79 with female source partners (P = 0.05). The annual rate of acquisition was higher (31.8%) in susceptible, female partners who lacked antibodies to either HSV type 1 or 2 at entry compared with females with HSV type 1 antibodies at entry (9.1%). Couples avoiding transmission of HSV reported fewer days with genital lesions in source partners. Detailed histories were available at the time of transmission in 13 couples. In nine couples, transmission occurred when the source partner was reported to be asymptomatic and in four, it resulted from sexual contact at the time of prodrome (1 case) or within hours before lesions were first noticed by the source partner (3 cases). Conclusions: Despite clear recognition of genital herpes in source partners, there was substantial risk for transmission; in 70% of patients, transmission appeared to result from sexual contact during periods of asymptomatic viral shedding. The risk for acquisition of HSV was higher in women than men, and previous HSV type 1 infection appeared to reduce the risk for acquisition of HSV type 2 infection among women.	UNIV NEW MEXICO, DEPT MED, ALBUQUERQUE, NM 87131 USA; UNIV WASHINGTON, PACIFIC MED CTR,DEPT LAB MED,ROOM 9301, 1200 12TH AVE S, SEATTLE, WA 98144 USA	University of New Mexico; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-20381, AI-30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731, R01AI020381] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1987, J VIROL, V61, P264, DOI 10.1128/JVI.61.2.264-268.1987; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BERNSTEIN DI, 1985, J MED VIROL, V15, P251, DOI 10.1002/jmv.1890150306; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; Handsfield H.H., 1990, PRINCIPLES PRACTICE, P1613; HOLMES KK, 1970, AM J EPIDEMIOL, V91, P170, DOI 10.1093/oxfordjournals.aje.a121125; HOOPER RR, 1978, AM J EPIDEMIOL, V108, P136, DOI 10.1093/oxfordjournals.aje.a112597; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; THIN RNT, 1971, BRIT J VENER DIS, V47, P27; WENTWORTH BB, 1973, HEALTH LAB SCI, V10, P75; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; YEAGER AS, 1984, PEDIATRICS, V73, P188	22	385	395	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					197	202		10.7326/0003-4819-116-3-197	http://dx.doi.org/10.7326/0003-4819-116-3-197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1309413				2022-12-24	WOS:A1992HB35600004
J	MICHEL, G; RITTER, A; GERKEN, G; ZUMBUSCHENFELDE, KHM; DECKER, R; MANNS, MP				MICHEL, G; RITTER, A; GERKEN, G; ZUMBUSCHENFELDE, KHM; DECKER, R; MANNS, MP			ANTI-GOR AND HEPATITIS-C VIRUS IN AUTOIMMUNE LIVER-DISEASES	LANCET			English	Article							AUTOANTIBODIES; ANTIBODIES	Anti-GOR is an autoantibody found in hepatitis C virus (HCV) infection. We have studied the specificity of this antibody for HCV infection in various groups of autoimmune liver diseases. Anti-HCV was detected by a second generation HCV enzyme-linked immunosorbent assay in 14 of 29 patients with liver-kidney-microsomal (LKM-1) -antibody-positive autoimmune hepatitis type 2 and in all 6 control patients with HCV-RNA-positive chronic hepatitis C. Anti-HCV was not found in those with antinuclear-antibody-positive autoimmune hepatitis type 1 (10 patients), with soluble-liver-protein-antibody-positive autoimmune hepatitis type 3 (8), with primary biliary cirrhosis (9), with systemic lupus erythematosus (SLE) (10), or in healthy controls (13). Anti-GOR was detected in 11 of 14 patients with autoimmune hepatitis type 2 who were all positive for anti-HCV but only in 1 of 15 LKM-1 patients who were negative for anti-HCV. We did not find anti-GOR in any other group of autoimmune liver disease, SLE, or control sera, but this antibody was detected in 3 of 6 patients with chronic hepatitis C. Autoimmune hepatitis type 2 patients who were anti-GOR positive and anti-HCV positive were less likely to be female, were older (p < 0.001), and had lower LKM-1 antibody titres (p < 0.001), lower disease activity, and responded less effectively to immuno- suppression than did those who were anti-HCV negative/anti-GOR negative. The findings show that anti-GOR reflects HCV-specific autoimmunity. HCV seems to induce autoimmunity to both GOR (an HCV-specific autoepitope) and LKM-1 (an epitope that is also recognised by autoimmune hepatitis sera of a different cause). Anti-GOR and LKM-1 antibodies contribute to a better differentiation of chronic hepatitis, a finding that has therapeutic implications.	MED HSCH HANNOVER,ZENTRUM INNERE MED,DEPT GASTROENTEROL & HEPATOL,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY; ABBOTT LABS,EUROPEAN RES & DEV,WIESBADEN,GERMANY; UNIV MAINZ,DEPT MED 1,W-6500 MAINZ,GERMANY	Hannover Medical School; Johannes Gutenberg University of Mainz								ESTEBAN JI, 1989, LANCET, V2, P294; FUSCONI M, 1990, LANCET, V336, P823, DOI 10.1016/0140-6736(90)93297-3; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MANNS M, 1989, J HEPATOL, V9, P272, DOI 10.1016/0168-8278(89)90063-9; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; VENTO S, 1989, LANCET, V2, P926; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	11	193	192	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					267	269		10.1016/0140-6736(92)91332-3	http://dx.doi.org/10.1016/0140-6736(92)91332-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346282				2022-12-24	WOS:A1992HB52900004
J	RAJFER, J; ARONSON, WJ; BUSH, PA; DOREY, FJ; IGNARRO, LJ				RAJFER, J; ARONSON, WJ; BUSH, PA; DOREY, FJ; IGNARRO, LJ			NITRIC-OXIDE AS A MEDIATOR OF RELAXATION OF THE CORPUS CAVERNOSUM IN RESPONSE TO NONADRENERGIC, NONCHOLINERGIC NEUROTRANSMISSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; SMOOTH-MUSCLE RELAXATION; INDUCED PENILE ERECTION; RELAXING FACTOR; ENDOTHELIAL-CELLS; IMPOTENT MEN; CYCLIC-GMP; L-ARGININE; ARTERY; HEMODYNAMICS	Background. Nitric oxide has been identified as an endothelium-derived relaxing factor in blood vessels. We tried to determine whether it is involved in the relaxation of the corpus cavernosum that allows penile erection. The relaxation of this smooth muscle is known to occur in response to stimulation by nonadrenergic, noncholinergic neurons. Methods. We studied strips of corpus cavernosum tissue obtained from 21 men in whom penile prostheses were inserted because of impotence. The mounted smooth-muscle specimens were pretreated with guanethidine and atropine and submaximally contracted with phenylephrine. We then studied the smooth-muscle relaxant responses to stimulation by an electrical field and to nitric oxide. Results. Electrical-field stimulation caused a marked, transient, frequency-dependent relaxation of the corpus cavernosum that was inhibited in the presence of N-nitro-L-arginine and N-amino-L-arginine, which selectively inhibit the biosynthesis of nitric oxide from L-arginine. The addition of excess L-arginine, but not D-arginine, largely reversed these inhibitory effects. The specific liberation of nitric oxide (by S-nitroso-N-acetylpenicillamine) caused rapid, complete, and concentration-dependent relaxation of the corpus cavernosum. The relaxation caused by either electrical stimulation or nitric oxide was enhanced by a selective inhibitor of cyclic guanosine monophosphate (GMP) phosphodiesterase (M&B 22,948). Relaxation was inhibited by methylene blue, which inhibits cyclic GMP synthesis. Conclusions. Our findings support the hypothesis that nitric oxide is involved in the nonadrenergic, noncholinergic neurotransmission that leads to the smooth-muscle relaxation in the corpus cavernosum that permits penile erection. Defects in this pathway may cause some forms of impotence.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV UROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center				Bush, Margaret/0000-0003-1937-2640	NHLBI NIH HHS [HL35014, HL40922] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040922, R01HL035014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON PO, 1984, J PHYSIOL-LONDON, V350, P209, DOI 10.1113/jphysiol.1984.sp015197; BARNES CD, 1965, DRUG DOSAGE LABORATO, P261; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; DETEJADA IS, 1988, AM J PHYSIOL, V254, pH459, DOI 10.1152/ajpheart.1988.254.3.H459; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; FOURNIER GR, 1987, J UROLOGY, V137, P163, DOI 10.1016/S0022-5347(17)43911-5; FUCHS AM, 1989, J UROLOGY, V141, P1353, DOI 10.1016/S0022-5347(17)41305-X; FUKUTO JM, 1990, BIOCHEM BIOPH RES CO, V168, P458, DOI 10.1016/0006-291X(90)92343-X; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1990, NATURE, V347, P131, DOI 10.1038/347131b0; IGNARRO LJ, 1987, CIRC RES, V60, P82, DOI 10.1161/01.RES.60.1.82; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JUENEMANN KP, 1986, J UROLOGY, V136, P158, DOI 10.1016/S0022-5347(17)44763-X; JUENEMANN KP, 1987, J UROLOGY, V138, P871, DOI 10.1016/S0022-5347(17)43406-9; KLINGE E, 1977, ACTA PHYSIOL SCAND, V100, P354, DOI 10.1111/j.1748-1716.1977.tb05961.x; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LUE TF, 1986, J UROLOGY, V135, P479, DOI 10.1016/S0022-5347(17)45697-7; LUE TF, 1983, J UROLOGY, V130, P1237, DOI 10.1016/S0022-5347(17)51768-1; OTTESEN B, 1984, BRIT MED J, V288, P9, DOI 10.1136/bmj.288.6410.9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHABSIGH R, 1988, UROLOGY, V32, P83, DOI 10.1016/0090-4295(88)90303-2; STACKL W, 1988, J UROLOGY, V140, P66, DOI 10.1016/S0022-5347(17)41488-1; WOOD KS, 1990, BIOCHEM BIOPH RES CO, V170, P80, DOI 10.1016/0006-291X(90)91243-L; 1989, DHHS871751 NAT CTR H; 1988, VITAL HLTH STATIS 13, V93	33	775	818	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					90	94		10.1056/NEJM199201093260203	http://dx.doi.org/10.1056/NEJM199201093260203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1309211				2022-12-24	WOS:A1992GY04500003
J	FOOR, F; PARENT, SA; MORIN, N; DAHL, AM; RAMADAN, N; CHREBET, G; BOSTIAN, KA; NIELSEN, JB				FOOR, F; PARENT, SA; MORIN, N; DAHL, AM; RAMADAN, N; CHREBET, G; BOSTIAN, KA; NIELSEN, JB			CALCINEURIN MEDIATES INHIBITION BY FK506 AND CYCLOSPORINE OF RECOVERY FROM ALPHA-FACTOR ARREST IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CYCLOPHILIN; GENE; PROTEIN; CDNA	THE structurally unrelated immunosuppressants FK506 and cyclosporin A (CsA) act similarly, inhibiting a Ca2+-dependent signal required for interleukin-2 transcription and T-cell activation1. Each drug binds to its cytosolic receptor, FKBP-12 and cyclophilin, respectively, and the drug-receptor complexes inhibit the Ca2+/calmodulin-dependent protein phosphatase, calcineurin2-4. In yeast, calcineurin has been implicated in recovery from alpha-mating factor arrest5,6. Here we show that FK506 bound to yeast FKBP-12 appears to form a complex with yeast calcineurin. Moreover, recovery from mating factor arrest is highly sensitive to FK506 or CsA, and this sensitivity requires the presence of FKBP-12 or cyclophilin, respectively. These results define a key physiological target of an FK506- and CsA-sensitive signal pathway in yeast, suggest a high degree of mechanistic conservation with mammalian cells, and indicate that further examination of the yeast system should provide insight into the same process in T cells.	MERCK RES LABS,POB 2000,BLDG R80Y-2A97,RAHWAY,NJ 07065	Merck & Company								BARNES DA, 1986, MOL CELL BIOL, V6, P2828, DOI 10.1128/MCB.6.8.2828; BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; NIELSEN JB, 1992, P NATL ACAD SCI USA, V89, P7471, DOI 10.1073/pnas.89.16.7471; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0	14	200	206	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					682	684						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1281518				2022-12-24	WOS:A1992KD08200059
J	IINO, M; ENDO, M				IINO, M; ENDO, M			CALCIUM-DEPENDENT IMMEDIATE FEEDBACK-CONTROL OF INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CHANNELS; TRISPHOSPHATE; OSCILLATIONS; PHOSPHATES; CEREBELLUM	THE temporal and spatial distribution of increases in intracellular Ca2+ concentration is an important factor in cellular signal transduction1. Inositol 1,4,5-trisphosphate (InsP3) plays a key part in agonist-induced Ca2+ release1, which can take place abruptly2 and in a confined space3 by a mechanism that is not fully understood. Here we analyse the kinetics of InsP3-induced Ca2+ release following flash photolysis4-7 of Caged InsP3 or caged Ca2+, and demonstrate that Ca2+-dependent immediate feedback control is an important determinant of the time course of Ca2+ release. The positive feedback mechanism is also important for the 'loading dependence' of InsP3-induced Ca2+ release8. Furthermore, our results support the operation of positive cooperativity in channel opening9 and feedback control augments the steep InsP3 concentration-Ca2+ release relation. These inherent properties of InsP3-induced Ca2+ release are expected to give rise to temporally abrupt and/or spatially confined Ca2+ release within the cell.			IINO, M (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KAPLAN JH, 1990, ANNU REV PHYSIOL, V52, P897; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; SOMLYO AP, 1990, REV PHYSL, V52, P857; WATRAS J, 1991, J NEUROSCI, V11, P3239	24	266	269	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1992	360	6399					76	78		10.1038/360076a0	http://dx.doi.org/10.1038/360076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1331809				2022-12-24	WOS:A1992JW71700059
J	MUIR, KW; RODGER, JC; DEBONO, JS; MCDONALD, H; IRVING, JB				MUIR, KW; RODGER, JC; DEBONO, JS; MCDONALD, H; IRVING, JB			DRUGS AND THE EXERCISE TEST	BRITISH MEDICAL JOURNAL			English	Article									MONKLANDS DIST GEN HOSP,AIRDRIE ML6 0JS,LANARK,SCOTLAND; ST JOHNS HOSP,LIVINGSTON,W LOTHIAN,SCOTLAND				Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; de Bono, Johann S/0000-0002-2034-595X				AKHRAS F, 1991, LANCET, V338, P1036, DOI 10.1016/0140-6736(91)91900-F; CURTIS JL, 1991, AM HEART J, V121, P1655, DOI 10.1016/0002-8703(91)90009-7; Lollgen H, 1988, Eur Heart J, V9 Suppl K, P3; SCHLANT RC, 1986, CIRCULATION, V74, P653; 1990, ANN INTERN MED, V113, P703	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					808	809		10.1136/bmj.305.6857.808-a	http://dx.doi.org/10.1136/bmj.305.6857.808-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1301028	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JT25600023
J	BENFENATI, F; VALTORTA, F; RUBENSTEIN, JL; GORELICK, FS; GREENGARD, P; CZERNIK, AJ				BENFENATI, F; VALTORTA, F; RUBENSTEIN, JL; GORELICK, FS; GREENGARD, P; CZERNIK, AJ			SYNAPTIC VESICLE-ASSOCIATED CA2+/CALMODULIN-DEPENDENT PROTEIN KINASE-II IS A BINDING-PROTEIN FOR SYNAPSIN-I	NATURE			English	Article							POSTSYNAPTIC DENSITY PROTEIN; BRAIN; FRAGMENTS; CLEAVAGE; RELEASE; ASSAY	SYNAPSIN I is a synaptic vesicle-associated phosphoprotein that is involved in the modulation of neurotransmitter release1. Ca2+ calmodulin-dependent protein kinase II, which phosphorylates two sites in the carboxy-terminal region of synapsin I, causes synapsin I to dissociate from synaptic vesicles2 and increases nerotransmitter release3,4. Conversely, the dephosphorylated form of synapsin I, but not the form phosphorylated by Ca2+/calmodulin-dependent protein kinase II, inhibits neurotransmitter release4-6. The amino-terminal region of synapsin I interacts with membrane phospholipids, whereas the C-terminal region binds to a protein component of synaptic vesicles7,8. Here we demonstrate that the binding of the C-terminal region of synapsin I involves the regulatory domain of a synaptic vesicle-associated form of Ca2+/calmodulin-dependent protein kinase II. Our results indicate that this form of the kinase functions both as a binding protein for synapsin I, and as an enzyme that phosphorylates synapsin I and promotes its dissociation from the vesicles.	UNIV MILAN,CNR,CTR CYTOPHARMACOL,BRUNO CECCARELLI CTR,S RAFFAELE SCI INST,I-20122 MILAN,ITALY; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Rockefeller University	BENFENATI, F (corresponding author), UNIV MODENA,INST HUMAN PHYSIOL,VIA CAMPI 287,I-41100 MODENA,ITALY.		Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; Gorelick, Fred/0000-0001-8293-6803	Telethon [112] Funding Source: Medline	Telethon(Fondazione Telethon)		BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GOELZ SE, 1981, P NATL ACAD SCI-BIOL, V78, P2130, DOI 10.1073/pnas.78.4.2130; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IMADA M, 1980, BIOCHIM BIOPHYS ACTA, V625, P179, DOI 10.1016/0005-2795(80)90282-2; JAHN R, 1984, P NATL ACAD SCI-BIOL, V81, P1684, DOI 10.1073/pnas.81.6.1684; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MCGUINNESS TL, 1983, FEBS LETT, V163, P329, DOI 10.1016/0014-5793(83)80846-1; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; WU K, 1992, P NATL ACAD SCI USA, V89, P3015, DOI 10.1073/pnas.89.7.3015	26	242	246	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					417	420		10.1038/359417a0	http://dx.doi.org/10.1038/359417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1328883				2022-12-24	WOS:A1992JQ62400057
J	HARRIS, PL				HARRIS, PL			REDUCING THE MORTALITY FROM ABDOMINAL AORTIC-ANEURYSMS - NEED FOR A NATIONAL SCREENING-PROGRAM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURGICAL-TREATMENT; POPULATION				HARRIS, PL (corresponding author), BROADGREEN HOSP, LIVERPOOL L14 3LB, MERSEYSIDE, ENGLAND.							ARMOUR RH, 1977, BRIT MED J, V2, P1055, DOI 10.1136/bmj.2.6094.1055; BARODOI JC, 1991, ANN VASC SURG, V5, P491; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; Bengtsson H, 1989, Eur J Vasc Surg, V3, P497, DOI 10.1016/S0950-821X(89)80123-9; BERGQVIST D, 1992, ANN CHIR GYNAECOL FE, V81, P205; BLAMEY RW, 1986, RECENT ADV SURGERY, V12, P29; COLLIN J, 1989, SURG GYNECOL OBSTET, V169, P527; COLLIN J, 1988, LANCET, V2, P613; COLLIN J, 1990, CAUSE MANAGEMENT ANE; COLLIN J, 1989, BMJ-BRIT MED J, V299, P49; ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; MCGREGOR JC, 1975, SCOT MED J, V20, P133, DOI 10.1177/003693307502000313; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; OKELLY TJ, 1989, BRIT J SURG, V76, P479, DOI 10.1002/bjs.1800760517; POWELL JT, 1990, CLIN SCI, V78, P13, DOI 10.1042/cs0780013; SCOTT RAP, 1986, BRIT J SURG, V73, P318; SCOTT RAP, 1988, BRIT MED J, V296, P1709, DOI 10.1136/bmj.296.6638.1709-a; SMITH FCT, 1992, BRIT J SURG, V79, P358; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; TURK KAD, 1965, P ROY SOC MED, V58, P869, DOI 10.1177/003591576505811P109; 1984, MORTALITY STATISTICS; 1992, HLTH NATION STRATEGY; 1986, ENGLAND WALES MORTAL	26	55	55	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1992	305	6855					697	699		10.1136/bmj.305.6855.697	http://dx.doi.org/10.1136/bmj.305.6855.697			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1296605	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JP51100029
J	ROTH, D; FERNANDEZ, JA; BABISCHKIN, S; DEMATTOS, A; BUCK, BE; QUAN, S; OLSON, L; BURKE, GW; NERY, JR; ESQUENAZI, V; SCHIFF, ER; MILLER, J				ROTH, D; FERNANDEZ, JA; BABISCHKIN, S; DEMATTOS, A; BUCK, BE; QUAN, S; OLSON, L; BURKE, GW; NERY, JR; ESQUENAZI, V; SCHIFF, ER; MILLER, J			DETECTION OF HEPATITIS-C VIRUS-INFECTION AMONG CADAVER ORGAN DONORS - EVIDENCE FOR LOW TRANSMISSION OF DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; ORGAN TRANSPLANTATION; CADAVER	NON-B-HEPATITIS; NON-A; LIVER-DISEASE; TRANSPLANT RECIPIENTS; BLOOD-DONORS; ANTIBODIES; ASSAY; RNA	Objective: To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) and HCV RNA among cadaver organ donors and to correlate these results with donor liver histologic abnormalities and evidence for transmission of disease through organ transplantation. Design: Retrospective testing of stored serum samples from cadaver organ donors for anti-HCV and HCV RNA. Setting: Transplantation service of the University of Miami/Jackson Memorial Medical Center and other cooperative medical centers furnishing follow-up data. Subjects: Of 1096 cadaver organ donors harvested between 1 January 1979 and 28 February 1991, 484 had stored serum samples available for analysis. Recipients of organs from recombinant immunoblot assay (RIBA)-positive donors for whom adequate follow-up was available were also included in the analysis. Measurements: Samples were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA). Confirmatory testing was done using a second-generation RIBA. Hepatitis C viral RNA was detected in serum using the polymerase chain reaction. Liver biopsies were obtained from the organ donor and interpreted blindly by a pathologist unaware of the clinical data. Liver chemistry profiles and serum sample analysis for HCV RNA were done for transplant recipients. Results: From the 484 cadaver organ donors, 89 samples (18%; 95% CI, 15% to 21%) were reactive by ELISA. Of these, 33 (6.8%; CI, 4.6% to 9%) were RIBA seropositive. Hepatitis C viral RNA sequences were detected in 50% of the RIBA-positive serum samples tested. Liver tissue was available from 24 of the 33 RIBA-positive donors and showed chronic active hepatitis in 16, chronic persistent hepatitis in 2, and no abnormality in 6. Among the 46 recipients of a kidney from a RIBA-positive donor, 13 (28%; CI, 15% to 41%) developed post-transplant liver disease, of which only 4 cases were highly suggestive of viral transmission from the donor. Little morbidity and no mortality could be attributed to liver disease in this cohort of recipients. Conclusions: These data suggest that HCV transmission by organ transplantation is low and that the consequences of infection are small. If the medical condition of the potential recipient is so serious that other options no longer exist, the use of an organ from an anti-HCV-seropositive donor should be considered.							NIDDK NIH HHS [R01DK25243] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CHA TA, 1991, J CLIN MICROBIOL, V29, P2528, DOI 10.1128/JCM.29.11.2528-2534.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CZAFA AJ, 1990, MAYO CLIN P, V65, P1303; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; ESTEBAN JI, 1989, LANCET, V2, P294; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MADDREY WC, 1990, HEPATOLOGY TXB LIVER, P1025; MILGROM M, 1989, TRANSPLANT P, V21, P3934; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PONZ E, 1991, KIDNEY INT, V40, P748, DOI 10.1038/ki.1991.270; QUAN S, 1990, 2ND P INT S HEP C VI; ROTH D, 1991, TRANSPLANTATION, V51, P396, DOI 10.1097/00007890-199102000-00024; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; 1989, 1ST P INT S HEP C VI, P25	23	93	94	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					470	475		10.7326/0003-4819-117-6-470	http://dx.doi.org/10.7326/0003-4819-117-6-470			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1323944				2022-12-24	WOS:A1992JN25700005
J	DONAHUE, JG; MUNOZ, A; NESS, PM; BROWN, DE; YAWN, DH; MCALLISTER, HA; REITZ, BA; NELSON, KE				DONAHUE, JG; MUNOZ, A; NESS, PM; BROWN, DE; YAWN, DH; MCALLISTER, HA; REITZ, BA; NELSON, KE			THE DECLINING RISK OF POSTTRANSFUSION HEPATITIS-C VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; POSTTRANSFUSION HEPATITIS; TRANSMITTED VIRUSES; CARDIAC-SURGERY; BLOOD-DONORS; ANTIBODY; RECIPIENTS; TRANSMISSION; ANTIGEN	Background. The most common serious complication of blood transfusion is post-transfusion hepatitis from the hepatitis C virus (HCV). Blood banks now screen blood donors for surrogate markers of non-A, non-B hepatitis and antibodies to HCV, but the current risk of post-transfusion hepatitis C is unknown. Methods. From 1985 through 1991, blood samples and medical information were obtained prospectively from patients before and at least six months after cardiac surgery. The stored serum samples were tested for antibodies to HCV by enzyme immunoassay, and by recombinant immunoblotting if positive. Results. Of the 912 patients who received transfusions before donors were screened for surrogate markers, 35 seroconverted to HCV, for a risk of 3.84 percent per patient (0.45 percent per unit transfused). For the 976 patients who received transfusions after October 1986 with blood screened for surrogate markers, the risk of seroconversion was 1.54 percent per patient (0.19 percent per unit). For the 522 patients receiving transfusions since the addition in May 1990 of screening for antibodies to HCV, the risk was 0.57 percent per patient (0.03 percent per unit). The trend toward decreasing risk with increasingly stringent screening of donors was statistically significant (P<0.001). After we controlled for the method of donor screening, the risk of seroconversion was strongly associated (P<0.001) with the volume of blood transfused, but not with the use of particular blood components. Conclusions. The incidence of post-transfusion hepatitis C has decreased markedly since the implementation of donor screening for surrogate markers and antibodies to HCV. The current risk of post-transfusion hepatitis is about 3 per 10,000 units transfused.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,RM 763,BALTIMORE,MD 21205; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; ST LUKES EPISCOPAL HOSP,DEPT CARDIAC PATHOL,HOUSTON,TX 77030; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT CARDIAC SURG,BALTIMORE,MD 21205; METHODIST HOSP,HOUSTON,TX 77030	Johns Hopkins University; Baylor College of Medicine; Saint Lukes Episcopal Hospital; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; The Methodist Hospital System; The Methodist Hospital - Houston					NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NHLBI NIH HHS [N01-HB-86-7025, R01-HL-45333-01A2] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045333] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; Aach RD, 1978, VIRAL HEPATITIS, P383; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; BOVE JR, 1987, NEW ENGL J MED, V317, P242, DOI 10.1056/NEJM198707233170411; BRADLEY DW, 1986, SEMIN LIVER DIS, V6, P56, DOI 10.1055/s-2008-1040794; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; Cox DR., 1989, ANAL BINARY DATA; DIENSTAG JL, 1986, SEMIN LIVER DIS, V6, P67, DOI 10.1055/s-2008-1040795; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P743; ESTEBAN JI, 1989, LANCET, V2, P294; ESTEBAN JI, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P431; HANSON MR, 1987, TRANSFUSION, V27, P107, DOI 10.1046/j.1537-2995.1987.27187121451.x; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LARSEN J, 1990, TRANSFUSION, V30, P431, DOI 10.1046/j.1537-2995.1990.30590296376.x; LEE SD, 1991, J INFECT DIS, V163, P1354, DOI 10.1093/infdis/163.6.1354; NAGACHINTA T, 1987, J INFECT DIS, V156, P967, DOI 10.1093/infdis/156.6.967; SHIBATA M, 1991, BLOOD, V77, P1157; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; 1982, MMWR, V31, P652; 1991, LANCET, V338, P1040	27	628	631	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					369	373		10.1056/NEJM199208063270601	http://dx.doi.org/10.1056/NEJM199208063270601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1320736				2022-12-24	WOS:A1992JG35600001
J	MULLER, T; MOLLER, T; BERGER, T; SCHNITZER, J; KETTENMANN, H				MULLER, T; MOLLER, T; BERGER, T; SCHNITZER, J; KETTENMANN, H			CALCIUM ENTRY THROUGH KAINATE RECEPTORS AND RESULTING POTASSIUM-CHANNEL BLOCKADE IN BERGMANN GLIAL-CELLS	SCIENCE			English	Article							BRAIN	Glutamate receptors, the most abundant excitatory transmitter receptors in the brain, are not restricted to neurons; they have also been detected on glial cells. Bergmann glial cells in mouse cerebellar slices revealed a kainate-type glutamate receptor with a sigmoid current-to-voltage relation, as demonstrated with the patch-clamp technique. Calcium was imaged with fura-2, and a kainate-induced increase in intracellular calcium concentration was observed, which was blocked by the non-N-methyl-D-aspartate (NMDA) glutamate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and by low concentrations of external calcium, indicating that there was an influx of calcium through the kainate receptor itself. The entry of calcium led to a marked reduction in the resting (passive) potassium conductance of the cell. Purkinje cells, which have glutamatergic synapses, are closely associated with Bergmann glial cells and therefore may provide a functionally important stimulus.	UNIV HEIDELBERG,DEPT NEUROBIOL,NEUENHEIMER FELD 345,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST BRAIN RES,W-6000 FRANKFURT,GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society			Möller, Thomas/W-8974-2019; Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291				BLANKENFELD G, 1992, MOL NEUROBIOL, V5, P31; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FINDLAY I, 1987, PFLUG ARCH EUR J PHY, V410, P313, DOI 10.1007/BF00580282; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ito M, 1984, CEREBELLUM NEURAL CO; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829	14	312	316	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1563	1566		10.1126/science.1317969	http://dx.doi.org/10.1126/science.1317969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317969				2022-12-24	WOS:A1992HY07500031
J	KULLMANN, DM; NICOLL, RA				KULLMANN, DM; NICOLL, RA			LONG-TERM POTENTIATION IS ASSOCIATED WITH INCREASES IN QUANTAL CONTENT AND QUANTAL AMPLITUDE	NATURE			English	Article							PRESYNAPTIC MECHANISM; HIPPOCAMPAL SLICES; PERFORANT PATH; NEURONS; INDUCTION; ALGORITHM; RELEASE	LONG-TERM potentiation (LTP) of synaptic transmission in CA1 neurons of the hippocampus, elicited by the conjunction of presynaptic firing and postsynaptic depolarization, is an important model of plasticity, which may underlie memory storage 1-3. Although induction of LTP takes place in the postsynaptic cell 4-7, it is not clear whether it is expressed through an enhancement of transmitter release 8-12 or through an increased postsynaptic response to the same amount of transmitter 13-16. Analysis of the trial-to-trial amplitude fluctuations of synaptic signals, that is quantal analysis, gives an important insight into the probabilistic mechanisms of transmission, although attempts to apply it to the mode of expression of LTP have so far yielded inconsistent results 9-12,15, at least in part because they have relied on models of transmitter release that have not been confirmed experimentally 17-19. Here we report clear evidence for quantal fluctuation in a subset of cells. Induction of LTP in these cells causes abrupt increases in either quantal content or quantal amplitude, or both. This shows that two different mechanisms can underlie the maintenance of LTP.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Kullmann, Dimitri M/A-3162-2009	Kullmann, Dimitri M/0000-0001-6696-3545				BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1989, J NEUROSCI METH, V30, P231, DOI 10.1016/0165-0270(89)90134-9; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1991, NATURE, V252, P722; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; VORONIN LL, 1990, NEUROPHYSIOLOGY+, V22, P341; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167	31	232	234	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					240	244		10.1038/357240a0	http://dx.doi.org/10.1038/357240a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1317014				2022-12-24	WOS:A1992HV19500054
J	RAY, CA; BLACK, RA; KRONHEIM, SR; GREENSTREET, TA; SLEATH, PR; SALVESEN, GS; PICKUP, DJ				RAY, CA; BLACK, RA; KRONHEIM, SR; GREENSTREET, TA; SLEATH, PR; SALVESEN, GS; PICKUP, DJ			VIRAL INHIBITION OF INFLAMMATION - COWPOX VIRUS ENCODES AN INHIBITOR OF THE INTERLEUKIN-1-BETA CONVERTING ENZYME	CELL			English	Article							VACCINIA VIRUS; REACTIVE SITE; STRUCTURAL EVIDENCE; EXPRESSION SYSTEM; MESSENGER-RNA; CLEAVAGE SITE; DNA-SEQUENCE; PROTEASE; PURIFICATION; GENERATION	Cowpox virus effectively inhibits inflammatory responses against viral infection in the chick embryo. This study demonstrates that one of the viral genes necessary for this inhibition, the crmA gene (a cytokine response modifier gene), encodes a serpin that is a specific inhibitor of the interleukin-1-beta converting enzyme. This serpin can prevent the proteolytic activation of interleukin-1-beta, thereby suppressing an interleukin-1-beta response to infection. However, the modification of this single cytokine response is not sufficient to inhibit inflammatory responses. This suggests that cowpox virus encodes several cytokine response modifiers that act together to inhibit the release of pro-inflammatory cytokines in response to infection. These viral counter measures to host defenses against infection may contribute significantly to the pathology associated with poxvirus infections.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; IMMUNEX CORP, DEPT PROT CHEM, SEATTLE, WA 98101 USA	Duke University; Immunex Corporation	RAY, CA (corresponding author), DUKE UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, DURHAM, NC 27710 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023886] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI23886] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CERRETTI DP, 1992, IN PRESS SCIENCE; CHUA TP, 1990, IMMUNOLOGY, V69, P202; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1988, INFLAMMATION BASIC P, P195; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FREDRICKSON TN, 1992, IN PRESS VIROLOGY; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goebel S.J., 1990, VIROLOGY, V179, P517; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; KISO U, 1988, FEBS LETT, V230, P51, DOI 10.1016/0014-5793(88)80640-9; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOTWAL GJ, 1989, J VIROL, V63, P600, DOI 10.1128/JVI.63.2.600-606.1989; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORII M, 1983, J BIOL CHEM, V258, P2749; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; PICKUP DJ, 1984, P NATL ACAD SCI-BIOL, V81, P6817, DOI 10.1073/pnas.81.21.6817; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1991, SCIENCE, V72, P1349; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; TABOR S, 1990, J BIOL CHEM, V265, P8322; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; [No title captured]	50	921	976	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					597	604		10.1016/0092-8674(92)90223-Y	http://dx.doi.org/10.1016/0092-8674(92)90223-Y			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1339309				2022-12-24	WOS:A1992HV08900004
J	WANG, JF; CECH, TR				WANG, JF; CECH, TR			TERTIARY STRUCTURE AROUND THE GUANOSINE-BINDING SITE OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; SEQUENCE-SPECIFIC CLEAVAGE; SELF-SPLICING RNA; ENDORIBONUCLEASE ACTIVITY; DNA; SUBSTRATE; CATALYSIS; RESOLUTION; INTRONS; ACID	A cleavage reagent directed to the active site of the Tetrahymena catalytic RNA was synthesized by derivatization of the guanosine substrate with a metal chelator. When complexed with iron(II), this reagent cleaved the RNA in five regions. Cleavage at adenosine 207, which is far from the guanosine-binding site in the primary and secondary structure, provides a constraint for the higher order folding of the RNA. This cleavage site constitutes physical evidence for a key feature of the Michel-Westhof model. Targeting a reactive entity to a specific site should be generally useful for determining proximity within folded RNA molecules or ribonucleoprotein complexes.	UNIV COLORADO, DEPT CHEM & BIOCHEM, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BEEN MD, 1987, COLD SPRING HARB SYM, V52, P147, DOI 10.1101/SQB.1987.052.01.019; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P855, DOI 10.1021/bi00534a007; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, UNPUB; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHU BCF, 1985, P NATL ACAD SCI USA, V82, P963, DOI 10.1073/pnas.82.4.963; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HNATOWICH DJ, 1982, INT J APPL RADIAT IS, V33, P327, DOI 10.1016/0020-708X(82)90144-2; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; IVANOVSKAYA MG, 1987, NUCLEOS NUCLEOT, V6, P913, DOI 10.1080/15257778708073437; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LOHMAN TM, 1990, BIOCHEMISTRY-US, V29, P5220; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOORE MJ, IN PRESS SCIENCE; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WANG JC, UNPUB; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	38	85	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					526	529		10.1126/science.1315076	http://dx.doi.org/10.1126/science.1315076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1315076				2022-12-24	WOS:A1992HQ18700065
J	WEGNER, M; CAO, ZD; ROSENFELD, MG				WEGNER, M; CAO, ZD; ROSENFELD, MG			CALCIUM-REGULATED PHOSPHORYLATION WITHIN THE LEUCINE ZIPPER OF C/EBP-BETA	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; ENHANCER-BINDING-PROTEIN; MOLECULAR-CLONING; RAT-BRAIN; TRANSCRIPTION FACTOR; JUN ENCODES; CALMODULIN; GENE; EXPRESSION; FAMILY	Alterations in intracellular calcium levels activate several signal transduction pathways resulting in distinct patterns of gene expression. Here, a pathway for calcium-mediated signals is demonstrated that involves C/EBP-beta, a member of the bZip family of transcription factors. In pituitary cells C/EBP-beta was phosphorylated in response to increased intracellular calcium concentrations as a consequence of the activation of a calcium-calmodulin-dependent protein kinase. Phosphorylation of serine at position 276 within the leucine zipper of C/EBP-beta appeared to confer calcium-regulated transcriptional stimulation of a promoter that contained binding sites for C/EBP-beta.	UNIV CALIF SAN DIEGO,EUKARYOT REGULATORY BIOL PROGRAM,CELLULAR & MOLEC MED BLDG,LA JOLLA,CA 92093; CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; Carnegie Institution for Science; HRL Laboratories; Howard Hughes Medical Institute; University of California System; University of California San Diego				Wegner, Michael/0000-0002-4586-3294				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FUKUNAGA K, 1986, BIOMED RES-TOKYO, V7, P405; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENGARD P, 1978, SCIENCE, V199, P146, DOI 10.1126/science.22932; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HATADA Y, 1983, J NEUROCHEM, V40, P1082, DOI 10.1111/j.1471-4159.1983.tb08096.x; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, COMMUNICATION; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WEGNER M, UNPUB; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	44	353	356	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					370	373		10.1126/science.256.5055.370	http://dx.doi.org/10.1126/science.256.5055.370			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1314426				2022-12-24	WOS:A1992HP03200034
J	CUMANO, A; PAIGE, CJ; ISCOVE, NN; BRADY, G				CUMANO, A; PAIGE, CJ; ISCOVE, NN; BRADY, G			BIPOTENTIAL PRECURSORS OF B-CELLS AND MACROPHAGES IN MURINE FETAL LIVER	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; LYMPHOCYTE PRECURSORS; EXPRESSION; ANTIBODIES; FAMILY; MOUSE; DIFFERENTIATION; PURIFICATION; CLONING; GENES	LYMPHOCYTES (B and T cells) derive continuously from the same multipotential stem cells that produce myeloid cells, including erythrocytes, granulocytes and macrophages 1,2. Tri- and bipotential myeloid intermediates between the multipotential stem cells and later unipotential cells have been identified using clonal methods in culture. Although similar methods have detected committed pre-B cells in mouse fetal liver 3, earlier progenitors with additional non-B lineage options have not been demonstrated in normal tissues. We report the characterization and purification of fetal liver cells that generate clones containing both macrophages and B cells, identified biochemically and morphologically. The common origin of the two cell types was shown by culture of single precursor cells. Their dual potential and unrearranged immunoglobulin loci place the precursors before exclusive B-lineage commitment in the haematopoietic hierarchy. The availability of such cells in purified form will allow direct study of lineage choice in cells having both lymphoid and non-lymphoid options.			CUMANO, A (corresponding author), ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA.			Cumano, Ana/0000-0002-4578-959X				BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; CUMANO A, 1992, EMBO J, V11, P590; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRISON DE, 1980, BLOOD, V55, P77; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LECLAIR KP, 1986, EMBO J, V5, P3227, DOI 10.1002/j.1460-2075.1986.tb04633.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MELCHERS F, 1976, COLD SPRING HARB SYM, V41, P147; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OHARA A, 1991, INT IMMUNOL, V3, P703, DOI 10.1093/intimm/3.7.703; PAIGE CJ, 1983, NATURE, V302, P711, DOI 10.1038/302711a0; RAFF MC, 1976, NATURE, V259, P224, DOI 10.1038/259224a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STALL AM, 1984, J IMMUNOL, V132, P787; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	30	315	318	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1992	356	6370					612	615		10.1038/356612a0	http://dx.doi.org/10.1038/356612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348572				2022-12-24	WOS:A1992HP03100052
J	ASHER, J				ASHER, J			NEWSCASTER NEURONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ASHER, J (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							DESIMONE R, 1991, SCIENCE, V254, P1377; 1991, BRAIN RES, V542, P1	2	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1584	1584		10.1001/jama.267.12.1584	http://dx.doi.org/10.1001/jama.267.12.1584			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1311777				2022-12-24	WOS:A1992HJ59700006
J	HAN, R; BREITBURD, F; MARCHE, PN; ORTH, G				HAN, R; BREITBURD, F; MARCHE, PN; ORTH, G			LINKAGE OF REGRESSION AND MALIGNANT CONVERSION OF RABBIT VIRAL PAPILLOMAS TO MHC CLASS-II GENES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; EPIDERMODYSPLASIA VERRUCIFORMIS; CERVICAL DYSPLASIA	HUMAN papillomaviruses associated with cutaneous 1 and anogenital 2 cancers induce intraepithelial precursor lesions which may regress spontaneously or progress into invasive carcinomas 3,4. Cell mediated immune responses are probably involved in regression of precancerous lesions 1,5-8 and the polymorphism of the genes responsible may thus have a key role in the variability of the host response. Skin warts and cancers induced in rabbits by Shope papillomavirus 9-12 provide a model to test this hypothesis. We analysed a restriction-fragment-length polymorphism of major histocompatibility complex class I and class II genes 13,14 and T-cell receptor beta-chain genes 15 in infected domestic rabbits. We found a strong linkage between wart regression and a DR-alpha EcoRI fragment, and an increased relative risk of malignant transformation associated with a DQ-alpha PvuII fragment. This indicates a genetic control of wart evolution, involving genes in the class II region of the major histocompatibility complex.	INST PASTEUR, INSERM, U190, UNITE PAPILLOMAVIRUS, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE; INST PASTEUR, CNRS, URA 359, UNITE IMMUNOCHIM ANALYT, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			ORTH, Gérard C/C-2518-2009; Marche, Patrice N/K-5060-2013	Marche, Patrice N/0000-0002-8930-9340				Beard JW, 1934, J EXP MED, V60, P723, DOI 10.1084/jem.60.6.723; BEUTLER B, 1990, J INVEST DERMATOL, V95, pS81, DOI 10.1111/1523-1747.ep12874797; BOURKER GF, 1985, INTERPRETATION USES; CARMICHAEL JA, 1989, AM J OBSTET GYNECOL, V160, P916, DOI 10.1016/0002-9378(89)90310-4; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; COOPER KD, 1990, J INVEST DERMATOL, V94, P769, DOI 10.1111/1523-1747.ep12874631; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; GEORGES E, 1984, J VIROL, V51, P530, DOI 10.1128/JVI.51.2.530-538.1984; HAUSEN HZ, 1989, CANCER RES, V49, P4677; Hurst EW, 1933, J EXP MED, V58, P607, DOI 10.1084/jem.58.5.607; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KREIDER JW, 1981, ADV CANCER RES, V35, P81, DOI 10.1016/S0065-230X(08)60909-4; MAJEWSKI S, 1990, J AM ACAD DERMATOL, V22, P423, DOI 10.1016/0190-9622(90)70058-P; MALEJCZYK J, 1991, CELL IMMUNOL, V136, P155, DOI 10.1016/0008-8749(91)90390-W; MARCHE PN, 1986, J IMMUNOL, V137, P1729; MARCHE PN, 1989, IMMUNOGENETICS, V29, P273, DOI 10.1007/BF00717913; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; NASSERI M, 1984, J VIROL, V51, P706, DOI 10.1128/JVI.51.3.706-712.1984; ORTH G, 1987, PAPOVAVIRIDAE, V2, P199; PAYAMI H, 1989, AM J HUM GENET, V45, P541; Rous P, 1935, J EXP MED, V62, P523, DOI 10.1084/jem.62.4.523; SITTISOMBUT N, 1989, J IMMUNOGENET, V16, P63; Tagami H, 1985, Clin Dermatol, V3, P170, DOI 10.1016/0738-081X(85)90062-8; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; YOSHIKAWA T, 1990, IMMUNOGENETICS, V32, P398, DOI 10.1007/BF00241633	26	129	132	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					66	68						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1347151				2022-12-24	WOS:A1992HG60200057
J	GOODWIN, FK				GOODWIN, FK			NEED TO LOSE WEIGHT AGAIN - OH RATS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							FRASER C, 1991, J BIOL CHEM, V266, P24053	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					910	910						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1310338				2022-12-24	WOS:A1992HD15500003
J	DEBONO, DP; SAMANI, NJ; SPYT, TJ; HARTSHORNE, T; THRUSH, AJ; EVANS, DH				DEBONO, DP; SAMANI, NJ; SPYT, TJ; HARTSHORNE, T; THRUSH, AJ; EVANS, DH			TRANSCUTANEOUS ULTRASOUND MEASUREMENT OF BLOOD-FLOW IN INTERNAL MAMMARY ARTERY TO CORONARY-ARTERY GRAFTS	LANCET			English	Article								Transcutaneous doppler ultrasound was used to examine internal-mammary-artery (IMA) blood-flow in 26 patients with IMA coronary bypass grafts. The ungrafted right IMA could be seen in all of 19 patients, the grafted left IMA in 16 of 26, and the grafted right IMA in 3 of 7. The velocity profile recorded from the proximal part of the grafted IMA is distinct from that of an ungrafted artery, with a systolic peak which reflects graft capacitance in the face of high intramyocardial resistance, and a diastolic peak which represents graft conductance when intramyocardial resistance is low. Total graft blood-flow can be estimated from the mean velocity and the measured vessel diameter, resting flows ranged from 22 to 79 ml/min. In recently grafted patients, resting graft blood-flow correlated with myocardial "run-off" estimated from preoperative arteriograms; graft blood-flow increased appropriately with exercise. This simple, non-invasive technique to measure IMA graft blood-flow may find applications for routine postoperative follow-up of patients with IMA grafts and for studies on the physiology and pharmacology of coronary artery blood-flow.	UNIV LEICESTER,DEPT CARDIOL,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT SURG,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT MED PHYS,LEICESTER LE1 7RH,ENGLAND	University of Leicester; University of Leicester; University of Leicester								BARNER HB, 1982, ANN THORAC SURG, V34, P408, DOI 10.1016/S0003-4975(10)61402-6; BRANDT PWT, 1977, CLIN RADIOL, V28, P261; CANVER CC, 1991, J VASC SURG, V13, P294, DOI 10.1016/0741-5214(91)90222-G; Evans DH, 1989, DOPPLER ULTRASOUND P, P233; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; MILLS NL, 1989, J THORAC CARDIOV SUR, V98, P73; SONS H, 1989, European Heart Journal, V10, P304	7	77	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					379	381		10.1016/0140-6736(92)90076-F	http://dx.doi.org/10.1016/0140-6736(92)90076-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346657				2022-12-24	WOS:A1992HD65900001
J	GRIFFITH, JP; GRIFFITH, DL; RAYMENT, I; MURAKAMI, WT; CASPAR, DLD				GRIFFITH, JP; GRIFFITH, DL; RAYMENT, I; MURAKAMI, WT; CASPAR, DLD			INSIDE POLYOMAVIRUS AT 25-A RESOLUTION	NATURE			English	Article							SIMIAN VIRUS-40; MINICHROMOSOMES; INVITRO; VP1	EMPTY capsids and complete virions of polyomavirus crystallize isomorphously 1. Here we use difference Fourier analysis of X-ray diffraction data at 25-angstrom resolution from these crystals to obtain an electron-density map of the inside of the virion. The polyomavirus capsid is built from 72 pentamers of VP1 that form three different types of connections in the T = 7d icosahedral surface lattice 2. Self-assembly of purified recombinant VP1 into capsid-like aggregates 3,4 has shown that switching of the bonding specificity to form the unanticipated 5 non-equivalent connections is an inherent property of the VP1 pentamers. Our map of the inside of the virion displays 72 prongs of electron density extending from the core into the axial cavities of the VP1 pentamers. We identify these prongs with the VP2 and VP3 molecules, which may function to guide the assembly of the highly ordered capsid on the nucleohistone core. The atomic structure of the closely related simian virus-40 capsid has been determined from the high-resolution diffraction data 6. Our polyomavirus map, calculated using all the low-resolution diffraction data, shows no indication of regular order inside the spherical core.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University			rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835				ADOLPH KW, 1979, SCIENCE, V203, P1117, DOI 10.1126/science.218286; AMBROSE C, 1987, NUCLEIC ACIDS RES, V15, P3703, DOI 10.1093/nar/15.9.3703; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CLEVER J, 1991, VIROLOGY, V181, P78, DOI 10.1016/0042-6822(91)90472-N; COLE CN, 1977, J VIROL, V24, P277, DOI 10.1128/JVI.24.1.277-294.1977; DUBOCHET J, 1986, EMBO J, V5, P519, DOI 10.1002/j.1460-2075.1986.tb04241.x; GHARAKHANIAN E, 1988, P NATL ACAD SCI USA, V85, P6607, DOI 10.1073/pnas.85.18.6607; KRAUZEWICZ N, 1990, J VIROL, V64, P4414, DOI 10.1128/JVI.64.9.4414-4420.1990; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIN W, 1984, J VIROL, V50, P363, DOI 10.1128/JVI.50.2.363-371.1984; MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991; RAYMENT I, 1983, ACTA CRYSTALLOGR B, V39, P505, DOI 10.1107/S0108768183002785; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Tooze J., 1981, COLD SPRING HARB MON, Vsecond	18	89	93	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					652	654		10.1038/355652a0	http://dx.doi.org/10.1038/355652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1311415				2022-12-24	WOS:A1992HD54700061
J	JESSUS, C; BEACH, D				JESSUS, C; BEACH, D			OSCILLATION OF MPF IS ACCOMPANIED BY PERIODIC ASSOCIATION BETWEEN CDC25 AND CDC2-CYCLIN-B	CELL			English	Article							MATURATION-PROMOTING FACTOR; CELL-DIVISION CYCLE; FISSION YEAST CDC25; HISTONE H-1 KINASE; CONTROL GENE CDC2+; SEA-URCHIN EGGS; PROTEIN-KINASE; MEIOTIC MATURATION; SCHIZOSACCHAROMYCES-POMBE; CYTOPLASMIC FACTOR	Activation of maturation-promoting factor at the onset of mitosis requires the tyrosine dephosphorylation of one of its components, the cdc2 protein kinase. cdc25 is the specific tyrosine phosphatase that activates cdc2. We find that Xenopus oocytes contain a relative of cdc25, p72. In Xenopus embryos the abundance of p72 does not oscillate during the cell cycle. However, p72 directly associates with cdc2-cyclin B in a cell cycle-dependent manner, reaching a peak at M phase. The M phase kinase that associates with p72 is catalytically active. These results suggest that the mechanism by which cdc25 triggers cdc2 activation involves a periodic physical association between cdc25 and the cyclin B-cdc2 complex and also that mitotic control can be affected by mechanisms other than transcriptional regulation of the cdc25 gene.			JESSUS, C (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069620] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM69620] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLAKHA RC, 1988, J CELL BIOL, V106, P1445, DOI 10.1083/jcb.106.5.1445; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JESSUS C, 1987, J CELL SCI, V87, P705; JESSUS C, 1991, DEVELOPMENT, V111, P813; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; KOBAYASHI AH, 1991, J CELL BIOL, V114, P755; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WEINTRAUB H, 1982, CR ACAD SCI III-VIE, V295, P787; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	64	101	104	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					323	332		10.1016/0092-8674(92)90473-P	http://dx.doi.org/10.1016/0092-8674(92)90473-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310257				2022-12-24	WOS:A1992HB35300011
J	WANG, WD; CAREY, M; GRALLA, JD				WANG, WD; CAREY, M; GRALLA, JD			POLYMERASE-II PROMOTER ACTIVATION - CLOSED COMPLEX-FORMATION AND ATP-DRIVEN START SITE OPENING	SCIENCE			English	Article							RNA-POLYMERASE; TRANSCRIPTION INITIATION; MECHANISM INVIVO; GAL4 DERIVATIVES; DNA; REQUIREMENT; INVITRO; GENE	Studies on bacterial RNA polymerases have divided the initiation pathway into three steps, namely (i) promoter binding to form the closed complex; (ii) DNA melting to form an open complex, and (iii) messenger RNA initiation. Potassium permanganate was used to detect DNA melting by mammalian RNA polymerase II in vitro. Closed complexes formed in a rate-limiting step that was stimulated by the activator GAL4-VP16. Adenosine triphosphate was then hydrolyzed to rapidly melt the DNA within the closed complex to form an open complex. Addition of nucleoside triphosphates resulted in the melted bubble moving away from the start site, completing initiation.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928; Carey, Michael/0000-0003-3899-6280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046424, R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46424, GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER CC, 1981, J MOL BIOL, V149, P189, DOI 10.1016/0022-2836(81)90298-9; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FIRE A, 1984, J BIOL CHEM, V259, P2509; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x; Wang W., UNPUB; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	34	198	199	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1992	255	5043					450	453		10.1126/science.1310361	http://dx.doi.org/10.1126/science.1310361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1310361				2022-12-24	WOS:A1992HA59000036
J	BIECHE, I; CHAMPEME, MH; MATIFAS, F; HACENE, K; CALLAHAN, R; LIDEREAU, R				BIECHE, I; CHAMPEME, MH; MATIFAS, F; HACENE, K; CALLAHAN, R; LIDEREAU, R			LOSS OF HETEROZYGOSITY ON CHROMOSOME-7Q AND AGGRESSIVE PRIMARY BREAST-CANCER	LANCET			English	Article							SHORT ARM; CELL CARCINOMA; ALLELE LOSS; GENES; DELETIONS; LUNG; 11P; ADENOCARCINOMA; METASTASIS; ONCOGENE	Genetic alterations are believed to be important in the origin and dissemination of breast cancer. Cytogenetic rearrangements on chromosome 7 are common in breast tumours. We used the c-met proto-oncogene probe, which detects sequences on chromosome 7q31, to analyse tumour and blood leucocyte DNA samples from 245 patients with primary breast cancers. The pmetH polymorphic probe detected a high frequency of allele loss (40.5%) among the 121 informative (heterozygous) patients. This genetic alteration was not significantly associated with standard prognostic features including tumour size, histopathological grade, and lymph-node or steroid receptor status. However, patients with loss of heterozygosity on chromosome 7q31 in primary tumour DNA had significantly shorter metastasis-free survival (p = 0.00022) and overall survival (p = 0.0036) after surgery than patients without this alteration. These findings indicate that this region of chromosome 7 might be the site of a breast tumour or metastasis suppressor gene.	CTR RENE HUGUENIN,ONCOVIROL LAB,5 RUE GASTON LATOUCHE,F-92211 ST CLOUD,FRANCE; CTR RENE HUGUENIN,DEPT MED STAT,F-92211 ST CLOUD,FRANCE; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	Rene Huguenin Hospital; Rene Huguenin Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BIECHE I, 1990, INT J CANCER, V46, P1136, DOI 10.1002/ijc.2910460632; BIECHE I, 1990, HUM GENET, V85, P101; BLOOM HJG, 1957, BRIT J CANCER, V11, P35; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; COLLARD JG, 1987, CANCER RES, V47, P6666; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEY MF, 1989, BRIT J CANCER, V59, P750, DOI 10.1038/bjc.1989.157; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; LEISTER I, 1990, CANCER RES, V50, P7232; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUNBERG C, 1987, P NATL ACAD SCI USA, V84, P2372; MACKAY J, 1988, LANCET, V2, P1384; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; Maniatis T., 1982, MOL CLONING; MERLO GR, 1989, CANCER RES, V49, P6966; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; OLUMI AF, 1990, CANCER RES, V50, P7081; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SKINNER MA, 1990, CANCER RES, V50, P2303; SOBEL ME, 1990, JNCI-J NATL CANCER I, V82, P267, DOI 10.1093/jnci/82.4.267; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; TRENT JM, 1985, BREAST CANCER RES TR, V5, P221, DOI 10.1007/BF01806017; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; 1989, CYTOGENET CELL GENET, V51, P713; 1980, EUR J CANCER, V16, P1513	40	185	185	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					139	143		10.1016/0140-6736(92)90208-K	http://dx.doi.org/10.1016/0140-6736(92)90208-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346009				2022-12-24	WOS:A1992GZ96800002
J	SPRENGER, F; NUSSLEINVOLHARD, C				SPRENGER, F; NUSSLEINVOLHARD, C			TORSO RECEPTOR ACTIVITY IS REGULATED BY A DIFFUSIBLE LIGAND PRODUCED AT THE EXTRACELLULAR TERMINAL REGIONS OF THE DROSOPHILA EGG	CELL			English	Article							FEMALE STERILE MUTATIONS; TYROSINE KINASE-ACTIVITY; DORSAL-VENTRAL POLARITY; TOLL GENE-PRODUCT; SIGNAL TRANSDUCTION; TRUNCATED RECEPTOR; CONSERVED FEATURES; EMBRYONIC TERMINI; RNA-POLYMERASE; 2ND CHROMOSOME	torso encodes a receptor tyrosine kinase (torso) required for anterior and posterior terminal development of the Drosophila embryo. Injecting eggs with in vitro synthesized torso mRNAs revealed that torso activation is governed by an extracellular molecule, presumably the torso ligand, produced at terminal regions of the egg during early embryogenesis. In the absence of torso, the ligand shows no apparent localization, indicating that it is diffusible and normally bound by an excess of torso receptor at the egg poles. Mutant ligand-binding torso proteins can suppress telson formation in a dominant negative manner, suggesting that the ligand is limited in amount. Analysis of torso mutations indicates that torso functions as a tyrosine kinase and that gain-of-function mutations causing ligand-independent activation are located in the extracellular domain.	MAX PLANCK INST ENTWICKLUNGSBIOL, GENET ABT, W-7400 TUBINGEN, GERMANY	Max Planck Society								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BERGER SL, 1987, GUIDE MOL CLONING TE, V152; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; DICKSON B, 1992, IN PRESS GENES DEV, V6; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEINE G, 1981, EUR J BIOCHEM, V116, P419; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1986, GENETICS, V113, P695; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PIGNONI F, 1992, DEV BIOL, V115, P221; Roberts D.B., 1986, P1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1989, GENETICS, V121, P101; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENS LM, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P145; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZABAD J, 1989, GENETICS, V122, P823; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARN RM, 1982, DEV BIOL, V89, P540, DOI 10.1016/0012-1606(82)90344-X; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WHITTAKER J, 1990, DIABETES CARE, V13, P576, DOI 10.2337/diacare.13.6.576; Wieschaus E., 1986, P199; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	55	137	137	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					987	1001		10.1016/0092-8674(92)90394-R	http://dx.doi.org/10.1016/0092-8674(92)90394-R			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333890				2022-12-24	WOS:A1992KB99000011
J	PARKER, L; CRAFT, AW; DALE, G; BELL, S; COLE, M; MCGILL, AC; SEVIOUR, JA; SMITH, J				PARKER, L; CRAFT, AW; DALE, G; BELL, S; COLE, M; MCGILL, AC; SEVIOUR, JA; SMITH, J			SCREENING FOR NEUROBLASTOMA IN THE NORTH OF ENGLAND	BRITISH MEDICAL JOURNAL			English	Article							NEURO-BLASTOMA; CHILDHOOD NEUROBLASTOMA; SAPPORO CITY; JAPAN	Objective-To determine the feasibility of establishing a system of screening for neuroblastoma. Design-Prospective study of mass screening in four clearly defined geographical areas. Setting-Four health districts of the Northern region of England. Subjects-20 829 babies aged 6 months, 92% of target population. Interventions-Collection of urine on filter paper for analysis of content of homovanillic and vanillylmandelic acid in relation to urinary creatinine concentrations. Main outcome measures-Derivation of reference range. Identification of babies with homovanillic or vanillylmandelic acid >3 SD above the mean (positive cases). Investigation of positive cases for evidence of neuroblastoma. Results-The upper limit of normal (3 SD above the mean) for vanillylmandelic acid was 15 mumol/mmol creatinine and for homovanillic acid 24 mumol/mmol creatinine. Of the 20 829 babies screened, 2537 (12.2%) required a second sample to be taken because the first sample was inadequate. Of these, 527 (2.5%) provided a liquid urine specimen and 10 (0.04%) had positive results for neuroblastoma. Two of them had neuroblastoma (true positives) and eight did not (false positives). A further three children from the cohort were subsequently found to have neuroblastoma; they had raised homovanillic acid or vanillylmandelic acid values, or both, but screened negative at 6 months. Conclusions-Screening for neuroblastoma is possible in the health care system of the United Kingdom. Evaluation of the efficacy of screening in reducing the mortality from neuroblastoma requires a controlled trial.	NEWCASTLE GEN HOSP,DEPT CLIN BIOCHEM,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	PARKER, L (corresponding author), MED SCH NEWCASTLE UPON TYNE,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.			PARKER, LOUISE/0000-0002-5188-8113				BRODEUR GM, 1987, CANCER RES, V47, P4248; COLE M, 1992, MED PEDIATR ONCOL, V20, P84, DOI 10.1002/mpo.2950200119; COLE M, IN PRESS ARCH DIS CH; CRAFT AW, 1987, BRIT J CANCER, V56, P853, DOI 10.1038/bjc.1987.305; DALE G, 1988, ANN CLIN BIOCHEM, V25, P233, DOI 10.1177/000456328802500306; EVANS AE, 1987, CANCER, V59, P1853, DOI 10.1002/1097-0142(19870601)59:11<1853::AID-CNCR2820591102>3.0.CO;2-F; HANAWA Y, 1990, MED PEDIATR ONCOL, V18, P472, DOI 10.1002/mpo.2950180607; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MIZUTA M, 1988, JPN J PUBLIC HLTH, V35, P179; NISHI M, 1990, J PEDIATR SURG, V25, P545, DOI 10.1016/0022-3468(90)90570-Y; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; NISHI M, 1989, PEDIATR RES, V26, P603, DOI 10.1203/00006450-198912000-00018; PARKER L, 1991, CANCER SCREENING, P337; RUTHVEN CRJ, 1979, CHEM DIAGNOSIS DISEA, P1239; SAWADA T, 1984, LANCET, V2, P271; SAWADA T, 1991, CANCER SCREENING, P337; SEVIOUR JA, 1988, J CHROMATOGR-BIOMED, V432, P273, DOI 10.1016/S0378-4347(00)80652-0; SHAFFORD EA, 1984, J CLIN ONCOL, V2, P742, DOI 10.1200/JCO.1984.2.7.742; TUCHMAN M, 1990, PEDIATRICS, V86, P765; TUCHMAN M, 1987, PEDIATRICS, V79, P203	20	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1260	1263		10.1136/bmj.305.6864.1260	http://dx.doi.org/10.1136/bmj.305.6864.1260			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1303649	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JZ52100023
J	ZIEGELSTEIN, RC; CHENG, L; CAPOGROSSI, MC				ZIEGELSTEIN, RC; CHENG, L; CAPOGROSSI, MC			FLOW-DEPENDENT CYTOSOLIC ACIDIFICATION OF VASCULAR ENDOTHELIAL-CELLS	SCIENCE			English	Article							DEPOLARIZATION-INDUCED ALKALINIZATION; INTRACELLULAR PH REGULATION; LYMPHOCYTE VOLUME REGULATION; ACTIVATING FACTOR PRODUCTION; ESTER INDUCED ACTIVATION; BOVINE AORTIC-CELLS; CHICK HEART-CELLS; NA+-H+ EXCHANGE; SHEAR-STRESS; PROXIMAL TUBULES	Hemodynamic shear stress affects endothelial cell structure and function, but little is known about the signal transduction mechanisms involved in these processes. The effect of laminar shear stress on cytosolic pH (pH(i)) was examined in rat aortic endothelial cells cultured in glass capillary tubes. Shear stress forces led to a rapid decrease in pH(i) (maximal effect 0.09 pH unit at 13.4 dynes per square centimeter). Removal of specific ions or addition of exchange inhibitors suggests that in vascular endothelial cells shear stress forces activate both an alkali extruder, sodium ion-independent chloride-bicarbonate ion exchange, and an acid extruder, sodium-hydrogen ion exchange; the net effect in physiologic buffer with the bicarbonate ion is a decrease in pH(i).	NIA,FAMILY PRACTICE RES CTR,CARDIOVASC SCI LAB,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,DIV CARDIOL,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK PS, 1992, AM J PHYSIOL, V263, pH276, DOI 10.1152/ajpheart.1992.263.1.H276; BLANK PS, AM J PHYSL; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; CAPOGROSSI MC, UNPUB; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLE OF, 1986, CELL BIOL INT REP, V10, P399, DOI 10.1016/0309-1651(86)90034-2; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; ESCOBALES N, 1990, AM J PHYSIOL, V259, pC640, DOI 10.1152/ajpcell.1990.259.4.C640; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GLEESON D, 1990, AM J PHYSIOL, V258, pG299, DOI 10.1152/ajpgi.1990.258.2.G299; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HSIEH HJ, 1992, J CELL PHYSIOL, V150, P552, DOI 10.1002/jcp.1041500316; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; KITAZONO T, 1988, BIOCHEM BIOPH RES CO, V152, P1304, DOI 10.1016/S0006-291X(88)80427-3; LANSMAN JB, 1988, NATURE, V331, P481, DOI 10.1038/331481a0; LIU S, 1990, J GEN PHYSIOL, V96, P1247, DOI 10.1085/jgp.96.6.1247; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; NAKACHE M, 1988, P NATL ACAD SCI USA, V85, P1841, DOI 10.1073/pnas.85.6.1841; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF342, DOI 10.1152/ajprenal.1989.256.2.F342; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF354, DOI 10.1152/ajprenal.1989.256.2.F354; THOMAS RC, 1989, NATURE, V337, P601, DOI 10.1038/337601a0; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; WHITAKER JE, 1991, ANAL BIOCHEM, V194, P330, DOI 10.1016/0003-2697(91)90237-N; ZIEGELSTEIN RC, UNPUB; ZIEGELSTEIN RC, 1991, AM J PHYSIOL, V260, pH1698	34	110	111	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					656	659		10.1126/science.1329207	http://dx.doi.org/10.1126/science.1329207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329207				2022-12-24	WOS:A1992JU74500059
J	BACKX, PH; YUE, DT; LAWRENCE, JH; MARBAN, E; TOMASELLI, GF				BACKX, PH; YUE, DT; LAWRENCE, JH; MARBAN, E; TOMASELLI, GF			MOLECULAR LOCALIZATION OF AN ION-BINDING SITE WITHIN THE PORE OF MAMMALIAN SODIUM-CHANNELS	SCIENCE			English	Article							VOLTAGE-DEPENDENT ACTION; CALF PURKINJE-FIBERS; POTASSIUM CHANNELS; NA CHANNELS; TETRODOTOXIN; BLOCK; SAXITOXIN; MYOCYTES; MUSCLE; MODEL	Sodium channels are the major proteins that underlie excitability in nerve, heart, and skeletal muscle. Chemical reaction rate theory was used to analyze the blockage of single wild-type and mutant sodium channels by cadmium ions. The affinity of cadmium for the native tetrodotoxin (TTX)-resistant cardiac channel was much higher than its affinity for the TTX-sensitive skeletal muscle isoform of the channel (mu-l). Mutation of Tyr401 to Cys, the corresponding residue in the cardiac sequence, rendered mu-l highly susceptible to cadmium blockage but resistant to TTX. The binding site was localized approximately 20% of the distance down the electrical field, thus defining the position of a critical residue within the sodium channel pore.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOMED ENGN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Marban, Eduardo/GWC-8514-2022		NHLBI NIH HHS [K08 HL2421, K11 HL02639, R01 HL36957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002421, R01HL036957, K11HL002639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1990, BIOPHYS J, V57, pA298; BAER M, 1976, NATURE, V263, P344, DOI 10.1038/263344a0; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOWERS CW, 1985, BRAIN RES, V340, P143, DOI 10.1016/0006-8993(85)90783-8; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COHEN CJ, 1981, J GEN PHYSIOL, V78, P383, DOI 10.1085/jgp.78.4.383; DIFRANCESCO D, 1985, PROC R SOC SER B-BIO, V223, P475, DOI 10.1098/rspb.1985.0013; FRELIN C, 1986, EUR J PHARMACOL, V122, P245, DOI 10.1016/0014-2999(86)90109-3; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HALLOWAY SF, 1989, PFLUEGERS ARCH, V414, P613; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HILLE B, 1975, J GEN PHYSIOL, V66, P535, DOI 10.1085/jgp.66.5.535; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MARTELL AE, 1989, CRITICAL STABILITY C, V1, P47; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PUSCH M, 1991, EUR BIOPHYS J, V20, P127, DOI 10.1007/BF01561134; RAVINDRAN A, 1991, J GEN PHYSIOL, V97, P89, DOI 10.1085/jgp.97.1.89; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHILD L, 1991, J GEN PHYSIOL, V97, P117, DOI 10.1085/jgp.97.1.117; SCHILD L, 1991, BIOPHYS J, V59, P523, DOI 10.1016/S0006-3495(91)82269-X; SHEETS MF, IN PRESS J PHYSL; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VASSILEV PM, 1986, AM J PHYSIOL, V251, pH475, DOI 10.1152/ajpheart.1986.251.2.H475; VISENTIN S, 1990, PFLUG ARCH EUR J PHY, V417, P213, DOI 10.1007/BF00370702; YAMAMOTO D, 1984, BIOPHYS J, V45, P337, DOI 10.1016/S0006-3495(84)84159-4; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911	41	248	251	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					248	251		10.1126/science.1321496	http://dx.doi.org/10.1126/science.1321496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321496				2022-12-24	WOS:A1992JC58500041
J	BORGULYA, P; KISHI, H; UEMATSU, Y; VONBOEHMER, H				BORGULYA, P; KISHI, H; UEMATSU, Y; VONBOEHMER, H			EXCLUSION AND INCLUSION OF ALPHA-T-CELL AND BETA-T-CELL RECEPTOR ALLELES	CELL			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; TRANSGENIC MICE; ANTIGEN RECEPTOR; CHAIN GENES; B-CELLS; EXPRESSION; DIFFERENTIATION; THYMOCYTES; DELETION; IDENTIFICATION	Exclusion and inclusion of T cell receptor (TCR) genes were analyzed in alpha-beta-TCR transgenic mice. Both transgenes are expressed unusually early on the surface of CD4-8-, HSA+, IL-2R- thymocytes. These progenitor cells give rise to progeny, which at the single-cell level contains endogenous-alpha but not beta-TCR-RNA as well as protein, in addition to products encoded by the transgenes. Thus, the surface expression of an alpha-beta-TCR does not prevent further alpha-TCR rearrangement in immature thymocytes that still transcribe RAG-1 and RAG-2 genes. Reduced levels of RAG-1 and RAG-2 RNA are detectable only in CD4+8+ TCR(high) cells, which result from positive selection in the thymus. The results suggest that a developing T cell may try different alpha-beta-TCRs for binding to thymic MHC ligands, and that recombination at the alpha-locus ceases only after positive selection.			BORGULYA, P (corresponding author), BASEL INST IMMUNOL,487 GRENZACHERSTR,CH-4005 BASEL,SWITZERLAND.							ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; COUEZ D, 1991, INT IMMUNOL, V3, P719, DOI 10.1093/intimm/3.7.719; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; HUGHES EN, 1981, J BIOL CHEM, V256, P7023; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAKI R, 1980, SCIENCE, V209, P1366, DOI 10.1126/science.6774416; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MAROLLEAU JP, 1988, CELL, V55, P291, DOI 10.1016/0092-8674(88)90052-9; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; RITCHIE KA, 1984, NATURE, V312, P517, DOI 10.1038/312517a0; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WABL M, 1982, P NATL ACAD SCI-BIOL, V79, P6976, DOI 10.1073/pnas.79.22.6976; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WILSON A, 1988, J IMMUNOL, V140, P1461; WILSON A, 1988, J IMMUNOL, V140, P1470; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	44	335	338	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					529	537		10.1016/0092-8674(92)90453-J	http://dx.doi.org/10.1016/0092-8674(92)90453-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316241				2022-12-24	WOS:A1992HT07800014
J	CALVERT, GM; HORNUNG, RW; SWEENEY, MH; FINGERHUT, MA; HALPERIN, WE				CALVERT, GM; HORNUNG, RW; SWEENEY, MH; FINGERHUT, MA; HALPERIN, WE			HEPATIC AND GASTROINTESTINAL EFFECTS IN AN OCCUPATIONAL COHORT EXPOSED TO 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCARIC ACID EXCRETION; HUMAN HEALTH; P-DIOXIN; SEVESO; TCDD; WORKERS; CHILDREN; AREA	Objective. - To examine the effect of occupational exposure to substances contaminated with 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) on the liver and gastrointestinal system. Design. - A medical survey. Participants. - The exposed participants were employed at two chemical plants more than 15 years earlier in the manufacture of sodium trichlorophenol and its derivatives. The reference group consisted of individuals with no occupational exposure to phenoxy herbicides and who lived within the communities of the workers. A total of 281 workers and 260 unexposed referents participated in the medical study. Measurements and Main Results. - The workers had substantial exposure to substances contaminated with TCDD, as evidenced by a mean serum TCDD level, lipid adjusted, of 220 pg per gram of lipid compared with a mean of 7 pg per gram of lipid in the referents. Compared with the unexposed reference group, workers had a statistically significantly elevated risk for an out-of-range gamma-glutamyltransferase (GGT) level (odds ratio, 2.27; 95% confidence interval, 1.17 to 4.39 [unadjusted for confounders]). In multivariate analyses run with logistic regression, a statistically significant interaction was found between TCDD exposure and lifetime alcohol consumption, indicating that the elevated risk for an out-of-range GGT was confined to those workers with a history of alcohol consumption and that the risk among the alcohol-consuming workers for an out-of-range GGT increased with increasing TCDD level. No difference was found between workers and referents for any of the other liver and gastrointestinal outcomes of interest. Conclusions. - This study found no evidence of an elevated risk for clinical hepatic or gastrointestinal disease in a group of workers with high exposure to TCDD. However, TCDD-exposed workers with a history of sufficient alcohol consumption were found to have a statistically significantly elevated risk for an out-of-range GGT compared with referents.			CALVERT, GM (corresponding author), NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,INDUSTRWIDE,CINCINNATI,OH 45226, USA.							BONACCORSI A, 1978, AMBIO, V7, P234; BOND GG, 1983, BRIT J IND MED, V40, P318; CALVERT G, IN PRESS CHEMOSPHERE; CALVERT GM, 1991, AM REV RESPIR DIS, V144, P1302, DOI 10.1164/ajrccm/144.6.1302; FINGERHUT M, 1990, PB91125971; GOLDBERG DM, 1979, CLIN ENZYMOL, P123; GOLDMANN PJ, 1973, HAUTARZT, V24, P149; GUZELIAN PS, 1985, ENVIRON HEALTH PERSP, V60, P159, DOI 10.2307/3429958; HOFFMAN RE, 1986, JAMA-J AM MED ASSOC, V255, P2031, DOI 10.1001/jama.255.15.2031; HOOK GER, 1975, CHEM-BIOL INTERACT, V10, P199; IDEO G, 1982, CLIN CHIM ACTA, V120, P273, DOI 10.1016/0009-8981(82)90368-0; IDEO G, 1985, ENVIRON HEALTH PERSP, V60, P151, DOI 10.2307/3429957; LATHROP GD, 1987, ADA188262; LATHROP GD, 1984, ADA138340; MARTIN JV, 1984, BRIT J IND MED, V41, P254; MAY G, 1982, BRIT J IND MED, V39, P128; MOCARELLI P, 1986, JAMA-J AM MED ASSOC, V256, P2687, DOI 10.1001/jama.256.19.2687; MOSES M, 1984, AM J IND MED, V5, P161, DOI 10.1002/ajim.4700050303; NILSSEN O, 1990, AM J EPIDEMIOL, V132, P318, DOI 10.1093/oxfordjournals.aje.a115661; PAZDEROVAVEJLUPKOVA J, 1981, ARCH ENVIRON HEALTH, V36, P5, DOI 10.1080/00039896.1981.10667598; REGGIANI G, 1980, J TOXICOL ENV HEALTH, V6, P27, DOI 10.1080/15287398009529828; SCHECTER A, 1986, CHEMOSPHERE, V15, P1273, DOI 10.1016/0045-6535(86)90401-7; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SUSKIND RR, 1984, JAMA-J AM MED ASSOC, V251, P2372, DOI 10.1001/jama.251.18.2372; SUSKIND RR, 1978, JOINT C NATIONAL I E, P7; SWEENEY MH, 1989, CHEMOSPHERE, V19, P973, DOI 10.1016/0045-6535(89)90443-8; SWEENEY MH, 1990, THESIS U MICHIGAN AN; WOLFE WH, 1991, ADA241874; 1987, SAS STAT GUIDE PERSO	29	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2209	2214		10.1001/jama.267.16.2209	http://dx.doi.org/10.1001/jama.267.16.2209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1348289				2022-12-24	WOS:A1992HN84100031
J	HUNTER, CA; JENNINGS, FW; ADAMS, JH; MURRAY, M; KENNEDY, PGE				HUNTER, CA; JENNINGS, FW; ADAMS, JH; MURRAY, M; KENNEDY, PGE			SUBCURATIVE CHEMOTHERAPY AND FATAL POSTTREATMENT REACTIVE ENCEPHALOPATHIES IN AFRICAN TRYPANOSOMIASIS	LANCET			English	Article							GAMBIENSE SLEEPING SICKNESS; ARSENICAL ENCEPHALOPATHY; TRIAL; DNA	The treatment of late-stage African sleeping sickness in man is often complicated by a post-treatment reactive encephalopathy. The basis of this pathological reaction was investigated in a mouse model of African trypanosomiasis. Subcurative treatment with diminazene aceturate, which did not clear parasites from the central nervous system, resulted in a post-treatment meningoencephalitis similar to that seen in man. By contrast, a curative regimen of melaminylthioarsenite and 5-nitroimidazole, which cleared parasites from the central nervous system, did not cause any pathological reaction in the mice. This result indicates that subcurative treatment leads to the development of the post-treatment encephalopathy. Evidence that this may also be the case in man was provided by the detection of trypanosome DNA with the polymerase chain reaction in the brains of 9 patients who had died as the result of a post-treatment reaction. Our findings suggest that more aggressive treatment regimens, which ensure the elimination of trypanosomes from the central nervous system, may prevent post-treatment reactions in patients.	UNIV GLASGOW,DEPT VET MED,GLASGOW G61 1QH,SCOTLAND; UNIV GLASGOW,DEPT VET PARASITOL,GLASGOW G61 1QH,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow			Hunter, Christopher/H-1970-2011					ADAMS JH, 1986, NEUROPATH APPL NEURO, V12, P81, DOI 10.1111/j.1365-2990.1986.tb00682.x; AROZ JOL, 1987, T R SOC TROP MED HYG, V81, P192; FOULKES JR, 1975, J TROP MED HYG, V78, P72; HALLER L, 1986, AM J TROP MED HYG, V35, P94, DOI 10.4269/ajtmh.1986.35.94; HUNTER CA, 1991, INFECT IMMUN, V59, P4636, DOI 10.1128/IAI.59.12.4636-4640.1991; HURST EW, 1959, J PATHOL BACTERIOL, V77, P523, DOI 10.1002/path.1700770224; Jennings F W, 1983, Contrib Microbiol Immunol, V7, P147; JENNINGS FW, 1991, TROP MED PARASITOL, V42, P157; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; MURRAY PK, 1974, IMMUNOLOGY, V27, P825; ORMEROD WE, 1971, AFRICAN TRYPANOSOMIA, P588; PEPIN J, 1989, LANCET, V1, P1246, DOI 10.1016/S0140-6736(89)92340-4; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; POLTERA AA, 1980, T ROY SOC TROP MED H, V74, P706, DOI 10.1016/0035-9203(80)90183-2; SLOOF P, 1983, NUCLEIC ACIDS RES, V11, P3889, DOI 10.1093/nar/11.12.3889; VANNIEUWENHOVE S, 1985, T ROY SOC TROP MED H, V79, P692, DOI 10.1016/0035-9203(85)90195-6; VEEKEN HJGM, 1989, TROP GEOGR MED, V41, P113; 1986, WHO TECH REP SER, V739	19	42	42	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					956	958		10.1016/0140-6736(92)91531-C	http://dx.doi.org/10.1016/0140-6736(92)91531-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348799				2022-12-24	WOS:A1992HP03600004
J	LI, QX; YOUNG, LS; NIEDOBITEK, G; DAWSON, CW; BIRKENBACH, M; WANG, F; RICKINSON, AB				LI, QX; YOUNG, LS; NIEDOBITEK, G; DAWSON, CW; BIRKENBACH, M; WANG, F; RICKINSON, AB			EPSTEIN-BARR-VIRUS INFECTION AND REPLICATION IN A HUMAN EPITHELIAL-CELL SYSTEM	NATURE			English	Article							HUMAN LYMPHOCYTES-B; LATENT MEMBRANE-PROTEIN; CROSS-LINKED ENVELOPE; HUMAN EPIDERMAL-CELLS; NASOPHARYNGEAL CARCINOMA; MONOCLONAL-ANTIBODIES; INSITU HYBRIDIZATION; HUMAN KERATINOCYTES; EBV/C3D RECEPTOR; BURKITT-LYMPHOMA	EPSTEIN-BARR virus, a human herpesvirus with oncogenic potential, infects two target tissues in vivo: B lymphocytes, where the infection is largely non-productive 1, and stratified squamous epithelium in which virus replication occurs 2,3. The interaction with B cells, initiated through virus binding to the B-cell surface molecule CR2 (ref. 4), has been studied in vitro and the virus 'latent' genes associated with B-cell growth transformation defined 5. By comparison, viral infection of epithelium remains poorly understood, reflecting the lack of an appropriate cell-culture model. Here we describe the development of such a model using as targets CR2-expressing transfected cells of two independent human epithelial lines. A high proportion of these cells bind virus and become actively infected, expressing the small EBER RNAs (small non-polyadenylated virus-coded RNAs) and the Epstein-Barr nuclear antigen 1 but not other latent proteins; thereafter, under conditions favouring epithelial differentiation, up to 30% of the cells can be induced to enter virus productive cycle with some progressing to full virus replication. We find significant differences between laboratory virus strains in their ability to infect epithelium that do not correlate with their B-cell growth-transforming activity.	UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	University of Birmingham; Harvard University; Brigham & Women's Hospital			Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				AHEARN JM, 1988, P NATL ACAD SCI USA, V85, P9307, DOI 10.1073/pnas.85.23.9307; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; CANTALOUBE JF, 1990, EUR J IMMUNOL, V20, P409, DOI 10.1002/eji.1830200226; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; KIEFF E, 1990, VIROLOGY, P1889; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; LIN JC, 1984, J VIROL, V50, P50, DOI 10.1128/JVI.50.1.50-55.1984; MILANI S, 1989, HEPATOLOGY, V10, P84, DOI 10.1002/hep.1840100117; MILLER G, 1981, SCIENCE, V212, P452, DOI 10.1126/science.6259735; MOORE MD, 1987, P NATL ACAD SCI USA, V84, P9194, DOI 10.1073/pnas.84.24.9194; NIEDOBITEK G, 1989, HUM PATHOL, V20, P796, DOI 10.1016/0046-8177(89)90075-0; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; PARKINSON EK, 1984, CARCINOGENESIS, V5, P1071, DOI 10.1093/carcin/5.8.1071; PEARSON GR, 1983, J VIROL, V47, P193, DOI 10.1128/JVI.47.1.193-201.1983; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; RUBIN AL, 1986, CANCER RES, V46, P2356; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SHAPIRO IM, 1983, SCIENCE, V215, P1225; SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VROMAN B, 1985, J VIROL, V53, P107, DOI 10.1128/JVI.53.1.107-113.1985; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047; WEIS JJ, 1986, P NATL ACAD SCI USA, V83, P5639, DOI 10.1073/pnas.83.15.5639; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991	39	172	188	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					347	350		10.1038/356347a0	http://dx.doi.org/10.1038/356347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312681				2022-12-24	WOS:A1992HK79400067
J	MOLLA, A; JANG, SK; PAUL, AV; REUER, Q; WIMMER, E				MOLLA, A; JANG, SK; PAUL, AV; REUER, Q; WIMMER, E			CARDIOVIRAL INTERNAL RIBOSOMAL ENTRY SITE IS FUNCTIONAL IN A GENETICALLY ENGINEERED DICISTRONIC POLIOVIRUS	NATURE			English	Article							ENCEPHALOMYOCARDITIS VIRUS-RNA; 5'-UNTRANSLATED REGION; SECONDARY STRUCTURE; GENE ORGANIZATION; INITIATION SITE; TRANSLATION; NEUROVIRULENCE; PROTEINASES; EXPRESSION; ELEMENTS	HIGH mutation rates have driven RNA viruses to shorten their genomes to the minimum possible size 1. Mammalian (+)-strand RNA viruses and retroviruses have responded by reducing the number of cis-acting regulatory elements, a constraint that has led to the emergence of the polyprotein 2. Poliovirus is a (+)-stranded picornavirus whose polyprotein, encoded by an open reading frame spanning most of the viral RNA 3, is processed by virus-encoded proteinases 4,5. Despite their genetic austerity, picornaviruses have retained long 5' untranslated regions 6-8, which harbour cis-acting elements that promote initiation of translation independently of the uncapped 5' end of the viral messenger RNA 9-12. These elements are termed 'internal ribosomal entry sites' 10 and are formed from highly structured RNA segments 13-15 of at least 400 nucleotides 16. How these elements function-is not known, but special RNA-binding proteins may be involved 17. The ribosome or its 40S subunit probably binds at or near a Y(n)X(m)AUG motif (where Y is a pyrimidine and X is a purine) at the 3' border of the internal ribosomal entry site 17, which either provides the initiating codon 16,18 or enables the ribosome to translocate to one downstream (E.W. et al., submitted). Initiation from most eukaryotic messenger RNAs usually occurs by ribosomal recognition of the 5' and subsequent scanning to the AUG codon 19. Here we describe a genetic strategy for the dissection of polyproteins which proves that an internal ribosomal entry site element can initiate translation independently of the 5' end.			MOLLA, A (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.		Jang, Sung K/P-1230-2017					ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; DAVIS BD, 1980, MICROBIOLOGY, P874; DORNER AJ, 1982, J VIROL, V42, P1017, DOI 10.1128/JVI.42.3.1017-1028.1982; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; NICKLIN MJH, 1987, P NATL ACAD SCI USA, V84, P4002, DOI 10.1073/pnas.84.12.4002; PALMENBERG AC, 1987, UCLA S CELLULAR BIOL, V54, P25; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; PILIPENKO EV, 1989, VIROLOGY, V168, P201, DOI 10.1016/0042-6822(89)90259-6; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; REANNEY DC, 1984, S SOC GEN MICROBIOL, V35, P175; RUECKERT RR, 1990, VIROLOGY, P507; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330	29	105	118	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					255	257		10.1038/356255a0	http://dx.doi.org/10.1038/356255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313153				2022-12-24	WOS:A1992HJ94400063
J	PULSINELLI, W				PULSINELLI, W			PATHOPHYSIOLOGY OF ACUTE ISCHEMIC STROKE	LANCET			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA; BRAIN-DAMAGE; THRESHOLDS				PULSINELLI, W (corresponding author), CORNELL UNIV,MED CTR,COLL MED,CEREBROVASC DIS RES CTR,DEPT NEUROL & NEUROSCI,1300 YORK AVE,NEW YORK,NY 10021, USA.							ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P43; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1987, J NEUROSCI, V7, P369; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GINSBERG MD, 1990, CEREBROVAS BRAIN MET, V2, P58; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; KRAIG RP, 1990, J CEREBR BLOOD F MET, V10, P104, DOI 10.1038/jcbfm.1990.13; LEVY DE, 1975, J NEUROL NEUROSUR PS, V38, P1197, DOI 10.1136/jnnp.38.12.1197; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; OBRENOVITCH TP, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P97; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PULSINELLI W, IN PRESS PROG BRAIN; PULSINELLI WA, 1983, J NEUROCHEM, V40, P1500, DOI 10.1111/j.1471-4159.1983.tb13599.x; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165	22	256	265	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					533	536		10.1016/0140-6736(92)90347-6	http://dx.doi.org/10.1016/0140-6736(92)90347-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346887				2022-12-24	WOS:A1992HF63100012
J	PAGANO, M; DRAETTA, G; JANSENDURR, P				PAGANO, M; DRAETTA, G; JANSENDURR, P			ASSOCIATION OF CDK2 KINASE WITH THE TRANSCRIPTION FACTOR-E2F DURING S-PHASE	SCIENCE			English	Article							ADENOVIRUS E1A PROTEINS; FACTOR E2F; CYCLIN-A; ACTIVATION; CELLS; GENE; PHOSPHORYLATION; IDENTIFICATION; COMPLEXES; BINDING	The transcription factor E2F controls the expression of several proliferation-related genes and is a target of the adenovirus E1A oncogene. In human cells, both cyclin A and the cdk2 protein kinase were found in complexes with E2F. Although the total amounts of cdk2 were constant in the cell cycle, binding to E2F was detected only when cells entered S phase, a time when the cdk2 kinase is activated. These data suggest that the interaction between cdk2 and E2F requires an active kinase that has cyclin A as a targeting component.	GERMAN CANC RES CTR,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	PAGANO, M (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY.		Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; pagano, michele/0000-0003-3210-2442				BAEUERLE P, 1989, GENE DEV, V3, P1681; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALDIN V, UNPUB; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUMAR V, 1988, CELL, V55, P507; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; PAGANO M, IN PRESS PROG GROWTH; PAGANO M, IN PRESS EMBO J; PAGANO M, UNPUB; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; THALMEIER K, 1989, GENE DEV, V3, P327; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	39	250	255	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1144	1147		10.1126/science.1312258	http://dx.doi.org/10.1126/science.1312258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1312258				2022-12-24	WOS:A1992HF63200047
J	LUCAS, A; MORLEY, R; COLE, TJ; LISTER, G; LEESONPAYNE, C				LUCAS, A; MORLEY, R; COLE, TJ; LISTER, G; LEESONPAYNE, C			BREAST-MILK AND SUBSEQUENT INTELLIGENCE QUOTIENT IN CHILDREN BORN PRETERM	LANCET			English	Article							BIRTH-WEIGHT INFANTS; MOTHERS CHOICE; DIET	There is considerable controversy over whether nutrition in early life has a long-term influence on neurodevelopment. We have shown previously that, in preterm infants, mother's choice to provide breast milk was associated with higher developmental scores at 18 months. We now report data on intelligence quotient (IQ) in the same children seen at 7 1/2-8 years. IQ was assessed in 300 children with an abbreviated version of the Weschler Intelligence Scale for Children (revised Anglicised). Children who had consumed mother's milk in the early weeks of life had a significantly higher IQ at 7 1/2-8 years than did those who received no maternal milk. An 8.3 point advantage (over half a standard deviation) in IQ remained even after adjustment for differences between groups in mother's education and social class (p < 0.0001). This advantage was associated with being fed mother's milk by tube rather than with the process of breastfeeding. There was a dose-response relation between the proportion of mother's milk in the diet and subsequent IQ. Children whose mothers chose to provide milk but failed to do so had the same IQ as those whose mothers elected not to provide breast milk. Although these results could be explained by differences between groups in parenting skills or genetic potential (even after adjustment for social and educational factors), our data point to a beneficial effect of human milk on neurodevelopment.	UNIV CAMBRIDGE,DEPT PAEDIAT,CAMBRIDGE,ENGLAND; NORFOLK & NORWICH HOSP,DEPT COMMUNITY CHILD HLTH,NORWICH NR1 3SR,NORFOLK,ENGLAND; JESSOP HOSP WOMEN,DEPT PAEDIAT,SHEFFIELD S3 7RE,S YORKSHIRE,ENGLAND	University of Cambridge; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	LUCAS, A (corresponding author), MRC,DUNN NUTR UNIT,DOWNHAMS LANE,MILTON RD,CAMBRIDGE CB4 1XJ,ENGLAND.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				BROAD B, 1972, NZ MED J, V76, P28; LUCAS A, 1989, ARCH DIS CHILD, V64, P1570, DOI 10.1136/adc.64.11.1570; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; LUCAS A, 1988, ARCH DIS CHILD, V63, P48, DOI 10.1136/adc.63.1.48; McNemar Q, 1974, J CONSULT CLIN PSYCH, V42, P145, DOI DOI 10.1037/H0035842; MORLEY R, 1988, ARCH DIS CHILD, V63, P1382, DOI 10.1136/adc.63.11.1382; POLLOCK JI, 1989, ARCH DIS CHILD, V64, P763, DOI 10.1136/adc.64.5.763; READ LC, 1988, FETAL NEONATAL GROWT, P131; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; Rogerson BCF, 1939, J MENT SCI, V85, P1163, DOI 10.1192/bjp.85.359.1163; SACK J, 1980, HUMAN MILK ITS BIOL, P56; SILVA PA, 1978, AUST PAEDIATR J, V14, P265; TAYLOR B, 1977, NEW ZEAL MED J, V85, P235; [No title captured]; 1974, ANGLICIZED REVISED E; [No title captured]	17	825	861	2	100	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					261	264		10.1016/0140-6736(92)91329-7	http://dx.doi.org/10.1016/0140-6736(92)91329-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346280				2022-12-24	WOS:A1992HB52900002
J	MURAKAMI, Y; MATSUFUJI, S; KAMEJI, T; HAYASHI, S; IGARASHI, K; TAMURA, T; TANAKA, K; ICHIHARA, A				MURAKAMI, Y; MATSUFUJI, S; KAMEJI, T; HAYASHI, S; IGARASHI, K; TAMURA, T; TANAKA, K; ICHIHARA, A			ORNITHINE DECARBOXYLASE IS DEGRADED BY THE 26S-PROTEASOME WITHOUT UBIQUITINATION	NATURE			English	Article							RETICULOCYTE LYSATE; PEST HYPOTHESIS; MOUSE KIDNEY; 26S COMPLEX; DEGRADATION; PROTEINS; CELLS; PROTEASE; PURIFICATION; TURNOVER	ORNITHINE decarboxylase (ODC), a key enzyme in polyamine biosynthesis, is the most rapidly turned over mammalian enzyme1. We have shown that its degradation is accelerated by ODC antizyme2,3, an inhibitory protein induced by polyamines4,5. This is a new type of enzyme regulation and may be a model for selective protein degradation. Here we report the identification of the protease responsible for ODC degradation. Using a cell-free degradation system, we demonstrate that immunodepletion of proteasomes from cell extracts causes almost complete loss of ATP- and antizyme-dependent degradation of ODC. In addition, purified 26S proteasome complex, but not the 20S proteasome, catalyses ODC degradation in the absence of ubiquitin. These results strongly suggest that the 26S proteasome, widely viewed as specific for ubiquitin-conjugated proteins, is the main enzyme responsible for ODC degradation. The 26S proteasome may therefore have a second role in ubiquitin-independent proteolysis.	CHIBA UNIV,FAC PHARMACEUT SCI,CHIBA 260,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Chiba University; Tokushima University	MURAKAMI, Y (corresponding author), JIKEI UNIV,DEPT NUTR,MINATO KU,TOKYO 105,JAPAN.		Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556; Igarashi, Kazuei/0000-0003-3751-3187				ARMON T, 1990, J BIOL CHEM, V265, P20723; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KAMEJI T, IN PRESS BIOCH J; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; LI X, 1992, MOL CELL BIOL, V12, P3356; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; NISHIYAMA M, 1988, PREP BIOCHEM, V18, P227, DOI 10.1080/00327488808062524; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROGRES S, 1986, SCIENCE, V234, P20; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SHERMAN MY, 1992, EMBO J, V11, P71; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J BIOL CHEM, V263, P16209	31	690	700	3	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					597	599		10.1038/360597a0	http://dx.doi.org/10.1038/360597a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1334232				2022-12-24	WOS:A1992KB95900089
J	RANDHAWA, PS; JAFFE, R; DEMETRIS, AJ; NALESNIK, M; STARZL, TE; CHEN, YY; WEISS, LM				RANDHAWA, PS; JAFFE, R; DEMETRIS, AJ; NALESNIK, M; STARZL, TE; CHEN, YY; WEISS, LM			EXPRESSION OF EPSTEIN-BARR VIRUS-ENCODED SMALL RNA (BY THE EBER-1 GENE) IN LIVER SPECIMENS FROM TRANSPLANT RECIPIENTS WITH POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSITU HYBRIDIZATION; DISORDERS; EBV; LYMPHOMAS; TISSUES; INDIVIDUALS; LYMPHOCYTES; PATHOLOGY; HEPATITIS; THERAPY	Background. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression. We postulated that the tissue expression of the small RNA transcribed by the EBER-1 gene during latent EBV infection would identify patients at risk for PTLD. Methods. We studied EBER-1 gene expression in liver specimens obtained from 24 patients 2 days to 22 months before the development of PTLD, using in situ hybridization with an oligonucleotide probe. Control specimens were obtained from 20 recipients of allografts with signs of injury due to organ retrieval, acute graft rejection, or viral hepatitis in whom PTLD had not developed 9 to 71 months after the biopsy. Results. Of the 24 patients with PTLD, 17 (71 percent) had specimens in which 1 to 40 percent of mononuclear cells were positive for the EBER-1 gene. In addition, 10 of these 17 patients (59 percent) had specimens with histopathological changes suggestive of EBV hepatitis. In every case, EBER-1-positive cells were found within the lymphoproliferative lesions identified at autopsy. Only 2 of the 20 controls (10 percent) had specimens with EBER-1-positive cells (P<0.001), and such cells were rare. Conclusions. EBER-1 gene expression in liver tissue precedes the occurrence of clinical and histologic PTLD. The possibility of identifying patients at risk by the method we describe here and preventing the occurrence of PTLD by a timely reduction of immunosuppression needs to be addressed by future prospective studies.	UNIV PITTSBURGH, DIV TRANSPLANTAT BIOL, PITTSBURGH, PA 15260 USA; PRESBYTERIAN UNIV HOSP, PITTSBURGH TRANSPLANT INST, PITTSBURGH, PA USA; PRESBYTERIAN UNIV HOSP, DEPT SURG, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA USA; CITY HOPE NATL MED CTR, DEPT PATHOL, DUARTE, CA 91010 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City of Hope			Randhawa, Parmjeet/H-4285-2019		NCI NIH HHS [CA-50341] Funding Source: Medline; NHLBI NIH HHS [HL-13108] Funding Source: Medline; NIAAA NIH HHS [A-3176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050341] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAMBER M, 1981, GUT, V22, P854, DOI 10.1136/gut.22.10.854; BUSH JL, 1989, LAB MED, V20, P318, DOI 10.1093/labmed/20.5.318; CROUSE CA, 1990, J CLIN MICROBIOL, V28, P1026, DOI 10.1128/JCM.28.5.1026-1032.1990; DEMETRIS AJ, 1987, PATHOL ANNU, V22, P347; Gowing N F, 1975, Pathol Annu, V10, P1; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; KATZ BZ, 1989, J INFECT DIS, V160, P589, DOI 10.1093/infdis/160.4.589; KIKUTA H, 1988, NATURE, V333, P455, DOI 10.1038/333455a0; LOCKER J, 1989, AM J PATHOL, V135, P977; LUKES RJ, 1958, AM J PATHOL, V34, P586; MARKIN RS, 1987, GASTROENTEROLOGY, V93, P1210, DOI 10.1016/0016-5085(87)90246-0; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; RANDHAWA PS, 1990, AM J SURG PATHOL, V14, P538, DOI 10.1097/00000478-199006000-00004; RANDHAWA PS, 1991, AM J PATHOL, V138, P1027; ROONEY C, 1989, J VIROL, V63, P1531, DOI 10.1128/JVI.63.4.1531-1539.1989; SCHUURMAN HJ, 1989, AM J CLIN PATHOL, V91, P461, DOI 10.1093/ajcp/91.4.461; Sheibani K, 1984, Semin Diagn Pathol, V1, P235; SHIBATA D, 1991, BLOOD, V77, P1527; STARZL TE, 1984, LANCET, V1, P583; STRAUCH B, 1974, LANCET, V1, P234; SU IJ, 1991, BLOOD, V77, P799; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; WEISS LM, 1990, AM J PATHOL, V137, P979; WEISS LM, 1991, AM J PATHOL, V139, P1259; WEISS LM, 1991, J HISTOCHEM CYTOCHEM, V39, P1237, DOI 10.1177/39.9.1918942; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	30	160	161	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1710	1714		10.1056/NEJM199212103272403	http://dx.doi.org/10.1056/NEJM199212103272403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1331789	Green Accepted			2022-12-24	WOS:A1992KA89700003
J	MEZEY, E; PALKOVITS, M				MEZEY, E; PALKOVITS, M			LOCALIZATION OF TARGETS FOR ANTIULCER DRUGS IN CELLS OF THE IMMUNE-SYSTEM	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR GENES; GASTRIC-ACID SECRETION; DUODENAL-ULCER; DOPAMINE AGONISTS; MOLECULAR-CLONING; PARIETAL-CELLS; RAT; CYSTEAMINE; PROPIONITRILE; EXPRESSION	The gastric mucosa consists of the epithelium, which lines the lumen, the lamina propria, and the muscularis mucosae. The targets of drugs used to treat stomach and duodenal ulcers are thought to be the acid-secreting parietal cells of the epithelium. However, immune cells in the lamina propria are the only cells that showed detectable messenger RNAs for histamine, muscarinic, gastrin, and dopamine receptors by in situ hybridization histochemistry. None of the epithelial cells expressed any of these messenger RNAs. Thus, the targets of antiulcer drugs seem to be cells of the immune system in the gut and not parietal cells, as generally believed. This conclusion may revise the thinking about ulcer formation and may shed light on the etiology of such chronic small intestinal diseases as Crohn's disease.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892; NINCDS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	MEZEY, E (corresponding author), SEMMELWEIS UNIV MED,SCH MED,NEUROMORPHOL LAB,H-1085 BUDAPEST 8,HUNGARY.		Palkovits, Miklos/F-2707-2013; Mezey, Eva/A-8105-2008	Palkovits, Miklos/0000-0003-0578-0387; Mezey, Eva/0000-0002-5907-4691				BIENENSTOCK J, 1980, IMMUNOLOGY, V41, P249; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANDBORG LL, 1969, GASTROENTEROLOGY, V57, P191; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BRIMBLECOMBE RW, 1975, J INT MED RES, V3, P86, DOI 10.1177/030006057500300205; BRUNTON LL, 1990, PHARM BASE THERAPEUT, V1, P897; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHUANG CN, 1991, SCAND J GASTROENTERO, V26, P95, DOI 10.3109/00365529109093184; CRABBE PA, 1966, GASTROENTEROLOGY, V51, P305; CRABBE PA, 1965, LAB INVEST, V14, P235; FIOCCHI C, 1990, IMMUNOLOGY IMMUNOPAT, P107; GALLAGHER G, 1987, J PHARMACOL EXP THER, V240, P883; GLAVIN GB, 1989, J PHARMACOL EXP THER, V251, P726; GLAVIN GB, 1990, DIGEST DIS SCI, V35, P1153, DOI 10.1007/BF01537589; GLAVIN GB, 1991, BRAIN RES REV, V16, P301, DOI 10.1016/0165-0173(91)90012-W; GLAVIN GB, 1987, LIFE SCI, V41, P1397, DOI 10.1016/0024-3205(87)90615-1; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUTH PH, 1966, GASTROENTEROLOGY, V50, P562; GUYTON AC, 1980, TXB MED PHYSL; HERNANDEZ DE, 1987, LIFE SCI, V41, P2717, DOI 10.1016/0024-3205(87)90464-4; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LAMOROUX A, 1987, EMBO J, V6, P3921; LETH R, 1987, AM J PHYSIOL, V253, pG497, DOI 10.1152/ajpgi.1987.253.4.G497; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MEZEY E, 1989, NUCLEIC ACIDS RES, V17, P2125, DOI 10.1093/nar/17.5.2125; MEZEY E, UNPUB; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; OISHI T, 1987, J PHARMACOL EXP THER, V240, P879; Roitt I.M., 1988, ESSENTIAL IMMUNOLOGY; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SIKIRIC P, 1991, DIGEST DIS SCI, V36, P905, DOI 10.1007/BF01297139; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SOLL AH, 1984, AM J PHYSIOL, V247, pG715, DOI 10.1152/ajpgi.1984.247.6.G715; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SZABO S, 1979, LANCET, V2, P880; SZABO S, 1987, J PHARMACOL EXP THER, V240, P871; SZABO S, 1988, TOXICOL PATHOL, V16, P205, DOI 10.1177/019262338801600213; SZABO S, 1987, CHRONOBIOL INT, V4, P31, DOI 10.3109/07420528709078506; SZABO S, 1979, DIGEST DIS SCI, V24, P471, DOI 10.1007/BF01299831; SZABO S, 1979, Gastroenterology, V76, P1257; SZABO S, 1982, ADV DOPAMINE RES, V37, P165; TOMASI TB, 1968, NEW ENGL J MED, V279, P1327, DOI 10.1056/NEJM196812122792408; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; YOUNG WS, 1986, MOL BRAIN RES, V1, P231, DOI 10.1016/0169-328X(86)90029-X	48	83	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1662	1665		10.1126/science.1333642	http://dx.doi.org/10.1126/science.1333642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1333642				2022-12-24	WOS:A1992KA89600041
J	JONES, EY; DAVIS, SJ; WILLIAMS, AF; HARLOS, K; STUART, DI				JONES, EY; DAVIS, SJ; WILLIAMS, AF; HARLOS, K; STUART, DI			CRYSTAL-STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF A SOLUBLE FORM OF THE CELL-ADHESION MOLECULE CD2	NATURE			English	Article							ERYTHROCYTE RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; ANTIGEN; PROTEIN; BINDING; RECOGNITION; EXPRESSION; FRAGMENT	The crystal structure of a soluble form of the T lymphocyte antigen CD2 provides the first complete view of the extracellular region of a cell adhesion molecule. The topology of the molecule, which comprises two immunoglobulin-like domains, is the same as that of the first two domains of CD4 but the relative domain orientation is altered by a fairly flexible linker region. The putative ligand-binding beta-sheet forms a flat surface towards the top of the molecule. Crystal contacts between these surfaces suggest a plausible model for the adhesive interaction.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	JONES, EY (corresponding author), LAB MOLEC BIOPHYS, REX RICHARDS BLDG, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CLARK SJ, 1988, J EXP MED, V167, P1861, DOI 10.1084/jem.167.6.1861; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DAVIS SJ, IN PRESS PROTEIN ENG; DECKERT M, 1991, FASEB J, V5, pA614; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HUNIG T, 1985, J EXP MED, V162, P890, DOI 10.1084/jem.162.3.890; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES EY, 1991, ISOMORPHOUS REPLACEM, P39; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; McPherson A, 1982, PREPARATION ANAL PRO; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SPRINGER TA, 1991, NATURE, V353, P704, DOI 10.1038/353704a0; SPRUYT LL, 1991, J EXP MED, V174, P1407, DOI 10.1084/jem.174.6.1407; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STAUNTON DE, 1989, J EXP MED, V169, P1087, DOI 10.1084/jem.169.3.1087; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; YAGITA H, IN PRESS J EXP MED	49	307	315	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					232	239		10.1038/360232a0	http://dx.doi.org/10.1038/360232a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279440				2022-12-24	WOS:A1992JY96000042
J	SCHULTE, RJ; CAMPBELL, MA; FISCHER, WH; SEFTON, BM				SCHULTE, RJ; CAMPBELL, MA; FISCHER, WH; SEFTON, BM			TYROSINE PHOSPHORYLATION OF CD22 DURING B-CELL ACTIVATION	SCIENCE			English	Article							ANTIGEN RECEPTOR COMPLEX; LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; PHOSPHOLIPASE-C; KINASE; PHOSPHOTYROSINE; STIMULATION	Ligation of the antigen receptor on B cells induces the rapid phosphorylation of tyrosine on a number of cellular proteins. A monoclonal antibody that recognized a tyrosine-phosphorylated cell surface protein that was present in activated B cells was generated. Amino acid sequence analysis showed that this 140-kilodalton protein was CD22, a B cell-specific cell surface glycoprotein and putative extracellular ligand of the protein tyrosine phosphatase CD45. Tyrosine phosphorylation of CD22 may be important in B cell signal transduction, possibly through regulation of the adhesiveness of activated B cells.	SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186; SALK INST,PEPTIDE BIOL LAB,SAN DIEGO,CA 92186	Salk Institute; Salk Institute					NATIONAL CANCER INSTITUTE [R01CA017289, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA17289] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESMARTINEZ JE, 1992, EUR J IMMUNOL, V22, P845, DOI 10.1002/eji.1830220332; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CARTER RH, 1991, J IMMUNOL, V147, P3663; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; DIMINNO G, 1983, BLOOD, V61, P140; DORKEN B, 1986, J IMMUNOL, V136, P4470; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANE PJL, 1991, J IMMUNOL, V146, P715; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, J IMMUNOL, V138, P98; PEZZUTTO A, 1987, LEUKOCYTE TYPING, V3, P361; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; SCHULTE RJ, UNPUB; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90071-J; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEINANDS J, 1990, EMBO J, V9, P449; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	51	139	140	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					1001	1004		10.1126/science.1279802	http://dx.doi.org/10.1126/science.1279802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1279802				2022-12-24	WOS:A1992JW79600037
J	PALABRICA, T; LOBB, R; FURIE, BC; ARONOVITZ, M; BENJAMIN, C; HSU, YM; SAJER, SA; FURIE, B				PALABRICA, T; LOBB, R; FURIE, BC; ARONOVITZ, M; BENJAMIN, C; HSU, YM; SAJER, SA; FURIE, B			LEUKOCYTE ACCUMULATION PROMOTING FIBRIN DEPOSITION IS MEDIATED INVIVO BY P-SELECTIN ON ADHERENT PLATELETS	NATURE			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; GMP-140; NEUTROPHILS; RECEPTOR	THE glycoprotein P-selectin is a cell adhesion molecule of stimulated platelets and endothelial cells, which mediates the interaction of these cells with neutrophils and monocytes1,2. It is a membrane component of cell storage granules3-6, and is a member of the selectin family which includes E-selectin and L-selectin7,8. P-selectin recognizes both lineage-specific carbohydrate ligands on monocytes and neutrophils, including the Lewis x antigen, sialic acid, and a protein component9-12. In inflammation and thrombosis, P-selectin may mediate the interaction of leukocytes with platelets bound in the region of tissue injury and with stimulated endothelium1,2. To evaluate the role of P-selectin in platelet-leukocyte adhesion in vivo, the accumulation of leukocytes within an experimental thrombus was explored in an arteriovenous shunt model in baboons13. A Dacron graft implanted within an arteriovenous shunt is thrombogenic, accumulating platelets and fibrin within its lumen. These bound platelets express P-selectin14. Here we show that antibody inhibition of leukocyte binding to P-selectin expressed on platelets immobilized on the graft blocks leukocyte accumulation and inhibits the deposition of fibrin within the thrombus. These results indicate that P-selectin is an important adhesion molecule on platelets, mediating platelet-leukocyte binding in vivo, that the presence of leukocytes in thrombi is mediated by P-selectin, and that these leukocytes promote fibrin deposition.	NEW ENGLAND MED CTR,DIV CARDIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; BIOGEN INC,CAMBRIDGE,MA 02142; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Biogen; Tufts University	PALABRICA, T (corresponding author), NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.							BAUMAN J M, 1986, Journal of Nuclear Medicine Technology, V14, P15; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; LAMOYI E, 1986, METHOD ENZYMOL, V121, P652; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LERNER EA, 1981, YALE J BIOL MED, V54, P377; LOBB RR, 1991, J IMMUNOL, V147, P124; MACKEY WC, 1984, J SURG RES, V37, P112, DOI 10.1016/0022-4804(84)90170-7; MCAFEE JG, 1976, J NUCL MED, V17, P408; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; NIEMETZ J, 1972, J CLIN INVEST, V51, P307, DOI 10.1172/JCI106815; PALABRICA TM, 1989, P NATL ACAD SCI USA, V86, P1036, DOI 10.1073/pnas.86.3.1036; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROSEBROUGH SF, 1988, J NUCL MED, V29, P1212; SAUVAGE LR, 1976, HEALING ARTERIAL PRO; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; THAKAU ML, 1977, J NUCL MED, V518, P1022; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	26	702	736	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					848	851		10.1038/359848a0	http://dx.doi.org/10.1038/359848a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279433				2022-12-24	WOS:A1992JV77700070
J	HIRSCHOWITZ, L; RAFFLE, AE; MACKENZIE, EFD; HUGHES, AO				HIRSCHOWITZ, L; RAFFLE, AE; MACKENZIE, EFD; HUGHES, AO			LONG-TERM FOLLOW-UP OF WOMEN WITH BORDERLINE CERVICAL SMEAR TEST-RESULTS - EFFECTS OF AGE AND VIRAL-INFECTION ON PROGRESSION TO HIGH-GRADE DYSKARYOSIS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; GYNECOLOGICAL CYTO-PATHOLOGY; CANCER; TERMINOLOGY; COLPOSCOPY; MANAGEMENT; ATYPIA; RISK	Objective - To follow up and assess the significance of borderline change in cervical smears. Design - Retrospective study of women undergoing routine cervical cytological screening in 1981. Setting - Avon Cervical Screening Programme, covering 250 000 women in Bristol and Weston super Mare. Subjects - 437 women showing borderline cervical changes in 1981 and 437 age matched controls with normal results in 1981. Main outcome measures - Cytological progression to high grade dyskaryosis (cervical intraepithelial neoplasia grade III or invasive carcinoma). Results - During follow up ranging from 13 to 106 months 98 of the 437 women (22.4%) with borderline cytological changes on routine cervical cytology screening had a subsequent smear test showing high grade dyskaryosis compared with three of the 437 women (0.9%) in the control group. The risk of progression was greater in women aged 20 to 39 than in those aged 40 and over. Human papillomavirus infection had initially been diagnosed cytologically in 101 of the 437 (23%) women with borderline results. Significantly fewer of these women developed high grade dyskaryosis (13/98 (13%) v 88/339 (26%), p < 0.05). Conclusions - Women with borderline smear test results are at increased risk of developing high grade dyskaryosis, particularly if the borderline changes occur without cytological features of human papillomavirus infection. Progression occurs within three years in 50% of cases, although a linearly increasing risk was sustained over the nine years of follow up and was greatest in women aged 20 to 39. Careful follow up of these women is indicated.	BRISTOL ROYAL INFIRM & GEN HOSP,DEPT HISTOPATHOL,BRISTOL BS2 8HW,AVON,ENGLAND; SOUTHMEAD GEN HOSP,DEPT PUBL HLTH MED,BRISTOL BS10 5NB,AVON,ENGLAND; SOUTHMEAD GEN HOSP,DEPT CYTOL,BRISTOL BS10 5NB,AVON,ENGLAND; BRISTOL MED SCH,DEPT EPIDEMIOL,BRISTOL B58 2PR,ENGLAND	Bristol Royal Infirmary; Southmead Hospital; Southmead Hospital; University of Bristol								CAMPION MJ, 1986, LANCET, V2, P237; DAVIS RM, 1972, OBSTET GYNECOL, V40, P23; EVANS DMD, 1987, J CLIN PATHOL, V40, P530, DOI 10.1136/jcp.40.5.530; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1967; HULKA BS, 1968, AM J OBSTET GYNECOL, V101, P190, DOI 10.1016/0002-9378(68)90187-7; JENKINS D, 1987, LANCET, V1, P748; KINLEN LJ, 1978, LANCET, V2, P463; KIRKUP W, 1982, BRIT J OBSTET GYNAEC, V89, P571, DOI 10.1111/j.1471-0528.1982.tb03662.x; KITCHENER HC, 1988, BRIT J OBSTET GYNAEC, V95, P182, DOI 10.1111/j.1471-0528.1988.tb06849.x; KITCHENER HC, 1988, BRIT J OBSTET GYNAEC, V95, P1089, DOI 10.1111/j.1471-0528.1988.tb06783.x; KRISTENSEN GB, 1991, ACTA CYTOL, V35, P47; MITCHELL H, 1986, LANCET, V1, P573; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NUOVO GJ, 1988, AM J SURG PATHOL, V12, P198, DOI 10.1097/00000478-198803000-00005; NYIRJESY I, 1972, J AMER MED ASSOC, V222, P691; PAIRWUTI S, 1991, ACTA CYTOL, V35, P40; RAFFLE AE, 1990, BMJ-BRIT MED J, V301, P907, DOI 10.1136/bmj.301.6757.907; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SINGER A, 1991, BRIT MED J, V302, P251, DOI 10.1136/bmj.302.6771.251; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; TIDY JA, 1989, LANCET, V1, P434; 1989, LANCET, V2, P1051	24	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1209	1212		10.1136/bmj.304.6836.1209	http://dx.doi.org/10.1136/bmj.304.6836.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1325232	Bronze, Green Published			2022-12-24	WOS:A1992HT96400018
J	HOLICK, MF; SHAO, Q; LIU, WW; CHEN, TC				HOLICK, MF; SHAO, Q; LIU, WW; CHEN, TC			THE VITAMIN-D CONTENT OF FORTIFIED MILK AND INFANT FORMULA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The fortification of milk and infant formula with vitamin D has had an important role in eliminating rickets in children and osteomalacia in adults. A recent outbreak of vitamin D intoxication caused by drinking milk fortified with excess vitamin D has led to questions about the level of vitamin D in milk from other producers. Methods. We used high-performance liquid chromatography to measure vitamin D in samples of 13 brands of milk with various fat contents and 5 brands of infant formula purchased at random from local supermarkets in five Eastern states. Results. Only 12 (29 percent) of the 42 samples of the 13 brands of milk and none of the 10 samples of the 5 brands of infant formula contained 80 to 120 percent of the amount of vitamin D stated on the label. Twenty-six of the 42 milk samples (62 percent) contained less than 80 percent of the amount claimed on the label. No vitamin D was detected in 3 of the 14 samples of skim milk tested (lower limit of assay, 4.7 IU per quart [5.0 IU per liter]). One milk sample labeled as containing vitamin D2 (ergocalciferol) contained vitamin D3 (cholecalciferol). Seven of the 10 samples of infant formula contained more than 200 percent of the amount stated on the label; the sample with the highest concentration contained 419 percent of the stated amount. None of the samples of infant formula contained less than the amount stated. Conclusions. Milk and infant-formula preparations rarely contain the amount of vitamin D stated on the label and may be either underfortified or overfortified. Since both underfortification and overfortification are hazardous, better monitoring of the fortification process is needed.	BOSTON UNIV,SCH MED,VITAMIN D SKIN & BONE RES LAB,BOSTON,MA 02118	Boston University	HOLICK, MF (corresponding author), BOSTON CITY HOSP,80 E CONCORD ST,M-1013,BOSTON,MA 02118, USA.			Holick, Michael/0000-0001-6023-9062; Chen, Tai/0000-0002-5704-5694	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004390] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36963] Funding Source: Medline; NIA NIH HHS [AG-04390] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN TC, 1990, J NUTR BIOCHEM, V1, P272, DOI 10.1016/0955-2863(90)90078-Y; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; Hess AF, 1921, J AMER MED ASSOC, V77, P39; Hess AF, 1924, J BIOL CHEM, V62, P301; Holick M. F., 1990, BONE MINERAL RES ANN, P313; HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464; HOLICK MF, 1989, LANCET, V2, P1104; HOLLIS BW, 1983, ANAL BIOCHEM, V131, P211, DOI 10.1016/0003-2697(83)90157-4; Huldschinsky K, 1919, DEUT MED WOCHENSCHR, V45, P712, DOI 10.1055/s-0028-1137830; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; Jeans PC, 1938, J PEDIATR-US, V13, P730, DOI 10.1016/S0022-3476(38)80162-1; KAVOOKJIAN H, 1990, ORTHOPED T, V14, P580; REYNODS SL, 1984, ANALYST, V19, P489; SHELDON W, 1943, ARCH DIS CHILD, V18, P58; SOKOLOFF L, 1978, AM J SURG PATHOL, V2, P21, DOI 10.1097/00000478-197803000-00003; STEENBOCK H, 1924, J BIOL CHEM, V61, P45; TANNER JT, 1988, J ASSOC OFF ANA CHEM, V71, P607; [No title captured]	18	147	149	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1178	1181		10.1056/NEJM199204303261802	http://dx.doi.org/10.1056/NEJM199204303261802			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1313548	Bronze			2022-12-24	WOS:A1992HR00800002
J	SHIVJI, MKK; KENNY, MK; WOOD, RD				SHIVJI, MKK; KENNY, MK; WOOD, RD			PROLIFERATING CELL NUCLEAR ANTIGEN IS REQUIRED FOR DNA EXCISION REPAIR	CELL			English	Article							XERODERMA PIGMENTOSUM CELLS; SINGLE-STRAND BREAKS; HUMAN-FIBROBLASTS; POLYMERASE-DELTA; AUXILIARY PROTEIN; CYCLIN PCNA; REPLICATION; COMPLEMENTATION; ALPHA; INHIBITION	Fractionation of extracts from human cell lines allows nucleotide excision repair of damaged DNA to be resolved into discrete incision and polymerization stages. Generation of incised intermediates depends on the XP-A protein, a polypeptide that recognizes sites of damaged DNA, and on the human single-stranded DNA-binding protein HSSB. The proliferating cell nuclear antigen (PCNA) is required for the DNA synthesis that converts the nicked intermediates to completed repair events. This need for PCNA implies that repair synthesis is carried out by DNA polymerase-delta or epsilon. The ability to visualize repair intermediates in the absence of PCNA facilitates dissection of the multiprotein reaction that leads to incision of damaged DNA in a major pathway of cellular defense against mutagens.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	SHIVJI, MKK (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEJONGE AJR, 1985, MUTAT RES, V150, P99, DOI 10.1016/0027-5107(85)90106-X; DRESLER SL, 1984, J BIOL CHEM, V259, P3947; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FORNACE AJ, 1976, P NATL ACAD SCI USA, V73, P39, DOI 10.1073/pnas.73.1.39; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JONES CJ, 1989, CARCINOGENESIS, V10, P1197, DOI 10.1093/carcin/10.7.1197; KAUFMANN WK, 1990, CARCINOGENESIS, V11, P15, DOI 10.1093/carcin/11.1.15; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TANAKA K, 1977, P NATL ACAD SCI USA, V74, P2958, DOI 10.1073/pnas.74.7.2958; THIELMANN HW, 1991, CANCER RES, V51, P3456; THNG JPH, 1985, MUTAT RES, V165, P139; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WASEEM NH, 1990, J CELL SCI, V96, P121; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; ZUBER M, 1989, MOL CELL BIOL, V9, P57, DOI 10.1128/MCB.9.1.57	39	773	785	14	118	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					367	374		10.1016/0092-8674(92)90416-A	http://dx.doi.org/10.1016/0092-8674(92)90416-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348971				2022-12-24	WOS:A1992HQ18300015
J	LI, ZW; TAUBE, H				LI, ZW; TAUBE, H			USE OF A DIHYDROGEN OSMIUM COMPLEX AS A VERSATILE H-1-NMR RECOGNITION PROBE	SCIENCE			English	Article								A new recognition probe for biomolecules, [en2OS(eta-2-H-2)]2+ (1; en, ethylenediamine), is reported. In aqueous solution, 1 binds readily to a variety of biomolecules, including nucleotides, RNA, amino acids, peptides, and phospholipids. In each case, binding leads to a characteristic proton nuclear magnetic resonance (H-1 NMR) for the dihydrogen that appears in a spectral window in the range delta = 0 to -20 parts per million, and as well to characteristic values of the coupling J(HD) and of the relaxation time T1. Small structural differences in molecules such as DGMP (2'-deoxyguanosine 5'-monophosphate) and IMP (inosine 5'-monophosphate) or Asp and Glu can readily be distinguished, such as when 1 binds to the N-7 position of the nucleobase of DGMP or IMP and when 1 binds to the carboxylate of Asp or Glu. Upon one-electron oxidation of the metal center, diamagnetic 1 is converted to a paramagnetic probe.	STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013638, R37GM013638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13638-24] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRABTREE RH, 1990, ACCOUNTS CHEM RES, V23, P95, DOI 10.1021/ar00172a001; ISIED S, 1974, INORG CHEM, V13, P1545, DOI 10.1021/ic50137a001; Jardetzky O., 1981, NMR MOL BIOL; KUBAS GJ, 1988, ACCOUNTS CHEM RES, V21, P120, DOI 10.1021/ar00147a005; LaMar G. N., 1973, NMR PARAMAGNETIC MOL; Li Z.B., UNPUB; LI ZW, 1991, J AM CHEM SOC, V113, P8946, DOI 10.1021/ja00023a052; LIM HS, 1972, INORG CHEM, V11, P1460, DOI 10.1021/ic50113a003; Mildvan A S, 1978, Methods Enzymol, V49, P322; PYLE AM, 1990, PROG INORG CHEM, V38, P413; Stryer L, 1981, BIOCHEMISTRY; TAUBE H, 1973, SURV PROG CHEM, V6, P1; WISHART JF, 1984, INORG CHEM, V23, P2997, DOI 10.1021/ic00187a020; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	15	32	34	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					210	213		10.1126/science.1348872	http://dx.doi.org/10.1126/science.1348872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1348872				2022-12-24	WOS:A1992HM89600025
J	RAYMOND, M; GROS, P; WHITEWAY, M; THOMAS, DY				RAYMOND, M; GROS, P; WHITEWAY, M; THOMAS, DY			FUNCTIONAL COMPLEMENTATION OF YEAST-STE6 BY A MAMMALIAN MULTIDRUG RESISTANCE MDR-GENE	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; BACTERIAL TRANSPORT PROTEINS; HORMONE A-FACTOR; CLASS-II REGION; SACCHAROMYCES-CEREVISIAE; P-GLYCOPROTEIN; IDENTIFICATION; FAMILY; HOMOLOGY; PRODUCT	Multidrug resistance in mammalian tumor cells is associated with the overexpression of mdr genes encoding P-glycoproteins, which function as drug efflux pumps. A yeast homolog of mdr, STE6, mediates export of a-factor mating peptide. Yeast MATa cells carrying a ste6 deletion produce no extracellular a-factor and therefore are defective in mating. Expression of a complementary DNA for the mouse mdr3 gene in a yeast ste6 deletion strain restored ability to export a-factor and to mate. A mutation (a serine to phenylalanine substitution at amino acid 939) known to affect the activity of the mdr3 gene product abolished its ability to complement the yeast ste6 deletion. Thus, functions of P-glyco-proteins in normal mammalian cells may include the transmembrane export of endogenous peptides.	MCGILL UNIV, DEPT BIOL, MONTREAL H3A 1B1, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3A 1B1, QUEBEC, CANADA	McGill University; McGill University	RAYMOND, M (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, QUEBEC, CANADA.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPRAGUE GF, 1981, J MOL BIOL, V153, P305, DOI 10.1016/0022-2836(81)90280-1; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEDEN M, 1989, MOL GEN GENET, V219, P439, DOI 10.1007/BF00259617; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TOHE A, 1981, J BACTERIOL, V145, P1421, DOI 10.1128/JB.145.3.1421-1424.1981; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P83; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713	38	207	219	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					232	234		10.1126/science.1348873	http://dx.doi.org/10.1126/science.1348873			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1348873				2022-12-24	WOS:A1992HM89600032
J	HOCH, M; GERWIN, N; TAUBERT, H; JACKLE, H				HOCH, M; GERWIN, N; TAUBERT, H; JACKLE, H			COMPETITION FOR OVERLAPPING SITES IN THE REGULATORY REGION OF THE DROSOPHILA GENE KRUPPEL	SCIENCE			English	Article							HORMONE RECEPTOR SUPERFAMILY; BICOID PROTEIN; DNA-BINDING; GAP GENES; GLUCOCORTICOID RECEPTOR; ANTERIOR PATTERN; FUSHI-TARAZU; C-JUN; EMBRYO; EXPRESSION	A 730-base pair element regulates expression of the Drosophila gap gene Kruppel (Kr) in response to the fly anterior morphogen bicoid (bcd). Two hormone receptor-like proteins, encoded by the genes knirps (kni) and tailless (tll), bind specifically to the element. In vitro, kni protein competes with the homeodomain-containing bcd protein in binding to a 16-base pair target sequence. In vivo experiments suggest that both kni and tll act as competitive repressors of bcd-mediated activation of Kr. These results suggest a mechanism by which developmental genes can be regulated in response to an activating morphogen gradient antagonized by repressors.			HOCH, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,W-3400 GOTTINGEN,GERMANY.							AKAM M, 1987, DEVELOPMENT, V101, P1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; MANGELSDORF KK, 1991, NATURE, V345, P224; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STRECKER TR, 1988, DEVELOPMENT, V102, P721; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	60	111	112	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					94	97		10.1126/science.1348871	http://dx.doi.org/10.1126/science.1348871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1348871				2022-12-24	WOS:A1992HL82200034
J	DANIELS, N				DANIELS, N			HIV-INFECTED PROFESSIONALS, PATIENT RIGHTS, AND THE SWITCHING DILEMMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The ethical issues surrounding the Centers for Disease Control and American Medical Association guidelines for health professionals infected with the human immunodeficiency virus are examined and discussed. Although human immunodeficiency virus transmission risks during surgery are lower than many risks we routinely face, it is not irrational for a patient to want to switch from an infected professional to an uninfected one. The American Medical Association claim that physicians have a duty to avoid imposing any identifiable risks is implausible. Knowing the Centers for Disease Control estimate of risks gives us no way to decide whether the rights of patients or those of handicapped (infected) workers should be given priority. Granting priority to patient rights, either by giving patients the opportunity to know the risks they face and to switch to another provider, or by removing infected providers (compulsory switching), makes us all worse off. This gives us reason to reject these guidelines and emphasize other infection control measures.			DANIELS, N (corresponding author), TUFTS UNIV,DEPT PHILOSOPHY,MEDFORD,MA 02168, USA.				NATIONAL LIBRARY OF MEDICINE [R01LM005005] Funding Source: NIH RePORTER; NLM NIH HHS [1 R01LM05005] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Barnes M, 1990, Law Med Health Care, V18, P311; GROSS J, 1991, NY TIMES        0818, V140, P1; LANDESMAN SH, 1991, ARCH INTERN MED, V151, P655, DOI 10.1001/archinte.151.4.655; LEARY W, 1975, NY TIMES        1215, V140, P38; LOWENFELS AB, 1991, NEW ENGL J MED, V325, P888, DOI 10.1056/NEJM199109193251212; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; Parmet W E, 1990, Law Med Health Care, V18, P331; Taylor M., 1987, POSSIBILITY COOPERAT; WILSON R, 1979, TECHNOL REV, V81, P41; WOLFF C, 1991, NY TIMES        0727, V140, pA1; WOLFF C, 1991, NY TIMES        0729, V140, pB1; 1990, PUB L, V101, P104; 1991, MMWR, V40, P1; 1991, ESTIMATES RISK ENDEM; 1991, UNPUB RECOMMENDATION; 1991, AMA STATEMENT HIV IN	16	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1368	1371		10.1001/jama.267.10.1368	http://dx.doi.org/10.1001/jama.267.10.1368			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1311045				2022-12-24	WOS:A1992HG67800031
J	HADDAD, J; DENY, P; MUNZGOTHEIL, C; AMBROSINI, JC; TRINCHET, JC; PATERON, D; MAL, F; CALLARD, P; BEAUGRAND, M				HADDAD, J; DENY, P; MUNZGOTHEIL, C; AMBROSINI, JC; TRINCHET, JC; PATERON, D; MAL, F; CALLARD, P; BEAUGRAND, M			LYMPHOCYTIC SIALADENITIS OF SJOGRENS-SYNDROME ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS LIVER-DISEASE	LANCET			English	Article							SALIVARY-GLAND BIOPSIES	Viral infection has often been suggested as a possible cause of Sjogren's syndrome or chronic lymphocytic sialadenitis, and Epstein-Barr virus has been found in the salivary glands of patients with this condition. After we had noted Sjogren's syndrome in several patients infected with hepatitis C virus (HCV), a virus also excreted in saliva, we set up a prospective study to investigate the association of chronic lymphocytic sialadenitis, with or without symptoms, to chronic HCV liver disease. The histological appearances of labial salivary glands in patients with proven HCV hepatitis or cirrhosis were compared with those in dead controls. Histological changes characteristic of Sjogren's syndrome were significantly more common in HCV-infected patients (16 of 28, 57%) compared with controls (1 of 20, 5%). Focal lymphocytic sialadenitis characteristic of Sjogren's syndrome (though only 10 patients had xerostomia and none complained of xerophthalmia) appears to be common in patients with chronic HCV liver disease; if this association is confirmed, identification of the underlying mechanism may improve our understanding of both disorders.	HOP JEAN VERDIER, DEPT HEPATOGASTROENTEROL, SERV HEPATOGASTROENTEROL, AVE 14 JUILLET, F-93143 BONDY, FRANCE; HOP AVICENNE, DEPT MICROBIOL, BOBIGNY, FRANCE; HOP JEAN VERDIER, DEPT PATHOL, F-93140 BONDY, FRANCE; HOP JEAN VERDIER, DEPT ORAL MED, F-93140 BONDY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP			Deny, Paul/C-6099-2011					ABE K, 1987, J INFECT DIS, V155, P1078, DOI 10.1093/infdis/155.5.1078; BLOCH KJ, 1965, MEDICINE, V44, P187, DOI 10.1097/00005792-196505000-00001; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; FLESCHER E, 1991, AM J MED, V90, P283, DOI 10.1016/0002-9343(91)80006-8; FOX RI, 1986, J IMMUNOL, V137, P3162; GOLDING PL, 1970, BRIT MED J, V4, P340, DOI 10.1136/bmj.4.5731.340; GREENSPAN JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KOJIMA A, 1980, Experimental Animals (Tokyo), V29, P409; MAGRIN S, 1991, J HEPATOL, V13, P56, DOI 10.1016/0168-8278(91)90864-8; MARIETTE X, 1991, AM J MED, V90, P286, DOI 10.1016/0002-9343(91)80007-9; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; Moutsopoulos H. M., 1987, SJOGRENS SYNDROME CL, P258; SCOTT J, 1980, J BIOL BUCCALE, V8, P187; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; TODROS L, 1991, J HEPATOL, V13, P128, DOI 10.1016/0168-8278(91)90874-B; VENTO S, 1989, LANCET, V2, P926	19	479	487	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1992	339	8789					321	323		10.1016/0140-6736(92)91645-O	http://dx.doi.org/10.1016/0140-6736(92)91645-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346409	Green Published			2022-12-24	WOS:A1992HC77100002
J	POSADA, J; COOPER, JA				POSADA, J; COOPER, JA			REQUIREMENTS FOR PHOSPHORYLATION OF MAP KINASE DURING MEIOSIS IN XENOPUS OOCYTES	SCIENCE			English	Article							NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; STIMULATED PROTEIN; PHOSPHOTYROSYL PROTEIN; PC12 CELLS; TYROSINE; ACTIVATION; IDENTIFICATION; PURIFICATION; PHOSPHATASES	Mitogen-activated protein (MAP) kinases are activated in response to a variety of extracellular stimuli by phosphorylation on tyrosine and threonine residues. Xp42 is a Xenopus laevis MAP kinase that is activated during oocyte maturation. Modified forms of Xp42 that lacked enzymatic activity or either of the phosphorylation sites were expressed in Xenopus oocytes. When meiotic maturation was induced with progesterone, each mutant Xp42 was phosphorylated, indicating that at least one kinase was activated that can phosphorylate Xp42 on tyrosine and threonine. Phosphorylation of one residue is not strictly dependent on phosphorylation of the other.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Posada, James/0000-0003-3582-9612	NATIONAL CANCER INSTITUTE [F32CA008860, P01CA028151] Funding Source: NIH RePORTER; NCI NIH HHS [CA-28151, CA-08860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, UNPUB; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STRATTON KR, 1991, J NEUROCHEM, V56, P147, DOI 10.1111/j.1471-4159.1991.tb02574.x; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAO H, 1990, J BIOL CHEM, V265, P15471; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	45	290	297	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					212	215		10.1126/science.1313186	http://dx.doi.org/10.1126/science.1313186			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1313186				2022-12-24	WOS:A1992GY70400041
J	MIRALLES, GD; OFALLON, JR; TALLEY, NJ				MIRALLES, GD; OFALLON, JR; TALLEY, NJ			PLASMA-CELL DYSCRASIA WITH POLYNEUROPATHY - THE SPECTRUM OF POEMS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; PERIPHERAL-NERVE MYELIN; MONOCLONAL GAMMOPATHY; OSTEOSCLEROTIC MYELOMA; SKIN CHANGES; NEUROPATHY; PARAPROTEINEMIA; FEATURES; ANTIBODY; TISSUE	Background. The POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome and osteosclerotic myeloma (polyneuropathy and sclerotic bone lesions) may both be manifestations of plasma-cell dyscrasia, but the interrelation of these diseases is not clear. We therefore set out to define the clinical spectrum of disease in patients with plasma-cell dyscrasia and polyneuropathy who have the complete or incomplete form of the POEMS syndrome or osteosclerotic myeloma. Methods. Among 2714 patients with plasma-cell dyscrasia who were identified between 1973 and 1989, we reviewed the cases of those with polyneuropathy and plasma-cell dyscrasia who fulfilled the criteria for the POEMS syndrome or osteosclerotic myeloma. Results. Thirty-eight patients (1.4 percent) with a median age of 51 years were identified, 22 of whom were male. By definition, all had polyneuropathy (37 combined sensorimotor, and 1 primarily motor). Other findings included osteosclerotic bone lesions (82 percent), skin abnormalities (58 percent), lymphadenopathy (42 percent), papilledema (37 percent), peripheral edema (29 percent), hepatomegaly (24 percent), splenomegaly (21 percent), and ascites (11 percent). Thirty-three patients (87 percent) had an abnormal M protein in serum or urine (17 had IgA-lambda and 12 IgG-lambda). Five patients fulfilled all the criteria for the POEMS syndrome. The estimated five-year survival in the 38 patients was 60 percent, which was significantly better than the 20 percent survival in 869 patients with multiple myeloma (P<0.05). The clinical course was similar among the patients with the complete form of the POEMS syndrome and those with the incomplete form. Conclusions. Plasma-cell dyscrasia with polyneuropathy is a rare multisystem disease that often presents with osteosclerotic bone lesions. The differentiation of the POEMS syndrome from so-called osteosclerotic myeloma with peripheral neuropathy appears to have no clinical value.	MAYO CLIN & MAYO FDN, DIV GASTROENTEROL & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, CANC STAT UNIT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic			Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092				AGUAYO A, 1964, J NEUROL NEUROSUR PS, V27, P562, DOI 10.1136/jnnp.27.6.562; BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; BESINGER UA, 1981, SCIENCE, V213, P1027, DOI 10.1126/science.7268405; BRAUN PE, 1982, J NEUROCHEM, V39, P1261, DOI 10.1111/j.1471-4159.1982.tb12563.x; CROW RS, 1956, BRIT MED J, V2, P802, DOI 10.1136/bmj.2.4996.802; DRIEDGER H, 1980, MEDICINE, V59, P301, DOI 10.1097/00005792-198007000-00005; DYCK PJ, 1991, NEW ENGL J MED, V325, P1482, DOI 10.1056/NEJM199111213252105; EVISON G, 1967, BRIT J RADIOL, V40, P81, DOI 10.1259/0007-1285-40-470-81; HAFLER DA, 1986, NEUROLOGY, V36, P75, DOI 10.1212/WNL.36.1.75; JULIEN J, 1978, ARCH NEUROL-CHICAGO, V35, P423, DOI 10.1001/archneur.1978.00500310025005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY JJ, 1981, NEUROLOGY, V31, P24, DOI 10.1212/WNL.31.1.24; KELLY JJ, 1983, NEUROLOGY, V33, P202, DOI 10.1212/WNL.33.2.202; KOJIMA M, 1983, JPN J CLIN ONCOL, V13, P557; KYLE RA, 1975, MAYO CLIN PROC, V50, P29; KYLE RA, 1976, MONOCLONAL GAMMOPATH; LATOV N, 1980, NEW ENGL J MED, V303, P618, DOI 10.1056/NEJM198009113031105; LATOV N, 1981, NEUROLOGY, V31, P1530, DOI 10.1212/WNL.31.12.1530; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mayo C M, 1968, Trans Am Neurol Assoc, V93, P240; MEIER C, 1985, J NEUROL, V232, P204, DOI 10.1007/BF00313781; MONACO S, 1990, NEW ENGL J MED, V322, P649, DOI 10.1056/NEJM199003083221002; MORLEY JB, 1967, J NEUROL NEUROSUR PS, V30, P432, DOI 10.1136/jnnp.30.5.432; MYERS BM, 1991, AM J MED, V90, P646; NAKANISHI T, 1984, NEUROLOGY, V34, P712, DOI 10.1212/WNL.34.6.712; ODELBERGJOHNSON O, 1959, ACTA RADIOL, V52, P139, DOI 10.3109/00016925909171139; REITAN JB, 1980, ACTA MED SCAND, V208, P137; REULECKE M, 1988, NEUROLOGY, V38, P614, DOI 10.1212/WNL.38.4.614; SEMBLE EL, 1986, ARTHRITIS RHEUM, V29, P286, DOI 10.1002/art.1780290218; SHELLEY WB, 1987, ARCH DERMATOL, V123, P85, DOI 10.1001/archderm.123.1.85; Shimpo S, 1968, Nihon Rinsho, V26, P2444; Silberstein L E, 1985, J Clin Apher, V2, P253, DOI 10.1002/jca.2920020309; TAKATSUKI K, 1983, JPN J CLIN ONCOL, V13, P543; TRENTHAM DE, 1976, ANN INTERN MED, V84, P271, DOI 10.7326/0003-4819-84-3-271; WALDENSTROM JG, 1978, ACTA MED SCAND, V203, P297; WIERNIK PH, 1991, NEOPLASTIC DISEASES	36	216	222	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1919	1923		10.1056/NEJM199212313272705	http://dx.doi.org/10.1056/NEJM199212313272705			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1333569				2022-12-24	WOS:A1992KE50500005
J	MOMBURG, F; ORTIZNAVARRETE, V; NEEFJES, J; GOULMY, E; VANDEWAL, Y; SPITS, H; POWIS, SJ; BUTCHER, GW; HOWARD, JC; WALDEN, P; HAMMERLING, GJ				MOMBURG, F; ORTIZNAVARRETE, V; NEEFJES, J; GOULMY, E; VANDEWAL, Y; SPITS, H; POWIS, SJ; BUTCHER, GW; HOWARD, JC; WALDEN, P; HAMMERLING, GJ			PROTEASOME SUBUNITS ENCODED BY THE MAJOR HISTOCOMPATIBILITY COMPLEX ARE NOT ESSENTIAL FOR ANTIGEN PRESENTATION	NATURE			English	Article							CLASS-II REGION; MULTICATALYTIC PROTEINASE; LINKED LMP; HUMAN MHC; GENE; MOLECULES; ANTIBODY; TRANSPORTERS; INVITRO	MAJOR histocompatibility complex (MHC) class I molecules bind and deliver peptides derived from endogenously synthesized proteins to the cell surface for survey by cytotoxic T lymphocytes. It is believed that endogenous antigens are generally degraded in the cytosol, the resulting peptides being translocated into the endoplasmic reticulum where they bind to MHC class I molecules. Transporters containing an ATP-binding cassette encoded by the MHC class II region seem to be responsible for this transport1-8. Genes coding for two subunits of the '20S' proteasome (a multicatalytic proteinase) have been found in the vicinity of the two transporter genes in the MHC class II region, indicating that the proteasome could be the unknown proteolytic entity in the cytosol involved in the generation of MHC class I-binding peptides9-13. By introducing rat genes encoding the MHC-linked transporters into a human cell line lacking both transporter and proteasome subunit genes, we show here that the MHC-encoded proteasome subunits are not essential for stable MHC class I surface expression, or for processing and presentation of antigenic peptides from influenza virus and an intracellular protein.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND; MAX PLANCK INST BIOL,W-7400 TUBINGEN,GERMANY	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Max Planck Society	MOMBURG, F (corresponding author), GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.		Neefjes, Jacques J.C./H-8780-2017; Ortiz-Navarrete, Vianney/H-1932-2016	Neefjes, Jacques J.C./0000-0001-6763-2211; Powis, Simon/0000-0003-4218-2984; Howard, Jonathan/0000-0003-2756-5143; Ortiz-Navarrete, Vianney/0000-0001-6546-9713				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HORAI S, 1992, IMMUNOGENETICS, V16, P135; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MULLER C, 1983, HUM IMMUNOL, V6, P189, DOI 10.1016/0198-8859(83)90092-7; MULLER C, 1985, HUM IMMUNOL, V14, P333, DOI 10.1016/0198-8859(85)90241-1; MULLER C, 1981, HUM IMMUNOL, V5, P269; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	32	267	274	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					174	177		10.1038/360174a0	http://dx.doi.org/10.1038/360174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1299222	Green Submitted			2022-12-24	WOS:A1992JX75200065
J	SPRIGGS, MK; HRUBY, DE; MALISZEWSKI, CR; PICKUP, DJ; SIMS, JE; BULLER, RML; VANSLYKE, J				SPRIGGS, MK; HRUBY, DE; MALISZEWSKI, CR; PICKUP, DJ; SIMS, JE; BULLER, RML; VANSLYKE, J			VACCINIA AND COWPOX VIRUSES ENCODE A NOVEL SECRETED INTERLEUKIN-1-BINDING PROTEIN	CELL			English	Article							INVERTED TERMINAL REPEAT; EPIDERMAL GROWTH-FACTOR; OPEN READING FRAME; B-CELL GROWTH; IMMUNOGLOBULIN SUPERFAMILY; EXPRESSION VECTORS; INFLUENZA-VIRUS; IL-1 RECEPTOR; T-CELLS; INFECTION	Supernatants from vaccinia virus (VV)-infected CV-1 cells were examined and found to contain a 33 kd protein capable of binding murine interleukin-1beta (mIL-1beta). A VV open reading frame (ORF) that exhibits 30% amino acid identity to the type II IL-1 receptor was expressed in CV-1-EBNA cells and shown specifically to bind mIL-1beta. A similar ORF from cowpox virus was expressed and also specifically bound mIL-1beta. A recombinant VV was constructed in which this ORF was disrupted (vB15RKO). Supernatants from vB15RKO-infected cells did not contain an IL-1-binding protein. Supernatants from VV-infected CV-1 cells were capable of inhibiting IL-1-induced murine lymphocyte proliferation in vitro while supernatants from vB15RKO infected cells did not. Intracranial inoculation of mice with vB15RKO suggests that this ORF is involved in VV virulence. The possible role of a virus-encoded IL-1-binding protein in the pathology of a poxvirus infection and its relationship to other poxvirus-encoded immune modulators is discussed.	IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101; OREGON STATE UNIV,DEPT MICROBIOL,CORVALLIS,OR 97331; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	Oregon State University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SPRIGGS, MK (corresponding author), IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101, USA.			Sims, John/0000-0002-5667-9185	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21335-06] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCAMI A, 1992, CELL, V71; BECKER S, 1991, J IMMUNOL, V147, P4307; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLANDEN RV, 1975, NATURE, V254, P269, DOI 10.1038/254269a0; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BOOTH RJ, 1984, J IMMUNOL, V133, P1346; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1985, NATURE, V317, P813, DOI 10.1038/317813a0; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEYERLE KL, 1992, IN PRESS J IMMUNOL; DOWER SK, 1990, CELLULAR MOL MECHANI, V1, P137; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; ELANGO N, 1986, P NATL ACAD SCI USA, V83, P1906, DOI 10.1073/pnas.83.6.1906; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FARRAR WL, 1987, J IMMUNOL, V139, P459; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FRANKE CA, 1985, MOL CELL BIOL, V5, P1918, DOI 10.1128/MCB.5.8.1918; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HOWARD M, 1983, J EXP MED, V157, P1529, DOI 10.1084/jem.157.5.1529; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HRUBY DE, 1990, CLIN MICROBIOL REV, V3, P153, DOI 10.1128/CMR.3.2.153-170.1990; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; LAW KM, 1992, J GEN VIROL, V73, P549, DOI 10.1099/0022-1317-73-3-549; LUGMAN M, 1992, EUR J IMMUNOL, V22, P95; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARTIN M, 1988, TRENDS PHARMACOL SCI, V9, P171, DOI 10.1016/0165-6147(88)90033-8; McFadden G., 1988, Virus diseases in laboratory and captive animals, P37; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; PICKUP DJ, 1984, P NATL ACAD SCI-BIOL, V81, P6817, DOI 10.1073/pnas.81.21.6817; PIKE BL, 1985, P NATL ACAD SCI USA, V82, P8153, DOI 10.1073/pnas.82.23.8153; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REISNER AH, 1985, NATURE, V313, P801, DOI 10.1038/313801a0; Sambrook J., 1989, MOL CLONING LAB MANU; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VACHERON F, 1990, J GEN VIROL, V71, P477, DOI 10.1099/0022-1317-71-2-477	53	294	303	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					145	152		10.1016/0092-8674(92)90273-F	http://dx.doi.org/10.1016/0092-8674(92)90273-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1339315				2022-12-24	WOS:A1992JQ62300014
J	BOOKER, GW; BREEZE, AL; DOWNING, AK; PANAYOTOU, G; GOUT, I; WATERFIELD, MD; CAMPBELL, ID				BOOKER, GW; BREEZE, AL; DOWNING, AK; PANAYOTOU, G; GOUT, I; WATERFIELD, MD; CAMPBELL, ID			STRUCTURE OF AN SH2 DOMAIN OF THE P85-ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL-3-OH KINASE	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURES; SIGNAL TRANSDUCTION; PROTEIN STRUCTURES; DISTANCE DATA; PROGRAM; CONFORMATIONS; DYNAMICS	RECEPTOR protein-tyrosine kinases, through phosphorylation of specific tyrosine residues, generate high-affinity binding sites which direct assembly of multienzyme signalling complexes1,2. Many of these signalling proteins, including phospholipase C-gamma, GTPase-activating protein and phosphatidylinositol-3-OH kinase, contain src-homology 2 (SH2) domains, which bind with high affinity and specificity to tyrosine-phosphorylated sequences3,4. The critical role played by SH2 domains in signalling has been highlighted by recent studies showing that mutation of specific phosphorylation sites on the platelet-derived growth factor receptor impair its association with phosphatidylinositol-3-OH kinase, preventing growth factor-induced mitogenesis5,6. Here we report the solution structure of an isolated SH2 domain from the 85K regulatory subunit of phosphatidylinositol-3-OH kinase, determined using multidimensional nuclear magnetic resonance spectroscopy. The structure is characterized by a central region of beta-sheet flanked by two alpha-helices, with a highly flexible loop close to functionally important residues previously identified by site-directed mutagenesis7,8.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; ICI PLC,PHARMACEUT,PROT STRUCT FUNCT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Oxford; Ludwig Institute for Cancer Research				Breeze, Alexander/0000-0001-9723-3350				BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, PROTEIN ENG, V1, P399, DOI 10.1093/protein/1.5.399; BRUNGER AT, 1988, XPLOR MANUAL; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HILES I, IN PRESS CELL; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maniatis T., 1982, MOL CLONING; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1991, FEBS LETT, V285, P327	28	169	171	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					684	687		10.1038/358684a0	http://dx.doi.org/10.1038/358684a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1323062				2022-12-24	WOS:A1992JJ88200059
J	LENSCHOW, DJ; ZENG, YJ; THISTLETHWAITE, JR; MONTAG, A; BRADY, W; GIBSON, MG; LINSLEY, PS; BLUESTONE, JA				LENSCHOW, DJ; ZENG, YJ; THISTLETHWAITE, JR; MONTAG, A; BRADY, W; GIBSON, MG; LINSLEY, PS; BLUESTONE, JA			LONG-TERM SURVIVAL OF XENOGENEIC PANCREATIC-ISLET GRAFTS INDUCED BY CTLA4IG	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; T-CELL; REJECTION; CTLA-4; TRANSPLANTATION; ACTIVATION; RECEPTOR; MOUSE	Antigen-specific T cell activation depends on T cell receptor-ligand interaction and co-stimulatory signals generated when accessory molecules bind to their ligands, such as CD28 to the B7 (also called BB1) molecule. A soluble fusion protein of human CTLA-4 (a protein homologous to CD28) and the immunoglobulin (Ig) G1 Fc region (CTLA4Ig) binds to human and murine B7 with high avidity and blocks T cell activation in vitro. CTLA4Ig therapy blocked human pancreatic islet rejection in mice by directly affecting T cell recognition of B7+ antigen-presenting cells. In addition, CTLA4Ig induced long-term, donor-specific tolerance, which may have applications to human organic transplantation.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT SURG,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Bristol-Myers Squibb					NIAID NIH HHS [AI29531] Funding Source: Medline; NIDDK NIH HHS [R29 DK40092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI029531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DAMLE NK, 1992, J IMMUNOL, V148, P1985; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; GILL RG, 1989, J IMMUNOL, V143, P2176; HAO L, 1987, J IMMUNOL, V139, P4022; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPER K, 1991, J IMMUNOL, V147, P1037; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, UNPUB; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LUCAS PJ, 1990, J IMMUNOL, V144, P4548; MOSES RD, 1992, TRANSPLANTATION, V53, P203, DOI 10.1097/00007890-199201000-00039; MOSES RD, 1990, J EXP MED, V172, P567, DOI 10.1084/jem.172.2.567; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RICORDI C, 1991, TRANSPLANTATION, V52, P519, DOI 10.1097/00007890-199109000-00026; TAN PH, UNPUB; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; YOKOCHI T, 1982, J IMMUNOL, V128, P823; ZENG YJ, 1992, TRANSPLANTATION, V53, P277, DOI 10.1097/00007890-199202010-00005	24	1157	1269	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					789	792		10.1126/science.1323143	http://dx.doi.org/10.1126/science.1323143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323143				2022-12-24	WOS:A1992JG85100032
J	MOSS, SJ; SMART, TG; BLACKSTONE, CD; HUGANIR, RL				MOSS, SJ; SMART, TG; BLACKSTONE, CD; HUGANIR, RL			FUNCTIONAL MODULATION OF GABA(A) RECEPTORS BY CAMP-DEPENDENT PROTEIN-PHOSPHORYLATION	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; A RECEPTOR; SUBUNIT COMPOSITION; MOLECULAR-BIOLOGY; KINASE-C; GAMMA-2-SUBUNIT; DESENSITIZATION; PHARMACOLOGY; POTENTIATION; EXPRESSION	Gamma-aminobutyric acid(A) (GABA(A)) receptors are ligand-gated ion channels that mediate inhibitory synaptic transmission in the central nervous system. The role of protein phosphorylation in the modulation of GABA(A) receptor function was examined with cells transiently transfected with GABA(A) receptor subunits. GABA(A) receptors consisting of the alpha-1 and beta-1 or the alpha-1, beta-1, and gamma-2, subunits were directly phosphorylated on the beta-1 subunit by adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA). The phosphorylation decreased the amplitude of the GABA response of both receptor types and the extent of rapid desensitization of the GABA(A) receptor that consisted of the alpha-1 and beta-1 subunits. Site-specific mutagenesis of the serine residue phosphorylated by PKA completely eliminated the PKA phosphorylation and modulation of the GABA(A) receptor. In primary embryonic rat neuronal cell cultures, a similar regulation of GABA(A) receptors by PKA was observed. These results demonstrate that the GABA(A) receptor is directly modulated by protein phosphorylation and suggest that neurotransmitters or neuropeptides that regulate intracellular cAMP levels may modulate the responses of neurons to GABA and consequently have profound effects on synaptic excitability.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV LONDON,DEPT PHARMACOL,LONDON WC1N 1AX,ENGLAND	Howard Hughes Medical Institute; Johns Hopkins University; University of London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; LEIDENHEIMER NJ, 1991, J NEUROCHEM, V57, P722, DOI 10.1111/j.1471-4159.1991.tb03806.x; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; MOSS SJ, UNPUB; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SESSLER FM, 1989, BRAIN RES, V499, P27, DOI 10.1016/0006-8993(89)91132-3; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TICKU MK, 1990, MOL PHARMACOL, V38, P719; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WANG JB, IN PRESS J MOL NEURO	29	267	270	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					661	665		10.1126/science.1323140	http://dx.doi.org/10.1126/science.1323140			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1323140				2022-12-24	WOS:A1992JF85200034
J	SAITOH, H; TOMKIEL, J; COOKE, CA; RATRIE, H; MAURER, M; ROTHFIELD, NF; EARNSHAW, WC				SAITOH, H; TOMKIEL, J; COOKE, CA; RATRIE, H; MAURER, M; ROTHFIELD, NF; EARNSHAW, WC			CENP-C, AN AUTOANTIGEN IN SCLERODERMA, IS A COMPONENT OF THE HUMAN INNER KINETOCHORE PLATE	CELL			English	Article							MAMMALIAN KINETOCHORE; CENTROMERE PROTEINS; AUTO-ANTIGEN; ANTICENTROMERE ANTIBODIES; CHROMOSOME CONDENSATION; ELECTRON-MICROSCOPY; AUTOIMMUNE SERA; DNA; FAMILY; CELLS	We have isolated and characterized a set of overlapping cDNA clones that encode the human centromere autoantigen centromere protein C (CENP-C). The identity of these clones has been established using several criteria. First, they were shown to encode a polypeptide that migrates at the expected position for CENP-C on SDS-polyacrylamide gel electrophoresis. Second, we have demonstrated that this polypeptide shares at least two epitopes with human CENP-C. Polyclonal antibodies were raised to fusion proteins encoded by nonoverlapping regions of the cDNA clones. These antibodies were shown to recognize a protein at a position appropriate for CENP-C on immunoblots of human chromosomal proteins. In addition, we used indirect immunofluorescence to demonstrate that these antibodies recognize centromeres of HeLa chromosomes in the expected pattern for CENP-C. Localization of CENP-C by immunoelectron microscopy reveals that this protein is a component of the inner kinetochore plate.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06032	University of Connecticut	SAITOH, H (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37986] Funding Source: Medline; NIGMS NIH HHS [GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; COMINGS DE, 1971, EXP CELL RES, V67, P97, DOI 10.1016/0014-4827(71)90625-2; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DARLINGTON CD, 1936, CYTOLOGIA, V7, P242; EARNSHAW W, 1986, J CLIN INVEST, V77, P426, DOI 10.1172/JCI112320; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7813, DOI 10.1093/nar/13.21.7813; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MITCHISON TJ, 1985, J CELL BIOL, V101, P776; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; RATTNER JB, 1987, CHROMOSOMA, V95, P175, DOI 10.1007/BF00330348; REIDER CL, 1982, INT REV CYTOL, V79, P1; REIDER CL, 1990, J CELL BIOL, V110, P81; RIJHSINGHANI AG, 1988, OBSTET GYNECOL, V71, P991; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; ROTHFIELD N, 1987, ARTHRITIS RHEUM, V30, P1416, DOI 10.1002/art.1780301214; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1168, DOI 10.1093/nar/19.5.1168-a; Sharp LW., 1934, INTRO CYTOLOGY; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN L, 1984, NUCLEIC ACIDS RES, V12, P2669, DOI 10.1093/nar/12.6.2669; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; WITT PL, 1980, CHROMOSOMA, V81, P483, DOI 10.1007/BF00368158; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285	50	312	322	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					115	125		10.1016/0092-8674(92)90538-N	http://dx.doi.org/10.1016/0092-8674(92)90538-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1339310				2022-12-24	WOS:A1992JC95700013
J	MISTRY, PK; SMITH, SJ; ALI, M; HATTON, CSR; MCINTYRE, N; COX, TM				MISTRY, PK; SMITH, SJ; ALI, M; HATTON, CSR; MCINTYRE, N; COX, TM			GENETIC DIAGNOSIS OF GAUCHERS-DISEASE	LANCET			English	Article							HUMAN GLUCOCEREBROSIDASE GENE; MUTATION; DNA; HETEROGENEITY; PSEUDOGENE; SEQUENCE; CLONING; TYPE-1; LEVEL	The inherited disorder Gaucher's disease can be caused by various mutations in the glucocerebrosidase gene. Some mutations may be associated with greater severity, and there is a need for methods of gene analysis that would facilitate screening and diagnosis. We have studied the molecular basis of Gaucher's disease in twelve unrelated patients of diverse ethnic origin by means of the amplification refractory mutation system (ARMS). Primers for the polymerase chain reaction were designed to discriminate between mutant and wild-type alleles of glucocerebrosidase and to allow separation from products of the related pseudogene. The nucleotide 1226 mutation (asparagine 370 --> serine) and 84GG (an insertional frameshift mutation) were found exclusively in five patients of Ashkenazi Jewish descent (7 and 2 of the 1 0 disease alleles, respectively). Two point mutations, at nucleotides 1448 (leucine 444 --> proline) and 1504 (arginine 463 --> cysteine), were found in 4 and 3 alleles, respectively; they were associated with rapidly progressive disease and neurological involvement in non-Jewish patients. The ARMS procedure for direct detection of common mutations in glucocerebrosidase will facilitate genetic counselling and screening programmes for individuals at risk of Gaucher's disease.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND; WEXHAM PK HOSP,DEPT HAEMATOL,SLOUGH,BERKS,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT MED,LONDON,ENGLAND	Addenbrooke's Hospital; University of Cambridge; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Smith, Stuart/0000-0001-7266-6790	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1991, NEW ENGL J MED, V325, P1354; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; BEUTLER E, 1991, NEW ENGL J MED, V325, P1809; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; DAHL N, 1990, AM J HUM GENET, V47, P275; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GRAVES PN, 1988, DNA-J MOLEC CELL BIO, V7, P521, DOI 10.1089/dna.1.1988.7.521; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; JOHN SWM, 1991, NUCLEIC ACIDS RES, V19, P408, DOI 10.1093/nar/19.2.408; KAWAME H, 1991, AM J HUM GENET, V49, P1378; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OHASHI T, 1991, J BIOL CHEM, V266, P3661; PERBAL B, 1988, PRACTICAL GUIDE MOL, P340; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; THEOPHILUS B, 1989, AM J HUM GENET, V45, P212; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; WIGDERSON M, 1989, AM J HUM GENET, V44, P365; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	25	45	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					889	892		10.1016/0140-6736(92)90928-V	http://dx.doi.org/10.1016/0140-6736(92)90928-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348297				2022-12-24	WOS:A1992HN48300003
J	HANN, BC; STIRLING, CJ; WALTER, P				HANN, BC; STIRLING, CJ; WALTER, P			SEC65 GENE-PRODUCT IS A SUBUNIT OF THE YEAST SIGNAL RECOGNITION PARTICLE REQUIRED FOR ITS INTEGRITY	NATURE			English	Article							PROTEIN	PROTEIN targeting to the endoplasmic reticulum (ER) in mammalian cells is catalysed by the signal recognition particle (SRP), which consists of six protein subunits and an RNA subunit 1,2. Saccharomyces cerevisiae SRP is a 16S particle, of which only two subunits have been identified: a protein subunit, SRP54p, which is homologous to the mammalian SRP54 subunit, and an RNA subunit, scR1 (ref. 3). The sec65-1 mutant yeast cells 4 are temperature-sensitive for growth and defective in the translocation of several secreted and membrane-bound proteins. The DNA sequence of the SEC65 gene suggests that its product is related to mammalian SRP19 subunit and may have a similar functions 5. Here we show that SEC65p is a subunit of the S. cervisiae SRP and that it is required for the stable association of another subunit, SRP54p, with SRP. Overexpression of SRP54p suppresses both growth and protein translocation defects in sec65-1 mutant cells.	UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester	HANN, BC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, IN PRESS MOL BIOL CE; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	9	56	59	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					532	533		10.1038/356532a0	http://dx.doi.org/10.1038/356532a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1313947				2022-12-24	WOS:A1992HN23100062
J	SIXBEY, JW; YAO, QY				SIXBEY, JW; YAO, QY			IMMUNOGLOBULIN-A-INDUCED SHIFT OF EPSTEIN-BARR-VIRUS TISSUE TROPISM	SCIENCE			English	Article							TRANS-EPITHELIAL TRANSPORT; INTESTINAL M-CELLS; NASOPHARYNGEAL CARCINOMA; SECRETORY COMPONENT; MEMBRANE ANTIGEN; NPC PATIENTS; B-CELLS; IGA; RECEPTOR; ANTIBODY	Increased immunoglobulin A (IgA) antibodies to the Epstein-Barr virus (EBV) appear months to years before the clinical onset of nasopharyngeal carcinoma and define populations at high risk for this EBV-associated epithelial cancer common in south China. In the human HT-29 epithelial cell line, polymeric IgA (pIgA) specific for EBV promoted infection of the otherwise refractory epithelial cells. When bound to pIgA, EBV entered epithelial cells through secretory component-mediated IgA transport but no longer infected B lymphocytes. Such an immune-induced shift in EBV tissue tropism provides a paradigm for endogenous spread of EBV in the immune host that predicts infectious sequelae of epithelium.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOLEC BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	SIXBEY, JW (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [R01CA038877, R23CA038877, P30CA021765, R01CA052258] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA52258, CA38877] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI MY, 1967, UICC UNION INT CONTR, V1, P138; BISWAS R, 1985, BIOCHEMISTRY-US, V24, P3795, DOI 10.1021/bi00335a056; BRANDTZAEG P, 1981, CLIN EXP IMMUNOL, V44, P221; BROWN WR, 1977, GASTROENTEROLOGY, V73, P1333; CHINTALACHARUVU KR, 1991, J CELL PHYSIOL, V148, P35, DOI 10.1002/jcp.1041480105; CRAGO SS, 1978, J EXP MED, V147, P1832, DOI 10.1084/jem.147.6.1832; DAVID EM, 1988, J IMMUNOL METHODS, V108, P231, DOI 10.1016/0022-1759(88)90424-3; DELACROIX DL, 1983, J CLIN INVEST, V71, P358, DOI 10.1172/JCI110777; DESGRANGES C, 1977, INT J CANCER, V19, P627, DOI 10.1002/ijc.2910190506; DESGRANGES C, 1977, INT J CANCER, V20, P881, DOI 10.1002/ijc.2910200610; EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HASHIDO M, 1989, J CLIN MICROBIOL, V27, P2609, DOI 10.1128/JCM.27.11.2609-2611.1989; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HEREMANS JF, 1974, ANTIGENS, V2, P365; HOFFMAN GJ, 1980, P NATL ACAD SCI-BIOL, V77, P2979, DOI 10.1073/pnas.77.5.2979; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; INOUYE S, 1978, J CLIN MICROBIOL, V8, P1; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; MARSH M, 1984, BIOCHEM J, V218, P1; MILLER G, 1990, VIROLOGY, P1921; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NOMORI H, 1985, JPN J CLIN ONCOL, V15, P95; PONZI AN, 1985, J CLIN MICROBIOL, V22, P505, DOI 10.1128/JCM.22.4.505-509.1985; RAO CK, 1987, RECENT ADV MUCOSAL B, P1071; RICKINSON AB, 1985, BRIT MED BULL, V41, P75, DOI 10.1093/oxfordjournals.bmb.a072030; ROQUEBARREIRA MC, 1985, J IMMUNOL, V134, P1740; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1991, J INFECT DIS, V163, P1008, DOI 10.1093/infdis/163.5.1008; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; THORLEYLAWSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P5307, DOI 10.1073/pnas.77.9.5307; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737; WRIGHT DH, 1985, BURKITTS LYMPHOMA HU, P37; YAO Q, UNPUB; YAO QY, 1991, INT J CANCER, V48, P45; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; ZENG Y, 1985, ADV CANCER RES, V44, P121, DOI 10.1016/S0065-230X(08)60027-5	45	179	192	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1578	1580		10.1126/science.1312750	http://dx.doi.org/10.1126/science.1312750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1312750				2022-12-24	WOS:A1992HJ80900043
J	FEDERMAN, AD; CONKLIN, BR; SCHRADER, KA; REED, RR; BOURNE, HR				FEDERMAN, AD; CONKLIN, BR; SCHRADER, KA; REED, RR; BOURNE, HR			HORMONAL-STIMULATION OF ADENYLYL CYCLASE THROUGH GI-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							MUSCARINIC K+-CHANNEL; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; RAT-BRAIN; RECEPTOR; PATHWAYS; PHOSPHOLIPASE-A2; TRANSDUCIN; ACTIVATE; CLONING	AGONIST-BOUND receptors activate heterotrimeric (alpha-beta-gamma) G proteins by catalysing replacement by GTP of GDP bound to the alpha-subunit, resulting in dissociation of alpha-GTP from the beta-gamma-subunits. In most cases, alpha-GTP carries the signal to effectors, as in hormonal stimulation 1-4 and inhibition 5,6 of adenylyl cyclase by alpha(s) and alpha(i) respectively. By contrast, genetic evidence in yeast 7 and studies in mammalian cells 8-10 suggest that beta-gamma-subunits of G proteins may also regulate effector pathways. Indeed, of the four recombinant mammalian adenylyl cyclases available for study 11-14, two, adenylyl cyclases II and IV, are stimulated by beta-gamma. This effect of beta-gamma requires costimulation by alpha(s)-GTP 14,15. This conditional pattern of effector responsiveness led to the prediction 15 that receptors coupled to many G proteins will mediate elevation of cellular cyclic AMP, provided that G(s) is also active. We now confirm this prediction. Coexpression of mutationally active alpha(s) with adenylyl cyclase II converted agonists that act through 'inhibitory' receptors (coupled to G(i)) into stimulators of cAMP synthesis. Experiments using pertussis toxin and a putative scavenger of beta-gamma, the alpha-subunit of transducin, suggest that beta-gamma-subunits of the G(i) proteins mediated this stimulation. These findings assign a new signalling function to beta-gamma-subunits of G(i) proteins, the conditional stimulation of cAMP synthesis by adenylyl cyclase II.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Johns Hopkins University			Reed, Russell/HGU-0528-2022; Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BIRNBAUMER LA, 1990, REV PHARM TOX, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRASER CM, 1989, J BIOL CHEM, V264, P11754; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUYER CA, 1990, J BIOL CHEM, V265; HILL DR, 1985, BRIT J PHARMACOL, V84, P249; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KARBON EW, 1985, MOL PHARMACOL, V27, P53; KAZIRO Y, 1991, REV BIOCH, V60, P349; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WHITEWAY M, 1988, COLD SPRING HARB SYM, V53, P585, DOI 10.1101/SQB.1988.053.01.067; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	28	567	571	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					159	161		10.1038/356159a0	http://dx.doi.org/10.1038/356159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1312225				2022-12-24	WOS:A1992HH73100062
J	FARNDON, PA; DELMASTRO, RG; EVANS, DGR; KILPATRICK, MW				FARNDON, PA; DELMASTRO, RG; EVANS, DGR; KILPATRICK, MW			LOCATION OF GENE FOR GORLIN SYNDROME	LANCET			English	Note							CELL CARCINOMA SYNDROME	The Gorlin (naevoid-basal-cell-carcinoma) syndrome is an autosomal dominant disorder characterised by multiple naevoid basal-cell carcinomas, recurrent odontogenic keratocysts, skeletal anomalies, intracranial calcification, and developmental malformations. Characterisation of the gene that causes the syndrome may improve our understanding of the pathogenesis of other basal-cell carcinomas. By linkage analysis, we have shown that the gene is located on chromosome 9q22.3-q31; the most likely position is between DNA markers D9S12 and D9S53. Location of the gene for Gorlin syndrome offers the possibility that DNA markers can be used in risk estimation and presymptomatic identification of patients for surveillance.	ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester	FARNDON, PA (corresponding author), UNIV BIRMINGHAM,BIRMINGHAM MATERN HOSP,DEPT CLIN GENET,BIRMINGHAM B15 2TG,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON P, 1988, J MED GENET, V25, P638; FARNDON PA, 1991, CYTOGENET CELL GENET, V58, P2112; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; OTT J, 1974, AM J HUM GENET, V26, P588; Ott J., 1991, ANAL HUMAN GENETIC L; SPRINGATE JE, 1986, J PEDIATR SURG, V21, P908, DOI 10.1016/S0022-3468(86)80023-9; WEBER JL, 1989, AM J HUM GENET, V44, P388	8	303	307	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					581	582		10.1016/0140-6736(92)90868-4	http://dx.doi.org/10.1016/0140-6736(92)90868-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347096				2022-12-24	WOS:A1992HH07500006
J	ELLERBY, LM; NISHIDA, CR; NISHIDA, F; YAMANAKA, SA; DUNN, B; VALENTINE, JS; ZINK, JI				ELLERBY, LM; NISHIDA, CR; NISHIDA, F; YAMANAKA, SA; DUNN, B; VALENTINE, JS; ZINK, JI			ENCAPSULATION OF PROTEINS IN TRANSPARENT POROUS SILICATE-GLASSES PREPARED BY THE SOL-GEL METHOD	SCIENCE			English	Article							SUPEROXIDE-DISMUTASE	Novel sol-gel synthetic techniques were used to immobilize copper-zinc superoxide dismutase (CuZnSOD), cytochrome c, and myoglobin (Mb) by encapsulation in stable, optically transparent, porous silica glass matrices under mild conditions such that the biomolecules retained their characteristic reactivities and spectroscopic properties. The resulting glasses allowed transport of small molecules into and out of the glasses at reasonable rates but nevertheless retained the protein molecules within their pores. Chemical reactions of the immobilized proteins could be monitored by means of changes in their visible absorption spectra. Silica glasses containing the immobilized proteins were observed to have similar reactivities and spectroscopic properties to those found for the proteins in solution. For example, encapsulated CuZnSOD was demetallated and remetallated, encapsulated ferricytochrome c was reduced and then reoxidized, and encapsulated met Mb was reduced to deoxy Mb and then reacted either with dioxygen to make oxy Mb or with carbon monoxide to make carbonyl Mb.	UNIV CALIF LOS ANGELES,DEPT MAT SCI & ENGN,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	ELLERBY, LM (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIGMS NIH HHS [GM28222, T32 GM08375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222, T32GM008375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN S, 1990, MATER LETT, V10, P1, DOI 10.1016/0167-577X(90)90002-4; BRINKER CJ, 1990, SOL GEL SCI PHYSICS; ELLERBY LM, UNPUB; ESQUIVIAS L, 1988, 3RD P INT C ULTR PRO, P255; FEE JA, 1972, J BIOL CHEM, V247, P60; HARRISON PM, 1985, METALLOPROTEINS 2; HARRISON PM, 1985, METALLOPROTEINS 1; HENCH LL, 1990, CHEM REV, V90, P33, DOI 10.1021/cr00099a003; KLEIN LC, 1985, ANNU REV MATER SCI, V15, P227; MCKIERNAN J, 1989, J PHYS CHEM-US, V93, P2129, DOI 10.1021/j100342a081; MCKIERNAN JM, 1990, J PHYS CHEM-US, V94, P5652, DOI 10.1021/j100378a007; MOSBACH K, 1987, IMMOBOLIZED ENZYMES, V1335; POUXVIEL JC, 1989, J PHYS CHEM-US, V93, P2134, DOI 10.1021/j100342a082; Valentine J.S., 1981, COPPER PROTEINS, P291; VALENTINE JS, 1985, J CHEM EDUC, V62, P990, DOI 10.1021/ed062p990; YAMANAKA SA, UNPUB	16	679	694	3	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1113	1115		10.1126/science.1312257	http://dx.doi.org/10.1126/science.1312257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1312257				2022-12-24	WOS:A1992HF63200036
J	FORTINI, ME; SIMON, MA; RUBIN, GM				FORTINI, ME; SIMON, MA; RUBIN, GM			SIGNALING BY THE SEVENLESS PROTEIN TYROSINE KINASE IS MIMICKED BY RAS1 ACTIVATION	NATURE			English	Article							DEVELOPING DROSOPHILA EYE; ELEGANS VULVAR INDUCTION; CELL FATE; GENE; MELANOGASTER; RECEPTOR; EXPRESSION; ENCODES; SEQUENCE; DOMAIN	CELL-FATE specification of R7 photoreceptors in the developing Drosophila eye depends on an inductive signal from neighbouring R8 cells. Mutations in three genes, sevenless (sev), bride-of-sevenless (boss) and seven-in-absentia (sina) cause the R7 precursor to become a non-neural cone cell 1-3. The sev gene encodes a receptor protein tyrosine kinase (Sev) localized on the R7 surface, activated by a boss-encoded ligand presented by R8 (refs 4-6). The sina gene encodes a nuclear factor required in R7 (ref. 3). Reduction in the dosage of the Ras1 gene impairs Sev-mediated signalling, suggesting that activation of Ras1 may be an important consequence of Sev activation 7. We report here that Ras1 activation may account for all of the signalling action of Sev; an activated Ras1Val12 protein rescues the normal R7 precursor from transformation into a cone cell in sev and boss null mutants and induces the formation of supernumerary R7 cells. Similar activation of the Drosophila Ras2 protein does not produce these effects, demonstrating Ras protein specificity.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1991, P NATL ACAD SCI USA, V88, P6853, DOI 10.1073/pnas.88.15.6853; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BROCK HW, 1987, GENE, V51, P129, DOI 10.1016/0378-1119(87)90301-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Maniatis T., 1982, MOL CLONING; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	284	285	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					559	561		10.1038/355559a0	http://dx.doi.org/10.1038/355559a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1311054				2022-12-24	WOS:A1992HC52600063
J	HEYMAN, RA; MANGELSDORF, DJ; DYCK, JA; STEIN, RB; EICHELE, G; EVANS, RM; THALLER, C				HEYMAN, RA; MANGELSDORF, DJ; DYCK, JA; STEIN, RB; EICHELE, G; EVANS, RM; THALLER, C			9-CIS RETINOIC ACID IS A HIGH-AFFINITY LIGAND FOR THE RETINOID-X RECEPTOR	CELL			English	Article							INTESTINAL RECEPTOR; VITAMIN-A; IDENTIFICATION; GENE; EXPRESSION; ELEMENT; GAMMA	All-trans retinoic acid (RA) has previously been shown to modulate the transcriptional properties of the retinoic acid receptor (RAR) and retinoid X receptor (RXR). The inability of all-trans RA to bind to RXR suggests that it may be metabolized to a more active high affinity ligand. We report here an experimental approach that has identified 9-cis RA as an RXR ligand. It is up to 40-fold more potent than all-trans RA in transfection assays and binds with high affinity. The production of 9-cis RA in cultured cells and the identification of this molecule in liver and kidney demonstrates the existence of this molecule in living organisms. The discovery of this novel hormone points to the key role retinoid metabolism may have in generating new signaling pathways.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOMED SCI,LA JOLLA,CA 92093; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Salk Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego; Baylor College of Medicine	HEYMAN, RA (corresponding author), LIGAN PHARMACEUT INC,SAN DIEGO,CA 92121, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796				Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALLEGRETTO EA, 1987, J BIOL CHEM, V262, P1312; BERGER TS, 1992, IN PRESS J STEROID B; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BROWN PS, 1959, NATURE, V184, P1377, DOI 10.1038/1841377a0; COREY EJ, 1968, J AM CHEM SOC, V90, P5616, DOI 10.1021/ja01022a059; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KLIEWER SA, 1992, IN PRESS P NATL ACAD; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1992, RETINOIDS NORMAL DEV; MATSUI M., 1958, JOUR VITAMINOL, V4, P178; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1979, P NATL ACAD SCI USA, V76, P5485, DOI 10.1073/pnas.76.11.5485; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; SUMMERS MD, 1987, TEXAS AGR EXP STAT B, V155; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WECKSLER WR, 1979, ANAL BIOCHEM, V92, P314, DOI 10.1016/0003-2697(79)90664-X; WEDDEN S, 1990, METHOD ENZYMOL, V190, P201; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	30	1698	1796	7	81	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					397	406		10.1016/0092-8674(92)90479-V	http://dx.doi.org/10.1016/0092-8674(92)90479-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310260				2022-12-24	WOS:A1992HB35300017
J	GOODWIN, FK				GOODWIN, FK			ALCOHOLICS KIN DONT LIKE DIAZEPAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					480	480		10.1001/jama.267.4.480	http://dx.doi.org/10.1001/jama.267.4.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309583				2022-12-24	WOS:A1992GZ43900006
J	RINTALA, M; MUSTAJOKI, P				RINTALA, M; MUSTAJOKI, P			COULD MANNEQUINS MENSTRUATE	BRITISH MEDICAL JOURNAL			English	Article							MENARCHE		UNIV HELSINKI,CENT HOSP,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; Helsinki University Central Hospital	MUSTAJOKI, P (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND.							FRISCH RE, 1985, PERSPECT BIOL MED, V28, P611; PATTON GC, 1990, PSYCHOL MED, V20, P383, DOI 10.1017/S0033291700017700; SCOTT EC, 1982, J ADOLESCENT HEALTH, V2, P249, DOI 10.1016/S0197-0070(82)80059-4; SMITH DP, 1977, AM J CLIN NUTR, V30, P560, DOI 10.1093/ajcn/30.4.560; STEINKAMP RC, 1965, J CHRON DIS, V18, P1291, DOI 10.1016/0021-9681(65)90162-1	5	14	14	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1575	1576		10.1136/bmj.305.6868.1575	http://dx.doi.org/10.1136/bmj.305.6868.1575			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286395	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992KD77100032
J	MEYERS, C; FRATTINI, MG; HUDSON, JB; LAIMINS, LA				MEYERS, C; FRATTINI, MG; HUDSON, JB; LAIMINS, LA			BIOSYNTHESIS OF HUMAN PAPILLOMAVIRUS FROM A CONTINUOUS CELL-LINE UPON EPITHELIAL DIFFERENTIATION	SCIENCE			English	Article							VIRUS-INFECTION; TERMINAL DIFFERENTIATION; MOLECULAR MARKERS; UTERINE CERVIX; EXPRESSION; PROTEINS; INVITRO; KERATINOCYTE; REPLICATION; FILAGGRIN	The study of the human pathogen papillomaviruses (HPVs) has been hampered by the inability to propagate the virus in tissue culture. The addition of 12-O-tetradecanoyl phorbol-13-acetate to the media of organotypic (raft) cultures increased expression of physiological markers of keratinocyte differentiation and concomitantly induced production of virions. Capsid production was detected in differentiated suprabasal cells. Virions approximately 54 nanometers in size were observed by electron microscopy in raft tissue cross sections in the suprabasal layers. Virions purified through isopycnic gradients were found to contain type 31b DNA and exhibited an icosahedral shape similar to that of papillomaviruses found in clinical samples.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago								ASSELINEAU D, 1986, J INVEST DERMATOL, V86, P181, DOI 10.1111/1523-1747.ep12284237; BALL RD, 1978, J BIOL CHEM, V253, P5861; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; CRAWFORD DH, 1986, IMMUNOLOGY, V59, P405; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; DAVIES AH, 1991, J VIROL, V65, P6838, DOI 10.1128/JVI.65.12.6838-6844.1991; DUNN AEG, 1968, J ULTRA MOL STRUCT R, V22, P282, DOI 10.1016/S0022-5320(68)90021-X; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KREIDER JW, 1990, VIROLOGY, V177, P415, DOI 10.1016/0042-6822(90)90503-J; KREIDER JW, 1987, J VIROL, V61, P590, DOI 10.1128/JVI.61.2.590-593.1987; LAURENCE J, 1990, BLOOD, V75, P696; LAVERTY CR, 1978, ACTA CYTOL, V22, P195; LEWIS RM, 1989, REV INFECT DIS, V11, P736; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEYERS C, 1992, PAPILLOMAVIRUS RES, V3, P1; MEYERS CLF, UNPUB; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORIN C, 1980, ACTA CYTOL, V24, P82; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PFISTER H, 1987, PAPILLOMAVIRUSES HUM, P1; PILOTTI S, 1981, J CLIN PATHOL, V34, P532, DOI 10.1136/jcp.34.5.532; POLYAK SJ, 1991, J VIROL, V65, P3575, DOI 10.1128/JVI.65.7.3575-3582.1991; RADER JS, 1990, ONCOGENE, V5, P571; SALZMAN NP, 1987, PAPOVAVIRIDAE, V2; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; SYRJANEN K, 1987, PAPILLOMAVIRUSES HUM; Taichman L.B., 1987, PAPOVAVIRIDEA, P109; VIAC J, 1978, J INVEST DERMATOL, V70, P263, DOI 10.1111/1523-1747.ep12541415; WEINSHENKER BG, 1988, J IMMUNOL, V140, P1626; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5	35	375	390	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					971	973		10.1126/science.1323879	http://dx.doi.org/10.1126/science.1323879			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323879				2022-12-24	WOS:A1992JH82700037
J	KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B				KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B			DIFFERENT BETA-SUBUNITS DETERMINE G-PROTEIN INTERACTION WITH TRANSMEMBRANE RECEPTORS	NATURE			English	Article							GTP-BINDING PROTEINS; MUSCARINIC K+-CHANNEL; GAMMA-SUBUNITS; ADENYLATE-CYCLASE; INHIBITION; TRANSDUCIN; PHOSPHOLIPASE-A2; DIVERSITY; RHODOPSIN; ACTIVATE	REGULATORY GTP-binding proteins (G proteins) are membrane-attached heterotrimers (alpha, beta, gamma) that mediate cellular responses to a wide variety of extracellular stimuli1,2. They undergo a cycle of guanine-nucleotide exchange and GTP hydrolysis, during which they dissociate into alpha-subunit and beta-gamma-complex1. The roles of G-protein alpha-subunits in these processes and for the specificity of signal transduction are largely established; the beta- and gamma-subunits are essential for receptor-induced G-protein activation and seem to be less diverse and less specific. Although the complementary DNAs for several beta-subunits have been cloned2,5-8, isolated subunits have only been studied as beta-gamma-complexes3,9-12. Functional differences have been ascribed to the gamma-subunit on the basis of extensive sequence similarity among beta-subunits and apparent heterogeneity in gamma-subunit sequences13,14. Beta-gamma-complexes can inter act directly or indirectly with different effectors10,11,15-20. They seem to be interchangeable in their interaction with pertussis toxin-sensitive alpha-subunits3, so we tested this by microinjecting antisense oligonucleotides into nuclei of a rat pituitary cell line to suppress the synthesis of individual beta-subunits selectively. Here we show that two out of four subtypes of beta-subunits tested (beta-1 and beta-3) are selectively involved in the signal transduction cascades from muscarinic M4 (ref. 4) and somatostatin receptors, respectively, to voltage-dependent Ca2+ channels.	FREE UNIV BERLIN,INST PHARMAKOL,W-1000 BERLIN 33,GERMANY	Free University of Berlin	KLEUSS, C (corresponding author), FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY.							BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1987, J BIOL CHEM, V262, P11897; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; OKABE K, 1990, J BIOL CHEM, V265, P12854; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F	23	373	376	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					424	426		10.1038/358424a0	http://dx.doi.org/10.1038/358424a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322501				2022-12-24	WOS:A1992JF85300059
J	JOCE, R; WOOD, D; BROWN, D; BEGG, N				JOCE, R; WOOD, D; BROWN, D; BEGG, N			PARALYTIC POLIOMYELITIS IN ENGLAND AND WALES, 1985-91	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain all cases of paralytic poliomyelitis in England and Wales during 1985-91 and to determine the source of infection in each case. Design-Descriptive study of cases reported between 1985 and 1991. Setting-All health districts in England and Wales. Subjects-Patients normally resident in England and Wales whose clinical features were consistent with paralytic poliomyelitis or with laboratory evidence of recent poliovirus infection and compatible symptoms. Main outcome measures-Clinical, epidemiological, and laboratory features in identified cases. Results-Of 54 suspected cases of poliomyelitis, 33 were excluded, leaving 21 cases, of which 13 were vaccine associated (nine recipient and four contact) cases, five were imported cases, and three were cases whose source of infection was unknown. No cases due to indigenous wild polioviruses were identified; two were imported cases due to wild viruses. One patient died during the acute phase of the illness, and two children with previously unrecognised severe congenital immune deficiency died between one and two months after the onset of paralysis after the first or second dose of oral polio vaccine. The estimated risk of vaccine associated paralysis is 1.46 per million for the first dose, 0.49 for the second, zero for the third and fourth doses, and 0.33 for the fifth. Conclusions-Indigenous wild poliovirus seems to have been eradicated, although wild virus may be imported; improved surveillance of suspected cases including immediate notification and characterisation of the virus to ensure that eradication is maintained is essential.	PUBL HLTH LAB SERV,COMMUNICABLE SURVEILLANCE CTR,LONDON NW9 5EQ,ENGLAND; E & N HERTFORDSHIRE HLTH AUTHOR,WELWYN GARDEN CIT AL8 6RD,HERTS,ENGLAND; NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,HERTS,ENGLAND; PUBL HLTH LAB SERV,VIRUS REFERENCE LAB,LONDON NW9 5EQ,ENGLAND	Public Health England; National Institute for Biological Standards & Control; Public Health England								BEGG NT, 1987, EPIDEMIOL INFECT, V99, P97, DOI 10.1017/S0950268800066905; COLLINGHAM KE, 1978, LANCET, V1, P976; EVANS DMA, 1985, NATURE, V314, P548, DOI 10.1038/314548a0; Hall S M, 1988, Arch Dis Child, V63, P344; HOVI T, 1986, J INFECT DIS, V153, P998, DOI 10.1093/infdis/153.5.998; KUBLI D, 1987, BRIT MED J, V295, P169, DOI 10.1136/bmj.295.6591.169; VANWEZEL AL, 1978, INTERVIROLOGY, V11, P2; WHITE PMB, 1986, BRIT MED J, V293, P1153, DOI 10.1136/bmj.293.6555.1153; 1988, EVALUATION POLIOMYEL; 1982, B WORLD HEALTH ORGAN, V69, P231; 1988, WHO WEEKLY EPIDEMIOL, V63, P161; 1990, MANUAL VIROLOGICAL I; 1990, IMMUNISATION INFECTI; 1989, WHO WEEKLY EPIDEMIOL, V64, P273	14	61	63	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					79	82		10.1136/bmj.305.6845.79	http://dx.doi.org/10.1136/bmj.305.6845.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1322218	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1992JD85000019
J	MOSS, WT				MOSS, WT			CONSERVATIVE SURGERY AND RADIATION FOR INTRADUCTAL BREAST-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MOSS, WT (corresponding author), OREGON HLTH SCI UNIV,PORTLAND,OR 97201, USA.							SILVERSTEIN MJ, 1990, CANCER, V66, P102, DOI 10.1002/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					266	266						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1318979				2022-12-24	WOS:A1992JB27900036
J	HUNT, DF; MICHEL, H; DICKINSON, TA; SHABANOWITZ, J; COX, AL; SAKAGUCHI, K; APPELLA, E; GREY, HM; SETTE, A				HUNT, DF; MICHEL, H; DICKINSON, TA; SHABANOWITZ, J; COX, AL; SAKAGUCHI, K; APPELLA, E; GREY, HM; SETTE, A			PEPTIDES PRESENTED TO THE IMMUNE-SYSTEM BY THE MURINE CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE-I-A(D)	SCIENCE			English	Article							MHC CLASS; PROTEIN ANTIGENS; BINDING PEPTIDES; SEQUENCE	Between 650 and 2000 different peptides are associated with the major histocompatibility complex class II molecule I-A(d). Sequences for nine of these were obtained by a combination of automated Edman degradation and tandem mass spectrometry. All of the peptides are derived from secretory or integral membrane proteins that are synthesized by the antigen-presenting cell itself. Peptides were 16 to 18 residues long, had ragged NH2- and COOH-termini, and contained a six-residue binding motif that was variably placed within the peptide chain. Binding data on truncated peptides suggest that the peptide binding groove on class II molecules can be open at both ends.	NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; CYTEL CORP, SAN DIEGO, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUNT, DF (corresponding author), UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA.		Hunt, Donald F/I-6936-2012; Sette, Alessandro/AFO-8916-2022	Hunt, Donald F/0000-0003-2815-6368; Cox, Andrea/0000-0002-9331-2462; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018634] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18634] Funding Source: Medline; NIGMS NIH HHS [GM37357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; ESNARD F, 1990, BIOL CHEM H-S, V371, P161; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; HYLDIGNIELSEN JJ, 1983, NUCLEIC ACIDS RES, V11, P5055, DOI 10.1093/nar/11.15.5055; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LI Z, 1989, NUCLEIC ACIDS RES, V17, P447, DOI 10.1093/nar/17.1.447; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; RAJAVASHISTH TB, 1985, P NATL ACAD SCI USA, V82, P8085, DOI 10.1073/pnas.82.23.8085; ROBERTS KP, 1990, MOL ENDOCRINOL, V4, P531, DOI 10.1210/mend-4-4-531; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SETTE A, 1988, J IMMUNOL, V141, P45; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1992, J IMMUNOL, V148, P844; SETTE A, 1990, J IMMUNOL, V145, P1809; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1990, NATURE, V348, P213	28	664	691	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1992	256	5065					1817	1820		10.1126/science.1319610	http://dx.doi.org/10.1126/science.1319610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1319610				2022-12-24	WOS:A1992JA43400036
J	FARLEY, MM; STEPHENS, DS; BRACHMAN, PS; HARVEY, RC; SMITH, JD; WENGER, JD				FARLEY, MM; STEPHENS, DS; BRACHMAN, PS; HARVEY, RC; SMITH, JD; WENGER, JD			INVASIVE HAEMOPHILUS-INFLUENZAE DISEASE IN ADULTS - A PROSPECTIVE, POPULATION-BASED SURVEILLANCE	ANNALS OF INTERNAL MEDICINE			English	Article						HAEMOPHILUS-INFLUENZAE; PNEUMONIA; LUNG DISEASES; PREGNANCY; DRUG RESISTANCE, MICROBIAL; AMPICILLIN	NONTYPABLE HEMOPHILUS-INFLUENZAE; GENITOURINARY TRACT INFECTIONS; ANTIMICROBIAL RESISTANCE; OLIGOSACCHARIDE PORTION; PNEUMONIA; AMPICILLIN; SPECTRUM; LIPOOLIGOSACCHARIDE; EPIGLOTTITIS; MENINGITIS	Objective: To define the incidence of and possible risk factors for invasive Haemophilus influenzae disease in adults. Design: Prospective, population-based surveillance of hospital and referral bacteriology laboratories. Setting: Metropolitan Atlanta, Georgia community. Patients: All patients with H. influenzae isolated from normally sterile sites (blood, cerebrospinal fluid, joint, pleura) from 1 December 1988 through 31 May 1990. Measurements: Isolates of H. influenzae were analyzed for serotype and biotype status, outer membrane proteins, lipooligosaccharide phenotypes, ribotyping patterns and 13-lactamase production. Results: A total of 194 cases of invasive H. influenzae occurred (annual incidence of 5.6 cases/100 000 population), of which 47 (24%) were in adults 18 years old or older (annual incidence 1.7 cases/100 000 adults). Adults with invasive H. influenzae ranged from 18 to 96 years; 79% were women. Bacteremic pneumonia accounted for 70% of the adult cases. Other sources for invasive H. influenzae in adults were obstetric infections, epiglottitis, and tracheobronchitis; one patient had meningitis. Underlying conditions were noted in 92% of the patients. Chronic lung disease was the most common risk factor, but pregnancy (annual incidence, 4.9/100 000 pregnant women), HIV infection (annual incidence, 41/100 000 known HIV-infected adults), and malignancy were also important. Overall mortality was 28% in adults, and over half of pregnancy-related infections resulted in fetal death. Fifty percent of the 40 isolates available for testing were serotype b; 47.5%, nontypable; and 2.5%, serotype f. Sixteen of the 45 isolates (36%) were ampicillin-resistant. Based on biotypes, outer membrane protein profiles, lipooligosaccharide phenotypes, and ribotyping patterns, the type b isolates showed less heterogeneity than the nontypable isolates but were distinguishable from one another. Conclusions: Adult cases currently represent one quarter of all cases of invasive H. influenzae disease. Half of the reported adult cases were caused by type b H. influenzae, and the rate of ampicillin resistance in H. influenzae isolates from adults was higher than previously reported. Haemophilus influenzae is an important cause of bacteremia in compromised adults.	OFF EPIDEMIOL, DEPT HUMAN RESOURCES, ATLANTA, GA 30309 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, MENINGITIS & SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	FARLEY, MM (corresponding author), ATLANTA DEPT VET AFFAIRS MED CTR, RES SERV 151, 1670 CLAIRMONT RD, DECATUR, GA 30033 USA.		Stephens, David S/A-8788-2012					ALBRITTON WL, 1978, ARCH INTERN MED, V138, P1819, DOI 10.1001/archinte.138.12.1819; BARENKAMP SJ, 1981, J INFECT DIS, V143, P668, DOI 10.1093/infdis/143.5.668; BERCZY J, 1973, LANCET, V1, P1197; BERK SL, 1982, ARCH INTERN MED, V142, P537, DOI 10.1001/archinte.142.3.537; BRUNHAM RC, 1988, J INFECT DIS, V158, P510, DOI 10.1093/infdis/158.3.510; CROWE HM, 1987, ARCH INTERN MED, V147, P241, DOI 10.1001/archinte.147.2.241; DOERN GV, 1986, DIAGN MICR INFEC DIS, V4, P95, DOI 10.1016/0732-8893(86)90143-4; DOERN GV, 1988, ANTIMICROB AGENTS CH, V32, P180, DOI 10.1128/AAC.32.2.180; GLODE MP, 1984, PEDIATR INFECT DIS J, V3, P548, DOI 10.1097/00006454-198411000-00013; GULIG PA, 1987, INFECT IMMUN, V55, P513, DOI 10.1128/IAI.55.3.513-520.1987; HALL GD, 1983, DIAGN MICR INFEC DIS, V1, P65, DOI 10.1016/0732-8893(83)90034-2; HIRSCHMANN JV, 1979, MEDICINE, V58, P80, DOI 10.1097/00005792-197901000-00005; JAKACKI R, 1990, ANN INTERN MED, V112, P143, DOI 10.7326/0003-4819-112-2-143; JANOFF EN, 1990, 30TH INT C ANT AG CH; KHAN W, 1974, JAMA-J AM MED ASSOC, V229, P298, DOI 10.1001/jama.229.3.298; KILIAN M, 1976, J GEN MICROBIOL, V93, P9, DOI 10.1099/00221287-93-1-9; KRISTENSEN K, 1989, SCAND J INFECT DIS, V21, P651, DOI 10.3109/00365548909021693; LEVIN DC, 1977, AM J MED, V62, P219, DOI 10.1016/0002-9343(77)90317-5; MAYOSMITH MF, 1986, NEW ENGL J MED, V314, P1133, DOI 10.1056/NEJM198605013141801; MENDELMAN PM, 1984, ANTIMICROB AGENTS CH, V26, P235, DOI 10.1128/AAC.26.2.235; MOXON ER, 1990, PRINCIPLES PRACTICE, P1722; MURPHY TF, 1983, J INFECT DIS, V147, P838, DOI 10.1093/infdis/147.5.838; MUSHER DM, 1983, ANN INTERN MED, V99, P444, DOI 10.7326/0003-4819-99-4-444; NORDEN CW, 1978, MED CLIN N AM, V62, P1037, DOI 10.1016/S0025-7125(16)31753-9; PATRICK CC, 1987, INFECT IMMUN, V55, P2902, DOI 10.1128/IAI.55.12.2902-2911.1987; QUENTIN R, 1989, J CLIN MICROBIOL, V27, P2286, DOI 10.1128/JCM.27.10.2286-2294.1989; Quinones C A, 1989, Semin Respir Infect, V4, P12; QUINTILIANI R, 1971, AM J MED, V50, P781, DOI 10.1016/0002-9343(71)90186-0; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SIMON HB, 1980, AM J MED, V69, P219, DOI 10.1016/0002-9343(80)90381-2; SPAGNUOLO PJ, 1982, MEDICINE, V61, P74, DOI 10.1097/00005792-198203000-00002; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STULL TL, 1988, J INFECT DIS, V157, P280, DOI 10.1093/infdis/157.2.280; TAKALA AK, 1990, ARCH INTERN MED, V150, P2573, DOI 10.1001/archinte.150.12.2573; TOMEH MO, 1974, JAMA-J AM MED ASSOC, V229, P295; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WALLACE RJ, 1983, REV INFECT DIS, V5, P123; WALLACE RJ, 1981, J INFECT DIS, V144, P101, DOI 10.1093/infdis/144.2.101; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS JD, 1986, REV INFECT DIS, V8, pS555; 1988, NCCLS M7T2 NAT COMM	42	125	127	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					806	812		10.7326/0003-4819-116-10-806	http://dx.doi.org/10.7326/0003-4819-116-10-806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1314530				2022-12-24	WOS:A1992HT80200004
J	GOLOVKINA, TV; CHERVONSKY, A; DUDLEY, JP; ROSS, SR				GOLOVKINA, TV; CHERVONSKY, A; DUDLEY, JP; ROSS, SR			TRANSGENIC MOUSE MAMMARY-TUMOR VIRUS SUPERANTIGEN EXPRESSION PREVENTS VIRAL-INFECTION	CELL			English	Article							T-CELLS; DNA; TOLERANCE; TRANSMISSION; SEQUENCES; RECEPTOR; GLAND; GENES; MICE; RNA	Endogenous mouse mammary tumor virus (MMTV) proviruses have recently been shown to cosegregate genetically with the minor lymphocyte-stimulating loci, also termed self-superantigens. The antigenic activity has been localized to the open reading frame (ORF) protein encoded in the long terminal repeat of MMTV. We show here that unlike their nontransgenic littermates, transgenic mice expressing high levels of an ORF protein derived from the C3H exogenous MMTV specifically delete their V-beta-14+ T cells and do not become infected with this virus when it is present in their mother's milk. Thus, it appears that MMTV utilizes cells of the immune system in its infection pathway, and mice that retain endogenous MMTVs should be immune to infection by exogenous virus. These results offer possible new approaches to anti-viral therapy or immunization.	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Chicago; University of Texas System; University of Texas Austin	GOLOVKINA, TV (corresponding author), UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612, USA.			Chervonsky, Alexander/0000-0001-7547-871X; Ross, Susan R/0000-0002-3094-3769	NCI NIH HHS [R01 CA45954, R01 CA34780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034780, R01CA045954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRITSCH EF, 1977, J VIROL, V24, P461, DOI 10.1128/JVI.24.2.461-469.1977; GUDKOV AV, 1989, INT J CANCER, V44, P1052, DOI 10.1002/ijc.2910440619; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HESTON WE, 1945, J NATL CANCER I, V5, P289; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169; ICHIMARU M, 1991, CANCER DETECT PREV, V15, P177; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; NANDI S, 1973, ADV CANCER RES, V17, P353; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SAJI F, 1990, CANCER, V66, P1933, DOI 10.1002/1097-0142(19901101)66:9<1933::AID-CNCR2820660914>3.0.CO;2-5; SALMONS B, 1987, VIRUS RES, V8, P81, DOI 10.1016/0168-1702(87)90022-0; SELTZER V, 1990, OBSTET GYNECOL, V75, P713; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; SQUARTINI F, 1970, CANCER RES, V30, P2069; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TSUBURA A, 1988, CANCER RES, V48, P6555; VARMUS HE, 1973, J MOL BIOL, V79, P663, DOI 10.1016/0022-2836(73)90070-3; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1992, IN PRESS J EXP MED; ZIEGLER JB, 1985, LANCET, V1, P896	43	226	229	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					637	645		10.1016/0092-8674(92)90227-4	http://dx.doi.org/10.1016/0092-8674(92)90227-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1316806				2022-12-24	WOS:A1992HV08900008
J	SUPHIOGLU, C; SINGH, MB; TAYLOR, P; BELLOMO, R; HOLMES, P; PUY, R; KNOX, RB				SUPHIOGLU, C; SINGH, MB; TAYLOR, P; BELLOMO, R; HOLMES, P; PUY, R; KNOX, RB			MECHANISM OF GRASS-POLLEN-INDUCED ASTHMA	LANCET			English	Article							EXTRACT	Many asthmatics are sensitive to rye-grass pollen, but pollen grains are too large to penetrate the lower airways. Our aim was to investigate the mechanism by which rye-grass pollen causes asthma. A major allergen of rye-grass pollen, Lol pIX, is located in intracellular starch granules within pollen grains. In-vitro tests showed that pollen grains are ruptured in rainwater by osmotic shock, each grain releasing about 700 starch granules into the environment. These granules are small enough to enter the airways (< 3-mu-m in diameter). The starch granules were present in atmospheric samples taken during the pollen season, and showed a 50-fold increase in atmospheric concentration on days following rainfall. Isolated granules elicited IgE-mediated responses in asthmatic patients, and 4 patients with rainfall-associated asthma who underwent an inhalation challenge test had striking bronchial constriction after exposure to starch granules. Starch granules released from rye-grass pollen seem to be capable of causing asthma.	UNIV MELBOURNE,SCH BOT,PARKVILLE,VIC 3052,AUSTRALIA; MONASH MED CTR,DEPT RESP MED,CLAYTON,VIC,AUSTRALIA; ALFRED HOSP,ALLERGY & RESP IMMUNOL UNIT,PRAHRAN,VIC 3181,AUSTRALIA	University of Melbourne; Monash University; Florey Institute of Neuroscience & Mental Health			Puy, Robert/AAU-6374-2020	Puy, Robert/0000-0001-7001-6313; Singh, Mohan/0000-0001-9427-8975				BELLOMO R, IN PRESS MED J AUST; HILL DJ, 1979, MED J AUSTRALIA, V1, P426, DOI 10.5694/j.1326-5377.1979.tb127014.x; ONG EK, 1990, INT ARCH ALLER A IMM, V93, P338, DOI 10.1159/000235263; PACKE GE, 1985, LANCET, V2, P199; PAGGIARO PL, 1990, RESPIRATION, V57, P51; SALVAGGIO JE, 1967, J ALLERGY, V30, P227; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STEWART GA, 1985, MED J AUSTRALIA, V143, P426, DOI 10.5694/j.1326-5377.1985.tb123117.x; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	10	295	301	0	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					569	572		10.1016/0140-6736(92)90864-Y	http://dx.doi.org/10.1016/0140-6736(92)90864-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347092				2022-12-24	WOS:A1992HH07500002
J	CLEARY, PP; KAPLAN, EL; HANDLEY, JP; WLAZLO, A; KIM, MH; HAUSER, AR; SCHLIEVERT, PM				CLEARY, PP; KAPLAN, EL; HANDLEY, JP; WLAZLO, A; KIM, MH; HAUSER, AR; SCHLIEVERT, PM			CLONAL BASIS FOR RESURGENCE OF SERIOUS STREPTOCOCCUS-PYOGENES DISEASE IN THE 1980S	LANCET			English	Article							SHOCK-LIKE SYNDROME; GROUP-A; INFECTION; EPIDEMIC; EXOTOXIN; STRAINS	During the 1980s there was a resurgence of serious Streptococcus pyogenes infections with complications, including rheumatic fever, sepsis, severe soft-tissue invasion, and toxic-shock-like syndrome (TSLS). We have investigated the suggested association between expression of a scarlet fever toxin, SPE A, and systemic toxicity, and the possibility that a new highly virulent clone of S pyogenes has emerged and spread world wide. We studied serotype M1 strains, the serotype most commonly associated with serious complications. 19 isolates from patients with sepsis, with or without TSLS, and 48 from patients with uncomplicated pharyngitis or superficial skin infection were subjected to restriction-enzyme digestion and electrophoresis, 56 isolates (19 serious, 37 uncomplicated disease) were then examined by hybridisation to an speA gene probe. 17 (90%) of the 19 serious-disease isolates had a characteristic ("invasive", I) restriction-fragment profile and were positive for the speA gene. Significantly lower proportions of the isolates from patients with uncomplicated disease had the I profile-(21/48 [44%]; p = 0.0035) and speA (20/37 [54%]; p < 0.001). These findings suggest that the strains from patients with serious disease are a unique clone, which became the predominant cause of severe streptococcal infections in the United States and elsewhere in the late 1980s.	UNIV MINNESOTA,WHO,COLLABORATING CTR REFERENCE & RES STREPTOCOCCI,DEPT PEDIAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; World Health Organization	CLEARY, PP (corresponding author), UNIV MINNESOTA,DEPT MICROBIOL,BOX 196,UMHC,MINNEAPOLIS,MN 55455, USA.			Schlievert, Patrick/0000-0001-8314-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036611, R55HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016722] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36611] Funding Source: Medline; NIAID NIH HHS [AI16722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atwater RM, 1927, AM J HYG, V7, P343, DOI 10.1093/oxfordjournals.aje.a120418; BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BEGOVAC J, 1990, PEDIATR INFECT DIS J, V9, P369, DOI 10.1097/00006454-199005000-00013; BELANI K, 1991, PEDIATR INFECT DIS J, V10, P351, DOI 10.1097/00006454-199105000-00001; CLEARY PP, 1988, J INFECT DIS, V158, P1317, DOI 10.1093/infdis/158.6.1317; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; GAWORZEWSKA ET, 1988, EPIDEMIOL INFECT, V3100, P257; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HRIBALOVA V, 1988, ANN INTERN MED, V108, P772, DOI 10.7326/0003-4819-108-5-772_2; JOHNSON DR, 1990, IN PRESS 11TH P LANC; JOHNSON LP, 1986, J BACTERIOL, V166, P623, DOI 10.1128/jb.166.2.623-627.1986; LEE PK, 1989, J CLIN MICROBIOL, V27, P1890, DOI 10.1128/JCM.27.8.1890-1892.1989; MARSHALL GS, 1991, PEDIATR INFECT DIS J, V10, P339, DOI 10.1097/00006454-199104000-00018; MARTIN NJ, 1990, J CLIN MICROBIOL, V28, P1881, DOI 10.1128/JCM.28.9.1881-1886.1990; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; SCHLIEVERT PM, 1979, J INFECT DIS, V140, P676, DOI 10.1093/infdis/140.5.676; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STOLLERMAN GH, 1975, MOD CONC CARDIOV DIS, V44, P35; YU CE, 1989, INFECT IMMUN, V57, P3715, DOI 10.1128/IAI.57.12.3715-3719.1989	21	270	275	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					518	521		10.1016/0140-6736(92)90339-5	http://dx.doi.org/10.1016/0140-6736(92)90339-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346879				2022-12-24	WOS:A1992HF63100004
J	FRIEDLAND, IR; KLUGMAN, KP				FRIEDLAND, IR; KLUGMAN, KP			FAILURE OF CHLORAMPHENICOL THERAPY IN PENICILLIN-RESISTANT PNEUMOCOCCAL MENINGITIS	LANCET			English	Article							ANTIBIOTICS; ORGANISM	First-line therapy for meningitis is often penicillin plus chloramphenicol. Penicillin-resistant Streptococcus pneumoniae (PRSP) infections are increasing world wide, but the efficacy of chloramphenicol for PRSP meningitis is unknown. We therefore prospectively assessed children with pneumococcal meningitis treated with penicillin plus chloramphenicol over 27 months to compare outcome of penicillin-susceptible S pneumoniae (PSSP) meningitis with that of PRSP meningitis. 68 children with pneumococcal meningitis who survived 24 hours were evaluated, of whom 25 had chloramphenicol-susceptible PRSP meningitis that was treated initially with chloramphenicol. 20 (80%) of these 25 children had an unsatisfactory outcome (death, serious neurological deficit, or poor clinical response). By contrast, 14 (33%) of 43 children with PSSP meningitis (treated with benzylpenicillin) had an adverse outcome (p < 0.001). Despite similar zone sizes on antibiotic disc testing (indicating chloramphenicol susceptibility) the chloramphenicol minimum bactericidal concentrations (MBCs) of PRSP isolates were significantly higher than those of PSSP isolates. The higher chloramphenicol MBCs resulted in borderline cerebrospinal-fluid bactericidal activity in many cases of PRSP meningitis and frequent treatment failure. Current definitions of chloramphenicol susceptibility of S pneumoniae may be inappropriate for management of pneumococcal meningitis. We suggest that chloramphenicol should not be used for the management of PRSP meningitis, alternative agents, such as third-generation cephalosporins, are more appropriate.	S AFRICAN INST MED RES,MRC,EMERGENT PATHOGEN RES UNIT,JOHANNESBURG 2000,SOUTH AFRICA; BARAGWANATH HOSP,DEPT PAEDIAT,JOHANNESBURG 2013,SOUTH AFRICA; BARAGWANATH HOSP,DEPT CLIN MICROBIOL,JOHANNESBURG 2013,SOUTH AFRICA; UNIV WITWATERSRAND,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand								CAPUTO GM, 1983, ANN INTERN MED, V98, P416, DOI 10.7326/0003-4819-98-3-416_2; Facklam RR, 1985, MANUAL CLIN MICROBIO, V4th, P154; FRIEDLAND IR, 1991, PEDIATR INFECT DIS J, V10, P705, DOI 10.1097/00006454-199109000-00018; IZER PV, 1978, PEDIATRICS, V61, P157; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; MCCRACKEN GH, 1985, ANTIMICROB AGENTS CH, V27, P141, DOI 10.1128/AAC.27.2.141; MOELLERING RC, 1989, J ANTIMICROB CHEMOTH, V24, P1; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PAREDES A, 1976, PEDIATRICS, V58, P378; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WONG UK, 1991, PEDIATR INFECT DIS J, V10, P122; 1990, NCCLS M7A2 NAT COMM	13	150	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					405	408		10.1016/0140-6736(92)90087-J	http://dx.doi.org/10.1016/0140-6736(92)90087-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346668				2022-12-24	WOS:A1992HD65900012
J	TASSABEHJI, M; READ, AP; NEWTON, VE; HARRIS, R; BALLING, R; GRUSS, P; STRACHAN, T				TASSABEHJI, M; READ, AP; NEWTON, VE; HARRIS, R; BALLING, R; GRUSS, P; STRACHAN, T			WAARDENBURG SYNDROME PATIENTS HAVE MUTATIONS IN THE HUMAN HOMOLOG OF THE PAX-3 PAIRED BOX GENE	NATURE			English	Article							CONSERVATION; DOMAIN; MOUSE	WAARDENBURG'S syndrome (WS) is an autosomal dominant combination of deafness and pigmentary disturbances, probably caused by defective function of the embryonic neural crest 1,2. We have mapped one gene for WS to the distal part of chromosome 2 (ref. 3). On the basis of their homologous chromosomal location, their close linkage to an alkaline phosphatase gene, and their related phenotype, we suggested that WS and the mouse mutant Splotch 4,5 might be homologous. Splotch is caused by mutation in the mouse Pax-3 gene 6,7. This gene is one of a family of eight Pax genes known in mice which are involved in regulating embryonic development; each contains a highly conserved transcription control sequence, the paired box 8. Here we show that some families with WS have mutations in the human homologue 9 of Pax-3. Mutations in a related gene, Pax-6, which, like Pax-3, has both a paired box and a paired-type homeobox sequence, cause the Small-eye mutation in mice 10 and aniridia in man 11. Thus mutations in the Pax genes are important causes of human developmental defects.	UNIV MANCHESTER,ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND; MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY; UNIV MANCHESTER,CTR AUDIOL,MANCHESTER M13 9PL,LANCS,ENGLAND; MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	University of Manchester; Max Planck Society; University of Manchester; Max Planck Society			Balling, Rudi/E-9680-2010	Balling, Rudi/0000-0003-2902-5650	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIAS S, 1971, Birth Defects Original Article Series, V7, P87; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; COLLIER S, 1989, EMBO J, V8, P1393, DOI 10.1002/j.1460-2075.1989.tb03520.x; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; EPSTEIN DJ, 1991, GENOMICS, V10, P89, DOI 10.1016/0888-7543(91)90488-Z; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FOY C, 1990, AM J HUM GENET, V46, P1017; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; KEEN J, 1991, TRENDS GENET, V7, P5; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WAARDENBURG PJ, 1951, AM J HUM GENET, V3, P195; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	18	591	602	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					635	636		10.1038/355635a0	http://dx.doi.org/10.1038/355635a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1347148				2022-12-24	WOS:A1992HD54700054
J	PERGOLIZZI, RG; ERSTER, SH; GOONEWARDENA, P; BROWN, WT				PERGOLIZZI, RG; ERSTER, SH; GOONEWARDENA, P; BROWN, WT			DETECTION OF FULL FRAGILE-X MUTATION	LANCET			English	Note								In fragile X syndrome, the most common inherited cause of mental deficiency, the underlying mutation is a large increase in the number of CGG repeats in a gene on chromosome X. We have developed a polymerase chain reaction (PCR) method to amplify across the full mutation in affected individuals. In this report, a fragile X family including a positive prenatally diagnosed fetus was analysed by PCR, and the results are consistent with direct genomic Southern blot analysis. Genetic screening of at-risk populations for fragile X can now be achieved by PCR rapidly, inexpensively, and on small samples.	CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,DEPT RES,MANHASSET,NY 11030; CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,DEPT PEDIAT,MANHASSET,NY 11030	Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Northwell Health; North Shore University Hospital			Brown, William/GXN-2777-2022					BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DOBKIN CS, 1991, LANCET, V338, P957; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LATIMER LJP, 1991, J BIOL CHEM, V266, P13849; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P1; TEMPLE IK, 1990, LANCET, V336, P1131, DOI 10.1016/0140-6736(90)92608-K; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H	10	78	81	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					271	272		10.1016/0140-6736(92)91334-5	http://dx.doi.org/10.1016/0140-6736(92)91334-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346284				2022-12-24	WOS:A1992HB52900006
J	MANABE, T; RENNER, P; NICOLL, RA				MANABE, T; RENNER, P; NICOLL, RA			POSTSYNAPTIC CONTRIBUTION TO LONG-TERM POTENTIATION REVEALED BY THE ANALYSIS OF MINIATURE SYNAPTIC CURRENTS	NATURE			English	Article							FROG NEUROMUSCULAR JUNCTION; HIPPOCAMPAL SLICES; RAT HIPPOCAMPUS; PERFORANT PATH; NEURONS; TRANSMISSION; INDUCTION; RELEASE; TRANSMITTER	Miniature excitatory synaptic currents were recorded from CA1 pyramidal cells in hippocampal slices to study the site of the persistent change in synaptic efficacy during long-term potentiation. Induction of long-term potentiation produced a large increase in the amplitude of these currents. Such a change in amplitude suggests an increase in postsynaptic transmitter sensitivity.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ASZTELY F, 1991, BRAIN RES, V558, P153, DOI 10.1016/0006-8993(91)90734-D; BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELMQVIST D, 1965, J PHYSIOL-LONDON, V177, P463, DOI 10.1113/jphysiol.1965.sp007605; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; Katz B., 1966, NERVE MUSCLE SYNAPSE; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; RAHAMIMOFF R, 1973, J PHYSIOL-LONDON, V228, P241, DOI 10.1113/jphysiol.1973.sp010084; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; THIBAULT O, 1989, BRAIN RES, V476, P170, DOI 10.1016/0006-8993(89)91553-9; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W; VORONIN LL, 1990, NEUROPHYSIOLOGY+, V22, P341; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	34	301	303	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					50	55		10.1038/355050a0	http://dx.doi.org/10.1038/355050a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1346229				2022-12-24	WOS:A1992GY22800045
J	WRANA, JL; ATTISANO, L; CARCAMO, J; ZENTELLA, A; DOODY, J; LAIHO, M; WANG, XF; MASSAGUE, J				WRANA, JL; ATTISANO, L; CARCAMO, J; ZENTELLA, A; DOODY, J; LAIHO, M; WANG, XF; MASSAGUE, J			TGF-BETA SIGNALS THROUGH A HETEROMERIC PROTEIN-KINASE RECEPTOR COMPLEX	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MOLECULAR-WEIGHT RECEPTOR; MEMBRANE PROTEOGLYCAN; CELL-PROLIFERATION; EXPRESSION CLONING; FIBROBLAST GROWTH; BINDING-PROTEINS; ACTIVIN RECEPTOR; IDENTIFICATION; TRANSDUCTION	Transforming growth factor beta (TGFbeta) binds with high affinity to the type II receptor, a transmembrane protein with a cytoplasmic serine/threonine kinase domain. We show that the type II receptor requires both its kinase activity and association with another TGFbeta-binding protein, the type I receptor, to signal growth inhibition and early gene responses. Receptors I and II associate as interdependent components of a heteromeric complex: receptor I requires receptor II to bind TGFbeta, and receptor II requires receptor I to signal. This mode of operation points to fundamental differences between this receptor and the protein-tyrosine kinase cytokine receptors.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Duke University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA-34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEBKOWSKI JS, 1986, MOL CELL BIOL, V6, P1838, DOI 10.1128/MCB.6.5.1838; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELOCHE, 1992, MOL BIOL CELL, V3, P63; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1991, BIOCHEM J, V273, P523, DOI 10.1042/bj2730523; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	1453	1503	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1003	1014		10.1016/0092-8674(92)90395-S	http://dx.doi.org/10.1016/0092-8674(92)90395-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333888				2022-12-24	WOS:A1992KB99000012
J	HASEGAWA, H; SKACH, W; BAKER, O; CALAYAG, MC; LINGAPPA, V; VERKMAN, AS				HASEGAWA, H; SKACH, W; BAKER, O; CALAYAG, MC; LINGAPPA, V; VERKMAN, AS			A MULTIFUNCTIONAL AQUEOUS CHANNEL FORMED BY CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; XENOPUS OOCYTES; CHLORIDE CHANNEL; MESSENGER-RNA; EXPRESSION; WATER; PERMEABILITY; CELLS	The cystic fibrosis gene product (CFTR) is a complex protein that functions as an adenosine 3,5-monophosphate (cAMP)-stimulated ion channel and possibly as a regulator of intracellular processes. In order to determine whether the CFTR molecule contains a functional aqueous pathway, anion, water, and urea transport were measured in Xenopus oocytes expressing CFTR. Cyclic AMP agonists induced a Cl- conductance of 94 microsiemens and an increase in water permeability of 4 x 10(-4) centimeter per second that was inhibited by a Cl- channel blocker and was dependent on anion composition. CFTR has a calculated single channel water conductance of 9 x 10(-13) cubic centimeter per second, suggesting a pore-like aqueous pathway. Oocytes expressing CFTR also showed cAMP-stimulated transport of urea but not the larger solute sucrose. Thus CFTR contains a cAMP-stimulated aqueous pore that can transport anions, water, and small solutes. The results also provide functional evidence for water movement through an ion channel.	UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK043840, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FINKELSTEIN A, 1987, DISTINGUISHED LECTUR, V4, pCH2; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GREEN ME, 1992, BIOPHYS J, V62, P101, DOI 10.1016/S0006-3495(92)81792-7; ILLINGER D, 1989, CELL BIOPHYS, V14, P17, DOI 10.1007/BF02797388; LEUCHTAG HR, 1992, BIOPHYS J, V62, P22, DOI 10.1016/S0006-3495(92)81766-6; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; SKACH W, UNPUB; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WANGEMANN P, 1986, PFLUG ARCH        S2, V407, P128; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; ZHANG R, IN PRESS J CELL BIOL	30	134	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1477	1479		10.1126/science.1279809	http://dx.doi.org/10.1126/science.1279809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279809				2022-12-24	WOS:A1992JZ62500026
J	HEGINBOTHAM, L; ABRAMSON, T; MACKINNON, R				HEGINBOTHAM, L; ABRAMSON, T; MACKINNON, R			A FUNCTIONAL CONNECTION BETWEEN THE PORES OF DISTANTLY RELATED ION CHANNELS AS REVEALED BY MUTANT K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNEL; SELECTIVE CONDUCTANCE; COMPLEMENTARY-DNA; ACTIVATED CHANNEL; CALCIUM CHANNELS; SODIUM-CHANNEL; DROSOPHILA-EAG; RETINAL RODS; TEA BLOCKADE; SHAKER	The overall sequence similarity between the voltage-activated K+ channels and cyclic nucleotide-gated ion channels from retinal and olfactory neurons suggests that they arose from a common ancestor. On the basis of sequence comparisons, mutations were introduced into the pore of a voltage-activated K+ channel. These mutations confer the essential features of ion conduction in the cyclic nucleotide-gated ion channels; the mutant K+ channels display little selectivity among monovalent cations and are blocked by divalent cations. The property of K+ selectivity is related to the presence of two amino acids that are absent from the pore-forming region of the cyclic nucleotide-gated channels. These data demonstrate that very small differences in the primary structure of an ion channel can account for extreme functional diversity, and they suggest a possible connection between the pore-forming regions of K+, Ca2+, and cyclic nucleotide-gated ion channels.			HEGINBOTHAM, L (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.				NIGMS NIH HHS [GM43949, GM47400] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400, R01GM043949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B., 1991, IONIC CHANNELS EXCIT; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1981, NATURE, V292, P502, DOI 10.1038/292502a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	42	372	380	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1152	1155		10.1126/science.1279807	http://dx.doi.org/10.1126/science.1279807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1279807				2022-12-24	WOS:A1992JX85200033
J	SCHIAVO, G; BENFENATI, F; POULAIN, B; ROSSETTO, O; DELAURETO, PP; DASGUPTA, BR; MONTECUCCO, C				SCHIAVO, G; BENFENATI, F; POULAIN, B; ROSSETTO, O; DELAURETO, PP; DASGUPTA, BR; MONTECUCCO, C			TETANUS AND BOTULINUM-B NEUROTOXINS BLOCK NEUROTRANSMITTER RELEASE BY PROTEOLYTIC CLEAVAGE OF SYNAPTOBREVIN	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; SMALL SYNAPTIC VESICLES; CHROMAFFIN CELLS; DISTINCT SITES; SYNAPSIN-I; EXOCYTOSIS; TOXIN; CHAINS; GENES; BIND	CLOSTRIDIAL neurotoxins, including tetanus toxin and the seven serotypes of botulinum toxin (A-G), are produced as single chains and cleaved to generate toxins with two chains joined by a single disulphide bond (Fig. 1). The heavy chain (M(r) 100,000 (100K)) is responsible for specific binding to neuronal cells and cell penetration of the light chain (50K), which blocks neurotransmitter release1-9. Several lines of evidence have recently suggested that clostridial neurotoxins could be zinc endopeptidases2,10-14. Here we show that tetanus and botulinum toxins serotype B are zinc endopeptidases, the activation of which requires reduction of the interchain disulphide bond. The protease activity is localized on the light chain and is specific for synaptobrevin, an integral membrane protein of small synaptic vesicles. The rat synaptobrevin-2 isoform is cleaved by both neurotoxins at the same single site, the peptide bond Gln 76-Phe 77, but the isoform synaptobrevin-1, which has a valine at the corresponding position, is not cleaved. The blocking of neurotransmitter release of Aplysia neurons injected with tetanus toxin or botulinum toxin serotype B is substantially delayed by peptides containing the synaptobrevin-2 cleavage site. These results indicate that tetanus and botulinum B neurotoxins block neurotransmitter release by cleaving synaptobrevin2, a protein that, on the basis of our results, seems to play a key part in neurotransmitter release.	UNIV PADUA,CRIBI,I-35131 PADUA,ITALY; UNIV MODENA,INST FISIOL UMANA,I-41100 MODENA,ITALY; CNRS,NEUROBIOL MOLEC & CELLULAIRE LAB,F-91118 GIF SUR YVETTE,FRANCE; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706	University of Padua; Universita di Modena e Reggio Emilia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Wisconsin System; University of Wisconsin Madison	SCHIAVO, G (corresponding author), UNIV PADUA,CNR,CTR BIOMEMBRANE,DIPARTIMENTO SCI BIOMED,75 VIA TRIESTE,I-35131 PADUA,ITALY.		rossetto, ornella/AAC-3866-2022	rossetto, ornella/0000-0002-6113-3857; Schiavo, Giampietro/0000-0002-4319-8745	Telethon [170] Funding Source: Medline	Telethon(Fondazione Telethon)		ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DECAMILLI P, REV PHYSL, V52, P625; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FONTANA A, 1983, METHOD ENZYMOL, V91, P311; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOCHWESER J, 1982, NEW ENGL J MED, V306, P214; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; POULAIN B, 1990, J PHYSIOL-PARIS, V84, P247; POULAIN B, 1992, J BIOL CHEM, V11, P3577; POULAIN B, 1991, J BIOL CHEM, V266, P1; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, IN PRESS J BIOL CHEM; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, REV NEUROSCI, V14, P93; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; [No title captured]; [No title captured]	31	1408	1467	3	123	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					832	835		10.1038/359832a0	http://dx.doi.org/10.1038/359832a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1331807				2022-12-24	WOS:A1992JV77700065
J	SMITH, WC; HARLAND, RM				SMITH, WC; HARLAND, RM			EXPRESSION CLONING OF NOGGIN, A NEW DORSALIZING FACTOR LOCALIZED TO THE SPEMANN ORGANIZER IN XENOPUS EMBRYOS	CELL			English	Article							MESSENGER-RNA; LAEVIS; AXIS; MESODERM; PATTERN; EMBRYOGENESIS; INDUCTION; ACTIVIN; XWNT-8; GENE	We have cloned a cDNA encoding a novel polypeptide capable of inducing dorsal development in Xenopus embryos. RNA transcripts from this clone rescue normal development when injected into ventralized embryos and result in excessive head development at high doses. Therefore, we have named the cDNA nog. gin. noggin cDNA contains a single reading frame encoding a 26 kd protein with a hydrophobic amino-terminal sequence, suggesting that it is secreted. In Northern blot analysis this cDNA hybridizes to two mRNAs that are expressed both maternally and zygotically. Although noggin transcript is not localized in the oocyte and cleavage stage embryo, zygotic transcripts are initially restricted to the presumptive dorsal mesoderm and reach their highest levels at the gastrula stage in the dorsal lip of the blastopore (Spemann organizer). In the neurula, noggin is transcribed in the notochord and prechordal mesoderm. The activity of exogenous noggin RNA in embryonic axis induction and the localized expression of endogenous noggin transcripts suggest that noggin plays a role in normal dorsal development.			SMITH, WC (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.							ALTABA ARI, 1992, IN PRESS DEVELOPMENT; BLUMBERG B, 1991, NATURE, V253, P194; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FRANK D, 1992, DEVELOPMENT, V115, P439; FRANK D, 1991, DEVELOPMENT, V113, P1387; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KIMELMAN D, 1992, IN PRESS DEVELOPMENT; KLOC M, 1989, DEVELOPMENT, V107, P899; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PENG HB, 1991, METHOD CELL BIOL, V36, P661; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	37	989	1027	0	52	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					829	840		10.1016/0092-8674(92)90316-5	http://dx.doi.org/10.1016/0092-8674(92)90316-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1339313				2022-12-24	WOS:A1992JL66300014
J	RIZZUTO, R; SIMPSON, AWM; BRINI, M; POZZAN, T				RIZZUTO, R; SIMPSON, AWM; BRINI, M; POZZAN, T			RAPID CHANGES OF MITOCHONDRIAL CA2+ REVEALED BY SPECIFICALLY TARGETED RECOMBINANT AEQUORIN	NATURE			English	Article							CALCIUM; CELLS; CA-2+; INVOLVEMENT; RECEPTOR; PROTEINS	INTRODUCTION of Ca2+ indicators (photoproteins, fluorescent dyes) that can be trapped in the cytosolic compartment of living cells has yielded major advances in our knowledge of Ca2+ homeostasis1,2. Ca2+ however regulates functions not only in the cytosol but also within various organelles3,4 where indicators have not yet been specifically targeted. Here we present a novel procedure by which the free Ca2+ concentration of mitochondria, [Ca2+]m, can be monitored continuously at rest and during stimulation. The complementary DNA for the Ca2+ sensitive photoprotein aequorin was fused in frame with that encoding a mitochondrial presequence. The hybrid cDNA was transfected into bovine endothelial cells and stable clones were obtained expressing variable amounts of mitochondrially targeted apoaequorin. The functional photoprotein could be reconstituted in intact cells by incubation with purified coelenterazine and [Ca2+]m could thus be monitored in situ. This allowed the unprecedented direct demonstration that agonist-stimulated elevations of cytosolic free Ca2+, [Ca2+]i, (measured in parallel with Fura-2) evoke rapid and transient increases of [Ca2+]m, which can be prevented by pretreatment with a mitochondrial uncoupler. The possibility of targeting aequorin to cellular organelles not only offers a new and powerful method for studying aspects of Ca2+ homeostasis that up to now could not be directly approached, but might also be used in the future as a tool to report in situ a variety of apparently unrelated phenomena of wide biological interest.	UNIV OXFORD, PHYSIOL LAB, OXFORD OX1 3PT, ENGLAND	University of Oxford	RIZZUTO, R (corresponding author), UNIV PADUA, DEPT BIOMED SCI, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Rizzuto, Rosario/B-6312-2008; Brini, Marisa/K-5189-2016	Rizzuto, Rosario/0000-0001-7044-5097; Brini, Marisa/0000-0001-5141-0243	Telethon [126] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Blinks J.R., 1978, Methods in Enzymology, V57, P292; CASADEI J, 1990, P NATL ACAD SCI USA, V87, P2047, DOI 10.1073/pnas.87.6.2047; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DEPIERRE JW, 1974, J BIOL CHEM, V249, P7111; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KNIGHT MR, 1991, FEBS LETT, V282, P405, DOI 10.1016/0014-5793(91)80524-7; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; Sambrook J., 1989, MOL CLONING; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHIMOMURA O, 1991, CELL CALCIUM, V12, P635, DOI 10.1016/0143-4160(91)90060-R; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANAHASHI H, 1990, GENE, V96, P249, DOI 10.1016/0378-1119(90)90260-X; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49	36	782	826	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					325	327		10.1038/358325a0	http://dx.doi.org/10.1038/358325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1322496				2022-12-24	WOS:A1992JE68400062
J	OROURKE, B; BACKX, PH; MARBAN, E				OROURKE, B; BACKX, PH; MARBAN, E			PHOSPHORYLATION-INDEPENDENT MODULATION OF L-TYPE CALCIUM CHANNELS BY MAGNESIUM-NUCLEOTIDE COMPLEXES	SCIENCE			English	Article							GUINEA-PIG HEART; SINGLE VENTRICULAR CELLS; ADENOSINE-TRIPHOSPHATE; INWARD RECTIFICATION; POTASSIUM CHANNELS; CARDIAC MYOCYTES; CYCLIC-AMP; INACTIVATION; CA-2+; BLOCK	Free magnesium ions and magnesium-nucleotide complexes can exert opposite effects on many fundamental cellular processes. Although increases in the intracellular concentration of magnesium ions inhibit the L-type calcium current in heart cells, magnesium-adenosine triphosphate complexes (MgATP) would be expected to increase the current by promoting channel phosphorylation. Rapid increases in the intracellular concentration of MgATP induced by flash photolysis of caged magnesium or caged ATP resulted in enhanced calcium current. The increase in calcium current was not prevented by blocking phosphorylation, revealing a previously unrecognized direct regulatory action of the magnesium-nucleotide complex.	JOHNS HOPKINS UNIV,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University			Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036957, R37HL036957, F32HL007227] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07227, HL 36957] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUS ZS, 1989, BELLJUU, V256, pC452; Aikawa J.K., 1981, MAGNESIUM ITS BIOL S; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARTALEJO CR, 1990, NATURE, V348; BACKX PH, 1991, AM J HYPERTENS, V4, P416; BELLES B, 1988, PFLUG ARCH EUR J PHY, V411, P353, DOI 10.1007/BF00587713; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P497, DOI 10.1113/jphysiol.1975.sp011027; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; GARNER PS, 1973, FEBS LETT, V34, P243, DOI 10.1016/0014-5793(73)80803-8; GOLDHABER JI, 1991, J PHYSIOL-LONDON, V443, P371, DOI 10.1113/jphysiol.1991.sp018838; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUME JR, 1991, P NATL ACAD SCI USA, V88, P6946; IRISAWA H, 1983, J PHYSIOL-LONDON, V338, P321, DOI 10.1113/jphysiol.1983.sp014675; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; RUBIN H, 1975, P NATL ACAD SCI USA, V72, P3551, DOI 10.1073/pnas.72.9.3551; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; TANIGUCHI J, 1983, CIRC RES, V53, P131, DOI 10.1161/01.RES.53.2.131; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TUNG RT, 1991, J PHYSIOL-LONDON, V437, P239, DOI 10.1113/jphysiol.1991.sp018593; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	35	113	113	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					245	248		10.1126/science.1321495	http://dx.doi.org/10.1126/science.1321495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321495				2022-12-24	WOS:A1992JC58500040
J	SULLIVAN, V; TALARICO, CL; STANAT, SC; DAVIS, M; COEN, DM; BIRON, KK				SULLIVAN, V; TALARICO, CL; STANAT, SC; DAVIS, M; COEN, DM; BIRON, KK			A PROTEIN-KINASE HOMOLOG CONTROLS PHOSPHORYLATION OF GANCICLOVIR IN HUMAN CYTOMEGALOVIRUS-INFECTED CELLS	NATURE			English	Article							HERPES-SIMPLEX VIRUS; VARICELLA-ZOSTER VIRUS; COMPLETE DNA-SEQUENCE; EPSTEIN-BARR VIRUS; GENOME; PHOSPHOTRANSFERASE; HERPESVIRUSES; EXPRESSION; ACYCLOVIR	HUMAN cytomegalovirus (HCMV) is a major pathogen in immunosuppressed individuals, including patients with acquired immune deficiency syndrome. The nucleoside analogue ganciclovir (9-(1,3-dihydroxy-2-propoxymethyl)-guanine) is one of the few drugs available to treat HCMV infections, but resistant virus is a growing problem in the clinic 1 and there is a critical need for new drugs. The study of ganciclovir-resistant mutants has indicated that the selective action of ganciclovir depends largely on virus-controlled phosphorylation in HCMV-infected cells 2-5. The enzyme(s) responsible have not been identified. Here we report that the HCMV gene UL97, whose predicted product shares regions of homology with protein kinases, guanylyl cyclase and bacterial phosphotransferases 6-8, controls phosphorylation of ganciclovir in HCMV-infected cells. A four-amino-acid deletion of UL97 in a conserved region, which in cyclic AMP-dependent protein kinase participates in substrate recognition 9, causes impaired ganciclovir phosphorylation. The implications of these results for antiviral drug development and drug resistance are discussed.	BURROUGHS WELLCOME CO, DIV VIROL, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund	SULLIVAN, V (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.							AGUT H, 1989, RES VIROLOGY, V140, P219, DOI 10.1016/S0923-2516(89)80099-8; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BIRON KK, 1986, P NATL ACAD SCI USA, V83, P8769, DOI 10.1073/pnas.83.22.8769; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BRITT WJ, 1986, J VIROL, V58, P185, DOI 10.1128/JVI.58.1.185-191.1986; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DILUCA D, 1990, VIROLOGY, V175, P199, DOI 10.1016/0042-6822(90)90200-B; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; FLECKENSTEIN B, 1982, GENE, V18, P39, DOI 10.1016/0378-1119(82)90054-3; FREITAS VR, 1985, ANTIMICROB AGENTS CH, V28, P240, DOI 10.1128/AAC.28.2.240; FYFE JA, 1983, MOL PHARMACOL, V24, P316; FYFE JA, 1978, J BIOL CHEM, V253, P8721; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; MAR EC, 1981, J GEN VIROL, V57, P149, DOI 10.1099/0022-1317-57-1-149; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MICHELSON S, 1984, VIROLOGY, V134, P259, DOI 10.1016/0042-6822(84)90295-2; ROBY C, 1986, J VIROL, V59, P714, DOI 10.1128/JVI.59.3.714-727.1986; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SMITH RF, 1989, J VIROL, V63, P450, DOI 10.1128/JVI.63.1.450-455.1989; SOMOGYI T, 1990, VIROLOGY, V174, P276, DOI 10.1016/0042-6822(90)90075-3; STANAT SC, 1991, ANTIMICROB AGENTS CH, V35, P2191, DOI 10.1128/AAC.35.11.2191	28	368	373	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					162	164		10.1038/358162a0	http://dx.doi.org/10.1038/358162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319560				2022-12-24	WOS:A1992JC58300056
J	CAMERON, HA; CLOSE, CF; YEO, WW; JACKSON, PR; RAMSAY, LE				CAMERON, HA; CLOSE, CF; YEO, WW; JACKSON, PR; RAMSAY, LE			INVESTIGATION OF SELECTED PATIENTS WITH HYPERTENSION BY THE RAPID-SEQUENCE INTRAVENOUS UROGRAM	LANCET			English	Article							RENAL-ARTERY STENOSIS; RENOVASCULAR HYPERTENSION; ANGIOPLASTY; MANAGEMENT	The rapid-sequence intravenous urogram (IVU) has tended to fall from favour for investigating hypertension because of its perceived imprecision for detecting renovascular disease. However, no study has examined the value of the IVU as a screening test in appropriately selected patients. We have analysed the diagnostic yield of the rapid-sequence IVU in hypertensive patients selected for features suggesting renal or renovascular disease in a retrospective review of case records from a hypertension clinic. The IVU was abnormal in 27% (95% Cl 21-32%) of 241 consecutive patients. The most common abnormalities were chronic pyelonephritis (6%); proven renovascular disease (5%); stone (4%); possible renovascular disease and simple cyst (each 3%); hydronephrosis (2%); and tumour and active tuberculosis (each 1%). The IVU led to intervention aiming to correct hypertension in 5% (95% Cl 2-8%) of patients, and revealed an abnormality needing intervention in its own right in 4% (95% Cl 2-6%). The IVU led to unnecessary invasive investigation in 3% of cases. Individual abnormalities could not be predicted from the clinical or laboratory features. The initial investigation in hypertensive patients with suspected renal or renovascular disease should be a general purpose test able to detect a wide range of abnormalities. The rapid-sequence IVU is the only single test capable of satisfying this requirement. In patients with features suggesting renovascular disease, a normal rapid-sequence IVU excludes renovascular disease with 93% probability, but is an imperfect screening test since it fails to diagnose about 20% of cases. Renal arteriography should be done despite a normal IVU when it is essential to exclude renovascular disease.	UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield				Yeo, Wilfred/0000-0001-9554-5203				ATKINSON A B, 1974, Journal of the Royal College of Physicians of London, V8, P175; BOOKSTEIN JJ, 1972, JAMA-J AM MED ASSOC, V220, P1195; BRAWN LA, 1987, LANCET, V2, P1313; CARMICHAEL DJS, 1986, LANCET, V1, P667; FAIRMAN MJ, 1974, POSTGRAD MED J, V50, P508, DOI 10.1136/pgmj.50.586.508; HAVEY RJ, 1985, JAMA-J AM MED ASSOC, V254, P388, DOI 10.1001/jama.254.3.388; LUSCHER TF, 1985, CARDIOLOGY, V72, P33, DOI 10.1159/000173942; MAXWELL MH, 1964, NEW ENGL J MED, V270, P213, DOI 10.1056/NEJM196401302700501; Pickering T, 1990, HYPERTENSION PATHOPH, P1539; PICKERING TG, 1988, LANCET, V2, P551; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; THORNBURY JR, 1982, AM J ROENTGENOL, V138, P43; THORNBURY JR, 1984, RADIOL CLIN N AM, V22, P333	13	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					658	661		10.1016/0140-6736(92)90805-D	http://dx.doi.org/10.1016/0140-6736(92)90805-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347347				2022-12-24	WOS:A1992HH74300013
J	CAPLAN, LR				CAPLAN, LR			INTRACEREBRAL HEMORRHAGE	LANCET			English	Article							HEMORRHAGE				CAPLAN, LR (corresponding author), TUFTS UNIV,DEPT NEUROL,750 WASHINGTON ST,NEMCH 314,BOSTON,MA 02111, USA.							CAPLAN L, 1988, NEUROLOGY, V38, P624, DOI 10.1212/WNL.38.4.624; FELDMANN E, 1991, STROKE, V22, P684; FISCHER CM, 1971, J NEUROPATHOL EXP NE, V30, P536; GILBERT JJ, 1983, STROKE, V14, P915, DOI 10.1161/01.STR.14.6.915; KASE CS, 1985, NEUROLOGY, V35, P943, DOI 10.1212/WNL.35.7.943; KASE CS, 1986, STROKE, V17, P590, DOI 10.1161/01.STR.17.4.590; LEVINE SR, 1988, STROKE, V19, P779, DOI 10.1161/01.STR.19.6.779; OJERMAN RG, 1983, STROKE, V14, P468; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213	9	135	140	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					656	658		10.1016/0140-6736(92)90804-C	http://dx.doi.org/10.1016/0140-6736(92)90804-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347346				2022-12-24	WOS:A1992HH74300012
J	DOUGLAS, NJ; THOMAS, S; JAN, MA				DOUGLAS, NJ; THOMAS, S; JAN, MA			CLINICAL-VALUE OF POLYSOMNOGRAPHY	LANCET			English	Article							HYPOPNEA SYNDROME; SLEEP	Polysomnography is used increasingly to investigate patients with possible sleep apnoea/hypopnoea syndrome (SAHS), but it has not been assessed critically. We thus examined prospectively the value of electrophysiological and respiratory monitoring in 200 consecutive adults (163 men, 37 women; mean [SD] age 50 [13] years) having polysomnography. At polysomnography, 91 patients had SAHS (> 15 apnoeas + hypopnoeas [A + H] per h asleep) and 11 had periodic limb-movement disorder. Recording sleep electrophysiologically was of no diagnostic value and SAHS could be as accurately defined by A + H per time in bed as by A + H per time asleep. 66% of patients with SAHS could be diagnosed with oximetry alone, but many of the undiagnosed patients had moderately severe SAHS and benefited from treatment. Neurophysiological sleep recording is unnecessary and oximetry alone is of limited value in the overnight in investigation of patients suspected of having SAHS.			DOUGLAS, NJ (corresponding author), CITY HOSP EDINBURGH,DEPT MED,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND.		Douglas, Neil/B-1491-2013					CHESHIRE K, IN PRESS ARCH INTERN; COOPER BG, 1991, THORAX, V46, P586, DOI 10.1136/thx.46.8.586; CROCKER BD, 1990, AM REV RESPIR DIS, V142, P14, DOI 10.1164/ajrccm/142.1.14; DOUGLAS NJ, 1979, LANCET, V1, P1; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HAPONIK EF, 1984, AM J MED, V77, P671, DOI 10.1016/0002-9343(84)90361-9; MARTIN RJ, 1985, SLEEP, V8, P371, DOI 10.1093/sleep/8.4.371; MCAVOY RD, 1988, GUIDELINES RESPIRATO; PARSONS M, 1986, Q J MED, V58, P295; Phillipson E.A., 1989, AM REV RESPIR DIS, V139, P559, DOI 10.1164/ajrccm/139.2.559; Rechtschaffen A, 1968, NIH PUBLICATION, V204; STRADLING J, 1989, J AMBULATORY MONIT, V2, P197; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; WHYTE KF, 1989, Q J MED, V72, P659; WHYTE KF, IN PRESS SLEEP; 1990, BTS NEWS, V5, P7; 1990, INT CLASSIFICATION S, P65	19	273	279	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					347	350		10.1016/0140-6736(92)91660-Z	http://dx.doi.org/10.1016/0140-6736(92)91660-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346422				2022-12-24	WOS:A1992HC77100017
J	TREACY, MN; NEILSON, LI; TURNER, EE; HE, X; ROSENFELD, MG				TREACY, MN; NEILSON, LI; TURNER, EE; HE, X; ROSENFELD, MG			TWIN OF I-POU - A 2 AMINO-ACID DIFFERENCE IN THE I-POU HOMEODOMAIN DISTINGUISHES AN ACTIVATOR FROM AN INHIBITOR OF TRANSCRIPTION	CELL			English	Article							DNA-BINDING DOMAIN; MAMMALIAN-CELLS; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; NEGATIVE REGULATOR; CELLULAR PROTEINS; GENE-EXPRESSION; STEROID BINDING; LEUCINE ZIPPER; C-ELEGANS	I-POU, a POU domain nuclear protein that lacks two conserved basic amino acids of the POU homeodomain is coexpressed in the developing Drosophila nervous system with a second POU domain transcription factor, Cf1-a. I-POU does not bind to DNA but forms a POU domain-mediated, high affinity heterodimer with Cf1-a, inhibiting its ability to bind and activate the dopa decarboxylase gene. The I-POU/Cf1-a dimerization interface encompasses only the N-terminal basic region and helices 1 and 2 of the POU homeodomains with precise amino acid and alpha-helical requirements. twin of I-POU, an alternatively spliced transcript of the I-POU gene, encodes a protein containing the two basic amino acid residues absent in I-POU. Twin of I-POU is incapable of dimerizing with Cf1-a, but can act as a positive transcription factor on targets distinct from those regulated by Cf1-a. These findings suggest that the I-POU genomic locus simultaneously generates both a specific activator and inhibitor of gene transcription, capable of modulating two distinct regulatory programs during neural development.	UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT BIOL, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	TREACY, MN (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.		Turner, Eric e/K-3556-2015	Turner, Eric e/0000-0001-5499-6788				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; AKAM M, 1987, DEVELOPMENT, V101, P1; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERMINGHAM JR, 1988, EMBO J, V7, P3211, DOI 10.1002/j.1460-2075.1988.tb03188.x; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; BUSTURIA A, 1990, EMBO J, V9, P3551, DOI 10.1002/j.1460-2075.1990.tb07565.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PRATT WB, 1988, J BIOL CHEM, V263, P267; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	83	107	108	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					491	505		10.1016/0092-8674(92)90186-G	http://dx.doi.org/10.1016/0092-8674(92)90186-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1346754				2022-12-24	WOS:A1992HD39800010
J	DALEY, CL; SMALL, PM; SCHECTER, GF; SCHOOLNIK, GK; MCADAM, RA; JACOBS, WR; HOPEWELL, PC				DALEY, CL; SMALL, PM; SCHECTER, GF; SCHOOLNIK, GK; MCADAM, RA; JACOBS, WR; HOPEWELL, PC			AN OUTBREAK OF TUBERCULOSIS WITH ACCELERATED PROGRESSION AMONG PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - AN ANALYSIS USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY	Background. Tuberculosis typically develops from a reactivation of latent infection. Clinical tuberculosis may also arise from a primary infection, and this is thought to be more likely in persons infected with the human immunodeficiency virus (HIV). However, the relative importance of these two pathogenetic mechanisms in this population is unclear. Methods. Between December 1990 and April 1991, tuberculosis was diagnosed in 12 residents of a housing facility for HIV-infected persons. In the preceding six months, two patients being treated for tuberculosis had been admitted to the facility. We investigated this outbreak using standard procedures plus analysis of the cultured organisms with restriction-fragment-length polymorphisms (RFLPs). Results. Organisms isolated from all 11 of the culture-positive residents had similar RFLP patterns, whereas the isolates from the 2 patients treated for tuberculosis in the previous six months were different strains. This implicated the first of the 12 patients with tuberculosis as the source of this outbreak. Among the 30 residents exposed to possible infection, active tuberculosis developed in 11 (37 percent), and 4 others (13 percent) had newly positive tuberculin skin tests. Of 28 staff members with possible exposure, at least 6 had positive tuberculin-test reactions, but none had tuberculosis. Conclusions. Newly acquired tuberculous infection in HIV-infected patients can spread readily and progress rapidly to active disease. There should be heightened surveillance for tuberculosis in facilities where HIV-infected persons live, and investigation of contacts must be undertaken promptly and be focused more broadly than is usual.	SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV GEOG MED,STANFORD,CA 94305; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; DEPT PUBL HLTH CITY & CTY SAN FRANCISCO,SAN FRANCISCO,CA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Stanford University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; San Francisco Department of Public Health			Daley, Charles L./AAC-3231-2021	Jacobs, William/0000-0003-3321-3080	NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [AIZ6170] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Bloch A B, 1989, Semin Respir Infect, V4, P157; DIPERRI G, 1989, LANCET, V2, P1502; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; MCADAM RA, 1990, MOL MICROBIOL, V4, P1607, DOI 10.1111/j.1365-2958.1990.tb02073.x; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; THEIRRY D, 1990, NUCLEIC ACIDS RES, V18, P188; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991	11	874	884	2	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					231	235		10.1056/NEJM199201233260404	http://dx.doi.org/10.1056/NEJM199201233260404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1345800	Bronze			2022-12-24	WOS:A1992HA43100004
J	DEFIGUEIREDO, CEP; ELLORY, JC; HENDRY, BM				DEFIGUEIREDO, CEP; ELLORY, JC; HENDRY, BM			ERYTHROCYTE CHOLINE UPTAKE AFTER RENAL-TRANSPLANTATION	LANCET			English	Article							TRANSPORT; HEMODIALYSIS; FAILURE; CARRIER; UREMIA; ACIDS; PUMP	Erythrocyte membrane choline transport is abnormally high in chronic renal failure. The aim of this study was to find out whether, and how quickly, this abnormality is reversed by renal transplantation. Ten adults with chronic renal failure were studied before and for up to 6 months after renal transplantation. Plasma creatinine concentration and erythrocyte uptake of radiolabelled choline were measured periodically for up to 6 months. The maximum rate of choline transport (V(max)) was abnormally high before transplantation and fell to normal values during the first week after transplantation. This fall matched that in plasma creatinine. A temporary rise in plasma creatinine in one patient, reversed by methylprednisolone treatment, was accompanied by a rise in choline flux, and graft failure in another patient was accompanied by a return to pretransplant rates of choline transport. Thus, the high rates of choline uptake in uraemia are rapidly reduced on recovery of renal function. The speed of the changes suggests the involvement of a plasma factor.	UNIV OXFORD,PHYSIOL LAB,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Poli=de-Figueiredo, Carlos Eduardo/A-2027-2013	Poli=de-Figueiredo, Carlos Eduardo/0000-0002-7333-8884				ANCELIN ML, 1991, BIOCHEM J, V273, P701, DOI 10.1042/bj2730701; Cole C H, 1968, Trans Assoc Am Physicians, V81, P213; COTTON JR, 1979, J CLIN INVEST, V63, P501, DOI 10.1172/JCI109328; DEVES R, 1986, J MEMBRANE BIOL, V93, P165, DOI 10.1007/BF01870808; DEVES R, 1979, BIOCHIM BIOPHYS ACTA, V557, P469, DOI 10.1016/0005-2736(79)90344-4; EDMONDSON RPS, 1975, CLIN SCI MOL MED, V49, P213, DOI 10.1042/cs0490213; ESTRADA C, 1990, J NEUROCHEM, V54, P1467, DOI 10.1111/j.1471-4159.1990.tb01193.x; FERVENZA FC, 1991, CLIN SCI, V80, P137, DOI 10.1042/cs0800137; FERVENZA FC, 1990, NEPHROL DIAL TRANSPL, V5, P594, DOI 10.1093/ndt/5.8.594; FERVENZA FC, 1989, NEPHRON, V53, P121, DOI 10.1159/000185723; GRAVES SW, 1983, ANN INTERN MED, V99, P604, DOI 10.7326/0003-4819-99-5-604; KAJI D, 1987, AM J PHYSIOL, V252, pF785, DOI 10.1152/ajprenal.1987.252.5.F785; KELLY RA, 1989, KIDNEY INT, V35, P595, DOI 10.1038/ki.1989.28; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; MARTIN K, 1977, MEMBRANE TRANSPORT R, P101; RUIZ P, 1990, NEW ENGL J MED, V322, P717, DOI 10.1056/NEJM199003153221102; WELT LG, 1964, T ASSOC AM PHYSICIAN, V77, P169; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	18	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					146	148		10.1016/0140-6736(92)90211-K	http://dx.doi.org/10.1016/0140-6736(92)90211-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346011				2022-12-24	WOS:A1992GZ96800004
J	HEALY, B				HEALY, B			EXERCISE RADIONUCLIDE ANGIOCARDIOGRAPHY PREDICTS CARDIAC DEATH IN PATIENTS WITH CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, CIRCULATION S1, V84, P52	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-24	WOS:A1992GY04600006
J	OBERHAUSER, AF; MONCK, JR; BALCH, WE; FERNANDEZ, JM				OBERHAUSER, AF; MONCK, JR; BALCH, WE; FERNANDEZ, JM			EXOCYTOTIC FUSION IS ACTIVATED BY RAB3A PEPTIDES	NATURE			English	Article							GTP-BINDING PROTEIN; PERITONEAL MAST-CELLS; CAPACITANCE MEASUREMENTS; MEMBRANE CAPACITANCE; SYNAPTIC VESICLES; GAMMA-S; TRANSPORT; ENDOCYTOSIS; SECRETION; MECHANISM	STUDIES of intracellular traffic in yeast and mammalian systems have implicated members of the Rab family of small GTP-binding proteins as regulators of membrane fusion1-10. We have used the patch clamp technique to measure exocytotic fusion events directly and investigate the role of GTP-binding proteins in regulating exocytosis in mast cells. Intracellular perfusion of mast cells with GTP-gammaS is sufficient to trigger complete exocytotic degranulation in the absence of other intracellular messengers11. Here we show that GTP is a potent inhibitor of GTP-gammaS-induced degranulation, indicating that sustained activation of a GTP-binding protein is sufficient for membrane fusion. We have found that synthetic oligopeptides, corresponding to part of the effector domain of Rab3a12, stimulate complete exocytotic degranulation, similar to that induced by GTP-gammaS. The response is selective for Rab3a sequence and is strictly dependent on Mg2+ and ATP. This suggests that sustained activation of a Rab3 protein causes exocytotic fusion. The peptide response can be accelerated by GDP-betaS, suggesting that Rab3a peptides compete with endogenous Rab3 proteins for a binding site on a target effector protein, which causes fusion on activation.	SCRIPPS RES INST, DEPT MOLEC & CELLULAR BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	OBERHAUSER, AF (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHYSIOL & BIOPHYS, ROCHESTER, MN 55905 USA.			Oberhauser, Andres/0000-0001-7375-7109				ALMERS W, 1987, J PHYSIOL-LONDON, V386, P205, DOI 10.1113/jphysiol.1987.sp016530; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DETOLEDO GA, 1990, J CELL BIOL, V110, P1033, DOI 10.1083/jcb.110.4.1033; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; LINDAU M, 1987, FEBS LETT, V222, P317, DOI 10.1016/0014-5793(87)80393-9; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; MONCK JR, IN PRESS J CELL BIOL; MOUSLI M, 1989, J PHARMACOL EXP THER, V250, P329; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PENNER R, 1987, BIOSCIENCE REP, V7, P313, DOI 10.1007/BF01121453; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	33	166	167	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					270	273		10.1038/360270a0	http://dx.doi.org/10.1038/360270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1331813				2022-12-24	WOS:A1992JY96000056
J	RUDNICKI, MA; BRAUN, T; HINUMA, S; JAENISCH, R				RUDNICKI, MA; BRAUN, T; HINUMA, S; JAENISCH, R			INACTIVATION OF MYOD IN MICE LEADS TO UP-REGULATION OF THE MYOGENIC HLH GENE MYF-5 AND RESULTS IN APPARENTLY NORMAL MUSCLE DEVELOPMENT	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; CREATINE-KINASE GENE; MOUSE EMBRYO; ACTIN GENE; EXPRESSION; FAMILY; DIFFERENTIATION; MEMBER; IDENTIFICATION; ENHANCER	The myogenic basic HLH transcription factor family of genes, composed of MyoD, myogenin, Myf-5, and Myf-6, are thought to regulate skeletal muscle differentiation. To understand the role of MyoD in myogenesis, we have introduced a null mutation of MyoD into the germline of mice. Surprisingly, mice lacking MyoD are viable and fertile. Histological examination of skeletal muscle failed to reveal any morphological abnormalities in these mice. Furthermore, Northern analysis revealed normal levels of skeletal muscle-specific mRNAs. Significantly, Myf-5 mRNA levels are elevated in postnatal mutant mice. Normally, Myf-5 expression becomes markedly reduced at day 12 of gestation when MyoD mRNA first appears. This suggests that Myf-5 expression is repressed by MyoD. Our results indicate that MyoD is dispensable for skeletal muscle development in mice, revealing some degree of functional redundancy in the control of the skeletal myogenic developmental program.	MIT, WHITEHEAD INST, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; UNIV HAMBURG, SCH MED, DEPT TOXICOL, W-2000 HAMBURG 13, GERMANY	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Hamburg			Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	NCI NIH HHS [5R35 CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bancroft JD, 1990, THEORY PRACTICE HIST; BLOCK NE, 1992, MOL CELL BIOL, V12, P2484, DOI 10.1128/MCB.12.6.2484; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Maniatis T., 1982, MOL CLONING; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MILLER JB, 1991, NEUROMUSCULAR DISORD, V61, P7; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; RUDNICKI MA, 1989, DEVELOPMENT, V107, P361; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; RUDNICKI MA, 1991, GENOME ANAL, V2, P13; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	48	813	848	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					383	390		10.1016/0092-8674(92)90508-A	http://dx.doi.org/10.1016/0092-8674(92)90508-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1330322				2022-12-24	WOS:A1992JW43500005
J	SIEGEL, D; GOLDEN, E; WASHINGTON, AE; MORSE, SA; FULLILOVE, MT; CATANIA, JA; MARIN, B; HULLEY, SB				SIEGEL, D; GOLDEN, E; WASHINGTON, AE; MORSE, SA; FULLILOVE, MT; CATANIA, JA; MARIN, B; HULLEY, SB			PREVALENCE AND CORRELATES OF HERPES-SIMPLEX INFECTIONS - THE POPULATION-BASED AIDS IN MULTIETHNIC NEIGHBORHOODS STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS TYPE-2 INFECTION; GENITAL HERPES; GLYCOPROTEIN-G; UNITED-STATES; ANTIBODIES; EPIDEMIOLOGY; RISK; IDENTIFICATION; CHILDREN; GENE	Objective.-To examine the extent and correlates of infection with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in an inner-city community, we studied the prevalence of antibodies to these viruses and their association with risk behaviors in a representative sample of unmarried white, black, and Hispanic adults living in San Francisco, Calif. Design.-Cross-sectional, community-based, random household survey. Participants.-In 1988 and 1989, we surveyed 1770 unmarried men and women aged 20 to 44 years from three San Francisco neighborhoods of varying geographic and cultural characteristics. Main Outcome Measures.-HSV-1 and HSV-2 antibodies based on an immunodot assay using type-specific glycoproteins gG-1 and gG-2. Results.- blood samples from 1212 participants available for testing, 750 (62%) had HSV-1 antibodies and 400 (33%) had HSV-2 antibodies. After controlling for other variables, HSV-1 antibody was significantly correlated (P<.05) with older age (in heterosexual men, women, and homosexually active men), less education (in heterosexual men and women), and Hispanic (especially those not born in the United States) or black race. HSV-2 antibody was significantly correlated (P<.05) with female gender, number of lifetime sexual partners and older age (in heterosexual men and women), and low levels of education and black or Hispanic race (in women). Among those with antibody to HSV-2, only 28 (19%) of 149 men and 32 (13%) of 251 women reported a history of genital herpes. However, most men (62%) and women (84%) who reported a history of genital herpes had HSV-2 antibodies. We observed a similar pattern (low sensitivity and moderate specificity) for a history of facial herpes and the presence of HSV-1 antibodies. After controlling for other variables, HSV-2 antibodies were associated with a lower frequency of HSV-1 antibodies among homosexual men infected with the human immunodeficiency virus. Conclusions.-HSV-1 antibodies were found in nearly two thirds of single urban adults and were most common among Hispanics not born in the United States. HSV-2 antibodies were found in one third of this population and were associated with risk behaviors for sexually transmitted diseases. For both facial and genital herpes infections, self-reporting of infection was very insensitive and moderately specific.	NEW YORK STATE PSYCHIAT INST & HOSP,HIV CTR CLIN & BEHAV STUDIES,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; COLUMBIA UNIV,NEW YORK,NY 10027; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; CTR DIS CONTROL,DIV SEXUALLY TRANSMITTED DIS LAB RES,ATLANTA,GA 30333; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143	New York State Psychiatry Institute; University of California System; University of California San Francisco; Columbia University; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco			Fullilove, Mindy Thompson/AAI-4919-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKERMANN M, 1986, VIROLOGY, V150, P207, DOI 10.1016/0042-6822(86)90280-1; ADLERSTORTHZ K, 1985, AM J OBSTET GYNECOL, V151, P582, DOI 10.1016/0002-9378(85)90143-7; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BECKER TM, 1985, JAMA-J AM MED ASSOC, V253, P1601, DOI 10.1001/jama.253.11.1601; BECKER TM, 1988, AM J EPIDEMIOL, V127, P1071, DOI 10.1093/oxfordjournals.aje.a114883; BLACK FL, 1970, AM J EPIDEMIOL, V91, P430, DOI 10.1093/oxfordjournals.aje.a121153; BLACK FL, 1975, SCIENCE, V187, P515, DOI 10.1126/science.163483; BLACK FL, 1974, AM J EPIDEMIOL, V100, P230, DOI 10.1093/oxfordjournals.aje.a112032; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GALLO D, 1986, J CLIN MICROBIOL, V23, P1049, DOI 10.1128/JCM.23.6.1049-1051.1986; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; GUINAN ME, 1985, EPIDEMIOL REV, V7, P127, DOI 10.1093/oxfordjournals.epirev.a036279; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; ISAGER H, 1983, ACTA PATH MICRO IM B, V91, P339; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; JOSEY WE, 1972, OBSTET GYNECOL SURV, V27, P295; KIEFF E, 1972, J VIROL, V9, P738, DOI 10.1128/JVI.9.5.738-745.1972; KJAER SK, 1990, AM J EPIDEMIOL, V131, P669, DOI 10.1093/oxfordjournals.aje.a115551; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LEE FK, 1986, J VIROL METHODS, V14, P111, DOI 10.1016/0166-0934(86)90041-8; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; LOWHAGEN GB, 1990, ACTA DERM-VENEREOL, V70, P330; MARSDEN HS, 1984, J VIROL, V50, P547, DOI 10.1128/JVI.50.2.547-554.1984; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P781, DOI 10.1056/NEJM197310112891505; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P719, DOI 10.1056/NEJM197310042891404; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P667, DOI 10.1056/NEJM197309272891305; NAHMIAS AJ, 1970, AM J EPIDEMIOL, V91, P539, DOI 10.1093/oxfordjournals.aje.a121165; OBERLE MV, 1989, AM J TROP MED HYG, V4, P224; PASQUINI P, 1988, EUR J CLIN MICROBIOL, V7, P54, DOI 10.1007/BF01962174; RAWLS WE, 1971, AM J OBSTET GYNECOL, V110, P682, DOI 10.1016/0002-9378(71)90254-7; RAWLS WE, 1981, HUMAN HERPESVIRUSES, P137; RICHMAN DD, 1986, J VIROL, V57, P647, DOI 10.1128/JVI.57.2.647-655.1986; ROIZMAN B, 1984, VIROLOGY, V133, P242, DOI 10.1016/0042-6822(84)90447-1; SANCHEZMARTINEZ D, 1991, J INFECT DIS, V164, P1196, DOI 10.1093/infdis/164.6.1196; SETH P, 1981, INDIAN J MED RES, V73, P475; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612	42	121	123	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1702	1708		10.1001/jama.268.13.1702	http://dx.doi.org/10.1001/jama.268.13.1702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1326673				2022-12-24	WOS:A1992JQ37600032
J	LEANING, MS; GALLIVAN, S; NEWLANDS, ES; DENT, J; BRAMPTON, M; SMITH, DB; BAGSHAWE, KD				LEANING, MS; GALLIVAN, S; NEWLANDS, ES; DENT, J; BRAMPTON, M; SMITH, DB; BAGSHAWE, KD			COMPUTER-SYSTEM FOR ASSISTING WITH CLINICAL INTERPRETATION OF TUMOR-MARKER DATA	BRITISH MEDICAL JOURNAL			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GERM-CELL TUMORS; HALF-LIFE; PROGNOSTIC-SIGNIFICANCE; INDUCTION CHEMOTHERAPY; OVARIAN-CARCINOMA; CANCER; CA-125; SURVIVAL	Objective-To design and evaluate a computer advisory system for the treatment of gestational trophoblastic tumour. Design-A comparison of clinicians' treatment decisions with those of the computer system. Two datasets were used: one to calibrate the system and one to independently evaluate it. Setting-Department of medical oncology. Patients-Computerised records of 290 patients with low risk gestational trophoblastic tumour for whom the advisory system could predict the adequacy of treatment. The calibration set comprised patients admitted during 1979-86 (227) and the test set patients during 1986-89 (63). Main outcome measures-The system's accuracy in predicting need to change treatment compared with clinicians' actions. The mean time faster that the system was in predicting the need to change treatment. Results-On the calibration dataset the system was 94% (164/174) accurate in predicting patients whose treatment was adequate, recommending change when none occurred in only 10 (6%) patients. In patients whose treatment was changed the system recommended change earlier than clinicians in 39/53 cases (74%), with a mean time advantage of 14.9 (SE 2.02) days. On the test dataset the system had an accuracy of 91% (31/34) in predicting treatment adequacy and a false positive rate of 9% (3/34). The system recommended change earlier than clinicians in 22/29 cases (76%), with a mean time advantage of 12.5 (2.22) days. Conclusions-The computer advisory system could improve patient management by reducing the time spent receiving ineffective treatment. This has implications for both patient time and clinical costs.	CHARING CROSS HOSP,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND	Imperial College London	LEANING, MS (corresponding author), UNIV LONDON UNIV COLL,DEPT STAT SCI,CLIN OPERAT RES UNIT,LONDON WC1E 6BT,ENGLAND.							ARMITAGE P, 1987, STATISTICAL METHODS; BAGSHAWE KD, 1989, BRIT J OBSTET GYNAEC, V96, P795, DOI 10.1111/j.1471-0528.1989.tb03318.x; BAGSHAWE KD, 1976, CANCER, V38, P1373, DOI 10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E; BARTELS C, 1987, P ECCO, P179; HAWKINS RE, 1989, BRIT J OBSTET GYNAEC, V96, P1395, DOI 10.1111/j.1471-0528.1989.tb06301.x; HUNTER VJ, 1990, AM J OBSTET GYNECOL, V163, P1164, DOI 10.1016/0002-9378(90)90680-6; LANGE PH, 1982, J UROLOGY, V128, P708, DOI 10.1016/S0022-5347(17)53149-3; PICOZZI V, 1985, P AM SOC CLIN ONCOL, V910, P102; PICOZZI VJ, 1984, ANN INTERN MED, V100, P183, DOI 10.7326/0003-4819-100-2-183; RUSTIN GJS, 1989, J CLIN ONCOL, V7, P1667, DOI 10.1200/JCO.1989.7.11.1667; TONER GC, 1990, CANCER RES, V50, P5904; VANDERBURG MEL, 1988, GYNECOL ONCOL, V30, P307, DOI 10.1016/0090-8258(88)90244-2; VOGELZANG NJ, 1982, CANCER RES, V42, P4855	13	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					804	807		10.1136/bmj.305.6857.804	http://dx.doi.org/10.1136/bmj.305.6857.804			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1330140	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JT25600021
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ZALCITABINE APPROVED FOR USE IN COMBINATION WITH ZIDOVUDINE FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, JAMA-J AM MED ASSOC, V267, P3262	1	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					705	705		10.1001/jama.268.6.705	http://dx.doi.org/10.1001/jama.268.6.705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1322467				2022-12-24	WOS:A1992JG66600005
J	FOREJT, J; GREGOROVA, S				FOREJT, J; GREGOROVA, S			GENETIC-ANALYSIS OF GENOMIC IMPRINTING - AN IMPRINTOR-1 GENE CONTROLS INACTIVATION OF THE PATERNAL COPY OF THE MOUSE TME LOCUS	CELL			English	Article								The T(hP) deletion on mouse chromosome 17 is lethal when inherited from the mother, because it deletes the T.associated maternal effect (Tme) locus, the paternal copy of which is inactivated by genomic imprinting. We have found a paternally nonimprinted Tme variant in crosses of T(hp) females with Mus m. musculus males. The data are consistent with the existence of a single Tme-unlinked gene, Imprintor-1 (Imp-1), with two alleles, one of which only causes imprinting at the Tme locus. Imp-1 is unlinked to the gene for cation-dependent Man-6-P receptor and acts prezygotically. Although Tme and Igf2r were thought to be identical, they show different patterns of imprinting in interspecies hybrids. The apparent nonequivalence of the Igf2r gene and Tme results in occurrence of viable mice lacking an active Igf2r gene. These mice are bigger at birth than their normal littermates, in accord with the proposed function of the IGF-II/Man-6-P receptor.			FOREJT, J (corresponding author), CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, VIDENSKA 1083, CS-14220 PRAGUE 4, CZECH REPUBLIC.		Forejt, Jiri/G-7719-2012; Forejt, Jiri/AAF-5276-2019	Forejt, Jiri/0000-0002-2793-3623; Forejt, Jiri/0000-0002-2793-3623				AGULNIK AI, 1991, J HERED, V82, P351, DOI 10.1093/oxfordjournals.jhered.a111099; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; ARTZT K, 1984, CELL, V39, P565, DOI 10.1016/0092-8674(84)90463-X; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CATTANACH BM, 1990, DEVELOPMENT, P63; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHANDRA HS, 1990, DEVELOPMENT, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; FOREJT J, 1988, GENET RES, V51, P111, DOI 10.1017/S0016672300024125; FOREJT J, 1980, GENET RES, V35, P165, DOI 10.1017/S0016672300014026; FOREJT J, 1991, MAMM GENOME, V1, P84, DOI 10.1007/BF02443783; FOREJT J, 1981, CURRENT TRENDS HISTO, V1, P103; GOODFELLOW P N, 1991, Current Biology, V1, P11, DOI 10.1016/0960-9822(91)90111-9; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HAIG D, 1991, PHILOS T ROY SOC B, V333, P1, DOI 10.1098/rstb.1991.0057; HAIG D, 1991, CELL, V64, P1045; HARVEY MB, 1991, DEVELOPMENT, V111, P1057; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; KIESS W, 1987, J BIOL CHEM, V262, P12745; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; Lewontin R. C., 1974, The genetic basis of evolutionary change.; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; PAVLJUKOVA H, 1981, MOUSE NEWS LETT, V65, P44; Peters JA, 1959, CLASSIC PAPERS GENET; PIRROTTA V, 1990, BIOESSAYS, V12, P409, DOI 10.1002/bies.950120903; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1990, DEVELOPMENT, P99; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; ROTH RA, 1990, KAR INS NCS, P73; RUVINSKY AO, 1990, DEV GENET, V11, P263, DOI 10.1002/dvg.1020110404; Sambrook J., 1989, MOL CLONING LAB MANU; SAPIENZA C, 1989, ANN NY ACAD SCI, V564, P24, DOI 10.1111/j.1749-6632.1989.tb25885.x; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHIMENTI J, 1987, J MOL BIOL, V194, P583, DOI 10.1016/0022-2836(87)90235-X; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SEARLE AG, 1990, GENET RES, V56, P237, DOI 10.1017/S0016672300035333; SENIOR PV, 1990, DEVELOPMENT, V109, P67; SILVER LM, 1987, MOL BIOL EVOL, V4, P473; SOLTER D, 1988, ANNU REV GENET, V22, P127; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TSAI JY, 1991, GENETICS, V129, P1159; VONDEIMLING OH, 1988, LAB ANIM-UK, V22, P61, DOI 10.1258/002367788780746610; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WASHBURN LL, 1983, NATURE, V303, P338, DOI 10.1038/303338a0; WINKING H, 1984, GENETICS, V108, P1013	65	107	107	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					443	450		10.1016/0092-8674(92)90168-C	http://dx.doi.org/10.1016/0092-8674(92)90168-C			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322799	Bronze			2022-12-24	WOS:A1992JH12400009
J	KOMURO, H; RAKIC, P				KOMURO, H; RAKIC, P			SELECTIVE ROLE OF N-TYPE CALCIUM CHANNELS IN NEURONAL MIGRATION	SCIENCE			English	Article							CEREBELLAR GRANULE CELLS; VERTEBRATE CELLS; EXPLANT CULTURES; CA2+ CHANNELS; RECEPTOR; DIFFERENTIATION; ACTIVATION; CURRENTS; DEPOLARIZATION; ASTROTACTIN	Analysis of neuronal migration in mouse cerebellar slice preparations by a laser scanning confocal microscope revealed that postmitotic granule cells initiate their migration only after the expression of N-type calcium channels on their plasmalemmal surface. Furthermore, selective blockade of these channels by addition of omega-conotoxin to the incubation medium curtailed cell movement. In contrast, inhibitors of L- and T-type calcium channels, as well as those of sodium and potassium channels, had no effect on the rate of granule cell migration. These results suggest that N-type calcium channels, which have been predominantly associated with neurotransmitter release in adult brain, also play a transient but specific developmental role in directed migration of immature neurons before the establishment of their synaptic circuits.			KOMURO, H (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA.							ANTONICEK H, 1988, J NEUROSCI, V8, P2961; ARTALEJO CR, 1992, NEURON, V8, P85, DOI 10.1016/0896-6273(92)90110-Y; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; CHUONG CM, 1990, EXPERIENTIA, V46, P892, DOI 10.1007/BF01939381; CONNOR JA, 1987, J NEUROSCI, V7, P1384; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; CULLCANDY SG, 1989, J PHYSIOL-LONDON, V414, P179, DOI 10.1113/jphysiol.1989.sp017683; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EDMONDSON JC, 1988, J CELL BIOL, V106, P505, DOI 10.1083/jcb.106.2.505; FISHELL G, 1991, DEVELOPMENT, V113, P755; FORSCHER P, 1989, TRENDS NEUROSCI, V12, P468, DOI 10.1016/0166-2236(89)90098-2; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HOCKBERGER PE, 1987, J NEUROSCI, V7, P1370; HOLLIDAY J, 1990, DEV BIOL, V141, P13, DOI 10.1016/0012-1606(90)90098-4; HORNE WA, 1991, J BIOL CHEM, V266, P13719; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KATER SB, 1991, J NEUROSCI, V11, P891; LOTURCO JJ, 1991, J NEUROSCI, V11, P792; MARCHETTI C, 1991, NEUROSCIENCE, V43, P121, DOI 10.1016/0306-4522(91)90422-K; MARTINMOUTOT N, 1990, NEUROSCI LETT, V115, P300, DOI 10.1016/0304-3940(90)90472-L; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MORAN D, 1991, AM J ANAT, V192, P14, DOI 10.1002/aja.1001920103; NEWGREEN DF, 1985, CELL TISSUE RES, V239, P329; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Rakic P, 1985, CELL CONTACT ADHESIO, P67; RAKIC P, 1988, PROG BRAIN RES, V73, P15; ROBSON SJ, 1989, NEUROSCI LETT, V104, P110, DOI 10.1016/0304-3940(89)90338-8; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SLESINGER PA, 1991, J PHYSIOL-LONDON, V435, P101, DOI 10.1113/jphysiol.1991.sp018500; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VIGERS AJ, 1991, DEV BRAIN RES, V60, P197, DOI 10.1016/0165-3806(91)90048-N; WAGNER JA, 1988, J NEUROSCI, V8, P3354	38	320	326	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					806	809		10.1126/science.1323145	http://dx.doi.org/10.1126/science.1323145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323145				2022-12-24	WOS:A1992JG85100038
J	MARTELLI, AM; GILMOUR, RS; BERTAGNOLO, V; NERI, LM; MANZOLI, L; COCCO, L				MARTELLI, AM; GILMOUR, RS; BERTAGNOLO, V; NERI, LM; MANZOLI, L; COCCO, L			NUCLEAR-LOCALIZATION AND SIGNALING ACTIVITY OF PHOSPHOINOSITIDASE-C-BETA IN SWISS 3T3 CELLS	NATURE			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; GROWTH-FACTOR; POLYPHOSPHOINOSITIDES; DIFFERENTIATION; PHOSPHORYLATION; INSULIN	THE hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdInsP2) is a widespread receptor-coupled signalling system at the plasma membrane of most eukaryotic cells. The existence of an entirely separate nuclear phosphoinositide signalling system is suggested from evidence that purified nuclei synthesize PtdInsP2 and phosphatidylinositol 4-phosphate (PtdInsP) in vitro1 and that a transient decrease in the mass of these lipids occurs when Swiss 3T3 cells are cultured in the presence of insulin-like growth factor-1 (IGF-1)2-4. These IGF-1-dependent changes in inositol lipids coincide with an increase in nuclear diacylglycerol4 and precede translocation to the nucleus and activation of protein kinase C (refs 5, 6). Circumstantial evidence that links these changes with mitosis comes from the isolation of a 3T3 clone that expresses the type-1 IGF receptor and binds IGF-1 peptide but does not respond mitogenically or show transient mass changes in nuclear inositol lipids7. A key question is how IGF-1 initiates the rapid breakdown of PtdInsP and PtdInsP2 in the nucleus. Here we present evidence that nuclei of 3T3 cells contain the beta-isozyme of phosphoinositidase C, whereas the gamma-isozyme is confined to the cytoplasm and that IGF-1 treatment stimulates exclusively the activity of nuclear phosphoinositidase C.	UNIV BOLOGNA, INST HUMAN ANAT, V IRNERIO 48, I-40126 BOLOGNA, ITALY; UNIV FERRARA, INST HUMAN ANAT, I-44100 FERRARA, ITALY; UNIV CHIETI, INST HUMAN ANAT, CHIETI, ITALY; IST RIZZOLI, CNR, INST CYTOMORPHOL, I-40136 BOLOGNA, ITALY; AFRC, INST ANIM PHYSIOL & GENET RES, CAMBRIDGE CB2 4AT, ENGLAND	University of Bologna; University of Ferrara; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			BERTAGNOLO, VALERIA/L-2864-2018; Neri, Luca Maria/AAU-1772-2021; Neri, Luca Maria/J-2462-2017; Cocco, Lucio/AAI-2206-2020	BERTAGNOLO, VALERIA/0000-0002-4742-2302; Neri, Luca Maria/0000-0002-7924-1477; Cocco, Lucio/0000-0002-9206-8277				BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P720, DOI 10.1016/0006-291X(89)90054-5; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; GARLAND RC, 1972, BIOCHEMISTRY-US, V11, P4712, DOI 10.1021/bi00775a012; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; KIM UH, 1991, J BIOL CHEM, V266, P1359; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANZOLI FA, 1989, ADV ENZYME REGUL, V28, P25; MARTELLI AM, 1991, BIOCHEM BIOPH RES CO, V177, P480, DOI 10.1016/0006-291X(91)92009-9; MARTELLI AM, 1991, FEBS LETT, V283, P243, DOI 10.1016/0014-5793(91)80598-W; MARTELLI AM, 1989, EXP CELL RES, V185, P191, DOI 10.1016/0014-4827(89)90048-7; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MICHELL R H, 1992, Current Biology, V2, P200, DOI 10.1016/0960-9822(92)90533-G; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; RYU SH, 1990, J BIOL CHEM, V265, P17941; SEYDEL U, 1991, J BIOL CHEM, V266, P7602; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THORNETJOMSLAND G, 1991, BIOL CELL, V71, P33, DOI 10.1016/0248-4900(91)90049-S; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; WU DQ, 1992, J BIOL CHEM, V267, P1811	28	327	332	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 16	1992	358	6383					242	245		10.1038/358242a0	http://dx.doi.org/10.1038/358242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1321347				2022-12-24	WOS:A1992JD58700056
J	RARICK, HM; ARTEMYEV, NO; HAMM, HE				RARICK, HM; ARTEMYEV, NO; HAMM, HE			A SITE ON ROD G-PROTEIN ALPHA-SUBUNIT THAT MEDIATES EFFECTOR ACTIVATION	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CGMP PHOSPHODIESTERASE; OUTER SEGMENTS; INHIBITORY SUBUNIT; TRANSDUCTION; CYCLASE; CASCADE; VISION; CHAIN	The heterotrimeric guanine nucleotide binding proteins (G proteins) are activated by sensory or hormone receptors. In turn, the G proteins activate effector proteins such as adenylyl cyclase, cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE), phospholipase C, and potassium and calcium ion channels by mechanisms that are poorly understood. A site on the alpha-subunit of the G protein transducin (alpha(t)) has been identified that interacts with and activates cGMP phosphodiesterase, the effector enzyme in rod photoreceptors. A 22-amino acid peptide, corresponding to residues 293 to 314 from the COOH-terminal region of alpha(t), fully mimicked alpha(t) and potently activated PDE. This region is adjacent to the receptor activation domain; thus, the alpha-subunit of this G protein has a site for interaction with both its effector and receptor that maps near the COOH-terminus.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, BOX 6998, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06062] Funding Source: Medline; NHLBI NIH HHS [T32 HL 07692-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHEE WW, 1989, J BIOL CHEM, V264, P5687; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; ITOH H, 1991, J BIOL CHEM, V266, P16226; KROLL S, 1989, J BIOL CHEM, V264, P4490; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MAY DC, 1985, J BIOL CHEM, V260, P5829; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; RARICK HM, UNPUB; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SPIEGEL AM, 1988, VITAM HORM, V44, P47; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1990, CELL SIGNAL, V2, P99, DOI 10.1016/0898-6568(90)90013-Z; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028	31	98	111	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					1031	1033		10.1126/science.1317058	http://dx.doi.org/10.1126/science.1317058			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1317058				2022-12-24	WOS:A1992HU22400042
J	MACKIE, R; HUNTER, JAA; AITCHISON, TC; HOLE, D; MCLAREN, K; RANKIN, R; BLESSING, K; EVANS, AT; HUTCHEON, AW; JONES, DH; SOUTAR, DS; WATSON, ACH; CORNBLEET, MA; SMYTH, JF				MACKIE, R; HUNTER, JAA; AITCHISON, TC; HOLE, D; MCLAREN, K; RANKIN, R; BLESSING, K; EVANS, AT; HUTCHEON, AW; JONES, DH; SOUTAR, DS; WATSON, ACH; CORNBLEET, MA; SMYTH, JF			CUTANEOUS MALIGNANT-MELANOMA, SCOTLAND, 1979-89	LANCET			English	Article								The Scottish Melanoma Group (SMG) was established in 1979 to assess mortality from and incidence, features, pathological data, and management of cutaneous malignant melanoma in Scotland. Incidence during the first five years and five-year survival have already been reported. We now have data about incidence and mortality over eleven years in relation to anatomical site and pathological types. From 1979 to 1989, 1354 male and 2459 female patients with primary cutaneous malignant melanomas were first diagnosed in Scottish residents. The incidence rate per 100 000 population per year has increased from 3.4 in 1979 to 7.1 in 1989 for men, and from 6.6 to 10.4 for women. The overall increase over eleven years is 82% (7.4% per year). The greatest rates of increase are seen in lesions of the superficial spreading histogenetic type, arising on the female leg and the male trunk. Following public education programmes started in 1985, the proportion of all melanomas less than 1.5 mm thick has shown a sustained and significant increase. Mortality data for 1661 patients for whom a minimum of five-year follow-up is available shows five-year survival of 71.6% overall (77.6% for women, 58.7% for men). The survival advantage for women persists when appropriate statistical adjustment is made for thickness, ulceration, and histogenetic type. These data are useful in designing public education programmes aimed at both primary and secondary prevention of melanoma and in auditing changes in trends that might result from such education.	UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,SCOTLAND; UNIV EDINBURGH,DEPT DERMATOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT ONCOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW,SCOTLAND; RAIGMORE HOSP,DEPT PATHOL,INVERNESS,SCOTLAND; RAIGMORE HOSP,DEPT DERMATOL,INVERNESS,SCOTLAND; UNIV ABERDEEN,DEPT PATHOL,ABERDEEN AB9 1FX,SCOTLAND; NINEWELLS HOSP,DEPT PATHOL,DUNDEE,SCOTLAND; ABERDEEN ROYAL INFIRM,DEPT ONCOL,ABERDEEN AB9 2ZB,SCOTLAND; CANNIESBURN HOSP,DEPT PLAST SURG,GLASGOW G61 1QL,SCOTLAND	University of Glasgow; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Aberdeen; University of Dundee; University of Aberdeen	MACKIE, R (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND.							ACKERMAN AB, 1980, HUM PATHOL, V11, P591, DOI 10.1016/S0046-8177(80)80069-4; CLARK WH, 1969, CANCER RES, V29, P705; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; DOHERTY VR, 1986, BRIT MED J, V292, P987, DOI 10.1136/bmj.292.6526.987; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; MACKIE RM, 1985, LANCET, V2, P859; MACKIE RM, IN PRESS BR MED J; MAGNUS K, 1991, INT J CANCER, V47, P12, DOI 10.1002/ijc.2910470104; OSTERLIND A, 1988, APMIS, V96, P953, DOI 10.1111/j.1699-0463.1988.tb00968.x	10	145	146	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					971	975		10.1016/0140-6736(92)91539-K	http://dx.doi.org/10.1016/0140-6736(92)91539-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348807				2022-12-24	WOS:A1992HP03600012
J	PELES, E; BACUS, SS; KOSKI, RA; LU, HS; WEN, DZ; OGDEN, SG; BENLEVY, R; YARDEN, Y				PELES, E; BACUS, SS; KOSKI, RA; LU, HS; WEN, DZ; OGDEN, SG; BENLEVY, R; YARDEN, Y			ISOLATION OF THE NEU/HER-2 STIMULATORY LIGAND - A 44KD GLYCOPROTEIN THAT INDUCES DIFFERENTIATION OF MAMMARY-TUMOR CELLS	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CARCINOMA; FACTOR-RECEPTOR; PROTO-ONCOGENE; NEU ONCOGENE; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; C-ERBB-2 ONCOGENE; LIVING CELLS; GENE	The neu/HER-2 proto-oncogene (also called erbB-2) encodes a transmembrane glycoprotein related to the epidermal growth factor receptor. We have purified to homogeneity a 44 kd glycoprotein from the medium of ras-transformed cells that stimulates phosphorylation of the Neu protein and retains activity after elution from the polyacrylamide gel. The protein is active at picomolar concentrations and displays a novel N-terminal sequence. Cross-linking experiments with radiolabeled p44 result in specific labeling of Neu, indicating that p44 is a ligand for Neu or a related receptor. The purified protein induces phenotypic differentiation of cultured human breast cancer cells, including altered morphology and synthesis of milk components. This is accompanied by an increase in nuclear area, inhibition of cell growth (probably by cell cycle arrest at the late S or the G2/M phases), and induction of DNA polyploidy. We propose the name Neu differentiation factor (NDF) for p44.	CELL ANAL SYST INC,ELMHURST,IL 60126; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Amgen	PELES, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		YARDEN, YOSEF/K-1467-2012	Peles, Elior/0000-0002-3325-0597	NATIONAL CANCER INSTITUTE [R43CA050843, R44CA050843, R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51712, CA-50843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1992, IN PRESS CANCER RES; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HUANG SS, 1990, J BIOL CHEM, V265, P3340; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNKAPILLER MW, 1986, MICROCHARACTERIZATIO, P223; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KING CR, 1989, ONCOGENE, V4, P13; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1981, CANCER RES, V41, P2842; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAVERNA D, 1991, GROWTH DIFF, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TSUDA H, 1989, CANCER RES, V49, P3104; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P67; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YARDEN Y, 1990, MOL IMMUNOL, V27, P1319, DOI 10.1016/0161-5890(90)90037-Z; ZHOU DJ, 1987, CANCER RES, V47, P6123	62	526	566	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					205	216		10.1016/0092-8674(92)90131-U	http://dx.doi.org/10.1016/0092-8674(92)90131-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348215				2022-12-24	WOS:A1992HM44500019
J	ROTH, DB; NAKAJIMA, PB; MENETSKI, JP; BOSMA, MJ; GELLERT, M				ROTH, DB; NAKAJIMA, PB; MENETSKI, JP; BOSMA, MJ; GELLERT, M			V(D)J RECOMBINATION IN MOUSE THYMOCYTES - DOUBLE-STRAND BREAKS NEAR T-CELL RECEPTOR DELTA REARRANGEMENT SIGNALS	CELL			English	Article							GAMMA-DELTA; SACCHAROMYCES-CEREVISIAE; IMMUNOGLOBULIN GENES; HOMOLOGOUS RECOMBINATION; SEQUENCE HOMOLOGIES; CODING SEGMENTS; MAMMALIAN-CELLS; DNA; GENERATION; MECHANISM	In the murine T cell receptor delta-locus, V(D)J recombination events frequently involve the D2 and J1 elements. Here we report the presence of double-strand breaks at recombination signals flanking D2 in approximately 2% of thymus DNA. An excised linear species containing the sequences between D2 and J1 and a circular product of the joining of D2 and J1 recombination signals were also found. Although broken molecules with signal ends were detected, no species with coding ends could be identified. Observation of these broken molecules in thymus, but not in liver or spleen, provides the first direct evidence for an association between specific cleavage of chromosomal DNA and recombination in mammalian cells, and supports a breakage-reunion model of V(D)J recombination.	FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center	ROTH, DB (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NCI NIH HHS [CA-04946] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NIAID NIH HHS [AI-13323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA004946, R01CA004946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DESIDERIO S, 1984, NATURE, V308, P860, DOI 10.1038/308860a0; ELLIOTT JF, 1988, NATURE, V331, P627; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HANIFORD DB, 1991, CELL, V64, P171; HENDRICKSON EA, 1988, GENE DEV, V2, P817, DOI 10.1101/gad.2.7.817; HENDRICKSON EA, 1991, MOL CELL BIOL, V11, P3155, DOI 10.1128/MCB.11.6.3155; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KATAOKA T, 1984, NUCLEIC ACIDS RES, V12, P5995, DOI 10.1093/nar/12.15.5995; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS S, 1985, SCIENCE, V228, P677, DOI 10.1126/science.3158075; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARYON E, 1991, MOL CELL BIOL, V11, P3268, DOI 10.1128/MCB.11.6.3268; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; RAVEH D, 1989, MOL GEN GENET, V220, P33; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; THOMPSON SD, 1991, EUR J IMMUNOL, V21, P1939, DOI 10.1002/eji.1830210824; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WAKE CT, 1985, MOL CELL BIOL, V5, P2080, DOI 10.1128/MCB.5.8.2080; WELLS FB, 1991, SCIENCE, V253, P903, DOI 10.1126/science.1831565; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WINOTO A, 1989, NATURE, V338, P430, DOI 10.1038/338430a0	64	173	173	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					41	53		10.1016/0092-8674(92)90117-U	http://dx.doi.org/10.1016/0092-8674(92)90117-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313336				2022-12-24	WOS:A1992HM44500005
J	DRESSLER, KA; MATHIAS, S; KOLESNICK, RN				DRESSLER, KA; MATHIAS, S; KOLESNICK, RN			TUMOR-NECROSIS-FACTOR-ALPHA ACTIVATES THE SPHINGOMYELIN SIGNAL TRANSDUCTION PATHWAY IN A CELL-FREE SYSTEM	SCIENCE			English	Article							PROTEIN-KINASE-C; LEUKEMIC HL-60 CELLS; GH3 PITUITARY-CELLS; LONG-CHAIN BASES; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; CERAMIDE KINASE; PHORBOL ESTERS; INHIBITION	The mechanism of tumor necrosis factor (TNF)-alpha signaling is unknown. TNF-alpha-signaling may involve sphingomyelin hydrolysis to ceramide by a sphingomyelinase and stimulation of a ceramide-activated protein kinase. In a cell-free system, TNF-alpha-induced a rapid reduction in membrane sphingomyelin content and a quantitative elevation in ceramide concentrations. Ceramide-activated protein kinase activity also increased. Kinase activation was mimicked by addition of sphingomyelinase but not by phospholipases A2, C, or D. Reconstitution of this cascade in a cell-free system demonstrates tight coupling to the receptor, suggesting this is a signal transduction pathway for TNF-alpha.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014207] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1-CA-42385] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM14207-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P28; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1991, J BIOL CHEM, V266, P11522; ENGELMANN H, 1990, J BIOL CHEM, V265, P13397; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HALL FL, 1991, J BIOL CHEM, V266, P17430; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, UNPUB; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P1823; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAO BG, 1976, J LIPID RES, V17, P506; RYFFEL B, 1991, AM J PATHOL, V139, P7; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SLIFE CW, 1989, J BIOL CHEM, V264, P1; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WILSON E, 1986, J BIOL CHEM, V261, P2616	42	446	465	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1715	1718		10.1126/science.1313189	http://dx.doi.org/10.1126/science.1313189			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1313189				2022-12-24	WOS:A1992HK81200042
J	JOE, EH; ANGELIDES, K				JOE, EH; ANGELIDES, K			CLUSTERING OF VOLTAGE-DEPENDENT SODIUM-CHANNELS ON AXONS DEPENDS ON SCHWANN-CELL CONTACT	NATURE			English	Article							RAT SPINAL-CORD; FREEZE-FRACTURE; MYELIN FORMATION; BASAL LAMINA; PERIPHERAL-NERVE; MEMBRANE; RANVIER; DIFFERENTIATION; INVITRO; FIBERS	IN myelinated nerves, segregation of voltage-dependent sodium channels to nodes of Ranvier is crucial for saltatory conduction along axons 1-4. As sodium channels associate 5 and colocalize with ankyrin at nodes of Ranvier 6, one possibility is that sodium channels are recruited and immobilized at axonal sites which are specified by the subaxolemmal cytoskeleton, independent of glial cell contact 7-10. Alternatively, segregation of channels at distinct sites along the axon may depend on glial cell contact 11-14. To resolve this question, we have examined the distribution of sodium channels, ankyrin and spectrin in myelination-competent cocultures of sensory neurons and Schwann cells by immunofluorescence, using sodium channel-, ankyrin- and spectrin-specific antibodies. In the absence of Schwann cells, sodium channels, ankyrin and spectrin are homogeneously distributed on sensory axons. When Schwann cells are introduced into these cultures, the distribution of sodium channels dramatically changes so that channel clusters on axons are abundant, but ankyrin and spectrin remain homogeneously distributed. Addition of latex beads or Schwann cell membranes does not induce channel clustering. Our results suggest that segregation of sodium channels on axons is highly dependent on interactions with active Schwann cells and that continuing axon-glial interactions are necessary to organize and maintain channel distribution during differentiation of myelinated axons.	BAYLOR COLL MED,DEPT BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	JOE, EH (corresponding author), BAYLOR COLL MED,DEPT MOLEC BIOPHYS,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; BIGBEE JW, 1989, BRAIN RES, V494, P182, DOI 10.1016/0006-8993(89)90161-3; BLACK JA, 1985, J NEUROCYTOL, V14, P79, DOI 10.1007/BF01150264; BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; BLACK JA, 1986, J NEUROCYTOL, V15, P745, DOI 10.1007/BF01625192; BLACK JA, 1981, J NEUROCYTOL, V10, P981, DOI 10.1007/BF01258525; BLACK JA, 1985, J NEUROCYTOL, V14, P887, DOI 10.1007/BF01224803; BOSTOCK H, 1978, J PHYSIOL-LONDON, V280, P273, DOI 10.1113/jphysiol.1978.sp012384; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CLARK MB, 1989, DEV BIOL, V133, P393, DOI 10.1016/0012-1606(89)90043-2; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; ELLISMAN MH, 1979, J NEUROCYTOL, V8, P719, DOI 10.1007/BF01206672; ELMER LW, 1990, BRAIN RES, V532, P222, DOI 10.1016/0006-8993(90)91763-7; FOSTER RE, 1980, SCIENCE, V210, P661, DOI 10.1126/science.6159685; FROEHNER SC, 1991, J CELL BIOL, V113, P1133; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; LEBEAU JM, 1987, J NEUROCYTOL, V16, P347, DOI 10.1007/BF01611346; OWENS GC, 1989, GLIA, V2, P119, DOI 10.1002/glia.440020208; RANSCHT B, 1987, J NEUROSCI, V7, P2936; RASMINSKY M, 1972, J PHYSIOL-LONDON, V227, P323, DOI 10.1113/jphysiol.1972.sp010035; RATNER N, 1984, J CELL BIOL, V98, P1150, DOI 10.1083/jcb.98.3.1150; REIGER F, 1986, J CELL BIOL, V103, P379; ROSENBLUTH J, 1984, NEUROSCI LETT, V48, P171, DOI 10.1016/0304-3940(84)90015-6; ROSENBLUTH J, 1979, J NEUROCYTOL, V8, P655, DOI 10.1007/BF01208515; ROSENBLUTH J, 1988, INT J DEV NEUROSCI, V6, P3, DOI 10.1016/0736-5748(88)90025-1; SMITH KJ, 1982, J NEUROL SCI, V54, P3; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; WAXMAN SG, 1985, SCIENCE, V228, P1502, DOI 10.1126/science.2409596; WAXMAN SG, 1980, PROC R SOC SER B-BIO, V209, P441, DOI 10.1098/rspb.1980.0105; WILEY CA, 1980, J CELL BIOL, V84, P261, DOI 10.1083/jcb.84.2.261; WILEYLIVINGSTON CA, 1980, DEV BIOL, V79, P334, DOI 10.1016/0012-1606(80)90120-7; WOOD PM, 1990, J NEUROSCI, V10, P3635	33	66	66	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					333	335		10.1038/356333a0	http://dx.doi.org/10.1038/356333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312680				2022-12-24	WOS:A1992HK79400062
J	EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B				EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B			INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS	LANCET			English	Article							HEMOPHILIA-A; CLASSIC HEMOPHILIA; LIFE EXPECTANCY; UNITED-KINGDOM; ANTIBODIES; FINLAND	The development of factor VIII:C inhibitors remains one of the most serious complications of repeated transfusion in patients with haemophilia A. The proportion of patients affected has been reported to range from 3.6% to 25%, but these figures have been derived mainly from retrospective data and from total numbers of known haemophiliacs instead of number at true risk. The assessment here is based on a prospective study, started in 1976, on the incidence of inhibitor development in haemophiliacs born after 1970 whose FVIII or FIX activity was 5% or less, and who had received replacement therapy at least once. 46 of 63 children with haemophilia A and 13 of 17 with haemophilia B fulfilled the enrolment criteria. Inhibitors developed only in haemophilia A patients who had previously been treated with FVIII products-inhibitor concentrations were high in 12 and low in 3. Inhibitors developed in 24% (15/63) of all haemophilia A patients, and in 52% (14/27) of those with severe disease. The incidence of inhibitor development for all haemophilia patients was 39.1 per 1000 patient-years of observation. All inhibitors were first detected when patients were aged 0.08-5.2 years. The cumulative risk was 33% at age 6 years. The findings indicate that previous reports have underestimated the risk of acquiring FVIII inhibitors. Prospective, standardised studies, especially in children, are needed for the assessment of the true risk of this complication.	UNIV HOSP FRANKFURT, DEPT ANGIOL, CTR INTERNAL MED, FRANKFURT, GERMANY	Goethe University Frankfurt; Goethe University Frankfurt Hospital	EHRENFORTH, S (corresponding author), UNIV HOSP FRANKFURT, DEPT HAEMATOL & ONCOL, CTR PAEDIAT, THEODOR STERN KAI 7, W-6000 FRANKFURT, GERMANY.		Scharrer, Inge/N-2999-2013	Gungor, Tayfun/0000-0002-3261-1186				ALLAIN JP, 1976, BLOOD, V47, P973; BIGGS R, 1974, BRIT J HAEMATOL, V26, P313, DOI 10.1111/j.1365-2141.1974.tb00476.x; BLOOM AL, 1991, THROMB HAEMOSTASIS, V66, P166; BRINKHOUS KM, 1972, THROMB DIATH HAEMO, V51, P315; Gill FM, 1984, FACTOR 8 INHIBITORS, P19; IKKALA E, 1982, BRIT J HAEMATOL, V52, P7, DOI 10.1111/j.1365-2141.1982.tb03856.x; IKKALA E, 1971, SCAND J HAEMATOL, V8, P16; KASPER CK, 1973, THROMB DIATH HAEMOST, V30, P263, DOI 10.1055/s-0038-1649073; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KESTEVEN PJ, 1984, THROMB HAEMOSTASIS, V52, P50; KREUZ W, 1991, ANN HEMATOL, V62, pA46; LANGDELL RD, 1953, J LAB CLIN MED, V41, P637; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; MCMILLAN CW, 1988, BLOOD, V71, P344; RASI V, 1990, BRIT J HAEMATOL, V76, P369, DOI 10.1111/j.1365-2141.1990.tb06370.x; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; RUGGERI ZM, 1977, WORKSHOP INHIBITORS, P45; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SCHWARZINGER I, 1987, AM J HEMATOL, V24, P241, DOI 10.1002/ajh.2830240303; SEREMETIS S, 1991, THROMB HAEMOSTASIS, V65, P1160; SHAPIRO S S, 1975, Seminars in Thrombosis and Hemostasis, V1, P336; SHAPIRO SS, 1984, SCAND J HAEMATOL, V33, P181; SHAPIRO SS, 1979, CLIN HAEMATOL, V8, P207; STENBJERG S, 1984, THROMB RES, V34, P533, DOI 10.1016/0049-3848(84)90257-3; STRAUSS HS, 1969, NEW ENGL J MED, V281, P866, DOI 10.1056/NEJM196910162811603	26	517	527	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					594	598		10.1016/0140-6736(92)90874-3	http://dx.doi.org/10.1016/0140-6736(92)90874-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347102				2022-12-24	WOS:A1992HH07500012
J	ANTHONYCAHILL, SJ; BENFIELD, PA; FAIRMAN, R; WASSERMAN, ZR; BRENNER, SL; STAFFORD, WF; ALTENBACH, C; HUBBELL, WL; DEGRADO, WF				ANTHONYCAHILL, SJ; BENFIELD, PA; FAIRMAN, R; WASSERMAN, ZR; BRENNER, SL; STAFFORD, WF; ALTENBACH, C; HUBBELL, WL; DEGRADO, WF			MOLECULAR CHARACTERIZATION OF HELIX-LOOP-HELIX PEPTIDES	SCIENCE			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATOR; COILED-COIL; PROTEIN; MOTIF; MYOD; RECOGNITION; ENHANCER; DIMERIZATION	A class of regulators of eukaryotic gene expression contains a conserved amino acid sequence responsible for protein oligomerization and binding to DNA. This structure consists of an arginine- and lysine-rich basic region followed by a helix-loop-helix motif, which together mediate specific binding to DNA. Peptides were prepared that span this motif in the MyoD protein; in solution, they formed alpha-helical dimers and tetramers. They bound to DNA as dimers and their alpha-helical content increased on binding. Parallel and antiparallel four-helix models of the DNA-bound dimer were constructed. Peptides containing disulfide bonds were engineered to test the correctness of the two models. A disulfide that is compatible with the parallel model promotes specific interaction with DNA, whereas a disulfide compatible with the antiparallel model abolishes specific binding. Electron paramagnetic resonance (EPR) measurements of nitroxide-labeled peptides provided intersubunit distance measurements that also supported the parallel model.	DUPONT MERCK PHARMACEUT CO, DEPT BIOTECHNOL, POB 80328, WILMINGTON, DE 19880 USA; BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	DuPont; Boston Biomedical Research Institute; University of California System; University of California Los Angeles			Stafford, Walter/ABC-6553-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014321, F32GM013731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14321, GM13731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BRUCCOLERI RE, 1986, BIOPHYS J, V49, P79, DOI 10.1016/S0006-3495(86)83601-3; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEGRADO WF, 1985, J AM CHEM SOC, V107, P7685; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HODGES R S, 1990, Peptide Research, V3, P123; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STAROVASNIK MA, 1991, 5TH S PROT SOC BALT; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TUDOS E, 1990, INT J PEPT PROT RES, V36, P236; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	38	154	155	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					979	983		10.1126/science.1312255	http://dx.doi.org/10.1126/science.1312255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1312255				2022-12-24	WOS:A1992HE60500039
J	LUCKHOFF, A; CLAPHAM, DE				LUCKHOFF, A; CLAPHAM, DE			INOSITOL 1,3,4,5-TETRAKISPHOSPHATE ACTIVATES AN ENDOTHELIAL CA2+-PERMEABLE CHANNEL	NATURE			English	Article							CALCIUM INFLUX; ADENINE-NUCLEOTIDES; CYTOSOLIC CALCIUM; IONIC CURRENTS; MAST-CELLS; 1,4,5-TRISPHOSPHATE; STIMULATION; RELEASE; CA-2+; ENTRY	RECEPTOR-MEDIATED increases in the cytosolic free calcium ion concentration in most mammalian cells result from mobilization of Ca2+ from intracellular stores as well as transmembrane Ca2+ influx. Inositol 1,4,5-trisphosphate (InsP3) releases calcium from intracellular stores 1 by opening a Ca2+-permeable channel in the endoplasmic reticulum 2-4. But the mechanism and regulation of Ca2+ entry into nonexcitable cells has remained elusive because the entry pathway has not been defined. Here we characterize a novel inositol 1,3,4,5-tetrakisphosphate (InsP4) and Ca2+-sensitive Ca2+-permeable channel in endothelial cells. We find that InsP4, which induces Ca2+ influx into acinar cells 5,6, enhances the activity of the Ca2+-permeable channel when exposed to the intracellular surface of endothelial cell inside-out patches. Our results suggest a molecular mechanism which is likely to be important for receptor-mediated Ca2+ entry.			LUCKHOFF, A (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA.		Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; COLDENSTANFIELD M, 1987, CIRC RES, V61, P632, DOI 10.1161/01.RES.61.5.632; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; LUCKHOFF A, 1986, J CELL PHYSIOL, V126, P414, DOI 10.1002/jcp.1041260312; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NILIUS B, 1991, NEWS PHYSIOL SCI, V6, P110; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; SCHILLING WP, 1989, AM J PHYSIOL, V257, pH778, DOI 10.1152/ajpheart.1989.257.3.H778; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0	29	413	413	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					356	358		10.1038/355356a0	http://dx.doi.org/10.1038/355356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309941				2022-12-24	WOS:A1992HA59100070
J	CHEN, LP; ASHE, S; BRADY, WA; HELLSTROM, I; HELLSTROM, KE; LEDBETTER, JA; MCGOWAN, P; LINSLEY, PS				CHEN, LP; ASHE, S; BRADY, WA; HELLSTROM, I; HELLSTROM, KE; LEDBETTER, JA; MCGOWAN, P; LINSLEY, PS			COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-CELLS; INTERLEUKIN-2 PRODUCTION; GENE-TRANSFER; ANTIGEN; ACTIVATION; RECEPTOR; SIGNAL; TUMORIGENICITY; RECOGNITION	Interaction of the B7 molecule on antigen-presenting cells with its receptors CD28 and CTLA-4 on T cells provides costimulatory signals for T cell activation. We have studied the effects of B7 on antitumor immunity to a murine melanoma that expresses a rejection antigen associated with the E7 gene product of human papillomavirus 16. While this E7+ tumor grows progressively in immunocompetent hosts, cotransfection of its cells with B7 led to tumor regression by a B7-dependent immune response mediated by CD8+ cytolytic T lymphocytes. The immune response induced by E7+B7+ tumor cells also caused regression of E7+B7-tumors at distant sites and was curative for established E7+B7- micrometastases. Our findings suggest that increasing T cell costimulation through the CD28 and CTLA-4 receptors may have therapeutic usefulness for generating immunity against tumors expressing viral antigens.			CHEN, LP (corresponding author), BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA.							AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1992, J IMMUNOL, V149, P1115; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOON T, 1992, ADV CANCER RES, V58, P177, DOI 10.1016/S0065-230X(08)60295-X; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CHEN L, 1992, J IMMUNOL, V148, P2617; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; DAMLE NK, 1992, J IMMUNOL, V148, P1985; ELLIOTT BE, 1989, ADV CANCER RES, V53, P181; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FELL HP, 1992, J BIOL CHEM, V267, P15552; FIDLER IJ, 1981, CANCER RES, V41, P3266; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hellstrom K., 1991, BIOL THERAPY CANCER, P35; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JANEWAY CA, 1989, COLD SH Q B, V54, P1; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNG G, 1987, P NATL ACAD SCI USA, V84, P4611, DOI 10.1073/pnas.84.13.4611; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LEY V, 1991, EUR J IMMUNOL, V21, P851, DOI 10.1002/eji.1830210350; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NIJHUIS EWP, 1990, CANCER IMMUNOL IMMUN, V32, P245, DOI 10.1007/BF01741708; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; TAN R, 1992, IN PRESS J IMMUNOL; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P	52	1038	1157	5	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1093	1102		10.1016/S0092-8674(05)80059-5	http://dx.doi.org/10.1016/S0092-8674(05)80059-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335364				2022-12-24	WOS:A1992KE60400005
J	PORCELLI, S; MORITA, CT; BRENNER, MB				PORCELLI, S; MORITA, CT; BRENNER, MB			CD1B RESTRICTS THE RESPONSE OF HUMAN CD4-8- LYMPHOCYTES-T TO A MICROBIAL ANTIGEN	NATURE			English	Article							GAMMA-DELTA CELLS; HLA CLASS-I; MONOCLONAL-ANTIBODIES; RECOGNITION; GENES; EXPRESSION; RECEPTOR; DIFFERENTIATION; THYMOCYTES; MOLECULES	MOLECULES encoded by the human CD1 locus on chromosome 1 (ref. 33) are recognized by selected CD4-8- T-cell clones expressing either alphabeta or gammadelta T-cell antigen receptors1,2. The known structural resemblance of CD1 molecules to antigen-presenting molecules encoded by major histocompatibility complex (MHC) genes on human chromosome 6 (refs 3, 4, 34, 35), suggested that CD1 may represent a family of antigen-presenting molecules separate from those encoded in the MHC1,5,6. Here we report that the proliferative and cytotoxic responses of human CD4-8-alphabetaTCR+ T cells specific for Mycobacterium tuberculosis can be restricted by CD1b, one of the four identified protein products of the CD1 locus. The responses of these T cells to M. tuberculosis seemed not to involve MHC encoded molecules, but were absolutely dependent on the expression of CD1b by the antigen-presenting cell and involved an antigen processing requirement similar to that seen in MHC class II-restricted antigen presentation. These results provide, to our knowledge, the first direct evidence for the proposed antigen-presenting function of CD1 molecules and suggest that the CD1 family plays a role in cell-mediated immunity to microbial pathogens.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	PORCELLI, S (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.		Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294				ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ANEGON I, 1991, J IMMUNOL, V147, P3973; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BLUESTONE JA, 1989, J IMMUNOL, V142, P1785; BOUMSELL L, 1989, LEUCOCYTE TYPING, V4, P251; BRODSKY FM, 1982, J IMMUNOL, V128, P129; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHESNUT RW, 1982, J IMMUNOL, V129, P2382; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FAVALORO EJ, 1986, DIS MARKERS, V4, P261; GLIMCHER LH, 1982, J EXP MED, V156, P640, DOI 10.1084/jem.156.2.640; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; LANIER LL, 1987, LEUKOCYTE TYPING, V3, P175; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; OLIVE D, 1984, IMMUNOGENETICS, V20, P253, DOI 10.1007/BF00364207; PANCHAMOORTHY G, 1991, J IMMUNOL, V147, P3360; PARHAM P, 1992, NATURE, V357, P193, DOI 10.1038/357193a0; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RONCAROLO MG, 1991, J IMMUNOL, V147, P781; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SHAW S, 1985, HUM IMMUNOL, V12, P191, DOI 10.1016/0198-8859(85)90336-2; SHIUE L, 1988, J EXP MED, V168, P1993, DOI 10.1084/jem.168.6.1993; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZENMOUR J, 1992, J IMMUNOL, V148, P1941; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	35	533	541	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					593	597		10.1038/360593a0	http://dx.doi.org/10.1038/360593a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1281285				2022-12-24	WOS:A1992KB95900088
J	YU, HT; ROSEN, MK; SHIN, TB; SEIDELDUGAN, C; BRUGGE, JS; SCHREIBER, SL				YU, HT; ROSEN, MK; SHIN, TB; SEIDELDUGAN, C; BRUGGE, JS; SCHREIBER, SL			SOLUTION STRUCTURE OF THE SH3 DOMAIN OF SRC AND IDENTIFICATION OF ITS LIGAND-BINDING SITE	SCIENCE			English	Article							COHERENCE TRANSFER SPECTROSCOPY; 3-DIMENSIONAL NMR-SPECTROSCOPY; MULTIPLE-QUANTUM COHERENCE; PROTEINS; SPECTRA; SIMPLIFICATION; ASSIGNMENTS; RECEPTOR; SYSTEMS; YEAST	The Src homology 3 (SH3) region is a protein domain of 55 to 75 amino acids found in many cytoplasmic proteins, including those that participate in signal transduction pathways. The solution structure of the SH3 domain of the tyrosine kinase Src was determined by multidimensional nuclear magnetic resonance methods. The molecule is composed of two short three-stranded anti-parallel beta sheets packed together at approximately right angles. Studies of the SH3 domain bound to proline-rich peptide ligands revealed a hydrophobic binding site on the surface of the protein that is lined with the side chains of conserved aromatic amino acids.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139	Harvard University; Takeda Pharmaceutical Company Ltd; Takeda Oncology				Yu, Hongtao/0000-0002-8861-049X	NATIONAL CANCER INSTITUTE [R37CA027951, R01CA027951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER; NCI NIH HHS [CA27951] Funding Source: Medline; NCRR NIH HHS [1-S10-RR04870] Funding Source: Medline; NIGMS NIH HHS [GM44993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; BAX A, 1981, J MAGN RESON, V43, P478, DOI 10.1016/0022-2364(81)90060-3; BOLTON PH, 1982, CHEM PHYS LETT, V89, P139, DOI 10.1016/0009-2614(82)83390-3; BOLTON PH, 1982, J MAGN RESON, V48, P336, DOI 10.1016/0022-2364(82)90288-8; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, XPLOR MANUAL; BRUNGER AT, 1992, XPLOR MANUAL 5 3 0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOYAMA S, UNPUB; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER B, COMMUNICATION; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMUTH SP, 1989, MOL CELL BIOL, V9, P1109; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PATTERSON Y, 1990, SCIENCE, V249, P755; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Potts W M, 1988, Oncogene Res, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; WAGNER G, 1983, J MAGN RESON, V55, P151, DOI 10.1016/0022-2364(83)90284-6; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZY, UNPUB; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	43	306	317	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1665	1668		10.1126/science.1280858	http://dx.doi.org/10.1126/science.1280858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1280858				2022-12-24	WOS:A1992KA89600042
J	AUVINEN, M; PAASINEN, A; ANDERSSON, LC; HOLTTA, E				AUVINEN, M; PAASINEN, A; ANDERSSON, LC; HOLTTA, E			ORNITHINE DECARBOXYLASE ACTIVITY IS CRITICAL FOR CELL-TRANSFORMATION	NATURE			English	Article							ROUS-SARCOMA VIRUS; POLYAMINE METABOLISM; GENE-EXPRESSION; TYROSINE; GROWTH; PHOSPHORYLATION; AMPLIFICATION; INDUCTION; KINASES; DNA	THE enzyme ornithine decarboxylase is the key regulator of the synthesis of polyamines1-3 which are essential for cell proliferation4,5. Expression of this enzyme is transiently increased upon stimulation by growth factors1-3, but becomes constitutively activated during cell transformation induced by carcinogens6,7, viruses8-10 or oncogenes11-14. To test whether ornithine decarboxylase could be a common mediator of transformation and oncogenic itself, we transfected NIH3T3 cells with expression vectors carrying the complementary DNA encoding human ornithine decarboxylase in sense and antisense orientations. The increased expression of the enzyme (50-100-times endogenous levels) induced not only cell transformation, but also anchorage-independent growth in soft agar and increased tyrosine phosphorylation of a protein of M(r) 130K. Expression of ornithine decarboxylase antisense RNA was associated with an epithelioid morphology and reduced cell proliferation. Moreover, blocking the endogenous enzyme using specific inhibitor or synthesizing antisense RNA prevented transformation of rat fibroblasts by temperature-sensitive v-src oncogene. Our results imply that the gene encoding ornithine decarboxylase is a proto-oncogene central for regulation of cell growth and transformation.	UNIV HELSINKI,DEPT PATHOL,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki								BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; CHANG BK, 1988, BIOCHEM BIOPH RES CO, V157, P264, DOI 10.1016/S0006-291X(88)80042-1; DON S, 1975, CANCER RES, V35, P3618; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSON RL, 1980, J CELL BIOL, V87, P319, DOI 10.1083/jcb.87.2.319; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; GILMOUR SK, 1987, CANCER RES, V47, P1221; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HADDOX MK, 1980, CANCER RES, V40, P604; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; JANNE OA, 1984, ANN NY ACAD SCI, V438, P72, DOI 10.1111/j.1749-6632.1984.tb38277.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KATZ A, 1989, EMBO J, V8, P1163, DOI 10.1002/j.1460-2075.1989.tb03487.x; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; POHJANPELTO P, 1981, NATURE, V293, P475, DOI 10.1038/293475a0; Sambrook J., 1989, MOL CLONING LAB MANU; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEILER N, 1990, CANCER RES, V50, P5077; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TONIN PN, 1989, ONCOGENE, V4, P1117; YUSPA SH, 1976, NATURE, V262, P402, DOI 10.1038/262402a0	34	640	657	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					355	358		10.1038/360355a0	http://dx.doi.org/10.1038/360355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280331				2022-12-24	WOS:A1992JZ63000055
J	TORNOS, MP; PERMANYERMIRALDA, G; OLONA, M; GIL, M; GALVE, E; ALMIRANTE, B; SOLERSOLER, J				TORNOS, MP; PERMANYERMIRALDA, G; OLONA, M; GIL, M; GALVE, E; ALMIRANTE, B; SOLERSOLER, J			LONG-TERM COMPLICATIONS OF NATIVE VALVE INFECTIVE ENDOCARDITIS IN NONADDICTS - A 15-YEAR FOLLOW-UP-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOCARDITIS; HEART VALVE DISEASE; AORTIC VALVE; DEATH, SUDDEN, CARDIAC; HEART VALVE PROSTHESIS	DISEASE	Objective: To describe the incidence and clinical manifestations of long-term cardiac complications of endocarditis. Design: Cohort study. Setting: University-affiliated tertiary medical center. Patients: One hundred twelve consecutive patients, survivors from a series of 140 non-addicted patients with a first episode of infective endocarditis on native valves hospitalized from 1975 to 1990. Thirty-two patients had had valve replacement during the active phase of the infection, and the remaining 80 patients received medical treatment alone. Measurements: Relapse, recurrence, need for late cardiac surgery, and cardiac mortality. Results: Relapses occurred in three patients (2.7%) and recurrences in five patients (4.5%, incidence density at 15 years, 0.0030 per patient-year). Late cardiac surgery was needed by 47% of the patients treated medically during the active phase, and most had surgery in the first 2 years of follow-up (incidence density, 0.25 per patient-year at 2 years). Aortic valve involvement (relative risk, 2.66; 95% Cl, 1.15 to 6.17) and end-diastolic diameter greater than 60 mm (relative risk, 1.04; 95% Cl, 1.03 to 2.43) were associated with the need for late surgery in univariate analysis. Multiple logistic regression analysis showed aortic valve involvement to be an independent predictor of the need for late surgery (relative risk, 3.04; Cl, 1.23 to 7.54). Only 2 of the 32 patients who had surgery during the active infection needed a second operation during follow-up. At the end of follow-up, the number of patients who had surgery after the onset of the infection was 86 (60% of the whole series). Cardiac death occurred in 16 patients; most deaths were sudden or postoperative and occurred in the first 2 years of follow-up (incidence density, 0.047 per patient-year at 2 years). Independent predictors of death were not found. Survival was 90% at 2 years, 88% at 5 years, 81 % at 10 years, and 61 % at 15 years. Conclusions: Survival after infective endocarditis is fair (81% probability of survival at 10 years), and the most common types of cardiac death are sudden and postoperative. Aortic valve involvement is an independent predictor of the need for late cardiac surgery. The rate of recurrences is not negligible (incidence density at 15 years, 0.0030 per patient-year).			TORNOS, MP (corresponding author), UNIV BARCELONA, HOSP GEN VALL DHEBRON, P VALL DHEBRON SN, E-08035 BARCELONA, SPAIN.			Almirante, Benito/0000-0002-1189-2361				BADDOUR LM, 1988, REV INFECT DIS, V10, P1163; BAYLISS R, 1983, BRIT HEART J, V50, P513, DOI 10.1136/hrt.50.6.513; CALDERWOOD SB, 1986, J THORAC CARDIOV SUR, V92, P776; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; DAVID TE, 1990, ANN THORAC SURG, V49, P701, DOI 10.1016/0003-4975(90)90006-R; DELAHAYE JP, 1989, ARCH MAL COEUR VAISS, V82, P543; DURACK DT, 1990, HEART, P1230; GERACI JE, 1982, MAYO CLIN PROC, V57, P145; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; KAYE D, 1991, HARRISONS PRINCIPLES, P508; KAYE D, 1976, INFECTIVE ENDOCARDIT, P201; Kleimbaum DG., 1982, EPIDEMIOLOGIC RES PR, P96; KOMSHIAN SV, 1990, REV INFECT DIS, V12, P693; MCANULTY JH, 1979, JAMA-J AM MED ASSOC, V242, P77, DOI 10.1001/jama.242.1.77; ORMISTON JA, 1981, AUST NZ J MED, V11, P620, DOI 10.1111/j.1445-5994.1981.tb03536.x; PRINGLE SD, 1989, INT J CARDIOL, V24, P179, DOI 10.1016/0167-5273(89)90302-1; RICE LB, 1991, REV INFECT DIS, V13, P1; SCHELD WM, 1990, PRINCIPLES PRACTICE, P670; STECKELBERG JM, 1991, ANN INTERN MED, V114, P635, DOI 10.7326/0003-4819-114-8-635; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; STEIN DS, 1987, REV INFECT DIS, V9, P908; TORNOSMAS MP, 1984, EUR HEART J, V5, P107, DOI 10.1093/eurheartj/5.suppl_C.107; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WEINSTEIN L, 1988, HEART DISEASE TXB CA, P1093	25	123	124	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					567	572		10.7326/0003-4819-117-7-567	http://dx.doi.org/10.7326/0003-4819-117-7-567			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1306055				2022-12-24	WOS:A1992JQ22600004
J	CHEN, J; MARTIN, BL; BRAUTIGAN, DL				CHEN, J; MARTIN, BL; BRAUTIGAN, DL			REGULATION OF PROTEIN SERINE-THREONINE PHOSPHATASE TYPE-2A BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CATALYTIC SUBUNIT ISOTYPES; RABBIT SKELETAL-MUSCLE; AMINO-ACID SEQUENCE; SEA STAR OOCYTES; S6 KINASE; PHOSPHOPROTEIN PHOSPHATASE; TRANSFORMING GENE; RAT-LIVER; INSULIN	Extracellular signals that promote cell growth activate cascades of protein kinases. The kinases are dephosphorylated and deactivated by a single type-2A protein phosphatase. The catalytic subunit of type-2A protein phosphatase was phosphorylated by tyrosine-specific protein kinases. Phosphorylation was enhanced in the presence of the phosphatase inhibitor okadaic acid, consistent with an autodephosphorylation reaction. More than 90% of the activity of phosphatase 2A was lost when thioadenosine triphosphate was used to produce a thiophosphorylated protein resistant to autodephosphorylation. Phosphorylation in vitro occurred exclusively on Tyr307. Phosphorylation was catalyzed by p60v-src, p56lck, epidermal growth factor receptors, and insulin receptors. Transient deactivation of phosphatase 2A might enhance transmission of cellular signals through kinase cascades within cells.	BROWN UNIV, DIV BIOL & MED, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brown University								AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; Chen J., UNPUB; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CICRELLI MF, 1988, J BIOL CHEM, V263, P2009; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KLARLUND JK, 1991, J BIOL CHEM, V266, P4052; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE EYC, 1979, WIN MIAM S, V16, P483; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARTENSEN TM, 1982, J BIOL CHEM, V257, P9648; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SHRINER C, 1988, METHOD ENZYMOL, V159, P346; SILVA OBDC, 1987, FEBS LETT, V226, P176; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TACHIBANA T, 1981, J AM CHEM SOC, V103, P2471; TAKEDA M, 1983, J BIOL CHEM, V258, P10453; TAMURA S, 1980, EUR J BIOCHEM, V104, P347, DOI 10.1111/j.1432-1033.1980.tb04435.x; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521	41	552	563	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1992	257	5074					1261	1264		10.1126/science.1325671	http://dx.doi.org/10.1126/science.1325671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325671				2022-12-24	WOS:A1992JL05000028
J	MATSUMURA, M; FREMONT, DH; PETERSON, PA; WILSON, IA				MATSUMURA, M; FREMONT, DH; PETERSON, PA; WILSON, IA			EMERGING PRINCIPLES FOR THE RECOGNITION OF PEPTIDE ANTIGENS BY MHC CLASS-I MOLECULES	SCIENCE			English	Article							CYTOTOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGEN; BINDING SITE; CELLS; IDENTIFICATION; HLA-B27; COMPLEX; HLA-A2	Class I major histocompatibility complex (MHC) molecules interact with self and foreign peptides of diverse amino acid sequences yet exhibit distinct allele-specific selectivity for peptide binding. The structures of the peptide-binding specificity pockets (subsites) in the groove of murine H-2K(b) as well as human histocompatibility antigen class I molecules have been analyzed. Deep but highly conserved pockets at each end of the groove bind the amino and carboxyl termini of peptide through extensive hydrogen bonding and, hence, dictate the orientation of peptide binding. A deep polymorphic pocket in the middle of the groove provides the chemical and structural complementarity for one of the peptide's anchor residues, thereby playing a major role in allele-specific peptide binding. Although one or two shallow pockets in the groove may also interact with specific peptide side chains, their role in the selection of peptide is minor. Thus, usage of a limited number of both deep and shallow pockets in multiple combinations appears to allow the binding of a broad range of peptides. This binding occurs with high affinity, primarily because of extensive interactions with the peptide backbone and the conserved hydrogen bonding network at both termini of the peptide. Interactions between the anchor residue (or residues) and the corresponding allele-specific pocket provide sufficient extra binding affinity not only to enhance specificity but also to endure the presentation of the peptide at the cell surface for recognition by T cells.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	MATSUMURA, M (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Fremont, Daved/0000-0002-8544-2689	NCI NIH HHS [CA-09523, CA-97489] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FREMONT DH, 1992, SCIENCE, V257, pR30; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JANIN J, 1990, J BIOL CHEM, V265, P16027; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; Klein J., 1986, NATURAL HIST MAJOR H; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LANGLADE P, UNPUB; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, IN PRESS J BIOL CHEM; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO Y, UNPUB; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SAPER MA, IN PRESS CELL; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; VANBLEEK GM, 1990, NATURE, V348, P213; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7	43	685	754	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					927	934		10.1126/science.1323878	http://dx.doi.org/10.1126/science.1323878			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323878				2022-12-24	WOS:A1992JH82700025
J	GILLE, H; SHARROCKS, AD; SHAW, PE				GILLE, H; SHARROCKS, AD; SHAW, PE			PHOSPHORYLATION OF TRANSCRIPTION FACTOR P62TCF BY MAP KINASE STIMULATES TERNARY COMPLEX-FORMATION AT C-FOS PROMOTER	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; DIRECTED PROTEIN-KINASE; PROLIFERATIVE CELLS; LATE PHASE; S6 KINASE; ACTIVATION; IDENTIFICATION; P58CYCLIN; INSULIN	TRANSCRIPTION of the proto-oncogene c-fos is stimulated rapidly and transiently by serum growth factors and mitogens1. Critical for this response is the serum-response element which is bound in vivo in a ternary complex containing the transcription factors p67SRF and p62TCF (ref. 2). Disruption of the ternary complex correlates with impaired induction by serum and phorbol ester3,4. Mitogen-activated protein (MAP) kinase is a serine/threonine kinase which is activated 1-5 minutes after treatment of cells with mitogens and growth factors5-8 that induce re-entry into the cell cycle, making MAP kinase a candidate for the transmission of proliferative signals. Here we show that p62TCF is phosphorylated by MAP kinase in vitro and that phosphorylation results in enhanced ternary complex formation. Serum-starved Swiss 3T3 cells treated with epidermal growth factor, which induces MAP kinase in these cells9, are induced to express c-fos and yield p62TCF active in ternary complex formation. In contrast, treatment of Swiss 3T3 cells with insulin, which does not activate MAP kinase under these conditions9, does not lead to enhanced ternary complex formation nor does it induce c-fos transcription. Our results link the expression of the human c-fos proto-oncogene to signal transduction pathways known to be activated before its own induction.			GILLE, H (corresponding author), MAX PLANCK INST IMMUNBIOL, SPEMANN LABS, POSTFACH 1169, W-7800 FREIBURG, GERMANY.			SHAW, Peter/0000-0002-2598-4283				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUHROW SA, 1983, J BIOL CHEM, V258, P7824; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FERRARI S, 1991, METHOD ENZYMOL, V200, P159; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HALL FL, 1991, J BIOL CHEM, V266, P17430; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P31; HOSHI M, 1988, J BIOL CHEM, V263, P5396; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4	31	918	933	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1992	358	6385					414	417		10.1038/358414a0	http://dx.doi.org/10.1038/358414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322499				2022-12-24	WOS:A1992JF85300056
J	PATTNAIK, AK; BALL, LA; LEGRONE, AW; WERTZ, GW				PATTNAIK, AK; BALL, LA; LEGRONE, AW; WERTZ, GW			INFECTIOUS DEFECTIVE INTERFERING PARTICLES OF VSV FROM TRANSCRIPTS OF A CDNA CLONE	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; RNA-POLYMERASE; INFLUENZA-VIRUS; VACCINIA VIRUS; REPLICATION; EXPRESSION; AMPLIFICATION; MUTATIONS; PROTEINS; VECTORS	The generation of infectious defective interfering (DI) particles of vesicular stomatitis virus (VSV) entirely from cDNA clones is reported. Bacteriophage T7 RNA polymerase was used to direct the transcription of a complete negative-stranded genomic RNA from a cDNA clone of a VSV DI RNA in cells simultaneously expressing the five VSV proteins from separately transfected cDNA clones. The negative-stranded transcript was encapsidated with N protein, replicated by the VSV polymerase, and the replicated RNAs were assembled and budded to yield infectious DI virions. No helper VSV was required. Replication occurred at high levels and was assayed by direct biochemical means. An exact 3' terminus of the initial transcript, which was generated by autolytic cleavage using a ribozyme from hepatitis delta virus, was critical for replication.			PATTNAIK, AK (corresponding author), UNIV ALABAMA, SCH MED, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA.		Pattnaik, Asit K./X-1531-2019	Pattnaik, Asit K./0000-0002-9581-6787	NIAID NIH HHS [R37 AI18270, R37-AI12464, AI20181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020181, R37AI012464, R37AI018270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON RF, 1988, J VIROL, V62, P3581, DOI 10.1128/JVI.62.10.3581-3588.1988; BALL LA, 1992, J VIROL, V66, P2335, DOI 10.1128/JVI.66.4.2335-2345.1992; COLLINS PL, 1991, P NATL ACAD SCI USA, V88, P9663, DOI 10.1073/pnas.88.21.9663; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DZIANOTT AM, 1988, NUCLEIC ACIDS RES, V16, P10940, DOI 10.1093/nar/16.22.10940; EMERSON SU, 1972, J VIROL, V10, P297, DOI 10.1128/JVI.10.2.297-309.1972; EMERSON SU, 1975, J VIROL, V15, P1348, DOI 10.1128/JVI.15.6.1348-1356.1975; ENAMI M, 1990, P NATL ACAD SCI USA, V87, P3802, DOI 10.1073/pnas.87.10.3802; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; KEENE JD, 1978, P NATL ACAD SCI USA, V75, P3225, DOI 10.1073/pnas.75.7.3225; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MEIER E, 1984, J VIROL, V51, P515, DOI 10.1128/JVI.51.2.515-521.1984; MOYER SA, 1991, J VIROL, V65, P2170, DOI 10.1128/JVI.65.5.2170-2178.1991; PARK KH, 1991, P NATL ACAD SCI USA, V88, P5537, DOI 10.1073/pnas.88.13.5537; PATTNAIK AK, 1990, J VIROL, V64, P2948, DOI 10.1128/JVI.64.6.2948-2957.1990; PATTNAIK AK, 1991, P NATL ACAD SCI USA, V88, P1379, DOI 10.1073/pnas.88.4.1379; PATTON JT, 1984, J VIROL, V49, P303, DOI 10.1128/JVI.49.2.303-309.1984; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SORIA M, 1974, VIROLOGY, V61, P270, DOI 10.1016/0042-6822(74)90261-X; SULLENDER WM, 1991, J VIROL, V65, P5425, DOI 10.1128/JVI.65.10.5425-5434.1991; WERTZ GW, 1981, NUCLEIC ACIDS RES, V9, P6487, DOI 10.1093/nar/9.23.6487	26	246	270	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					1011	1020		10.1016/0092-8674(92)90619-N	http://dx.doi.org/10.1016/0092-8674(92)90619-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1318785				2022-12-24	WOS:A1992HY79200012
J	VANLIESHOUT, JJ; TENHARKEL, ADJ; WIELING, W				VANLIESHOUT, JJ; TENHARKEL, ADJ; WIELING, W			PHYSICAL MANEUVERS FOR COMBATING ORTHOSTATIC DIZZINESS IN AUTONOMIC FAILURE	LANCET			English	Note							PRESSURE	Some patients with orthostatic hypotension combat orthostatic dizziness by leg-crossing and squatting. Changes in blood pressure with these manoeuvres were studied in 7 patients with hypoadrenergic orthostatic hypotension and in 6 healthy subjects. Without leg-crossing, 5 of the patients reported dizziness within 10 min of standing up. Crossing of the legs allowed all to stand for 1 0 min or more, and there was an associated increase in mean blood pressure of 13 (SD 6) mm Hg compared with 1 (4) in healthy controls, the corresponding figures for squatting were 44 (18) and 8 (6) mm Hg. Patients with orthostatic intolerance should be told about these blood-pressure-raising manoeuvres.			VANLIESHOUT, JJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR F4 264,DEPT MED,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Van Lieshout, Johannes/P-5499-2019; Ten Harkel, Arend/ABE-1169-2021; van Lieshout, Johannes J/B-6674-2011	Van Lieshout, Johannes/0000-0002-3646-2122; van Lieshout, Johannes J/0000-0002-3646-2122				BIAGGIONI I, 1990, NEUROLOGY, V40, P370, DOI 10.1212/WNL.40.2.370; GUYTON AC, 1962, CIRC RES, V11, P431, DOI 10.1161/01.RES.11.3.431; Hainsworth R, 1988, AUTONOMIC FAILURE TX, P142; IMHOLZ BPM, 1990, CARDIOVASC RES, V24, P214, DOI 10.1093/cvr/24.3.214; Jeffers WA, 1941, AM J MED SCI, V202, P1, DOI 10.1097/00000441-194107000-00001; SHARPEYSCHAFER EP, 1956, BRIT MED J, V1, P1072, DOI 10.1136/bmj.1.4975.1072; SMITH ML, 1987, MED SCI SPORT EXER, V19, P436; VANLIESHOUT JJ, 1989, CLIN SCI, V76, P523, DOI 10.1042/cs0760523	8	109	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					897	898		10.1016/0140-6736(92)90932-S	http://dx.doi.org/10.1016/0140-6736(92)90932-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348300				2022-12-24	WOS:A1992HN48300006
J	FOWKES, FGR; CONNOR, JM; SMITH, FB; WOOD, J; DONNAN, PT; LOWE, GDO				FOWKES, FGR; CONNOR, JM; SMITH, FB; WOOD, J; DONNAN, PT; LOWE, GDO			FIBRINOGEN GENOTYPE AND RISK OF PERIPHERAL ATHEROSCLEROSIS	LANCET			English	Article							ISCHEMIC HEART-DISEASE; PLASMA-FIBRINOGEN; CARDIOVASCULAR-DISEASE; HEMOSTATIC VARIABLES; DETERMINANTS; SMOKING; MEN	There is conflicting evidence about the influence of fibrinogen genotype on plasma fibrinogen concentrations, and the relation between genotype and atherosclerotic disease has not been studied. In a population-based case-control study we aimed to find out whether certain fibrinogen genotypes are associated with an increased risk of peripheral atherosclerosis. 121 subjects with peripheral arterial disease and 126 healthy controls matched for age and sex were selected from a random population sample aged 55-74 years in the Edinburgh Artery Study. Mean fibrinogen concentrations were higher in cases than in controls (3.12 [95% confidence interval 2.99-3.26] vs 2.75 [2.64-2.85], p < 0.001). A greater proportion of cases than controls were homozygous or heterozygous for an allele at the beta-fibrinogen locus (4.2 kb allele, Bcl I digestion); the allele frequency was 0.197 in cases and 0.097 in controls (p < 0.005). Extended haplotypes for 4.2 kb heterozygotes were also associated with an increased risk of peripheral arterial disease. However, haplotype had only a small effect on the association of plasma fibrinogen concentration with disease, and the relation of haplotype with disease was independent of age, sex, social class, smoking status, plasma fibrinogen, alcohol consumption, body mass index, and diabetes mellitus. We conclude that variation at the beta-fibrinogen locus is associated with an increased risk of peripheral atherosclerosis. The influence is not mediated simply by way of increased fibrinogen concentrations but could be due to a structurally variant fibrinogen or linkage disequilibrium with a neighbouring gene.	UNIV GLASGOW,WESTERN INFIRM,DUNCAN GUTHRIE INST,DEPT MED GENET,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,MOLEC MED LAB,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow	FOWKES, FGR (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.			Donnan, Peter/0000-0001-7828-0610				[Anonymous], 1980, CLASSIFICATION OCCUP; BAKER JD, 1978, ARCH SURG-CHICAGO, V113, P1171; BERG K, 1989, CLIN GENET, V36, P229; BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; CONNOR JM, IN PRESS J MED GENET; DIXON WJ, 1988, BMDP STATISTICAL SOF; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1992, AM J EPIDEMIOL, V135, P331; FULLER JH, 1979, BMJ-BRIT MED J, V2, P964, DOI 10.1136/bmj.2.6196.964; HAMSTEN A, 1987, LANCET, V2, P988; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; KANNEL W B, 1990, Journal of the American College of Cardiology, V15, p156A; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LOWE GDO, 1991, BR J HAEMATOL S1, V77, P27; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Prineas R., 1982, MINNESOTA CODE MANUA; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; Sambrook J., 1989, MOL CLONING LAB MANU; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Smith WCS, 1991, EPIDEMIOLOGY PERIPHE, P117; STONE MC, 1984, ATHEROSCLEROSIS CARD, P3; THOMAS AE, 1991, THROMB HAEMOSTASIS, V65, P487; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YARNELL JWG, 1983, J EPIDEMIOL COMMUN H, V37, P137, DOI 10.1136/jech.37.2.137; [No title captured]	31	127	129	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					693	696		10.1016/0140-6736(92)90596-U	http://dx.doi.org/10.1016/0140-6736(92)90596-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347581				2022-12-24	WOS:A1992HK32000001
J	THOMAS, SM; DEMARCO, M; DARCANGELO, G; HALEGOUA, S; BRUGGE, JS				THOMAS, SM; DEMARCO, M; DARCANGELO, G; HALEGOUA, S; BRUGGE, JS			RAS IS ESSENTIAL FOR NERVE GROWTH FACTOR-INDUCED AND PHORBOL ESTER-INDUCED TYROSINE PHOSPHORYLATION OF MAP KINASES	CELL			English	Article							PROTEIN-KINASE; PC12 CELLS; TRANSFORMED FIBROBLASTS; SIGNAL TRANSDUCTION; 3T3 CELLS; P21; DIACYLGLYCEROL; REQUIREMENT; ONCOGENE; DIFFERENTIATION	Treatment of PC12 cells with nerve growth factor (NGF) induces a rapid increase in tyrosine phosphorylation of multiple cellular proteins. Expression of a dominant inhibitory Ras mutant specifically blocked NGF- and TPA-induced tyrosine phosphorylation of two proteins of approximately 42 and 44 kd. Conversely, expression of an oncogenic variant of Ras induced tyrosine phosphorylation of the same 42 and 44 kd proteins. The 44 kd protein was immunoprecipitated with an antibody directed against extracellular signal-regulated kinase 1/mitogen-activated protein kinase (MAPK) and the 42 kd protein comigrated with a 42 kd MAPK, indicating that at least one and probably both Ras-regulated phosphoproteins are MAPKs. In addition, MAPK activation, as measured by in vitro phosphorylation of myelin basic protein, was also regulated by Ras. Ras was not required for NGF-induced activation of Trk or tyrosine phosphorylation of PLC-gamma-1. Thus, NGF-induced tyrosine phosphorylation occurs both prior to and following Ras action, and Ras plays a critical role in the NGF- and TPA-induced tyrosine phosphorylation of MAPKs.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	THOMAS, SM (corresponding author), UNIV PENN,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104, USA.			D'Arcangelo, Gabriella/0000-0003-1575-1010	NCI NIH HHS [CA47572] Funding Source: Medline; NINDS NIH HHS [NS18218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALLEMAIN GL, 1991, MOL CELL BIOL, V11, P1002; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1990, CURRENT TOPICS MICRO; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P509; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MALLER J, 1991, Current Biology, V1, P334, DOI 10.1016/0960-9822(91)90104-5; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P133; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1992, IN PRESS MOL CELL BI; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUGGIERI R, 1991, NATURE, V353, P390, DOI 10.1038/353390a0; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VILA J, 1988, J CELL PHYSIOL, V135, P285, DOI 10.1002/jcp.1041350216; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	68	698	704	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1031	1040		10.1016/0092-8674(92)90075-N	http://dx.doi.org/10.1016/0092-8674(92)90075-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312392				2022-12-24	WOS:A1992HK67400007
J	WOOD, KW; SARNECKI, C; ROBERTS, TM; BLENIS, J				WOOD, KW; SARNECKI, C; ROBERTS, TM; BLENIS, J			RAS MEDIATES NERVE GROWTH-FACTOR RECEPTOR MODULATION OF 3 SIGNAL-TRANSDUCING PROTEIN-KINASES - MAP KINASE, RAF-1, AND RSK	CELL			English	Article							CELL-PROLIFERATION; ONCOGENE PRODUCTS; PC12 CELLS; PHOSPHORYLATION; REQUIREMENT; ACTIVATION; TYROSINE; DIFFERENTIATION; STIMULATION; INHIBITION	p21c-ras plays a critical role in mediating tyrosine kinase-stimulated cell growth and differentiation. However, the pathways through which p21c-ras propagates these signals remain unknown. We report that in PC12 cells, expression of a dominant inhibitory mutant of ras, c-Ha-ras(Asn-17), antagonizes growth factor- and phorbol ester-induced activation of the erk-encoded family of MAP kinases, the 85-92 kd RSKs, and the kinase(s) responsible for hyperphosphorylation of the proto-oncogene product Raf-1. In addition, we find that expression of the activated ras oncogene is sufficient to stimulate these events. These data indicate that ras mediates nerve growth factor receptor and protein kinase C modulation of MAP kinases, RSKs, and Raf-1.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	WOOD, KW (corresponding author), HARVARD UNIV, DIV MED SCI, PROGRAM CELL & DEV BIOL, CAMBRIDGE, MA 02138 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA050661, R01CA043803] Funding Source: NIH RePORTER; NCI NIH HHS [CA43803, CA50661] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; THOMAS SM, 1992, CELL; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WILLIAMS NG, 1992, IN PRESS P NATL ACAD; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	55	913	924	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1041	1050		10.1016/0092-8674(92)90076-O	http://dx.doi.org/10.1016/0092-8674(92)90076-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312393				2022-12-24	WOS:A1992HK67400008
J	SHPETNER, HS; VALLEE, RB				SHPETNER, HS; VALLEE, RB			DYNAMIN IS A GTPASE STIMULATED TO HIGH-LEVELS OF ACTIVITY BY MICROTUBULES	NATURE			English	Article							TEMPERATURE-SENSITIVE MUTANT; BRAIN CYTOPLASMIC DYNEIN; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; BINDING PROTEINS; TUMOR-METASTASIS; ACTIVATED ATPASE; GENE; IDENTIFICATION; TRANSLOCATION	DYNAMIN was initially identified in calf brain tissue as a protein of relative molecular mass 100,000 which induced nucleotide-sensitive bundling of microtubules 1. Purified dynamin showed only trace ATPase activity. But in combination with an activating factor removed during the purification, it exhibited microtubule-activated ATPase activity and dynamin-induced bundles showeD evidence of ATP-dependent force production 1. Dynamin is the product of the DrosophiLa gene shibire 2.3, which has been implicated in synaptic vesicle recycling 4,5 and, more generally, in the budding of endocytic vesicles from the plasma membrane 6,7 . Dynamin also shows 8 extensive homology with proteins that participate in vacuolar protein sorting 9 and spindle pole-body separation 10 in yeast, and in interferon-induced viral resistance 11,12 in mammals. All members of this family contain consensus sequence elements consistent with GTP binding near their amino termini, although none has been shown to have GTPase activity. We report here that dynamin is a specific GTPase which can be stimulated to very high levels of activity by microtubules.			SHPETNER, HS (corresponding author), WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA.							Agarwal R P, 1978, Methods Enzymol, V51, P376; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BLOOM GS, 1983, J CELL BIOL, V96, P1523, DOI 10.1083/jcb.96.6.1523; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURNS RG, 1981, EUR J BIOCHEM, V117, P515; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HENDERSON JF, 1973, NUCLEOTIDE METABOLIS, P18; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; PENNINGROTH SM, 1977, J MOL BIOL, V115, P643, DOI 10.1016/0022-2836(77)90108-5; POLLARD TD, 1991, REV PHYSL, V53, P653; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VIKSTROM KL, 1991, METHOD ENZYMOL, V196, P506; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	39	189	194	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					733	735		10.1038/355733a0	http://dx.doi.org/10.1038/355733a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1311055				2022-12-24	WOS:A1992HE60400066
J	CHISAKA, O; MUSCI, TS; CAPECCHI, MR				CHISAKA, O; MUSCI, TS; CAPECCHI, MR			DEVELOPMENTAL DEFECTS OF THE EAR, CRANIAL NERVES AND HINDBRAIN RESULTING FROM TARGETED DISRUPTION OF THE MOUSE HOMEOBOX GENE HOX-1.6	NATURE			English	Article							STEM-CELLS; EXPRESSION; EMBRYO; MURINE; GENOME; CHICK	Gene targeting in mouse embryo-derived stem cells has been used to generate mice with a disruption in the homeobox gene Hox-1.6 Mice heterozygous at the Hox-1.6 locus appear normal, whereas Hox-1.6-/Hox-1.6- mice die at or shortly after birth. These homozygotes exhibit profound defects in the formation of the external, middle and inner ears as well as in specific hindbrain nuclei, and in cranial nerves and ganglia. The affected tissues lie within a narrow region along the anteroposterior axis of the mouse but are of diverse embryonic origin. The set of defects associated with the disruption of Hox-1.6 is distinct from and nonoverlapping with that of the closely linked Hox-1.5 gene. But both mutations cause loss, rather than homeotic transformation, of tissues and structures.			CHISAKA, O (corresponding author), UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DEOL MS, 1980, MORPHOGENESIS MALFOR, P243; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HUNT P, 1991, DEVELOPMENT, V112, P43; INGHAM PN, 1989, NATURE, V335, P25; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; Le Douarin N., 1999, DEV CELL BIOL SERIES, V2nd, DOI [10.1017/CBO9780511897948, DOI 10.1017/CBO9780511897948, 10.1017/cbo9780511897948]; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, IN PRESS DEVELOPMENT; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Van de Water T R, 1980, Birth Defects Orig Artic Ser, V16, P147; VANDEWATER TR, 1980, MORPHOGENESIS MALFOR, P5	30	480	499	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					516	520		10.1038/355516a0	http://dx.doi.org/10.1038/355516a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346922				2022-12-24	WOS:A1992HC52600047
J	ALEDORT, LM; HILGARTNER, MW; PIKE, MC; GJERSET, GF; KOERPER, MA; LIAN, EYC; LUSHER, JM; MOSLEY, JW				ALEDORT, LM; HILGARTNER, MW; PIKE, MC; GJERSET, GF; KOERPER, MA; LIAN, EYC; LUSHER, JM; MOSLEY, JW			VARIABILITY IN SERIAL CD4 COUNTS AND RELATION TO PROGRESSION OF HIV-I INFECTION TO AIDS IN HEMOPHILIC PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EDINBURGH HEMOPHILIAC COHORT; CONTROLLED TRIAL; QUALITY-CONTROL; ZIDOVUDINE; FOLLOW; TYPE-1; RISK; AZT	Objective - To examine the CD4 count and its near term changes relative to progression to AIDS within 30 months and to subsequent CD4 counts. Design - Longitudinal clinical and laboratory study. Setting - Haemophilia treatment centres in six large American cities. Patients - 555 people with congenital clotting disorders who were infected with HIV, initially without AIDS, and seen at follow up for 6-30 months in 1986-9. Main outcome measures - Absolute CD4 counts and incidence of AIDS. Results - Outset CD4 count and age were independently related to progression to AIDS (p < 0.0001 and p < 0.005 respectively). Patients with CD4 counts of 0.30-0.49 X 10(9) cells/l had an age adjusted risk of AIDS within 30 months of only 9% that of patients with counts < 0.20 X 10(9)/l. Children under 10 years old had only 16% of the CD4 adjusted risk of AIDS of people aged greater-than-or-equal-to 45 years. Analysis of 149 patients' CD4 counts at the beginning and end of two successive six month intervals showed an average decrease of 11% in each six months regardless of the outset count (greater-than-or-equal-to 0.20 X 10(9)/l). For individual patients the decrease in the second six month period was unaffected by the decrease in the first six month period. Conclusions - Antiviral treatment of asymptomatic people, particularly children, with CD4 counts greater-than-or-equal-to 0.3 X 10(9)/l is questionable if predicated on near term progression to AIDS. Because of individual CD4 count variability and the low rate of progression to AIDS near term declines in individual CD4 counts are a poor index for identifying people who will rapidly progress to AIDS.	MT SINAI MED CTR,MED,NEW YORK,NY 10029; CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021; UNIV SO CALIF,DEPT PREVENT MED,LOS ANGELES,CA 90089; PUGET SOUND BLOOD CTR,MED,SEATTLE,WA 98104; UNIV CALIF SAN FRANCISCO,MED,SAN FRANCISCO,CA 94143; WAYNE STATE UNIV,PAEDIAT,DETROIT,MI 48202; UNIV MIAMI,MED,MIAMI,FL 33152	Icahn School of Medicine at Mount Sinai; Cornell University; NewYork-Presbyterian Hospital; University of Southern California; Puget Sound Blood Center; University of California System; University of California San Francisco; Wayne State University; University of Miami					DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047003, N01HB097074] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-9-7074, N01-HB-4-7003] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN BL, 1990, NEW ENGL J MED, V323, P755; COX DR, 1972, J R STAT SOC B, V34, P187; CUTHBERT RJG, 1990, BMJ-BRIT MED J, V301, P956, DOI 10.1136/bmj.301.6758.956; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DETRUCHIS P, 1991, LANCET, V337, P1109, DOI 10.1016/0140-6736(91)91766-N; EDWARDS VM, 1989, AM J CLIN PATHOL, V91, P75, DOI 10.1093/ajcp/91.1.75; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; Goedert James J., 1990, Annals of Epidemiology, V1, P129, DOI 10.1016/1047-2797(90)90004-C; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HAMILTON JD, 1990, NEW ENGL J MED, V323, P754, DOI 10.1056/NEJM199009133231112; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V260, P2694, DOI 10.1001/jama.260.18.2694; KLEINBAUM DG, 1988, APPLIED REGRESSION A; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MEDLEY GF, 1988, PROC R SOC SER B-BIO, V233, P367, DOI 10.1098/rspb.1988.0026; MOSS AR, 1990, J ACQ IMMUN DEF SYND, V3, pS69; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PARKER JW, 1990, CLIN IMMUNOL IMMUNOP, V55, P187, DOI 10.1016/0090-1229(90)90097-A; PHILLIPS AN, 1991, LANCET, V337, P389; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SIMMONDS P, 1988, BRIT MED J, V296, P593, DOI 10.1136/bmj.296.6622.593; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; Vermund Sten H., 1990, Annals of Epidemiology, V1, P141, DOI 10.1016/1047-2797(90)90005-D; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MMWR, V36, P3	31	35	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					212	216		10.1136/bmj.304.6821.212	http://dx.doi.org/10.1136/bmj.304.6821.212			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1346752	Green Published, Bronze			2022-12-24	WOS:A1992HA98000022
J	EISENLOHR, LC; BACIK, I; BENNINK, JR; BERNSTEIN, K; YEWDELL, JW				EISENLOHR, LC; BACIK, I; BENNINK, JR; BERNSTEIN, K; YEWDELL, JW			EXPRESSION OF A MEMBRANE PROTEASE ENHANCES PRESENTATION OF ENDOGENOUS ANTIGENS TO MHC CLASS I-RESTRICTED LYMPHOCYTES-T	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANGIOTENSIN-CONVERTING ENZYME; CELL-SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; INFLUENZA NUCLEOPROTEIN; VACCINIA VIRUS; RECOGNITION; MOLECULES	We find that expression of the membrane dipeptidyl carboxypeptidase angiotensin-converting enzyme (ACE) enhances presentation of certain endogenously synthesized peptides to major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes. ACE appears to function only in an intracellular secretory compartment of antigen-presenting cells. ACE-enhanced antigen presentation requires the expression of the putative antigenic peptide transporters, TAP1 and TAP2. These findings demonstrate that a protease can influence the processing of endogenously synthesized antigens and strongly suggest that longer peptides can be transported from the cytosol to a secretory compartment where trimming of antigenic peptides to the lengths preferred by MHC class I molecules can occur if the appropriate protease is present.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20906; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University			yewdell, jyewdell@nih.gov jonathan/A-1702-2012					ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BENNINK JR, 1986, J VIROL, V57, P786, DOI 10.1128/JVI.57.3.786-791.1986; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481; EISENLOHR LC, 1992, J IMMUNOL METHODS, V154, P131, DOI 10.1016/0022-1759(92)90220-N; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KOSLOWSKI S, 1992, J EXP MED, V175, P1417; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; NEELS HM, 1983, CLIN CHEM, V29, P1399; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1988, J IMMUNOL, V141, P3324; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANPEL A, 1989, IMMUNOGENETICS, V29, P75; WEI L, 1991, J BIOL CHEM, V266, P5540; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; YEWDELL JW, 1988, CELL, V52, P843, DOI 10.1016/0092-8674(88)90426-6; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	47	161	165	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					963	972		10.1016/0092-8674(92)90392-P	http://dx.doi.org/10.1016/0092-8674(92)90392-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333889				2022-12-24	WOS:A1992KB99000009
J	WANG, MX; CHURCH, GM				WANG, MX; CHURCH, GM			A WHOLE GENOME APPROACH TO INVIVO DNA-PROTEIN INTERACTIONS IN ESCHERICHIA-COLI	NATURE			English	Article							MANNITOL MTL OPERON; ESCHERICHIA-COLI; RESTRICTION ENZYMES; BINDING-SITES; METHYLATION; SEQUENCE; GENE; METHYLTRANSFERASE; ENDONUCLEASE; RECOGNITION	THE increasingly rapid pace at which genomic DNA sequences are being determined has created a need for more efficient techniques to determine which parts of these sequences are bound in vivo by the proteins controlling processes such as gene expression, DNA replication and chromosomal mechanics. Here we describe a whole-genome approach to identify and characterize such DNA sequences. The method uses endogenous or artificially introduced methylases to methylate all genomic targets except those protected in vivo by protein or non-protein factors interfering with methylase action. These protected targets remain unmethylated in purified genomic DNA and are identified using methylation-sensitive restriction endonucleases. When the method was applied to the Escherichia coli genome, 0.1% of the endogenous adenine methyltransferase (Dam methylase) targets were found to be unmethylated. Five foreign methylases were examined by transfection. Database-matched DNA sequences flanking the in vivo-protected Dam sites all fell in the non-coding regions of seven E. coli operons (mtl, cdd, flh, gut, car, psp and fep). In the first four operons these DNA sequences closely matched the consensus sequence that binds to the cyclic AMP-receptor protein. The in vivo protection at the Dam site upstream of the car operon was correlated with a downregulation of car expression, as expected of a feedback repressor-binding model.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Jefferson University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	WANG, MX (corresponding author), THOMAS JEFFERSON UNIV,WILLS EYE HOSP,DIV RES,ONCOL RES LAB,PHILADELPHIA,PA 19107, USA.			church, george/0000-0001-6232-9969				BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BIRD AP, 1978, J MOL BIOL, V118, P27, DOI 10.1016/0022-2836(78)90242-5; BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x; BRAATEN BA, 1992, P NATL ACAD SCI USA, V89, P4250, DOI 10.1073/pnas.89.10.4250; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CAMPBELL JL, 1988, GENE, V74, P189, DOI 10.1016/0378-1119(88)90283-1; CARTWRIGHT IL, 1991, BIOTECHNIQUES, V11, P188; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; DAVIS T, 1988, MOL MICROBIOL, V2, P405, DOI 10.1111/j.1365-2958.1988.tb00045.x; EBRIGHT R, 1982, MOL STRUCTURE BIOL A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEHER Z, 1989, CURR GENET, V16, P461, DOI 10.1007/BF00340726; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GUNASEKERA A, 1990, NUCLEIC ACIDS RES, V18, P6853, DOI 10.1093/nar/18.23.6853; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JIANG W, 1990, MOL MICROBIOL, V4, P2003, DOI 10.1111/j.1365-2958.1990.tb02050.x; KWOH TJ, 1988, NUCLEIC ACIDS RES, V16, P11489, DOI 10.1093/nar/16.24.11489; LENGELER J, 1978, MOL GEN GENET, V164, P163, DOI 10.1007/BF00267381; LYONS SM, 1984, J BACTERIOL, V159, P421, DOI 10.1128/JB.159.1.421-423.1984; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; RAZIN A, 1980, NUCLEIC ACIDS RES, V8, P1783, DOI 10.1093/nar/8.8.1783; RINGQUIST S, 1992, P NATL ACAD SCI USA, V89, P4539, DOI 10.1073/pnas.89.10.4539; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SALUZ HP, 1991, TRENDS GENET, V7, P207, DOI 10.1016/0168-9525(91)90366-X; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SILVERMAN M, 1974, J BACTERIOL, V120, P1196, DOI 10.1128/JB.120.3.1196-1203.1974; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; STORMO GD, 1989, P NATL ACAD SCI USA, V86, P1183, DOI 10.1073/pnas.86.4.1183; VALENTINHANSEN P, 1989, MOL MICROBIOL, V3, P1385, DOI 10.1111/j.1365-2958.1989.tb00120.x; VOVIS GF, 1977, J MOL BIOL, V115, P525, DOI 10.1016/0022-2836(77)90169-3; WILSON GG, 1988, GENE, V74, P281, DOI 10.1016/0378-1119(88)90304-6; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YMADA M, 1987, J BIOL CHEM, V265, P5455	36	56	58	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					606	610		10.1038/360606a0	http://dx.doi.org/10.1038/360606a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1334233				2022-12-24	WOS:A1992KB95900092
J	HILL, AVS; ELVIN, J; WILLIS, AC; AIDOO, M; ALLSOPP, CEM; GOTCH, FM; GAO, XM; TAKIGUCHI, M; GREENWOOD, BM; TOWNSEND, ARM; MCMICHAEL, AJ; WHITTLE, HC				HILL, AVS; ELVIN, J; WILLIS, AC; AIDOO, M; ALLSOPP, CEM; GOTCH, FM; GAO, XM; TAKIGUCHI, M; GREENWOOD, BM; TOWNSEND, ARM; MCMICHAEL, AJ; WHITTLE, HC			MOLECULAR ANALYSIS OF THE ASSOCIATION OF HLA-B53 AND RESISTANCE TO SEVERE MALARIA	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; T-CELL EPITOPES; MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOTOXIC LYMPHOCYTES-T; CLASS-I MOLECULES; CIRCUMSPOROZOITE PROTEIN; LIVER-STAGE; VACCINE DEVELOPMENT; SURFACE-ANTIGENS; VIRAL-ANTIGEN	The protective association between the human leukocyte antigen HLA-B53 and severe malaria was investigated by sequencing of peptides eluted from this molecule followed by screening of candidate epitopes from pre-erythrocytic-stage antigens of Plasmodium falciparum in biochemical and cellular assays. Among malaria-immune Africans, HLA-B53-restricted cytotoxic T lymphocytes recognized a conserved nonamer peptide from liver-stage-specific antigen-1 (LSA-1), but no HLA-B53-restricted epitopes were identified in other antigens. These findings indicate a possible molecular basis for this HLA-disease association and support the candidacy of liver-stage-specific antigen-1 as a malaria vaccine component.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND; MRC LABS,BANJUL,SENEGAMBIA; UNIV TOKYO,INST MED SCI,MINAMI KU,TOKYO 108,JAPAN	University of Oxford; University of Tokyo	HILL, AVS (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		Takiguchi, Masafumi/E-7468-2013; HILL, Adrian V>S>/C-1306-2008	Townsend, Alain/0000-0002-3702-0107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; Amiel J.L, 1967, HISTOCOMPAT TEST, V1967, P79; ARNOT D, 1989, PARASITOL TODAY, V5, P138, DOI 10.1016/0169-4758(89)90077-X; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; CARRENO BM, 1992, J IMMUNOL, V148, P894; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLYDE DF, 1973, AM J MED SCI, V266, P398, DOI 10.1097/00000441-197312000-00001; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; DOOLAN DL, 1991, INFECT IMMUN, V60, P765; DRUIHLE P, 1989, NEW STRATEGIES PARAS; ELLIS SA, 1985, HUM IMMUNOL, V13, P13, DOI 10.1016/0198-8859(85)90023-0; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; ELVIN J, IN PRESS J IMMUN MET; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199; GUERINMARCHAND C, 1987, NATURE, V329, P164, DOI 10.1038/329164a0; HARRIS R, 1969, NATURE, V221, P1062, DOI 10.1038/2211062a0; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HAYASHI H, 1990, IMMUNOGENETICS, V32, P195, DOI 10.1007/BF02114973; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOLLINGDALE MR, 1990, IMMUNOL LETT, V25, P71, DOI 10.1016/0165-2478(90)90094-7; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; LOCKYER M, 1990, PARASITOL TODAY, V6, P76, DOI 10.1016/0169-4758(90)90213-N; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; MCCUTCHAN TF, 1990, IMMUNOL LETT, V25, P23, DOI 10.1016/0165-2478(90)90085-5; MCGREGOR IA, 1968, MALARIA PRINCIPLES P, P559; MEIS JFGM, 1986, CELL TISSUE RES, V244, P345, DOI 10.1007/BF00219210; MELLOUK S, 1990, LANCET, V335, P721, DOI 10.1016/0140-6736(90)90832-P; MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L; NIXON DF, 1992, IMMUNOLOGY, V76, P515; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PERLMANN P, 1990, Immunology Letters, V25, P1; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SEDEGAH M, 1992, J IMMUNOL, V149, P966; SUHRBIER A, 1990, INFECT IMMUN, V58, P2834, DOI 10.1128/IAI.58.9.2834-2839.1990; SUHRBIER A, 1991, PARASITOL TODAY, V7, P160, DOI 10.1016/0169-4758(91)90120-D; SUTTON J, IN PRESS EUR J IMMUN; TIWARI JL, 1985, HLA DISEASE ASS; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; VANBLEEK GM, 1990, NATURE, V348, P213; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WEISS WR, 1990, J EXP MED, V171, P1083; YAMAMOTO J, 1990, P NATL ACAD SCI USA, V87, P2583, DOI 10.1073/pnas.87.7.2583; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J; ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O	65	596	618	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					434	439		10.1038/360434a0	http://dx.doi.org/10.1038/360434a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280333				2022-12-24	WOS:A1992KA79700049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALERT ON CHANGES IN STANDARDIZED CAT ALLERGEN EXTRACT PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-24	WOS:A1992JW61600006
J	VUKMANOVIC, S; GRANDEA, AG; FAAS, SJ; KNOWLES, BB; BEVAN, MJ				VUKMANOVIC, S; GRANDEA, AG; FAAS, SJ; KNOWLES, BB; BEVAN, MJ			POSITIVE SELECTION OF LYMPHOCYTES-T INDUCED BY INTRATHYMIC INJECTION OF A THYMIC EPITHELIAL-CELL LINE	NATURE			English	Article							PEPTIDE BINDING; VIRAL PEPTIDES; ANTIGEN; MHC; SELF; RECOGNITION; REPERTOIRE; THYMOCYTES; MOLECULES; MUTATIONS	T LYMPHOCYTES recognize antigens as peptide fragments associated with molecules encoded by the major histocompatibility complex (MHC) and expressed on the surface of antigen-presenting cells'. In the thymus, T cells bearing alphabeta receptors that react with the MHC molecules expressed by radioresistant stromal elements are positively selected for maturation2-5. In (A x B --> A) bone marrow chimaeras, T cells restricted to the MHC-A haplotype are positively selected, whereas MHC-B-reactive thymocytes are not. We investigated whether the introduction of particular thymic stromal elements bearing MHC-B molecules could alter the fate of B-reactive T cells in these (A x B --> A) chimaeras. Thymic epithelial cell (TEC) lines expressing H-2b were introduced by intrathymic injection into (H-2b/s --> H2s) bone marrow chimaeras and we measured their ability to generate H-2b-restricted cytotoxic T-lymphocytes (CTLs). We report here that one TEC line, 427.1, was able positively to select CTLs specific for influenza and vesicular stomatitis virus antigens in association with class I H-2b molecules. In addition, line 427.1 can process cytoplasmic proteins for presentation to H-2K(b)- and H-2D(b)-restricted CTLs. Thus, a TEC line capable of normal class I MHC antigen processing and presentation in vitro can induce positive selection after intrathymic injection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; The Wistar Institute; University of Pennsylvania	VUKMANOVIC, S (corresponding author), UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195, USA.			Vukmanovic, Stanislav/0000-0003-3547-8349; Knowles, Barbara B./0000-0002-2597-5619	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI019335-19, R01 AI019335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019335] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FINK PJ, 1988, IMMUNOL TODAY, V9, P377, DOI 10.1016/0167-5699(88)91238-8; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; GRANDEA AG, 1992, P NATL ACAD SCI USA, V89, P2794, DOI 10.1073/pnas.89.7.2794; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; MARRACK P, 1988, IMMUNOL TODAY, V9, P308, DOI 10.1016/0167-5699(88)91324-2; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MIZUOCHI T, 1992, J EXP MED, V175, P1601, DOI 10.1084/jem.175.6.1601; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P23; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPRENT J, 1978, J EXP MED, V146, P1838; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YEWDELL JW, IN PRESS ADV IMMUN; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	32	104	106	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					729	732		10.1038/359729a0	http://dx.doi.org/10.1038/359729a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331804	Green Accepted			2022-12-24	WOS:A1992JU65000056
J	SAVARIT, D; DECOCK, KM; SCHUTZ, R; KONATE, S; LACKRITZ, E; BONDURAND, A				SAVARIT, D; DECOCK, KM; SCHUTZ, R; KONATE, S; LACKRITZ, E; BONDURAND, A			RISK OF HIV-INFECTION FROM TRANSFUSION WITH BLOOD NEGATIVE FOR HIV ANTIBODY IN A WEST AFRICAN CITY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; TRANSMISSION; AIDS	Objective-To estimate the risk of infection with HIV (HIV 1 or HIV 2, or both) from transfusion of a screened unit of blood in a high prevalence area in west Africa. Design-Retrospective cohort study for january-July 1991. Setting-National Blood Transfusion Centre, Abidjan, Cote d'Ivoire. Subjects-Repeat donors (5831 units of blood) and first time donors (5076 units) in the first five months of 1991. Main outcome measures-Prevalence and estimated incidence of HIV infection in repeat and first time donors; estimated rate of potentially infected, HIV antibody negative units; and rate of (false negative) potentially infected units assuming a laboratory test sensitivity of 99%. Results-Overall HIV prevalence was 11.0% in first time donors and 2.1% in repeat donors. In the first seven months of 1991, 29 HIV antibody positive (27 HIV 1, 1 HIV 2, 1 dually reactive) donors with a seronegative unit of blood earlier in the year were identified; 26 had donated blood eight weeks or less before their estimated dates of seroconversion and may have been infectious (minimum rate 26/5831 (4-5/1000 potentially infected units)). Estimated incidence of infection in repeat donors was 1.2-2.5%. Laboratory test insensitivity would result in an estimated 1.1/1000 false negative units from first time donors and 0.211000 units from regular donors. The overall rate of potentially infected units (all donors, seroconversions, and errors) was estimated at 5.4-10.6/1000. Conclusions-The risk of HIV infection from a single unit of blood remains substantial (5.4-10.6/1000 units). To prevent infection from blood transfusion in areas of high incidence and prevalence of HIV all but absolutely essential transfusions should be avoided, and donors with low incidence of HIV infection should be selected.	CTR NATL TRANSFUS SANGUINE,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,DIV PARASIT DIS,MALARIA BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Lackritz, Eve/0000-0002-5397-7291				ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CHIEWSILP P, 1991, LANCET, V338, P1341, DOI 10.1016/0140-6736(91)92650-Q; COUROUCE AM, 1990, REV FR TRANSFUS HEM, V33, P431, DOI 10.1016/S1140-4639(05)80060-7; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DECOCK KM, 1988, AM J EPIDEMIOL, V127, P1250, DOI 10.1093/oxfordjournals.aje.a114917; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; JULIEN AM, 1988, LANCET, V2, P1248; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MILLER HG, 1990, AIDS 2ND DECADE, P289; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; ZUCK TF, 1988, NEW ENGL J MED, V318, P511, DOI 10.1056/NEJM198802253180809; 1990, B WORLD HEALTH ORGAN, V68, P262	17	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					498	502		10.1136/bmj.305.6852.498	http://dx.doi.org/10.1136/bmj.305.6852.498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1327367	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JL60900016
J	WILLIAMS, G; PATRICK, AW				WILLIAMS, G; PATRICK, AW			HUMAN INSULIN AND HYPOGLYCEMIA - BURNING ISSUE OR HOT AIR	BRITISH MEDICAL JOURNAL			English	Article							HYPOGLYCEMIA UNAWARENESS; AWARENESS; SYMPTOMS; IDDM				WILLIAMS, G (corresponding author), UNIV LIVERPOOL,DEPT MED,POB 147,LIVERPOOL L69 3BX,ENGLAND.							COLAGIURI S, 1992, LANCET, V339, P1432, DOI 10.1016/0140-6736(92)92028-E; CORP E, 1986, NEUROSCI LETT, V79, P17; COX DJ, 1991, PSYCHOSOM MED, V53, P453, DOI 10.1097/00006842-199107000-00010; DIAMOND MP, 1991, J CLIN ENDOCR METAB, V72, P1388, DOI 10.1210/jcem-72-6-1388; EGGER M, 1991, DIABETES CARE, V14, P1001, DOI 10.2337/diacare.14.11.1001; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; GALE EAM, 1989, LANCET, V2, P1264; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; KERN W, 1990, DIABETES, V39, P1091, DOI 10.2337/diabetes.39.9.1091; KERR D, 1991, DIABETES, V40, P1057, DOI 10.2337/diabetes.40.8.1057; Lawrence RD, 1941, LANCET, V2, P602; LINDE B, 1991, TXB DIABETES, P371; MARAN A, 1992, DIABETIC MED S1, V9, pA11; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PATRICK AW, 1992, DIABETIC MED, V9, P579, DOI 10.1111/j.1464-5491.1992.tb01843.x; SCHWARTZ MW, 1990, AM J PHYSIOL, V259, pE378, DOI 10.1152/ajpendo.1990.259.3.E378; TEUSCHER A, 1987, LANCET, V2, P382; 1991, LANCET, V338, P950; 1991, BMJ, V303, P1265	20	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					355	357		10.1136/bmj.305.6849.355	http://dx.doi.org/10.1136/bmj.305.6849.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1294086	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JJ03200026
J	KESSLER, DA				KESSLER, DA			THE BASIS OF THE FDAS DECISION ON BREAST IMPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.								0	251	254	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1713	1715		10.1056/NEJM199206183262525	http://dx.doi.org/10.1056/NEJM199206183262525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1309171	Bronze			2022-12-24	WOS:A1992HY62800032
J	EDLIN, BR; TOKARS, JI; GRIECO, MH; CRAWFORD, JT; WILLIAMS, J; SORDILLO, EM; ONG, KR; KILBURN, JO; DOOLEY, SW; CASTRO, KG; JARVIS, WR; HOLMBERG, SD				EDLIN, BR; TOKARS, JI; GRIECO, MH; CRAWFORD, JT; WILLIAMS, J; SORDILLO, EM; ONG, KR; KILBURN, JO; DOOLEY, SW; CASTRO, KG; JARVIS, WR; HOLMBERG, SD			AN OUTBREAK OF MULTIDRUG-RESISTANT TUBERCULOSIS AMONG HOSPITALIZED-PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; ASSOCIATION; SHELTER	Background. Since 1990 several clusters of multidrug-resistant tuberculosis have been identified among hospitalized patients with the acquired immunodeficiency syndrome (AIDS). We investigated one such cluster in a voluntary hospital in New York. Methods. We compared exposures among 18 patients with AIDS in whom tuberculosis resistant to isoniazid and streptomycin was diagnosed from January 1989 through April 1990 (the case patients) with exposures among 30 control patients who had AIDS and tuberculosis susceptible to isoniazid, streptomycin, or both. We also compared exposures among the 14 case patients hospitalized during the six months before the diagnosis of tuberculosis (the exposure period) with those among 44 control patients with AIDS matched for duration of hospitalization. Mycobacterium tuberculosis isolates were typed with analysis of restriction-fragment-length polymorphism (RFLP). Results. Case patients with drug-resistant tuberculosis were significantly more likely than controls with drug-susceptible tuberculosis to have been hospitalized during their exposure periods (14 of 18 vs. 10 of 30) (odds ratio, 7.0; 95 percent confidence interval, 1.6 to 36; P = 0.006). Case patients hospitalized during their exposure periods were significantly more likely to have been hospitalized on the same ward as a patient with infectious drug-resistant tuberculosis than were either controls with drug-susceptible tuberculosis hospitalized during their exposure periods or controls matched for duration of hospitalization (13 of 14 vs. 2 of 10 and 23 of 44) (odds ratio, 52; 95 percent confidence interval, 3.1 to 2474; P < 0.001; and odds ratio, infinity; 95 percent confidence interval, 2.4 to infinity; P = 0.005, respectively). Among those hospitalized on the same ward, the rooms of case patients were closer to that of the nearest patient with infectious tuberculosis than were the rooms of controls matched for duration of hospitalization. M. tuberculosis isolates from 15 of 16 case patients had identical patterns on RFLP analysis. Of 16 patients' rooms tested with air-flow studies, only 1 had the recommended negative-pressure ventilation. Conclusions. Multidrug-resistant tuberculosis is readily transmitted among hospitalized patients with AIDS. Physicians must be alert to this danger and must enforce adherence to the measures recommended to prevent nosocomial transmission of tuberculosis.	CTR DIS CONTROL,HOSP INFECT PROGRAM,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333; COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10032	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	EDLIN, BR (corresponding author), CTR DIS CONTROL,DIV HIV AIDS,MAILSTOP E-45,ATLANTA,GA 30333, USA.		Sordillo, Emilia Mia/AAF-3012-2021; Edlin, Brian R/F-2966-2018; Castro, Kenneth G/P-1882-2018	Sordillo, Emilia Mia/0000-0001-7787-3051; Edlin, Brian R/0000-0001-8172-8797; Castro, Kenneth G/0000-0001-7964-6354				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DESPREZ RM, 1990, PRINCIPLES PRACTICE, P1881; DIPERRI G, 1989, LANCET, V2, P1502; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; Kent PT, 1985, PUBLIC HLTH MYCOBACT, P159; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; PELLETIER AR, 1991, 40TH ANN C EP INT SE, P43; SALOMON N, 1991, 31ST INT C ANT AG CH, P152; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; VALWAY SE, 1992, 41ST ANN C EP INT SE, P30; 1985, MMWR, V34, P429; 1991, MMWR, V40, P585; [No title captured]; 1991, MMWR, V40, P129; 1990, MMWR S, V39, pRR17	23	743	762	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1514	1521		10.1056/NEJM199206043262302	http://dx.doi.org/10.1056/NEJM199206043262302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1304721				2022-12-24	WOS:A1992HW97200002
J	KOUTSKY, LA; STEVENS, CE; HOLMES, KK; ASHLEY, RL; KIVIAT, NB; CRITCHLOW, CW; COREY, L				KOUTSKY, LA; STEVENS, CE; HOLMES, KK; ASHLEY, RL; KIVIAT, NB; CRITCHLOW, CW; COREY, L			UNDERDIAGNOSIS OF GENITAL HERPES BY CURRENT CLINICAL AND VIRAL-ISOLATION PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS-INFECTION; TYPE-2 INFECTION; IMMUNE-RESPONSE; NATURAL-HISTORY; WESTERN BLOT; WOMEN; PREVALENCE; DIAGNOSIS; IMMUNOFLUORESCENCE; MANIFESTATIONS	Background. The current clinical strategy for diagnosing genital herpes simplex virus (HSV) infection in women relies on clinical findings plus the selective use of viral culture. The effectiveness of this approach for identifying women with genital herpes is unknown. Methods. We performed physical examinations, colposcopy, Pap smears, viral cultures, and HSV type-specific serologic assays of 779 randomly selected women attending a sexually transmitted disease clinic. Results. Evidence of HSV type 2 infection was detected in 363 women (47 percent), and 9 others (1 percent) had positive cultures indicative of urogenital or anal infection with HSV type 1. Of these 372 women, only 82 (22 percent) had symptoms. Fourteen women (4 percent) had viral shedding without symptoms, 60 (16 percent) had formerly had symptomatic episodes, and 216 (58 percent) had antibodies to HSV-2 with neither viral shedding nor a history of clinical episodes. Characteristic ulcerations of the external genitalia were present in only two thirds of the 66 women with positive HSV cultures; the others had atypical genital lesions or asymptomatic viral shedding. Isolation of HSV from a genitourinary tract specimen was the most sensitive (77 percent) test for confirming a first episode of infection. The detection of HSV-2-specific antibodies was the most sensitive (97 percent) way to confirm symptomatic reactivations of HSV-2 infection. HSV-2 serologic testing also identified the 290 women with asymptomatic HSV-2 infections (37 percent), including 14 (5 percent) who were shedding virus asymptomatically on the day of the examination. Conclusions. The current strategy for diagnosing genital HSV infection in women misses many cases. Newly developed type-specific serologic methods can identify women with recurrent genital HSV-2 infection, as well as those with unrecognized or subclinical infection.	UNIV WASHINGTON,SCH PUBL HLTH,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			, Holmes/K-6215-2019; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL CANCER INSTITUTE [R01CA034493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI012192, R01AI020381] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34493] Funding Source: Medline; NIAID NIH HHS [AI-12192, AI-20381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1985, J MED VIROL, V17, P153, DOI 10.1002/jmv.1890170208; ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1987, J VIROL METHODS, V18, P159, DOI 10.1016/0166-0934(87)90121-2; BADER C, 1978, J INFECT DIS, V138, P897, DOI 10.1093/infdis/138.6.897; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; Davis W, 1980, IARC SCI PUBL, V32, P192; DORSKY DI, 1987, ANN INTERN MED, V107, P859, DOI 10.7326/0003-4819-107-6-859; ESCHENBACH DA, 1988, AM J OBSTET GYNECOL, V158, P819, DOI 10.1016/0002-9378(88)90078-6; FLEISS JL, 1981, STATISTICAL METHODS, P51; GUINAN ME, 1985, EPIDEMIOL REV, V7, P127, DOI 10.1093/oxfordjournals.epirev.a036279; GUINAN ME, 1981, NEW ENGL J MED, V304, P759, DOI 10.1056/NEJM198103263041305; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KAUFMAN RH, 1973, CANCER RES, V33, P1446; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LIPSON SM, 1987, J CLIN MICROBIOL, V25, P391, DOI 10.1128/JCM.25.2.391-394.1987; LYNCH PJ, 1970, CUTIS, V6, P79; MANN SL, 1984, J INFECT DIS, V149, P1026, DOI 10.1093/infdis/149.6.1026; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MERTZ GL, 1984, JAMA-J AM MED ASSOC, V242, P1147; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; PAPANICOLAOU GN, 1963, ATLAS EXFOLIATIVE CY, P3; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; WADE JC, 1984, J INFECT DIS, V149, P750, DOI 10.1093/infdis/149.5.750; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; 1991, HIV AIDS Q EPIDEMIOL	38	229	233	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1533	1539		10.1056/NEJM199206043262305	http://dx.doi.org/10.1056/NEJM199206043262305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1315930				2022-12-24	WOS:A1992HW97200005
J	PRUKSANANONDA, P; HALL, CB; INSEL, RA; MCINTYRE, K; PELLETT, PE; LONG, CE; SCHNABEL, KC; PINCUS, PH; STAMEY, FR; DAMBAUGH, TR; STEWART, JA				PRUKSANANONDA, P; HALL, CB; INSEL, RA; MCINTYRE, K; PELLETT, PE; LONG, CE; SCHNABEL, KC; PINCUS, PH; STAMEY, FR; DAMBAUGH, TR; STEWART, JA			PRIMARY HUMAN HERPESVIRUS-6 INFECTION IN YOUNG-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXANTHEM-SUBITUM; ANTIBODY; PREVALENCE; DNA; IDENTIFICATION; AMPLIFICATION; SEQUENCES; INFANTS; HBLV; RASH	Background. Human herpesvirus 6 (HHV-6) is a recently discovered virus that, on the basis of serologic evidence, appears to infect most children by the age of three years. However, the clinical manifestations of primary HHV-6 infection have not been well defined. Methods. We studied consecutive children two years old or younger who presented to an emergency ward with febrile illnesses. Our evaluation included the isolation of HHV-6 from peripheral-blood mononuclear cells, an immunofluorescent-antibody assay, the detection of HHV-6 by the polymerase chain reaction (PCR), and restriction-endonuclease-fragment profiles of HHV-6 isolates. Results. HHV-6 was isolated from 34 of 243 acutely ill children (14 percent). The children with viremia had irritability, high temperatures (mean, 39.7-degrees-C), and inflammation of tympanic membranes (in 21), but few other localizing signs. Two children were hospitalized, but all 34 recovered after an average of four days of fever. The rash characteristic of roseola, which has been associated with HHV-6 infection, was noted in only three children. In 29 children (85 percent), serum samples obtained during convalescence had at least a fourfold increase in IgG antibody titers; 4 infants less than three months old who presumably had maternal antibody did not have this increase. HHV-6 was isolated from blood obtained during convalescence in only one child, but in two thirds of the children the virus could be detected by PCR. The isolates had genomic heterogeneity, indicating the presence of multiple strains. Conclusions. Primary infection with HHV-6 is a major cause of acute febrile illness in young children. Such infection is associated with varied clinical manifestations, viremia, and the frequent persistence of the viral genome in mononuclear cells.	UNIV ROCHESTER,SCH MED,DEPT PEDIAT,601 ELMWOOD AVE,BOX 689,ROCHESTER,NY 14642; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; DUPONT MERCK PHARMACEUT,WILMINGTON,DE	University of Rochester; Centers for Disease Control & Prevention - USA				Pellett, Philip/0000-0002-8536-8343				ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; AGUT H, 1988, LANCET, V1, P712; ASANO Y, 1991, J PEDIATR-US, V118, P891, DOI 10.1016/S0022-3476(05)82200-0; ASANO Y, 1989, J PEDIATR-US, V114, P535, DOI 10.1016/S0022-3476(89)80689-4; ASANO Y, 1989, J PEDIATR-US, V115, P264, DOI 10.1016/S0022-3476(89)80078-2; AUBIN JT, 1991, J CLIN MICROBIOL, V29, P367, DOI 10.1128/JCM.29.2.367-372.1991; Breese Jr. BB., 1941, NEW YORK J MED, V41, P1854; BRIGGS M, 1988, LANCET, V1, P1058; BROWN NA, 1988, LANCET, V2, P396; DOWNING RG, 1987, LANCET, V2, P390; JARRETT RF, 1988, LEUKEMIA, V2, P496; KIKUTA H, 1989, J INFECT DIS, V160, P550, DOI 10.1093/infdis/160.3.550; KNOWLES WA, 1988, LANCET, V2, P912; KONDO K, 1990, J CLIN MICROBIOL, V28, P970, DOI 10.1128/JCM.28.5.970-974.1990; KRUEGER GRF, 1988, J VIROL METHODS, V21, P125, DOI 10.1016/0166-0934(88)90059-6; LINDQUESTER GJ, 1991, VIROLOGY, V182, P102, DOI 10.1016/0042-6822(91)90653-S; PELLETT PE, 1990, ADV EXP MED BIOL, V278, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SUGA S, 1989, PEDIATRICS, V83, P1003; TAKAHASHI K, 1988, LANCET, V1, P1463; UEDA K, 1989, J INFECT DIS, V159, P750, DOI 10.1093/infdis/159.4.750; YAMANISHI K, 1988, LANCET, V1, P1065	24	213	219	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1445	1450		10.1056/NEJM199205283262201	http://dx.doi.org/10.1056/NEJM199205283262201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1315416				2022-12-24	WOS:A1992HV46900001
J	GREEN, A; GALE, EAM; PATTERSON, CC				GREEN, A; GALE, EAM; PATTERSON, CC			INCIDENCE OF CHILDHOOD-ONSET INSULIN-DEPENDENT DIABETES-MELLITUS - THE EURODIAB ACE STUDY	LANCET			English	Article							RISING INCIDENCE; CHILDREN; EUROPE; IDDM; AGE	EURODIAB ACE is a collaborative European study that was set up to assess incidence of childhood insulin-dependent diabetes mellitus (IDDM) in Europe, test the proposal of a south-north gradient, and to gather information to determine the causes and pathogenesis of the disease. Here, the basic epidemiological results are reported. Newly diagnosed cases of IDDM in children aged up to 15 years were identified prospectively in twenty-four geographically well-defined study regions in Europe and Israel (a total of 16.8 million children) during 1989 and 1990. 3060 cases were identified with estimated ascertainment rates exceeding 90% in all study regions. Age-standardised and sex-standardised incidence rates varied widely, ranging from 4.6 (northern Greece) to 42.9 (two regions in Finland) cases per 100 000 per year. Rates in southern Europe were generally higher than previously assumed, and there was an unexpectedly high incidence in Sardinia, which had the second highest rate (30.2 cases per 100 000 per year) recorded in Europe. Eastern European regions had generally low rates. The collaborative network now established provides a framework for further studies to examine the complex interaction between genetic and environmental factors in the cause and pathogenesis of IDDM.	ODENSE UNIV,GENET EPIDEMIOL RES UNIT,DK-5230 ODENSE,DENMARK; ST BARTHOLOMEWS HOSP,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; QUEENS UNIV BELFAST,DEPT EPIDEMIOL & PUBL HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	University of Southern Denmark; University of London; Queen Mary University London; Queens University Belfast				Gorus, Frans/0000-0002-9007-6177				AKERBLOM HK, 1985, DIABETES CARE, V8, P10, DOI 10.2337/diacare.8.1.S10; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BISHOP YMM, 1974, DISCRETE MULTIVARIAT, P229; CARCASSI C, 1990, DIABETES S1, V39; Christy M, 1979, Diabetes Care, V2, P127, DOI 10.2337/diacare.2.2.127; DEBEAUFORT CE, 1988, DIABETOLOGIA, V31, P758, DOI 10.1007/BF00274779; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; GREEN A, 1986, DIABETES 1985, P443; GREEN A, IN PRESS DIABETES EU; HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982; HOURS M, 1984, REV EPIDEMIOL SANTE, V32, P107; JONER G, 1989, DIABETOLOGIA, V32, P79, DOI 10.1007/BF00505178; KALITS I, 1990, DIABETOLOGIA, V33, P346, DOI 10.1007/BF00404638; LAPORTE RE, 1985, DIABETES CARE, V8, P101, DOI 10.2337/diacare.8.1.S101; LARON Z, 1985, DIABETES CARE, V8, P24, DOI 10.2337/diacare.8.1.S24; LESTRADET H, 1977, DIABETES METAB, V3, P29; LEVYMARCHAL C, 1990, DIABETOLOGIA, V33, P465, DOI 10.1007/BF00405107; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; REWERS M, 1987, DIABETES, V36, P106, DOI 10.2337/diabetes.36.1.106; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SCHOBER E, 1988, ACTA PAEDIATR SCAND, V77, P299, DOI 10.1111/j.1651-2227.1988.tb10646.x; SHUBNIKOV E, 1991, DIABETES S1, V40; SOLTESZ G, 1990, DIABETIC MED, V7, P111, DOI 10.1111/j.1464-5491.1990.tb01343.x; THORSSON AV, 1991, MAY INT S EP ET IDDM; TUOMILEHTOWOLF E, 1989, LANCET, V2, P299; VAANDRAGER GJ, 1984, DIABETOLOGIA, V27, P203	29	403	408	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					905	909		10.1016/0140-6736(92)90938-Y	http://dx.doi.org/10.1016/0140-6736(92)90938-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348306				2022-12-24	WOS:A1992HN48300012
J	BERGSAGEL, DJ; FINEGOLD, MJ; BUTEL, JS; KUPSKY, WJ; GARCEA, RL				BERGSAGEL, DJ; FINEGOLD, MJ; BUTEL, JS; KUPSKY, WJ; GARCEA, RL			DNA-SEQUENCES SIMILAR TO THOSE OF SIMIAN VIRUS-40 IN EPENDYMOMAS AND CHOROID-PLEXUS TUMORS OF CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-BRAIN-TUMORS; B-LYMPHOTROPIC PAPOVAVIRUS; TRANSGENIC MICE; JC-VIRUS; PANCREATIC-ISLETS; POLYOMAVIRUS-JC; T-ANTIGEN; SV40; HAMSTERS; TISSUE	Background. Ependymomas and papillomas of the choroid plexus occur in early childhood. The ubiquitous human polyomaviruses, BK virus and JC virus, have been associated with the induction of these neoplasms in animal models. A related monkey polyomavirus, simian virus 40 (SV40), is highly tumorigenic in rodents and also induces choroid plexus papillomas. Methods. We tested the possibility that polyomaviruses were associated with these tumors in humans. Tumors from 31 children - 20 with choroid plexus neoplasms and 11 with ependymomas - were evaluated for the presence of polyomavirus T-antigen gene sequences by means of amplification with the polymerase chain reaction. Results. Ten of the 2O choroid plexus tumors and 10 of the 11 ependymomas contained amplification products that preferentially hybridized to probes specific for SV40 viral DNA rather than BK or JC viral DNA. In two specimens, DNA sequencing demonstrated that the amplified sequence was identical to the sequence of that region of the SV40 gene. In three other specimens, amplification with SV40-specific primers revealed a 574-bp segment of the SV40 viral gene. In 7 of 11 tumors examined by immunohistochemical staining, viral T antigen was expressed in the nuclei of the neoplastic cells. Conclusions. Half of the choroid plexus tumors and most of the ependymomas that we studied contained and expressed a segment of T-antigen gene related to SV40. These results suggest that SV40 or a closely related virus may have an etiologic role in the development of these neoplasms during childhood, as in animal models.	CHILDRENS HOSP MED CTR, DANA FARBER CANC INST,DIV PEDIAT ONCOL,D1620, 44 BINNEY ST, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DANA FARBER CANC INST, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine			Bergsagel, Daniel John/I-6464-2019	Butel, Janet/0000-0002-6876-3245	NATIONAL CANCER INSTITUTE [R01CA022555] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22555] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICARDI J, 1969, ARCH FR PEDIATR, V26, P1103; BRADE L, 1980, J MED VIROL, V6, P301, DOI 10.1002/jmv.1890060405; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; CORALLINI A, 1978, J NATL CANCER I, V61, P875; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DOUGHERTY RM, 1976, J GEN VIROL, V33, P61, DOI 10.1099/0022-1317-33-1-61; DUBENSKY TW, 1984, J VIROL, V50, P779, DOI 10.1128/JVI.50.3.779-783.1984; DUBENSKY TW, 1984, J VIROL, V50, P541, DOI 10.1128/JVI.50.2.541-546.1984; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, FED PROC, V21, P930; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2658, DOI 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO;2-C; GARDNER SD, 1971, LANCET, V1, P1253; GEISSLER E, 1990, PROG MED VIROL, V37, P211; Gibson P E, 1983, Prog Clin Biol Res, V105, P119; GREENLEE JE, 1978, ANN NEUROL, V3, P479, DOI 10.1002/ana.410030604; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAUSEN HZ, 1987, CANCER, V59, P1692, DOI 10.1002/1097-0142(19870515)59:10<1692::AID-CNCR2820591003>3.0.CO;2-F; HEIDEMAN RL, 1989, PRINCIPLES PRACTICE, P505; Higuchi R, 1989, AMPLIFICATIONS, V2, P1; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; ISRAEL MA, 1978, VIROLOGY, V90, P187, DOI 10.1016/0042-6822(78)90302-1; KANDA T, 1986, J VIROL, V59, P531, DOI 10.1128/JVI.59.2.531-534.1986; KAWASAKI ES, 1990, PCR PROTOCOLS GUIDE, P153; KIRSCHSTEIN RL, 1962, NATURE, V195, P299, DOI 10.1038/195299b0; KOSAKA H, 1980, J NEUROSURG, V52, P367, DOI 10.3171/jns.1980.52.3.0367; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; LANFORD RE, 1979, VIROLOGY, V97, P295, DOI 10.1016/0042-6822(79)90341-6; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; Maniatis T., 1982, MOL CLONING; MCCANCE DJ, 1977, INFECT IMMUN, V18, P196, DOI 10.1128/IAI.18.1.196-202.1977; MEINKE W, 1979, NEUROLOGY, V29, P1590, DOI 10.1212/WNL.29.12.1590; PADGETT BL, 1971, LANCET, V1, P1257; PADGETT BL, 1976, PROG MED VIROL, V22, P1; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; PATER MM, 1980, VIRUSES NATURALLY OC, V7, P329; RABSON AS, 1962, J NATL CANCER I, V29, P765; ROBINOW M, 1984, J PEDIATR-US, V104, P404, DOI 10.1016/S0022-3476(84)81105-1; Scherneck S, 1979, Zentralbl Neurochir, V40, P121; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TABUCHI K, 1978, INT J CANCER, V21, P12, DOI 10.1002/ijc.2910210104; TAVIS JE, 1989, J VIROL, V63, P901, DOI 10.1128/JVI.63.2.901-911.1989; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; Tooze J, 1980, DNA TUMOR VIRUSES; UCHIDA S, 1979, J NATL CANCER I, V63, P119; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEISS AF, 1975, P NATL ACAD SCI USA, V72, P609, DOI 10.1073/pnas.72.2.609; WOLD WSM, 1978, P NATL ACAD SCI USA, V75, P454, DOI 10.1073/pnas.75.1.454; YOGO Y, 1990, J VIROL, V64, P3139, DOI 10.1128/JVI.64.6.3139-3143.1990; ZANG KD, 1979, NATURWISSENSCHAFTEN, V66, P59, DOI 10.1007/BF00369369; ZIMMERMANN W, 1981, ACTA VIROL, V25, P199	59	369	374	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					988	993		10.1056/NEJM199204093261504	http://dx.doi.org/10.1056/NEJM199204093261504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1312224				2022-12-24	WOS:A1992HM28500004
J	DAMBLYCHAUDIERE, C; JAMET, E; BURRI, M; BOPP, D; BASLER, K; HAFEN, E; DUMONT, N; SPIELMANN, P; GHYSEN, A; NOLL, M				DAMBLYCHAUDIERE, C; JAMET, E; BURRI, M; BOPP, D; BASLER, K; HAFEN, E; DUMONT, N; SPIELMANN, P; GHYSEN, A; NOLL, M			THE PAIRED BOX GENE POX-NEURO - A DETERMINANT OF POLY-INNERVATED SENSE-ORGANS IN DROSOPHILA	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE COMPLEX; SPATIAL EXPRESSION; DNA; LOCUS; MELANOGASTER; EMBRYOS; SEGMENTATION; ELEMENTS	This study describes the structure and function of pox neuro (poxn), a gene previously isolated by virtue of a conserved domain, the paired box, which it shares with the segmentation genes paired and gooseberry. Its expression pattern has been analyzed, particularly during development of the PNS. We propose that poxn is a "neuroblast identity" gene acting in both the PNS and the CNS on the basis of the following evidence. Its expression is restricted to four neuronal precursors in each hemisegment: two neuronal stem cells (neuroblasts) in the CNS, and two sensory mother cells (SMCs) in the PNS. The SMCs that express poxn produce the poly-innervated external sense organs of the larva. In poxn- embryos, poly-innervated sense organs are transformed into mono-innervated. Conversely, ectopic expression of poxn in embryos transformed with a heat-inducible poxn gene can switch mono-innervated to poly-innervated sense organs. Expression of poxn in the wing disc is restricted to the SMCs of the poly-innervated sense organs, suggesting that poxn also determines the lineage of poly-innervated adult sense organs.	UNIV ZURICH,INST MOLEK BIOL 2,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich; University of Zurich	DAMBLYCHAUDIERE, C (corresponding author), UNIV LIBRE BRUXELLES,GENET LAB,B-1640 RHODE ST GENESE,BELGIUM.		Jamet, Elisabeth/Z-2476-2019; Bopp, Daniel/L-3517-2018	Bopp, Daniel/0000-0002-0740-9672; Basler, Konrad/0000-0003-3534-1529; Spielmann, Patrick/0000-0001-7056-0351				BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; Bate C.M., 1978, HDB SENSORY PHYSL, V9, P1, DOI [10.1007/978-3-642-66880-7_1, DOI 10.1007/978-3-642-66880-7_1]; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1986, ROUX ARCH DEV BIOL, V195, P222, DOI 10.1007/BF02438954; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAVIS MB, 1988, GENETICS, V120, P755; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1991, IN PRESS DETERMINANT; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; FREI E, 1985, EMBO J, V4, P979, DOI 10.1002/j.1460-2075.1985.tb03727.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; Hertweck H, 1931, Z WISS ZOOL ABT A, V139, P559; HUANG F, 1991, DEVELOPMENT, V111, P1087; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; Kankel D.R., 1980, Genetics and Biology of Drosophila, V2d, P295; Keilin D, 1911, CR HEBD ACAD SCI, V153, P977; Keilin D., 1915, B SCI FR BELG, V49, P15; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LAKES R, 1990, CELL TISSUE RES, V259, P93, DOI 10.1007/BF00571434; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Maniatis T., 1982, MOL CLONING; NORNES HO, 1990, DEVELOPMENT, V109, P797; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TIX S, 1989, DEVELOPMENT, V107, P855; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199	60	118	120	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					159	172		10.1016/0092-8674(92)90127-X	http://dx.doi.org/10.1016/0092-8674(92)90127-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348214	Green Accepted			2022-12-24	WOS:A1992HM44500015
J	GRIESHAMMER, U; SASSOON, D; ROSENTHAL, N				GRIESHAMMER, U; SASSOON, D; ROSENTHAL, N			A TRANSGENE TARGET FOR POSITIONAL REGULATORS MARKS EARLY ROSTROCAUDAL SPECIFICATION OF MYOGENIC LINEAGES	CELL			English	Article							FAST SKELETAL-MUSCLE; MOTONEURON PROJECTION PATTERNS; DIFFERENT SEGMENTAL LEVELS; EMBRYONIC CHICK HINDLIMB; HOMEODOMAIN-DNA COMPLEX; MYOSIN LIGHT CHAIN-1; GENE FAMILY; ENHANCER-BINDING; ACTIN PROMOTER; CELL LINEAGES	In transgenic mice, muscle-specific regulatory elements from the myosin light chain (MLC) 1/3 locus drive graded expression of a linked CAT reporter gene in selected fast muscles along the anteroposterior axis of the adult animal. The gradient of MLC-CAT transcripts is established early in development, during the generation of somites from the paraxial mesoderm and the activation of myogenic factor gene expression, and is not reflected in the expression of the endogenous MLC1 gene. At later embryonic stages, the gradient of MLC-CAT transcripts persists in intercostal and intervertebral muscles, but is not maintained in other axial muscles. Profiles of CAT transgene activity reveal that the gradient is generated during the maturation of increasingly caudal somites, opposite to the direction of somite development, and is retained in dissociated somite cultures. We propose that coexpression of myogenic factors is necessary but not sufficient to regulate expression of the MLC-CAT transgene, which is responsive to additional positional cues in the embryo.			GRIESHAMMER, U (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X; Rosenthal, Nadia/0000-0002-7599-7365	NATIONAL INSTITUTE ON AGING [R01AG008920] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG08920] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGNALL KM, 1989, DEVELOPMENT, V107, P931; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHEVALLIER A, 1979, J EMBRYOL EXP MORPH, V49, P73; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GAUTHIER GF, 1979, J CELL BIOL, V81, P10, DOI 10.1083/jcb.81.1.10; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1988, DEV BIOL, V126, P394, DOI 10.1016/0012-1606(88)90149-2; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LOWEY S, 1971, NATURE, V234, P81, DOI 10.1038/234081a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Meinhardt H., 1982, MODELS BIOL PATTERN; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; ROSENTHAL N, 1992, IN PRESS REGULATION; ROY RK, 1982, FEBS LETT, V149, P22, DOI 10.1016/0014-5793(82)81063-6; RUGH R, 1968, MOUSE ITS REPRODUCTI; RUTZ R, 1982, DEV BIOL, V90, P399, DOI 10.1016/0012-1606(82)90389-X; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEIDEL U, 1989, J BIOL CHEM, V264, P16109; STERN CD, 1987, DEVELOPMENT, V99, P261; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; VIVARELLI E, 1986, DEV BIOL, V117, P319, DOI 10.1016/0012-1606(86)90374-X; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WALSH K, 1988, MOL CELL BIOL, V8, P1800, DOI 10.1128/MCB.8.4.1800; WALSH K, 1987, J BIOL CHEM, V262, P9429; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WHALEN RG, 1982, MUSCLE DEV MOL CELLU, P25; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; [No title captured]	86	81	81	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					79	93		10.1016/0092-8674(92)90120-2	http://dx.doi.org/10.1016/0092-8674(92)90120-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313337				2022-12-24	WOS:A1992HM44500008
J	MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME				MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME			EXCESSIVE CHROMIUM INTAKE IN CHILDREN RECEIVING TOTAL PARENTERAL-NUTRITION	LANCET			English	Article							MILD PERIPHERAL NEUROPATHY; GLUCOSE-TOLERANCE; DEFICIENCY; SUPPLEMENTATION; SUFFICIENCY; VITAMINS; INFANTS; INSULIN; BLOOD; SERUM	Various expert bodies have recommended that the daily parental intake of chromium in children receiving total parenteral nutrition (TPN) should be 0.20-mu-g/kg. To test whether this-recommendation is appropriate, we assessed chromium intake, serum chromium concentrations, and renal function in 15 children receiving TPN. The median duration of TPN use was 9.5 (range 1.3-14) years. The children's glomerular filtration rate (GFR), measured by plasma clearance of indium-111-DTPA was lower than that of non-TPN controls (70 [SD 17) vs 110 [10] ml/min per 1.73 m2). The daily chromium intake averaged 0.15 (0.09) mu-g/kg daily but the serum chromium concentration was 20 (4 to 42) times higher than that of the controls (2.1 [1.2] vs 0.10 [0.03] mu-g/l; p < 0.0001). GFR was significantly inversely correlated with serum chromium concentration (r = -0.60, p < 0.02), daily chromium intake (r = -0.69, p <0.01), cumulative parenteral chromium intake (r = -0.72, p < 0.01), and TPN duration (r = -0.52, p < 0.05). We discontinued chromium supplementation of TPN solutions and reassessed the children a year later. Contaminating chromium concentrations were 1.0-1.8-mu-g/l in TPN solutions and 0.9-mu-g/l in fat emulsions. Drinking water contained 4.3-5.7-mu-g/l. Thus, the chromium intake without supplementation was only 0.05 (0.01) mu-g/kg daily. The mean serum chromium concentration fell to 0.50 (0.30) mu-g/l but was still significantly higher than that in the controls (p < 0.01). The GFR did not change significantly (65 [14] ml/min per 1.73 m2). No patient has shown signs of chromium deficiency. Although our patients were receiving less than the recommended chromium intake during supplementation, their high serum concentrations suggested excessive intake. The recommended parenteral chromium intake for children should be lowered.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV PEDIAT GASTROENTEROL & NUTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ANDERSON RA, 1989, SCI TOTAL ENVIRON, V86, P75, DOI 10.1016/0048-9697(89)90196-4; BROWN RO, 1986, DIGEST DIS SCI, V31, P661, DOI 10.1007/BF01318699; BYRNE WJ, 1979, SURG GYNECOL OBSTET, V149, P593; CASEY CE, 1984, BRIT J NUTR, V52, P73, DOI 10.1079/BJN19840072; CHASSON AL, 1961, AM J CLIN PATHOL, V35, P83, DOI 10.1093/ajcp/35.1_ts.83; ESPINAL J, 1987, NATURE, V328, P574, DOI 10.1038/328574a0; EVANS GW, 1973, BIOCHEM BIOPH RES CO, V50, P718, DOI 10.1016/0006-291X(73)91303-X; FREUND H, 1979, JAMA-J AM MED ASSOC, V241, P496, DOI 10.1001/jama.241.5.496; GHISOLFI J, 1984, JOURNEES PARISIENNES, P97; GREENE HL, 1988, AM J CLIN NUTR, V48, P1324; GURSON CT, 1971, AM J CLIN NUTR, V24, P1313; HAMBRIDGE KM, 1989, TXB GASTROENTEROLOGY, P398; HOPKINS LL, 1968, AM J CLIN NUTR, V21, P203, DOI 10.1093/ajcn/21.3.203; ITO Y, 1990, JPEN-PARENTER ENTER, V14, P610, DOI 10.1177/0148607190014006610; JEEJEEBHOY KN, 1977, AM J CLIN NUTR, V30, P531; KIEN CL, 1986, JPEN-PARENTER ENTER, V10, P662, DOI 10.1177/0148607186010006662; KUMPULAINEN J, 1980, AM J CLIN NUTR, V33, P2299, DOI 10.1093/ajcn/33.11.2299; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; MERTZ W, 1969, PHYSIOL REV, V49, P163, DOI 10.1152/physrev.1969.49.2.163; MOORE MC, 1986, PEDIATRICS, V77, P530; RIALES R, 1981, AM J CLIN NUTR, V34, P2670, DOI 10.1093/ajcn/34.12.2670; SCHERMAIER AJ, 1985, CLIN CHIM ACTA, V152, P123, DOI 10.1016/0009-8981(85)90183-4; SCHROEDER HA, 1966, J NUTR, V88, P439, DOI 10.1093/jn/88.4.439; SCHWARZ K, 1959, ARCH BIOCHEM BIOPHYS, V85, P292, DOI 10.1016/0003-9861(59)90479-5; 1989, FOOD NUTRITION BOARD, P242; 1988, CHROMIUM ENV HLTH CR, P61; 1979, DIABETES, V28, P1039; 1979, JAMA-J AM MED ASSOC, V241, P2051	28	70	70	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					385	388		10.1016/0140-6736(92)90078-H	http://dx.doi.org/10.1016/0140-6736(92)90078-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346659				2022-12-24	WOS:A1992HD65900003
J	JORGENSEN, JL; ESSER, U; FAZEKAS DE ST GROTH, B; REAY, PA; DAVIS, MM				JORGENSEN, JL; ESSER, U; FAZEKAS DE ST GROTH, B; REAY, PA; DAVIS, MM			MAPPING T-CELL RECEPTOR PEPTIDE CONTACTS BY VARIANT PEPTIDE IMMUNIZATION OF SINGLE-CHAIN TRANSGENICS	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; BETA-CHAIN; ANTIGEN RECEPTOR; JUNCTIONAL REGIONS; MHC MOLECULE; RECOGNITION; GENES; SPECIFICITY; DETERMINANT; USAGE	To test models of T-cell recognition, mice transgenic for T-cell receptor-alpha or beta-chain have been immunized with variant peptides that force changes in the resulting T-cell response. In particular, charge substitutions on the peptide often elicit reciprocal charges in the junctional (CDR3) sequences of T-cell receptor V(alpha) or V(beta) chains, indicating direct T-cell receptor-peptide contact, and allowing derivation of a topology for the T-cell receptor-MHC interaction. At one position on the peptide, variants transformed a homogeneous V(beta) response into a very heterogeneous one.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	JORGENSEN, JL (corresponding author), STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.		de St Groth, Barbara Fazekas/O-3017-2017	de St Groth, Barbara Fazekas/0000-0001-6817-9690; Davis, Mark/0000-0001-6868-657X				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AEBISCHER T, 1990, EUR J IMMUNOL, V20, P523, DOI 10.1002/eji.1830200310; AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; BOTSTEIN D, 1982, ANNU REV GENET, V16, P61, DOI 10.1146/annurev.ge.16.120182.000425; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHEN SZ, 1990, BIOTECHNIQUES, V8, P32; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FOX BS, 1987, J IMMUNOL, V139, P1578; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HUPPI KE, 1988, IMMUNOGENETICS, V27, P51, DOI 10.1007/BF00404444; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAI MZ, 1990, J IMMUNOL, V144, P4851; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; ROCK KL, 1985, HYBRIDOMA TECHNOLOGY, P527; RODEWALD HR, 1989, J IMMUNOL, V143, P4238; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHWARTZ RH, 1985, J IMMUNOL, V135, P2598; SORGER SB, 1990, J IMMUNOL, V144, P1127; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TJOELKER LW, 1990, P NATL ACAD SCI USA, V87, P7856, DOI 10.1073/pnas.87.20.7856; TOMONARI K, 1990, IMMUNOGENETICS, V32, P60, DOI 10.1007/BF01787331; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; WHITE J, 1989, J IMMUNOL, V143, P1822; WITHER J, 1991, J IMMUNOL, V146, P3513; YANAGI Y, 1990, J VIROL, V64, P5919, DOI 10.1128/JVI.64.12.5919-5926.1990; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0	51	530	534	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					224	230		10.1038/355224a0	http://dx.doi.org/10.1038/355224a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1309938				2022-12-24	WOS:A1992GZ69400056
J	BOUVET, P; BELASCO, JG				BOUVET, P; BELASCO, JG			CONTROL OF RNASE-E-MEDIATED RNA DEGRADATION BY 5'-TERMINAL BASE-PAIRING IN ESCHERICHIA-COLI	NATURE			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; RIBONUCLEASE-E; BACILLUS-SUBTILIS; PROCESSING ENZYME; PRIMER FORMATION; STABILITY; AMS; PLASMID; GENE	DESPITE the variety of messenger RNA half-lives in bacteria (0.5-30 min in Escherichia coli) and their importance in controlling gene expression, their molecular basis remains obscure. The life-time of an entire mRNA molecule can be determined by features near,its 5' end, but no 5' exoribonuclease has been identified in any prokaryotic organism1-6. A mutation that inactivates E. coli RNase E also increases the average lifetime of bulk E. coli mRNA and of many individual messages, suggesting that cleavage by this endonuclease may be the rate-determining step in the degradation of most mRNAs in E. coli7-16. We have investigated the substrate preference of RNase E in E. coli by using variants of RNA I, a small untranslated RNA whose swift degradation in vivo is initiated by RNase E cleavage at an internal site. We report here that RNase E has an unprecedented substrate specificity for an endoribonuclease, as it preferentially cleaves RNAs that have several unpaired nucleotides at the 5' end. The sensitivity of RNase E to 5'-terminal base pairing may explain how determinants near the 5' end can control rates of mRNA decay in bacteria.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; UNIV RENNES 1,BIOL & GENET DEV LAB,CNRS,UA 256,F-35042 RENNES,FRANCE	Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes			, Bouvet/AAC-8779-2020	Bouvet, Philippe/0000-0003-4524-2233				APIRION D, 1978, GENETICS, V90, P659; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; BECHHOFER DH, 1989, J BACTERIOL, V171, P5803, DOI 10.1128/jb.171.11.5803-5811.1989; BELASCO JG, 1986, CELL, V46, P245, DOI 10.1016/0092-8674(86)90741-5; CANNISTRARO VJ, 1985, J BACTERIOL, V161, P820, DOI 10.1128/JB.161.2.820-822.1985; CHEN LH, 1991, J BACTERIOL, V173, P4578, DOI 10.1128/jb.173.15.4578-4586.1991; DEUTSCHER MP, 1990, POSTTRANSCRIPTIONAL, P1; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; FORCHHAMMER J, 1972, J MOL BIOL, V71, P687, DOI 10.1016/S0022-2836(72)80032-9; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GORSKI K, 1985, CELL, V43, P461, DOI 10.1016/0092-8674(85)90176-X; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MORIKAWA N, 1969, NATURE, V223, P37, DOI 10.1038/223037a0; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MORSE DE, 1969, NATURE, V223, P40, DOI 10.1038/223040a0; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SANDLER P, 1989, J BACTERIOL, V171, P6680, DOI 10.1128/jb.171.12.6680-6688.1989; SANDLER P, 1988, J MOL BIOL, V203, P905, DOI 10.1016/0022-2836(88)90116-7; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YAMAMOTO T, 1975, J MOL BIOL, V92, P289, DOI 10.1016/0022-2836(75)90228-4	32	191	196	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					488	491		10.1038/360488a0	http://dx.doi.org/10.1038/360488a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280335				2022-12-24	WOS:A1992KA79700067
J	TARAGIN, MI; WILLETT, LR; WILCZEK, AP; TROUT, R; CARSON, JL				TARAGIN, MI; WILLETT, LR; WILCZEK, AP; TROUT, R; CARSON, JL			THE INFLUENCE OF STANDARD OF CARE AND SEVERITY OF INJURY ON THE RESOLUTION OF MEDICAL MALPRACTICE CLAIMS	ANNALS OF INTERNAL MEDICINE			English	Article						MALPRACTICE; SEVERITY OF ILLNESS INDEX; INSURANCE, LIABILITY; JURISPRUDENCE; PROFESSIONAL PRACTICE	PHYSICIANS	Objective: To explore how frequently physicians lose medical malpractice cases despite providing standard care and to assess whether severity of patient injury influences the frequency of plaintiff payment. Design: Retrospective cohort study. Setting: Physicians from the state of New Jersey insured by one insurance company from 1977 to 1992. Participants: A total of 12 829 physicians involved in 8231 closed malpractice cases. Measurements: Physician care and claim severity were prospectively determined by the insurance company using a standard process. Results: Physician care was considered defensible in 62% of the cases and indefensible in 25% of the cases, in almost half of which the physician admitted error. In the remaining 13% of cases, it was unclear whether physician care was defensible. The plaintiff received a payment in 43% of all cases. Payment was made 21 % of the time if physician care was considered defensible, 91% if considered indefensible, and 59% if considered unclear. The severity of the injury was classified as low, medium, or high in 28%, 47%, and 25% of the cases, respectively. Severity of injury had a small but significant association (P < 0.001) with the frequency of plaintiff payment (low severity, 39%; medium severity, 43%; and high severity, 47%). The severity of injury was not associated with the payment rate in cases resolved by a jury (low severity, 23%; medium severity, 25%; and high severity, 23%). Conclusions: In malpractice cases, physicians provide care that is usually defensible. The defensibility of the case and not the severity of patient injury predominantly influences whether any payment is made. Even in cases that require a jury verdict, the severity of patient injury has little effect on whether any payment is made. Our findings suggest that unjustified payments are probably uncommon.	UNIV MED & DENT NEW JERSEY, COOK COLL, NEW BRUNSWICK, NJ 08903 USA; NEW JERSEY MED INTERINSURANCE EXCHANGE, LAWRENCEVILLE, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	TARAGIN, MI (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DIV GEN INTERNAL MED, 97 PATERSON ST, NEW BRUNSWICK, NJ 08903 USA.							Boggs J S, 1987, J Fla Med Assoc, V74, P767; BOVBJERG RR, 1991, JAMA-J AM MED ASSOC, V265, P2836, DOI 10.1001/jama.265.21.2836; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; SAMUEL FE, 1986, LIABILITY THREAT SLO; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SLOAN FA, 1990, LAW SOC REV, V24, P997, DOI 10.2307/3053617; TARAGIN MI, 1992, IN PRESS AM J MED, P93; WEISS BD, 1986, J FAM PRACTICE, V23, P55; 1987, CONTINUING NEED LEGI; 1987, GAOHRD8755 GEN ACC O; 1989, AM MED NEWS     0106; 1987, GAOHRD8721 GEN ACC O; 1984, PHYSICIAN CHARACTERI; 1986, GAOHRD8650 GEN ACC O	18	118	118	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1992	117	9					780	784		10.7326/0003-4819-117-9-780	http://dx.doi.org/10.7326/0003-4819-117-9-780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV424	1308760				2022-12-24	WOS:A1992JV42400013
J	SCHLUEDERBERG, A; STRAUS, SE; PETERSON, P; BLUMENTHAL, S; KOMAROFF, AL; SPRING, SB; LANDAY, A; BUCHWALD, D				SCHLUEDERBERG, A; STRAUS, SE; PETERSON, P; BLUMENTHAL, S; KOMAROFF, AL; SPRING, SB; LANDAY, A; BUCHWALD, D			CHRONIC FATIGUE SYNDROME RESEARCH - DEFINITION AND MEDICAL OUTCOME ASSESSMENT	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; DIAGNOSIS, DIFFERENTIAL; SLEEP DISORDERS	BARR VIRUS-INFECTION; FIBROMYALGIA; POPULATION	A workshop was held 18 to 19 March 1991 at the National Institutes of Health to address critical issues in research concerning the chronic fatigue syndrome (CFS). Case definition, confounding diagnoses, and medical outcome assessment by laboratory and other means were considered from the perspectives of key medical specialties involved in CFS research. It was recommended that published Centers for Disease Control (CDC) case-definition criteria be modified to exclude fewer patients from analysis because of a history of psychiatric disorder. Specific recommendations were made concerning the inclusion or exclusion of other major confounding diagnoses, and a standard panel of laboratory tests was specified for initial patient evaluation. The workshop emphasized the importance of recognizing other conditions that could explain the patient's symptoms and that may be treatable. It was viewed as essential for the investigator to screen for psychiatric disorder using a combination of self-report instruments followed by at least one structured interview to identity patients who should be excluded from studies or considered as a separate subgroup in data analysis. Because CFS is not a homogeneous abnormality and because there is no single pathogenic mechanism, research progress may depend upon delineation of these and other patient subgroups for separate data analysis. Despite preliminary data, no physical finding or laboratory test was deemed confirmatory of the diagnosis of CFS. For assessment of clinical status, investigators must rely on the use of standardized instruments for patient self-reporting of fatigue, mood disturbance, functional status, sleep disorder, global well-being, and pain. Further research is needed to develop better instruments for quantifying these domains in patients with CFS.	NIMH, BETHESDA, MD 20892 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA; RUSH UNIV, MED CTR, DEPT IMMUNOL MICROBIOL, CHICAGO, IL 60612 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Brigham & Women's Hospital; Rush University; Harborview Medical Center; University of Washington; University of Washington Seattle	SCHLUEDERBERG, A (corresponding author), NIAID, DMID, VIROL BRANCH, ROOM 3A-16, SOLAR BLDG, BETHESDA, MD 20892 USA.							BAROFSKY I, 1991, REV INFECT DIS, V13, pS94; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BEYAERT R, 1991, CYTOKINE, V3, P284, DOI 10.1016/1043-4666(91)90496-Z; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; BUCHWALD D, 1987, ARTHRITIS RHEUM, V30, P1132, DOI 10.1002/art.1780301007; CANNON JG, 1985, SCIENCE, V227, P1247, DOI 10.1126/science.3871966; COLBURN TR, 1976, ISA T, V15, P149; DEMITRACK MA, 1991, BIOL PSYCHIAT, V30, P747, DOI 10.1016/0006-3223(91)90231-A; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; ENDRES S, 1989, EUR J IMMUNOL, V19, P2327, DOI 10.1002/eji.1830191222; First M.B., 1989, STRUCTURED CLIN INTE; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; HERBERMAN RB, 1991, REV INFECT DIS, V13, pS84; HOLMES GP, 1988, ANN INTERN MED, V109, P512; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOLMES GP, 1991, REV INFECT DIS, V13, pS53; JONES JF, 1987, ANNU REV MED, V38, P195, DOI 10.1146/annurev.med.38.1.195; KATON W, 1992, IN PRESS ARCH INTERN; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; LEWIS SF, 1991, REV INFECT DIS, V13, pS98; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MILLER AH, 1986, J CLIN PSYCHIAT, V47, P529; PETERSON PK, 1991, MINN MED, V74, P21; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; REDMOND CK, 1991, REV INFECT DIS, V13, pS90; ROBINS LN, 1985, NIMH DIAGNOSTIC INTE; SCHULTE PA, 1991, REV INFECT DIS, V13, pS87; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRAUS SE, 1988, J ALLERGY CLIN IMMUN, V81, P791, DOI 10.1016/0091-6749(88)90933-5; WOLFE F, 1989, Arthritis and Rheumatism, V32, pS47; 1989, NCCLS H42P NAT COMM	37	258	259	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					325	331		10.7326/0003-4819-117-4-325	http://dx.doi.org/10.7326/0003-4819-117-4-325			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1322076				2022-12-24	WOS:A1992JH46400010
J	MIYAZAKI, S; YUZAKI, M; NAKADA, K; SHIRAKAWA, H; NAKANISHI, S; NAKADE, S; MIKOSHIBA, K				MIYAZAKI, S; YUZAKI, M; NAKADA, K; SHIRAKAWA, H; NAKANISHI, S; NAKADE, S; MIKOSHIBA, K			BLOCK OF CA2+ WAVE AND CA2+ OSCILLATION BY ANTIBODY TO THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN FERTILIZED HAMSTER EGGS	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; PERIODIC INCREASE; CA-2+ RELEASE; FREE CALCIUM; GUINEA-PIG; TRISPHOSPHATE; EXPRESSION; PURIFICATION; RYANODINE; PROTEIN	The concentration of cytoplasmic free calcium (Ca2+) increases in various stimulated cells in a wave (Ca2+ wave) and in periodic transients (Ca2+ oscillations). These phenomena are explained by inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release (IICR) and Ca2+-induced Ca2+ release (CICR) from separate intracellular stores, but decisive evidence is lacking. A monoclonal antibody to the IP3 receptor inhibited both IICR and CICR upon injection of IP3 and Ca2+ into hamster eggs, respectively. The antibody completely blocked sperm-induced Ca2+ waves and Ca2+ oscillations. The results indicate that Ca2 release in fertilized hamster eggs is mediated solely by the IP3 receptor, and Ca2+-sensitized IICR, but not CICR, generates Ca2+ waves and Ca2+ oscillations.	JICHI MED SCH, DEPT BIOCHEM, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, SUITA, OSAKA 565, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC NEUROBIOL, MINATO KU, TOKYO 108, JAPAN	Jichi Medical University; Osaka University; University of Tokyo	MIYAZAKI, S (corresponding author), TOKYO WOMENS MED COLL, DEPT PHYSIOL, 8-1 KAWADA CHO, SHINJUKU KU, TOKYO 162, JAPAN.		Nakanishi, Setsuko/G-5871-2015; Yuzaki, Michisuke/K-5328-2013; Mikoshiba, Katsuhiko/N-7943-2015	Nakanishi, Setsuko/0000-0003-4909-2113; Yuzaki, Michisuke/0000-0002-5750-3544; 				BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IGUSA Y, 1986, J PHYSIOL-LONDON, V377, P193, DOI 10.1113/jphysiol.1986.sp016181; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jaffe L. A., 1985, BIOL FERTILIZATION, P127; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; LONGO FJ, 1974, ANAT RECORD, V179, P27, DOI 10.1002/ar.1091790104; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1991, CELL CALCIUM, V12, P205, DOI 10.1016/0143-4160(91)90021-6; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WIER WG, 1991, CELL CALCIUM, V12, P241, DOI 10.1016/0143-4160(91)90024-9; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737	30	477	481	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					251	255		10.1126/science.1321497	http://dx.doi.org/10.1126/science.1321497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321497				2022-12-24	WOS:A1992JC58500042
J	TADMOR, B; PUTTERMAN, C; NAPARSTEK, Y				TADMOR, B; PUTTERMAN, C; NAPARSTEK, Y			EMBRYONAL GERM-LAYER ANTIGENS - TARGET FOR AUTOIMMUNITY	LANCET			English	Note							CELL-ADHESION MOLECULES; DISEASE	Histopathological analysis of some systemic autoimmune diseases and syndromes led us to the conclusion that the common feature of the organs involved might be their embryonal origin. We suggest that organs derived from the same germ layer express common germ-layer-specific antigens. Such antigens could serve as target antigens for the autoimmune response.	HADASSAH UNIV HOSP,CLIN IMMUNOL & ALLERGY UNIT,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ALDOBENSON MA, 1989, ARTHRITIS ALLIED CON, P972; BOTTAZZO GF, 1983, LANCET, V2, P1115; BRYANT GL, 1986, SEMIN ARTHRITIS RHEU, V15, P297, DOI 10.1016/0049-0172(86)90025-9; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; CHRISTENSEN E, 1980, GASTROENTEROLOGY, V78, P236; DANGELO WA, 1969, AM J MED, V46, P428, DOI 10.1016/0002-9343(69)90044-8; GECZY AF, 1986, J EXP MED, V164, P932, DOI 10.1084/jem.164.3.932; HAYNES BF, 1980, MEDICINE, V59, P426, DOI 10.1097/00005792-198011000-00003; LANGMAN J, 1988, MED EMBRYOLOGY; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MENDELSOHN J, 1988, HARRISONS PRINCIPLES, P430; NEDELEC J, 1990, J NEUROIMMUNOL, V29, P49, DOI 10.1016/0165-5728(90)90146-E; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; OKADA Y, 1990, LANCET, V335, P1302, DOI 10.1016/0140-6736(90)91187-F; PRYSTOWSKY SD, 1978, ARCH DERMATOL, V114, P705, DOI 10.1001/archderm.114.5.705; ROITT IM, 1988, ESSENTIAL IMMUNOLOGY, P238; ROTHFIELD N, 1982, ARTHRITIS RHEUM, V25, P624, DOI 10.1002/art.1780250604; ROUGON G, 1986, J BIOL CHEM, V261, P3396; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	19	19	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					975	978		10.1016/0140-6736(92)91540-O	http://dx.doi.org/10.1016/0140-6736(92)91540-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348808				2022-12-24	WOS:A1992HP03600013
J	DALGLEISH, AG; WILSON, S; GOMPELS, M; LUDLAM, C; GAZZARD, B; COATES, AM; HABESHAW, J				DALGLEISH, AG; WILSON, S; GOMPELS, M; LUDLAM, C; GAZZARD, B; COATES, AM; HABESHAW, J			T-CELL RECEPTOR VARIABLE GENE-PRODUCTS AND EARLY HIV-1 INFECTION	LANCET			English	Article							IMMUNE-DEFICIENCY SYNDROME; AIDS; PATHOGENESIS; ENVELOPE; SYSTEM; CD4	To assess the hypothesis that the human immunodeficiency virus (HIV) might mimic major histocompatibility complex (MHC) allodeterminants and interact with T-cell receptors (TCRs) of alloreactive T-cells, we have done a preliminary analysis of the range of alpha-beta-TCR gene products in 16 HIV-1 -seropositive individuals with normal CD4 counts and in 16 healthy HIV-1-negative controls. Using a panel of monoclonal antibodies with a two-colour direct immunofluorescence method, we found a significant increase in the expression of the V-beta-5.3 subfamily in the HIV-positive patient group compared with controls (p < 0.01). Selected increase in expression of V-beta sequences has been described in various autoimmune conditions and our findings raise the possibility that the immunopathological damage from HIV infection may be due to the induction of autoreactivity. If HIV does mimic MHC II, the normal immune response to the virus could represent an autoimmune process similar to graft-versus-host disease.	ROYAL INFIRM,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ST MARYS HOSP,LONDON,ENGLAND; HIVER LTD,LONDON NW1,ENGLAND	Royal Infirmary of Edinburgh; Imperial College London	DALGLEISH, AG (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CELLULAR & MOLEC SCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Dalgleish, Angus/AAZ-4450-2020	Dalgleish, Angus/0000-0003-3511-3059; Coates, Anthony/0000-0001-8052-3175				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; BRANDLE D, 1991, EUR J IMMUNOL, V21, P2195, DOI 10.1002/eji.1830210930; CLOUSE KA, 1991, J IMMUNOL, V147, P2892; DALGLEISH AG, 1991, BRIT MED BULL, V47, P21, DOI 10.1093/oxfordjournals.bmb.a072457; DALGLEISH AG, 1990, AIDS NEW VIRUSES; DANES TF, 1991, NEW ENGL J MED, V325, P238; DIGIORGI L, 1990, CLIN EXP IMMUNOL, V79, P130; HABESHAW JA, 1989, J ACQ IMMUN DEF SYND, V2, P457; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HENEY D, 1991, BRIT J HAEMATOL, V78, P23, DOI 10.1111/j.1365-2141.1991.tb04377.x; HOUNSELL L, IN PRESS MOL ASPECTS; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; KAY RA, 1991, CLIN EXP IMMUNOL, V85, P262; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; KNOBLOCH C, 1991, J IMMUNOL, V146, P4157; KNULST AC, 1991, EUR J IMMUNOL, V21, P103, DOI 10.1002/eji.1830210116; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUTZ CT, 1981, EUR J IMMUNOL, V11, P726, DOI 10.1002/eji.1830110911; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALLAL S, 1990, LANCET, V335, P1591, DOI 10.1016/0140-6736(90)91418-A; MANCA F, 1990, LANCET, V335, P811, DOI 10.1016/0140-6736(90)90935-X; MANCA F, 1991, J IMMUNOL, V146, P1964; ORBEA HA, 1991, IMMUNOL TODAY, V12, P356; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; SCHATTNER A, 1990, REV INFECT DIS, V12, P204; SCHECHTER MT, 1990, AIDS, V4, P185, DOI 10.1097/00002030-199003000-00002; SHEARER G, 1983, IMMUNOL TODAY, V4, P181, DOI 10.1016/0167-5699(83)90075-0; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P704; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2; STOTT J, 1991, NATURE, V353, P393; VIA CS, 1990, IMMUNOL TODAY, V11, P250, DOI 10.1016/0167-5699(90)90099-U; WATANABE M, 1991, J VIROL, V65, P3344, DOI 10.1128/JVI.65.6.3344-3348.1991; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; YANAGI Y, 1990, J VIROL, V64, P5919, DOI 10.1128/JVI.64.12.5919-5926.1990	38	104	105	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					824	828		10.1016/0140-6736(92)90277-A	http://dx.doi.org/10.1016/0140-6736(92)90277-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347855				2022-12-24	WOS:A1992HM44100002
J	GEDROYC, WMW; NEGUS, R; ALKUTOUBI, A; PALMER, A; TAUBE, D; HULME, B				GEDROYC, WMW; NEGUS, R; ALKUTOUBI, A; PALMER, A; TAUBE, D; HULME, B			MAGNETIC-RESONANCE ANGIOGRAPHY OF RENAL-TRANSPLANTS	LANCET			English	Article							ARTERY-STENOSIS; MR ANGIOGRAPHY	Stenosis of the artery of transplanted kidneys is an important cause of graft dysfunction. Diagnosis and follow-up of this condition normally requires intraarterial digital-subtraction angiography (IADSA), which is invasive and may cause complications. A possible alternative to IADSA is magnetic resonance angiography (MRA), and we have assessed this technique in 50 renal transplant patients who were referred for investigation of possible renal arterial stenosis. In every patient, MRA was compared prospectively with conventional IADSA. Compared with IADSA, MRA had a sensitivity of 83% and a specificity of 97%, and when all images were graded retrospectively for severity of stenosis, the two techniques showed a significant correlation (r = 0.74, p < 0.001). MRA can provide an accurate image of the renal transplant artery in a non-invasive manner with a high sensitivity and specificity.	ST MARYS HOSP,RENAL UNIT,LONDON W2 1NY,ENGLAND	Imperial College London	GEDROYC, WMW (corresponding author), ST MARYS HOSP,DEPT RADIOL,LONDON W2 1NY,ENGLAND.							DEANE C, 1990, TRANSPLANT P, V22, P1395; EDELMAN RR, 1990, CLIN MAGNETIC RESONA, P109; GREENSTEIN SM, 1987, TRANSPLANTATION, V43, P29, DOI 10.1097/00007890-198701000-00007; KIM D, 1990, RADIOLOGY, V174, P727, DOI 10.1148/radiology.174.3.2305057; PERNICONE JR, 1990, AM J NEURORADIOL, V11, P457; TILNEY NL, 1984, ANN SURG, V199, P454, DOI 10.1097/00000658-198404000-00013	6	52	52	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					789	791		10.1016/0140-6736(92)91905-N	http://dx.doi.org/10.1016/0140-6736(92)91905-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347813				2022-12-24	WOS:A1992HL50100013
J	MATHEWS, LS; VALE, WW; KINTNER, CR				MATHEWS, LS; VALE, WW; KINTNER, CR			CLONING OF A 2ND TYPE OF ACTIVIN RECEPTOR AND FUNCTIONAL-CHARACTERIZATION IN XENOPUS EMBRYOS	SCIENCE			English	Article							MESODERM INDUCTION; HOMOLOG; LAEVIS	A complementary DNA coding for a second type of activin receptor (ActRIIB) has been cloned from Xenopus laevis that fulfills the structural criteria of a transmembrane protein serine kinase. Ectodermal explants from embryos injected with activin receptor RNA show increased sensitivity to activin, as measured by the induction of muscle actin RNA. In addition, injected embryos display developmental defects characterized by inappropriate formation of dorsal mesodermal tissue. These results demonstrate that this receptor is involved in signal transduction and are consistent with the proposed role of activin in the induction and patterning of mesoderm in Xenopus embryos.	SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute; Salk Institute					NICHD NIH HHS [HD-13275, HD-07343] Funding Source: Medline; NIDDK NIH HHS [DK-26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CHO KWY, 1991, CELL, V65, P1; COOKE J, 1989, DEVELOPMENT, V107, P229; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; KINTNER CR, 1985, J EMBRYOL EXP MORPH, V89, P37; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KINTNER CR, UNPUB; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SYMES K, 1987, DEVELOPMENT, V101, P339; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; YU R, UNPUB	25	219	235	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1702	1705		10.1126/science.1313188	http://dx.doi.org/10.1126/science.1313188			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1313188				2022-12-24	WOS:A1992HK81200037
J	KOLL, H; GUIARD, B; RASSOW, J; OSTERMANN, J; HORWICH, AL; NEUPERT, W; HARTL, FU				KOLL, H; GUIARD, B; RASSOW, J; OSTERMANN, J; HORWICH, AL; NEUPERT, W; HARTL, FU			ANTIFOLDING ACTIVITY OF HSP60 COUPLES PROTEIN IMPORT INTO THE MITOCHONDRIAL MATRIX WITH EXPORT TO THE INTERMEMBRANE SPACE	CELL			English	Article							TRANSLOCATION CONTACT SITES; CYTOCHROME C1 PRESEQUENCE; ESCHERICHIA-COLI; PROCESSING PEPTIDASE; YEAST MITOCHONDRIA; RIBULOSEBISPHOSPHATE-CARBOXYLASE; PRECURSOR PROTEINS; SENSITIVE METHOD; BINDING-PROTEIN; INNER MEMBRANE	Cytochrome b2 reaches the intermembrane space of mitochondria by transport into the matrix followed by export across the inner membrane. While in the matrix, the protein interacts with hsp60, which arrests its folding prior to export. The bacterial-type export sequence in pre-cytochrome b2 functions by inhibiting the ATP-dependent release of the protein from hsp60. Release for export apparently requires, in addition to ATP, the interaction of the signal sequence with a component of the export machinery in the inner membrane. Export can occur before import is complete provided that a critical length of the polypeptide chain has been translocated into the matrix. Thus, hsp60 combines two activities: catalysis of folding of proteins destined for the matrix, and maintaining proteins in an unfolded state to facilitate their channeling between the machineries for import and export across the inner membrane. Antifolding signals such as the hydrophobic export sequence in cytochrome b2 may act as switches between these two activities.	UNIV PIERRE & MARIE CURIE, CTR GENET MOLEC, CNRS, F-91190 GIF SUR YVETTE, FRANCE; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; MEM SLOAN KETTERING CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Howard Hughes Medical Institute; Yale University; Memorial Sloan Kettering Cancer Center; Yale University	KOLL, H (corresponding author), INST PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY.		Hartl, F. Ulrich/Y-8206-2019					APPLEBY CA, 1959, BIOCHEM J, V71, P492, DOI 10.1042/bj0710492; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HALLERMAYER G, 1977, EUR J BIOCHEM, V81, P523, DOI 10.1111/j.1432-1033.1977.tb11978.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MACIEWICZ RA, 1988, ANAL BIOCHEM, V175, P85, DOI 10.1016/0003-2697(88)90364-8; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PAULING L, 1951, P NATL ACAD SCI USA, V37, P729, DOI 10.1073/pnas.37.11.729; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; STUART RA, 1990, J BIOL CHEM, V265, P20210; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; Towbin H., 1979, P NATL ACAD SCI USA, V79, P267; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	61	183	186	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1163	1175		10.1016/0092-8674(92)90086-R	http://dx.doi.org/10.1016/0092-8674(92)90086-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1347713	Green Published			2022-12-24	WOS:A1992HK67400018
J	THIEMANN, A; GRUNDER, S; PUSCH, M; JENTSCH, TJ				THIEMANN, A; GRUNDER, S; PUSCH, M; JENTSCH, TJ			A CHLORIDE CHANNEL WIDELY EXPRESSED IN EPITHELIAL AND NONEPITHELIAL CELLS	NATURE			English	Article							CYSTIC-FIBROSIS; RECEPTOR SHOWS; LINE T84; CONDUCTANCE; TRANSPORT; CLONING; GENE; CAMP	CHLORIDE channels have several functions, including the regulation of cell volume 1,2 stabilizing membrane potential 3,4, signal transduction 5,6 and transepithelial transport 7. The plasma membrane Cl- channels already cloned belong to different structural classes: ligand-gated channels 5,6, voltage-gated channels 8,9, and possibly transporters of the ATP-binding-cassette type (if the cystic fibrosis transmembrane regulator 10 is a Cl- channel 11-13). The importance of chloride channels is illustrated by the phenotypes that can result from their malfunction: cystic fibrosis, in which transepithelial transport is impaired, and myotonia 3, in which ClC-1, the principal skeletal muscle Cl- channel, is defective 9. Here we report the properties of ClC-2, a new member of the voltage-gated Cl- channel family. Its sequence is approximately 50% identical to either the Torpedo electroplax Cl- channel, ClC-0 (ref. 8), or the rat muscle Cl- channel, ClC-1 (ref. 9). Isolated initially from rat heart and brain, it is also expressed in pancreas, lung and liver, for example, and in pure cell lines of fibroblastic, neuronal, and epithelial origin, including tissues and cells affected by cystic fibrosis. Expression in Xenopus oocytes induces Cl- currents that activate slowly upon hyperpolarization and display a linear instantaneous current-voltage relationship. The conductivity sequence is Cl- greater-than-or-equal-to Br- > I-. The presence of ClC-2 in such different cell types contrasts with the highly specialized expression of ClC-1 (ref. 9) and also with the cloned cation channels, and suggests that its function is important for most cells.	UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	University of Hamburg			Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Jentsch, Thomas/0000-0002-3509-2553; Pusch, Michael/0000-0002-8644-8847				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MILLER C, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P383; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STRANGE K, 1991, AM J PHYSIOL, V260, pF225, DOI 10.1152/ajprenal.1991.260.2.F225; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	33	529	539	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					57	60		10.1038/356057a0	http://dx.doi.org/10.1038/356057a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1311421				2022-12-24	WOS:A1992HG60200054
J	ISOBE, M; YAGITA, H; OKUMURA, K; IHARA, A				ISOBE, M; YAGITA, H; OKUMURA, K; IHARA, A			SPECIFIC ACCEPTANCE OF CARDIAC ALLOGRAFT AFTER TREATMENT WITH ANTIBODIES TO ICAM-1 AND LFA-1	SCIENCE			English	Article							ADHESION MOLECULE-1 ICAM-1; CELL-ASSOCIATED ANTIGEN; MEDIATED CYTO-TOXICITY; MONOCLONAL-ANTIBODY; IMMUNE-SYSTEM; ACTIVATION; LIGAND; INHIBITION; RECEPTORS; MALA-2	An indefinite survival of cardiac allografts between fully incompatible mice strains was observed when monoclonal antibodies (MAbs) to intercellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-1 (LFA-1) were simultaneously administered after the transplantation for 6 days. Mice with long-term surviving cardiac allografts accepted skin grafts from the donor-strain but rejected skin grafts from a third-party strain. Because MAbs to ICAM-1 or LFA-1 alone were insufficient for prolonged tolerance, the two MAbs probably acted synergistically to induce specific unresponsiveness. Thus, ICAM-1-LFA-1 adhesion participates in the induction of allograft rejection and MAbs may be useful as therapeutic agents.	MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PATHOL RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,TOKYO 113,JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Juntendo University								ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; BENJAMIN RJ, 1988, EUR J IMMUNOL, V18, P1079, DOI 10.1002/eji.1830180717; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DANG LH, 1991, J IMMUNOL, V146, P3273; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFRANCO AL, 1991, NATURE, V351, P603, DOI 10.1038/351603a0; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GEPPERT TD, 1990, IMMUNOL REV, V117, P5, DOI 10.1111/j.1600-065X.1990.tb00566.x; ISOBE M, 1992, CIRCULATION, V85, P738, DOI 10.1161/01.CIR.85.2.738; ISOBE M, 1991, CIRCULATION, V84, P1246, DOI 10.1161/01.CIR.84.3.1246; MAKGOBA MW, 1988, EUR J IMMUNOL, V18, P637, DOI 10.1002/eji.1830180423; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NISHIMURA T, 1987, CELL IMMUNOL, V107, P32, DOI 10.1016/0008-8749(87)90263-2; NISHIMURA T, 1985, CELL IMMUNOL, V94, P122, DOI 10.1016/0008-8749(85)90090-5; PRIETO J, 1989, EUR J IMMUNOL, V19, P1551, DOI 10.1002/eji.1830190906; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKEI F, 1985, J IMMUNOL, V134, P1403; VANDIJKEN PJ, 1990, TRANSPLANTATION, V49, P882, DOI 10.1097/00007890-199005000-00009; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	26	782	829	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1125	1127		10.1126/science.1347662	http://dx.doi.org/10.1126/science.1347662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1347662				2022-12-24	WOS:A1992HF63200040
J	TIVERON, MC; BARBONI, E; RIVERO, FBP; GORMLEY, AM; SEELEY, PJ; GROSVELD, F; MORRIS, R				TIVERON, MC; BARBONI, E; RIVERO, FBP; GORMLEY, AM; SEELEY, PJ; GROSVELD, F; MORRIS, R			SELECTIVE-INHIBITION OF NEURITE OUTGROWTH ON MATURE ASTROCYTES BY THY-1 GLYCOPROTEIN	NATURE			English	Article							RAT; CULTURES; NEURONS; TISSUE; GROWTH; NERVE; CELLS; REGENERATION; EXPRESSION; ORIGIN	THY-1, the smallest member of the immunoglobulin superfamily 1, is a major cell-surface component expressed by several tissues 2. The protein 1, carbohydrate 3 and gene 4 Structures of this molecule are known, yet its function is not. It is highly expressed in nervous tissue 5, where it appears on virtually all neurons after the cessation of axonal growth 6. Here we show that expression of Thy-1 by a neural cell line inhibits neurite outgrowth on mature astrocytes, but not on other cellular substrata which include Schwann cells and embryonic glia. This inhibition of neurite extension on astrocytes can be reversed by low concentrations (nanomolar) of soluble Thy-1. If a similar interaction between neuronal Thy-1 and astrocytes occurs in vivo, it could stabilize neuronal connections and suppress axonal regrowth after injury in the astrocyte-rich areas of adult central nervous system.	UNIV ROME LA SAPIENZA,FAC MED & CHIRURG,DEPT HUMAN BIOPATHOL,I-00185 ROME,ITALY; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	Sapienza University Rome; MRC National Institute for Medical Research	TIVERON, MC (corresponding author), NATL INST MED RES,NEUROBIOL LAB,NORMAN & SADIE LEE RES CTR,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		TIVERON, Marie-Catherine/AAR-1142-2020; Morris, Roger/C-4615-2008					BAEHR M, 1990, GLIA, V3, P293, DOI 10.1002/glia.440030409; BARBONI E, 1991, IMMUNOLOGY, V72, P457; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CAJAL SRY, 1927, DEGENERATION REGENER, V2; CARLSTEDT T, 1989, BRAIN RES BULL, V22, P93, DOI 10.1016/0361-9230(89)90133-0; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; EMMETT CJ, 1988, BRAIN RES, V447, P223, DOI 10.1016/0006-8993(88)91123-7; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; Graziadei PPC, 1978, NEURONAL PLASTICITY, P131; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HATANAKA H, 1981, BRAIN RES, V215, P305, DOI 10.1016/0006-8993(81)90509-6; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; KOLLIAS G, 1987, CELL, V51, P21, DOI 10.1016/0092-8674(87)90006-7; KUCHEL PW, 1978, BIOCHEM J, V169, P411, DOI 10.1042/bj1690411; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; MORRIS R, 1985, DEV NEUROSCI-BASEL, V7, P133, DOI 10.1159/000112283; MORRIS RJ, 1980, BRAIN RES, V182, P119, DOI 10.1016/0006-8993(80)90835-5; NOBLE M, 1984, J NEUROSCI, V4, P1892; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; RAFF MC, 1979, BRAIN RES, V174, P283, DOI 10.1016/0006-8993(79)90851-5; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SIEGAL JD, 1990, EXP NEUROL, V109, P111; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; SPRINGER TA, 1991, NATURE, V353, P704, DOI 10.1038/353704a0; Stensaas LJ, 1987, PROG BRAIN RES <D>, V71, P457; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WILLIAMS AF, 1989, CELL SURFACE ANTIGEN, P49; XUE GP, 1991, DEVELOPMENT, V112, P161	30	127	128	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					745	748		10.1038/355745a0	http://dx.doi.org/10.1038/355745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1346926				2022-12-24	WOS:A1992HE60400071
J	JESSELL, TM; MELTON, DA				JESSELL, TM; MELTON, DA			DIFFUSIBLE FACTORS IN VERTEBRATE EMBRYONIC INDUCTION	CELL			English	Review							TYPE-2 ASTROCYTE DEVELOPMENT; CILIARY NEUROTROPHIC FACTOR; FIBROBLAST GROWTH-FACTOR; RETINOIC ACID RECEPTOR; CHICK LIMB BUD; TYROSINE KINASE RECEPTOR; EARLY XENOPUS EMBRYOS; PROTO-ONCOGENE INT-1; ACTIVIN-A; W-LOCUS		HARVARD UNIV, DEPT BIOCHEM, CAMBRIDGE, MA 02138 USA	Harvard University	JESSELL, TM (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEVELOPMENT, V112, P945; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOKE J, 1989, CIBA F SYMP, V144, P187; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURDON JB, 1987, DEVELOPMENT, V99, P285; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES EA, 1989, DEVELOPMENT, V107, P785; KAMEGAI M, 1990, NEURON, V4, P429, DOI 10.1016/0896-6273(90)90055-K; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LILLIEN LE, 1990, J CELL BIOL, V111, P635, DOI 10.1083/jcb.111.2.635; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; NAWA H, 1990, NEURON, V4, P269, DOI 10.1016/0896-6273(90)90101-K; NAWA H, 1991, J NEUROCHEM, V56, P2147, DOI 10.1111/j.1471-4159.1991.tb03479.x; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NIEUWKOOP PD, 1989, DEV GROWTH DIFFER, V32, P149; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAO MS, 1990, NEURON, V5, P899, DOI 10.1016/0896-6273(90)90350-O; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLACK JMW, 1991, DEVELOPMENT, V113, P661; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH SM, 1991, DEVELOPMENT, V111, P245; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H., 1938, EMBRYONIC DEV INDUCT; SUMMERBELL D, 1983, LIMB DEV REGENERAT A, P109; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1991, DEVELOPMENT, P113; TRAYNOR D, 1991, J BIOL CHEM, V266, P5291; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMAMORI T, 1991, P NATL ACAD SCI USA, V88, P7298, DOI 10.1073/pnas.88.16.7298; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	142	302	315	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					257	270		10.1016/0092-8674(92)90469-S	http://dx.doi.org/10.1016/0092-8674(92)90469-S			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310256				2022-12-24	WOS:A1992HB35300007
J	SHUAI, K; SCHINDLER, C; PREZIOSO, VR; DARNELL, JE				SHUAI, K; SCHINDLER, C; PREZIOSO, VR; DARNELL, JE			ACTIVATION OF TRANSCRIPTION BY IFN-GAMMA - TYROSINE PHOSPHORYLATION OF A 91-KD DNA-BINDING PROTEIN	SCIENCE			English	Article							ALPHA-STIMULATED TRANSCRIPTION; INTERFERON-ALPHA; CYTOPLASMIC ACTIVATION; RECONSTITUTED INVITRO; GEL-ELECTROPHORESIS; POSITIVE REGULATOR; ISGF3; GENE; KINASE	Interferon-gamma (IFN-gamma) induces the transcription of the gene encoding a guanylate binding protein by activating a latent cytoplasmic factor, GAF (gamma-activated factor). GAF is translocated to the nucleus and binds a DNA element, the gamma-activated site. Through cross-linking and the use of specific antibodies GAF was found to be a 91-kilodalton DNA binding protein that was previously identified as one of four proteins in interferon-stimulated gene factor-3 (ISGF-3), a transcription complex activated by IFN-alpha. The IFN-gamma-dependent activation of the 91-kilodalton DNA binding protein required cytoplasmic phosphorylation of the protein on tyrosine. The 113-kilodalton ISGF-3 protein that is phosphorylated in response to IFN-alpha was not phosphorylated nor translocated to the nucleus in response to IFN-gamma. Thus the two different ligands result in tyrosine phosphorylation of different combinations of latent cytoplasmic transcription factors that then act at different DNA binding sites.			SHUAI, K (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; EVANS RK, 1986, P NATL ACAD SCI USA, V83, P5382, DOI 10.1073/pnas.83.15.5382; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1992, P NATL ACAD SCI USA, V89, P7846; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOWARD OMZ, 1992, ONCOGENE, V7, P895; HUTNER T, 1992, CELL, V70, P375; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KA, UNPUB; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, UNPUB; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P31; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	27	708	730	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1808	1812		10.1126/science.1281555	http://dx.doi.org/10.1126/science.1281555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1281555				2022-12-24	WOS:A1992KB96400043
J	DRICKAMER, K				DRICKAMER, K			ENGINEERING GALACTOSE-BINDING ACTIVITY INTO A C-TYPE MANNOSE-BINDING PROTEIN	NATURE			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SITE; RAT; HOMOLOGY; LECTIN	CALCIUM-DEPENDENT or C-type carbohydrate-recognition domains are homologous protein modules found in a variety of animal lectins1. Selective binding of sugars by these domains is essential for glycoprotein clearance, cell-cell adhesion and pathogen neutralization. Although various C-type carbohydrate-recognition domains share sequence identity ranging from 20 to 55%, their sugar-binding characteristics vary widely. The structure of a mannose-binding carbohydrate-recognition domain in complex with a saccharide ligand suggests that two glutamic acid-asparagine pairs are essential determinants of ligand binding by this domain2. In C-type lectins that bind galactose with higher affinity than mannose, one of these pairs is replaced by glutamine-aspartic acid. Here we shift the sequence of the mannose-binding protein to correspond to that found in galactose-binding domains in order to test the importance of these residues in sugar-binding selectivity. This simple switch in the position of a single amide group alters the binding activity of the domain so that galactose becomes the preferred ligand.			DRICKAMER, K (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1991, J BIOL CHEM, V266, P4810; Maniatis T., 1982, MOL CLONING; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SIKDER SK, 1983, J BIOL CHEM, V258, P2520; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	18	443	467	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					183	186		10.1038/360183a0	http://dx.doi.org/10.1038/360183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1279438				2022-12-24	WOS:A1992JX75200068
J	WEISNER, C; SCHMIDT, L				WEISNER, C; SCHMIDT, L			GENDER DISPARITIES IN TREATMENT FOR ALCOHOL-PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; DEPENDENCE; PREVALENCE; HEALTH	Objective.-To examine women's access to treatment for alcohol problems in terms of the prevalence, characteristics, and treatment-seeking patterns of problem drinkers in a range of alcohol-specific and nonspecialized health care systems. Design.-In-person survey. Setting.-A Northern California county. Participants.-Consecutive samples of admissions in public alcohol treatment (n=381), drug treatment (n=210), mental health treatment (n=406), emergency health services (n=2626), primary health clinics (n=394), and adults in the county general population (n=3069). Primary Outcome Measures.-Prevalence and relative risk (RR) of problem drinking and rates of alcohol-related treatment episodes. Results.-Rates of problem drinking were higher among men than women across all samples. However, after accounting for gender differences in general population rates, women in all of the non-alcohol-specific clinical samples were at greater risk than men for problem drinking (eg, RR=5.6 for women and RR=2.1 for men in the mental health sample). Men reported a greater variety in types of services sought in past alcohol-related treatment encounters, but women experienced greater symptom severity. Conclusions.-Female problem drinkers were more likely than male problem drinkers to use non-alcohol-specific health care settings, particularly mental health treatment services, and to report greater symptom severity. Future research on women's access to services for alcohol problems should consider a range of health care systems and gender differences in seeking help.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT SOCIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley	WEISNER, C (corresponding author), ALCOHOL RES GRP,2000 HEARST AVE,BERKELEY,CA 94709, USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P30AA005595, P50AA005595] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-05595] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARMITAGE P, 1971, STATISTICAL METHODS; Baily S, 1990, Drug Alcohol Rev, V9, P125, DOI 10.1080/09595239000185181; BECKMAN LJ, 1986, J STUD ALCOHOL, V47, P135, DOI 10.15288/jsa.1986.47.135; BLUME SB, 1986, JAMA-J AM MED ASSOC, V256, P1467; BLUME SB, 1982, ALCOHOLISM CLIN PSYC, pCH13; CAETANO R, 1990, ALCOHOL ALCOHOLISM, V25, P303, DOI 10.1093/oxfordjournals.alcalc.a045004; CAETANO R, 1988, STUDY DIMENSIONS DEP; CELENTANO DD, 1980, J CHRON DIS, V33, P383, DOI 10.1016/0021-9681(80)90048-X; Cherpitel C, 1989, DRINKING CASUALTIES, P288; CHERPITEL CS, 1989, PRIMARY CARE STUDY; CHERPITEL CS, 1991, ALCOHOL ALCOHOLISM, V5, P627; Clark WB, 1982, ALCOHOL CONSUMPTION, P3; Clark WB, 1991, ALCOHOL AM DRINKING; CURLEE J, 1970, J PSYCHOL, V74, P239, DOI 10.1080/00223980.1970.9923735; FERRENCE RG, 1980, SERVICES ALCOHOLICS; FERRENCE RG, 1980, RES ADV ALCOHOL DRUG, V5, P69; Fillmore K.M., 1984, ALCOHOL PROBLEMS WOM, P7; FURST C, 1981, UTILIZATION ALCOHOL; GLASS IB, 1988, BRIT J ADDICT, V83, P1105; GOMBERG E, 1974, WOMEN THERAPY, pCH7; HILTON M, 1991, ALCOHOL AM DRINKING, P256; HORN JL, 1970, Q J STUD ALCOHOL, V31, P40; Jones K R, 1979, Med Care, V17, P1; MARSH JC, 1982, J SOC ISSUES, V38, P1, DOI 10.1111/j.1540-4560.1982.tb00114.x; MCINTOSH ID, 1982, INT J ADDICT, V17, P609, DOI 10.3109/10826088209053007; MECHANIC D, 1979, J HEALTH SOC BEHAV, V20, P387, DOI 10.2307/2955413; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; REED BG, 1987, J PSYCHOACTIVE DRUGS, V19, P151, DOI 10.1080/02791072.1987.10472399; RODIN J, 1990, AM PSYCHOL, V45, P1018, DOI 10.1037/0003-066X.45.9.1018; ROMAN PM, 1988, ADM881574US DEP HLTH; ROOM R, 1988, 14TH ANN ALC EP S BE; RUSH B, 1983, CAN J PUBLIC HEALTH, V74, P270; SANDMAIER M, 1980, INVISIBLE ALCOHOLICS; SCHMIDT L, 1992, HOSP COMMUNITY PSYCH, V43, P245; SCHMIDT L, 1988, COSTA COUNTRY MENTAL; SCHUCKIT M A, 1979, American Journal of Psychiatry, V136, P611; STEPHENS C, 1987, COSTA COUNTY 4 HOSPI; THOM B, 1986, BRIT J ADDICT, V81, P777; Weisner C, 1987, Recent Dev Alcohol, V5, P203; WEISNER C, IN PRESS AM J DRUG A; WEISNER C, IN PRESS J STUD ALCO; WEISNER C, 1988, COMMUNITY RESPONSE S; WILSNACK SC, 1991, AM J PUBLIC HEALTH, V81, P305, DOI 10.2105/AJPH.81.3.305; ZUNG BJ, 1982, PSYCHIAT FORUM, V11, P32; 1990, HIGHLIGHTS 1989 NATI; 1990, BROADENING BASE ALCO, P23; 1991, C ASSESSING FUTURE R	47	233	234	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1872	1876		10.1001/jama.268.14.1872	http://dx.doi.org/10.1001/jama.268.14.1872			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1328695				2022-12-24	WOS:A1992JR43900035
J	FARCI, P; ALTER, HJ; GOVINDARAJAN, S; WONG, DC; ENGLE, R; LESNIEWSKI, RR; MUSHAHWAR, IK; DESAI, SM; MILLER, RH; OGATA, N; PURCELL, RH				FARCI, P; ALTER, HJ; GOVINDARAJAN, S; WONG, DC; ENGLE, R; LESNIEWSKI, RR; MUSHAHWAR, IK; DESAI, SM; MILLER, RH; OGATA, N; PURCELL, RH			LACK OF PROTECTIVE IMMUNITY AGAINST REINFECTION WITH HEPATITIS-C VIRUS	SCIENCE			English	Article							NON-B-HEPATITIS; EXPERIMENTALLY INFECTED CHIMPANZEES; TRANSFUSION-ASSOCIATED HEPATITIS; NON-A-HEPATITIS; VIRAL-HEPATITIS; ENVELOPE PROTEIN; LONG-TERM; POSTTRANSFUSION HEPATITIS; CROSS-CHALLENGE; HUMAN CARRIERS	Some individuals infected with hepatitis C virus (HCV) experience multiple episodes of acute hepatitis. It is unclear whether these episodes are due to reinfection with HCV or to reactivation of the original virus infection. Markers of viral replication and host immunity were studied in five chimpanzees sequentially inoculated over a period of 3 years with different HCV strains of proven infectivity. Each rechallenge of a convalescent chimpanzee with the same or a different HCV strain resulted in the reappearance of viremia, which was due to infection with the subsequent challenge virus. The evidence indicates that HCV infection does not elicit protective immunity against reinfection with homologous or heterologous strains, which raises concerns for the development of effective vaccines against HCV.	NIH,WARREN G MARGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892; RANCHO LOS AMIGOS MED CTR,DOWNEY,CA 90242; GEORGETOWN UNIV,DEPT MICROBIOL,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD 20852; ABBOTT LABS,EXPTL BIOL RES,N CHICAGO,IL 60064	National Institutes of Health (NIH) - USA; Georgetown University; Abbott Laboratories	FARCI, P (corresponding author), NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892, USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Aach RD, 1978, VIRAL HEPATITIS, P383; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; Alter HJ, 1978, VIRAL HEPATITIS, P359; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BENN S, 1985, SCIENCE, V230, P949, DOI 10.1126/science.2997922; BRADLEY DW, 1980, J MED VIROL, V6, P185, DOI 10.1002/jmv.1890060302; BRADLEY DW, 1979, J MED VIROL, V3, P253, DOI 10.1002/jmv.1890030403; BRADLEY DW, 1981, J INFECT DIS, V143, P210, DOI 10.1093/infdis/143.2.210; BROTMAN B, 1985, J INFECT DIS, V151, P618, DOI 10.1093/infdis/151.4.618; BURK KH, 1984, HEPATOLOGY, V4, P808, DOI 10.1002/hep.1840040502; BUUKH J, 1992, P NATL ACAD SCI USA, V89, P187; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CRASKE J, 1978, LANCET, V2, P1051; DIENES HP, 1990, J HEPATOL, V10, P77, DOI 10.1016/0168-8278(90)90076-4; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; Eder G, 1988, VIRAL HEPATITIS LIVE, P550; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; FARCI P, UNPUB; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; GALBRAITH RM, 1979, LANCET, V1, P951; GOVINDARAJAN S, UNPUB; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HIJIKATA M, 1990, JPN J CANCER RES, V81, P1195, DOI 10.1111/j.1349-7006.1990.tb02676.x; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; HOLLINGER FB, 1980, J INFECT DIS, V142, P400, DOI 10.1093/infdis/142.3.400; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HRUBY MA, 1978, JAMA-J AM MED ASSOC, V240, P1355; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KNODELL RG, 1976, LANCET, V1, P557; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; MOSLEY JW, 1977, NEW ENGL J MED, V296, P75, DOI 10.1056/NEJM197701132960204; NORKRANS G, 1980, JAMA-J AM MED ASSOC, V243, P1056, DOI 10.1001/jama.243.10.1056; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; PRINCE AM, 1992, J INFECT DIS, V165, P438, DOI 10.1093/infdis/165.3.438; PURCELL RH, 1985, HEPATOLOGY, V5, P1091, DOI 10.1002/hep.1840050606; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; RIZZETTO M, 1986, PROG LIVER DIS, V8, P417; SEEFF LB, 1978, VIRAL HEPATITIS, P371; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; TABOR E, 1984, TRANSFUSION, V24, P224, DOI 10.1046/j.1537-2995.1984.24384225027.x; TAEBOR E, 1979, J INFECT DIS, V140, P789; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TAKEUCHI K, 1990, GENE, V91, P287, DOI 10.1016/0378-1119(90)90102-W; TAKEUCHI K, 1990, J GEN VIROL, V71, P3027, DOI 10.1099/0022-1317-71-12-3027; TSIQUAYE KN, 1979, LANCET, V1, P1135; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIZAWA H, 1981, GASTROENTEROLOGY, V81, P107; 883109225	64	663	705	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					135	140		10.1126/science.1279801	http://dx.doi.org/10.1126/science.1279801			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1279801				2022-12-24	WOS:A1992JQ61900036
J	NAKAMURA, Y; KOMATSU, N; NAKAUCHI, H				NAKAMURA, Y; KOMATSU, N; NAKAUCHI, H			A TRUNCATED ERYTHROPOIETIN RECEPTOR THAT FAILS TO PREVENT PROGRAMMED CELL-DEATH OF ERYTHROID-CELLS	SCIENCE			English	Article							BONE-MARROW; CLONING; EXPRESSION; GENE; MEGAKARYOCYTES; ESTABLISHMENT; GROWTH; LINE; RAT	A form of the human erythropoietin receptor (EPOR) was identified in which the cytoplasmic region is truncated by alternative splicing. The truncated form of the receptor (EPOR-T) is the most prevalent form of EPOR in early-stage erythroid progenitor cells, but the full-length EPOR (EPOR-F) becomes the most prevalent form in late-stage progenitors. EPOR-T can transduce a mitogenic signal. However, cells transfected with EPOR-T are more prone to programmed cell death than those expressing EPOR-F. EPOR-F may transduce a signal to prevent programmed cell death that is independent of the mitogenic signal, and alternative splicing of the EPOR gene may have an important role in erythropoiesis.	INST PHYS & CHEM RES RIKEN, TSUKUBA LIFE SCI CTR, CELL GROWTH & DIFFERENTIAT LAB, 3-1-1 KOYADAI, TSUKUBA, JAPAN	RIKEN			Nakamura, Yukio/A-5263-2016	Nakamura, Yukio/0000-0001-8056-4946				BERRIDGE MV, 1988, BLOOD, V72, P970; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; FRASER JK, 1989, EXP HEMATOL, V17, P10; GREGORY CJ, 1976, J CELL PHYSIOL, V89, P289, DOI 10.1002/jcp.1040890212; HEATH DS, 1976, BLOOD, V47, P777; JONES SS, 1990, BLOOD, V76, P31; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LANDSCHULZ KT, 1989, BLOOD, V73, P1476; LOKEN MR, 1987, BLOOD, V69, P255; MAOUCHE L, 1991, BLOOD, V78, P2557; NOGUCHI CT, 1991, BLOOD, V78, P2548; OKUNO Y, 1990, CANCER, V66, P1544, DOI 10.1002/1097-0142(19901001)66:7<1544::AID-CNCR2820660719>3.0.CO;2-9; PARACIOS R, 1985, CELL, V41, P727; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WINKELMANN JC, 1990, BLOOD, V76, P24; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; [No title captured]	21	161	166	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1138	1141		10.1126/science.257.5073.1138	http://dx.doi.org/10.1126/science.257.5073.1138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1324524				2022-12-24	WOS:A1992JJ88400039
J	KYRIAKIS, JM; APP, H; ZHANG, XF; BANERJEE, P; BRAUTIGAN, DL; RAPP, UR; AVRUCH, J				KYRIAKIS, JM; APP, H; ZHANG, XF; BANERJEE, P; BRAUTIGAN, DL; RAPP, UR; AVRUCH, J			RAF-1 ACTIVATES MAP KINASE-KINASE	NATURE			English	Article							THREONINE PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; T-CELL ACTIVATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INSULIN; PATHWAYS; CASCADE	THE normal cellular homologue of the acutely transforming oncogene v-raf is c-raf-1, which encodes a serine/threonine protein kinase that is activated by many extracellular stimuli1. The physiological substrates of the protein c-Raf-1 are unknown. The mitogen-activated protein (MAP) kinases Erk1 and 2 are also activated by mitogens through phosphorylation of Erk tyrosine and threonine residues catalysed by a protein kinase of relative molecular mass 50,000, MAP kinase-kinase (MAPK-K)2-7. Here we report that MAPK-K as well as Erk1 and 2 are constitutively active in v-raf-transformed cells. MAPK-K partially purified from v-raf-transformed cells or from mitogen-treated cells3 can be deactivated by phosphatase 2A. c-Raf-1 purified after mitogen stimulation can reactivate the phosphatase 2A-inactivated MAPK-K over 30-fold in vitro. c-Raf-1 reactivation of MAPK-K coincides with the selective phosphorylation at serine/threonine residues of a polypeptide with M(r) 50,000 which coelutes precisely on cation-exchange chromatography with the MAPK-K activatable by c-Raf-1. These results indicate that c-Raf-1 is an immediate upstream activator of MAPK-K in vivo. To our knowledge, MAPK-K is the first physiological substrate of the c-raf-1 protooncogene product to be identified.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Brown University	KYRIAKIS, JM (corresponding author), MASSACHUSETTS GEN HOSP,MED SERV,DIABET UNIT,149 13TH ST,BOSTON,MA 02129, USA.							AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALLEMAIN GL, 1992, MOL CELL BIOL, V12, P2222; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GROVE JR, 1987, SCIENCE, V238, P530; HSI ED, 1989, J BIOL CHEM, V264, P10836; JONES SW, 1989, J BIOL CHEM, V264, P7747; KYRIAKIS JM, 1990, BIOCHIM BIOPHYS ACTA, V1054, P73, DOI 10.1016/0167-4889(90)90207-T; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKEDA M, 1988, J BIOL CHEM, V258, P10455; TROPPMAIR J, IN PRESS ONCOGENE	26	1189	1208	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					417	421		10.1038/358417a0	http://dx.doi.org/10.1038/358417a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322500				2022-12-24	WOS:A1992JF85300057
J	BURNASHEV, N; KHODOROVA, A; JONAS, P; HELM, PJ; WISDEN, W; MONYER, H; SEEBURG, PH; SAKMANN, B				BURNASHEV, N; KHODOROVA, A; JONAS, P; HELM, PJ; WISDEN, W; MONYER, H; SEEBURG, PH; SAKMANN, B			CALCIUM-PERMEABLE AMPA-KAINATE RECEPTORS IN FUSIFORM CEREBELLAR GLIAL-CELLS	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; GLUTAMATE; ASTROCYTES; CHANNELS; CULTURES; MORPHOLOGY; <H-3>GABA; CLONING; FAMILY	Glutamate-operated ion channels (GluR channels) of the L-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-kainate subtype are found in both neurons and glial cells of the central nervous system. These channels are assembled from the GluR-A, -B, -C, and -D subunits; channels containing a GluR-B subunit show an outwardly rectifying current-voltage relation and low calcium permeability, whereas channels lacking the GluR-B subunit are characterized by a doubly rectifying current-voltage relation and high calcium permeability. Most cell types in the central nervous system coexpress several subunits, including GluR-B. However, Bergmann glia in rat cerebellum do not express GluR-B subunit genes. In a subset of cultured cerebellar glial cells, likely derived from Bergmann glial cells, GluR channels exhibit doubly rectifying current-voltage relations and high calcium permeability, whereas GluR channels of cerebellar neurons have low calcium permeability. Thus, differential expression of the GluR-B subunit gene in neurons and glia is one mechanism by which functional properties of native GluR channels are regulated.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; ALL UNION BIOTECHNOL RES INST, MOSCOW 117246, USSR; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Wisden, William/A-4071-2011; Burnashev, Nail/G-4056-2013	Wisden, William/0000-0003-4743-0334; Monyer, Hannah/0000-0002-9332-5749; Jonas, Peter/0000-0001-5001-4804				BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; GRANDES P, 1991, EUR J NEUROSCI, V3, P1370, DOI 10.1111/j.1460-9568.1991.tb00070.x; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JOHNSTONE SR, 1986, DEV BRAIN RES, V24, P63, DOI 10.1016/0165-3806(86)90173-2; JONAS P, IN PRESS J PHYSL LON; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEVI G, 1983, DEV BRAIN RES, V10, P227, DOI 10.1016/0165-3806(83)90139-6; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; ORTEGA A, 1991, NEUROSCIENCE, V41, P335, DOI 10.1016/0306-4522(91)90331-H; OZAWA S, 1991, J NEUROPHYSIOL, V66, P2, DOI 10.1152/jn.1991.66.1.2; RAFF MC, 1983, J NEUROSCI, V3, P1289; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SOMOGYI P, 1990, NEUROSCIENCE, V35, P9, DOI 10.1016/0306-4522(90)90116-L; SONTHEIMER H, 1988, GLIA, V1, P328, DOI 10.1002/glia.440010505; TEICHBERG VI, 1991, FASEB J, V5, P3086, DOI 10.1096/fasebj.5.15.1660422; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; WYLLIE DJA, 1992, J PHYSIOL-LONDON, V446, pP598	27	383	386	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1992	256	5063					1566	1570		10.1126/science.1317970	http://dx.doi.org/10.1126/science.1317970			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317970				2022-12-24	WOS:A1992HY07500032
J	FLANIGAN, T; WHALEN, C; TURNER, J; SOAVE, R; TOERNER, J; HAVLIR, D; KOTLER, D				FLANIGAN, T; WHALEN, C; TURNER, J; SOAVE, R; TOERNER, J; HAVLIR, D; KOTLER, D			CRYPTOSPORIDIUM INFECTION AND CD4 COUNTS	ANNALS OF INTERNAL MEDICINE			English	Note						CRYPTOSPORIDIOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; CD4-CD8 RATIO; HUMAN IMMUNODEFICIENCY VIRUS		Cryptosporidium infection in immunocompetent persons is associated with self-limited diarrhea. In contrast, in persons with the acquired immunodeficiency syndrome (AIDS), cryptosporidiosis causes persistent enteritis that is refractory to treatment. In our clinical practices, we observed men infected with the human immunodeficiency virus (HIV) who had self-limited diarrhea due to Cryptosporidium infection. To better define the characteristics associated with self-limited disease, we did a retrospective chart review of HIV-seropositive patients with Cryptosporidium infection. We compared 13 HIV-positive persons with self-limited cryptosporidiosis with 34 persons with AIDS who had persistent Cryptosporidium infection. The mean CD4 count was significantly greater in patients with self-limited infection (312 cells/mm3, range, 14 to 651 cells/mm3) than in patient with persistent infection (57 cells/mm3, range 4 to 150 cells/mm3, P < 0.001). A similar relationship was found for the mean CD8 count, the mean ratio of CD4 to CD8 count, and the mean hematocrit. All patients with CD4 counts of 180 cells/mm3 or greater (n = 8) cleared the infection spontaneously over a period of 7 days to 1 month. This observation is important both in predicting the natural history of Cryptosporidium infection and in designing therapeutic trials.	UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; GRAD HOSP PHILADELPHIA, PHILADELPHIA, PA 19146 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA; WHITMAN WALKER CLIN, WASHINGTON, DC 20009 USA; UNIV CALIF SAN DIEGO, CTR TREATMENT, SAN DIEGO, CA 92103 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY 10025 USA	University Hospitals of Cleveland; University of Pennsylvania; Pennsylvania Medicine; Cornell University; NewYork-Presbyterian Hospital; University of California System; University of California San Diego; Mount Sinai St. Luke's; Mount Sinai West	FLANIGAN, T (corresponding author), MIRIAM HOSP, DEPT GEOG MED, 164 SUMMIT AVE, PROVIDENCE, RI 02906 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025879] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-25879, AI-01038] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONNOLLY GM, 1988, GUT, V29, P593, DOI 10.1136/gut.29.5.593; FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986; GREENBERG RE, 1989, GASTROENTEROLOGY, V97, P1327, DOI 10.1016/0016-5085(89)91708-3; HOJLYNG N, 1990, 6 INT C AIDS SAN FRA; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; 1987, MMWR, V36, pS3; 1986, SUGI SUPPLEMENTAL LI, P270	8	198	205	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					840	842		10.7326/0003-4819-116-10-840	http://dx.doi.org/10.7326/0003-4819-116-10-840			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1348918				2022-12-24	WOS:A1992HT80200009
J	BARR, LC; BAUM, M				BARR, LC; BAUM, M			TIME TO ABANDON TNM STAGING OF BREAST-CANCER	LANCET			English	Editorial Material							PROGNOSTIC INDEX		ROYAL MARSDEN HOSP,BREAST UNIT,FULHAM RD,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust				Barr, Lester/0000-0003-4030-8192				BRYAN RM, 1986, BRIT J SURG, V73, P267, DOI 10.1002/bjs.1800730408; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HAAGENSON CD, 1986, MASTECTOMY SUPPLEMEN, P949; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Hermanek P, 1987, TNM CLASSIFICATION M; HUTTER RVP, 1987, ARCH SURG-CHICAGO, V122, P1235; ROSNER D, 1991, CANCER, V68, P1482, DOI 10.1002/1097-0142(19911001)68:7<1482::AID-CNCR2820680704>3.0.CO;2-J; SCANLON EF, 1990, CANCER, V65, P2110, DOI 10.1002/1097-0142(19900501)65:9+<2110::AID-CNCR2820651405>3.0.CO;2-Z; SCHOTTENFELD D, 1976, CANCER, V38, P1001, DOI 10.1002/1097-0142(197608)38:2<1001::AID-CNCR2820380252>3.0.CO;2-5; SLAMON DJ, 1991, J NATL CANCER I, V83, P229, DOI 10.1093/jnci/83.4.229; 1991, JAMA-J AM MED ASSOC, V265, P391; 1992, LANCET, V339, P71	13	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					915	917		10.1016/0140-6736(92)90941-U	http://dx.doi.org/10.1016/0140-6736(92)90941-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348309				2022-12-24	WOS:A1992HN48300015
J	PAULMICHL, M; LI, Y; WICKMAN, K; ACKERMAN, M; PERALTA, E; CLAPHAM, D				PAULMICHL, M; LI, Y; WICKMAN, K; ACKERMAN, M; PERALTA, E; CLAPHAM, D			NEW MAMMALIAN CHLORIDE CHANNEL IDENTIFIED BY EXPRESSION CLONING	NATURE			English	Article							CANINE KIDNEY-CELLS; CYSTIC-FIBROSIS; XENOPUS OOCYTES; ION CHANNELS; CONDUCTANCE; MEMBRANE; PROTEINS; DISEASE; VOLUME	ION channels selectively permeable to chloride ions regulate cell functions as diverse as excitability and control of cell volume 1-5. Using expression cloning techniques, a complementary DNA from an epithelial cell line has been isolated, sequenced and its putative structure examined by site-directed mutagenesis. This cDNA, encoding a 235-amino-acid protein, gave rise to a chloride-selective outward current when expressed in Xenopus oocytes. The expressed, outwardly rectifying chloride current was calcium-insensitive and was blocked by nucleotides applied to the cell surface. Mutation of a putative nucleotide-binding site resulted in loss of nucleotide block but incurred dependence on extracellular calcium concentration. The unusual sequence of this putative channel protein suggests a new class of ion channels not related to other previously cloned chloride channels 6-11.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,BOSTON,MA 02115	Mayo Clinic; Harvard University			Clapham, David/R-5974-2019	Wickman, Kevin/0000-0002-5179-9540; Clapham, David/0000-0002-4459-9428				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; GUY HR, 1985, BIOPHYS J, V47, P61, DOI 10.1016/S0006-3495(85)83877-7; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hille B, 1984, IONIC CHANNELS EXCIT; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOLB HA, 1985, PFLUG ARCH EUR J PHY, V403, P262, DOI 10.1007/BF00583597; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANG F, 1986, PFLUG ARCH EUR J PHY, V407, P158, DOI 10.1007/BF00580668; Lang F., 1990, Comparative Physiology, V4, P1; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Maniatis T., 1982, MOL CLONING; PAULMICHL M, 1989, PFLUG ARCH EUR J PHY, V413, P456, DOI 10.1007/BF00594173; PAULMICHL M, 1988, FEBS LETT, V234, P263, DOI 10.1016/0014-5793(88)80094-2; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SOLC CK, 1991, AM J PHYSIOL, V261, P658; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WANGEMANN P, 1986, PFLUGERS ARCH, V407, pS141; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	30	335	348	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					238	241		10.1038/356238a0	http://dx.doi.org/10.1038/356238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313151				2022-12-24	WOS:A1992HJ94400057
J	SIMON, MN; PELEGRINI, O; VERON, M; KAY, RR				SIMON, MN; PELEGRINI, O; VERON, M; KAY, RR			MUTATION OF PROTEIN KINASE-A CAUSES HETEROCHRONIC DEVELOPMENT OF DICTYOSTELIUM	NATURE			English	Article							AMINO-ACID-SEQUENCE; REGULATORY SUBUNIT; CYCLIC-AMP; CAENORHABDITIS-ELEGANS; CELL-DIFFERENTIATION; SIGNAL TRANSDUCTION; DISCOIDEUM; REQUIREMENTS; MUTANTS; FORMS	IN heterochronic mutants the relative timing of developmental events is altered compared with the wild type. This generally results in a disordered embryo 1,2, though heterochronic mutations may also be an important source of evolutionary variation 3. In the rapidly developing (rde) mutants of Dictyostelium, stalk and spore cells differentiate before morphogenesis is complete. We have traced the lesion in one class of these mutants to the regulatory subunit of cyclic AMP-dependent protein kinase (pk-A). Inactivation of this protein results in the unrestrained activity of the catalytic subunit, so prematurely triggering terminal cell differentiation.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	SIMON, MN (corresponding author), INST PASTEUR,UNITE BIOCHIM CELLULAIRE,CNRS,URA 1129,F-75724 PARIS 15,FRANCE.			Kay, Robert R/0000-0001-9836-7967				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; BONNER JT, 1982, AM NAT, V119, P530, DOI 10.1086/283930; DEGUNZBURG J, 1982, EMBO J, V1, P1063, DOI 10.1002/j.1460-2075.1982.tb01297.x; DEGUNZBURG J, 1984, BIOCHEMISTRY-US, V23, P3805, DOI 10.1021/bi00312a003; DEVREOTES PN, 1979, J CELL BIOL, V80, P300, DOI 10.1083/jcb.80.2.300; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; INNIS MA, 1990, PCR PROTOCOLS; KAY RR, 1989, DEVELOPMENT, V105, P753; KESSIN RH, 1977, CELL, V10, P703, DOI 10.1016/0092-8674(77)90104-0; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERKLE RK, 1984, CELL DIFFER DEV, V14, P257, DOI 10.1016/0045-6039(84)90014-9; MUTZEL R, 1988, BIOCHEMISTRY-US, V27, P481, DOI 10.1021/bi00401a069; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NEWELL PC, 1988, J CELL SCI, V89, P123; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; REYMOND CD, 1987, NUCLEIC ACIDS RES, V15, P8118, DOI 10.1093/nar/15.19.8118; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; SONNEBORN DR, 1963, DEV BIOL, V7, P79, DOI 10.1016/0012-1606(63)90108-8; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, REV BIOCH, V59, P971; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0	27	121	123	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					171	172		10.1038/356171a0	http://dx.doi.org/10.1038/356171a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1312226				2022-12-24	WOS:A1992HH73100066
J	FOWLER, KB; STAGNO, S; PASS, RF; BRITT, WJ; BOLL, TJ; ALFORD, CA				FOWLER, KB; STAGNO, S; PASS, RF; BRITT, WJ; BOLL, TJ; ALFORD, CA			THE OUTCOME OF CONGENITAL CYTOMEGALOVIRUS-INFECTION IN RELATION TO MATERNAL ANTIBODY STATUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; INCLUSION DISEASE; VIRUS INFECTION; PREGNANCY; INFANTS; GROWTH	Background. Intrauterine transmission of cytomegalovirus (CMV) can occur whether a mother has prior immunity or acquires CMV for the first time during pregnancy. The degree of protection afforded an infected infant by the presence of antibody in the mother before conception is uncertain. Methods. We compared the outcomes of CMV-infected infants born to mothers who acquired primary CMV infection during pregnancy (primary-infection group) with those of CMV-infected infants born to mothers with immunity (recurrent-infection group). Screening for viruria identified 197 newborns with congenital CMV infection. Stored serum samples were used to categorize maternal infection as either primary or recurrent. We followed 125 infants from the primary-infection group and 64 from the recurrent-infection group. Serial medical, audiologic, psychometric, and eye examinations were used to identify sequelae of CMV infection. Results. Only infants in the primary-infection group had symptomatic CMV infection at birth (18 percent). After a mean follow-up of 4.7 years, one or more sequelae were seen in 25 percent of the primary-infection group and in 8 percent of the recurrent-infection group. Thirteen percent of infants whose mothers had primary infection during pregnancy had mental impairment (IQ less-than-or-equal-to 70), as compared with none of those whose mothers had recurrent CMV infections. Sensorineural hearing loss was found in 15 percent of those in the primary-infection group and in only 5 percent of those in the recurrent-infection group. Bilateral hearing loss was identified only among children in the primary-infection group (8 percent). Conclusions. The presence of maternal antibody to CMV before conception provides substantial protection against damaging congenital CMV infection in the newborn. Primary maternal infection during pregnancy is associated with more severe sequelae of congenital CMV infection.	UNIV ALABAMA, DEPT PSYCHOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	FOWLER, KB (corresponding author), UNIV ALABAMA, DEPT PEDIAT, 1600 7TH AVE S, SUITE 752, BIRMINGHAM, AL 35294 USA.			Pass, Robert/0000-0003-2029-0247	NCRR NIH HHS [M01 RR000032, RR0032] Funding Source: Medline; NICHD NIH HHS [HD10699] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHLFORS K, 1981, NEW ENGL J MED, V305, P284; BERENBERG W, 1970, PEDIATRICS, V46, P403; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; DAHLE AJ, 1979, J SPEECH HEAR DISORD, V44, P220, DOI 10.1044/jshd.4402.220; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; GOLDENBERG RL, 1985, AM J OBSTET GYNECOL, V152, P980, DOI 10.1016/0002-9378(85)90543-5; GRIFFITHS PD, 1982, J INFECT DIS, V145, P647, DOI 10.1093/infdis/145.2.647; HANSHAW JB, 1976, NEW ENGL J MED, V295, P468, DOI 10.1056/NEJM197608262950902; KUMAR ML, 1973, NEW ENGL J MED, V288, P1370, DOI 10.1056/NEJM197306282882603; Matthews D.E., 1988, USING UNDERSTANDING, P67; MCCRACKE.GH, 1969, AM J DIS CHILD, V117, P522, DOI 10.1001/archpedi.1969.02100030524005; MEDEARIS DN, 1964, B JOHNS HOPKINS HOSP, V114, P181; MEDEARIS DN, 1982, NEW ENGL J MED, V306, P985, DOI 10.1056/NEJM198204223061609; MELISH ME, 1973, AM J DIS CHILD, V126, P190, DOI 10.1001/archpedi.1973.02110190168011; PACKMAN S, 1991, P443; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PASS RF, 1980, PEDIATRICS, V66, P758; REYNOLDS DW, 1974, NEW ENGL J MED, V290, P291, DOI 10.1056/NEJM197402072900601; REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101; RUTTER D, 1985, LANCET, V2, P1182; Stagno S, 1981, Birth Defects Orig Artic Ser, V17, P31; STAGNO S, 1985, J CLIN MICROBIOL, V21, P930, DOI 10.1128/JCM.21.6.930-935.1985; STAGNO S, 1982, NEW ENGL J MED, V306, P945, DOI 10.1056/NEJM198204223061601; STAGNO S, 1977, PEDIATRICS, V59, P669; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203; STAGNO S, 1990, INFECT DIS, P241; WELLER TH, 1962, NEW ENGL J MED, V266, P1233, DOI 10.1056/NEJM196206142662401; 1987, SAS STAT GUIDE PERSO, P519	30	780	806	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					663	667		10.1056/NEJM199203053261003	http://dx.doi.org/10.1056/NEJM199203053261003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1310525				2022-12-24	WOS:A1992HG11700003
J	NEWCOMBE, DS				NEWCOMBE, DS			IMMUNE SURVEILLANCE, ORGANOPHOSPHORUS EXPOSURE, AND LYMPHOMAGENESIS	LANCET			English	Article							MONOCYTE ESTERASE-ACTIVITY; NATURAL-KILLER CELLS; EPSTEIN-BARR; INTOXICATION; ABERRATIONS; INHIBITION; PESTICIDES; MORTALITY; INDUSTRY; WORKERS	Prevalence of lymphoproliferative disorders is increased in populations with various chemical exposures, including organophosphorus compounds. Lymphomas are also more common in individuals with a substantially decreased monocyte esterase activity. Organophosphorus compounds inhibit esterases associated with monocytes, natural killer (NK) cells, lymphokine-activated killer (LAK) cells, and cytotoxic T lymphocytes, and these inhibitory effects impair immune surveillance and cytotoxic functions mediated by such cells. Lymphoma development is also associated with Epstein-Barr virus (EBV) and human herpesvirus-6 (HHV-6) infections, which are regulated by cytotoxic immune responses mediated by monocytes, T cells, and NK cells. My hypothesis is that lymphomagenesis is a multistep process, and the absence or inhibition of monocyte esterase and perhaps other immune cell esterases alters esterase-dependent detoxification of a factor critical for the early steps of oncogenesis. Also, such an enzyme deficit might impair the processes that regulate the dissemination and limit the total burden of pathogens such as the lymphoma-associated herpesviruses. An added risk to any viral-mediated lymphoproliferation might be an organophosphorus-induced oncogenic genetic change.			NEWCOMBE, DS (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							ALAVANJA MCR, 1990, J NATL CANCER I, V82, P840, DOI 10.1093/jnci/82.10.840; ALAVANJA MCR, 1987, J NATL CANCER I, V78, P247; AMBINDER RF, 1990, MOL CELL PROBE, V4, P397, DOI 10.1016/0890-8508(90)90030-4; AMBINDER RF, 1990, HEMATOL ONCOL CLIN N, V4, P821, DOI 10.1016/S0889-8588(18)30469-6; BIEMER JJ, 1990, ANN CLIN LAB SCI, V20, P175; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BLAIR A, 1985, SCAND J WORK ENV HEA, V11, P397, DOI 10.5271/sjweh.2208; DULOUT FN, 1985, MUTAT RES, V143, P237, DOI 10.1016/0165-7992(85)90087-9; EMMETT EA, 1985, J OCCUP ENVIRON MED, V27, P905; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; HALL NEL, 1991, AM J IND MED, V19, P145, DOI 10.1002/ajim.4700190203; KIRALY J, 1979, ARCH ENVIRON CON TOX, V8, P309, DOI 10.1007/BF01056247; LAVECCHIA C, 1989, BRIT J CANCER, V60, P385, DOI 10.1038/bjc.1989.290; LEE MJ, 1977, BLOOD, V50, P947; MANDEL JS, 1989, AM J IND MED, V15, P207, DOI 10.1002/ajim.4700150209; MARKEY GM, 1990, J CLIN PATHOL, V43, P282, DOI 10.1136/jcp.43.4.282; MCCORMICK JA, 1991, BRIT J HAEMATOL, V77, P287, DOI 10.1111/j.1365-2141.1991.tb08572.x; MULE JJ, 1985, J IMMUNOL, V135, P646; Newcombe D.S., 1992, CLIN IMMUNOTOXICOLOG, P349; OEHMICHEN M, 1984, FORENSIC SCI INT, V25, P181, DOI 10.1016/0379-0738(84)90192-0; OERTEL J, 1985, BRIT J HAEMATOL, V61, P717, DOI 10.1111/j.1365-2141.1985.tb02886.x; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; REYNOLDS T, 1991, J NATL CANCER I, V83, P232, DOI 10.1093/jnci/83.4.232; ROGERS KE, 1988, J IMMUNOL, V140, P564; ROGERS KE, 1986, IMMUNOPHARMACOLOGY, V12, P193; RUZICSKA P, 1973, MUTAT RES, V21, P187; SOBTI RC, 1982, MUTAT RES, V102, P89, DOI 10.1016/0165-1218(82)90149-5; STEINER PE, 1960, CANCER-AM CANCER SOC, V13, P1084, DOI 10.1002/1097-0142(196011/12)13:6&lt;1085::AID-CNCR2820130603&gt;3.0.CO;2-Y; SUBAR M, 1988, BLOOD, V72, P667; TALCOTT RE, 1979, TOXICOL APPL PHARM, V49, P107, DOI 10.1016/0041-008X(79)90282-5; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VANBAO T, 1974, HUMANGENETIK, V24, P33; WU TC, 1991, AM J PATHOL, V138, P1461; YODER J, 1973, MUTAT RES, V21, P335	35	32	33	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	1992	339	8792					539	541		10.1016/0140-6736(92)90349-8	http://dx.doi.org/10.1016/0140-6736(92)90349-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346889				2022-12-24	WOS:A1992HF63100014
J	MOSER, CC; KESKE, JM; WARNCKE, K; FARID, RS; DUTTON, PL				MOSER, CC; KESKE, JM; WARNCKE, K; FARID, RS; DUTTON, PL			NATURE OF BIOLOGICAL ELECTRON-TRANSFER	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTERS; BACTERIAL REACTION CENTERS; RHODOPSEUDOMONAS-VIRIDIS; CHARGE SEPARATION; FREE-ENERGY; RHODOBACTER-SPHAEROIDES; DELAYED FLUORESCENCE; TRANSFER RATES; MOLECULES; RECOMBINATION	Powerful first-order analysis of intraprotein electron transfer is developed from electron-transfer measurements both in biological and in chemical systems. A variation of 20 angstrom in the distance between donors and acceptors in protein changes the electron-transfer rate by 10(12)-fold. Protein presents a uniform electronic barrier to electron tunnelling and a uniform nuclear characteristic frequency, properties similar to an organic glass. Selection of distance, free energy and reorganization energy are sufficient to define rate and directional specificity of biological electron transfer, meeting physiological requirements in diverse systems.	UNIV PENN, DEPT BIOCHEM & BIOPHYS, JOHNSON RES FDN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568				ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANTOLOVICH M, 1991, J PHYS CHEM-US, V95, P1933, DOI 10.1021/j100158a010; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; CARITHERS RP, 1975, BIOCHIM BIOPHYS ACTA, V387, P194, DOI 10.1016/0005-2728(75)90103-6; CHANCE B, 1960, P NATL ACAD SCI USA, V46, P19, DOI 10.1073/pnas.46.1.19; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; CHIDSEY CED, 1984, BIOCHIM BIOPHYS ACTA, V766, P424, DOI 10.1016/0005-2728(84)90258-5; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; COWAN JA, 1988, ANN NY ACAD SCI, V550, P68, DOI 10.1111/j.1749-6632.1988.tb35324.x; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; DEVAULT D, 1966, BIOPHYS J, V6, P825, DOI 10.1016/S0006-3495(66)86698-5; DRACHEVA SM, 1988, EUR J BIOCHEM, V171, P253, DOI 10.1111/j.1432-1033.1988.tb13784.x; FOX LS, 1990, SCIENCE, V247, P1069, DOI 10.1126/science.247.4946.1069; FRANZEN S, 1990, J PHYS CHEM-US, V94, P5135, DOI 10.1021/j100375a068; GAINES GL, 1991, J AM CHEM SOC, V113, P719, DOI 10.1021/ja00002a076; Gamow G, 1928, Z PHYS, V51, P204, DOI 10.1007/BF01343196; GIANGIACOMO KM, 1989, P NATL ACAD SCI USA, V86, P2658, DOI 10.1073/pnas.86.8.2658; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOLTEN D, 1978, BIOCHIM BIOPHYS ACTA, V501, P112, DOI 10.1016/0005-2728(78)90100-7; HOLZAPFEL W, 1990, P NATL ACAD SCI USA, V87, P5168, DOI 10.1073/pnas.87.13.5168; HOLZAPFEL W, 1989, CHEM PHYS LETT, V160, P1, DOI 10.1016/0009-2614(89)87543-8; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; KNAPP S, 1991, J AM CHEM SOC, V113, P4010, DOI 10.1021/ja00010a064; LEVICH VG, 1959, DOKL AKAD NAUK SSSR+, V124, P123; LOCKHART DJ, 1990, J PHYS CHEM-US, V94, P6987, DOI 10.1021/j100381a015; MACQUEEN DB, 1991, J AM CHEM SOC, V113, P7470, DOI 10.1021/ja00020a003; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MEADE TJ, 1989, J AM CHEM SOC, V111, P4353, DOI 10.1021/ja00194a030; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHELBEYERLE ME, 1988, BIOCHIM BIOPHYS ACTA, V932, P52, DOI 10.1016/0005-2728(88)90139-9; MILLER JR, 1984, J AM CHEM SOC, V106, P5057, DOI 10.1021/ja00330a004; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; PARSON WW, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251, DOI 10.1016/0005-2728(90)90192-7; PARSON WW, 1975, BIOCHIM BIOPHYS ACTA, V387, P265, DOI 10.1016/0005-2728(75)90109-7; PERKINS TA, 1990, J PHYS CHEM-US, V94, P8745, DOI 10.1021/j100388a001; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P44, DOI 10.1016/0005-2728(82)90315-2; SHOPES RJ, 1987, BIOCHIM BIOPHYS ACTA, V893, P409, DOI 10.1016/0005-2728(87)90093-4; SHOPES RJ, 1987, PHOTOSYNTH RES, V12, P165, DOI 10.1007/BF00047946; SHOPES RJ, 1985, BIOCHIM BIOPHYS ACTA, V806, P348, DOI 10.1016/0005-2728(85)90242-7; SHUVALOV VA, 1983, FEBS LETT, V160, P51, DOI 10.1016/0014-5793(83)80934-X; TAKAHASHI E, 1991, FEBS LETT, V283, P140, DOI 10.1016/0014-5793(91)80572-K; THERIEN MJ, 1991, ADV CHEM SER, V228, P191; TIEDE DM, 1988, PHOTOSYNTHETIC BACTE, P13; WASIELEWSKI MR, 1985, J AM CHEM SOC, V107, P1080, DOI 10.1021/ja00290a066; WASIELEWSKI MR, 1989, TETRAHEDRON, V45, P4785, DOI 10.1016/S0040-4020(01)85152-8; WASIELEWSKI MR, 1985, PORPHYRINS EXCITED S, P154	50	1646	1670	5	323	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1992	355	6363					796	802		10.1038/355796a0	http://dx.doi.org/10.1038/355796a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311417				2022-12-24	WOS:A1992HF63600045
J	BROOK, JD; MCCURRACH, ME; HARLEY, HG; BUCKLER, AJ; CHURCH, D; ABURATANI, H; HUNTER, K; STANTON, VP; THIRION, JP; HUDSON, T; SOHN, R; ZEMELMAN, B; SNELL, RG; RUNDLE, SA; CROW, S; DAVIES, J; SHELBOURNE, P; BUXTON, J; JONES, C; JUVONEN, V; JOHNSON, K; HARPER, PS; SHAW, DJ; HOUSMAN, DE				BROOK, JD; MCCURRACH, ME; HARLEY, HG; BUCKLER, AJ; CHURCH, D; ABURATANI, H; HUNTER, K; STANTON, VP; THIRION, JP; HUDSON, T; SOHN, R; ZEMELMAN, B; SNELL, RG; RUNDLE, SA; CROW, S; DAVIES, J; SHELBOURNE, P; BUXTON, J; JONES, C; JUVONEN, V; JOHNSON, K; HARPER, PS; SHAW, DJ; HOUSMAN, DE			MOLECULAR-BASIS OF MYOTONIC-DYSTROPHY - EXPANSION OF A TRINUCLEOTIDE (CTG) REPEAT AT THE 3' END OF A TRANSCRIPT ENCODING A PROTEIN-KINASE FAMILY MEMBER	CELL			English	Article							MUSCULAR-DYSTROPHY; CHROMOSOME-19; LOCUS; MEMBRANE; LINKAGE; REGION; MAP; DNA	Using positional cloning strategies, we have identified a CTG triplet repeat that undergoes expansion in myotonic dystrophy patients. This sequence is highly variable in the normal population. PCR analysis of the interval containing this repeat indicates that unaffected individuals have between 5 and 27 copies. Myotonic dystrophy patients who are minimally affected have at least 50 repeats, while more severely affected patients have expansion of the repeat containing segment up to several kilobase pairs. The CTG repeat is transcribed and is located in the 3' untranslated region of an mRNA that is expressed in tissues affected by myotonic dystrophy. This mRNA encodes a polypeptide that is a member of the protein kinase family.	UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; CHARING CROSS & WESTMINSTER MED SCH, DEPT ANAT, LONDON W6 8RF, ENGLAND	Cardiff University; Imperial College London	BROOK, JD (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.		Buxton, Jessica/L-9849-2019; Buxton, Jessica L/I-4033-2014	Buxton, Jessica L/0000-0002-0918-9335; johnson, keith/0000-0002-8578-5921; Brook, John David/0000-0002-5946-6740; Stanton, Vincent/0000-0002-2205-6000; Snell, Russell/0000-0002-8166-4014	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG 00299] Funding Source: Medline; NHLBI NIH HHS [HL-41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BROOK JD, 1991, J MED GENET, V28, P84, DOI 10.1136/jmg.28.2.84; BROOK JD, 1991, HUM GENET, V87, P65, DOI 10.1007/BF01213095; BROOK JD, 1992, IN PRESS GENOMICS; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; BUTTERFIELD DA, 1974, BIOCHEMISTRY-US, V13, P5078, DOI 10.1021/bi00722a003; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; DYKEN PR, 1973, NEUROLOGY, V23, P465, DOI 10.1212/WNL.23.5.465; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARLEY HG, 1991, HUM GENET, V87, P73, DOI 10.1007/BF01213096; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HULL KL, 1976, J PHYSIOL-LONDON, V254, P169, DOI 10.1113/jphysiol.1976.sp011227; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JANSEN G, IN PRESS GENOMICS; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1989, GENOMICS, V5, P596, DOI 10.1016/0888-7543(89)90028-1; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; RENAUD JF, 1986, NATURE, V319, P678, DOI 10.1038/319678a0; ROSES AD, 1973, P NATL ACAD SCI USA, V70, P1855, DOI 10.1073/pnas.70.6.1855; ROSES AD, 1974, NATURE, V250, P245, DOI 10.1038/250245a0; SEILER D, 1970, SCHWEIZ MED WSCHR, V100, P1374; SHUTLER G, 1992, IN PRESS GENOMICS; SMEETS H, 1990, AM J HUM GENET, V46, P492; TSIFIDIS C, 1991, AM J HUM GENET, V49, P961; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	44	2075	2136	2	78	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					799	808		10.1016/0092-8674(92)90154-5	http://dx.doi.org/10.1016/0092-8674(92)90154-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1310900				2022-12-24	WOS:A1992HF44000019
J	MCCLATCHEY, AI; VANDENBERGH, P; PERICAKVANCE, MA; RASKIND, W; VERELLEN, C; MCKENNAYASEK, D; RAO, K; HAINES, JL; BIRD, T; BROWN, RH; GUSELLA, JF				MCCLATCHEY, AI; VANDENBERGH, P; PERICAKVANCE, MA; RASKIND, W; VERELLEN, C; MCKENNAYASEK, D; RAO, K; HAINES, JL; BIRD, T; BROWN, RH; GUSELLA, JF			TEMPERATURE-SENSITIVE MUTATIONS IN THE III-IV-CYTOPLASMIC LOOP REGION OF THE SKELETAL-MUSCLE SODIUM-CHANNEL GENE IN PARAMYOTONIA-CONGENITA	CELL			English	Article							RAT-BRAIN; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; CDNA SEQUENCE; CLONED CDNA; INACTIVATION; DROSOPHILA; MYOTONIA	Paramyotonia congenita (PMC), a dominant disorder featuring cold-induced myotonia (muscle stiffness), has recently been genetically linked to a candidate gene, the skeletal muscle sodium channel gene SCN4A. We have now established that SCN4A is the disease gene in PMC by identifying two different single-base coding sequence alterations in PMC families. Both mutations affect highly conserved residues in the III-IV cytoplasmic loop, a portion of the sodium channel thought to pivot in response to membrane depolarization, thereby blocking and inactivating the channel. Abnormal function of this cytoplasmic loop therefore appears to produce the Na+ current abnormality and the unique temperature-sensitive clinical phenotype in this disorder.	MASSACHUSETTS GEN HOSP,DAY NEUROMUSCULAR RES,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; CATHOLIC UNIV LOUVAIN,CLIN UNIV ST LUC,DEPT NEUROL,B-1200 BRUSSELS,BELGIUM; DUKE UNIV,DEPT MED,DIV NEUROSURG,DURHAM,NC 27706; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV CONNECTICUT,CTR HLTH,DEPT NEUROL,FARMINGTON,CT 06032; SEATTLE VET AFFAIRS HOSP,DIV NEUROL,SEATTLE,WA 98195	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Duke University; University of Washington; University of Washington Seattle; University of Connecticut	MCCLATCHEY, AI (corresponding author), MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET LAB,BOSTON,MA 02129, USA.		Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	NINDS NIH HHS [NS22224, NS24279, NS26630] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630, P01NS024279, R01NS022224] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; ENGEL AG, 1986, MYOLOGY, P1843; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; HOSHI T, 1990, SCIENCE, V250, P506; IAZZO PA, 1991, NEUROMUSC DISORDERS, V1, P47; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P116; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOCH MC, 1991, J MED GENET, V28, P583, DOI 10.1136/jmg.28.9.583; KOCH MC, 1991, IN PRESS HUM GENET; LEHMANNHORN F, 1990, MUSCLE NERVE, V13, P528, DOI 10.1002/mus.880130609; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P363, DOI 10.1002/mus.880100414; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P633, DOI 10.1002/mus.880100709; LEHMANNHORN F, 1991, PFLUG ARCH EUR J PHY, V418, P297, DOI 10.1007/BF00370530; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MCCLATCHEY AI, 1992, IN PRESS AM J HUM GE; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; RASKIND WH, 1991, AM J HUM GENET, V48, P335; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROJAS CV, 1991, IN PRESS NATURE; SALKOFF L, 1987, NUCLEIC ACIDS RES, V15, P8569, DOI 10.1093/nar/15.20.8569; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P11; SEIZINGER BR, 1986, NATURE, V322, P664; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VANDENBERGH P, 1991, NEUROLOGY S1, V41, P419; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937	44	222	228	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					769	774		10.1016/0092-8674(92)90151-2	http://dx.doi.org/10.1016/0092-8674(92)90151-2			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1310898				2022-12-24	WOS:A1992HF44000016
J	LEWIS, MJ; PELHAM, HRB				LEWIS, MJ; PELHAM, HRB			LIGAND-INDUCED REDISTRIBUTION OF A HUMAN KDEL RECEPTOR FROM THE GOLGI-COMPLEX TO THE ENDOPLASMIC-RETICULUM	CELL			English	Article							LUMINAL ER PROTEINS; GIANT HELA-CELLS; BREFELDIN-A; THIAMINE PYROPHOSPHATASE; MEMBRANE-PROTEIN; YEAST; ANTIBODIES; IDENTIFICATION; LOCALIZATION; COMPARTMENT	Resident luminal endoplasmic reticulum (ER) proteins carry a targeting signal (usually KDEL in animal cells) that allows their retrieval from later stages of the secretory pathway. In yeast, the receptor that promotes this selective retrograde transport has been identified as the product of the ERD2 gene. We describe here the properties of a human homolog of this protein (hERD2). Overproduction of hERD2 improves retention of a protein with a weakly recognized variant signal (DDEL). Moreover, overexpression of KDEL or DDEL ligands causes a redistribution of hERD2 from the Golgi apparatus to the ER. Mutation of hERD2 alters the ligand specificity of this effect, implying that it interacts directly with the retained proteins. Ligand control of receptor movement may limit retrograde flow and thus minimize fruitless recycling of secretory proteins.			LEWIS, MJ (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							BRETSCHER MS, 1983, P NATL ACAD SCI-BIOL, V80, P454, DOI 10.1073/pnas.80.2.454; BRETSCHER MS, 1983, EMBO J, V2, P599, DOI 10.1002/j.1460-2075.1983.tb01469.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARIUZZA RA, 1983, J MOL BIOL, V170, P1055, DOI 10.1016/S0022-2836(83)80206-X; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; PUDDINGTON L, 1986, J CELL BIOL, V102, P2147, DOI 10.1083/jcb.102.6.2147; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SARASTE J, 1991, IN PRESS J CELL SCI; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0	34	340	345	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					353	364		10.1016/0092-8674(92)90476-S	http://dx.doi.org/10.1016/0092-8674(92)90476-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310258				2022-12-24	WOS:A1992HB35300014
J	SIMONETTI, RG; CAMMA, C; FIORELLO, F; COTTONE, M; RAPICETTA, M; MARINO, L; FIORENTINO, G; CRAXI, A; CICCAGLIONE, A; GIUSEPPETTI, R; STROFFOLINI, T; PAGLIARO, L				SIMONETTI, RG; CAMMA, C; FIORELLO, F; COTTONE, M; RAPICETTA, M; MARINO, L; FIORENTINO, G; CRAXI, A; CICCAGLIONE, A; GIUSEPPETTI, R; STROFFOLINI, T; PAGLIARO, L			HEPATITIS-C VIRUS-INFECTION AS A RISK FACTOR FOR HEPATOCELLULAR-CARCINOMA IN PATIENTS WITH CIRRHOSIS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C VIRUS; LIVER NEOPLASMS; HEPATITIS, VIRAL, NON-A, NON-B; HEPATITIS-B; LIVER CIRRHOSIS	POST-TRANSFUSION HEPATITIS; NON-B-HEPATITIS; CHRONIC NON-A; BLOOD-DONORS; ANTIBODIES; PREVALENCE; ETIOLOGY; ALCOHOL	Objective: To determine whether chronic hepatitis C virus (HCV) infection is an independent risk factor for hepatocellular carcinoma and whether it increases the cirrhosis-related risk for hepatocellular carcinoma. Design: Two pair-matched case-control studies. Setting: A referral-based hospital. Patients: In study I, 212 patients with hepatocellular carcinoma (197 of whom had known underlying cirrhosis) were compared with controls who had chronic nonhepatic diseases. In study II, the 197 patients with hepatocellular carcinoma and cirrhosis were compared with 197 pair-matched controls who had cirrhosis but not hepatocellular carcinoma. Measurements: Levels of antibody to HCV (anti-HCV), hepatitis B surface antigen (HBsAg), and antibody to hepatitis B core antigen (anti-HBc) were assayed, and alcohol abuse was assessed by history. Main Results: In study I, 151 patients (71%) with hepatocellular carcinoma were anti-HCV positive compared with 11 controls (5%) with chronic nonhepatic diseases (odds ratio, 42; 95% Cl, 22 to 95). Multivariate analysis showed that anti-HCV was an independent risk factor for hepatocellular carcinoma (odds ratio, 69; Cl, 15 to 308). The analysis also showed that HBsAg (odds ratio, 8.7; Cl, 1.5 to 50) and anti-HBc (odds ratio, 4.2 (Cl, 1.7 to 11) were risk factors for hepatocellular carcinoma. No statistically significant interaction was found between anti-HCV and the markers of HBV infection. In study II, 146 patients (74%) with hepatocellular carcinoma and cirrhosis were anti-HCV positive compared with 122 patients (62%) with cirrhosis alone (odds ratio, 1.8; Cl, 1.1 to 2.8). Multivariate analysis confirmed that anti-HCV (odds ratio, 2.0; Cl, 1.3 to 32) and HBsAg (odds ratio, 2.0; Cl, 1.0 to 4.2) were independent risk factors for hepatocellular carcinoma. Conclusions: Hepatitis C virus infection is a risk factor for hepatocellular carcinoma, apparently by inducing cirrhosis and, to a lesser extent, by enhancing the risk in patients with cirrhosis. Hepatitis C virus infection acts independently of HBV infection (another risk factor) and of alcohol abuse, age, or gender.	UNIV PALERMO, IST MED GEN & PNEUMOL, I-90134 PALERMO, ITALY; IST SUPER SANITA, I-00161 ROME, ITALY	University of Palermo; Istituto Superiore di Sanita (ISS)			Giuseppetti, Roberto/AAA-6508-2021; CICCAGLIONE, ANNA RITA/M-2956-2015; Craxi, Antonio/K-9529-2016	Giuseppetti, Roberto/0000-0001-9958-164X; CICCAGLIONE, ANNA RITA/0000-0002-3791-3781; Cottone, Mario/0000-0003-1523-7556; Craxi, Antonio/0000-0002-4480-9544; CAMMA', CALOGERO/0000-0002-9224-1914				ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER HJ, 1990, J GASTROEN HEPATOL, V5, P78, DOI 10.1111/j.1440-1746.1990.tb01783.x; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BOSCH FX, 1989, FALK SYMP, V51, P3; BRESLOW N, 1982, BIOMETRICS, V38, P661, DOI 10.2307/2530047; Breslow N, 1980, STATISTICAL METHODS, V32; BRUIX J, 1989, LANCET, V2, P1004; CAPORASO N, 1991, J HEPATOL, V12, P367, DOI 10.1016/0168-8278(91)90841-X; CHIARAMONTE M, 1990, ASPETTI EPIDEMIOLOGI, P11; COLOMBO M, 1989, LANCET, V2, P1006; DAZZA MC, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92733-X; ESTEBAN JI, 1989, LANCET, V2, P294; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; HASAN F, 1990, HEPATOLOGY, V12, P589, DOI 10.1002/hep.1840120323; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1987, AM J GASTROENTEROL, V78, P777; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEVRERO M, 1991, J HEPATOL, V12, P60, DOI 10.1016/0168-8278(91)90910-4; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; MAGRIN S, 1991, J GASTROENTEROL, V23, P312; OKUDA K, 1986, DIGEST DIS SCI, V31, pS133; PAGLIARO L, 1983, HEPATO-GASTROENTEROL, V30, P48; RESNICK RH, 1983, DIGEST DIS SCI, V28, P908, DOI 10.1007/BF01317042; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; SANCHIS J, 1990, 1990 P INT S VIR HEP, P439; SIMONETTI RG, 1989, LANCET, V2, P1338; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; SIRCHIA G, 1990, VOX SANG, V59, P26, DOI 10.1111/j.1423-0410.1990.tb02109.x; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TREMOLADA F, 1990, LANCET, V335, P300, DOI 10.1016/0140-6736(90)90129-S; VARGAS V, 1990, ANN INTERN MED, V112, P232, DOI 10.7326/0003-4819-112-3-232_2; VILLA E, 1988, CANCER-AM CANCER SOC, V62, P611, DOI 10.1002/1097-0142(19880801)62:3<611::AID-CNCR2820620328>3.0.CO;2-0; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M; WEJSTAL R, 1987, SCAND J GASTROENTERO, V22, P1115, DOI 10.3109/00365528708991968; YARRISH RL, 1980, INT J CANCER, V26, P711, DOI 10.1002/ijc.2910260603; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; ZAMAN SN, 1985, LANCET, V1, P1357; 1988, SAS STAT USERS GUIDE, P189	40	357	360	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					97	102		10.7326/0003-4819-116-2-97	http://dx.doi.org/10.7326/0003-4819-116-2-97			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1309286				2022-12-24	WOS:A1992GZ35600001
J	HEALY, B				HEALY, B			BETTER TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-24	WOS:A1992GY04600005
J	OVEREND, A; HALL, WW; GODWIN, PGR				OVEREND, A; HALL, WW; GODWIN, PGR			DOES EARWAX LOSE ITS PATHOGENS ON YOUR AURISCOPE OVERNIGHT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To describe the organisms cultured from general practitioners' auriscope earpieces; and to explore general practitioners' perceptions of the possibility of cross infection from contaminated auriscope earpieces and of how their auriscope earpieces are cleaned. Design-Microbiological survey of auriscope ear-pieces in two general practices and a semistructured questionnaire sent to 105 general practitioners. Setting-General practitioners served by one district general hospital microbiology laboratory in the north of England. Results-Organisms were cultured from 41 (93%) of 44 auriscope earpieces, of which 14 (32%) carried potential pathogens; four (9%) were heavily contaminated. Of the 85 (81%) general practitioners who responded, 72 (85%) believed that contaminated auriscope earpieces could cause serious infection, 66 (78%) did not clean earpieces between patients, and 70 (82%) thought that patients would mind if they knew that dirty earpieces were used. Conclusions-Almost a third of auriscope ear-pieces were contaminated by pathogenic bacteria. Although general practitioners suspected this, most did not ensure that a clean earpiece was used for each patient.	TOWNHEAD SURG,SETTLE BD24 9JA,N YORKSHIRE,ENGLAND; AIREDALE DIST GEN HOSP,KEIGHLEY,W YORKSHIRE,ENGLAND		HALL, WW (corresponding author), TOWNHEAD SURG,SETTLE BD24 9JA,N YORKSHIRE,ENGLAND.							AYLIFFE GAJ, 1992, CONTROL HOSPITAL INF; BROOK I, 1985, AM J OTOLARYNG, V6, P111, DOI 10.1016/S0196-0709(85)80048-X; CASSISI N, 1977, ANN OTO RHINOL LARYN, V86, P1; CHAI TJ, 1980, CHEMOTHERAPY, V18, P638; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; LENNETTE EH, 1980, MANUAL CLIN MICROBIO; MARCY SM, 1985, PEDIATR INFECT DIS J, V4, P192; MARCY SM, 1985, PEDIATR INFECT DIS J, V4, pS27, DOI 10.1097/00006454-198505010-00007; Roethlisberger FJ., 1939, MANAGEMENT WORKER; Rosenstock I., 1979, HEALTH PSYCHOL, P161; SHETH KJ, 1986, PEDIATRICS, V77, P920; STONE M, 1984, ANN OTO RHINOL LARYN, V93, P183, DOI 10.1177/000348948409300217; 1992, PRACTICE PLUS DIAGNO; 1990, INTRUCTION LEAFLET D	14	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1571	1573		10.1136/bmj.305.6868.1571	http://dx.doi.org/10.1136/bmj.305.6868.1571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286392	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992KD77100029
J	SMITH, RG; HAMILTON, S; HOFMANN, F; SCHNEIDER, T; NASTAINCZYK, W; BIRNBAUMER, L; STEFANI, E; APPEL, SH				SMITH, RG; HAMILTON, S; HOFMANN, F; SCHNEIDER, T; NASTAINCZYK, W; BIRNBAUMER, L; STEFANI, E; APPEL, SH			SERUM ANTIBODIES TO L-TYPE CALCIUM CHANNELS IN PATIENTS WITH AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOTOR-NEURON DISEASE; EATON MYASTHENIC SYNDROME; GRAY-MATTER DISEASE; SKELETAL-MUSCLE; SPINAL-CORD; PROTEINS; SUBUNIT; AUTOANTIBODIES; IGG; AUTOIMMUNITY	Background and Methods. Sporadic amyotrophic lateral sclerosis is a chronic, progressive degenerative disease of the motor neurons of the spinal cord and motor cortex. The cause is unknown. Recent electrophysiologic studies in animals indicate that immunoglobulins from patients with this disease alter presynaptic voltage-dependent calcium currents and calcium-dependent release of neurotransmitters. To determine whether similar interactions might be identified biochemically, we used an enzyme-linked immunosorbent assay (ELISA) to detect the reaction of serum IgG with purified complexes of L-type voltage-gated calcium channels from rabbit skeletal muscle. The results from patients with amyotrophic lateral sclerosis were compared with those obtained from patients with other types of motor neuron disease, patients with autoimmune. and non-autoimmune neurologic diseases, and normal subjects. Results. Serum samples from 36 of 48 patients with sporadic amyotrophic lateral sclerosis (75 percent) contained IgG that reacted with L-type calcium-channel protein, and serum reactivity on ELISA correlated with the rate of disease progression (Spearman rank-correlation coefficient, 0.62). Reactive serum was present in only 1 of 25 normal subjects and 1 of 35 control patients with no motor neuron disease. Antibodies to L-type voltage-gated calcium channels were identified in 6 of 9 patients with Lambert-Eaton syndrome, and in 3 of 15 patients with Guillain-Barre syndrome. Conclusions. Antibodies to L-type voltage-gated calcium channels are present in the serum of patients with amyotrophic lateral sclerosis, and antibody titers correlate with the rate of disease progression. Together with previous data, these results suggest a role for autoimmune mechanisms in the pathogenesis of sporadic amyotrophic lateral sclerosis.	BAYLOR COLL MED,DEPT NEUROL,6501 FANNIN,NB 302,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV SAARLAND,W-6650 HOMBURG,GERMANY	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Saarland University				Hamilton, Susan/0000-0003-0241-9369				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; APPEL SH, 1986, ARCH NEUROL-CHICAGO, V43, P234, DOI 10.1001/archneur.1986.00520030026007; APPEL SH, 1991, P NATL ACAD SCI USA, V88, P647, DOI 10.1073/pnas.88.2.647; APPEL SH, 1988, ARCH NEUROL-CHICAGO, V45, P381, DOI 10.1001/archneur.1988.00520280027011; APPEL SH, 1991, CURRENT NEUROLOGY, V10, P287; APPEL V, 1987, ANN NEUROL, V22, P328, DOI 10.1002/ana.410220308; CRAWFORD GD, 1992, J NEUROSCI, V12, P3392; DELBONO O, 1991, AM J PHYSIOL, V260, pC1347, DOI 10.1152/ajpcell.1991.260.6.C1347; DELBONO O, 1991, J PHYSIOL-LONDON, V444, P723, DOI 10.1113/jphysiol.1991.sp018903; ENDO T, 1984, J IMMUNOL, V132, P1793; ENGEL AG, 1989, ANN NY ACAD SCI, V560, P278, DOI 10.1111/j.1749-6632.1989.tb24105.x; ENGELHARDT JI, 1989, ANN NEUROL, V26, P368, DOI 10.1002/ana.410260310; ENGELHARDT JI, 1990, ARCH NEUROL-CHICAGO, V47, P1210, DOI 10.1001/archneur.1990.00530110068019; ENGELHARDT JI, 1990, J NEUROIMMUNOL, V27, P21, DOI 10.1016/0165-5728(90)90132-7; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAUSER SL, 1986, NEUROLOGY, V36, P1614, DOI 10.1212/WNL.36.12.1614; HORWICH MS, 1974, ARCH NEUROL-CHICAGO, V30, P332, DOI 10.1001/archneur.1974.00490340060015; HOU KC, 1986, BIOTECHNIQUES, V4, P358; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULSIZER S C, 1991, Society for Neuroscience Abstracts, V17, P1159; INGVARMAEDER M, 1986, ACTA NEUROL SCAND, V74, P218, DOI 10.1111/j.1600-0404.1986.tb07858.x; KELEMEN J, 1983, ARCH NEUROL-CHICAGO, V40, P752, DOI 10.1001/archneur.1983.04050110070012; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; LANG B, 1987, J PHYSIOL-LONDON, V390, P257, DOI 10.1113/jphysiol.1987.sp016698; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MAGNELLI V, IN PRESS J PHYSL LON; MEININGER V, 1990, Neurology, V40, P183; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; MULDER DW, 1969, CONT NEUROLOGY S, V2, P12; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NASTAINCZYK W, 1990, GEN PHYSIOL BIOPHYS, V9, P321; NORMAN RI, 1989, ANN NY ACAD SCI, V560, P258, DOI 10.1111/j.1749-6632.1989.tb24103.x; OLDSTONE MBA, 1976, LANCET, V2, P169; ORDONEZ G, 1989, NEUROLOGY, V39, P683, DOI 10.1212/WNL.39.5.683; PALO J, 1978, LANCET, V1, P1270; PESTRONK A, 1989, ANN NEUROL, V25, P98, DOI 10.1002/ana.410250118; POWERS AC, 1985, ANNU REV MED, V36, P533; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROWLAND LP, 1984, TRENDS NEUROSCI, V7, P110, DOI 10.1016/S0166-2236(84)80236-2; SAKAMOTA J, 1991, PHYSIOLOGIST, V34, P109; SAWADA T, 1992, Biophysical Journal, V61, pA401; SCHNEIDER T, IN PRESS METHODS MOL, V13; SCOTT D, 1985, J BIOL CHEM, V260, P736; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; SMITH R G, 1991, Society for Neuroscience Abstracts, V17, P1451; STEFANSSON K, 1985, SCIENCE, V228, P1117, DOI 10.1126/science.4039466; TAJTI J, 1991, J NEUROIMMUNOL, V34, P143, DOI 10.1016/0165-5728(91)90123-O; TOUZEAU G, 1986, NEUROLOGY, V36, P573, DOI 10.1212/WNL.36.4.573; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6; YOUNGER DS, 1990, NEUROLOGY, V40, P595, DOI 10.1212/WNL.40.4.595; [No title captured]	57	173	179	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1721	1728		10.1056/NEJM199212103272405	http://dx.doi.org/10.1056/NEJM199212103272405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1331790				2022-12-24	WOS:A1992KA89700005
J	SCHUTZE, S; POTTHOFF, K; MACHLEIDT, T; BERKOVIC, D; WIEGMANN, K; KRONKE, M				SCHUTZE, S; POTTHOFF, K; MACHLEIDT, T; BERKOVIC, D; WIEGMANN, K; KRONKE, M			TNF ACTIVATES NF-KAPPA-B BY PHOSPHATIDYLCHOLINE-SPECIFIC PHOSPHOLIPASE-C-INDUCED ACIDIC SPHINGOMYELIN BREAKDOWN	CELL			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; ENHANCER-BINDING-PROTEIN; GH3 PITUITARY-CELLS; IMMUNODEFICIENCY VIRUS TYPE-1; NIEMANN-PICK DISEASE; HUMAN LYMPHOCYTES-T; FACTOR-ALPHA; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	In this paper, we describe a phospholipid transmission pathway mediating tumor necrosis factor (TNF) activation of the nuclear transcription factor kappaB (NF-kappaB). Central to this TNF signaling route is the second messenger-like molecule ceramide, which is generated by sphingomyelin (SM) breakdown catalyzed by a sphingomyelinase (SMase). SMase activation is secondary to the generation of 1,2-diacylglycerol (DAG) produced by a TNF-responsive PC-specific phospholipase C (PC-PLC). The functional coupling of these two C type phospholipases is revealed by D609, a selective inhibitor of PC-PLC. SMase itself, or SMase-inducing regimens such as exogenous PLC or synthetic DAGs, induces NF-kappaB activation at pH 5.0, suggesting the operation of an acidic SMase. A model is proposed in which a TNF-responsive PC-PLC via DAG couples to an acidic SMase, resulting in the generation of ceramide, which eventually triggers rapid induction of nuclear NF-kappaB activity.	UNIV GOTTINGEN, ZENTRUM INNERE MED, HAMATOL ONKOL ABT, W-3400 GOTTINGEN, GERMANY	University of Gottingen	SCHUTZE, S (corresponding author), TECH UNIV MUNICH, INST MED MIKROBIOL & HYG, W-8000 MUNICH 80, GERMANY.		Schütze, Stefan/C-8596-2011					ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ATKINSON YH, 1990, IMMUNOLOGY, V70, P82; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; FAURE R, 1992, J BIOL CHEM, V267, P11215; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KORATCHER S, 1978, ENZYMES LIPID METABO, P221; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LE JM, 1987, LAB INVEST, V56, P234; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.bi.55.070186.003311; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; RAO BG, 1976, J LIPID RES, V17, P506; RAO GR, 1981, BIOCHEM J, V198, P9, DOI 10.1042/bj1980009; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSTENBECK I, 1990, J CHROMATOGR-BIOMED, V525, P85, DOI 10.1016/S0378-4347(00)83381-2; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TOMITA M, 1990, J BIOCHEM-TOKYO, V108, P811, DOI 10.1093/oxfordjournals.jbchem.a123285; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZOU L, 1989, BIOTECHNOL APPL BIOC, V11, P217	72	1046	1061	2	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					765	776		10.1016/0092-8674(92)90553-O	http://dx.doi.org/10.1016/0092-8674(92)90553-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330325				2022-12-24	WOS:A1992JZ63300007
J	WEITZMAN, M; GORTMAKER, SL; SOBOL, AM; PERRIN, JM				WEITZMAN, M; GORTMAKER, SL; SOBOL, AM; PERRIN, JM			RECENT TRENDS IN THE PREVALENCE AND SEVERITY OF CHILDHOOD ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHANGING PATTERNS; BEHAVIOR PROBLEMS; NEW-ZEALAND; CHILDREN; MORTALITY; HOSPITALIZATION; RATES; HEALTH; RISKS	Objective.-To examine changes in the prevalence and distribution of childhood asthma and its relationship with various measures of children's health and functioning between 1981 and 1988. It was hypothesized that there would be an increase in the prevalence of asthma, especially among black children, and that available measures would suggest a deterioration in the health and functioning of children with asthma over this period. Design.-Analyses of data from the Child Health Supplements to the National Health Interview Survey. Setting and Sample.-Nationally representative random sample of 15 224 children aged 0 to 17 years in 1981 and 17 110 in 1988. Main Outcome Measures.-Changes in (1) the prevalence and distribution of asthma, and (2) among children with asthma, the percentage of children hospitalized, days spent in bed, school days lost in the year prior to survey, and parent ratings and reports of children's overall health status and behavior problems. Results.-The estimated prevalence of childhood asthma increased from 3.1% in 1981 to 4.3% in 1988 (P<.0001), with similar increases for children, adolescents, and both sexes. Increases occurred among white children (2.7% to 4.1%; P<.0001) but not black children (5.3% vs 5.1%; not significant). Among those with asthma in 1988 compared with 1981, there was better overall health status (11% vs 24% fair/poor; P<.0001) and fewer with 30 or more days spent in bed in the last year (3.9% vs 7.2%; P<.04). We also observed trends toward a lower rate of hospitalization in the last year (10% vs 14%; P=.07), fewer school days missed (2% vs 6% with >30 days; P=.08), and a lower rate of extreme behavior problem scores (13% vs 18%; P=.09) in 1988 compared with 1981. Reductions were similar among both black and white children. Conclusions.-These results indicate that the estimated prevalence of asthma among children in the United States increased by almost 40%, and that although the increase occurred exclusively among white children, the prevalence of asthma still remains higher in black children than in white children. There was no support for increasing asthma severity and functional impact among either black or white children with asthma in 1988 compared with 1981. These findings provide no evidence to support the beliefs that asthma prevalence is increasing largely among black children or that the severity of asthma among most children in the United States is increasing.	UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; HARVARD UNIV,SCH PUBL HLTH,DEPT BEHAV SCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	University of Rochester; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Perrin, James/0000-0002-1810-3708				ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURT ML, 1989, ARCH DIS CHILD, V64, P1452; BURT ML, 1987, J EPIDEMIOL COMMUNIT, V41, P185; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CYPRESS BK, 1983, VITAL HLTH STAT 13, V75, P13; EVANS R, 1987, CHEST, V91, P652; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MCCORMICK MC, 1990, J PEDIATR-US, V117, P687, DOI 10.1016/S0022-3476(05)83322-0; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; MULLALLY DI, 1984, ANN ALLERGY, V53, P15; NEWACHECK PW, 1986, AM J PUBLIC HEALTH, V76, P178, DOI 10.2105/AJPH.76.2.178; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; PERRIN JM, 1991, AJDC, V145, P415; PETERSON JL, 1986, J MARRIAGE FAM, V48, P295, DOI 10.2307/352397; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SUDMAN S, 1976, APPL SAMPLING, P69; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN M, 1986, J CHRON DIS, V39, P799, DOI 10.1016/0021-9681(86)90082-2; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1992, PEDIATRICS, V90, P342; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1982, VITAL HLTH STAT 10, V14, P1; 1989, STATISTICAL ABSTRACT, P462; 1990, PHS901232 NAT CTR HL, P16; 1973, PHS DHEW HRA741511 P, P1	40	285	287	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2673	2677		10.1001/jama.268.19.2673	http://dx.doi.org/10.1001/jama.268.19.2673			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX680	1304735				2022-12-24	WOS:A1992JX68000029
J	BEAM, KG; ADAMS, BA; NIIDOME, T; NUMA, S; TANABE, T				BEAM, KG; ADAMS, BA; NIIDOME, T; NUMA, S; TANABE, T			FUNCTION OF A TRUNCATED DIHYDROPYRIDINE RECEPTOR AS BOTH VOLTAGE SENSOR AND CALCIUM-CHANNEL	NATURE			English	Article							DYSGENIC SKELETAL-MUSCLE; 2 SIZE FORMS; CHARGE MOVEMENT; ALPHA-1; PHOSPHORYLATION; SUBUNITS; CELLS; CDNAS; ACID; RAT	THE skeletal muscle dihydropyridine (DHP) receptor serves dual functions, as a voltage sensor for excitation-contraction coupling and as an L-type calcium channel1-3. Biochemical analysis indicates the presence of two forms of the DHP receptor polypeptide in skeletal muscle, a full-length translation product present as a minor species and a much more abundant form that has a truncated carboxy-terminus4-6. On the basis of these and other observations7, it has been proposed8 that, in skeletal muscle, only the full-length DHP receptor can function as a calcium channel and that the truncated form can only function as a voltage sensor for excitation-contraction coupling. To resolve this issue, we have now constructed a complementary DNA (pC6DELTA1) encoding a protein corresponding to the truncated DHP receptor in skeletal muscle. Expression of pC6DELTA1 in dysgenic myotubes fully restores both excitation-contraction coupling and calcium current, consistent with the idea that a single class of DHP receptors performs both functions.	KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MOLEC GENET,KYOTO 606,JAPAN	Kyoto University; Kyoto University	BEAM, KG (corresponding author), COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT PHYSIOL,FT COLLINS,CO 80523, USA.		Tuluc, Petronel/C-2527-2011					ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LAI Y, 1990, J BIOL CHEM, V265, P20839; LAMB GD, 1987, J PHYSIOL-LONDON, V393, P595, DOI 10.1113/jphysiol.1987.sp016843; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	18	95	95	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					169	171		10.1038/360169a0	http://dx.doi.org/10.1038/360169a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1331811				2022-12-24	WOS:A1992JX75200063
J	WANG, JX; BEST, PM				WANG, JX; BEST, PM			INACTIVATION OF THE SARCOPLASMIC-RETICULUM CALCIUM-CHANNEL BY PROTEIN-KINASE	NATURE			English	Article							PURIFIED RYANODINE RECEPTOR; RABBIT SKELETAL-MUSCLE; RELEASE CHANNEL; CA-2+ CHANNELS; FIBERS; PHOSPHORYLATION; SARCOBALLS; EXPRESSION; SYSTEM	THE ryanodine receptor protein of skeletal muscle sarcoplasmic reticulum (SR) membranes is a calcium ion channel which allows movement of calcium from the SR lumen into the cytoplasm during muscle activation1-5. Gating of this channel is modulated by a number of physiologically important substances including calcium. Interestingly, calcium has both activating and inactivating effects which are concentration- and tissue-specific. In skeletal muscle, calcium-dependent inactivation of calcium release occurs at concentrations reached physiologically, suggesting that calcium may modulate the release process by a negative feedback mechanism6-9. To determine the cellular mechanism responsible for calcium-dependent inactivation, we have investigated the ability of protein phosphorylation to affect single channel gating behaviour using the patch clamp technique. Here we demonstrate that the ryanodine receptor protein/calcium release channel of skeletal muscle SR is inactivated under conditions permissive for protein phosphorylation. This inactivation is reversed by the application of phosphatase and prevented by a peptide inhibitor specific for calcium/calmodulin-dependent protein kinase II. The results provide evidence for an endogenous protein kinase which is closely associated with the ryanodine receptor protein and regulates channel gating.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; UNIV ILLINOIS,SCH MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Wang, Jixin/0000-0001-9285-1002				BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; HALS GD, 1989, J GEN PHYSIOL, V93, P385, DOI 10.1085/jgp.93.3.385; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KIM DH, 1986, J BIOL CHEM, V261, P1674; KWOK WM, 1991, PFLUG ARCH EUR J PHY, V419, P166, DOI 10.1007/BF00373003; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LUTTGAU HC, 1968, J PHYSIOL-LONDON, V194, P51; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORII H, 1987, J BIOCHEM-TOKYO, V102, P263, DOI 10.1093/oxfordjournals.jbchem.a122050; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STEIN P, 1988, BIOPHYS J, V54, P357, DOI 10.1016/S0006-3495(88)82967-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	23	119	120	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					739	741		10.1038/359739a0	http://dx.doi.org/10.1038/359739a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331805				2022-12-24	WOS:A1992JU65000059
J	JOHNSON, E				JOHNSON, E			MEMORY CIRCUIT AND SCHIZOPHRENIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1992, AM J PSYCHIAT, V149, P890	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-24	WOS:A1992JN25600007
J	GEGNER, JA; GRAHAM, DR; ROTH, AF; DAHLQUIST, FW				GEGNER, JA; GRAHAM, DR; ROTH, AF; DAHLQUIST, FW			ASSEMBLY OF AN MCP RECEPTOR, CHEW, AND KINASE CHEA COMPLEX IN THE BACTERIAL CHEMOTAXIS SIGNAL TRANSDUCTION PATHWAY	CELL			English	Article							DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; PROTEIN-PHOSPHORYLATION; METHYLESTERASE; SITE; OVEREXPRESSION; DEMETHYLATION; ATTRACTANTS; METHYLATION; REPELLENTS	We examined the binding interactions of the methylation-dependent chemotaxis receptors Tsr and Tar with the chemotaxis-specific protein kinase CheA and the coupling factor CheW. Receptor directly bound CheW, but receptor-CheA binding was dependent upon the presence of CheW. These observations in combination with our previous identification of a CheW-CheA complex suggest that CheW physically links the kinase to the receptor. The ternary complex of receptor, CheW, and CheA is both kinetically and thermodynamically stable at physiological concentrations. Stability is not significantly altered by changes associated with attractant or repellent binding to the receptor. Such binding greatly modulates the kinase activity of CheA. Our results demonstrate that modulation of the kinase activity does not require association-dissociation of the ternary complex. This suggests that the receptor signal is transduced through conformational changes in the ternary complex rather than through changes in the association of the kinase CheA with receptor and/or CheW.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	University of Oregon; University of Oregon					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007759, R01GM033677, R37GM033677] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07759, GM33677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; KEHRY MR, 1985, J BACTERIOL, V161, P105, DOI 10.1128/JB.161.1.105-112.1985; KEHRY MR, 1985, J BACTERIOL, V163, P983, DOI 10.1128/JB.163.3.983-990.1985; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MESIBOV R, 1972, J BACTERIOL, V112, P315, DOI 10.1128/JB.112.1.315-326.1972; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Osborn M J, 1974, Methods Enzymol, V31, P642; ROLLINS C, 1981, CELL, V25, P333, DOI 10.1016/0092-8674(81)90051-9; SANDERS DA, 1989, J BACTERIOL, V171, P6271, DOI 10.1128/jb.171.11.6271-6278.1989; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STEWART RC, 1988, J BACTERIOL, V170, P5728, DOI 10.1128/jb.170.12.5728-5738.1988; STOCK A, 1987, J BIOL CHEM, V262, P535; TSANG N, 1973, SCIENCE, V181, P60, DOI 10.1126/science.181.4094.60; TSO WW, 1974, J BACTERIOL, V118, P560, DOI 10.1128/JB.118.2.560-576.1974	35	317	320	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					975	982		10.1016/0092-8674(92)90247-A	http://dx.doi.org/10.1016/0092-8674(92)90247-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326408				2022-12-24	WOS:A1992JN78100012
J	ZHANG, XK; LEHMANN, J; HOFFMANN, B; DAWSON, MI; CAMERON, J; GRAUPNER, G; HERMANN, T; TRAN, P; PFAHL, M				ZHANG, XK; LEHMANN, J; HOFFMANN, B; DAWSON, MI; CAMERON, J; GRAUPNER, G; HERMANN, T; TRAN, P; PFAHL, M			HOMODIMER FORMATION OF RETINOID X-RECEPTOR INDUCED BY 9-CIS RETINOIC ACID	NATURE			English	Article							THYROID-HORMONE; RESPONSIVE ELEMENT; GENE; IDENTIFICATION; BINDING; ISOFORM; GAMMA	RETINOID response pathways are mediated by two classes of receptors, the retinoic acid receptors (RARs)1-6 and the retinoid X receptors (RXRs)7-11. A central question is whether distinct response pathways are regulated by these two classes of receptors. The observation that the stereoisomer 9-cis-retinoic acid binds with high affinity to RXRs12,13 suggested that this retinoid has a distinct role in controlling RXR activity, but it was almost simultaneously discovered that RXRs function as auxiliary receptors for RARs and related receptors, and are essential for DNA binding and function of those receptors9,10,14-17. Hence, although RARs seem to operate effectively only as heterodimeric RAR/RXR complexes, RXRs themselves apparently function predominantly, if not exclusively, as auxiliary receptors. Here we report that 9-cis-retinoic acid induces RXR homodimer formation. Our results demonstrate a new mechanism for retinoid action by which a ligand-induced homodimer mediates a distinct retinoid response pathway.	LA JOLLA CANC RES FDN,CTR CANC,10901 N TORREY PINES RD,LA JOLLA,CA 92037; SRI INT,DIV LIFE SCI,MENLO PK,CA 94025	Sanford Burnham Prebys Medical Discovery Institute; SRI International								BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HERMANN T, IN PRESS MOL ENDOCR; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	563	575	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					587	591		10.1038/358587a0	http://dx.doi.org/10.1038/358587a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1323763				2022-12-24	WOS:A1992JH82900061
J	SILVA, AJ; PAYLOR, R; WEHNER, JM; TONEGAWA, S				SILVA, AJ; PAYLOR, R; WEHNER, JM; TONEGAWA, S			IMPAIRED SPATIAL-LEARNING IN ALPHA-CALCIUM-CALMODULIN KINASE-II MUTANT MICE	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; RABBIT FOLLOWING STIMULATION; HIPPOCAMPAL-LESIONS; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; PERFORANT PATH; DENTATE AREA; RAT-BRAIN	Although long-term potentiation (LTP) has been studied as the mechanism for hippocampus-dependent learning and memory, evidence for this hypothesis is still incomplete. The mice with a mutation in the alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII), a synaptic protein enriched in the hippocampus, are appropriate for addressing this issue because the hippocampus of these mice is deficient in LTP but maintains intact postsynaptic mechanisms. These mutant mice exhibit specific learning impairments, an indication that alpha-CaMKII has a prominent role in spatial learning, but that it is not essential for some types of non-spatial learning. The data considerably strengthen the contention that the synaptic changes exhibited in LTP are the basis for spatial memory.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309	Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder	SILVA, AJ (corresponding author), MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				BEKKERS JH, 1990, COLD SPRING HARBOR S, V50; BENSON DL, 1991, J NEUROSCI, V11, P1540; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DAVIS M, 1992, TRENDS PHARMACOL SCI, V13, P35, DOI 10.1016/0165-6147(92)90014-W; DAVIS S, 1992, J NEUROSCI, V12, P21; DOUGLAS RJ, 1964, PSYCHON SCI, V1, P187, DOI 10.3758/BF03342856; Eccles, 2013, PHYSL SYNAPSES; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FOREMAN NP, 1983, PHYSIOL BEHAV, V30, P711, DOI 10.1016/0031-9384(83)90167-1; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HEBB DO, 1949, ORG BEHAVIOR; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KIMBLE DP, 1963, J COMP PHYSIOL PSYCH, V56, P273, DOI 10.1037/h0048903; LEATON RN, 1981, J COMP PHYSIOL PSYCH, V95, P813, DOI 10.1037/h0077832; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALLINOW R, 1989, SCIENCE, V245, P862; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OGORMAN S, 1991, SCIENCE, V251, P135; PAYLOR R, UNPUB; ROBERTS WW, 1986, J COMP PHYSIOL PSYCH, V55, P695; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; SILVA AJ, 1992, SCIENCE, V257, P204; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; SUTHERLAND R J, 1991, Society for Neuroscience Abstracts, V17, P483; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TEITELBAUM H, 1963, J COMP PHYSIOL PSYCH, V56, P284, DOI 10.1037/h0047052; UPCHURCH M, 1988, PHARMACOL BIOCHEM BE, V29, P325, DOI 10.1016/0091-3057(88)90164-5; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9	40	1048	1087	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					206	211		10.1126/science.1321493	http://dx.doi.org/10.1126/science.1321493			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JC585	1321493				2022-12-24	WOS:A1992JC58500027
J	HONG, SC; CHELOUCHE, A; LIN, RH; SHAYWITZ, D; BRAUNSTEIN, NS; GLIMCHER, L; JANEWAY, CA				HONG, SC; CHELOUCHE, A; LIN, RH; SHAYWITZ, D; BRAUNSTEIN, NS; GLIMCHER, L; JANEWAY, CA			AN MHC INTERACTION SITE MAPS TO THE AMINO-TERMINAL HALF OF THE T-CELL RECEPTOR ALPHA-CHAIN VARIABLE DOMAIN	CELL			English	Article							CLASS-II MHC; ANTIGEN-BINDING SITE; BETA-CHAIN; MONOCLONAL-ANTIBODY; FOREIGN ANTIGEN; DIRECTED MUTAGENESIS; JUNCTIONAL REGIONS; RECOGNITION; SPECIFICITY; MOLECULES	We have used cloned T cell receptor (TCR) genes from closely related CD4 T cell lines to probe the interaction of the TCR with several specific major histocompatibility complex (MHC) class II ligands. Complementarity determining region 3 (CDR3) equivalents of both alpha and beta-TCR chains are required for antigen-MHC recognition. Our data provide novel information about the rotational orientation of TCR-MHC contacts in that exchange of the amino terminal portion of the TCR alpha-chain containing the putative CDR1 and CDR2 regions results in both gain and loss of MHC class II specificity by the resulting receptor. These two TCRs differ primarily in recognition of polymorphisms in the second hypervariable region of the MHC class II alpha-chain. These results document the involvement of CDR1 and/or CDR2 of the TCR alpha-chain in MHC recognition and suggest a rotational orientation of this TCR to its MHC ligand.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10032 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA	Columbia University; Harvard University; Harvard T.H. Chan School of Public Health	HONG, SC (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014579, R37AI014579] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-14579] Funding Source: Medline; NIGMS NIH HHS [GM39275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ASHWELL JD, 1986, J IMMUNOL, V136, P389; BARBER LD, 1991, J IMMUNOL, V147, P2346; BERKOWITZ N, 1992, J IMMUNOL, V148, P309; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUERSTEDDE JM, 1989, J EXP MED, V169, P1645, DOI 10.1084/jem.169.5.1645; BUERSTEDDE JM, 1988, J EXP MED, V167, P473, DOI 10.1084/jem.167.2.473; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; COHN LE, 1986, P NATL ACAD SCI USA, V83, P747, DOI 10.1073/pnas.83.3.747; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DAVIS CB, 1989, J EXP MED, V169, P2239, DOI 10.1084/jem.169.6.2239; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELLABONA P, 1991, EUR J IMMUNOL, V21, P209, DOI 10.1002/eji.1830210131; DEMOTZ S, 1991, P NATL ACAD SCI USA, V88, P8730, DOI 10.1073/pnas.88.19.8730; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; ECKELS DD, 1990, HUM IMMUNOL, V27, P240, DOI 10.1016/0198-8859(90)90054-S; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; ESCH TR, 1989, CELL IMMUNOL, V123, P226, DOI 10.1016/0008-8749(89)90282-7; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GLIMCHER LH, 1987, IMMUNOL TODAY, V8, P274, DOI 10.1016/0167-5699(87)90188-5; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANEWAY CA, 1982, BEHRING I MITT, V70, P200; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KARR RW, 1990, J EXP MED, V172, P273, DOI 10.1084/jem.172.1.273; KAYE J, 1988, NATURE, V336, P580, DOI 10.1038/336580a0; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Klein J., 1986, NATURAL HIST MAJOR H; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAI MZ, 1990, J IMMUNOL, V144, P4851; LANG B, 1990, HUM IMMUNOL, V27, P378, DOI 10.1016/0198-8859(90)90088-7; LECHLER RI, 1990, IMMUNOL TODAY, V11, P83, DOI 10.1016/0167-5699(90)90033-6; LEE JM, 1991, J IMMUNOL, V146, P2952; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOMBARDI G, 1991, J IMMUNOL, V147, P2034; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MELLINS E, 1990, P NATL ACAD SCI USA, V87, P4785, DOI 10.1073/pnas.87.12.4785; NAKAGAWA TY, 1991, EUR J IMMUNOL, V21, P2851, DOI 10.1002/eji.1830211129; NALEFSKI EA, 1990, J BIOL CHEM, V265, P8842; PANINABORDIGNON P, 1989, COLD SPRING HARB SYM, V54, P445; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; PORTOLES P, 1989, J IMMUNOL, V142, P4169; PORTOLES P, 1989, EUR J IMMUNOL, V19, P83, DOI 10.1002/eji.1830190114; ROJO JM, 1988, J IMMUNOL, V140, P1081; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; ROSLONIEC EF, 1989, J IMMUNOL, V143, P50; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SORGER SB, 1990, IMMUNOGENETICS, V31, P118, DOI 10.1007/BF00661222; STAERZ UD, 1985, J IMMUNOL, V134, P3994; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; VONBOEHMER H, 1979, EUR J IMMUNOL, V9, P592, DOI 10.1002/eji.1830090804; WEI BY, 1991, INT IMMUNOL, V3, P833, DOI 10.1093/intimm/3.8.833; WILSON DB, 1968, J EXP MED, V128, P1157, DOI 10.1084/jem.128.5.1157; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; YAGI JJ, 1990, J IMMUNOL, V144, P892; Zinkernagel R.M., 1979, ADV IMMUNOL, V27, P52	73	96	96	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					999	1009		10.1016/0092-8674(92)90618-M	http://dx.doi.org/10.1016/0092-8674(92)90618-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1318787				2022-12-24	WOS:A1992HY79200011
J	ARMSTRONG, M; DALY, AK; CHOLERTON, S; BATEMAN, DN; IDLE, JR				ARMSTRONG, M; DALY, AK; CHOLERTON, S; BATEMAN, DN; IDLE, JR			MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE	LANCET			English	Note							4-HYDROXYLATION; METABOLISM; ETIOLOGY	The frequency of fifteen genotypes of CYP2D6 (debrisoquine 4-hydroxylase) in 53 patients with Parkinson's disease was determined by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses and compared with the findings in 72 healthy controls. The commonest mutant allele, CYP2D6B, was twice as frequent among patients as in controls, with an approximate relative risk ratio of 2.70 (95% confidence interval 1.14-6.41; p = 0.0063) for subjects homozygous or heterozygous for this allele.	MED SCH NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; MED SCH NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK			Daly, Ann/H-3144-2011	Daly, Ann/0000-0002-7321-0629; Bateman, David Nicholas/0000-0002-8971-862X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBEAU A, 1985, LANCET, V2, P1213; BENITEZ J, 1990, J NEUROL NEUROSUR PS, V53, P289, DOI 10.1136/jnnp.53.4.289; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; DALY AK, 1991, PHARMACOGENETICS, V1, P33, DOI 10.1097/00008571-199110000-00006; FONNEPFISTER R, 1987, BIOCHEM BIOPH RES CO, V148, P1144, DOI 10.1016/S0006-291X(87)80252-8; OHTA S, 1990, LIFE SCI, V46, P599, DOI 10.1016/0024-3205(90)90128-E; POIRIER J, 1987, LANCET, V2, P386; TANNER CM, 1987, CAN J NEUROL SCI, V14, P419, DOI 10.1017/S0317167100037835; TYNDALE R, 1991, PHARMACOGENETICS, V1, P26, DOI 10.1097/00008571-199110000-00005; TYNDALE RF, 1991, MOL PHARMACOL, V40, P63	10	244	246	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1017	1018		10.1016/0140-6736(92)90537-D	http://dx.doi.org/10.1016/0140-6736(92)90537-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349052				2022-12-24	WOS:A1992HQ43500005
J	PITT, GS; MILONA, N; BORLEIS, J; LIN, KC; REED, RR; DEVREOTES, PN				PITT, GS; MILONA, N; BORLEIS, J; LIN, KC; REED, RR; DEVREOTES, PN			STRUCTURALLY DISTINCT AND STAGE-SPECIFIC ADENYLYL CYCLASE GENES PLAY DIFFERENT ROLES IN DICTYOSTELIUM DEVELOPMENT	CELL			English	Article							GUANYLATE-CYCLASE; GUANINE-NUCLEOTIDES; SURFACE RECEPTOR; G-PROTEINS; DISCOIDEUM; BINDING; DNA; EXPRESSION; ACTIVATION; MUTANTS	We have isolated two adenylyl cyclase genes, designated ACA and ACG, from Dictyostelium. The proposed structure for ACA resembles that proposed for mammalian adenylyl cyclases: two large hydrophilic domains and two sets of six transmembrane spans. ACG has a novel structure, reminiscent of the membrane-bound guanylyl cyclases. An aca mutant, created by gene disruption, has little detectable adenylyl cyclase activity and falls to aggregate, demonstrating that cAMP is required for cell-cell communication. cAMP is not required for motility, chemotaxis, growth, and cell division, which are unaffected. Constitutive expression in aca- cells of either ACA or ACG, which is normally expressed only during germination, restores aggregation and the ability to complete the developmental program. ACA expression restores receptor and guanine nucleotide-regulated adenylyl cyclase activity, while activity in cells expressing ACG is insensitive to these regulators. Although they lack ACA, which has a transporter-like structure, the cells expressing ACG secrete cAMP constitutively.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	PITT, GS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA.		Reed, Russell/HGU-0528-2022; Pitt, Geoffrey/L-4927-2019	Pitt, Geoffrey/0000-0003-2246-0289	NIGMS NIH HHS [T32GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, DICTYOSTELIUM DISCOI, P299; DEVREOTES PN, 1982, DEV DICTYOSTELIUM DI, P117; DOWD BF, 1989, ANNU REV NEUROSCI, V12, P67; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KALPAXIS D, 1991, GENETICS, V11, P396; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KESSIN RH, 1979, P NATL ACAD SCI USA, V76, P5450, DOI 10.1073/pnas.76.11.5450; KIMMEL AR, 1982, DEV DICTYOSTELIUM DI, P234; KLEIN C, 1976, FEBS LETT, V68, P125, DOI 10.1016/0014-5793(76)80419-X; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PODGORSKI G, 1984, MOL CELL BIOL, V4, P2784, DOI 10.1128/MCB.4.12.2784; PUGSLEY A, 1989, PROTEIN TARGETTING; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; PUPILLO M, 1988, COLD SPRING HARB SYM, V53, P657, DOI 10.1101/SQB.1988.053.01.075; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; ROOS W, 1975, FEBS LETT, V53, P139, DOI 10.1016/0014-5793(75)80005-6; ROOS W, 1976, FEBS LETT, V68, P170, DOI 10.1016/0014-5793(76)80429-2; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAAP P, 1986, DIFFERENTIATION, V33, P1, DOI 10.1111/j.1432-0436.1986.tb00404.x; Schultz G., 1984, METHOD ENZYMAT AN, P379; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VERGHESE MW, 1985, J BIOL CHEM, V260, P6769; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989; 1990, SPRING CATALOG, P19	56	288	292	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					305	315		10.1016/0092-8674(92)90411-5	http://dx.doi.org/10.1016/0092-8674(92)90411-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348970				2022-12-24	WOS:A1992HQ18300010
J	HIBBS, JR; FRICKHOFEN, N; ROSENFELD, SJ; FEINSTONE, SM; KOJIMA, S; BACIGALUPO, A; LOCASCIULLI, A; TZAKIS, AG; ALTER, HJ; YOUNG, NS				HIBBS, JR; FRICKHOFEN, N; ROSENFELD, SJ; FEINSTONE, SM; KOJIMA, S; BACIGALUPO, A; LOCASCIULLI, A; TZAKIS, AG; ALTER, HJ; YOUNG, NS			APLASTIC-ANEMIA AND VIRAL-HEPATITIS - NON-A, NON-B, NON-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS; HEMOPHILIACS; SERUM	Objective. - To test the hypothesis that the rare, often fatal, syndrome of hepatitis-associated aplasia is associated with hepatitis C virus infection. Design. - Case series. Setting. - Tertiary referral centers in the United States, Japan, Italy, and Germany. Patients. - Twenty-eight patients with onset of aplastic anemia within 90 days after seeking medical attention for jaundice, or having serum transaminase levels 150% or more of normal (hepatitis-associated aplasia patients) and three patients who developed aplastic anemia following liver transplantation for non-A, non-B hepatitis. Outcome Measures. - Presence of hepatitis C in serum, bone marrow, and liver samples, detected by the polymerase chain reaction; antibody testing; and percentage of activated peripheral cytotoxic T lymphocytes determined by immunophenotyping. Results. - Hepatitis ribonucleic acid was present in the serum samples of 10 (36%) patients with hepatitis-associated aplasia. However, hepatitis C virus viremia was associated with transfusions received after the onset of aplasia: seven (58%) of 12 patients with hepatitis-associated aplasia who had received 21 or more units of blood products at the time of serum sampling were viremic, compared with only three (19%) of 16 patients with hepatitis-associated aplasia who had received 20 or less units of blood products (P < .05). Hepatitis C virus was not found in blood and bone marrow samples of three National Institutes of Health case patients tested at the time of diagnosis. None of three livers from non-A, non-B hepatitis patients who developed aplastic anemia after liver transplantation contained hepatitis C virus ribonucleic acid. Activated CD8+ T lymphocytes were elevated three- to 20-fold early in the course of hepatitis-associated aplasia. Conclusions. - Our results implicate a novel, non-A, non-B, and non-C agent in both hepatitis-associated aplasia and fulminant hepatitis.	US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,KENSINGTON,MD; NIH,DEPT TRANSFUS MED,BETHESDA,MD 20892; NAGOYA HOSP 1ST,JAPANESE RED CROSS,CHILDRENS MED CTR,DIV HEMATOL ONCOL,NAGOYA,JAPAN; SAN MARTINO HOSP,DIV HEMATOL 2,CTR BONE MARROW TRANSPLANT,GENOA,ITALY; UNIV ULM,DEPT MED 3,W-7900 ULM,GERMANY; HOSP SAN GERARDO,DIV PEDIAT HEMATOL,MILAN,ITALY; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; University of Genoa; IRCCS AOU San Martino IST; Ulm University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	HIBBS, JR (corresponding author), NHLBI,CLIN HEMATOL BRANCH,10-7C103,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F35HL008279] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08279-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; FOON KA, 1984, ANN INTERN MED, V100, P657, DOI 10.7326/0003-4819-100-5-657; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; HAGLER L, 1975, MEDICINE, V54, P139, DOI 10.1097/00005792-197554020-00003; Hardy WD, 1980, FELINE LEUKEMIA VIRU; ISSARAGRISIL S, 1991, BLOOD, V77, P2166; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KURTZMAN GJ, 1989, BLOOD, V74, P71; LINET MS, 1985, ARCH INTERN MED, V145, P635, DOI 10.1001/archinte.145.4.635; LINET MS, 1989, LEUKEMIA RES, V13, P3, DOI 10.1016/0145-2126(89)90025-8; NAKAO S, 1989, BLOOD, V74, P1235; PERRILLO RP, 1981, JAMA-J AM MED ASSOC, V245, P494, DOI 10.1001/jama.245.5.494; PHILLIPS MJ, 1991, NEW ENGL J MED, V324, P455, DOI 10.1056/NEJM199102143240705; POL S, 1990, ANN INTERN MED, V113, P435; Sambrook J., 1989, MOL CLONING LAB MANU; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702; ULRICH PP, 1990, J CLIN INVEST, V86, P1609, DOI 10.1172/JCI114882; WANG WC, 1986, AM J MED SCI, V291, P304, DOI 10.1097/00000441-198605000-00003; YOUNG NS, 1986, BRIT J HAEMATOL, V62, P1, DOI 10.1111/j.1365-2141.1986.tb02893.x; YOUNG NS, 1990, JAMA-J AM MED ASSOC, V263, P3065, DOI 10.1001/jama.263.22.3065; YOUNG NS, 1992, CECILS TXB MED, P831; ZELDIS JB, 1983, AM J MED, V74, P64, DOI 10.1016/0002-9343(83)91119-1; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501; [No title captured]	31	96	99	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2051	2054						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1313118				2022-12-24	WOS:A1992HM65000030
J	KARL, SA; AVISE, JC				KARL, SA; AVISE, JC			BALANCING SELECTION AT ALLOZYME LOCI IN OYSTERS - IMPLICATIONS FROM NUCLEAR RFLPS	SCIENCE			English	Article							GROWTH-RATE; CRASSOSTREA-VIRGINICA; AMERICAN OYSTER; MYTILUS-EDULIS; MITOCHONDRIAL-DNA; GENETIC-VARIATION; HETEROZYGOSITY; POPULATION; DOMINANCE	Population genetic analyses that depend on the assumption of neutrality for allozyme markers are used widely. Restriction fragment length polymorphisms in nuclear DNA of the American oyster evidence a pronounced population subdivision concordant with mitochondrial DNA. This finding contrasts with a geographic uniformity in allozyme frequencies previously thought to reflect high gene flow mediated by the pelagic gametes and larvae. The discordance likely is due to selection on protein electrophoretic characters that balances allozyme frequencies in the face of severe constraints to gene flow. These results raise a cautionary note for studies that rely on assumptions of neutrality for allozyme markers.	UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602	University System of Georgia; University of Georgia								AVISE JC, IN PRESS OIKOS; BUROKER NE, 1983, MAR BIOL, V75, P99, DOI 10.1007/BF00392635; BUROKER NE, 1979, J FISH RES BOARD CAN, V36, P1313, DOI 10.1139/f79-189; DIEHL WJ, 1985, MAR BIOL, V88, P265, DOI 10.1007/BF00392588; GARTON DW, 1984, GENETICS, V108, P445; HILBISH TJ, 1985, EVOLUTION, V39, P1302, DOI [10.2307/2408787, 10.1111/j.1558-5646.1985.tb05696.x]; HILBISH TJ, 1985, SCIENCE, V229, P52, DOI 10.1126/science.4012310; KARL SA, IN PRESS GENETICS; Koehn R.K., 1983, P115; KOEHN RK, 1987, AM SCI, V75, P134; KOEHN RK, 1984, MAR BIOL, V82, P1, DOI 10.1007/BF00392757; LEWONTIN RC, 1973, GENETICS, V74, P175; MITTON JB, 1985, J EXP MAR BIOL ECOL, V90, P73, DOI 10.1016/0022-0981(85)90075-9; MITTON JB, 1984, ANNU REV ECOL SYST, V15, P479; NEI M, 1978, GENETICS, V89, P583; REEB CA, 1990, GENETICS, V124, P397; SINGH SM, 1978, EVOLUTION, V32, P342, DOI 10.1111/j.1558-5646.1978.tb00650.x; WILSON AC, 1985, BIOL J LINN SOC, V26, P375, DOI 10.1111/j.1095-8312.1985.tb02048.x; ZOUROS E, 1980, EVOLUTION, V34, P856, DOI [10.2307/2407992, 10.1111/j.1558-5646.1980.tb04024.x]; [No title captured]	20	416	429	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					100	102		10.1126/science.1348870	http://dx.doi.org/10.1126/science.1348870			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1348870				2022-12-24	WOS:A1992HL82200036
J	KAUFMAN, PD; RIO, DC				KAUFMAN, PD; RIO, DC			P-ELEMENT TRANSPOSITION INVITRO PROCEEDS BY A CUT-AND-PASTE MECHANISM AND USES GTP AS A COFACTOR	CELL			English	Article							TRANSPOSABLE ELEMENT; BACTERIOPHAGE-MU; STRAND TRANSFER; DROSOPHILA; DNA; PROTEIN; VECTORS; TRANSFORMATION; INTEGRATION; PRODUCT	We have developed an in vitro reaction system for Drosophila P element transposition. Transposition products were recovered by selection in E. coli, and contained simple P element insertions flanked by 8 bp target site duplications as observed in vivo. Transposition required Mg+2 and partially purified P element transposase. Unlike other DNA rearrangement reactions, P element transposition in vitro used GTP as a cofactor; deoxyGTP, dideoxyGTP, or the nonhydrolyzable GTP analogs GMP-PNP or GMP-PCP were also used. Transposon DNA molecules cleaved at the P element termini were able to transpose, but those lacking 3'-hydroxyl groups were inactive. These biochemical data are consistent with genetic data suggesting that P element transposition occurs via a "cut-and-paste" mechanism.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)				Kaufman, Paul/0000-0003-3089-313X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD022857] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22857] Funding Source: Medline; NIGMS NIH HHS [GM47394] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BERG DE, 1989, MOBILE DNA, P185; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CRAIG NL, 1990, CELL, V62, P399, DOI 10.1016/0092-8674(90)90001-U; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; Engels W.R, 1989, MOBILE DNA, P437; ENGELS WR, 1984, SCIENCE, V226, P1194, DOI 10.1126/science.6095450; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; HANIFORD DB, 1991, CELL, V64, P171; ICHIKAWA H, 1990, J BIOL CHEM, V265, P18829; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KAUFMAN PD, 1991, NUCLEIC ACIDS RES, V19, P6336, DOI 10.1093/nar/19.22.6336; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PAL SK, 1988, J BACTERIOL, V170, P3554, DOI 10.1128/jb.170.8.3554-3560.1988; PALL ML, 1985, CURR TOP CELL REGUL, V25, P1; Pato ML, 1989, MOBILE DNA, P23; RIO DC, 1988, P NATL ACAD SCI USA, V85, P8929, DOI 10.1073/pnas.85.23.8929; RIO DC, 1990, ANNU REV GENET, V24, P543; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; RIO DC, 1991, TRENDS GENET, V7, P282, DOI 10.1016/0168-9525(91)90176-Q; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; THOMPSON JF, 1989, MOBILE DNA, P1; TSUBOTA SI, 1991, P NATL ACAD SCI USA, V88, P693, DOI 10.1073/pnas.88.3.693; [No title captured]	44	124	135	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					27	39		10.1016/0092-8674(92)90116-T	http://dx.doi.org/10.1016/0092-8674(92)90116-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313335				2022-12-24	WOS:A1992HM44500004
J	FERRIS, CD; CAMERON, AM; HUGANIR, RL; SNYDER, SH				FERRIS, CD; CAMERON, AM; HUGANIR, RL; SNYDER, SH			QUANTAL CALCIUM RELEASE BY PURIFIED RECONSTITUTED INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; LIPID VESICLES; TRISPHOSPHATE; PHOSPHATES; EXPRESSION; MECHANISM; FLUX	RELEASE of intracellular Ca2+ by inositol 1,4,5-trisphosphate (InsP3) occurs through specific receptor proteins 1 which are ligand-activated Ca2+ channels 2. Changes in intracellular Ca2+ regulate many cellular functions 3. This Ca2+ release is a discontinuous quantal process in which successive increments of InsP3 transiently release precise amounts of Ca2+ (refs 4-6). Possible explanations of quantal Ca2+ release have included rapid degradation of InsP3, reciprocity of Ca2+ release and sequestration, desensitization of InsP3 receptors 7, or actions of InsP3 on discrete compartments of Ca2+ with variable sensitivity to InsP3 (ref. 4). We successfully reconstituted InsP3-induced Ca2+ flux in vesicles containing only purified InsP3 receptor protein 2. The reconstituted vesicles retain the regulatory features of the InsP3 receptor, including phosphorylation sites 8 and modulation of Ca2+ release by adenine nucleotides 9. Using these reconstituted vesicles, we show here that quantal flux of Ca2+ elicited by InsP3 is a fundamental property of its receptor.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FERRIS CD, 1991, REV PHYSL, V54, P469; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1982, J BIOL CHEM, V257, P9372; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; ROSS CA, 1991, SOC NEUR ABSTR; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530	24	131	131	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					350	352		10.1038/356350a0	http://dx.doi.org/10.1038/356350a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312682				2022-12-24	WOS:A1992HK79400068
J	MANJARREZHERNANDEZ, HA; BALDWIN, TJ; AITKEN, A; KNUTTON, S; WILLIAMS, PH				MANJARREZHERNANDEZ, HA; BALDWIN, TJ; AITKEN, A; KNUTTON, S; WILLIAMS, PH			INTESTINAL EPITHELIAL-CELL PROTEIN-PHOSPHORYLATION IN ENTEROPATHOGENIC ESCHERICHIA-COLI DIARRHEA	LANCET			English	Note							KINASE-C; ADHESION; MYOSIN	The ability of enteropathogenic Escherichia coli (EPEC) to cause diarrhoea in man is associated with the formation of characteristic histopathological lesions in small-intestine enterocytes, with gross cytoskeletal damage and loss of brush-border microvilli. Investigation of enterocyte protein phosphorylation in response to EPEC infection showed that the major phosphorylated protein, identified by immunoprecipitation, is myosin light-chain an important cytoskeletal protein known to affect actin organisation in non-muscle cells. High enterocyte concentrations of actin and myosin were observed at sites of bacterial infection. Our findings indicate that enterocyte cytoskeletal changes in response to EPEC may be directly triggered by bacterial adherence through signal transduction pathways that stimulate protein kinase activity.	UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; NATL INST MED RES,PROT STRUCTURE LAB,LONDON NW7 1AA,ENGLAND; UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Leicester; MRC National Institute for Medical Research; University of Birmingham					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDWIN TJ, 1990, INFECT IMMUN, V58, P761, DOI 10.1128/IAI.58.3.761-765.1990; BENNETT JP, 1988, J CELL BIOL, V107, P2623, DOI 10.1083/jcb.107.6.2623; BLADWIN TJ, 1991, INFECT IMMUN, V59, P1599; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FONDACARO JD, 1985, AM J PHYSIOL, V249, pG422, DOI 10.1152/ajpgi.1985.249.3.G422; KELLER TCS, 1982, J CELL BIOL, V95, P943, DOI 10.1083/jcb.95.3.943; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; ROBINSBROWNE RM, 1987, REV INFECT DIS, V9, P28; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543	10	62	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					521	523		10.1016/0140-6736(92)90340-9	http://dx.doi.org/10.1016/0140-6736(92)90340-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346880				2022-12-24	WOS:A1992HF63100005
J	HOTH, M; PENNER, R				HOTH, M; PENNER, R			DEPLETION OF INTRACELLULAR CALCIUM STORES ACTIVATES A CALCIUM CURRENT IN MAST-CELLS	NATURE			English	Article							INOSITOL TRISPHOSPHATE; CA-2+ RELEASE; INFLUX; ENTRY; PHOSPHATES; MESSENGERS; IONOMYCIN; CHANNELS; MN-2+	IN many cell types, receptor-mediated Ca2+ release from internal stores is followed by Ca2+ influx across the plasma membrane 1-3. The sustained entry of Ca2+ is thought to result partly from the depletion of intracellular Ca2+ pools 4,5. Most investigations have characterized Ca2+ influx indirectly by measuring Ca2+-activated currents 6-9 or using Fura-2 quenching by Mn2+, which in some cells enters the cells by the same influx pathway 10,11 But only a few studies have investigated this Ca2+ entry pathway more directly 12-14. We have combined patch-clamp and Fura-2 measurements to monitor membrane currents in mast cells under conditions where intracellular Ca2+ stores were emptied by either inositol 1,4,5-trisphosphate, ionomycin, or excess of the Ca2+ chelator EGTA. The depletion of Ca2+ pools by these independent mechanisms commonly induced activation of a sustained calcium inward current that was highly selective for Ca2+ ions over Ba2+, Sr2+ and Mn2+. This Ca2+ current, which we term I(CRAC) (calcium release-activated calcium), is not voltage-activated and shows a characteristic inward rectification. It may be the mechanism by which electrically nonexcitable cells maintain raised intracellular Ca2+ concentrations and replenish their empty Ca2+ stores after receptor stimulation.			HOTH, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, W-3400 GOTTINGEN, GERMANY.			Hoth, Markus/0000-0001-7080-4643; Penner, Reinhold/0000-0002-5366-1537				ALBERT PR, 1984, J BIOL CHEM, V259, P5350; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KASS GEN, 1990, J BIOL CHEM, V265, P17486; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIU CM, 1978, J BIOL CHEM, V253, P5892; LLANO I, 1987, PFLUG ARCH EUR J PHY, V409, P499, DOI 10.1007/BF00583807; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUHLEN FV, 1991, P NATL ACAD SCI USA, V88, P926, DOI 10.1073/pnas.88.3.926; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	26	1500	1530	4	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					353	356		10.1038/355353a0	http://dx.doi.org/10.1038/355353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309940				2022-12-24	WOS:A1992HA59100069
J	BUCHWALD, D; CHENEY, PR; PETERSON, DL; HENRY, B; WORMSLEY, SB; GEIGER, A; ABLASHI, DV; SALAHUDDIN, SZ; SAXINGER, C; BIDDLE, R; KIKINIS, R; JOLESZ, FA; FOLKS, T; BALACHANDRAN, N; PETER, JB; GALLO, RC; KOMAROFF, AL				BUCHWALD, D; CHENEY, PR; PETERSON, DL; HENRY, B; WORMSLEY, SB; GEIGER, A; ABLASHI, DV; SALAHUDDIN, SZ; SAXINGER, C; BIDDLE, R; KIKINIS, R; JOLESZ, FA; FOLKS, T; BALACHANDRAN, N; PETER, JB; GALLO, RC; KOMAROFF, AL			A CHRONIC ILLNESS CHARACTERIZED BY FATIGUE, NEUROLOGIC AND IMMUNOLOGICAL DISORDERS, AND ACTIVE HUMAN HERPESVIRUS TYPE-6 INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; HERPESVIRUS-6, HUMAN; NEUROLOGIC MANIFESTATIONS; FATIGUE; IMMUNOLOGICAL DISEASES	BARR VIRUS-INFECTION; CHRONIC MONONUCLEOSIS SYNDROME; NATURAL-KILLER CELLS; MAGNETIC-RESONANCE; HUMAN-LYMPHOCYTES; SYNDROME AIDS; HUMAN-DISEASE; T-CELLS; HHV-6; HBLV	Objective: To conduct neurologic, immunologic, and virologic studies in patients with a chronic debilitating illness of acute onset. Design: Cohort study with comparison to matched, healthy control subjects. Patients: We studied 259 patients who sought care in one medical practice; 29% of the patients were regularly bedridden or shut-in. Main Outcome Measures: Detailed medical history, physical examination, conventional hematologic and chemistry testing, magnetic resonance imaging (MRI) studies lymphocyte phenotyping studies, and assays for active infection of patients' lymphocytes with human herpesvirus type 6 (HHV-6). Main Results: Patients had a higher mean (+/- SD) CD4/CD8 T-cell ratio than matched healthy controls (3.16 +/- 1.5 compared with 2.3 +/- 1.0, respectively; P < 0.003). Magnetic resonance scans of the brain showed punctate, subcortical areas of high signal intensity consistent with edema or demyelination in 78% of patients (95% Cl, 72% to 86%) and in 21% of controls (Cl, 11% to 36%) (P < 10(-9)). Primary cell culture of lymphocytes showed active replication of HHV-6 in 79 of 113 patients (70%; Cl, 61% to 78%) and in 8 of 40 controls (20%; Cl, 9% to 36%) (P < 10(-8)), a finding confirmed by assays using monoclonal antibodies specific for HHV-6 proteins and by polymerase chain reaction assays specific for HHV-6 DNA. Conclusions: Neurologic symptoms, MRI findings, and lymphocyte phenotyping studies suggest that the patients may have been experiencing a chronic, immunologically mediated inflammatory process of the central nervous system. The active replication of HHV-6 most likely represents reactivation of latent infection, perhaps due to immunologic dysfunction. Our study did not directly address whether HHV-6, a lymphotropic and gliotropic virus, plays a role in producing the symptoms or the immunologic and neurologic dysfunction seen in this illness. Whether the findings in our patients, who came from a relatively small geographic area, will be generalizable to other patients with a similar syndrome remains to be seen.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, 75 FRANCIS ST, BOSTON, MA 02115 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA; WASHOE CTY SHERIFFS DIV, DIV FORENS SCI, RENO, NV 89512 USA; CYTOMETRY ASSOCIATES, SAN DIEGO, CA 92121 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV SO CALIF, HUNTINGTON MEM HOSP, AIDS RES LAB, PASADENA, CA 91105 USA; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; STOCKTON RADIOL MED GRP, STOCKTON, CA 95204 USA; CTR DIS CONTROL, DIV VIROL, ATLANTA, GA 30333 USA; UNIV KANSAS, MED CTR, DEPT MICROBIOL, KANSAS CITY, KS 66103 USA; SPECIALTY LABS INC, SANTA MONICA, CA 90009 USA	Harvard University; Brigham & Women's Hospital; Harborview Medical Center; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California; Huntington Memorial Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centers for Disease Control & Prevention - USA; University of Kansas; University of Kansas Medical Center			Ablashi, Dharam/AAE-8934-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032246, R01AI027314, R01AI026788] Funding Source: NIH RePORTER; NIAID NIH HHS [U01AI32246, R01AI27314, R01AI26788] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; AWAD IA, 1987, NEUROSURGERY, V20, P222, DOI 10.1227/00006123-198702000-00004; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BRADLEY WG, 1984, NONINVASIVE MED IMAG, V1, P35; BUCHWALD D, 1990, J CLIN IMMUNOL, V10, P335, DOI 10.1007/BF00917479; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; BUCHWALD D, 1987, ARTHRITIS RHEUM, V30, P1132, DOI 10.1002/art.1780301007; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; COYLE PK, 1990, ANN NEUROL, V28, P243; CUNNINGHAM L, 1990, J GEN VIROL, V71, P1399, DOI 10.1099/0022-1317-71-6-1399; DALE JK, 1989, ANN INTERN MED, V110, P92, DOI 10.7326/0003-4819-110-1-92; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748; FRENKEL N, 1990, J VIROL, V64, P4598, DOI 10.1128/JVI.64.9.4598-4602.1990; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; GUPTA S, 1991, SCAND J IMMUNOL, V33, P319, DOI 10.1111/j.1365-3083.1991.tb01777.x; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; HENLE W, 1979, DIAGNOSTIC PROCEDURE, P441; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JENKINS R, 1991, POST VIRAL FATIGUE S; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; JOSEPHS SF, 1991, LANCET, V337, P1346, DOI 10.1016/0140-6736(91)93018-5; JOSEPHS SF, 1986, SCIENCE, V234, P601, DOI 10.1126/science.3020691; JUNGREIS CA, 1988, RADIOLOGY, V169, P101, DOI 10.1148/radiology.169.1.3420242; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KIRKPATRICK JB, 1987, RADIOLOGY, V162, P509, DOI 10.1148/radiology.162.2.3797666; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; KOMAROFF AL, 1990, AM J CLIN PATHOL, V93, P836; KOMAROFF AL, 1988, CLIN RES, V36, pA743; KOMAROFF AL, 1987, HOSP PRACT, V22, P71; KOMAROFF AL, 1988, J VIROL METHODS, V21, P3, DOI 10.1016/0166-0934(88)90047-X; Krueger G R, 1991, In Vivo, V5, P287; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LEVY JA, 1990, VIROLOGY, V178, P113, DOI 10.1016/0042-6822(90)90384-4; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; LLOYD AR, 1989, MED J AUSTRALIA, V151, P122, DOI 10.5694/j.1326-5377.1989.tb139594.x; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MURDOCH JC, 1988, NEW ZEAL MED J, V101, P511; POSKANZER DC, 1957, NEW ENGL J MED, V257, P356, DOI 10.1056/NEJM195708222570802; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SALIT IE, 1985, CAN MED ASSOC J, V133, P659; SAXINGER C, 1988, J VIROL METHODS, V21, P199, DOI 10.1016/0166-0934(88)90066-3; SHELOKOV A, 1957, NEW ENGL J MED, V257, P345, DOI 10.1056/NEJM195708222570801; SIGURDSSON B, 1956, LANCET, V270, P766; SIGURDSSON B, 1950, AM J HYG, V52, P222, DOI 10.1093/oxfordjournals.aje.a119421; STRAUS SE, 1988, J INFECT DIS, V157, P405, DOI 10.1093/infdis/157.3.405; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; SZE G, 1986, AM J NEURORADIOL, V7, P381; TOBI M, 1982, LANCET, V1, P61; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; WHITESIDE TL, 1989, CLIN IMMUNOL IMMUNOP, V53, P1, DOI 10.1016/0090-1229(89)90096-2; YOUSEF GE, 1988, LANCET, V1, P146; ZIMMERMAN RD, 1986, AM J ROENTGENOL, V146, P443, DOI 10.2214/ajr.146.3.443; 1957, BRIT MED J, V2, P895	70	279	287	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					103	113		10.7326/0003-4819-116-2-103	http://dx.doi.org/10.7326/0003-4819-116-2-103			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1309285				2022-12-24	WOS:A1992GZ35600002
J	BIKKINA, M; LARSON, MG; LEVY, D				BIKKINA, M; LARSON, MG; LEVY, D			PROGNOSTIC IMPLICATIONS OF ASYMPTOMATIC VENTRICULAR ARRHYTHMIAS - THE FRAMINGHAM HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						EXTRASYSTOLE; CORONARY DISEASE; ARRHYTHMIA; MYOCARDIAL INFARCTION	ACUTE MYOCARDIAL-INFARCTION; SUDDEN-DEATH; HEALTHY-SUBJECTS; DISEASE; HYPERTROPHY; FREQUENT; COMPLEX; ECTOPY; RISK; MASS	Objective: To evaluate the prevalence and prognostic significance of asymptomatic complex or frequent ventricular premature beats detected during ambulatory electrocardiographic (ECG) monitoring. Design: Cohort study with a follow-up period of 4 to 6 years. Setting: Population-based. Participants: Surviving patients of the original Framingham Heart Study cohort and offspring of original cohort members (2727 men and 3306 women). Measurements: One-hour ambulatory electrocardiography. Results: The age-adjusted prevalence of complex or frequent arrhythmia (more than 30 ventricular premature complexes per hour or multiform premature complexes, ventricular couplets, ventricular tachycardia, or R-on-T ventricular premature complexes) was 12% (95% Cl, 11% to 13%) in the 2425 men without clinically evident coronary heart disease and 33% (Cl, 24% to 42%) in the 302 men with coronary heart disease. The corresponding values in women (3064 without disease and 242 with disease) were 12% (Cl, 11 % to 13%) and 26% (Cl, 9% to 43%). After adjusting for age and traditional risk factors for coronary heart disease in a Cox proportional hazards model, men without coronary heart disease who had complex or frequent ventricular arrhythmias were at increased risk for both all-cause mortality (relative risk, 2.30; Cl, 1.65 to 3.20) and the occurrence of myocardial infarction or death from coronary heart disease (relative risk, 2.12; Cl, 1.33 to 3.38). In men with coronary heart disease and in women with and without coronary heart disease, complex or frequent arrhythmias were not associated with an increased risk for either outcome. Conclusions: In men who do not have clinically apparent coronary heart disease, the incidental detection of ventricular arrhythmias is associated with a twofold increase in the risk for all-cause mortality and myocardial infarction or death due to coronary heart disease. The preventive and therapeutic implications of these findings await further investigation.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254				[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1973, JAMA, V223, P1116; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BIGGER JT, 1977, PROG CARDIOVASC DIS, V19, P255, DOI 10.1016/0033-0620(77)90005-6; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CATS VM, 1979, AM J CARDIOL, V44, P1257, DOI 10.1016/0002-9149(79)90438-7; CHIANG BN, 1969, ANN INTERN MED, V70, P1159, DOI 10.7326/0003-4819-70-6-1159; CONNOLLY SJ, 1992, AM J CARDIOL, V69, P308, DOI 10.1016/0002-9149(92)90225-N; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DESOYZA N, 1978, AM J MED, V64, P377, DOI 10.1016/0002-9343(78)90215-2; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; ELKON KB, 1977, S AFR MED J, V52, P564; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; FISHER FD, 1973, CIRCULATION, V47, P712, DOI 10.1161/01.CIR.47.4.712; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HINKLE LE, 1969, AM J CARDIOL, V24, P629, DOI 10.1016/0002-9149(69)90451-2; HORAN MJ, 1984, JAMA-J AM MED ASSOC, V251, P380; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KENNEDY HL, 1980, ANN INTERN MED, V92, P179, DOI 10.7326/0003-4819-92-2-179; KENNEDY HL, 1976, AM J CARDIOL, V38, P141, DOI 10.1016/0002-9149(76)90140-5; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOPPES GM, 1980, AM J CARDIOL, V46, P322, DOI 10.1016/0002-9149(80)90079-X; KOTLER MN, 1973, CIRCULATION, V47, P959, DOI 10.1161/01.CIR.47.5.959; LEVY D, 1988, AM J CARDIOL, V62, P147, DOI 10.1016/0002-9149(88)91383-5; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1987, AM J CARDIOL, V59, P836, DOI 10.1016/0002-9149(87)91102-7; LEVY D, 1987, AM J CARDIOL, V60, P560, DOI 10.1016/0002-9149(87)90305-5; LICHSTEIN E, 1983, CIRCULATION, V67, P5; LIE KI, 1975, CIRCULATION, V52, P755, DOI 10.1161/01.CIR.52.5.755; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOSS AJ, 1974, CIRCULATION, V49, P460, DOI 10.1161/01.CIR.49.3.460; MOSS AJ, 1980, PROG CARDIOVASC DIS, V23, P33, DOI 10.1016/0033-0620(80)90004-3; OLSSON G, 1984, CIRCULATION, V69, P1129, DOI 10.1161/01.CIR.69.6.1129; PELL S, 1961, JAMA-J AM MED ASSOC, V175, P463, DOI 10.1001/jama.1961.03040060037008; RABKIN SW, 1981, AM HEART J, V101, P135, DOI 10.1016/0002-8703(81)90655-4; RODSTEIN M, 1971, CIRCULATION, V44, P617, DOI 10.1161/01.CIR.44.4.617; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; TALAJIC M, 1991, CAN J CARDIOL, V7, P96; 1991, SAS P217 SAS I INC T; 1989, SAS STAT USERS GUIDE, V1; [No title captured]	51	149	157	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					990	996		10.7326/0003-4819-117-12-990	http://dx.doi.org/10.7326/0003-4819-117-12-990			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1280018				2022-12-24	WOS:A1992KB98000003
J	NABAVI, N; FREEMAN, GJ; GAULT, A; GODFREY, D; NADLER, LM; GLIMCHER, LH				NABAVI, N; FREEMAN, GJ; GAULT, A; GODFREY, D; NADLER, LM; GLIMCHER, LH			SIGNALING THROUGH THE MHC CLASS-II CYTOPLASMIC DOMAIN IS REQUIRED FOR ANTIGEN PRESENTATION AND INDUCES B7 EXPRESSION	NATURE			English	Article							CELL ACTIVATION ANTIGEN-B7; T-CELLS; COSTIMULATORY SIGNAL; RESTRICTED ANTIGEN; MOLECULES; RECEPTOR; TRANSLOCATION; INTERLEUKIN-2; INDUCTION; PROVIDES	CLASS II major histocompatibility complex (MHC) molecules function as antigen-presenting elements as well as signal transducers on B lymphocytes. We previously reported that a B lymphoma cell transfectant, 5C2, expressing genetically engineered I-A(k) molecules with truncated cytoplasmic domains was severely impaired in both antigen presentation and in anti-Ia-induced intracytoplasmic signalling1-5. These two functions could be restored by preculturing 5C2 cells with cyclic AMP analogues6,7. Here we demonstrate that impaired signal transduction by truncated class II molecules results in a deficiency in induction of the newly defined B-cell accessory molecule B7 (ref. 8), which can be reversed by restoration of B7 expression. These data imply that contact of the T-cell antigen receptor with MHC/antigen ligand results in signal transmission through the class II cytoplasmic domain. This signal, which can be mimicked by dibutyryl cAMP, induces expression of B7, resulting in effective antigen presentation. The fact that crosslinking of surface class II MHC also induces B7 expression on normal resting human B cells9 supports this contention.	HARVARD UNIV,SCH PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; ROCHE RES CTR,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Godfrey, Dale/0000-0002-3009-5472				CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; DAMLE NK, 1991, EUR J IMMUNOL, V21, P1277, DOI 10.1002/eji.1830210527; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; NABAVI N, 1989, J IMMUNOL, V142, P1444; POLLOK KE, 1991, J IMMUNOL, V146, P1633; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; STPIERRE Y, 1991, J IMMUNOL, V147, P2875; STPIERRE Y, 1989, J IMMUNOL, V143, P808; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; YOKOCHI T, 1982, J IMMUNOL, V128, P823	20	336	359	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					266	268		10.1038/360266a0	http://dx.doi.org/10.1038/360266a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279442				2022-12-24	WOS:A1992JY96000054
J	KINGSLEY, DM; BLAND, AE; GRUBBER, JM; MARKER, PC; RUSSELL, LB; COPELAND, NG; JENKINS, NA				KINGSLEY, DM; BLAND, AE; GRUBBER, JM; MARKER, PC; RUSSELL, LB; COPELAND, NG; JENKINS, NA			THE MOUSE SHORT-EAR SKELETAL MORPHOGENESIS LOCUS IS ASSOCIATED WITH DEFECTS IN A BONE MORPHOGENETIC MEMBER OF THE TGF-BETA SUPERFAMILY	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MESODERM-INDUCING FACTOR; GENETIC-LINKAGE MAP; MESSENGER-RNA; EMBRYONIC-DEVELOPMENT; OSTEOGENIC PROTEIN; PATTERN-FORMATION; RETINOIC ACID; GERM LAYERS; ACTIVIN-A	The mouse short ear gene is required for normal growth and patterning of skeletal structures, and for repair of bone fractures in adults. We have carried out an extensive chromosome walk in the chromosome region that surrounds this locus. Here we show that the short ear region contains the gene for a TGFbeta-related protein called bone morphogenetic protein 5 (Bmp-5). This gene is deleted or rearranged in several independent mutations at the short ear locus. Mice homozygous for large deletions of the Bmp-5 coding region are viable and fertile. Mutations at the short ear locus provide an important new tool for defining the normal functions of BMPs in mammals. The specific skeletal defects seen in short-eared animals, which occur against a background of otherwise normal skeletal structures, suggest that particular aspects of skeletal morphology may be determined by individual members of a family of signaling factors that can induce the formation of cartilage and bone in vivo.	OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	United States Department of Energy (DOE); Oak Ridge National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KINGSLEY, DM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,BECKMAN CTR B300,STANFORD,CA 94305, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANO RM, 1990, DEVELOPMENT, V110, P435; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BATCHELOR AL, 1966, MUTAT RES, V3, P218, DOI 10.1016/0027-5107(66)90063-7; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DICKINSON ME, 1990, GENOMICS, V6, P673; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; GELBART WM, 1989, DEVELOPMENT, V107, P65; Green EL, 1942, J MORPHOL, V70, P1, DOI 10.1002/jmor.1050700102; GREEN EL, 1946, AM NAT, V80, P619, DOI 10.1086/281482; GREEN JD, 1951, AM J ANAT, V88, P1; GREEN MARGARET C., 1957, JOUR HEREDITY, V48, P205; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; GREEN MC, 1958, J EXP ZOOL, V137, P75, DOI 10.1002/jez.1401370105; GREEN MC, 1968, J EXP ZOOL, V167, P129, DOI 10.1002/jez.1401670202; Green MC., 1989, GENETIC VARIANTS STR, P12; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES CM, 1991, DEVELOPMENT, V111, P531; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KINGSLEY DM, 1990, EMBO J, V9, P395, DOI 10.1002/j.1460-2075.1990.tb08123.x; KINGSLEY DM, 1989, GENETICS, V123, P165; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lynch CJ, 1921, AM NAT, V55, P421, DOI 10.1086/279826; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NESBITT MN, 1973, MOUSE NEWS LETT, V49, P23; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; RAY RP, 1991, DEVELOPMENT, V113, P35; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REUTER R, 1990, DEVELOPMENT, V110, P1031; RINCHIK EM, 1986, GENETICS, V112, P321; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RUSSELL LB, 1989, P NATL ACAD SCI USA, V86, P3704, DOI 10.1073/pnas.86.10.3704; RUSSELL LB, 1971, MUTAT RES, V11, P107, DOI 10.1016/0027-5107(71)90036-4; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; RUSSELL WL, 1951, COLD SPRING HARB SYM, V16, P327, DOI 10.1101/SQB.1951.016.01.024; Sambrook J., 1989, MOL CLONING LAB MANU; SEARLE AG, 1989, GENETIC VARIANTS STR, P582; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	66	421	438	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					399	410		10.1016/0092-8674(92)90510-J	http://dx.doi.org/10.1016/0092-8674(92)90510-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1339316				2022-12-24	WOS:A1992JW43500007
J	WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; COLDITZ, G; MANSON, JE; SPIEGELMAN, D; ROSNER, B; HENNEKENS, CH; SPEIZER, FE				WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; COLDITZ, G; MANSON, JE; SPIEGELMAN, D; ROSNER, B; HENNEKENS, CH; SPEIZER, FE			DIETARY-FAT AND FIBER IN RELATION TO RISK OF BREAST-CANCER - AN 8-YEAR FOLLOW-UP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; CONSUMPTION; DISEASE; CARCINOGENESIS; QUESTIONNAIRE; REDUCTION; NUTRITION; HEALTH; RATS	Objective.-To address the hypotheses that dietary fat increases and fiber decreases the risk of breast cancer. Design.-Prospective cohort study with dietary assessment at baseline, using a validated, self-administered food frequency questionnaire. Setting/Participants.-89 494 women in the Nurses' Health Study who were 34 through 59 years of age in 1980 and who were followed up for 8 years (>95% complete). Results.-1439 incident cases of breast cancer were diagnosed, including 774 among postmenopausal women. After adjustment for age, established risk factors, and total energy intake, we observed no evidence of any positive association between total fat intake and breast cancer incidence (relative risks [RRs] for increasing quintiles of fat intake were 1.0, 0.85, 0.96, 0.91, and 0.90; 95% confidence interval for highest vs lowest quintile, 0.77 to 1.07). Among postmenopausal women alone, corresponding RRs were 1.0, 0.89, 1.00, 0.95, and 0.91. Comparing extreme deciles of total fat intake (greater-than-or-equal-to 49% vs <29% of total energy intake), the RR was 0.86 (95% confidence interval, 0.67 to 1.08). A similar absence of any positive association was observed without adjustment for energy intake; for tumors less than 2 cm as well as 2 cm or greater in diameter; for saturated, monounsaturated, and polyunsaturated fat; and after excluding the first 4 years of follow-up. Also, we found no suggestion of any positive association when using a more detailed and precise dietary questionnaire completed in 1984 (666 subsequent cases), even when women consuming less than 25% of energy from fat were used as the comparison group. No suggestion of a protective effect of dietary fiber was observed (RRs for increasing quintiles were 1.0, 0.95, 0.93, 1.02, and 1.02). Conclusions.-These data provide evidence against both an adverse influence of fat intake and a protective effect of fiber consumption by middle-aged women on breast cancer incidence over 8 years. Nevertheless, the positive association between intake of animal fat and risk of colon cancer observed in many studies provides ample reason to limit this source of energy.	HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University	WILLETT, WC (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA50597, CA40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356, R01CA050597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appleton B S, 1986, Adv Exp Med Biol, V206, P99; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Birt D F, 1986, Adv Exp Med Biol, V206, P69; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BOYAR AP, 1988, NUTR CANCER, V11, P93, DOI 10.1080/01635588809513975; COHEN LA, 1991, JNCI-J NATL CANCER I, V83, P496, DOI 10.1093/jnci/83.7.496; COHEN LA, 1990, MED HYPOTHESES, V31, P83, DOI 10.1016/0306-9877(90)90002-V; FREEDMAN LS, 1990, CANCER RES, V50, P5710; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V134, P714; GOLDIN BR, 1982, NEW ENGL J MED, V307, P1542, DOI 10.1056/NEJM198212163072502; GOODWIN PJ, 1987, JNCI-J NATL CANCER I, V79, P473; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; HEBERT JR, 1988, AM J CLIN NUTR, V47, P1068, DOI 10.1093/ajcn/47.6.1068; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HUNTER DJ, 1991, AM J EPIDEMIOL, V134, P715; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KNEKT P, 1990, AM J CLIN NUTR, V52, P903, DOI 10.1093/ajcn/52.5.903; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; MICOZZI MS, 1985, YEARB PHYS ANTHROPOL, V28, P175; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE R, 1990, J NATL CANCER I, V82, P129, DOI 10.1093/jnci/82.2.129; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; ROELS OA, 1958, J NUTR, V65, P115, DOI 10.1093/jn/65.1.115; ROSE DP, 1987, JNCI-J NATL CANCER I, V78, P623; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; STRYKER WS, 1991, J AM DIET ASSOC, V91, P172; SUN M, 1988, SCIENCE, V239, P17, DOI 10.1126/science.3336770; SWANSON CA, 1988, CANCER RES, V48, P5363; VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; WELSCH CW, 1983, J NATL CANCER I, V70, P215; WELSCH CW, 1992, CANCER RES, V52, pS2040; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1990, CANCER CAUSE CONTROL, V1, P103, DOI 10.1007/BF00053190; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1989, DIET HLTH; 1963, DEPT AGR HDB, V8	47	352	356	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2037	2044		10.1001/jama.268.15.2037	http://dx.doi.org/10.1001/jama.268.15.2037			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1328696				2022-12-24	WOS:A1992JT52000026
J	WRIGHT, TL; MAMISH, D; COMBS, C; KIM, M; DONEGAN, E; FERRELL, L; LAKE, J; ROBERTS, J; ASCHER, NL				WRIGHT, TL; MAMISH, D; COMBS, C; KIM, M; DONEGAN, E; FERRELL, L; LAKE, J; ROBERTS, J; ASCHER, NL			HEPATITIS-B VIRUS AND APPARENT FULMINANT NON-A, NON-B HEPATITIS	LANCET			English	Article							SURFACE-ANTIGEN; POLYPEPTIDE; SECRETION; SERUM; LIVER; DNA	While there is evidence that hepatitis C virus (HCV) does not cause fulminant non-A, non-B hepatitis, the causal agent remains unknown. To evaluate the role of hepatitis B virus (HBV) in this disease, we used a two-step polymerase chain reaction (PCR) to amplify the surface and core regions of HBV DNA in serum and liver samples taken prospectively from twenty-six patients (mean age 36 years, range 1 to 64) with acute hepatic failure undergoing liver transplantation. HBV DNA was absent from the serum of all patients before transplantation. Seventeen patients were diagnosed as having non-A, non-B hepatitis because they lacked serological evidence of hepatitis A virus or HBV infection. Liver samples were taken from twelve of these patients, and six samples were positive for HBV DNA. By contrast HBV DNA was not detected in liver from three patients with acute liver failure caused by hepatitis A or toxins. HCV RNA was not found in pretransplant samples by PCR. Four of the six patients with detectable HBV DNA in liver and presumptive non-A, non-B hepatitis had detectable HBV DNA in serum after transplantation. One additional patient who did not donate pretransplant liver had HBV DNA in a post-transplant serum sample. Thus, HBV DNA was present before or after transplantation in seven of seventeen patients with apparent non-A, non-B hepatitis. Three of five patients with detectable post-transplant serum HBV DNA were serologically positive for HBV surface antigen. These findings indicate that HBV may be a common cause of fulminant hepatic failure in patients lacking serological evidence of HBV infection.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	WRIGHT, TL (corresponding author), VET AFFAIRS MED CTR,4150 CLEMENT ST,SAN FRANCISCO,CA, USA.			Lake, John/0000-0002-4332-0528	NIAID NIH HHS [R29AI32242-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032242] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISMUTH H, 1987, ANN INTERN MED, V107, P337, DOI 10.7326/0003-4819-107-2-337; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; FAVOROV MO, 1992, IN PRESS J MED VIROL; FERAY C, 1991, HEPATOLOGY, V14, pA130; LAVINE JE, 1991, GASTROENTEROLOGY, V100, P263, DOI 10.1016/0016-5085(91)90611-N; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205; LIANG TJ, 1991, HEPATOLOGY, V14, pA129; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MAS A, 1990, HEPATOLOGY, V11, P1062, DOI 10.1002/hep.1840110624; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; PERSING DH, 1986, SCIENCE, V234, P1388, DOI 10.1126/science.3787251; SALLIE R, 1991, HEPATOLOGY, V14, pA68; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111; YANAGI M, 1991, NEW ENGL J MED, V324, P1895, DOI 10.1056/NEJM199106273242615; ZELDIS JB, 1989, J CLIN INVEST, V84, P1503, DOI 10.1172/JCI114326	22	134	135	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					952	955		10.1016/0140-6736(92)91530-L	http://dx.doi.org/10.1016/0140-6736(92)91530-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348798				2022-12-24	WOS:A1992HP03600003
J	BRIGHT, RA; EVERITT, DE				BRIGHT, RA; EVERITT, DE			BETA-BLOCKERS AND DEPRESSION - EVIDENCE AGAINST AN ASSOCIATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOCHEMICAL MANIFESTATIONS; PROPRANOLOL; THERAPY; HYPERTENSION; NEUROBIOLOGY; STRESS; DRUGS	Objective. - To evaluate the relationship between beta-blockers and depression. Design. - Case-control study. Setting. - New Jersey Medicaid recipients during July 1980 to December 1983. Participants. - New depression case patients (N = 4302) were identified from Medicaid claims for depression markers (antidepressant drugs, in-hospital depression diagnosis, or electroconvulsive therapy). Control patients were randomly selected and matched on the basis of Medicaid enrollment on the case patients' date for first depression marker (index date), birth year, sex, race, and nursing home residency status. Main Exposure Measure. - Beta-blocker use as evidenced by prescription claims in the year before the index date. Results. - Case patients overall were more likely to have taken beta-blockers (simple, matched odds ratio [OR] of 1.45; 95% confidence interval [Cl], 1.29 to 1.62). Controlling for confounders (benzodiazepine use, frequent outpatient visits, and frequent use of medications other than beta-blockers) resulted in a null effect (OR = 0.98; 95% Cl, 0.87 to 1.12). The ORs were consistently lower for case patients with a depression diagnosis or electroconvulsive therapy than for cases with only antidepressant use as a marker. These results did not vary by age, sex, race, nursing home status, or use of other selected specific medications. Conclusions. - Ongoing beta-blocker use was not causally related to markers of depression. The difference between this study and those it contradicts is that this one identified certain confounding variables that accounted for the apparent relationship.	BETH ISRAEL HOSP,DEPT MED,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Bright, Roselie A/D-2240-2016		FDA HHS [FD-0015-D] Funding Source: Medline	FDA HHS		AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; BRADBURN NM, 1987, SCIENCE, V236, P157, DOI 10.1126/science.3563494; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V40, P91; BULPITT CJ, 1989, J CARDIOVASC PHARM, V14, pS21; CARNEY RM, 1987, AM J MED, V83, P223, DOI 10.1016/0002-9343(87)90689-9; CRAIG TJ, 1982, NEW YORK STATE J MED, V82, P1439; CREMONABARBARO A, 1983, LANCET, V1, P185; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DIMSDALE JE, 1989, ARCH INTERN MED, V149, P514, DOI 10.1001/archinte.149.3.514; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; FLEMINGER R, 1978, BMJ-BRIT MED J, V1, P1182, DOI 10.1136/bmj.1.6121.1182; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GURLAND BJ, 1980, PSYCHOPATHOLOGY AGED, P37; JANKOVIC J, 1980, ANN INTERN MED, V93, P460, DOI 10.7326/0003-4819-93-3-460; KATON W, 1984, J CLIN PSYCHIAT, V45, P4; KRAMERGINSBERG E, 1989, J AM GERIATR SOC, V37, P507, DOI 10.1111/j.1532-5415.1989.tb05680.x; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993; LESSLER JT, 1984, 1 RES TRIANGL I TECH; ORSULAK PJ, 1989, J FAM PRACTICE, V28, P209; PAYKEL ES, 1982, J CLIN PSYCHOPHARM, V2, P14, DOI 10.1097/00004714-198202000-00004; PETRIE WM, 1982, AM J PSYCHIAT, V139, P92; ROBINS JM, 1986, BIOMETRICS, V42, P293, DOI 10.2307/2531050; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P250; SCHWARTZ AH, 1980, AM J PUBLIC HEALTH, V70, P406, DOI 10.2105/AJPH.70.4.406; STEPHEN SA, 1966, AM J CARDIOL, V18, P463, DOI 10.1016/0002-9149(66)90071-3; THIESSEN BQ, 1990, ARCH INTERN MED, V150, P2286, DOI 10.1001/archinte.150.11.2286; WEISSMAN MM, 1987, AM J PUBLIC HEALTH, V77, P445, DOI 10.2105/AJPH.77.4.445; WHITE WB, 1982, NEW ENGL J MED, V307, P558; 1987, PHYSICIAN CURRENT PR; 1989, INT CLASSIFICATION D	33	69	69	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1783	1787						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK672	1347572				2022-12-24	WOS:A1992HK67200027
J	MARGOLICK, JB; MUNOZ, A; VLAHOV, D; SOLOMON, L; ASTEMBORSKI, J; COHN, S; NELSON, KE				MARGOLICK, JB; MUNOZ, A; VLAHOV, D; SOLOMON, L; ASTEMBORSKI, J; COHN, S; NELSON, KE			CHANGES IN LYMPHOCYTE-T SUBSETS IN INTRAVENOUS-DRUG-USERS WITH HIV-1 INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PERIPHERAL-BLOOD; HOMOSEXUAL MEN; AIDS; COHORT; TYPE-1; CD4; SEROCONVERSION; MARKERS	Objective. - To evaluate changes in T-cell subsets in prevalent human immunodeficiency virus type 1 (HIV-1) seronegative and seropositive intravenous drug users (IVDUs) and in HIV-1 seropositive IVDUs with known time of seroconversion. Design. - Cohort study with a median 18-month follow-up. Setting. - Community-based clinic established to study the natural history of HIV infection in IVDUs. Subjects. - Eight hundred fifty-nine self-referred IVDUs aged 18 through 49 years who injected drugs within the last 10 years and who did not have an AIDS (acquired immunodeficiency syndrome)-defining illness; 152 were seronegative for HIV-1, 621 were seropositive, and 86 seroconverted during the study. Outcome Measures. - Proportions and absolute numbers of lymphocytes and CD3, CD4, and CD8 T cells as determined at 6-month intervals by flow cytometry and complete blood cell counts with automated differential. Results. - Median numbers of.CD4 lymphocytes at enrollment were 1061/mu-L (1.06 x 10(9)/L) for seronegative IVDUs, 508/mu-L for seropositive IVDUs, and 733/mu-L for those who seroconverted (enrolled a median of 4.5 months after seroconversion); the corresponding figures for CD8 lymphocytes were 628, 894, and 889/mu-L, respectively. Median rates of decline in absolute numbers and percentages of CD4 lymphocytes per 6 months were 7.6/mu-L (0.0%) for seropositive IVDUs and 55.1/mu-L (1.9%) for IVDUs who seroconverted (median follow-up after seroconversion was 12 months). Multivariate regression analysis that incorporated the within-individual correlation of the CD4 lymphocyte counts showed no significant change in these cells over time and no change due to use of drugs. Conclusion. - Our data suggest that progression of HIV-1 infection in IVDUs, as reflected in decline of CD4 cell counts, is no more rapid than that reported for other risk groups.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	MARGOLICK, JB (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, 615 N WOLFE ST, ROOM 7032, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R56DA004334, R01DA004334] Funding Source: NIH RePORTER; NIAID NIH HHS [AI72634] Funding Source: Medline; NIDA NIH HHS [DA05664, DA04334] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALCABES P, 1991, 7TH INT C AIDS FLOR; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; GALLI M, 1989, CLIN IMMUNOL IMMUNOP, V50, pS166, DOI 10.1016/0090-1229(89)90124-4; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; JARLAIS DCD, 1987, AIDS, V1, P105; KLIMAS NG, 1991, AM J MED, V90, P163, DOI 10.1016/0002-9343(91)80155-F; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; MUNOZ A, 1986, BIOMETRICS, V42, P653, DOI 10.2307/2531215; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; ROSENBLATT JD, 1990, BLOOD, V76, P409; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHOENBAUM EE, 1989, 5TH INT C AIDS MONTR, P157; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; STONEBURNER R, 1991, SCIENCE, V242, P916; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; Tukey J.W., 1977, EXPLORATORY DATA ANA; ULSTRUP JC, 1986, LANCET, V1, P1151; VLAHOV D, 1991, J DRUG ISSUES, V21, P759, DOI 10.1177/002204269102100406; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; ZOLLAPAZNER S, 1987, P NATL ACAD SCI USA, V84, P5404, DOI 10.1073/pnas.84.15.5404; 1987, MMWR, V36, pS3	29	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1631	1636		10.1001/jama.267.12.1631	http://dx.doi.org/10.1001/jama.267.12.1631			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1347321				2022-12-24	WOS:A1992HJ59700030
J	ARCHER, TK; LEFEBVRE, P; WOLFORD, RG; HAGER, GL				ARCHER, TK; LEFEBVRE, P; WOLFORD, RG; HAGER, GL			TRANSCRIPTION FACTOR LOADING ON THE MMTV PROMOTER - A BIMODAL MECHANISM FOR PROMOTER ACTIVATION	SCIENCE			English	Article							NUCLEAR FACTOR-I; MAMMALIAN-CELLS; BINDING-SITE; DNA-BINDING; PROTEINS; EXTRACTS; ELEMENT; INVIVO; CRUDE; SP1	The mouse mammary tumor virus (MMTV) promoter attains a phased array of six nucleosomes when introduced into rodent cells. This architecture excludes nuclear factor 1/CCAAT transcription factor (NF1/CTF) from the promoter before glucocorticoid treatment and hormone-dependent access of nucleolytic agents to promoter DNA. In contrast, when the promoter was transiently introduced into cells, NF1/CTF was bound constitutively and nucleolytic attack was hormone-independent. Thus, induction at this promoter was a bimodal process involving receptor-dependent remodeling of chromatin that allows NF1/CTF loading and direct receptor-mediated recruitment of additional transcription factors.	NCI,MOLEC VIROL LAB,HORMONE ACT & ONCOGENESIS SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lefebvre, Philippe/F-2685-2010; Archer, Trevor K/E-5191-2019	Lefebvre, Philippe/0000-0002-9366-5129; Archer, Trevor K/0000-0001-7651-3644				ARCHER TK, 1985, J BIOL CHEM, V260, P1676; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1989, STEROID THYROID HORM, P221; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KUHNEL B, 1986, J MOL BIOL, V190, P367, DOI 10.1016/0022-2836(86)90008-2; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WOLFFE A P, 1990, New Biologist, V2, P211; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	26	370	373	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1573	1576		10.1126/science.1347958	http://dx.doi.org/10.1126/science.1347958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1347958				2022-12-24	WOS:A1992HJ80900041
J	INOUE, J; KERR, LD; KAKIZUKA, A; VERMA, IM				INOUE, J; KERR, LD; KAKIZUKA, A; VERMA, IM			I-KAPPA-B-GAMMA, A 70 KD PROTEIN IDENTICAL TO THE C-TERMINAL HALF OF P110 NF-KAPPA-B - A NEW MEMBER OF THE I-KAPPA-B FAMILY	CELL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ENHANCER-BINDING-PROTEIN; REL ONCOGENE PRODUCT; CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; DORSAL PROTEIN; 65-KD SUBUNIT; DNA; DROSOPHILA	A cDNA corresponding to the 2.6 kb NF-kappa-B mRNA species present in a variety of lymphoid cell lines has been molecularly cloned. The deduced 607 amino acid sequence is identical to the sequence of the C-terminal region of 110 kd NF-kappa-B protein. A 70 kd protein can be identified in lymphoid cells using antibodies raised against the C-terminal region of pi 10 NF-kappa-B. Comparison of the two-dimensional tryptic peptide maps of the 70 kd protein expressed in cells and the in vitro translated product encoded by the cDNA display extensive homology. The 70 kd protein expressed in bacteria prevents sequence-specific DNA binding of p50-p65 NF-kappa-B heterodimer, p50 homodimer, and c-rel. p70 also interferes with transactivation by c-rel and prevents its nuclear translocation. The 70 kd protein, predominantly found in lymphoid cells, is a new member of the I-kappa-B family of proteins and is referred to as I-kappa-B-gamma.			INOUE, J (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186, USA.				FOGARTY INTERNATIONAL CENTER [F05TW004430] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444] Funding Source: NIH RePORTER; FIC NIH HHS [F5TWO4430] Funding Source: Medline; NCI NIH HHS [T2CA09370C] Funding Source: Medline; NIGMS NIH HHS [5R01GM26444] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE JI, 1992, IN PRESS P NATL ACAD; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LUO K, 1990, ONCOGENE, V5, P921; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	47	269	272	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1109	1120		10.1016/0092-8674(92)90082-N	http://dx.doi.org/10.1016/0092-8674(92)90082-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1339305				2022-12-24	WOS:A1992HK67400014
J	NISHIGUCHI, S; KUROKI, T; UEDA, T; FUKUDA, K; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; KOBAYASHI, K; OTANI, S; HAYASHI, N; SHIKATA, T				NISHIGUCHI, S; KUROKI, T; UEDA, T; FUKUDA, K; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; KOBAYASHI, K; OTANI, S; HAYASHI, N; SHIKATA, T			DETECTION OF HEPATITIS-C VIRUS-ANTIBODY IN THE ABSENCE OF VIRAL-RNA IN PATIENTS WITH AUTOIMMUNE HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C VIRUS; AUTOIMMUNE DISEASES; RNA, VIRAL; FALSE POSITIVE REACTIONS; RECOMBINANT IMMUNOBLOT ASSAY	NON-A; GENOME; PROTEIN; ASSAY	Objective: To determine whether laboratory findings showing antibodies to hepatitis C virus (HCV) in patients with autoimmune hepatitis represent false-positive results and to identify possible explanations for true-positive results in these patients. Design: Cross-sectional. Setting. University-based hospital. Patients: Fifty-two patients with non-A, non-B chronic hepatitis as a control group and 26 patients with classic chronic active autoimmune hepatitis. Measurements: Comparison of the results of five kinds of assays of HCV antibodies and HCV RNA. Main Results: Of 52 patients with non-A, non-B chronic hepatitis, HCV antibodies (anti-HCV) were detected in 42 patients (81%; 95% Cl, 67% to 90%) by a first-generation enzyme-linked immunosorbent assay (ELISA-I), in 39 patients (75%) by Sp42 ELISA, in 37 patients (71 %) by RIA-I, in 49 patients (94%) by ELISA-II, and in 48 patients (92%) by RIBA-II. We found HCV RNA in 47 patients (90%; Cl, 79% to 97%). Of the 26 patients with autoimmune hepatitis, anti-HCV were detected in 23 patients (88%; Cl, 70% to 98%) by ELISA-I, in 12 (46%) by both RIA-I and Sp42 ELISA, in 20 (77%) by ELISA-II, and in 9 (35%) by RIBA-II. However, HCV RNA was found in only five of these patients (19%; Cl, 7% to 39%). None of our patients, including controls, had antibodies to superoxide dismutase. Of the 21 patients who had autoimmune hepatitis that was completely responsive to steroid therapy, 18 had anti-HCV by ELISA-I, but 13 of these patients had negative results by RIBA-II, and only two patients had HCV RNA. Of the five patients who did not respond to steroid treatment, all had anti-HCV by ELISA-I, four had negative results by RIBA-II, and three had HCV RNA. Conclusions: Testing for HCV antibodies in patients with autoimmune hepatitis frequently elicits positive results when the ELISA-I or ELISA-II tests are used. Most of these appear to represent false-positive results because HCV RNA is usually absent from the serum. Such false positivity may result from previous infection with HCV or from cross-reaction of an epitope of HCV. Other patients with apparent autoimmune hepatitis who fail to respond to corticosteroid therapy may actually have chronic hepatitis C (or other non-A, non-B hepatitis) infection.	NIHON UNIV, SCH MED, TOKYO 101, JAPAN	Nihon University	NISHIGUCHI, S (corresponding author), OSAKA UNIV, SCH MED, DEPT INTERNAL MED 3, 1-5-7 ASAHI MACHI, ABENO KU, OSAKA 545, JAPAN.							BASSETTI D, 1991, LANCET, V337, P912; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; FUSCONI M, 1990, LANCET, V336, P823, DOI 10.1016/0140-6736(90)93297-3; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; ROBERTSON DAF, 1987, LANCET, V2, P9; TAKAHASHI T, 1990, ACTA HEPATOL JPN, V31, P1380; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q	19	94	110	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					21	25		10.7326/0003-4819-116-1-21	http://dx.doi.org/10.7326/0003-4819-116-1-21			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1309200				2022-12-24	WOS:A1992GX15700004
J	GODLEE, F				GODLEE, F			MEDICINAL-PLANTS - ANOTHER MANS POISON	BRITISH MEDICAL JOURNAL			English	Article																		FELLOWS LE, 1922, NEW DRUGS NATURAL SO; FLINT M, 1991, BIOL RESOURCES DEV C; SCALISE JA, 1988, VET HUM TOXICOL, V30, P426	3	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1583	1585		10.1136/bmj.305.6868.1583	http://dx.doi.org/10.1136/bmj.305.6868.1583			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286403	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992KD77100042
J	ELLERBROCK, TV; LIEB, S; HARRINGTON, PE; BUSH, TJ; SCHOENFISCH, SA; OXTOBY, MJ; HOWELL, JT; ROGERS, MF; WITTE, JJ				ELLERBROCK, TV; LIEB, S; HARRINGTON, PE; BUSH, TJ; SCHOENFISCH, SA; OXTOBY, MJ; HOWELL, JT; ROGERS, MF; WITTE, JJ			HETEROSEXUALLY TRANSMITTED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AMONG PREGNANT-WOMEN IN A RURAL FLORIDA COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUAL-BEHAVIOR; UNITED-STATES; TRANSMISSION; CRACK; RISK; EPIDEMIOLOGY; AIDS; HIV	Background. In the United States, an increasing proportion of women infected with the human immunodeficiency virus (HIV) live in nonmetropolitan areas. Little is known, however, about the risk factors for HIV transmission in women outside large cities. Methods. We interviewed and tested 1082 (99.8 percent) of 1084 consecutive pregnant women who registered for prenatal care at a public health clinic in western Palm Beach County, Florida. This rural agricultural area of about 36,000 people is known to have a high prevalence of HIV infection. Results. The seroprevalence of HIV was 5.1 percent (52 of 1011 women). Black women who were neither Haitian nor Hispanic had the highest rate of infection (8.3 percent [48 of 575]). Only 4 of 1009 women (0.4 percent) reported ever injecting drugs, and the 4 were HIV-sero-negative; however, 14 of 43 users of "crack" cocaine (33 percent) had HIV infection. At prenatal registration, 131 of 983 women (13 percent) tested positive for gonorrhea, chlamydial infection, or syphilis. By multivariate logistic-regression analysis, HIV infection was found to be independently associated with having used crack cocaine (odds ratio, 3.3; P<0.001), having had more than two sexual partners (odds ratio, 4.6; P<0.001), being black but neither Hispanic nor Haitian (odds ratio, 11; P<0.001), having had sexual intercourse with a high-risk partner (odds ratio, 5.6; P<0.001), and testing positive for syphilis (odds ratio, 3.1; P = 0.015). Nevertheless, 11 of the 52 HIV-infected women (21 percent) reported a total of only two to five sexual partners and no known high-risk partners, had never used crack cocaine, and had no positive tests for sexually transmitted disease. Conclusions. In the rural community we studied, most of the women with HIV infection acquired it through heterosexual contact. The increasing seroprevalence of HIV and the increasing incidence of syphilis and use of crack cocaine mean that other women may be at similar risk of acquiring heterosexually transmitted HIV infection.	FLORIDA STATE DEPT HLTH & REHABIL SERV,DIST 9 OFF,W PALM BEACH,FL; FLORIDA STATE DEPT HLTH & REHABIL SERV,AIDS PROGRAM,TALLAHASSEE,FL		ELLERBROCK, TV (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,1600 CLIFTON RD NE,MAILSTOP E-45,ATLANTA,GA 30333, USA.							ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BOWEN GS, 1990, FAM PLANN PERSPECT, V22, P62, DOI 10.2307/2135510; CARLSON RG, 1991, J PSYCHOACTIVE DRUGS, V23, P11, DOI 10.1080/02791072.1991.10472570; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHIPHANGWI I, 1990, 6TH INT C AIDS SAN F, V1, P158; DARROW WW, 1988, 4TH P INT C AIDS STO, V1, P273; DEBUONO BA, 1990, NEW ENGL J MED, V322, P821, DOI 10.1056/NEJM199003223221206; DEHOVITZ J, 1991, 7TH INT C AIDS FLOR, V2, P320; EDLIN B, 1991, 7TH INT C AIDS FLOR, V2, P68; ELLERBROCK TV, 1991, JAMA-J AM MED ASSOC, V265, P2971, DOI 10.1001/jama.265.22.2971; FRIEDMAN SR, 1988, 4TH INT C AIDS ABSTR, V2, P396; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; LAGA M, 1990, 6TH INT C AIDS SAN F, V1, P158; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; Lieb S, 1988, J Fla Med Assoc, V75, P301; MATI J, 1991, 7TH INT C AIDS FLOR, V2, P319; NARKUNAS JP, 1989, 5TH P INT C AIDS MON, P101; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; PUCCIO PS, 1991, DRUG OTHER SUBSTANCE; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P1432, DOI 10.1001/jama.264.11.1432; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; WASSER S, 1991, 119TH ANN M AM PUBL, P6; Wilkinson Alec., 1989, BIG SUGAR SEASONS CA; 1991, CENSUS POPULATION HO	25	104	105	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1704	1709		10.1056/NEJM199212103272402	http://dx.doi.org/10.1056/NEJM199212103272402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1308669	Bronze			2022-12-24	WOS:A1992KA89700002
J	TRIAS, J; JARLIER, V; BENZ, R				TRIAS, J; JARLIER, V; BENZ, R			PORINS IN THE CELL-WALL OF MYCOBACTERIA	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; TUBERCULOSIS; INFECTION; MEMBRANE; BARRIER	The cell wall of mycobacteria is an efficient permeability barrier that makes mycobacteria naturally resistant to most antibiotics. Liposome swelling assays and planar bilayer experiments were used to investigate the diffusion process of hydrophilic molecules through the cell wall of Mycobacterium chelonae and identify the main hydrophilic pathway. A 59-kilodalton cell wall protein formed a water-filled channel with a diameter of 2.2 nanometers and an average single-channel conductance equal to 2.7 nanosiemens in 1 M potassium chloride. These results suggest that porins can be found in the cell wall of a Gram-positive bacterium. A better knowledge of the hydrophilic pathways should help in the design of more effective antimycobacterial agents.	UNIV PARIS 06,BACTERIOL VIROL LAB,F-75634 PARIS 13,FRANCE; UNIV WURZBURG,LEHRSTUHL BIOTECHNOL,W-8700 WURZBURG,GERMANY	UDICE-French Research Universities; Sorbonne Universite; University of Wurzburg				Benz, Roland/0000-0002-9510-9265				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; DRAPER P, 1982, BIOL MYCOBACTERIA, P9; HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; JARLIER V, 1991, ANTIMICROB AGENTS CH, V35, P1937, DOI 10.1128/AAC.35.9.1937; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Minnikin DE, 1987, CHEMOTHERAPY TROPICA, P19; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; TRIAS J, UNPUB; WHEELER PR, 1988, BRIT MED BULL, V44, P547, DOI 10.1093/oxfordjournals.bmb.a072267; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308; 1982, TUBERCLE, V63, P157	16	164	173	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1479	1481		10.1126/science.1279810	http://dx.doi.org/10.1126/science.1279810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279810				2022-12-24	WOS:A1992JZ62500027
J	CAUX, C; DEZUTTERDAMBUYANT, C; SCHMITT, D; BANCHEREAU, J				CAUX, C; DEZUTTERDAMBUYANT, C; SCHMITT, D; BANCHEREAU, J			GM-CSF AND TNF-ALPHA COOPERATE IN THE GENERATION OF DENDRITIC LANGERHANS CELLS	NATURE			English	Article							COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; IDENTIFICATION; PROLIFERATION; VIABILITY; BLOOD	DENDRITIC cells comprise a system of highly efficient antigen-presenting cells which initiate immune responses such as the sensitization of T cells restricted by major histocompatibility complex molecules, the rejection of organ transplants and the formation of T-cell-dependent antibodies. Dendritic cells are found in many non-lymphoid tissues, such as skin (Langerhans cells) and mucosa, and they migrate after antigen capture through the afferent lymph or the bloodstream to lymphoid organs, where they efficiently present antigen to T cells1. Dendritic cells are difficult to isolate and, although they originate from bone marrow2,3 their site of maturation and the conditions that direct their growth and differentiation are still poorly characterized. Granulocyte macrophage-colony stimulating factor (GM-CSF) favours the outgrowth of dendritic cells from mouse peripheral blood4. Here we extend this finding to man and demonstrate that cooperation between GM-CSF and tumour necrosis factor-alpha (TNF-alpha) is crucial for the generation of human dendritic/Langerhans cells from CD34+ haematopoietic progenitors. The availability of large numbers of these cells should now facilitate the understanding of their role in immunological regulation and disorder.	HOP EDOUARD HERRIOT, INSERM, U346, F-69437 LYON 03, FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	CAUX, C (corresponding author), SCHERING PLOUGH CORP, IMMUNOL RES LAB, 27 CHEMIN PEUPLIERS, BP 11, F-69571 DARDILLY, FRANCE.		Caux, Christophe/G-2851-2013; dezutter-dambuyant, colette/F-5962-2013	Caux, Christophe/0000-0003-2438-833X; dezutter-dambuyant, colette/0000-0002-3866-4537				CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAUX C, 1990, BLOOD, V75, P2292; CAUX C, 1991, BLOOD, V78, P635; CROW MK, 1982, CLIN EXP IMMUNOL, V49, P338; DEZUTTERDAMBUYANT C, 1989, HYBRIDOMA, V8, P199, DOI 10.1089/hyb.1989.8.199; DEZUTTERDAMBUYANT C, 1985, J INVEST DERMATOL, V84, P465, DOI 10.1111/1523-1747.ep12272371; DJEU JY, 1992, TUMOR NECROSIS FACTO, P531; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GHIARA P, 1987, J IMMUNOL, V139, P3676; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KNIGHT SC, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P145; KOCH F, 1990, J EXP MED, V171, P159, DOI 10.1084/jem.171.1.159; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LUGER TA, 1989, ACTA DERM-VENEREOL, V69, P61; MALIK STA, 1992, TUMOR NECROSIS FACTO, P407; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; SORNASSE T, 1992, J EXP MED, V175, P15, DOI 10.1084/jem.175.1.15; STEINMAN RM, 1974, J EXP MED, V139, P1431, DOI 10.1084/jem.139.6.1431; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; VANDERIJN M, 1984, HUM IMMUNOL, V9, P201, DOI 10.1016/0198-8859(84)90025-9; VANVOORHIS WC, 1982, J EXP MED, V155, P1172, DOI 10.1084/jem.155.4.1172; VANVOORHIS WC, 1983, J EXP MED, V158, P174, DOI 10.1084/jem.158.1.174; WITMERPACK MD, 1987, J EXP MED, V166, P1484, DOI 10.1084/jem.166.5.1484	29	1426	1480	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					258	261		10.1038/360258a0	http://dx.doi.org/10.1038/360258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279441				2022-12-24	WOS:A1992JY96000051
J	PHILLIPS, GJ; SILHAVY, TJ				PHILLIPS, GJ; SILHAVY, TJ			THE ESCHERICHIA-COLI FFH-GENE IS NECESSARY FOR VIABILITY AND EFFICIENT PROTEIN EXPORT	NATURE			English	Article							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; 4.5S RNA; SACCHAROMYCES-CEREVISIAE; RIBONUCLEOPROTEIN; SEQUENCE; SUBUNIT	HOMOLOGUES of the gene encoding the 54K (M(r) 54,000) subunit of the mammalian signal recognition particle have been identified in different organisms1-5. The Escherichia coli homologue, termed ffh (for fifty-four homologue), specifies a protein (Ffh) that shares many properties with its eukaryotic counterpart, including association with mammalian 7S RNA6 and the ability to bind signal sequences specifically7,8. Ffh also associates with E. coli 4.5S RNA, showing that it can form a ribonucleoprotein complex in prokaryotes6,9,10. These results are intriguing because extensive genetic and biochemical characterization of E. coli failed to identify a signal recognition particle-like mechanism for protein export11 Here we address this issue directly by construction of a strain in which ffh expression is arabinose-dependent. Results of depletion experiments indicate that Ffh is important in protein translocation.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	PHILLIPS, GJ (corresponding author), COLL WILLIAM & MARY,DEPT BIOL,WILLIAMSBURG,VA 23185, USA.			Silhavy, Thomas/0000-0001-7672-5153				BASSFORD P, 1991, CELL, V65, P367, DOI 10.1016/0092-8674(91)90453-6; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HN, UNPUB; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BROWN S, 1991, NEW BIOL, V3, P430; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; DAVIS RW, 1986, ADV BACTERIAL GENETI; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; KOHL J, 1990, NUCLEIC ACIDS RES, V18, P1069, DOI 10.1093/nar/18.4.1069; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Silhavy T.J., 1984, EXPT GENE FUSIONS; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	23	237	240	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					744	746		10.1038/359744a0	http://dx.doi.org/10.1038/359744a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331806				2022-12-24	WOS:A1992JU65000061
J	DULIC, V; LEES, E; REED, SI				DULIC, V; LEES, E; REED, SI			ASSOCIATION OF HUMAN CYCLIN-E WITH A PERIODIC G(1)-S PHASE PROTEIN-KINASE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; CDC28 MUTATION; YEAST; GENE; COMPLEMENTATION; HOMOLOG; POLYMERASE; MITOSIS; FAMILY	G1 cyclins control the G1 to S phase transition in the budding yeast, Saccharomyces cerevisiae. Cyclin E was discovered in the course of a screen for human complementary DNAs that rescue a deficiency of G1 cyclin function in budding yeast. The amounts of both the cyclin E protein and an associated protein kinase activity fluctuated periodically through the human cell cycle; both were maximal in late G1 and early S phases. Cyclin E-associated kinase activity was correlated with the appearance of complexes containing cyclin E and the cyclin-dependent kinase Cdk2. Thus, the cyclin E-Cdk2 complex may constitute a human G1-S phase-specific regulatory protein kinase.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA	Scripps Research Institute; Harvard University; Massachusetts General Hospital				Dulic, Vjekoslav/0000-0003-1201-3901	NCI NIH HHS [CA55339] Funding Source: Medline; NIGMS NIH HHS [GM38328, GM46006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038328, P01GM046006, R01GM038328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, UNPUB; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLIOTT SG, 1978, P NATL ACAD SCI USA, V75, P4384, DOI 10.1073/pnas.75.9.4384; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS P, IN PRESS CELL; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEES E, IN PRESS GENES DEVD; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	27	879	906	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1958	1961		10.1126/science.1329201	http://dx.doi.org/10.1126/science.1329201			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1329201				2022-12-24	WOS:A1992JP59400035
J	SAMPSON, HA; MENDELSON, L; ROSEN, JP				SAMPSON, HA; MENDELSON, L; ROSEN, JP			FATAL AND NEAR-FATAL ANAPHYLACTIC REACTIONS TO FOOD IN CHILDREN AND ADOLESCENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; MAST-CELLS; ALLERGY; INFANTS; RELEASE; MICE	Background and Methods. Reports of fatal or near-fatal anaphylactic reactions to foods in children and adolescents are rare. We identified six children and adolescents who died of anaphylactic reactions to foods and seven others who nearly died and required intubation. All the cases but one occurred in one of three metropolitan areas over a period of 14 months. Our investigations included a review of emergency medical care reports, medical records, and depositions by witnesses to the events, as well as interviews with parents (and some patients). Results. Of the 13 children and adolescents (age range, 2 to 17 years), 12 had asthma that was well controlled. All had known food allergies, but had unknowingly ingested the foods responsible for the reactions. The reactions were to peanuts (four patients), nuts (six patients), eggs (one patient), and milk (two patients), all of which were contained in foods such as candy, cookies, and pastry. The six patients who died had symptoms within 3 to 30 minutes of the ingestion of the allergen, but only two received epinephrine in the first hour. All the patients who survived had symptoms within 5 minutes of allergen ingestion, and all but one received epinephrine within 30 minutes. The course of anaphylaxis was rapidly progressive and uniphasic in seven patients; biphasic, with a relatively symptom-free interval in three; and protracted in three, requiring intubation for 3 to 21 days. Conclusions. Dangerous anaphylactic reactions to food occur in children and adolescents. The failure to recognize the severity of these reactions and to administer epinephrine promptly increases the risk of a fatal outcome.	UNIV CONNECTICUT,HARTFORD HOSP,HARTFORD,CT 06112; JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT ALLERGY & IMMUNOL,BALTIMORE,MD 21205	Hartford Hospital; University of Connecticut; Johns Hopkins University					NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI24439] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1987, PEDIATRICS, V79, P683; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HA TY, 1987, EXP CELL BIOL, V5, P63; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SLOAN AE, 1986, J ALLERGY CLIN IMMUN, V78, P127, DOI 10.1016/0091-6749(86)90002-3; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; STARNES HF, 1990, J IMMUNOL, V145, P4185; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; VECCHIARELLI A, 1992, CLIN EXP ALLERGY, V22, P365, DOI 10.1111/j.1365-2222.1992.tb03097.x; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	19	1266	1306	1	98	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					380	384		10.1056/NEJM199208063270603	http://dx.doi.org/10.1056/NEJM199208063270603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1294076				2022-12-24	WOS:A1992JG35600003
J	BORTIN, MM; HOROWITZ, MM; GALE, RP; BARRETT, AJ; CHAMPLIN, RE; DICKE, KA; GLUCKMAN, E; KOLB, HJ; MARMONT, AM; MRSIC, M; SOBOCINSKI, KA; WEINER, RS; RIMM, AA				BORTIN, MM; HOROWITZ, MM; GALE, RP; BARRETT, AJ; CHAMPLIN, RE; DICKE, KA; GLUCKMAN, E; KOLB, HJ; MARMONT, AM; MRSIC, M; SOBOCINSKI, KA; WEINER, RS; RIMM, AA			CHANGING TRENDS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA IN THE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VERSUS-HOST DISEASE; CYTOMEGALO-VIRUS INFECTION; TOTAL-BODY IRRADIATION; T-CELL DEPLETION; ACUTE NONLYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; INTRAVENOUS IMMUNE GLOBULIN; ACUTE GRAFT; INCREASING UTILIZATION; APLASTIC-ANEMIA	Objective.-To identify changes in practice and outcome of bone marrow transplants for leukemia in the 1980s. Design.-Comparison of key explanatory and outcome variables in five 2-year cohorts, from 1980 through 1981 to 1988 through 1989, using a large database of detailed clinical information. Patients.-Recipients (7788) of bone marrow transplants for acute lymphoblastic, acute myelogenous, or chronic myelogenous leukemia reported to the International Bone Marrow Transplant Registry, Milwaukee, Wis, by 185 transplant teams worldwide. Results.-Linear increases occurred during the periods 1980 through 1981 to 1988 through 1989 as follows with 95% confidence intervals: (1) transplants for chronic myelogenous leukemia from 14%+/-2% to 35%+/-2%; (2) transplants from unrelated donors from 1%+/-1% to 7%+/-1%; (3) preparative regimens without radiation from 3%+/-1% to 30%+/-2%; and (4) use of methotrexate plus cyclosporine to prevent graft-vs-host disease from 2%+/-1% to 55%+/-2%. Among recipients of human lymphocyte antigen-identical sibling bone marrow, the 2-year probability of treatment-related mortality decreased by 6% to 22%. The probability of relapse decreased from 46%+/-6% to 38%+/-6% in intermediate leukemia but did not change appreciably in early or advanced leukemia. Probabilities of leukemia-free survival improved from 51%+/-4% to 57%+/-3% in early leukemia, from 28%+/-4% to 36%+/-5% in intermediate leukemia, and from 12%+/-4% to 18%+/-5% in advanced leukemia. A separate analysis of a homogenous population of patients indicated that improvements in outcome in the 1980s were due to improvements in transplant practice rather than improved patient selection. Conclusions.-Modest increases in leukemia-free survival rates occurred after human lymphocyte antigen-identical sibling bone marrow transplants in the 1980s. Improvements were due primarily to reductions in treatment-related mortality with little or no change in relapse risk. More effective antileukemia strategies and continued reductions in treatment-related toxic effects are needed.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, POB 26509, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DIV CANC & BLOOD DIS, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DIV BIOSTAT CLIN EPIDEMIOL, MILWAUKEE, WI 53226 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA; ROYAL POSTGRAD MED SCH, LONDON W12 0HS, ENGLAND; MD ANDERSON CANC CTR, HOUSTON, TX USA; CTR CANC PREVENT & TREATMENT, HOUSTON, TX USA; HOP ST LOUIS, F-75010 PARIS, FRANCE; UNIV MUNICH, W-8000 MUNICH 2, GERMANY; OSPED SAN MARTINO GENOVA, GENOA, ITALY; UNIV CROATIA, ZAGREB, CROATIA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of California System; University of California Los Angeles; Imperial College London; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Munich; University of Genoa; IRCCS AOU San Martino IST; State University System of Florida; University of Florida			horowitz, Mary/ABH-2173-2021; eliane, Gluckman/AAA-5024-2021		NCI NIH HHS [P01-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPERLEY JF, 1986, BONE MARROW TRANSPL, V1, P53; ASH RC, 1989, BLOOD, V74, pA163; ATKINSON K, 1991, EXP HEMATOL, V19, P578; BIGGS JC, 1986, TRANSPLANT P, V18, P253; BLUME KG, 1987, BLOOD, V69, P1015; BORTIN MM, 1989, TRANSPLANTATION, V48, P453, DOI 10.1097/00007890-198909000-00021; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; BORTIN MM, 1986, TRANSPLANTATION, V42, P229, DOI 10.1097/00007890-198609000-00001; BROCHSTEIN JA, 1987, NEW ENGL J MED, V317, P1618, DOI 10.1056/NEJM198712243172602; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; CLIFT RA, 1987, BONE MARROW TRANSPL, V2, P243; Cochran W. G., 1977, SAMPLING TECHNIQUES; DEEG HJ, 1985, BLOOD, V65, P1325, DOI 10.1182/blood.V65.6.1325.bloodjournal6561325; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GOTTLIEB DJ, 1989, BLOOD, V74, P2335; GRATWOHL A, 1987, Bone Marrow Transplantation, V2, P15; HERZIG RH, 1985, SEMIN ONCOL, V12, P184; HOROWITZ MM, 1989, BONE MARROW TRANSPL, V4, P221; KLINTMALM G, 1985, SCAND J INFECT DIS, V17, P157, DOI 10.3109/inf.1985.17.issue-2.06; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; NAVARI RM, 1984, AM J MED, V76, P564, DOI 10.1016/0002-9343(84)90274-2; PETERSEN FB, 1987, SCAND J INFECT DIS, V19, P559, DOI 10.3109/00365548709032423; PRENTICE HG, 1984, LANCET, V1, P472; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; RINGDEN O, 1986, BONE MARROW TRANSPL, V1, P41; SANTOS GW, 1983, NEW ENGL J MED, V309, P1347, DOI 10.1056/NEJM198312013092202; STORB R, 1985, BLOOD, V66, P698; STORB R, 1986, BLOOD, V68, P119; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STORB R, 1970, TRANSPLANTATION, V9, P240, DOI 10.1097/00007890-197003000-00007; THOMAS ED, 1982, INT J RADIAT ONCOL, V8, P817, DOI 10.1016/0360-3016(82)90083-9; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TORLONTANO G, 1981, EUR BONE MARROW TRAN, P41; TORRES A, 1989, BLUT, V58, P63, DOI 10.1007/BF00320650; TUTSCHKA PJ, 1986, VOX SANG, V51, P87, DOI 10.1111/j.1423-0410.1986.tb02014.x; WALDMANN H, 1984, LANCET, V2, P483; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12	40	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					607	612						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1321298				2022-12-24	WOS:A1992JF47300024
J	HAUGHN, L; GRATTON, S; CARON, L; SEKALY, RP; VEILLETTE, A; JULIUS, M				HAUGHN, L; GRATTON, S; CARON, L; SEKALY, RP; VEILLETTE, A; JULIUS, M			ASSOCIATION OF TYROSINE KINASE P56(LCK) WITH CD4 INHIBITS THE INDUCTION OF GROWTH THROUGH THE ALPHA-BETA T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; CROSS-LINKING; L3T4 MOLECULE; ACTIVATION; P56LCK; EXPRESSION; COMPLEX	THE membrane glycoprotein CD4 enhances antigen-mediated activation of T cells restricted by class II molecules of the major histocompatibility complex (MHC)1-3. This positive function has been attributed to the protein tyrosine kinase p56lck (ref. 4), which is noncovalently associated with the cytoplasmic portion of CD45,6, and is activated on CD4 aggregation7. Antigen presentation by MHC class II molecules coaggregates CD4 and the T-cell antigen receptor (TCR-alpha-beta-CD3)8. Thus, the mutual specificity of CD4 and TCR-alpha-beta for the MHC-antigen complex results in the juxtaposition of p56lck and TCRalpha-beta-CD39-13. In contrast, antibodies can abrogate antigen-induced14-17, as well as anti induced18-20 T-cell activation, indicating that CD4 might also transduce negative signals. The molecular basis for this opposing function remains unclear. Here we show that the CD4-p56lck complex prohibits the induction of activation signals through the TCR-CD3 complex when not specifically included in the signalling process. This negative effect does not require anti-CD4 treatment, indicating that the induction of distinct negative signals is probably not involved. Rather, the results demonstrate that the CD4-p56lck complex provides prerequisite signals for antigen-receptor-induced T-cell growth and thus characterize a molecular mechanism for functional constraints imposed on T-cell activation by the MHC.	MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, 3775 UNIV ST, MONTREAL H3A 2B4, QUEBEC, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, QUEBEC, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA	McGill University; McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANDERSON P, 1987, J IMMUNOL, V139, P678; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CAMBIER JC, 1988, SCAND J IMMUNOL, V27, P59, DOI 10.1111/j.1365-3083.1988.tb02323.x; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1987, EUR J IMMUNOL, V17, P529, DOI 10.1002/eji.1830170415; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; Ledbetter J A, 1990, Semin Immunol, V2, P99; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOLDWIN RL, 1987, J IMMUNOL, V139, P657; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; PIERRES A, 1984, J IMMUNOL, V132, P2775; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1980, MONOCLONAL ANTIBODIE, P185; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WASSMER P, 1985, J IMMUNOL, V135, P2237; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0	45	147	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					328	331		10.1038/358328a0	http://dx.doi.org/10.1038/358328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1322497				2022-12-24	WOS:A1992JE68400063
J	TRUOG, RD; BRETT, AS; FRADER, J				TRUOG, RD; BRETT, AS; FRADER, J			THE PROBLEM WITH FUTILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL INTENSIVE-CARE; FAMILY; RESUSCITATE; PATIENT; ORDERS; POLICY; ETHICS		UNIV PITTSBURGH,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	TRUOG, RD (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.		Frader, Joel/A-8610-2010					AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; [Anonymous], 1990, CRIT CARE MED, V18, P1435; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRAITHWAITE S, 1986, ANN INTERN MED, V104, P711, DOI 10.7326/0003-4819-104-5-711; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1987, CRIT CARE MED, V15, P138, DOI 10.1097/00003246-198702000-00012; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; ELSTEIN AS, 1976, SCIENCE, V194, P696, DOI 10.1126/science.982034; HACKLER JC, 1990, JAMA-J AM MED ASSOC, V264, P1281, DOI 10.1001/jama.264.10.1281; HIPPOCRATES, 1977, ETHICS MED HIST PERS, P6; LANTOS JD, 1989, AM J MED, V87, P81; LAPUMA J, 1987, WESTERN J MED, V146, P633; MEISEL A, 1989, RIGHT DIE, P104; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1983, PRESIDENTS COMMISSIO, P188; 1991, NY TIMES        0705, pA8; 1986, DO NOT RESISCIATE OR, P96; 1986, DO NOT RESUSCITATE O, P83; 1987, GUIDELINES TERMINATI, P112; 1974, JAMA-J AM MED ASSOC, V227, P864; 1987, GUIDELINES TERMINATI, P32; 1991, JAMA-J AM MED ASSOC, V265, P1868	36	302	305	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1560	1564		10.1056/NEJM199206043262310	http://dx.doi.org/10.1056/NEJM199206043262310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1285741				2022-12-24	WOS:A1992HW97200010
J	JOHNSON, E				JOHNSON, E			CRAVING NOT SUFFICIENT OR NECESSARY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2293	2293						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1314314				2022-12-24	WOS:A1992HR01500006
J	MULLER, D; KOLLER, BH; WHITTON, JL; LAPAN, KE; BRIGMAN, KK; FRELINGER, JA				MULLER, D; KOLLER, BH; WHITTON, JL; LAPAN, KE; BRIGMAN, KK; FRELINGER, JA			LCMV-SPECIFIC, CLASS-II RESTRICTED CYTOTOXIC T-CELLS IN BETA-2-MICROGLOBULIN DEFICIENT MICE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGENS; INFECTION; DISEASE; CLONES; LYSIS	Intracranial infection of normal mice with lymphocytic choriomeningitis virus (LCMV) causes meningitis and death mediated by CD8+ major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes (CTLs). Beta-2-microglobulin-deficient mice (beta-2M-/-) do not express functional MHC class I proteins and do not produce significant numbers of CD8+ T cells. When beta-2M-/- mice were infected with LCMV, many died from LCMV disease and produced a specific response to LCMV mediated by CD4+ CTLs that were class II-restricted. In these mice, CD4+ CTLs may compensate for the lack of CD8+ CTLs.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MED, DIV RHEUMATOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, LINEBERGER CANC RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill			Frelinger, Jeffrey A/F-2448-2014	Frelinger, Jeffrey A/0000-0002-2503-6267	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029324, R01AI020288, R37AI020288] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20288, AI-29324] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOLD LG, COMMUNICATION; BINNENDIJK RS, 1989, J IMMUNOL, V142, P2847; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROWNING M, 1990, J VIROL, V64, P3810, DOI 10.1128/JVI.64.8.3810-3816.1990; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BYRNE JA, 1984, J IMMUNOL, V133, P433; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DURAN LW, 1989, J IMMUNOL, V142, P288; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; KAPLAN DR, 1984, CELL IMMUNOL, V88, P193, DOI 10.1016/0008-8749(84)90064-9; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LAPAN KE, 1991, MOL IMMUNOL, V28, P499, DOI 10.1016/0161-5890(91)90164-F; LAPAN KE, IN PRESS HYBRIDOMA; LISOWSKAGROSPIERRE B, 1985, J CLIN INVEST, V76, P381, DOI 10.1172/JCI111974; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; McKenzie I F, 1979, Adv Immunol, V27, P179, DOI 10.1016/S0065-2776(08)60263-1; MOSKOPHIDIS D, 1987, J VIROL, V61, P1867, DOI 10.1128/JVI.61.6.1867-1874.1987; MULLER D, UNPUB; MURRAY R, 1990, CELL IMMUNOL, V128, P220, DOI 10.1016/0008-8749(90)90020-R; OEHEN S, 1991, SCIENCE, V251, P195, DOI 10.1126/science.1824801; OZATO K, 1981, J IMMUNOL, V126, P317; QUINN D, UNPUB; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; TING JPY, 1981, P NATL ACAD SCI-BIOL, V78, P3170, DOI 10.1073/pnas.78.5.3170; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YASUKAWA M, 1984, J IMMUNOL, V133, P422; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0	32	183	184	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1576	1578		10.1126/science.1347959	http://dx.doi.org/10.1126/science.1347959			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1347959				2022-12-24	WOS:A1992HJ80900042
J	BAMFORD, J				BAMFORD, J			CLINICAL EXAMINATION IN DIAGNOSIS AND SUBCLASSIFICATION OF STROKE	LANCET			English	Article							LACUNAR INFARCTION; NATURAL-HISTORY; DATA-BANK; DESIGN; PROJECT				BAMFORD, J (corresponding author), ST JAMES UNIV HOSP, DEPT NEUROL, BECKETT ST, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.		Bamford, John/ABE-6218-2021					ALLEN CMC, 1983, Q J MED, V52, P515; Aring CD, 1935, ARCH INTERN MED, V56, P435, DOI 10.1001/archinte.1935.00170010023002; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; GENT M, 1988, STROKE, V19, P1203, DOI 10.1161/01.STR.19.10.1203; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; HOROWITZ SH, 1991, STROKE, V22, P1245, DOI 10.1161/01.STR.22.10.1245; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MOHR JP, 1986, STROKE PATHOPHYSIOLO, P281; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; PRICE TR, 1986, STROKE PATHOPHYSIOLO, P1060; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SACCO SE, 1991, STROKE, V22, P1236, DOI 10.1161/01.STR.22.10.1236; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; STERMAN AB, 1987, STROKE, V18, P524, DOI 10.1161/01.STR.18.2.524; TURNEY TM, 1984, STROKE, V15, P790, DOI 10.1161/01.STR.15.5.790; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; 1989, STROKE BETTER MANAGE	23	56	57	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					400	402		10.1016/0140-6736(92)90085-H	http://dx.doi.org/10.1016/0140-6736(92)90085-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346666				2022-12-24	WOS:A1992HD65900010
J	JOHNSON, EM				JOHNSON, EM			MOUSE MODEL OF GAUCHER DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.								0	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-24	WOS:A1992JD47200005
J	JOHNSON, EM				JOHNSON, EM			PRENATAL COCAINE EXPOSURE AND SIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							OLSEN GD, 1992, J PHARM EXPT THE MAY	1	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-24	WOS:A1992JD47200004
J	AOUN, H				AOUN, H			FROM THE EYE OF THE STORM, WITH THE EYES OF A PHYSICIAN	ANNALS OF INTERNAL MEDICINE			English	Note						ACQUIRED IMMUNODEFICIENCY SYNDROME; PHYSICIAN-PATIENT RELATIONS; EDUCATION, MEDICAL; SOCIAL SUPPORT; ETHICS, MEDICAL		A physician acquires a terrible disease and, as a patient, is confronted with aspects of medical care that contribute to the suffering rather than the healing. As a result of these experiences, his views on what constitutes a good physician become simpler. A good physician cares for his patients and works toward preserving their dignity and independence. The issue is raised of whether current medical education can be effective in producing that caring physician, for it is particularly in caring for patients with catastrophic or incurable illnesses that the role of the physician is more, not less, important.										AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; AOUN H, 1991, NEW ENGL J MED, V324, P265, DOI 10.1056/NEJM199101243240412; Harrison TR, 1950, PRINCIPLES INTERNAL; NATELSON BH, 1990, TOMORROWS DOCTORS PA; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; RABIN D, 1982, NEW ENGL J MED, V307, P506, DOI 10.1056/NEJM198208193070827; RABIN R, 1985, 6 PARTS LOVE ONE FAM; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405	8	23	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					335	338		10.7326/0003-4819-116-4-335	http://dx.doi.org/10.7326/0003-4819-116-4-335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	11651175				2022-12-24	WOS:A1992HD54600012
